{"meta":{"query_hash":"85695e640686","filters":{"venue":"Leukemia & lymphoma/Leukemia and lymphoma"},"cohort_total":430,"direct_labels_cover":0,"predictions_cover":430,"exported":430,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/85695e640686","api":"https://metacan.xera.ac/api/v1/cohort?venue=Leukemia+%26+lymphoma%2FLeukemia+and+lymphoma"},"results":[{"id":"W1724875595","doi":"10.3109/10428194.2015.1086919","title":"Impact of time from diagnosis to initiation of curative-intent chemotherapy on clinical outcomes in patients with classical Hodgkin lymphoma","year":2015,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"ABVD; Medicine; Internal medicine; Chemotherapy; Lymphoma; Multivariate analysis; Univariate analysis; Oncology; Gastroenterology; Disease; Vincristine; Cyclophosphamide","score_opus":0.02645099087539054,"score_gpt":0.3144176601644274,"score_spread":0.28796666928903686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1724875595","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981504,0.0010607222,0.00006034155,0.00013932775,0.000016122822,0.0000027441604,0.000088144516,0.00000261411,0.00047961087],"genre_scores_gemma":[0.9996214,0.000121518504,0.000027995487,0.00002792027,0.0000152010525,0.0000020116113,0.00011944484,0.0000013568268,0.00006311835],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99954885,0.00013770639,0.000055841843,0.00007440748,0.00007370308,0.000109416265],"domain_scores_gemma":[0.99462515,0.0021953392,0.0019974262,0.00012911469,0.00023164881,0.0008212934],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008019598,0.00011459161,0.00022524553,0.0003255016,0.0002264145,0.0005843037,0.00022016633,0.00031333105,0.0011805417],"category_scores_gemma":[0.0081640445,0.000101788304,0.0003115275,0.00048256357,0.00020455371,0.00058834767,0.0003801327,0.00066304964,0.0001387213],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018797057,0.000082238555,0.9879609,0.000020547073,0.00006484737,0.0001544064,0.00005546642,0.000409586,0.00018676158,0.00004723392,0.00017333728,0.008964928],"study_design_scores_gemma":[0.00005299008,0.00071595097,0.9970535,0.000022075863,0.0000907585,0.00041279325,0.00020102266,0.0007822842,0.000136911,0.00014835777,0.00037484555,0.000008540868],"about_ca_topic_score_codex":0.0027407997,"about_ca_topic_score_gemma":0.0035279451,"teacher_disagreement_score":0.0027407997,"about_ca_system_score_codex":0.00059920765,"about_ca_system_score_gemma":0.00042870615,"threshold_uncertainty_score":0.0054497123},"labels":[],"label_agreement":null},{"id":"W1821529798","doi":"10.3109/10428194.2015.1071486","title":"Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate","year":2015,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Myeloid leukemia; Toxicity; Internal medicine; Incidence (geometry); Oncology","score_opus":0.012498052574899658,"score_gpt":0.2532419150282752,"score_spread":0.24074386245337553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1821529798","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936353,0.0036791493,0.00014738274,0.00025873608,0.000010757921,0.000026706675,0.000083036524,0.000007717665,0.0021511605],"genre_scores_gemma":[0.99891865,0.00066227,0.00010069662,0.00007945608,0.000026979069,0.000009694853,0.000094413306,0.0000014594082,0.00010648978],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99958044,0.000120745455,0.000074921954,0.000042968335,0.00011361997,0.00006716472],"domain_scores_gemma":[0.99904114,0.000183818,0.00053314585,0.000029339079,0.00007620974,0.00013628964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034027392,0.00011254403,0.00028491372,0.00041521504,0.00031929248,0.0003928658,0.00015505508,0.00031469137,0.00067166466],"category_scores_gemma":[0.0022075083,0.00009234273,0.00023621261,0.00055686885,0.0001816774,0.00034977353,0.00023566913,0.00045207856,0.000093219416],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00093942427,0.00016000007,0.9650212,0.000052193,0.00005436377,0.0015879167,0.00013585041,0.00016011776,0.0015756405,0.00013312857,0.00041458773,0.029765584],"study_design_scores_gemma":[0.00008302027,0.0013438886,0.9824082,0.00005959402,0.00006859569,0.011888816,0.0003187139,0.00058935856,0.00078629184,0.00014817376,0.0022963886,0.000009005575],"about_ca_topic_score_codex":0.000556781,"about_ca_topic_score_gemma":0.0008957918,"teacher_disagreement_score":0.00067166466,"about_ca_system_score_codex":0.0003376416,"about_ca_system_score_gemma":0.00033177136,"threshold_uncertainty_score":0.0024498105},"labels":[],"label_agreement":null},{"id":"W1902656250","doi":"10.3109/10428194.2015.1088651","title":"A link between hypercholesterolemia and chronic lymphocytic leukemia","year":2015,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Canadian Institutes of Health Research","keywords":"Chronic lymphocytic leukemia; Medicine; Incidence (geometry); Internal medicine; Cholesterol; Leukemia; Gastroenterology","score_opus":0.032955813149021185,"score_gpt":0.28930771969680397,"score_spread":0.2563519065477828,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1902656250","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99912864,0.00041756616,0.000041848547,0.00004773797,0.0000032040448,0.0000035251755,0.00008592736,0.0000026112523,0.00026893293],"genre_scores_gemma":[0.99968517,0.00011914914,0.000051102463,0.000012810729,0.000012592707,0.0000023934151,0.00007670232,6.1815166e-7,0.000039494607],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994918,0.00014262232,0.000091758055,0.000087316155,0.00008429166,0.000102231505],"domain_scores_gemma":[0.9967006,0.0010410012,0.0014488364,0.00017491436,0.00023776601,0.0003969316],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039279633,0.00010542917,0.0002631259,0.0011751989,0.00047486083,0.00046367862,0.00018876289,0.00038111984,0.0012945856],"category_scores_gemma":[0.002658532,0.00022282304,0.00022705636,0.0012996274,0.0003269366,0.00030007516,0.00028465007,0.00047297386,0.00014337317],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007055327,0.00001244532,0.9988475,0.0000043277523,0.000011063546,0.00012791288,0.000021923022,0.000006903347,0.0001586795,0.0000067493247,0.000021602329,0.00071040756],"study_design_scores_gemma":[0.000004059405,0.00006474609,0.99868816,0.0000041698677,0.000014744407,0.0009418592,0.00007643715,0.000067472734,0.000042745934,0.00001573075,0.00007756774,0.0000022329339],"about_ca_topic_score_codex":0.0033718403,"about_ca_topic_score_gemma":0.0035922485,"teacher_disagreement_score":0.0033718403,"about_ca_system_score_codex":0.00027671875,"about_ca_system_score_gemma":0.00032289117,"threshold_uncertainty_score":0.00670439},"labels":[],"label_agreement":null},{"id":"W1916555325","doi":"10.3109/10428194.2015.1085534","title":"Bortezomib and melphalan conditioning increases the rate of complete response and MRD negativity for patients with multiple myeloma undergoing single autologous stem cell transplant","year":2015,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Foothills Medical Centre; Calgary Laboratory Services; Baker Hughes (Canada)","funders":"","keywords":"Bortezomib; Medicine; Melphalan; Multiple myeloma; Oncology; Stem cell; Autologous stem-cell transplantation; Internal medicine; Chemotherapy; Surgery; Biology","score_opus":0.02112626161931841,"score_gpt":0.2377327960704628,"score_spread":0.2166065344511444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1916555325","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3361774,0.039198063,0.0022811384,0.53592074,0.007120741,0.0002072747,0.00057721965,0.00038085366,0.07813656],"genre_scores_gemma":[0.80216986,0.018854879,0.0024838285,0.14284271,0.01884827,0.00011849297,0.0004888444,0.00007978719,0.014113348],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99936324,0.0002456011,0.00007503916,0.00006420271,0.00016610215,0.000085862084],"domain_scores_gemma":[0.99740463,0.0016194931,0.00027247128,0.00011780866,0.0002569595,0.00032863865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007765993,0.00017538901,0.00063026865,0.00032755494,0.00047146482,0.0006153982,0.00035035575,0.0018423593,0.0032283529],"category_scores_gemma":[0.006193063,0.00011543884,0.00041439294,0.00045439065,0.00036935345,0.00054218236,0.00027212995,0.0020308846,0.0012072995],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036029073,0.00068907504,0.17680475,0.00046791794,0.00013292019,0.02654739,0.00035104572,0.0012518455,0.009010543,0.002769303,0.22713825,0.5512341],"study_design_scores_gemma":[0.0011180443,0.0046273726,0.34434813,0.0007159339,0.00047906142,0.15009125,0.00056382286,0.0061938185,0.006232757,0.017823776,0.46768007,0.00012601927],"about_ca_topic_score_codex":0.000761865,"about_ca_topic_score_gemma":0.002364722,"teacher_disagreement_score":0.0032283529,"about_ca_system_score_codex":0.0010126951,"about_ca_system_score_gemma":0.00055845117,"threshold_uncertainty_score":0.010799944},"labels":[],"label_agreement":null},{"id":"W1933195564","doi":"10.3109/10428194.2015.1055480","title":"Impact of time from diagnosis to initiation of curative chemotherapy on survival of patients with diffuse large B-cell lymphoma","year":2015,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada; BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Diffuse large B-cell lymphoma; Internal medicine; Chemotherapy; Lymphoma; Gastroenterology; Multivariate analysis; CHOP; Oncology; Surgery","score_opus":0.011959820987386145,"score_gpt":0.2533390327014776,"score_spread":0.24137921171409146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1933195564","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976029,0.0014712957,0.00003761308,0.0001719052,0.000014219029,0.0000024496862,0.0001337194,0.000004496065,0.0005612931],"genre_scores_gemma":[0.9994469,0.00020377379,0.000022169854,0.00004216149,0.000009324609,0.0000016596846,0.00018083736,0.0000016281937,0.000091546346],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996264,0.00010954858,0.00003366833,0.00006156663,0.00006453321,0.00010416596],"domain_scores_gemma":[0.9977246,0.0006757927,0.00088274915,0.000082646686,0.00016567268,0.0004684893],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005984551,0.00012508976,0.0002517704,0.00032144206,0.00023376133,0.0005799245,0.00024125716,0.00036013397,0.00089767284],"category_scores_gemma":[0.0036615126,0.00011239122,0.00034403946,0.00042572813,0.00024416437,0.00033217584,0.0003123432,0.00070808653,0.00014542927],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010225308,0.000050049905,0.99088913,0.000015379868,0.00006364251,0.000119540775,0.000040505565,0.00021772433,0.00029288486,0.00001548027,0.00018283555,0.0070902],"study_design_scores_gemma":[0.000019083993,0.00020290188,0.9988978,0.000013004054,0.000048043315,0.000198996,0.000086954395,0.00024112756,0.00004693729,0.000027260383,0.00021391301,0.0000039975644],"about_ca_topic_score_codex":0.015053406,"about_ca_topic_score_gemma":0.024117237,"teacher_disagreement_score":0.015053406,"about_ca_system_score_codex":0.00067647884,"about_ca_system_score_gemma":0.0007012024,"threshold_uncertainty_score":0.029931545},"labels":[],"label_agreement":null},{"id":"W1946080547","doi":"10.3109/10428194.2015.1080927","title":"Enhancing monoclonal antibody activity in chronic lymphocytic leukemia","year":2015,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research Institute in Oncology and Hematology; University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Chronic lymphocytic leukemia; Monoclonal antibody; Medicine; Leukemia; Antibody; Monoclonal; Cancer research; Immunology","score_opus":0.023307284470340316,"score_gpt":0.30278116081969697,"score_spread":0.27947387634935666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1946080547","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08565981,0.025864167,0.0014005924,0.80644286,0.0111727705,0.00014394984,0.00013325785,0.0001727922,0.06900986],"genre_scores_gemma":[0.5394806,0.01637171,0.0017196442,0.35486674,0.065465026,0.00009805664,0.0001599558,0.000041374966,0.021796767],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99917525,0.00031571032,0.00011206548,0.000058268244,0.00016256397,0.00017612579],"domain_scores_gemma":[0.9973646,0.0018305333,0.00023506551,0.00010030169,0.00016042156,0.00030918588],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016990459,0.00042609108,0.00083556265,0.00058554666,0.0011446347,0.0015188161,0.000954082,0.013891949,0.0025091518],"category_scores_gemma":[0.0053667617,0.00032414956,0.0006140806,0.0004490611,0.0015373513,0.0011446686,0.00080591574,0.0061420086,0.0011395969],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013917357,0.0006587889,0.029530138,0.00057099183,0.000118805045,0.3555858,0.0004360695,0.00086665485,0.008130452,0.03413894,0.4621448,0.10642687],"study_design_scores_gemma":[0.0020710288,0.0018645623,0.022434475,0.00070897536,0.00032920646,0.31987184,0.0006371277,0.004212075,0.00927818,0.029737258,0.60877866,0.00007656137],"about_ca_topic_score_codex":0.0013757193,"about_ca_topic_score_gemma":0.00257242,"teacher_disagreement_score":0.013891949,"about_ca_system_score_codex":0.0030164763,"about_ca_system_score_gemma":0.0012757132,"threshold_uncertainty_score":0.02188611},"labels":[],"label_agreement":null},{"id":"W1962960638","doi":"10.3109/10428194.2015.1091927","title":"A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191","year":2015,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Microtubule and mitosis dynamics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Princess Margaret Cancer Centre; University of Alberta; Juravinski Cancer Centre; Saint John Regional Hospital; Dalhousie University; University of New Brunswick; Queen's University","funders":"","keywords":"Multiple myeloma; Medicine; Refractory (planetary science); Internal medicine; Oncology; Clinical trial; Kinase; Malignancy; Aurora A kinase; Aurora kinase; Cancer; Biology; Cell cycle","score_opus":0.03363137153877019,"score_gpt":0.31310350323689096,"score_spread":0.2794721316981208,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1962960638","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.32382253,0.051413577,0.002709871,0.5483527,0.01962531,0.0025204718,0.0051838146,0.00055971637,0.045811925],"genre_scores_gemma":[0.59720016,0.018588912,0.004448188,0.31585523,0.013171035,0.0017589903,0.003548057,0.0001296799,0.045299795],"study_design_codex":"not_applicable","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99954164,0.00019106962,0.000034558514,0.00006285959,0.00008957234,0.00008031219],"domain_scores_gemma":[0.9993303,0.00028616996,0.000061322884,0.00003326987,0.00006135757,0.00022761822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015110068,0.0006022689,0.0013310448,0.00021155732,0.00061224116,0.00094155053,0.0008039855,0.0054483004,0.0030033346],"category_scores_gemma":[0.0015120605,0.00021760998,0.0007628654,0.0003391863,0.00054529327,0.00071955257,0.00029213194,0.005442405,0.0012678324],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.065270364,0.0048646526,0.010801647,0.0008375316,0.0007164986,0.010435173,0.00024163387,0.0018192186,0.015649332,0.0028390493,0.59894377,0.28758112],"study_design_scores_gemma":[0.34104973,0.07789452,0.052002504,0.00071759854,0.0014640022,0.014071089,0.00047938648,0.01083008,0.012756183,0.013149844,0.4753129,0.00027209969],"about_ca_topic_score_codex":0.0010608485,"about_ca_topic_score_gemma":0.0038979352,"teacher_disagreement_score":0.0054483004,"about_ca_system_score_codex":0.0012024376,"about_ca_system_score_gemma":0.00078763894,"threshold_uncertainty_score":0.010047138},"labels":[],"label_agreement":null},{"id":"W1963756566","doi":"10.1080/10428190500467917","title":"Sequential response-adapted induction and consolidation regimens idarubicin/cytarabine and mitoxantrone/etoposide in adult acute myelogenous leukemia: 10 year follow-up of a study by the Canadian Leukemia Studies Group","year":2006,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Royal University Hospital; Toronto General Hospital; Royal Victoria Hospital; McGill University; University of Saskatchewan; University of Alberta; Queen Elizabeth II Health Sciences Centre; Health Sciences Centre; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Idarubicin; Mitoxantrone; Etoposide; Cytarabine; Medicine; Internal medicine; Induction chemotherapy; Leukemia; Gastroenterology; Myeloid leukemia; Chemotherapy; Surgery","score_opus":0.015760184884850897,"score_gpt":0.2675952253422972,"score_spread":0.2518350404574463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1963756566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974964,0.0016326254,0.00006706831,0.000046613604,0.000013216674,0.00018275443,0.00019571271,0.000008899884,0.00035659067],"genre_scores_gemma":[0.9976641,0.00057731627,0.00014320234,0.00017107332,0.000032780703,0.000117419084,0.0009795714,0.0000025721465,0.00031180994],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992861,0.00020359902,0.000052231535,0.0000981503,0.0001877641,0.00017220051],"domain_scores_gemma":[0.9989686,0.00012527338,0.00039222618,0.00010483855,0.00010532098,0.00030380196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014160717,0.0004457813,0.0011197238,0.00025258498,0.0004085532,0.00047020146,0.0005802366,0.0005808641,0.0006743335],"category_scores_gemma":[0.0013801765,0.0002134113,0.0005782072,0.00051142677,0.0004658734,0.0003438765,0.0002611938,0.00080020784,0.00015741435],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34866065,0.026783986,0.3576453,0.00063796935,0.0038435676,0.0006397066,0.00066200603,0.0022132467,0.015643785,0.000117038435,0.0024680567,0.2406846],"study_design_scores_gemma":[0.059300028,0.23594825,0.69273037,0.00006853358,0.0014902428,0.0009388676,0.00014476328,0.00071371277,0.0033822705,0.00008128054,0.00516759,0.000034154084],"about_ca_topic_score_codex":0.010259006,"about_ca_topic_score_gemma":0.0137505885,"teacher_disagreement_score":0.010259006,"about_ca_system_score_codex":0.0012865799,"about_ca_system_score_gemma":0.0015975374,"threshold_uncertainty_score":0.020398557},"labels":[],"label_agreement":null},{"id":"W1965448482","doi":"10.1080/10428190802668873","title":"HLA risk markers for chronic myelogenous leukemia in Eastern Canada","year":2009,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University","funders":"","keywords":"Human leukocyte antigen; Chronic myelogenous leukemia; Immunology; Odds ratio; Antigen; Medicine; Leukemia; Population; Oncology; Internal medicine","score_opus":0.008109764680904099,"score_gpt":0.22981611971363863,"score_spread":0.22170635503273453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965448482","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99243915,0.0015683965,0.00014475682,0.00046175395,0.000013281333,0.000020122548,0.0008989908,0.000007303378,0.004446257],"genre_scores_gemma":[0.99754083,0.0007001304,0.0001706686,0.00006864063,0.000006168861,0.000006538404,0.0002685747,0.0000021260641,0.0012362227],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997553,0.000028664941,0.000017317954,0.000032293472,0.00008533851,0.00008109509],"domain_scores_gemma":[0.99951255,0.00005060415,0.000096089985,0.000017635728,0.00017756285,0.0001455868],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028284217,0.00014721291,0.00016847628,0.00081692805,0.0018304732,0.0005706449,0.0003164689,0.00018349093,0.0029657292],"category_scores_gemma":[0.0011195516,0.00012801515,0.00019976073,0.00147753,0.00037471327,0.00013429843,0.000474609,0.00032046108,0.00012119389],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006188109,0.000013119473,0.9930702,0.000011078196,0.000021952532,0.00014786528,0.00018561838,0.00009969624,0.00022545022,0.00021013731,0.0005863635,0.005366594],"study_design_scores_gemma":[0.0000094302295,0.000016682,0.99701416,0.000026030997,0.000029071096,0.00027449685,0.00061054184,0.0002198068,0.000095118055,0.00007812916,0.0016205512,0.0000059603017],"about_ca_topic_score_codex":0.9613422,"about_ca_topic_score_gemma":0.97033465,"teacher_disagreement_score":0.038657784,"about_ca_system_score_codex":0.0051016477,"about_ca_system_score_gemma":0.010279202,"threshold_uncertainty_score":0.07777083},"labels":[],"label_agreement":null},{"id":"W1967060888","doi":"10.3109/10428194.2011.559670","title":"Does pretreatment fluorescence<i>in situ</i>hybridization for<i>BCR–ABL</i>predict imatinib-associated hematologic toxicity in chronic myeloid leukemia?","year":2011,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Fluorescence in situ hybridization; Imatinib; Myeloid leukemia; Medicine; Chronic myelogenous leukemia; Philadelphia chromosome; Internal medicine; Gastroenterology; breakpoint cluster region; Leukemia; Hematology; Haematopoiesis; Myeloid; Immunology; Cancer research; Stem cell; Biology; Chromosomal translocation; Chromosome; Receptor","score_opus":0.015208323174291393,"score_gpt":0.24080128363944112,"score_spread":0.22559296046514973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1967060888","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9991973,0.0001410566,0.00016657963,0.000043943397,0.0000020595494,0.000007090921,0.000028727683,0.0000036946626,0.00040950478],"genre_scores_gemma":[0.99974364,0.00004117595,0.00009779525,0.000020901094,0.0000032633723,0.0000041134717,0.000044037,0.0000012752826,0.000043851596],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99975497,0.00006837464,0.000039759114,0.000044609496,0.000038062608,0.000054206223],"domain_scores_gemma":[0.99912614,0.00028205934,0.000363695,0.00004098856,0.00007277785,0.00011432531],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006202222,0.00019243528,0.00020561022,0.00046037344,0.00020195066,0.00033858235,0.0001673796,0.0003640571,0.0016603012],"category_scores_gemma":[0.0018697779,0.00014413199,0.00013271479,0.00027375403,0.00046689014,0.000341379,0.00018765673,0.00021894903,0.0003099538],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001264364,0.000015580272,0.99495524,0.0000062528056,0.0000066339976,0.000083376624,0.00002659936,0.000057130448,0.0024688663,0.00001099157,0.000045703528,0.00219729],"study_design_scores_gemma":[0.00001862825,0.00035145678,0.99403715,0.000009011573,0.000029312809,0.0016665397,0.00020022118,0.00074558175,0.0026101593,0.00005342708,0.00027477904,0.0000036499498],"about_ca_topic_score_codex":0.000983046,"about_ca_topic_score_gemma":0.001848441,"teacher_disagreement_score":0.0016603012,"about_ca_system_score_codex":0.00023893254,"about_ca_system_score_gemma":0.0001825216,"threshold_uncertainty_score":0.005554199},"labels":[],"label_agreement":null},{"id":"W1968585362","doi":"10.1080/10428190210181","title":"Malignant Evolution of Schnitzler's Syndrome--Chronic Urticaria and IgM Monoclonal Gammopathy: Report of a New Case and Review of the Literature","year":2002,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Inflammasome and immune disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Gammopathy; Dermatology; Waldenstrom macroglobulinemia; Bone marrow; Lymphoproliferative disorders; Macroglobulinemia; Bone pain; Chronic lymphocytic leukemia; Pathology; Monoclonal; Lymphoma; Multiple myeloma; Immunology; Leukemia; Monoclonal antibody; Antibody","score_opus":0.00895995537372538,"score_gpt":0.2407459136849422,"score_spread":0.23178595831121682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1968585362","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012608175,0.9810806,0.00082536065,0.0007144104,0.0005574395,0.000041579366,0.00008204445,0.00006206976,0.004028305],"genre_scores_gemma":[0.042835657,0.95046854,0.0016338762,0.0011852658,0.0009445046,0.00004206767,0.00018069897,0.000009422028,0.002700032],"study_design_codex":"design_other","study_design_gemma":"case_report","domain_scores_codex":[0.99973637,0.000040029143,0.000081569946,0.00004899971,0.000062589344,0.000030486797],"domain_scores_gemma":[0.999711,0.000110453875,0.000071389164,0.00001337023,0.00005000363,0.000043773663],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002618558,0.0009019477,0.0012920899,0.0037283022,0.00046103157,0.00081815384,0.00093771616,0.0013886846,0.0020222755],"category_scores_gemma":[0.00065511727,0.00027958013,0.00039597417,0.0034850005,0.00047661285,0.0014223651,0.00039749607,0.0005548698,0.0015548976],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015209286,0.0002418857,0.0077168485,0.017849406,0.0002542293,0.29963022,0.0006990439,0.00042758216,0.004853815,0.0009023157,0.03109271,0.6361798],"study_design_scores_gemma":[0.000040757444,0.000202336,0.015280831,0.0027103296,0.00039440702,0.76229525,0.0006611566,0.000256972,0.0010205029,0.00076078007,0.2163087,0.00006793248],"about_ca_topic_score_codex":0.0011320922,"about_ca_topic_score_gemma":0.0023186388,"teacher_disagreement_score":0.0037283022,"about_ca_system_score_codex":0.0004938377,"about_ca_system_score_gemma":0.00074022904,"threshold_uncertainty_score":0.006765127},"labels":[],"label_agreement":null},{"id":"W1968622004","doi":"10.3109/10428194.2010.496506","title":"Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond?","year":2010,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Biochemical and Molecular Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":144,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer; Université de Montréal","funders":"National Cancer Institute; U.S. Public Health Service","keywords":"Ribavirin; IMP dehydrogenase; Cancer; Medicine; Leukemia; Myeloid leukemia; EIF4E; Cancer research; Immunology; Biology; Virus; Hepatitis C virus; Internal medicine; Translation (biology); Transplantation; Mycophenolic acid; Gene; Genetics","score_opus":0.0170753322536928,"score_gpt":0.3112245452087337,"score_spread":0.29414921295504093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1968622004","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010747289,0.99744034,0.00011815865,0.00068265415,0.0002966573,0.00000343126,0.00000824798,0.0000068712857,0.0013360953],"genre_scores_gemma":[0.00082514755,0.9964611,0.0002057974,0.000698534,0.0002717917,0.0000069655753,0.000016031452,0.0000025212635,0.0015121013],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998599,0.00003536455,0.000015407133,0.000025879279,0.000049038073,0.00001449571],"domain_scores_gemma":[0.99983907,0.000059601844,0.000018060759,0.000007738953,0.000049596634,0.000025895157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004809613,0.000756674,0.0012623954,0.0013286239,0.0003075369,0.0010374265,0.0007311256,0.0014837529,0.0030319388],"category_scores_gemma":[0.0005116128,0.00022768503,0.00028963297,0.001929291,0.00069072645,0.0019103996,0.0005478055,0.0021045865,0.003752794],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012418388,0.00009688695,0.00013737069,0.005936882,0.000047335525,0.00030968184,0.00008260794,0.00031389188,0.0032710917,0.008331875,0.04559873,0.9357494],"study_design_scores_gemma":[0.00002139027,0.00007349446,0.00032586063,0.00091643323,0.000020731684,0.0009899975,0.000036093377,0.00006150433,0.00038145625,0.0024393792,0.99472356,0.000010164355],"about_ca_topic_score_codex":0.0010316097,"about_ca_topic_score_gemma":0.0019837683,"teacher_disagreement_score":0.0030319388,"about_ca_system_score_codex":0.00087571505,"about_ca_system_score_gemma":0.00069855084,"threshold_uncertainty_score":0.010142863},"labels":[],"label_agreement":null},{"id":"W1969392166","doi":"10.1080/10428190290017114","title":"ALK-positive Anaplastic Large T-cell Lymphoma Preceded by Epstein-Barr Virus Infection Complicated by Development of an Aorto-esophageal Fistula","year":2002,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Lymphoma; Epstein–Barr virus; Fistula; Anaplastic large-cell lymphoma; Anaplastic lymphoma kinase; Virus; Chemotherapy; Pathology; Immunology; Internal medicine; Radiology; Lung cancer","score_opus":0.009485274140353299,"score_gpt":0.23115687166377036,"score_spread":0.22167159752341706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969392166","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98913705,0.0024322476,0.0018332256,0.00068193837,0.0001187476,0.000058099133,0.000060034075,0.000090882975,0.005587864],"genre_scores_gemma":[0.99797064,0.0006616828,0.0005080507,0.00018599433,0.00022466609,0.000012182408,0.00003064907,0.0000065806967,0.0003995957],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9996568,0.000063152016,0.00003885066,0.0000709736,0.000040692586,0.00012957113],"domain_scores_gemma":[0.99830735,0.0006738442,0.00041589944,0.00013434152,0.000057606914,0.0004109345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028976137,0.0011984383,0.00079854194,0.0007926267,0.0015316826,0.00094428076,0.00040285374,0.0025778445,0.0012060117],"category_scores_gemma":[0.002925548,0.0008297896,0.00053412333,0.0005451511,0.0010478267,0.0011824156,0.000729617,0.0027168945,0.0005162051],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000078996,0.00004618275,0.014885146,0.000023395243,0.000007416003,0.9824222,0.00013476687,0.00005529793,0.0010814988,0.00012053817,0.00009071718,0.0010538483],"study_design_scores_gemma":[0.00002373152,0.00014477412,0.007956129,0.000009258321,0.000015892178,0.9906929,0.000078871395,0.00014154227,0.00048996514,0.00012292246,0.00031687986,0.000007155409],"about_ca_topic_score_codex":0.00072978914,"about_ca_topic_score_gemma":0.0010522538,"teacher_disagreement_score":0.0025778445,"about_ca_system_score_codex":0.00040788038,"about_ca_system_score_gemma":0.0005635786,"threshold_uncertainty_score":0.004034519},"labels":[],"label_agreement":null},{"id":"W1969461242","doi":"10.1080/10428190801993470","title":"Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: A phase II trial in the North Central Cancer Treatment Group","year":2008,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Cancer Agency","funders":"National Cancer Institute","keywords":"Medicine; Rituximab; DHAP; Chemotherapy; Oncology; Internal medicine; Lymphoma; Hodgkin lymphoma; Salvage therapy; Biology","score_opus":0.018076305265650464,"score_gpt":0.27221272113167416,"score_spread":0.2541364158660237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969461242","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926156,0.0049514966,0.0002012844,0.00035675857,0.000052164083,0.00063121284,0.00012771362,0.000041999727,0.0010218532],"genre_scores_gemma":[0.9871022,0.0050790827,0.0021741537,0.00088387955,0.00015807533,0.0016481734,0.00075813336,0.000020878055,0.0021754168],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9994978,0.0003724215,0.000013104405,0.000048066304,0.000031735428,0.00003693394],"domain_scores_gemma":[0.9994862,0.00011724668,0.00010384836,0.000050146715,0.000038225,0.00020427875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014274116,0.0005891518,0.0015281186,0.00026277392,0.00028617933,0.0004830732,0.00076662365,0.0006600837,0.0019664762],"category_scores_gemma":[0.00070601294,0.00034637793,0.00050248107,0.00040882494,0.00070198043,0.00042582775,0.0003227342,0.0014525128,0.00046151082],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5731759,0.022197818,0.017069627,0.0012839801,0.0016978711,0.0006489629,0.0005639595,0.003129392,0.027178908,0.00027936744,0.005449627,0.34732455],"study_design_scores_gemma":[0.6271707,0.3186868,0.040418588,0.00014849637,0.0007968068,0.00086721475,0.00016639114,0.0015229727,0.00247876,0.00023110514,0.007484565,0.00002754225],"about_ca_topic_score_codex":0.0017163246,"about_ca_topic_score_gemma":0.008873716,"teacher_disagreement_score":0.0019664762,"about_ca_system_score_codex":0.00083771156,"about_ca_system_score_gemma":0.0014043053,"threshold_uncertainty_score":0.007548988},"labels":[],"label_agreement":null},{"id":"W1969894871","doi":"10.1080/10428190310001615666","title":"Subdural Hematomas during CML Therapy with Imatinib Mesylate","year":2004,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Imatinib mesylate; Mesylate; Medicine; Imatinib; Subdural Hematomas; Oncology; Internal medicine; Myeloid leukemia; Surgery; Hematoma; Chemistry","score_opus":0.009542626261534072,"score_gpt":0.23355689386411407,"score_spread":0.22401426760258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969894871","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99773335,0.0012017268,0.00016544787,0.000040805226,0.000008700959,0.00002665466,0.00006311358,0.0000058044416,0.0007543574],"genre_scores_gemma":[0.9993975,0.00028889935,0.00007085058,0.000047531095,0.000013950668,0.000010799391,0.00008659,9.623914e-7,0.00008276576],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.9996437,0.0001132833,0.00004532769,0.000041311025,0.000089557565,0.000066866094],"domain_scores_gemma":[0.9989183,0.00027924287,0.0005338561,0.000071642484,0.00005370863,0.00014334245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028434332,0.0002367007,0.00035991723,0.00027703342,0.000513776,0.00036865042,0.0001427432,0.00023880658,0.0009285069],"category_scores_gemma":[0.0021984952,0.0001802353,0.00019904587,0.00038273202,0.0003253406,0.00032794612,0.00041403185,0.00043904033,0.00012718159],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024367922,0.00014437873,0.90881914,0.00016456946,0.00015317618,0.031322226,0.0016788061,0.0002862499,0.004931468,0.00024079318,0.0008763229,0.048945975],"study_design_scores_gemma":[0.00030378398,0.002174404,0.9367265,0.00006813744,0.0001483326,0.054000095,0.0008447095,0.0004956229,0.002353688,0.000235389,0.0026264652,0.000022682767],"about_ca_topic_score_codex":0.00087162975,"about_ca_topic_score_gemma":0.0012639565,"teacher_disagreement_score":0.0009285069,"about_ca_system_score_codex":0.00035951036,"about_ca_system_score_gemma":0.0002362225,"threshold_uncertainty_score":0.0031062365},"labels":[],"label_agreement":null},{"id":"W1970810546","doi":"10.3109/10428194.2011.594925","title":"Durable event-free survival following autologous stem cell transplant for relapsed or refractory follicular lymphoma: positive impact of recent rituximab exposure and low-risk Follicular Lymphoma International Prognostic Index score","year":2011,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Cancer Foundation; University of Calgary","funders":"","keywords":"Medicine; Rituximab; Internal medicine; Follicular lymphoma; International Prognostic Index; Oncology; Autologous stem-cell transplantation; Refractory (planetary science); Confidence interval; Lymphoma; Chemotherapy; Surgery","score_opus":0.015737094584909357,"score_gpt":0.24472084131699387,"score_spread":0.22898374673208452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970810546","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99887425,0.0008508878,0.00006708522,0.00003641108,0.0000026223252,0.000002396844,0.000041864954,0.0000051597776,0.00011928809],"genre_scores_gemma":[0.9996325,0.00011837848,0.0000274508,0.000023611972,0.000007677977,0.0000014966768,0.0001338623,0.0000010293761,0.000053975353],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997031,0.00008555896,0.000027032924,0.000046157755,0.000066399945,0.00007168578],"domain_scores_gemma":[0.9983658,0.00047471255,0.0007293003,0.0000854935,0.00007688162,0.0002677379],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075279665,0.00013226969,0.00045253904,0.0003607551,0.00018229151,0.00047187734,0.0003189207,0.00030623053,0.0005177919],"category_scores_gemma":[0.0022949174,0.00009713615,0.0002906972,0.00034545027,0.00030723124,0.00031102003,0.0002517322,0.00044184455,0.000117289856],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020414083,0.000119127675,0.97112983,0.000029445646,0.0001417723,0.00055551645,0.00009163133,0.00042841752,0.0012755358,0.00001716105,0.00018877725,0.02398134],"study_design_scores_gemma":[0.00003656755,0.0008287258,0.9968887,0.0000075523685,0.000074001466,0.000962072,0.000041812305,0.00058575417,0.00034330605,0.000039882787,0.00018724578,0.000004330281],"about_ca_topic_score_codex":0.0019192976,"about_ca_topic_score_gemma":0.003721056,"teacher_disagreement_score":0.0019192976,"about_ca_system_score_codex":0.0006173133,"about_ca_system_score_gemma":0.00030005912,"threshold_uncertainty_score":0.0044789314},"labels":[],"label_agreement":null},{"id":"W1971210973","doi":"10.1080/1042819021000040161","title":"It is ALL in the Heart: A Patient with Acute Lymphoblastic Leukemia and Cardiac Infiltration at Time of Diagnosis","year":2002,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Cardiac tumors and thrombi","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital","funders":"","keywords":"Medicine; Lymphoblastic Leukemia; Infiltration (HVAC); Lesion; Chemotherapy; Radiology; Cardiology; Leukemia; Internal medicine; Surgery","score_opus":0.010487275243052164,"score_gpt":0.22333701183906607,"score_spread":0.21284973659601392,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971210973","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9845979,0.0022131077,0.0012517755,0.003263654,0.00023232275,0.00009241609,0.00012574044,0.00008519504,0.008137974],"genre_scores_gemma":[0.99662626,0.0009728719,0.00054115773,0.0006781935,0.00046862382,0.000014176798,0.000058007412,0.000014538535,0.00062620646],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99952674,0.000058332455,0.00004471583,0.000100989186,0.00006200339,0.00020733853],"domain_scores_gemma":[0.9983315,0.00047420777,0.00035746468,0.000085355816,0.000084567924,0.0006668182],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030814027,0.001417462,0.0011485629,0.0015983575,0.0027493394,0.0017411917,0.0007339746,0.0035182876,0.0017523225],"category_scores_gemma":[0.003060392,0.0008990891,0.00060961425,0.0012251181,0.0014414706,0.0020419308,0.001084026,0.0034091691,0.0005550634],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005076114,0.000030306439,0.017410573,0.000020094398,0.000004698833,0.9803663,0.00030598877,0.00003767071,0.0006687104,0.00016460387,0.00017142133,0.000768827],"study_design_scores_gemma":[0.000011299094,0.00008474257,0.008452062,0.000012761398,0.00001620176,0.99011874,0.0002931641,0.00009802506,0.00028642133,0.00014737606,0.0004716324,0.0000074735462],"about_ca_topic_score_codex":0.0016822834,"about_ca_topic_score_gemma":0.0022846588,"teacher_disagreement_score":0.0035182876,"about_ca_system_score_codex":0.00073646364,"about_ca_system_score_gemma":0.00064860226,"threshold_uncertainty_score":0.005862057},"labels":[],"label_agreement":null},{"id":"W1971583640","doi":"10.1080/1042819021000046994","title":"Evaluation for the Development of 11q23 Rearrangements in Lymphoma Patients Treated with a High Dose VP-16 and Cyclophosphamide Salvage Regimen","year":2003,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre","funders":"McGill University","keywords":"Cyclophosphamide; Medicine; Regimen; Internal medicine; Salvage therapy; Lymphoma; Chemotherapy; Oncology; Cytogenetics; Chromosomal translocation; Transplantation; Gastroenterology; Surgery; Biology; Chromosome","score_opus":0.017610928255528475,"score_gpt":0.26809840145091446,"score_spread":0.250487473195386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971583640","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99941826,0.0002219576,0.000048279315,0.00001253156,0.0000015834299,0.0000057109337,0.00001935224,0.0000033415054,0.00026895906],"genre_scores_gemma":[0.99952734,0.00013714131,0.00010330716,0.000018388508,0.0000063985685,0.000007888273,0.0000637286,0.0000013089397,0.00013456651],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997887,0.00006718205,0.000023888158,0.000031925552,0.00004867197,0.00003970135],"domain_scores_gemma":[0.99956006,0.00012836329,0.00017131686,0.000021095388,0.00003705726,0.00008211702],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029944043,0.00015596584,0.00022303475,0.0009769817,0.00028817065,0.00041597034,0.00020916449,0.0003513257,0.0010953961],"category_scores_gemma":[0.0011481238,0.00018975232,0.0002033339,0.00043906062,0.00027590973,0.0002121429,0.00015970012,0.00023463149,0.00019318517],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003918978,0.00005961083,0.97804433,0.000015961352,0.000022594711,0.003126011,0.00020473829,0.000099066834,0.012629293,0.000025188296,0.00007268546,0.0053086365],"study_design_scores_gemma":[0.000025417417,0.0009155857,0.9853779,0.000009504191,0.00004199858,0.010039343,0.00020104733,0.00026897257,0.0025199614,0.000022758531,0.00057123834,0.000006152623],"about_ca_topic_score_codex":0.00083293783,"about_ca_topic_score_gemma":0.0010920303,"teacher_disagreement_score":0.0010953961,"about_ca_system_score_codex":0.00031885685,"about_ca_system_score_gemma":0.00014446552,"threshold_uncertainty_score":0.003664434},"labels":[],"label_agreement":null},{"id":"W1975979823","doi":"10.3109/10428194.2013.783211","title":"High dose salvage therapy with dose intensive cyclophosphamide, etoposide and cisplatin may increase transplant rates for relapsed/refractory aggressive non-Hodgkin lymphoma","year":2013,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Rituximab; Etoposide; Internal medicine; Salvage therapy; International Prognostic Index; Regimen; Gastroenterology; Cyclophosphamide; Refractory (planetary science); Surgery; Chemotherapy; Induction chemotherapy; Progression-free survival; Oncology; Lymphoma","score_opus":0.008772769486172028,"score_gpt":0.24535839739229398,"score_spread":0.23658562790612195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975979823","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985998,0.00082155573,0.00012920768,0.00005431498,0.000003647222,0.0000090837675,0.000027018728,0.000009971307,0.00034530266],"genre_scores_gemma":[0.99934036,0.0003012208,0.000114656454,0.000049905124,0.000012485374,0.000005550632,0.0000797461,0.0000028396069,0.000093184724],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997446,0.00010424299,0.000030428926,0.000028066172,0.000058539907,0.000034185385],"domain_scores_gemma":[0.99891126,0.0003871583,0.00045494424,0.000043043787,0.000026058027,0.00017741982],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005506956,0.00010500496,0.00029794086,0.00030217724,0.00016473603,0.00043675012,0.00023621981,0.00025429504,0.00095382385],"category_scores_gemma":[0.0017006552,0.0000801976,0.00025220212,0.0002793265,0.00018932835,0.00025382172,0.00021782421,0.00037959637,0.00018665011],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015698713,0.0002671493,0.9380195,0.00006579805,0.00009708782,0.002101685,0.0001106762,0.00054096885,0.004500797,0.00006541015,0.0004885366,0.05217244],"study_design_scores_gemma":[0.00011093828,0.002217268,0.984602,0.000018999295,0.00010313117,0.008470053,0.000115490635,0.0013751675,0.0019801063,0.000111273,0.0008899968,0.000005534032],"about_ca_topic_score_codex":0.0002847641,"about_ca_topic_score_gemma":0.0007589264,"teacher_disagreement_score":0.00095382385,"about_ca_system_score_codex":0.00039029363,"about_ca_system_score_gemma":0.00019350964,"threshold_uncertainty_score":0.003190875},"labels":[],"label_agreement":null},{"id":"W1977454299","doi":"10.3109/10428190009059264","title":"Genetic Susceptibility to Childhood Acute Lymphoblastic Leukemia","year":2000,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Glutathione Transferases and Polymorphisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":105,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; Université de Montréal","funders":"Fondation Charles-Bruneau","keywords":"Carcinogen; Gene; Biology; Genotype; Xenobiotic; Genetics; Allele; Disease; Genetic predisposition; Population; Cancer; Leukemia; CYP2D6; Immunology; Enzyme; Cancer research; Medicine; Internal medicine; Environmental health; Biochemistry","score_opus":0.009501121922564146,"score_gpt":0.2501183339075237,"score_spread":0.24061721198495956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1977454299","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949427,0.0011384798,0.00021995447,0.0001812377,0.000010915655,0.000019498475,0.00070913386,0.000019481318,0.0027585484],"genre_scores_gemma":[0.99803466,0.00064822094,0.00018475705,0.000029688712,0.000016758837,0.0000076059187,0.00042288727,0.000002866052,0.00065256614],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996308,0.00008165582,0.000017617458,0.00007756207,0.00011125681,0.000081049424],"domain_scores_gemma":[0.9993973,0.00011382667,0.00021907316,0.000036206187,0.00009206157,0.00014150537],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026943805,0.00030677055,0.0002833423,0.00096525595,0.0005050275,0.0004059666,0.00029058248,0.00027891426,0.0038541292],"category_scores_gemma":[0.0013491452,0.00012443509,0.00022684992,0.0014070261,0.00037077806,0.00010196132,0.000248818,0.00030502336,0.00027534657],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016785358,0.000035046654,0.98982275,0.00003803299,0.00008240439,0.00070716295,0.00016806036,0.00012332646,0.0020974106,0.00023165738,0.00030382158,0.006222518],"study_design_scores_gemma":[0.000007791382,0.00007078142,0.99636734,0.000017149796,0.000058670677,0.0014770014,0.00011518909,0.00011328629,0.00021683128,0.00009928281,0.0014530359,0.0000037004456],"about_ca_topic_score_codex":0.04114351,"about_ca_topic_score_gemma":0.027639894,"teacher_disagreement_score":0.04114351,"about_ca_system_score_codex":0.00063974113,"about_ca_system_score_gemma":0.00091392384,"threshold_uncertainty_score":0.08180803},"labels":[],"label_agreement":null},{"id":"W1977911898","doi":"10.1080/10428190290026259","title":"The Role of Interleukin 13 in Classical Hodgkin Lymphoma","year":2002,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Amgen (Canada); University of Toronto; Ontario Institute for Cancer Research","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Autocrine signalling; Lymphoma; Cancer research; Cytokine; STAT protein; Biology; Interleukin 9; Immune system; Immunology; Interleukin; Reed–Sternberg cell; Cell culture; Signal transduction; STAT3; Cell biology; Hodgkin lymphoma","score_opus":0.01843052369170105,"score_gpt":0.2748539430926376,"score_spread":0.25642341940093655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1977911898","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0041698166,0.9931727,0.00028484478,0.0005206671,0.00033877257,0.0000049682644,0.0000126682635,0.000009687441,0.0014857429],"genre_scores_gemma":[0.0443069,0.95175654,0.0005397469,0.00070590485,0.0010874183,0.000020220434,0.000046018577,0.0000037233672,0.0015335291],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998938,0.00002774476,0.000017258306,0.000017140292,0.000028076116,0.000015954689],"domain_scores_gemma":[0.9998789,0.00006160168,0.000023002976,0.0000027498302,0.000020078904,0.000013670807],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000269313,0.00021726583,0.0003985406,0.000576072,0.0001459988,0.0005415342,0.00021731369,0.00041074224,0.00064149435],"category_scores_gemma":[0.0002928162,0.00009644448,0.00017930625,0.0005517461,0.0005429348,0.00039027317,0.00036869227,0.00067554985,0.00025826384],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007515665,0.00009535769,0.0036149716,0.009672164,0.00010203378,0.0054456224,0.00040446728,0.00068016065,0.027504299,0.012207747,0.013163372,0.9263583],"study_design_scores_gemma":[0.00012840773,0.0008616248,0.01468671,0.0036887748,0.00030584284,0.021135721,0.00051252905,0.0005318025,0.013775745,0.0123695135,0.93195015,0.00005325122],"about_ca_topic_score_codex":0.0005092252,"about_ca_topic_score_gemma":0.00069018453,"teacher_disagreement_score":0.00064149435,"about_ca_system_score_codex":0.00042753055,"about_ca_system_score_gemma":0.00047272485,"threshold_uncertainty_score":0.003101945},"labels":[],"label_agreement":null},{"id":"W1978479182","doi":"10.3109/10428194.2015.1014360","title":"Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma","year":2015,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Cutaneous lymphoproliferative disorders research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"Celgene","keywords":"Romidepsin; Medicine; Erythroderma; Lymphoma; Cutaneous T-cell lymphoma; Disease; Mycosis fungoides; Compartment (ship); Dermatology; Clinical trial; Oncology; Immunology; Internal medicine; Histone deacetylase; Biology","score_opus":0.02046494650976327,"score_gpt":0.2879299070320824,"score_spread":0.2674649605223191,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1978479182","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963522,0.0020343673,0.00022855496,0.000048061895,0.000006538172,0.000049838243,0.00013857933,0.000012588723,0.0011292936],"genre_scores_gemma":[0.99940276,0.00019701871,0.00007539024,0.000037847003,0.000007437075,0.000014323789,0.00012805675,0.0000017500978,0.00013546052],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99917346,0.00038873169,0.000095596515,0.00011824832,0.00012176596,0.000102152364],"domain_scores_gemma":[0.998546,0.00069976127,0.00038985562,0.00006444662,0.00012113256,0.00017880136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001128911,0.0001771445,0.0007101857,0.00035883597,0.00013878163,0.0005479074,0.00013680565,0.00021463177,0.0007201919],"category_scores_gemma":[0.0023759436,0.00008590565,0.00035663476,0.00042232184,0.00021479842,0.00045713873,0.00021438308,0.0005734669,0.00017506987],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06064995,0.0016449152,0.69078463,0.00045790322,0.0010430485,0.0018554688,0.0007383414,0.0029550728,0.05392811,0.00024265346,0.0010352029,0.1846647],"study_design_scores_gemma":[0.0013856789,0.04859278,0.92750114,0.000051201343,0.0007867032,0.0034903386,0.000454707,0.0024060905,0.0115685975,0.00025529382,0.0034672297,0.00004009583],"about_ca_topic_score_codex":0.00029269088,"about_ca_topic_score_gemma":0.00047843475,"teacher_disagreement_score":0.001128911,"about_ca_system_score_codex":0.000406416,"about_ca_system_score_gemma":0.00020332537,"threshold_uncertainty_score":0.0059702992},"labels":[],"label_agreement":null},{"id":"W1978835230","doi":"10.1080/10428190310001617295","title":"Clinico-Biological Features and Prognostic Significance of PML/RARα Isoforms in Adult Patients with Acute Promyelocytic Leukemia Treated with All Trans Retinoic Acid (ATRA) and Chemotherapy","year":2003,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Retinoids in leukemia and cellular processes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Acute promyelocytic leukemia; Gene isoform; Clinical significance; Interquartile range; Internal medicine; Exon; Retinoic acid; Medicine; Gastroenterology; Chemotherapy; Oncology; Immunology; Biology; Pathology; Gene; Genetics","score_opus":0.0051514193786167525,"score_gpt":0.21096986542169105,"score_spread":0.2058184460430743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1978835230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9993278,0.0003703549,0.00004722592,0.000024241872,0.0000019305412,0.0000037299626,0.000044941615,0.0000031502611,0.00017667607],"genre_scores_gemma":[0.9996662,0.000096632386,0.00006472809,0.000015468038,0.000014574539,0.000004854227,0.00008946499,8.287577e-7,0.000047263093],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995752,0.000117885014,0.00007252816,0.00007918737,0.00008652151,0.000068696114],"domain_scores_gemma":[0.9983449,0.00038633446,0.0008164529,0.00007739458,0.000100991056,0.00027391256],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000429007,0.00024612347,0.00037587748,0.00082129234,0.00037359685,0.00048683977,0.00020442758,0.00041283725,0.0005669689],"category_scores_gemma":[0.002179628,0.00024244703,0.0002047674,0.0007118813,0.0003978602,0.00037828664,0.000241433,0.0003174546,0.00019593813],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046233067,0.000025530062,0.99516344,0.000006046268,0.000016415048,0.0008801855,0.000072476,0.00006220034,0.0013003697,0.000008586599,0.000032647593,0.001969746],"study_design_scores_gemma":[0.00002309749,0.00030778127,0.99281657,0.000006042863,0.000022617955,0.0060138563,0.00011116662,0.00019765706,0.00031188692,0.000026531934,0.00015747777,0.0000052990285],"about_ca_topic_score_codex":0.0005044158,"about_ca_topic_score_gemma":0.0005943992,"teacher_disagreement_score":0.00082129234,"about_ca_system_score_codex":0.00023552644,"about_ca_system_score_gemma":0.00014242642,"threshold_uncertainty_score":0.0022687912},"labels":[],"label_agreement":null},{"id":"W1981484881","doi":"10.1080/10428190601078605","title":"HLA-DR protein status predicts survival in patients with diffuse large B-cell lymphoma treated on the MACOP-B chemotherapy regimen","year":2007,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"American Cancer Society","keywords":"Regimen; Medicine; Internal medicine; International Prognostic Index; Diffuse large B-cell lymphoma; Proportional hazards model; Lymphoma; Human leukocyte antigen; Chemotherapy; Chemotherapy regimen; Oncology; Rituximab; Gastroenterology; Antigen; Immunology","score_opus":0.006734132314767544,"score_gpt":0.2154206246546265,"score_spread":0.20868649233985895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1981484881","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99963427,0.00017909134,0.000030808827,0.000019135017,0.000001810977,0.0000015749129,0.000017822722,0.0000013094744,0.00011412695],"genre_scores_gemma":[0.99979216,0.000055626264,0.000030268004,0.000015365387,0.000004889133,0.0000018682438,0.000059180264,6.5771434e-7,0.000039872575],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99982184,0.00007311915,0.000019038085,0.000024740642,0.000024095885,0.00003713582],"domain_scores_gemma":[0.99932873,0.00021634978,0.00022160291,0.000032832675,0.000040514915,0.00016002687],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031162848,0.00016812258,0.00022380013,0.00034106427,0.0002046936,0.0003395147,0.00015513066,0.00027935446,0.0007047612],"category_scores_gemma":[0.00146596,0.00015016452,0.00015285447,0.00037372543,0.00026631964,0.00026152324,0.00019876461,0.00034979737,0.00013204185],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036138034,0.000032803993,0.9963565,0.0000036354556,0.000021407002,0.000095126576,0.00003031207,0.000083114144,0.0006934176,0.000008777192,0.000070279544,0.0022432078],"study_design_scores_gemma":[0.000031950683,0.00055928994,0.997526,0.000005474167,0.000040973762,0.0007941188,0.000111351466,0.00052202004,0.00022145371,0.000029514378,0.00015497587,0.0000029672888],"about_ca_topic_score_codex":0.0009568303,"about_ca_topic_score_gemma":0.0015796135,"teacher_disagreement_score":0.0009568303,"about_ca_system_score_codex":0.00016096306,"about_ca_system_score_gemma":0.00014044395,"threshold_uncertainty_score":0.0023576617},"labels":[],"label_agreement":null},{"id":"W1982692072","doi":"10.3109/10428194.2011.570394","title":"Mechanism of Action of Pentostatin and Cladribine in Hairy Cell Leukemia","year":2011,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Deoxyadenosine; Cladribine; Deoxycoformycin; Deoxycytidine kinase; Biochemistry; Chemistry; Pentostatin; Adenosine deaminase; Molecular biology; Adenosine; Biology; Deoxycytidine","score_opus":0.052419454122607866,"score_gpt":0.32326350376375945,"score_spread":0.2708440496411516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982692072","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96733207,0.014681038,0.0043471875,0.0004284348,0.0001676014,0.0003471093,0.00090364827,0.00018681122,0.011606079],"genre_scores_gemma":[0.99258655,0.0035600436,0.0011401258,0.00011250588,0.00001958954,0.000067814115,0.00027092014,0.000007370084,0.0022350494],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9999237,0.000020383415,0.0000069637117,0.000010104398,0.000015596792,0.000023232105],"domain_scores_gemma":[0.99996185,0.0000061737446,0.000010118622,0.000005325797,0.0000031393117,0.000013368764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010334111,0.00022018586,0.00020948265,0.00018910138,0.00012842558,0.00016898419,0.00022724413,0.00025929516,0.0011521374],"category_scores_gemma":[0.000062548344,0.00007723311,0.00023933747,0.00012685734,0.00013705503,0.00013225897,0.00018290053,0.0002526435,0.00031290445],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009535352,0.00014561233,0.0011756456,0.00022842828,0.000026626334,0.00079938566,0.000041879757,0.00065179,0.96594787,0.001270037,0.0006861026,0.028073097],"study_design_scores_gemma":[0.0005668963,0.00506348,0.02780228,0.000039898066,0.0000997629,0.005448387,0.00008942766,0.0032183703,0.9211572,0.0003445898,0.036149036,0.000020748252],"about_ca_topic_score_codex":0.0009164045,"about_ca_topic_score_gemma":0.0010239352,"teacher_disagreement_score":0.0011521374,"about_ca_system_score_codex":0.00040029423,"about_ca_system_score_gemma":0.00014576859,"threshold_uncertainty_score":0.0038542747},"labels":[],"label_agreement":null},{"id":"W1984455044","doi":"10.1080/10428190701760029","title":"Alemtuzumab in clinical practice: A British Columbia experience","year":2008,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Lions Gate Hospital; University of British Columbia; Royal Columbian Hospital; Interior Health; Vancouver General Hospital; Eagle Ridge Hospital","funders":"","keywords":"Alemtuzumab; Medicine; Neutropenia; Internal medicine; Adverse effect; Chronic lymphocytic leukemia; Clinical trial; Surgery; Oncology; Leukemia; Chemotherapy; Transplantation","score_opus":0.02706911312920365,"score_gpt":0.32807800209074184,"score_spread":0.3010088889615382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984455044","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.921142,0.037737023,0.00071243953,0.006918381,0.00011513867,0.00028181967,0.00046255835,0.00007829649,0.03255231],"genre_scores_gemma":[0.97554046,0.015356026,0.0009349966,0.0027470218,0.00007887323,0.00007140826,0.0004878141,0.00003073487,0.004752645],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986022,0.0005071885,0.00009846815,0.00014424838,0.00046417632,0.00018379683],"domain_scores_gemma":[0.99642015,0.0006464894,0.000397312,0.00021684195,0.0010464148,0.0012727395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016278753,0.0002294439,0.0002266601,0.00062929303,0.0010072864,0.0016161937,0.0005541727,0.0006021432,0.0021326067],"category_scores_gemma":[0.0045349603,0.0001877797,0.000106007814,0.002000977,0.0006885602,0.00034099404,0.0008179052,0.00063748006,0.00040802755],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002325902,0.0015010021,0.32829118,0.0006740874,0.00012111578,0.0064826845,0.0041964515,0.00072731555,0.008773909,0.0013767018,0.022786137,0.6227436],"study_design_scores_gemma":[0.0008225814,0.0034331963,0.8123816,0.00065856794,0.0001423209,0.011019991,0.0027140477,0.0012441485,0.0025312477,0.00048592928,0.16446769,0.000098737204],"about_ca_topic_score_codex":0.28215224,"about_ca_topic_score_gemma":0.48313183,"teacher_disagreement_score":0.71784776,"about_ca_system_score_codex":0.0069860886,"about_ca_system_score_gemma":0.010359965,"threshold_uncertainty_score":0.5610199},"labels":[],"label_agreement":null},{"id":"W1984666457","doi":"10.3109/10428190109058004","title":"Prolonged Molecular and Clinical Remission after Treatment of a Patient with Follicular Lymphoma with Rituximab","year":2001,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"IC Design Education Center","keywords":"Rituximab; Medicine; Follicular lymphoma; Complete remission; Lymphoma; Refractory (planetary science); Internal medicine; Oncology; CD20; Follicular phase; Monoclonal; Clinical trial; Radiation therapy; Gastroenterology; Monoclonal antibody; Antibody; Chemotherapy; Immunology","score_opus":0.007920645523747646,"score_gpt":0.24652712978806582,"score_spread":0.23860648426431819,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984666457","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97627115,0.0038610296,0.0024099664,0.004771979,0.00019750804,0.00012643213,0.00016338052,0.00019307891,0.012005562],"genre_scores_gemma":[0.995329,0.00078990863,0.00056477776,0.0011583974,0.00022727162,0.000023163626,0.000097370284,0.000020988171,0.0017891623],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99958926,0.0000665555,0.000039487695,0.00007684446,0.00006724755,0.00016074153],"domain_scores_gemma":[0.99859315,0.00042793094,0.00020059923,0.00011562877,0.00009897358,0.00056378846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041063986,0.0005806042,0.0009017848,0.00088434375,0.0014603267,0.00063898554,0.0007487682,0.0034156232,0.0013979651],"category_scores_gemma":[0.0027374912,0.00035050692,0.00087192876,0.00055591343,0.00087913324,0.0008079015,0.00055677624,0.0030411729,0.0006689914],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045205714,0.00024291626,0.017955752,0.00006332831,0.000028134189,0.96116084,0.0009152634,0.00025348607,0.0062518516,0.00061394984,0.00069866533,0.011363876],"study_design_scores_gemma":[0.000050359467,0.0013266434,0.020519663,0.000025765117,0.000035253903,0.97369814,0.00019472149,0.00042699662,0.0017519027,0.00027760406,0.0016690687,0.000023847162],"about_ca_topic_score_codex":0.0022553403,"about_ca_topic_score_gemma":0.0021712997,"teacher_disagreement_score":0.0034156232,"about_ca_system_score_codex":0.0009145849,"about_ca_system_score_gemma":0.0006114469,"threshold_uncertainty_score":0.0066358447},"labels":[],"label_agreement":null},{"id":"W1985382327","doi":"10.1080/1042819031000067909","title":"CNS Prophylaxis and Treatment in Non-Hodgkin's Lymphoma: Variation in Practice and Lessons from the Literature","year":2003,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"CNS Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Internal medicine; Randomized controlled trial; Lymphoma; Chemotherapy; Disease","score_opus":0.009184027187279559,"score_gpt":0.25623875353245246,"score_spread":0.2470547263451729,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985382327","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.43117818,0.48670954,0.001189905,0.072717786,0.00071859616,0.0003120856,0.000444596,0.000042328735,0.006687005],"genre_scores_gemma":[0.8553675,0.1337164,0.0023229308,0.0072775944,0.0006482673,0.00020022604,0.00021901181,0.000024195291,0.00022381757],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.954101,0.028395405,0.007552766,0.0023679272,0.006756133,0.0008267176],"domain_scores_gemma":[0.74664176,0.18713173,0.033889435,0.006019591,0.023272716,0.0030447876],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.046370298,0.00018058864,0.0007070555,0.0031849032,0.00059488433,0.0030826118,0.0015549109,0.001674353,0.0011030823],"category_scores_gemma":[0.21062857,0.00041435362,0.00036581472,0.0071187257,0.004108046,0.0023942466,0.001308433,0.0010014394,0.00012120267],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009778442,0.00028620815,0.2526293,0.025778519,0.00096378557,0.00050072564,0.0340117,0.0007354785,0.0004387688,0.0030678564,0.011066102,0.6695437],"study_design_scores_gemma":[0.00077866344,0.0011824915,0.79434824,0.084932715,0.0015292875,0.001352301,0.04800271,0.0016040666,0.00055426545,0.0031691836,0.06233972,0.00020645345],"about_ca_topic_score_codex":0.06344429,"about_ca_topic_score_gemma":0.13213868,"teacher_disagreement_score":0.95362973,"about_ca_system_score_codex":0.0074181445,"about_ca_system_score_gemma":0.012832765,"threshold_uncertainty_score":0.24523252},"labels":[],"label_agreement":null},{"id":"W1987493240","doi":"10.3109/10428194.2010.483750","title":"Revisiting late relapses in acute myeloid leukemia","year":2010,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Myeloid leukemia; Medicine; Myeloid; Leukemia; Internal medicine; Cancer research; Oncology","score_opus":0.013045270587988864,"score_gpt":0.26275512068170864,"score_spread":0.24970985009371977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987493240","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016001709,0.017299173,0.00064394367,0.93309927,0.01634945,0.00004419939,0.00011136943,0.00008572664,0.016365089],"genre_scores_gemma":[0.17553312,0.018420152,0.0014850667,0.6348016,0.15727836,0.00006886665,0.00018608717,0.00011938133,0.012107326],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981804,0.00060779415,0.00034352866,0.00016393204,0.0002786975,0.0004256561],"domain_scores_gemma":[0.99239665,0.003682479,0.001031895,0.00041711458,0.0010701938,0.0014017747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027122549,0.00056832616,0.0012535666,0.0010430898,0.002310262,0.0032656095,0.0016885952,0.018096205,0.0025798143],"category_scores_gemma":[0.014133352,0.0004928187,0.0008183624,0.0009149013,0.0021117236,0.003464039,0.0015244002,0.016006015,0.0014358165],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005677263,0.00017732449,0.025378022,0.00065222813,0.00006953478,0.18422107,0.0013495206,0.0004723486,0.0024899913,0.010361753,0.673545,0.10071554],"study_design_scores_gemma":[0.0004592459,0.0005449419,0.022172838,0.0017746959,0.00023134271,0.27292183,0.003820132,0.0018070677,0.0014135089,0.016470507,0.6782654,0.000118514],"about_ca_topic_score_codex":0.0033542437,"about_ca_topic_score_gemma":0.010380886,"teacher_disagreement_score":0.018096205,"about_ca_system_score_codex":0.0043285005,"about_ca_system_score_gemma":0.0027124754,"threshold_uncertainty_score":0.031405628},"labels":[],"label_agreement":null},{"id":"W1988147245","doi":"10.1080/1042819021000040170","title":"Successful Treatment of Posttransplant Lymphoproliferative Disorder in a Renal Transplant Patient by Autologous Peripheral Blood Stem Cell Transplantation","year":2002,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Immunosuppression; Transplantation; Lymphoproliferative disorders; Chemotherapy; Lymphoma; Melphalan; Surgery; Stem cell; Post-transplant lymphoproliferative disorder; Rituximab; Gastroenterology; Oncology; Internal medicine","score_opus":0.006831870652802778,"score_gpt":0.20752843376571734,"score_spread":0.20069656311291456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988147245","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99002117,0.001124835,0.0027869581,0.001082331,0.0001320035,0.000081092956,0.000038795595,0.00012496766,0.0046078907],"genre_scores_gemma":[0.99755716,0.00039664772,0.00069086667,0.00033514647,0.00013856668,0.000021555954,0.000049415627,0.000011191105,0.00079947273],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99982375,0.000034398185,0.000018682786,0.000021156022,0.000031382213,0.00007063005],"domain_scores_gemma":[0.99970907,0.00007046507,0.000033913813,0.00003614399,0.000018737597,0.00013163978],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002339176,0.00044714403,0.0004975387,0.00040014545,0.0010492776,0.00045655126,0.00032930996,0.0011642199,0.00080782454],"category_scores_gemma":[0.0009971282,0.00016688829,0.00039063962,0.0002399871,0.0004792143,0.00040150608,0.00044756598,0.0010881465,0.00032420026],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012792365,0.0023878687,0.05687426,0.000157495,0.00010054468,0.83021283,0.0011800737,0.0020355873,0.020340892,0.0017454991,0.0017495373,0.081936225],"study_design_scores_gemma":[0.00052933925,0.0050293123,0.043500423,0.000042056898,0.00008641555,0.92985046,0.0002233166,0.0045630415,0.010605525,0.0010977514,0.0044359025,0.00003636994],"about_ca_topic_score_codex":0.00042300377,"about_ca_topic_score_gemma":0.00073059526,"teacher_disagreement_score":0.0011642199,"about_ca_system_score_codex":0.0003405743,"about_ca_system_score_gemma":0.0004559083,"threshold_uncertainty_score":0.002702415},"labels":[],"label_agreement":null},{"id":"W1988166471","doi":"10.3109/10428190109097680","title":"Liposomal Daunorubicin (Daunoxome) in Combination with Cyclophosphamide, Vincristine and Prednisolone (COP-X) as Salvage Therapy in Poor-Prognosis Non-Hodgkins Lymphoma","year":2001,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Neutropenia; Mucositis; Regimen; Gastroenterology; Vincristine; Cyclophosphamide; Surgery; Salvage therapy; Prednisolone; Lymphoma; Febrile neutropenia; CHOP; Chemotherapy","score_opus":0.008608960792715007,"score_gpt":0.2378536185548517,"score_spread":0.2292446577621367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988166471","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99823964,0.0013772913,0.00012425422,0.000045824276,0.0000067223427,0.00002482969,0.000015652588,0.0000072652656,0.00015847635],"genre_scores_gemma":[0.99888986,0.00053551496,0.000253046,0.000047393507,0.000028645563,0.000022978384,0.00005691154,0.0000019926863,0.00016364777],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99983144,0.00007597253,0.000015966312,0.000020785466,0.000018675502,0.000037093698],"domain_scores_gemma":[0.9998242,0.0000504731,0.000042274452,0.000011241178,0.000005736074,0.00006606196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003485388,0.00037847675,0.00036426852,0.00020572396,0.00028592083,0.00022659116,0.00023334312,0.00024919238,0.0004788641],"category_scores_gemma":[0.00053079607,0.0001876816,0.0002116154,0.00017906194,0.00032351172,0.00017915723,0.00018459719,0.00031391377,0.00019053664],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047672376,0.00926852,0.31329864,0.0009931959,0.0006122785,0.013332328,0.0021517228,0.0072113127,0.14501944,0.00053405715,0.00288506,0.45702103],"study_design_scores_gemma":[0.019978005,0.24641828,0.6443954,0.000250773,0.0008537139,0.024166917,0.001017233,0.009944273,0.031139562,0.0008352952,0.020905036,0.00009542091],"about_ca_topic_score_codex":0.00063895236,"about_ca_topic_score_gemma":0.0015090716,"teacher_disagreement_score":0.00063895236,"about_ca_system_score_codex":0.00032058026,"about_ca_system_score_gemma":0.0002241029,"threshold_uncertainty_score":0.0023260117},"labels":[],"label_agreement":null},{"id":"W1989577949","doi":"10.1080/10428190290033332","title":"Treatment of Elderly Hodgkin's Lymphoma Patients with a Novel 5-drug Regimen (ODBEP): A Phase II Study","year":2002,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"BC Cancer Agency","keywords":"Medicine; Internal medicine; Vincristine; Chemotherapy; Regimen; Lymphoma; Etoposide; Procarbazine; Prednisone; Combination chemotherapy; Gastroenterology; Neutropenia; Surgery; Oncology; Cyclophosphamide","score_opus":0.01424569885269534,"score_gpt":0.24476227634504188,"score_spread":0.23051657749234655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989577949","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985669,0.00080067664,0.000122016376,0.000036912177,0.000014188698,0.00020822597,0.000069659094,0.000004572336,0.00017692937],"genre_scores_gemma":[0.99497306,0.0023075212,0.0008939014,0.00027656325,0.000099365476,0.0004549487,0.00059114693,0.000004162966,0.00039930322],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997124,0.00014917205,0.000020532756,0.000031705877,0.000031429332,0.000054749937],"domain_scores_gemma":[0.9995634,0.00008298248,0.00009109949,0.000038615322,0.000025082865,0.00019867241],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011923499,0.00055038,0.000976316,0.00025144772,0.00021180154,0.00040404272,0.00033538722,0.0004605905,0.0007869206],"category_scores_gemma":[0.00062435336,0.00023874376,0.0006201081,0.0002972749,0.0004056142,0.0003943669,0.00023444297,0.0009326306,0.00014872129],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.46434024,0.1482897,0.07311726,0.0012467518,0.002233123,0.0008940439,0.000594388,0.003343318,0.065855235,0.000293944,0.0013976219,0.23839433],"study_design_scores_gemma":[0.13783245,0.7919672,0.060263902,0.000050860108,0.0007233972,0.00078692584,0.00011196103,0.00094002014,0.0044756792,0.000087498884,0.0027382337,0.000021831604],"about_ca_topic_score_codex":0.000546836,"about_ca_topic_score_gemma":0.0009837525,"teacher_disagreement_score":0.0011923499,"about_ca_system_score_codex":0.00032518525,"about_ca_system_score_gemma":0.0005407888,"threshold_uncertainty_score":0.006305814},"labels":[],"label_agreement":null},{"id":"W1989963052","doi":"10.3109/10428194.2011.555892","title":"Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials Group","year":2011,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre; University Health Network; Sunnybrook Health Science Centre","funders":"","keywords":"Sunitinib; Medicine; Neutropenia; Internal medicine; Refractory (planetary science); Pharmacodynamics; Diffuse large B-cell lymphoma; Oncology; Phases of clinical research; Toxicity; Clinical trial; Febrile neutropenia; Lymphoma; Gastroenterology; Pharmacokinetics; Cancer; Biology","score_opus":0.09485852275559409,"score_gpt":0.3912644948390851,"score_spread":0.296405972083491,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989963052","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993103,0.003717408,0.00035540407,0.00035566484,0.000058941838,0.0012464327,0.00041352812,0.00004600084,0.00070352934],"genre_scores_gemma":[0.9921566,0.002519061,0.0011986515,0.00043040342,0.0001821937,0.0016567132,0.0011253714,0.000019569985,0.0007114937],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9986916,0.0009078645,0.00007328859,0.000119830394,0.00010391286,0.00010339902],"domain_scores_gemma":[0.9988494,0.00025546626,0.0002655712,0.00009238796,0.00008092677,0.00045618333],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005229506,0.0013334157,0.0025973418,0.00051574747,0.00044868712,0.00080517813,0.0006749256,0.0011300639,0.0015703824],"category_scores_gemma":[0.0016888935,0.0005002808,0.001115223,0.00047746729,0.00082123675,0.0007449122,0.0002392022,0.0017623386,0.00036208314],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.75236255,0.054482996,0.017667636,0.0010725034,0.00242241,0.00040096903,0.0003459702,0.0029993767,0.037703637,0.00035523818,0.0040393416,0.12614731],"study_design_scores_gemma":[0.69670314,0.27599418,0.019550405,0.000028918723,0.0006533818,0.00042035404,0.00004621904,0.0016006177,0.0027258745,0.00013816536,0.00210758,0.000031210766],"about_ca_topic_score_codex":0.000725642,"about_ca_topic_score_gemma":0.0016754542,"teacher_disagreement_score":0.005229506,"about_ca_system_score_codex":0.00093851297,"about_ca_system_score_gemma":0.0012559139,"threshold_uncertainty_score":0.027656615},"labels":[],"label_agreement":null},{"id":"W1990370347","doi":"10.3109/10428194.2014.963075","title":"Incidence of pneumonitis in patients with non-Hodgkin lymphoma receiving chemoimmunotherapy with rituximab","year":2014,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Rituximab; Prednisone; Vincristine; Internal medicine; CHOP; Cyclophosphamide; Lymphoma; Chemoimmunotherapy; Gastroenterology; Ofatumumab; Oncology; Chemotherapy; Surgery","score_opus":0.0035991984274510364,"score_gpt":0.2022721831625936,"score_spread":0.19867298473514255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990370347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9991793,0.00038441102,0.000044380864,0.0000163288,0.0000021432886,0.0000064928995,0.000072030314,0.0000027019262,0.000292166],"genre_scores_gemma":[0.99962604,0.0001363009,0.000040221214,0.000014434181,0.0000091262455,0.0000049545392,0.000121077755,8.5984726e-7,0.000046887635],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994037,0.00018638936,0.00009430128,0.00010387674,0.00013470303,0.00007688012],"domain_scores_gemma":[0.9976895,0.00043032964,0.0014250267,0.00012301409,0.0001205237,0.0002116831],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005351086,0.00014529828,0.00035266162,0.00070392014,0.00021448202,0.00048087857,0.0002793012,0.00041424725,0.00094445754],"category_scores_gemma":[0.0024277258,0.0002294682,0.0003295298,0.0006776801,0.00023477066,0.00054046215,0.0003457354,0.00039311397,0.00018657287],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000076590964,0.000012546406,0.9987232,0.0000052764117,0.000014574475,0.0001152864,0.000023616403,0.000015526304,0.00013049204,0.000004807032,0.000021159476,0.00085688813],"study_design_scores_gemma":[0.0000058227306,0.00018597863,0.9977912,0.0000057289108,0.000016615058,0.0016553969,0.00007093504,0.00008469918,0.00007795343,0.0000066518223,0.000096998505,0.0000022008574],"about_ca_topic_score_codex":0.0010241844,"about_ca_topic_score_gemma":0.0012574381,"teacher_disagreement_score":0.0010241844,"about_ca_system_score_codex":0.00021646767,"about_ca_system_score_gemma":0.00017222931,"threshold_uncertainty_score":0.003159523},"labels":[],"label_agreement":null},{"id":"W1991589385","doi":"10.3109/10428194.2013.853298","title":"The clinical features, management and prognosis of primary and secondary indolent lymphoma of the bone: a retrospective study of the International Extranodal Lymphoma Study Group (IELSG #14 study)","year":2013,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Lymphoplasmacytic Lymphoma; Follicular lymphoma; Lymphoma; Internal medicine; Stage (stratigraphy); Retrospective cohort study; Gastroenterology; Pathology; Oncology; Waldenstrom macroglobulinemia","score_opus":0.011555288649860556,"score_gpt":0.2503653937384022,"score_spread":0.23881010508854167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1991589385","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99920005,0.00026766353,0.0000507841,0.000010920646,0.0000016036036,0.000012799224,0.00023199302,0.0000016425372,0.0002225914],"genre_scores_gemma":[0.99897975,0.0001300436,0.000037643735,0.000018448325,0.000008677385,0.000015005192,0.0007392943,0.0000017254908,0.00006948257],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994723,0.00016713969,0.0000741096,0.000104474515,0.00009524123,0.00008674303],"domain_scores_gemma":[0.9988182,0.00021810284,0.00052454916,0.000110344394,0.00010784535,0.00022087546],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00089004356,0.0003011993,0.0004847391,0.00094638695,0.00041172132,0.00072016654,0.00032176,0.00040752764,0.0009890641],"category_scores_gemma":[0.0014617299,0.000350221,0.00033947945,0.00121176,0.0003469814,0.0006164044,0.00051064056,0.0003489717,0.00029782866],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022879093,0.000030214762,0.9984705,0.0000063742227,0.000032538668,0.00016221136,0.000053760894,0.000023714096,0.00011364587,0.000007680806,0.000065046646,0.0008055433],"study_design_scores_gemma":[0.000035151243,0.00024965798,0.9979948,0.000006662672,0.00003358245,0.0011088073,0.00016947585,0.000080493075,0.00004790805,0.000018125205,0.00025064542,0.000004669321],"about_ca_topic_score_codex":0.0017873904,"about_ca_topic_score_gemma":0.0022151605,"teacher_disagreement_score":0.0017873904,"about_ca_system_score_codex":0.0003465348,"about_ca_system_score_gemma":0.00023994617,"threshold_uncertainty_score":0.004707098},"labels":[],"label_agreement":null},{"id":"W1992085012","doi":"10.3109/10428194.2013.802313","title":"2-[18F]fluoro-2-deoxy-<scp>d</scp>-glucose positron emission tomography/computed tomography examination in patients with chronic lymphocytic leukemia may reveal Richter transformation","year":2013,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Faculty of Medicine and Dentistry, University of Alberta","keywords":"Medicine; Positron emission tomography; Nuclear medicine; Chronic lymphocytic leukemia; Positron Emission Tomography-Computed Tomography; Standardized uptake value; Positron emission; Radiology; PET-CT; Leukemia; Internal medicine","score_opus":0.005696234891551276,"score_gpt":0.2163362870837772,"score_spread":0.21064005219222592,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992085012","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99856406,0.0010627006,0.00011192592,0.00003457602,0.0000034537807,0.000004337195,0.000025425292,0.000006085356,0.0001875127],"genre_scores_gemma":[0.999491,0.0002611395,0.00013391052,0.000021626101,0.0000143091875,0.0000026934338,0.000043359523,0.0000012815871,0.00003058277],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99966764,0.0001401029,0.000050734026,0.000055390083,0.000039084793,0.00004700689],"domain_scores_gemma":[0.99853396,0.0007178755,0.00036027748,0.00008153091,0.00008250589,0.00022383539],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007631821,0.00040403503,0.00040658127,0.0007556857,0.00025069513,0.00047014406,0.00019891173,0.00050138525,0.0006472764],"category_scores_gemma":[0.0026194544,0.00027103754,0.00026936433,0.00045485326,0.00049561035,0.00047100664,0.00020150634,0.00025512875,0.00020638645],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005204358,0.000028148515,0.99188966,0.00001972159,0.000018156257,0.0013537257,0.000037105085,0.000072665556,0.00164459,0.000007696983,0.000048033027,0.004360014],"study_design_scores_gemma":[0.00006153835,0.0011760585,0.9808897,0.00002576463,0.000086878375,0.014478604,0.00020388118,0.0009389032,0.001743766,0.00006811382,0.00031378644,0.000012844513],"about_ca_topic_score_codex":0.0009696443,"about_ca_topic_score_gemma":0.0013359084,"teacher_disagreement_score":0.0009696443,"about_ca_system_score_codex":0.00021055134,"about_ca_system_score_gemma":0.00019484639,"threshold_uncertainty_score":0.0040361285},"labels":[],"label_agreement":null},{"id":"W1995357901","doi":"10.3109/10428194.2010.490312","title":"Schedule- and dose-dependency of CPX-351, a synergistic fixed ratio cytarabine:daunorubicin formulation, in consolidation treatment against human leukemia xenografts","year":2010,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Celator Pharmaceuticals (Canada)","funders":"","keywords":"Daunorubicin; Cytarabine; Pharmacology; Medicine; Bone marrow; Leukemia; Drug; Therapeutic index; Myeloid leukemia; Internal medicine","score_opus":0.015134411913510911,"score_gpt":0.28125515738351764,"score_spread":0.26612074547000675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995357901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945695,0.0024900977,0.0013589379,0.00004326914,0.000016089894,0.00007961298,0.00023806927,0.00006747058,0.0011369467],"genre_scores_gemma":[0.99721766,0.0006432674,0.0013465261,0.00001567939,0.0000068638583,0.00003470844,0.00018848163,0.000014212062,0.00053241086],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99988604,0.000023581591,0.00000934304,0.000025734353,0.000030784748,0.00002464027],"domain_scores_gemma":[0.99989426,0.000026446438,0.000033392047,0.000009746709,0.000013322172,0.000022834593],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001981617,0.00025218,0.00020857123,0.00018237825,0.000095134994,0.0001926541,0.0001841303,0.00017880993,0.00044557612],"category_scores_gemma":[0.0001569475,0.00013309014,0.00014591083,0.00015764641,0.00015295987,0.00022116932,0.00011086978,0.00042596844,0.00015505582],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005469512,0.00020849796,0.00032011312,0.000049620983,0.000008518605,0.000020929652,0.00003575671,0.0009779115,0.98920584,0.00007955179,0.00007606559,0.008470296],"study_design_scores_gemma":[0.000047632897,0.0042387806,0.0061412365,0.0000050156177,0.000030709263,0.00012143828,0.000009707028,0.0017595197,0.9861027,0.000015874459,0.0015207288,0.0000067256065],"about_ca_topic_score_codex":0.0007205475,"about_ca_topic_score_gemma":0.0014618239,"teacher_disagreement_score":0.0007205475,"about_ca_system_score_codex":0.00025218842,"about_ca_system_score_gemma":0.00020542565,"threshold_uncertainty_score":0.0018297434},"labels":[],"label_agreement":null},{"id":"W1995513757","doi":"10.1080/10428190500051844","title":"Validation of tissue microarray immunohistochemistry staining and interpretation in diffuse large B-cell lymphoma","year":2005,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; BC Cancer Agency; University of California, San Francisco; University of Nebraska Medical Center","keywords":"Concordance; Immunohistochemistry; Medicine; Pathology; Tissue microarray; Stain; Lymphoma; Staining; Internal medicine","score_opus":0.0056392378217780745,"score_gpt":0.246330318001575,"score_spread":0.24069108017979693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995513757","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93095803,0.002286552,0.06111351,0.0001807749,0.00023117097,0.0009558034,0.0007302396,0.00046328714,0.0030806297],"genre_scores_gemma":[0.92009306,0.0007239034,0.07296476,0.00022030872,0.00007250323,0.0020276948,0.0025791763,0.00014516662,0.00117335],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.98365444,0.007645785,0.0023611821,0.0020785786,0.0037520665,0.0005078998],"domain_scores_gemma":[0.98657125,0.004726808,0.0009522874,0.0027882291,0.004734128,0.00022731062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.018790126,0.0006859079,0.00074397685,0.0017688088,0.00070003164,0.0009850975,0.00092885864,0.00080874225,0.0009581243],"category_scores_gemma":[0.02147527,0.0005233996,0.00047875248,0.0012958328,0.00062995276,0.00043410237,0.0007595725,0.00041057295,0.0008650895],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022096324,0.00040019266,0.34511238,0.0006035996,0.00042994678,0.0009118455,0.00131846,0.0034213436,0.58769375,0.00045899054,0.0014285153,0.056011286],"study_design_scores_gemma":[0.000090774025,0.0017479964,0.7472974,0.00014404257,0.00038884298,0.0034683885,0.0007726844,0.030404525,0.2053237,0.00038153143,0.009923414,0.000056620935],"about_ca_topic_score_codex":0.0013537317,"about_ca_topic_score_gemma":0.0021833011,"teacher_disagreement_score":0.018790126,"about_ca_system_score_codex":0.0005102331,"about_ca_system_score_gemma":0.00053422316,"threshold_uncertainty_score":0.099372864},"labels":[],"label_agreement":null},{"id":"W1996193488","doi":"10.3109/10428190009113384","title":"18-FDG-PET as a Prognostic Indicator in the Treatment of Aggressive Non-Hodgkin's Lymphoma-Comparison with CT","year":2000,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":248,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Medicine; Lymphoma; Radiology; Stage (stratigraphy); Positron emission tomography; Interim; Internal medicine; Nuclear medicine; Aggressive lymphoma; PET-CT; Rituximab","score_opus":0.010701937970799547,"score_gpt":0.2634812659616695,"score_spread":0.25277932799086994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996193488","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99249834,0.0057379245,0.0008202006,0.00011088157,0.000018492568,0.000016596956,0.00004561633,0.000008415221,0.00074350915],"genre_scores_gemma":[0.99850875,0.0006951332,0.0005110299,0.000025252462,0.000037375215,0.000010889594,0.00006320143,0.0000022999084,0.00014608321],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991916,0.0005607316,0.00005758002,0.000043705008,0.0000967842,0.000049647497],"domain_scores_gemma":[0.9983134,0.0009277037,0.00029291675,0.000089326044,0.00015357132,0.00022320195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001949829,0.0003072204,0.00045269026,0.0006633767,0.00012067414,0.0005606458,0.0001650933,0.00040214235,0.00043187971],"category_scores_gemma":[0.00438263,0.00017728694,0.00020207645,0.00050552835,0.0003343828,0.00045176045,0.0002581612,0.00034348268,0.0001756258],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057647233,0.00007890015,0.938023,0.0000550837,0.00008997336,0.00036445537,0.000092253205,0.00084133196,0.003944983,0.000059932543,0.00012894678,0.050556544],"study_design_scores_gemma":[0.0002295489,0.0029990587,0.983454,0.000050348943,0.00023448565,0.0035116372,0.00017161702,0.0056660287,0.0019608291,0.00021105228,0.0014904808,0.000020931113],"about_ca_topic_score_codex":0.0007109942,"about_ca_topic_score_gemma":0.0012439205,"teacher_disagreement_score":0.001949829,"about_ca_system_score_codex":0.0002212948,"about_ca_system_score_gemma":0.00011730595,"threshold_uncertainty_score":0.010311842},"labels":[],"label_agreement":null},{"id":"W1996846809","doi":"10.1080/1042819021000002901","title":"Phase II Study of Sequential Topotecan and Etoposide in Patients with Intermediate Grade Non-Hodgkin's Lymphoma: A National Cancer Institute of Canada Clinical Trials Group Study","year":2002,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research; Queen Elizabeth II Health Sciences Centre; Saskatoon Medical Imaging; Humber River Regional Hospital; Hamilton Health Sciences; BC Cancer Agency; Princess Margaret Cancer Centre","funders":"","keywords":"Topotecan; Medicine; Etoposide; Neutropenia; Internal medicine; Gastroenterology; Lymphoma; Regimen; Febrile neutropenia; Phases of clinical research; Chemotherapy; Surgery","score_opus":0.05278015313966829,"score_gpt":0.37454118198458514,"score_spread":0.32176102884491686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996846809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9832017,0.003401394,0.00049533264,0.00087779004,0.00012442589,0.007256016,0.0016032218,0.00007116017,0.0029688643],"genre_scores_gemma":[0.98116255,0.0028684626,0.0020002152,0.0017088592,0.00017605144,0.005465662,0.0027620404,0.000014652404,0.003841536],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.999382,0.00028718106,0.00002449032,0.00006448483,0.000091514994,0.00015025953],"domain_scores_gemma":[0.9990552,0.000074118805,0.00010103226,0.00004351564,0.00007928836,0.0006468177],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022356734,0.0014520143,0.002028723,0.00038605256,0.0005416328,0.000934564,0.001032657,0.0011334098,0.002627602],"category_scores_gemma":[0.00080282614,0.00060009555,0.00092062406,0.00057501654,0.0009288489,0.00041445834,0.0003127777,0.0024147134,0.00054031843],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.81447744,0.07298088,0.012326198,0.00076388574,0.0016024875,0.00049000286,0.00030882895,0.0021288285,0.02248025,0.00041422414,0.006082705,0.06594427],"study_design_scores_gemma":[0.77584577,0.19697641,0.02079096,0.000029308503,0.00036768202,0.00018957791,0.00006016623,0.0008942256,0.0011408129,0.00012944882,0.003552976,0.000022717533],"about_ca_topic_score_codex":0.027088743,"about_ca_topic_score_gemma":0.070473164,"teacher_disagreement_score":0.027088743,"about_ca_system_score_codex":0.002675967,"about_ca_system_score_gemma":0.0060517313,"threshold_uncertainty_score":0.053862095},"labels":[],"label_agreement":null},{"id":"W1997303669","doi":"10.1080/10428190601043252","title":"Characteristics and outcomes of acute myelogenous leukemia patients with very late relapse (&gt;5 years)","year":2007,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Cohort; Internal medicine; Complete remission; Leukemia; Chemotherapy; Oncology; Surgery","score_opus":0.0068160636290141114,"score_gpt":0.23682244162637736,"score_spread":0.23000637799736326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997303669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9995351,0.00013022884,0.00003433405,0.000020147254,0.0000020919315,0.0000034643804,0.000080865175,0.000002578283,0.00019114892],"genre_scores_gemma":[0.9996549,0.000026144036,0.000019338353,0.000023572184,0.00000509828,0.000004757125,0.00019863414,8.8635886e-7,0.00006660571],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998192,0.000033901895,0.000029209214,0.000027431744,0.000027448938,0.00006286559],"domain_scores_gemma":[0.99923193,0.00013128966,0.0003113297,0.000029056651,0.00005820435,0.00023812108],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030856716,0.00014671555,0.00026423583,0.00037831246,0.00028067167,0.00032596773,0.000150862,0.00036885784,0.0006819564],"category_scores_gemma":[0.0013931314,0.000085327294,0.00024124546,0.0003543921,0.00017460027,0.0002622053,0.00023775744,0.0002588676,0.00020543543],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025489824,0.00006429742,0.9946109,0.000007136197,0.000022642049,0.0009274032,0.00013315825,0.00012801954,0.00060269836,0.000026825552,0.00017432155,0.0030477464],"study_design_scores_gemma":[0.000026960566,0.00085934467,0.99337596,0.000008879161,0.00002407498,0.004682375,0.00019094844,0.00025707323,0.0001218144,0.00004798221,0.00039546425,0.000009049581],"about_ca_topic_score_codex":0.0009779069,"about_ca_topic_score_gemma":0.0010704763,"teacher_disagreement_score":0.0009779069,"about_ca_system_score_codex":0.00017396927,"about_ca_system_score_gemma":0.00013295037,"threshold_uncertainty_score":0.0022814274},"labels":[],"label_agreement":null},{"id":"W1997316354","doi":"10.3109/10428194.2014.999326","title":"A classification tree approach for improving the utilization of flow cytometry testing of blood specimens for B-cell non-Hodgkin lymphoproliferative disorders","year":2015,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Health Research Board; University of Calgary","keywords":"Flow cytometry; Logistic regression; Medicine; Receiver operating characteristic; Cytometry; Lymphoproliferative disorders; Immunology; Pathology; Internal medicine; Lymphoma","score_opus":0.055364893703796506,"score_gpt":0.2964314999325053,"score_spread":0.2410666062287088,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997316354","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10437141,0.0015838247,0.8850622,0.0016934724,0.00020149846,0.0006564498,0.0017093525,0.0024351976,0.0022865986],"genre_scores_gemma":[0.30607665,0.0006949,0.6868518,0.0004441464,0.00021264677,0.0006059665,0.004023601,0.0001086625,0.0009816582],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9977525,0.0009649971,0.00027472895,0.00032338273,0.00048646925,0.0001979008],"domain_scores_gemma":[0.9894868,0.0071154125,0.00064212206,0.00026162475,0.0021927725,0.00030114147],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0052622897,0.0010791313,0.0019623442,0.0043395916,0.0009444877,0.001965617,0.0015992138,0.0014748633,0.0016495803],"category_scores_gemma":[0.013657324,0.00044895711,0.001256046,0.0028189928,0.0002714306,0.0013461655,0.0009121365,0.0017340917,0.0007283166],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00068649,0.0011571667,0.046597052,0.0005521836,0.00052647287,0.0005762598,0.0005368884,0.18070212,0.0043176273,0.0048655896,0.013154896,0.7463273],"study_design_scores_gemma":[0.00007081586,0.00021142457,0.0040664314,0.00009969309,0.00016209186,0.00014363091,0.00010506358,0.9840845,0.00083553564,0.008050021,0.0021391066,0.00003163878],"about_ca_topic_score_codex":0.010812592,"about_ca_topic_score_gemma":0.012995978,"teacher_disagreement_score":0.010812592,"about_ca_system_score_codex":0.001313483,"about_ca_system_score_gemma":0.0024321931,"threshold_uncertainty_score":0.027829945},"labels":[],"label_agreement":null},{"id":"W1997358378","doi":"10.1080/10428190701713655","title":"The role of TRAIL death receptors in the treatment of hematological malignancies","year":2008,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Apoptosis; Receptor; Tumor necrosis factor alpha; Cancer research; Lymphoma; Leukemia; Monoclonal antibody; Programmed cell death; Immunology; Signal transduction; Medicine; Biology; Antibody; Cell biology; Internal medicine","score_opus":0.016842454943273993,"score_gpt":0.254111233069388,"score_spread":0.237268778126114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997358378","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002087956,0.9981504,0.0001818605,0.00023600148,0.00016495337,0.000005682189,0.0000090871645,0.000008260924,0.0010348422],"genre_scores_gemma":[0.00092654215,0.99777836,0.0002903441,0.00014079735,0.0001410044,0.0000071194067,0.000023183367,0.0000012310403,0.0006914579],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99980444,0.00003643129,0.000027943392,0.000026599186,0.000087394634,0.00001732353],"domain_scores_gemma":[0.9998072,0.00006471623,0.000029105338,0.0000080309355,0.000060426373,0.00003061766],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059970847,0.0007114988,0.0011634551,0.001669398,0.00027867826,0.00064280804,0.0008344547,0.000861013,0.002258944],"category_scores_gemma":[0.00047267327,0.00020970748,0.0003723002,0.0018894279,0.0004407556,0.001026768,0.000495527,0.0015493836,0.002525571],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009599426,0.000085691165,0.00017200822,0.0062516658,0.000054429256,0.00035049024,0.000050065362,0.0003603139,0.0028186825,0.0023485895,0.017558934,0.9698533],"study_design_scores_gemma":[0.000045827182,0.00019762963,0.001136714,0.0015900073,0.00008572487,0.0026507364,0.000049798666,0.00010250133,0.0009981422,0.0019999223,0.9911265,0.000016610362],"about_ca_topic_score_codex":0.0008599689,"about_ca_topic_score_gemma":0.001317867,"teacher_disagreement_score":0.002258944,"about_ca_system_score_codex":0.00071066024,"about_ca_system_score_gemma":0.0009331564,"threshold_uncertainty_score":0.007556975},"labels":[],"label_agreement":null},{"id":"W1998981539","doi":"10.1080/1042819031000149304","title":"Enhancement of Antineoplastic Action of 5-Aza-2′-deoxycytidine by Phenylbutyrate on L1210 Leukemic Cells","year":2003,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Cancer research; Leukemia; Phenylbutyrate; Histone deacetylase; Hypomethylating agent; Azacitidine; Epigenetics; DNA methylation; Deoxycytidine; In vitro; L1210 cells; Chromatin; Biology; Chemistry; Molecular biology; Histone; Pharmacology; DNA; Gene; Immunology; Cancer; Biochemistry; Cytotoxicity; Genetics; Gene expression","score_opus":0.008982724020270715,"score_gpt":0.24542381072931124,"score_spread":0.23644108670904052,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998981539","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895175,0.0047789617,0.0015788806,0.000090846086,0.000040420306,0.00007373981,0.0005216949,0.000069589965,0.003328177],"genre_scores_gemma":[0.9935689,0.0019803988,0.001739964,0.00004531085,0.000017725111,0.000044172124,0.00068482594,0.000016946033,0.0019016904],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998229,0.000055377455,0.000018154356,0.000026296426,0.000041612486,0.000035741145],"domain_scores_gemma":[0.999866,0.00003474729,0.000026998476,0.00001771549,0.000021861715,0.00003267601],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001683865,0.00049509853,0.000507055,0.000251285,0.00012294522,0.00025954374,0.00023090727,0.00022084796,0.0010916532],"category_scores_gemma":[0.00012509644,0.000119375254,0.0002637654,0.00020209572,0.00013875886,0.00015514043,0.00017121281,0.00046143914,0.00036428744],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019628106,0.00005090549,0.00012283506,0.000036862577,0.0000055378323,0.0000262275,0.000015421707,0.00009926941,0.99775594,0.000026312855,0.00002371406,0.0016406742],"study_design_scores_gemma":[0.00001957195,0.00092433015,0.0016658701,0.000004662874,0.000013332688,0.000077909666,0.000010641775,0.0003707339,0.99560225,0.000006259904,0.0013021334,0.0000024030544],"about_ca_topic_score_codex":0.0013078755,"about_ca_topic_score_gemma":0.0014441581,"teacher_disagreement_score":0.0013078755,"about_ca_system_score_codex":0.00017542564,"about_ca_system_score_gemma":0.00023297785,"threshold_uncertainty_score":0.0036519766},"labels":[],"label_agreement":null},{"id":"W1999897515","doi":"10.1080/10428190802108870","title":"Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma","year":2008,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":112,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"University Health Network","keywords":"Medicine; Salvage therapy; Autologous stem-cell transplantation; Chemotherapy; Lymphoma; Refractory (planetary science); Internal medicine; Oncology; Transplantation; Diffuse large B-cell lymphoma; Surgery; Biology","score_opus":0.012832555256231951,"score_gpt":0.2258245512521214,"score_spread":0.21299199599588944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1999897515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960198,0.002876493,0.00016773779,0.00011590006,0.000016219647,0.000019056377,0.00009949335,0.000012571471,0.00067264674],"genre_scores_gemma":[0.9989637,0.00040556162,0.000095930496,0.0000906674,0.000033219185,0.000010474025,0.00025007085,0.0000029811795,0.0001474557],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995795,0.00014826698,0.00006563822,0.000052931853,0.00010277943,0.00005079689],"domain_scores_gemma":[0.9985648,0.0005710674,0.00044112845,0.00009977421,0.000050255916,0.00027296285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008326216,0.00015348027,0.00066431693,0.00030143082,0.00012346507,0.00036626522,0.0001915215,0.0003111425,0.0014695016],"category_scores_gemma":[0.0027099175,0.00006394233,0.00046025042,0.00028442167,0.00022471313,0.00033185518,0.0002086504,0.00033003377,0.00025593516],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027651884,0.00075382617,0.6503873,0.00032437185,0.0008105597,0.0017803606,0.00024585816,0.0018606008,0.014274319,0.00023659057,0.0012210389,0.30045328],"study_design_scores_gemma":[0.00096603396,0.01712759,0.9647281,0.000071658316,0.0006801725,0.007238196,0.00015377045,0.0021206615,0.0036650517,0.00065246853,0.002579242,0.000017155438],"about_ca_topic_score_codex":0.00017657872,"about_ca_topic_score_gemma":0.0005430029,"teacher_disagreement_score":0.0014695016,"about_ca_system_score_codex":0.0003170484,"about_ca_system_score_gemma":0.00020898649,"threshold_uncertainty_score":0.0049159527},"labels":[],"label_agreement":null},{"id":"W2001321636","doi":"10.3109/10428194.2013.770847","title":"Pleurocidin-family cationic antimicrobial peptides mediate lysis of multiple myeloma cells and impair the growth of multiple myeloma xenografts","year":2013,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Antimicrobial Peptides and Activities","field":"Immunology and Microbiology","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Queen Elizabeth II Health Sciences Centre","funders":"Natural Sciences and Engineering Research Council of Canada; Dalhousie University; Beatrice Hunter Cancer Research Institute","keywords":"Multiple myeloma; Cancer research; Medicine; Cytotoxic T cell; Immune system; Malignancy; Cancer; Melphalan; Immunology; Internal medicine; Biology; In vitro; Biochemistry","score_opus":0.00705556771187292,"score_gpt":0.1908262009334524,"score_spread":0.1837706332215795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2001321636","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99575764,0.0011356464,0.0017010961,0.000055423094,0.000016322028,0.000027657437,0.00015210953,0.000050818897,0.001103191],"genre_scores_gemma":[0.99645543,0.00043601188,0.0012727038,0.000040782117,0.0000060702073,0.000021518517,0.00027578318,0.000008026647,0.0014836871],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998828,0.000024484512,0.000008966681,0.0000143802845,0.000037326412,0.000032100023],"domain_scores_gemma":[0.9998894,0.000028295926,0.000026871388,0.000013310728,0.000016597,0.000025589314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017923089,0.0002451576,0.00019201463,0.00012135879,0.00008092055,0.00016696278,0.00017493189,0.00023696918,0.0009854907],"category_scores_gemma":[0.00011033118,0.00006479208,0.00016241273,0.000074586664,0.00014913383,0.0001610025,0.00011896402,0.0005349057,0.00023579272],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009337104,0.000042613407,0.00009748596,0.000016883892,0.000002333182,0.000020780875,0.0000062253325,0.000045392633,0.9988482,0.000035146422,0.000022118487,0.0007693215],"study_design_scores_gemma":[0.000019213887,0.00071118213,0.0021817146,0.0000029844925,0.000006120733,0.00015154966,0.000013522153,0.00070017896,0.9953146,0.000018708719,0.00087847747,0.0000016234112],"about_ca_topic_score_codex":0.0003879533,"about_ca_topic_score_gemma":0.00040351364,"teacher_disagreement_score":0.0009854907,"about_ca_system_score_codex":0.00016352753,"about_ca_system_score_gemma":0.00014891798,"threshold_uncertainty_score":0.003296852},"labels":[],"label_agreement":null},{"id":"W2001606431","doi":"10.1080/10428190600942769","title":"Very high-dose methotrexate (33.6 g/m<sup>2</sup>) as central nervous system preventive therapy for childhood acute lymphoblastic leukemia: results of National Cancer Institute/Children's Cancer Group trials CCG-191P, CCG-134P and CCG-144P","year":2006,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"National Cancer Institute; U.S. Public Health Service; National Institutes of Health","keywords":"Medicine; Methotrexate; Internal medicine; Cancer; Neutropenia; Oncology; Neurocognitive; Leukemia; Chemotherapy","score_opus":0.014400841934127665,"score_gpt":0.28712327881736066,"score_spread":0.272722436883233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2001606431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93126863,0.06334463,0.00040974465,0.0010094523,0.000116564646,0.0004406943,0.0004780955,0.000030188163,0.0029020838],"genre_scores_gemma":[0.9792625,0.016864775,0.0014005356,0.0007158125,0.00011977503,0.00020696531,0.0006995402,0.000010165538,0.00071995694],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99941385,0.00043577308,0.000036385194,0.000032671418,0.000040464194,0.000040880503],"domain_scores_gemma":[0.9986895,0.0006518433,0.00026634685,0.00009780605,0.00004877366,0.00024575237],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018041201,0.000269285,0.0005952076,0.0002998564,0.00015837354,0.00047163744,0.00035534374,0.00045553426,0.00080056634],"category_scores_gemma":[0.0014840525,0.00011300849,0.0005563855,0.00049672555,0.00045091435,0.0002913142,0.00018136187,0.0011663747,0.00013417145],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38790423,0.00517292,0.027374718,0.002229147,0.003387135,0.00041388767,0.00028824096,0.0025466084,0.018649535,0.00093283784,0.0040402883,0.54706043],"study_design_scores_gemma":[0.32164243,0.4311622,0.17371702,0.0008269712,0.0071977023,0.0022626587,0.00024312072,0.0013359876,0.021367766,0.0013125509,0.038831607,0.000100018726],"about_ca_topic_score_codex":0.0018939468,"about_ca_topic_score_gemma":0.0059234076,"teacher_disagreement_score":0.0018939468,"about_ca_system_score_codex":0.0008323328,"about_ca_system_score_gemma":0.0007966088,"threshold_uncertainty_score":0.009541154},"labels":[],"label_agreement":null},{"id":"W2002379912","doi":"10.1080/1042819021000035707","title":"Association of Familial Leukemia with HLA Cw3: Is it Real?","year":2002,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sudbury Regional Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Leukemia; Myeloid leukemia; Anticipation (artificial intelligence); Human leukocyte antigen; Immunology; Medicine; Haplotype; Genetics; Allele; Biology; Antigen; Gene","score_opus":0.014329316963668234,"score_gpt":0.23759822062964506,"score_spread":0.22326890366597682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002379912","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97772115,0.008429153,0.0012647208,0.008079776,0.00014330824,0.000008410018,0.000080649406,0.000026493006,0.00424631],"genre_scores_gemma":[0.9961356,0.0022512262,0.00030944226,0.00056232326,0.00035082328,0.000005339182,0.000033085234,0.000002757325,0.00034948756],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996271,0.00013049324,0.00003505642,0.000067524255,0.000060825492,0.00007904261],"domain_scores_gemma":[0.9981749,0.00084681885,0.0005998778,0.00011649629,0.00010607573,0.0001558741],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005176041,0.00030845686,0.00029151843,0.0003545472,0.00061619293,0.00047293218,0.00030957873,0.0022270584,0.003563369],"category_scores_gemma":[0.0044903476,0.00019579919,0.00017147652,0.00072085485,0.0013291928,0.0010674018,0.0003122569,0.00069160084,0.00034793673],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00087821187,0.0001247238,0.73974127,0.0003241001,0.00018685409,0.18418694,0.0022476474,0.00021969034,0.0071056206,0.0069841985,0.0035618122,0.0544389],"study_design_scores_gemma":[0.00008601249,0.00042808708,0.2556045,0.00025518722,0.0002410562,0.7206572,0.0026670154,0.00049165194,0.0009283593,0.007897618,0.01068128,0.00006201679],"about_ca_topic_score_codex":0.00095417147,"about_ca_topic_score_gemma":0.0007656362,"teacher_disagreement_score":0.003563369,"about_ca_system_score_codex":0.00022558511,"about_ca_system_score_gemma":0.00024565085,"threshold_uncertainty_score":0.011920691},"labels":[],"label_agreement":null},{"id":"W2004634154","doi":"10.3109/10428194.2011.584004","title":"High-dose methotrexate based chemotherapy with deferred radiation for treatment of newly diagnosed primary central nervous system lymphoma","year":2011,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"CNS Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Western University; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Procarbazine; Primary central nervous system lymphoma; Regimen; Vincristine; Methotrexate; Internal medicine; Surgery; Radiation therapy; Chemotherapy; Oncology; Cyclophosphamide","score_opus":0.01676367970394319,"score_gpt":0.22984616716492057,"score_spread":0.21308248746097738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004634154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99246615,0.005602264,0.0006200387,0.00012128699,0.00004685275,0.00017302774,0.000037786118,0.000023019353,0.0009095424],"genre_scores_gemma":[0.9952899,0.0031129231,0.0007593445,0.00012152496,0.00010300281,0.000081623635,0.00012788684,0.0000052410155,0.00039853944],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996387,0.00019600586,0.000034212222,0.00003391091,0.00005082103,0.00004646007],"domain_scores_gemma":[0.9994679,0.00016562127,0.00010686492,0.00004602734,0.00001881515,0.00019472827],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072874664,0.00029447075,0.00059928163,0.00036200846,0.000388404,0.0003691259,0.0003968036,0.0002475737,0.00065414654],"category_scores_gemma":[0.0013259875,0.00015926991,0.00040881152,0.00031771045,0.00045027674,0.00025567957,0.00031330474,0.0007303252,0.0002310936],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.052295953,0.010631708,0.26979306,0.0013271517,0.00090224535,0.010800909,0.0011000081,0.0033750285,0.045916528,0.00026667587,0.0022697994,0.6013209],"study_design_scores_gemma":[0.016395198,0.25027138,0.668794,0.0003647086,0.001017585,0.027181845,0.00031830603,0.0044226465,0.015147209,0.0004364587,0.01558932,0.000061494306],"about_ca_topic_score_codex":0.00088440155,"about_ca_topic_score_gemma":0.0034636853,"teacher_disagreement_score":0.00088440155,"about_ca_system_score_codex":0.00048846414,"about_ca_system_score_gemma":0.0006318029,"threshold_uncertainty_score":0.0038539767},"labels":[],"label_agreement":null},{"id":"W2005532233","doi":"10.1080/1042819021000040125","title":"Intra-cerebral Relapse Following Prolonged Remission after Autologous Stem Cell Transplantation for Multiple Myeloma","year":2002,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Hospital and Health Sciences Centre; BC Cancer Agency","funders":"","keywords":"Multiple myeloma; Medicine; Autologous stem-cell transplantation; Transplantation; Complication; Stem cell; Pathophysiology; Central nervous system; Oncology; Internal medicine; Surgery; Biology","score_opus":0.015530059102037147,"score_gpt":0.2456129782174663,"score_spread":0.23008291911542916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005532233","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97998226,0.006306983,0.0017302702,0.0013732417,0.00017697085,0.00009283205,0.00013147068,0.00020801573,0.009998],"genre_scores_gemma":[0.9965611,0.001230808,0.00034888292,0.0006327743,0.00047598153,0.000023338336,0.00009631018,0.000028284401,0.00060250587],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99962485,0.00007345718,0.000034093944,0.000052122927,0.00007824443,0.00013711835],"domain_scores_gemma":[0.9976042,0.00070955884,0.0008869121,0.00026770946,0.00011716193,0.00041454483],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003384292,0.0009973748,0.001181049,0.00092313,0.001407872,0.0008827897,0.0013821108,0.0019433653,0.0019558754],"category_scores_gemma":[0.0033654575,0.00035010767,0.0007550138,0.0008463931,0.0013688385,0.0007930951,0.0012475817,0.0036897543,0.0008407675],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004796215,0.00010781233,0.019546332,0.000110058536,0.000066196386,0.9678349,0.00038917092,0.00013862256,0.0022022417,0.00020861793,0.0006885938,0.008227767],"study_design_scores_gemma":[0.00008660609,0.00038942258,0.02400579,0.00005188271,0.00010745643,0.97214264,0.00018380114,0.00030702882,0.0013473764,0.00029898694,0.001053809,0.000025228914],"about_ca_topic_score_codex":0.002307728,"about_ca_topic_score_gemma":0.0037898244,"teacher_disagreement_score":0.002307728,"about_ca_system_score_codex":0.0011130028,"about_ca_system_score_gemma":0.00075184245,"threshold_uncertainty_score":0.008075416},"labels":[],"label_agreement":null},{"id":"W2008241551","doi":"10.1080/10428190600572673","title":"Leukocyte count as a predictor of death during remission induction in acute myeloid leukemia","year":2006,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":112,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Induction chemotherapy; Myeloid leukemia; Internal medicine; Cohort; Myeloid; Immunology; Acute leukemia; Leukemia; Chemotherapy; Oncology; Gastroenterology","score_opus":0.010336622605659828,"score_gpt":0.25548349084621347,"score_spread":0.24514686824055365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2008241551","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9993837,0.00031060464,0.000061029186,0.000042655323,0.0000040078253,0.0000035481432,0.0000643655,0.0000060306697,0.00012396071],"genre_scores_gemma":[0.99961025,0.000079206984,0.00007452603,0.00001727383,0.000008532454,0.0000041297253,0.00015780308,0.0000015759476,0.000046603367],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99961483,0.000119767195,0.000054535896,0.00004016415,0.00010088344,0.00006967914],"domain_scores_gemma":[0.99700075,0.00089428574,0.0012668914,0.0000934242,0.0001755105,0.0005691868],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006773023,0.00017972084,0.0003188745,0.00054972275,0.00026283006,0.00046089114,0.00030385857,0.00039681268,0.00045223546],"category_scores_gemma":[0.0050827633,0.00012919535,0.00014307584,0.0006354471,0.0003439157,0.00032546374,0.00037159436,0.0006923391,0.00017349616],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020303595,0.00001626077,0.99815375,0.00000285569,0.000006711336,0.00005985892,0.000019778156,0.000093572744,0.00014624647,0.0000059281865,0.00007137367,0.0012205852],"study_design_scores_gemma":[0.000019301118,0.0002653756,0.9977054,0.0000042579163,0.000017941584,0.00067601335,0.00006712581,0.0008621702,0.00024946567,0.00003222815,0.00009702644,0.0000036993067],"about_ca_topic_score_codex":0.0016025306,"about_ca_topic_score_gemma":0.0017785049,"teacher_disagreement_score":0.0016025306,"about_ca_system_score_codex":0.00043752542,"about_ca_system_score_gemma":0.00037186992,"threshold_uncertainty_score":0.0035819411},"labels":[],"label_agreement":null},{"id":"W2009245880","doi":"10.3109/10428190903421177","title":"Lymphoma cells contribute to the augmentation of plasma sL-selectins in the serum of lymphoma-bearing mice","year":2009,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Cell Adhesion Molecules Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut National de la Recherche Scientifique","funders":"National Cancer Institute; Armand-Frappier Foundation; Canadian Institutes of Health Research; Terry Fox Foundation; Cancer Research Society","keywords":"Lymphoma; Selectin; In vitro; Glycoprotein; L-selectin; Immunology; Chemistry; In vivo; Cancer research; Cell adhesion molecule; Molecular biology; Medicine; Biology; Biochemistry","score_opus":0.012094395834983914,"score_gpt":0.26611915155099464,"score_spread":0.25402475571601074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2009245880","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947232,0.0011402213,0.002009989,0.00012742092,0.000020125284,0.000029504066,0.00035489257,0.0002494954,0.0013451345],"genre_scores_gemma":[0.99506855,0.0005565143,0.0011187486,0.00011025816,0.0000232885,0.000040748277,0.00054076756,0.000055061377,0.0024861104],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9995913,0.000083610445,0.000036475114,0.00007914719,0.00010668453,0.000102862134],"domain_scores_gemma":[0.9993231,0.00007823918,0.00020735264,0.000063042135,0.00007606248,0.00025219307],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025181094,0.0006213638,0.00034910627,0.0011453704,0.00018346959,0.0005722754,0.00022097706,0.00049524766,0.0020616238],"category_scores_gemma":[0.0003164351,0.00028823357,0.00027430686,0.00029606267,0.0003602277,0.00039287985,0.0003627832,0.0010744997,0.00079847383],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019569608,0.000078345605,0.0007559571,0.000016522354,0.0000054917464,0.00008959371,0.000037937305,0.000021836147,0.99755055,0.00008533249,0.00003908878,0.0011236123],"study_design_scores_gemma":[0.0000910562,0.001099411,0.014234888,0.000010541626,0.000050238268,0.00084802305,0.00008783822,0.0016236362,0.97979045,0.00013121462,0.0020217139,0.000010975166],"about_ca_topic_score_codex":0.00051292457,"about_ca_topic_score_gemma":0.0005767313,"teacher_disagreement_score":0.0020616238,"about_ca_system_score_codex":0.00041702946,"about_ca_system_score_gemma":0.00021058366,"threshold_uncertainty_score":0.0068968534},"labels":[],"label_agreement":null},{"id":"W2009764353","doi":"10.3109/10428194.2013.835404","title":"Genetic polymorphisms of<i>RAD51</i>and<i>XRCC3</i>and acute myeloid leukemia risk: a meta-analysis","year":2013,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"XRCC3; Odds ratio; Meta-analysis; Myeloid leukemia; Internal medicine; Oncology; Confidence interval; Population; Medicine; RAD51; Genotype; Biology; Bioinformatics; Genetics; Gene; Single-nucleotide polymorphism; DNA repair","score_opus":0.04042416432050826,"score_gpt":0.30393356689123646,"score_spread":0.2635094025707282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2009764353","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05203422,0.94404083,0.0017935205,0.00036556323,0.00021110558,0.00022270012,0.00082115474,0.00006155751,0.0004494095],"genre_scores_gemma":[0.6352099,0.35751945,0.0036204248,0.0007483227,0.0003631114,0.00055341696,0.0013267582,0.000052139774,0.00060649123],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9936034,0.0031564767,0.0013815715,0.0010234361,0.0005455476,0.0002896133],"domain_scores_gemma":[0.98921585,0.007816713,0.0014031113,0.000624515,0.00071712275,0.00022271134],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0093503855,0.002679489,0.010839222,0.00455334,0.00065863,0.0026190684,0.0017668103,0.0018433698,0.0022458013],"category_scores_gemma":[0.014974252,0.001488561,0.040859245,0.0069303573,0.00055806147,0.001037469,0.0013145186,0.0016352221,0.00031463886],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039121206,0.000034465837,0.025776347,0.044952624,0.91735,0.00026048216,0.00006701932,0.00087217113,0.0006535562,0.00009157756,0.00033278752,0.0056968834],"study_design_scores_gemma":[0.00031534117,0.00015532291,0.009023363,0.001906504,0.9874999,0.0001020995,0.000024892011,0.00030202538,0.000127728,0.00011608402,0.00041353214,0.000013187861],"about_ca_topic_score_codex":0.0060700984,"about_ca_topic_score_gemma":0.009127255,"teacher_disagreement_score":0.010839222,"about_ca_system_score_codex":0.0014350325,"about_ca_system_score_gemma":0.0015439895,"threshold_uncertainty_score":0.04945016},"labels":[],"label_agreement":null},{"id":"W2010726561","doi":"10.1080/1042819031000116698","title":"Acute Myelogenous Leukemia with t(8;21)—Identification of a Specific Immunophenotype","year":2003,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Vancouver Hospital and Health Sciences Centre; University of British Columbia; Leukemia & Lymphoma Society of Canada","funders":"","keywords":"CD33; CD34; Immunophenotyping; Leukemia; CD19; Medicine; Immunology; Internal medicine; Gastroenterology; Antigen; Oncology; Biology; Stem cell; Genetics","score_opus":0.010713451643626224,"score_gpt":0.2410863234620763,"score_spread":0.2303728718184501,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010726561","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99923444,0.00013852026,0.00015995442,0.00002255066,0.0000033494503,0.000004224377,0.000038487742,0.0000042804504,0.0003941458],"genre_scores_gemma":[0.9995634,0.000056530174,0.00021011462,0.000014781457,0.0000077022405,0.0000029374592,0.00007003109,8.779311e-7,0.00007358125],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99975103,0.00007856629,0.000030338919,0.00004165881,0.000056666187,0.000041721865],"domain_scores_gemma":[0.9992163,0.00028194737,0.00030726905,0.000044859447,0.000059752358,0.00008969412],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002972423,0.0002032707,0.00018705559,0.0005065577,0.00018834148,0.00031175328,0.00014941864,0.00034293218,0.0013023143],"category_scores_gemma":[0.001439526,0.00008839155,0.0001327168,0.0003927482,0.00029491354,0.00029023693,0.0002684296,0.00020057379,0.000329148],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015481193,0.000018469964,0.9902817,0.000012170551,0.0000075986154,0.00049532164,0.000031585325,0.00006246032,0.004239461,0.000028942502,0.00008853922,0.004578886],"study_design_scores_gemma":[0.000012233709,0.00037340465,0.96994543,0.000019059722,0.00003255665,0.024295636,0.00016096134,0.00081274734,0.003085506,0.00022044368,0.0010342837,0.000007767961],"about_ca_topic_score_codex":0.00027662195,"about_ca_topic_score_gemma":0.00042741545,"teacher_disagreement_score":0.0013023143,"about_ca_system_score_codex":0.00006964274,"about_ca_system_score_gemma":0.00012340376,"threshold_uncertainty_score":0.0043566227},"labels":[],"label_agreement":null},{"id":"W2011629215","doi":"10.3109/10428190009087023","title":"A Comparison of Elderly Patients with Aggressive Histology Lymphoma who Were Entered or Not Entered on to a Randomized Phase II Trial","year":2000,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton Health Sciences","funders":"","keywords":"Randomized controlled trial; Medicine; Internal medicine; Randomization; Surgery","score_opus":0.01806251221639087,"score_gpt":0.3000154975304829,"score_spread":0.281952985314092,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2011629215","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929517,0.0030232423,0.0006902428,0.00032486537,0.00030591243,0.0013767602,0.00019457203,0.000022491813,0.001110259],"genre_scores_gemma":[0.9924004,0.0010404575,0.00082036096,0.001064012,0.00031699255,0.0032064233,0.00056619995,0.000009371062,0.0005759025],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9931393,0.0050210804,0.0005999559,0.00045442712,0.00029516296,0.0004900482],"domain_scores_gemma":[0.99330515,0.003146319,0.0016982898,0.00061740476,0.00027431315,0.0009585002],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0057078013,0.0006313875,0.002575347,0.0003459827,0.0003332635,0.0010237006,0.0004743103,0.0014857725,0.0028292101],"category_scores_gemma":[0.011170571,0.0003172047,0.0023975323,0.00032601808,0.0007829891,0.0010934519,0.0005083629,0.0014678843,0.00039579888],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9618862,0.006003555,0.007588629,0.0003043687,0.0014144992,0.00007580484,0.00011006706,0.0006755272,0.0013365174,0.00034203866,0.00041478942,0.019847838],"study_design_scores_gemma":[0.63060135,0.34706366,0.015701128,0.00013543334,0.0013560595,0.00013308629,0.00014434385,0.001438949,0.00067333697,0.0009917893,0.0017248379,0.000035972575],"about_ca_topic_score_codex":0.00017502882,"about_ca_topic_score_gemma":0.0003314688,"teacher_disagreement_score":0.0057078013,"about_ca_system_score_codex":0.00054465333,"about_ca_system_score_gemma":0.001136569,"threshold_uncertainty_score":0.030186117},"labels":[],"label_agreement":null},{"id":"W2012098025","doi":"10.3109/10428194.2010.546015","title":"A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172)","year":2011,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; BC Cancer Agency; Princess Margaret Cancer Centre; Alberta Cancer Foundation; University Health Network; Queen Elizabeth II Health Sciences Centre; Juravinski Hospital","funders":"National Cancer Institute","keywords":"Gemcitabine; Bortezomib; Mantle cell lymphoma; Medicine; Internal medicine; Oncology; Adverse effect; Chemotherapy; Refractory (planetary science); Phases of clinical research; Lymphoma; Multiple myeloma","score_opus":0.07482145748558373,"score_gpt":0.33985409406348344,"score_spread":0.2650326365778997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2012098025","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96057695,0.011993329,0.00075147336,0.0014989609,0.00031274487,0.015030111,0.003124395,0.00016336392,0.006548725],"genre_scores_gemma":[0.9414753,0.010039657,0.0068978164,0.0035089334,0.0005002335,0.018688245,0.008556522,0.00006490409,0.010268355],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99918514,0.00045989867,0.000032236818,0.00008196285,0.00009809435,0.00014256455],"domain_scores_gemma":[0.99911684,0.00011088361,0.00014135105,0.00004695434,0.00006519126,0.000518801],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023584745,0.0013854601,0.0026931202,0.0006682424,0.0006946046,0.00082262774,0.0011930043,0.0014511116,0.004278901],"category_scores_gemma":[0.0011771304,0.00067319727,0.0010930555,0.001004569,0.00094231876,0.00045875783,0.000415072,0.0033168714,0.00069704326],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8350536,0.04586967,0.006274846,0.00079458224,0.0012820233,0.00036520069,0.00020370392,0.0014712563,0.018385414,0.00032864505,0.007371852,0.08259922],"study_design_scores_gemma":[0.79462224,0.19119827,0.007489363,0.00003526477,0.00033898655,0.00018239715,0.000029702202,0.00046023898,0.000944391,0.00008710121,0.0045952876,0.000016657437],"about_ca_topic_score_codex":0.011210407,"about_ca_topic_score_gemma":0.041319966,"teacher_disagreement_score":0.011210407,"about_ca_system_score_codex":0.002086425,"about_ca_system_score_gemma":0.0056742085,"threshold_uncertainty_score":0.022290349},"labels":[],"label_agreement":null},{"id":"W2012684467","doi":"10.1080/10428190600909578","title":"A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma","year":2007,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Collège de Maisonneuve","funders":"","keywords":"Medicine; Refractory (planetary science); Multiple myeloma; Adverse effect; Internal medicine; Lymphoproliferative disorders; Gastroenterology; Phases of clinical research; Toxicity; Surgery; Lymphoma","score_opus":0.025166442700866824,"score_gpt":0.3165357937164136,"score_spread":0.2913693510155468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2012684467","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99410784,0.0010931541,0.00059633376,0.00015423878,0.000046541372,0.0030844458,0.0003236983,0.00003404718,0.00055960997],"genre_scores_gemma":[0.9829664,0.0021460766,0.0037800334,0.0006094881,0.00012864546,0.0058098477,0.0019859078,0.000026542555,0.0025470178],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99964094,0.00020107091,0.000018639243,0.00005460628,0.000031861193,0.000052961263],"domain_scores_gemma":[0.99963677,0.000053048392,0.00007729935,0.00004045489,0.000029251325,0.00016315328],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018193888,0.0011059637,0.0013282285,0.00028527985,0.0004092642,0.000453141,0.00049619627,0.0006954674,0.0024162498],"category_scores_gemma":[0.0005499717,0.00039198925,0.0006699427,0.00030499048,0.00054566737,0.00043933862,0.000277295,0.0018280672,0.00047870365],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32733172,0.1367809,0.024550993,0.0013803939,0.0013392206,0.0009937504,0.0007400454,0.0028634013,0.34376982,0.00053438323,0.0040868,0.15562853],"study_design_scores_gemma":[0.23653175,0.7231814,0.02317799,0.00004376998,0.00036259936,0.0005703786,0.00008584551,0.00097201386,0.010622553,0.00011499226,0.004308642,0.00002802465],"about_ca_topic_score_codex":0.00037262315,"about_ca_topic_score_gemma":0.001238579,"teacher_disagreement_score":0.0024162498,"about_ca_system_score_codex":0.00033909388,"about_ca_system_score_gemma":0.0011912913,"threshold_uncertainty_score":0.009621978},"labels":[],"label_agreement":null},{"id":"W2012998597","doi":"10.1080/10428190400025112","title":"Predictive value of karyotype on outcome of autotransplants for acute myeloid leukemia in second remission","year":2005,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University of British Columbia","funders":"","keywords":"Myeloid leukemia; Medicine; Karyotype; Oncology; Value (mathematics); Internal medicine; Myeloid; Cancer research; Leukemia; Biology; Chromosome; Genetics; Gene","score_opus":0.015803030289344492,"score_gpt":0.29667028888014974,"score_spread":0.28086725859080525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2012998597","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9993851,0.00018564136,0.000050751813,0.00003483171,0.000005536997,0.0000026437194,0.000045479967,0.000003835596,0.00028621787],"genre_scores_gemma":[0.9997662,0.000040673523,0.000023716877,0.000012733528,0.000011964701,0.0000019804543,0.00008997426,0.0000019886945,0.00005091275],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997303,0.00009042279,0.000024102548,0.000040711802,0.000048011283,0.000066479624],"domain_scores_gemma":[0.99654156,0.001249838,0.0010808419,0.00013578913,0.0001496558,0.00084224314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052193395,0.00023803029,0.00023798402,0.00043442522,0.00018793749,0.00040353788,0.00021473679,0.0004898356,0.0020320427],"category_scores_gemma":[0.0032092321,0.00008570895,0.0002714399,0.0002996526,0.00029347243,0.0002522014,0.00026728166,0.0005836822,0.00023496682],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039687817,0.00002826936,0.99661356,0.0000030868857,0.000020461106,0.00019156275,0.000022106984,0.0001299317,0.00053552917,0.000012507767,0.000054340537,0.0019918976],"study_design_scores_gemma":[0.000018892408,0.0004042223,0.9971865,0.000004702616,0.000030711093,0.0013368226,0.00005421406,0.0005184867,0.0002636211,0.0000414967,0.00013598734,0.000004303666],"about_ca_topic_score_codex":0.00056744955,"about_ca_topic_score_gemma":0.00074672996,"teacher_disagreement_score":0.0020320427,"about_ca_system_score_codex":0.0001811785,"about_ca_system_score_gemma":0.00016457746,"threshold_uncertainty_score":0.00679785},"labels":[],"label_agreement":null},{"id":"W2013180434","doi":"10.3109/10428190009054894","title":"Lovastatin Induces a Pronounced Differentiation Response in Acute Myeloid Leukemias","year":2000,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Retinoids in leukemia and cellular processes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":80,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Ontario Institute for Cancer Research","funders":"","keywords":"Lovastatin; Myeloid leukemia; Myeloid; Cancer research; Acute promyelocytic leukemia; Retinoic acid; Leukemia; Haematopoiesis; Tretinoin; Biology; Apoptosis; Cytarabine; Immunology; Pharmacology; Cell culture; Endocrinology; Cell biology; Biochemistry; Cholesterol; Stem cell","score_opus":0.006092719136176638,"score_gpt":0.22499170836869092,"score_spread":0.21889898923251427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013180434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98929954,0.0055305474,0.001944984,0.00014073469,0.000039556482,0.000070482834,0.00069232355,0.0001232205,0.0021586153],"genre_scores_gemma":[0.9925298,0.0017115006,0.0016255828,0.00010966475,0.0000150066935,0.00003881416,0.0010081717,0.00001783677,0.0029434771],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998204,0.000027782387,0.000025466506,0.000027987044,0.00005534738,0.00004308605],"domain_scores_gemma":[0.9998938,0.000016852218,0.000027347773,0.000012595923,0.000018660769,0.000030764266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000854206,0.00020458493,0.00036430603,0.0002288586,0.00014800011,0.00030142194,0.00008807452,0.00017710835,0.0011144074],"category_scores_gemma":[0.00012249785,0.000100603516,0.00020716009,0.00018674516,0.000122048026,0.00010547865,0.00018351297,0.00041955113,0.00058860314],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013718939,0.000019300818,0.0002874408,0.000025107222,0.0000033060956,0.000048712718,0.00002212438,0.000014343082,0.99832946,0.00002636977,0.00002969383,0.001056856],"study_design_scores_gemma":[0.000030539963,0.00076965295,0.016002364,0.000008337259,0.000019372306,0.00064231333,0.00006862527,0.00028503663,0.9724892,0.00005377472,0.009625713,0.0000050492904],"about_ca_topic_score_codex":0.0007769254,"about_ca_topic_score_gemma":0.001471966,"teacher_disagreement_score":0.0011144074,"about_ca_system_score_codex":0.00029612475,"about_ca_system_score_gemma":0.00017079801,"threshold_uncertainty_score":0.003728032},"labels":[],"label_agreement":null},{"id":"W2013251910","doi":"10.3109/10428194.2011.604752","title":"Regulation of autophagy in hematological malignancies: role of reactive oxygen species","year":2011,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Autophagy in Disease and Therapy","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Research Manitoba; CancerCare Manitoba","funders":"","keywords":"Autophagy; Cancer research; Programmed cell death; Reactive oxygen species; Biology; Drug resistance; Bone marrow; Cancer; Myeloid; Immunology; Medicine; Apoptosis; Cell biology; Internal medicine","score_opus":0.026581577183491377,"score_gpt":0.27612582090251764,"score_spread":0.24954424371902625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013251910","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019483727,0.9987073,0.00010759638,0.00011469468,0.00007268763,0.0000030796273,0.000010269302,0.0000064926494,0.00078297744],"genre_scores_gemma":[0.0008241675,0.99836963,0.00017384894,0.00006760229,0.00006030664,0.000005108544,0.00002009168,9.1728566e-7,0.00047830187],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998934,0.00001879554,0.000017043803,0.00001835291,0.00004185447,0.000010573872],"domain_scores_gemma":[0.99991083,0.000026227006,0.000018387726,0.0000035968383,0.000027469367,0.000013545359],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023371853,0.0006013835,0.00137267,0.0017438751,0.00030127424,0.0006961391,0.0005243389,0.00079417246,0.0016719605],"category_scores_gemma":[0.00019941191,0.00018495925,0.0003573484,0.0016220039,0.00032846557,0.00082311156,0.00047010192,0.00099013,0.0015582066],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000082591476,0.000084157655,0.0002318824,0.013184236,0.00007863824,0.00048774303,0.00009585074,0.00038646584,0.0074571534,0.0032091697,0.020482225,0.95422],"study_design_scores_gemma":[0.00002194168,0.00014374174,0.0019035232,0.0026942259,0.00009803905,0.0038673135,0.00009092596,0.000116682015,0.0019618508,0.0026751542,0.98640126,0.000025437093],"about_ca_topic_score_codex":0.00066466327,"about_ca_topic_score_gemma":0.0010932408,"teacher_disagreement_score":0.0017438751,"about_ca_system_score_codex":0.0005076368,"about_ca_system_score_gemma":0.00064914953,"threshold_uncertainty_score":0.0055933},"labels":[],"label_agreement":null},{"id":"W2013425043","doi":"10.1080/10428190500272549","title":"Prognostic relevance of CD56 expression in multiple myeloma: A study including 107 cases treated with high-dose melphalan-based chemotherapy and autologous stem cell transplant","year":2005,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Melphalan; Multiple myeloma; Medicine; Chemotherapy; Bone marrow; Autologous stem-cell transplantation; Oncology; Internal medicine; Fluorescence in situ hybridization; Pathology; Biology","score_opus":0.020627777997041352,"score_gpt":0.26245457438802133,"score_spread":0.24182679639097998,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013425043","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99947196,0.0002481987,0.00008279182,0.000012485303,0.00000308477,0.0000045115353,0.00003451069,0.0000022474928,0.0001401435],"genre_scores_gemma":[0.9995395,0.00013663124,0.0000960727,0.000011594366,0.00000911355,0.0000044895423,0.00014129234,0.0000018571961,0.000059606373],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996613,0.0000773494,0.00004545767,0.00008625396,0.00007149531,0.000058215817],"domain_scores_gemma":[0.99920964,0.00024713058,0.00019033189,0.00009166987,0.00006731137,0.00019386093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003915501,0.00026008897,0.00049361936,0.00080355204,0.0006255652,0.0004762198,0.00025874816,0.00049020397,0.0008792593],"category_scores_gemma":[0.001333304,0.00031682994,0.00032198094,0.0008423726,0.00050825,0.00028083412,0.00039910903,0.00033474545,0.00029540795],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022451254,0.000054336182,0.99241287,0.000015039193,0.000046455767,0.0024444498,0.0001314535,0.000057810837,0.00213034,0.000013606099,0.00008081704,0.0023882533],"study_design_scores_gemma":[0.00003041178,0.000503091,0.976837,0.000008680427,0.00008889579,0.019862214,0.0003189026,0.00040253767,0.0012889242,0.000030355042,0.0006194981,0.000009484757],"about_ca_topic_score_codex":0.0012713174,"about_ca_topic_score_gemma":0.0014388832,"teacher_disagreement_score":0.0012713174,"about_ca_system_score_codex":0.00038420397,"about_ca_system_score_gemma":0.00033352958,"threshold_uncertainty_score":0.0029414296},"labels":[],"label_agreement":null},{"id":"W2014488544","doi":"10.1080/10428190290016890","title":"Cytogenetic Analysis in Mantle Cell Lymphoma: A Review of 214 Cases","year":2002,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"BC Cancer Agency","keywords":"Mantle cell lymphoma; Lymphoma; Mantle (geology); Cancer research; Ibrutinib; Medicine; Pathology; Internal medicine; Geology; Leukemia; Chronic lymphocytic leukemia; Geochemistry","score_opus":0.030705201939201874,"score_gpt":0.29829572606515825,"score_spread":0.26759052412595635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2014488544","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.40806863,0.5803196,0.0019017684,0.00069781934,0.00020619507,0.00006886077,0.0006803587,0.00014832862,0.007908521],"genre_scores_gemma":[0.6429823,0.35165426,0.0016889276,0.0005650357,0.0004197265,0.00008431698,0.001188385,0.00003362077,0.0013834514],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99916744,0.00012568584,0.00024077324,0.00012846997,0.0002656104,0.000072063805],"domain_scores_gemma":[0.9983216,0.0008746498,0.00039132484,0.00009365777,0.00024560565,0.00007319515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006796748,0.0005127975,0.0005560589,0.005089358,0.00039363114,0.0008085866,0.0010086164,0.00069385365,0.0014087249],"category_scores_gemma":[0.0032330884,0.00038536958,0.000303962,0.0047514844,0.0007210009,0.00066898187,0.0004492895,0.00029206646,0.0007145634],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033790906,0.00008537147,0.32457992,0.0047874562,0.0002632454,0.07948238,0.001608281,0.0006496599,0.0067443484,0.00024442747,0.0101201655,0.5710968],"study_design_scores_gemma":[0.000049119324,0.00031857216,0.49312428,0.0032217526,0.00044463153,0.40304583,0.0013866236,0.00029665756,0.002489556,0.00032528696,0.09524171,0.000056055596],"about_ca_topic_score_codex":0.0019188868,"about_ca_topic_score_gemma":0.001508838,"teacher_disagreement_score":0.005089358,"about_ca_system_score_codex":0.00042023073,"about_ca_system_score_gemma":0.00044675297,"threshold_uncertainty_score":0.0047126412},"labels":[],"label_agreement":null},{"id":"W2016355237","doi":"10.3109/10428194.2012.719614","title":"Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma","year":2012,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Lenalidomide; Medicine; Bortezomib; Multiple myeloma; Neutropenia; Internal medicine; Dexamethasone; Oncology; Adverse effect; Thalidomide; Gastroenterology; Surgery; Toxicity","score_opus":0.03254678982639751,"score_gpt":0.2968636568573042,"score_spread":0.2643168670309067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016355237","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97700435,0.020454383,0.00086243177,0.00015924616,0.000022623333,0.00013622853,0.0002988866,0.00004571272,0.001016175],"genre_scores_gemma":[0.9942807,0.0036769845,0.0011508304,0.00014676138,0.000059888236,0.00003581496,0.00042317997,0.00000609971,0.00021975885],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99961025,0.00015285991,0.00007623228,0.000057960013,0.00007020323,0.000032487733],"domain_scores_gemma":[0.999456,0.00014255343,0.00025430814,0.000038299375,0.000024973817,0.00008383897],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007366159,0.00020413773,0.00062062516,0.00054804183,0.00026238488,0.0003264865,0.00036167933,0.00021035611,0.00046005409],"category_scores_gemma":[0.0008127266,0.00013887919,0.0003827545,0.0006357787,0.0002574604,0.00023123003,0.00029276707,0.0003640741,0.0002566717],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009048688,0.00070632,0.5604724,0.0010650974,0.00050023815,0.005385478,0.0003045328,0.0012260377,0.038263593,0.000117277596,0.0021042281,0.3808061],"study_design_scores_gemma":[0.0015871205,0.021434188,0.9111191,0.00019815388,0.0005127288,0.038482785,0.00021755975,0.002322375,0.009509772,0.00022424822,0.014347535,0.000044406166],"about_ca_topic_score_codex":0.00056111923,"about_ca_topic_score_gemma":0.0017562564,"teacher_disagreement_score":0.0007366159,"about_ca_system_score_codex":0.00038257043,"about_ca_system_score_gemma":0.00046101047,"threshold_uncertainty_score":0.0038955808},"labels":[],"label_agreement":null},{"id":"W2016579260","doi":"10.3109/10428194.2011.584003","title":"The pandemic H1N1 influenza vaccine results in low rates of seroconversion for patients with hematological malignancies","year":2011,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Influenza Virus Research Studies","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Western University","funders":"American Society of Hematology","keywords":"Medicine; Seroconversion; Vaccination; Immunology; Influenza vaccine; Antibody; Antibody titer; Population; Titer; Pandemic; Flu season; Internal medicine; Disease; Coronavirus disease 2019 (COVID-19); Infectious disease (medical specialty)","score_opus":0.04350369681274826,"score_gpt":0.2998302026206843,"score_spread":0.2563265058079361,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016579260","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988668,0.0004968494,0.000053795982,0.00005916672,0.000007232957,0.0000039355937,0.000027199267,0.0000053775434,0.00047961922],"genre_scores_gemma":[0.9997178,0.000082960476,0.000029069448,0.000055311146,0.0000069934476,0.000001421171,0.000029797064,8.424272e-7,0.00007574354],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995803,0.0002029356,0.00004238507,0.000043584296,0.00006741647,0.000063275715],"domain_scores_gemma":[0.9978531,0.00092260435,0.0006275648,0.00017411612,0.00016550212,0.0002570439],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006681927,0.00011023358,0.0002722169,0.00023311074,0.00016888078,0.00038380077,0.00010902835,0.00029181095,0.0010504108],"category_scores_gemma":[0.0038881372,0.00013041018,0.00019997513,0.00018733546,0.00016595838,0.00020972785,0.0001152122,0.00032088294,0.0002556976],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00075260043,0.00010547131,0.98600787,0.000024564817,0.000041007184,0.00015721146,0.000109964276,0.0000354957,0.0023546168,0.000019682877,0.00023198676,0.01015938],"study_design_scores_gemma":[0.000040912997,0.0010490447,0.9963307,0.000010338163,0.00004404772,0.0009964264,0.00009540894,0.00014368916,0.0007265723,0.000021113476,0.00053841807,0.000003435136],"about_ca_topic_score_codex":0.0005364451,"about_ca_topic_score_gemma":0.0008089808,"teacher_disagreement_score":0.0010504108,"about_ca_system_score_codex":0.00011698893,"about_ca_system_score_gemma":0.00014797725,"threshold_uncertainty_score":0.0035337806},"labels":[],"label_agreement":null},{"id":"W2017217800","doi":"10.1080/10428190400025120","title":"Isolated central nervous system relapse in patients with chronic myeloid leukemia on imatinib mesylate","year":2005,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; Montreal Children's Hospital","funders":"","keywords":"Myeloid leukemia; Imatinib mesylate; Medicine; Imatinib; Central nervous system; Oncology; Internal medicine; Cancer research","score_opus":0.005834918914286738,"score_gpt":0.20399632849166588,"score_spread":0.19816140957737916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017217800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80371445,0.0058596446,0.000892317,0.095631175,0.002532482,0.00023919082,0.0007084246,0.00026762974,0.09015473],"genre_scores_gemma":[0.9702736,0.0024380242,0.00047149195,0.016331414,0.005058448,0.000046396748,0.0003271305,0.00004111869,0.0050123236],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9996977,0.000059694208,0.000038269638,0.000037790287,0.000055526354,0.00011110679],"domain_scores_gemma":[0.9988576,0.00040666587,0.0002055367,0.00003990911,0.00010897,0.00038136548],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002862184,0.00060015614,0.00088932854,0.0009997727,0.001416692,0.0009092678,0.0008048019,0.0040464574,0.006832945],"category_scores_gemma":[0.0029630978,0.0003639034,0.00068692816,0.0009113476,0.0006931542,0.0010442521,0.0005102178,0.0031861356,0.0010330933],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012922323,0.00021581973,0.110286705,0.00012830457,0.00007112163,0.83226895,0.0002169024,0.0003117599,0.0018732862,0.0004442843,0.035545982,0.017344717],"study_design_scores_gemma":[0.00043635495,0.0007173736,0.19662966,0.0002272772,0.00023544456,0.7838059,0.001027647,0.0028246166,0.0011523314,0.0013592895,0.011523858,0.000060323164],"about_ca_topic_score_codex":0.0055506066,"about_ca_topic_score_gemma":0.013276486,"teacher_disagreement_score":0.006832945,"about_ca_system_score_codex":0.0017619067,"about_ca_system_score_gemma":0.0009823219,"threshold_uncertainty_score":0.0228585},"labels":[],"label_agreement":null},{"id":"W2018665096","doi":"10.1080/10428190500054426","title":"Regression of lymphomatous skin deposits in a chronic lymphocytic leukemia patient treated with the Toll-like receptor-7/8 agonist, imiquimod","year":2005,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"The Scarborough Hospital; Grace (Canada); Sunnybrook Health Science Centre; Women's College Hospital; University of Toronto","funders":"National Institute on Aging","keywords":"Imiquimod; Chronic lymphocytic leukemia; Medicine; Agonist; Dermatology; Cancer research; Toll-like receptor; Toll; Leukemia; Receptor; Internal medicine; Oncology; Immunology","score_opus":0.008737558601018448,"score_gpt":0.24396892048485078,"score_spread":0.23523136188383234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018665096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99294287,0.0012446318,0.00077175995,0.00075144094,0.000046549027,0.00006793259,0.00008321855,0.00010777263,0.003983749],"genre_scores_gemma":[0.9980919,0.0003702039,0.0002806793,0.00019659373,0.000046349618,0.000009631706,0.00005188496,0.000004340688,0.00094835745],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99992466,0.000016619713,0.0000073495994,0.000018462359,0.0000128973625,0.000019981293],"domain_scores_gemma":[0.9998153,0.00004763916,0.000030819607,0.000015516149,0.000017569262,0.00007318362],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000119179065,0.00031247162,0.00037193747,0.00040785005,0.00047309313,0.00024030697,0.00015533107,0.0005484461,0.0008586723],"category_scores_gemma":[0.0005274281,0.0001362347,0.00016816154,0.00017371036,0.00028458034,0.00017313425,0.000111063535,0.000613101,0.00019668235],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005619248,0.0021647858,0.15818703,0.00027466298,0.0001644807,0.53031445,0.0014624788,0.00075893535,0.21719743,0.0006223806,0.0028861084,0.08034804],"study_design_scores_gemma":[0.00093995704,0.011355073,0.25178614,0.000051628173,0.00024116947,0.6838579,0.0004641296,0.0032531808,0.039626185,0.0003024118,0.00807889,0.000043305703],"about_ca_topic_score_codex":0.0012329245,"about_ca_topic_score_gemma":0.0013253215,"teacher_disagreement_score":0.0012329245,"about_ca_system_score_codex":0.00027988176,"about_ca_system_score_gemma":0.00022337974,"threshold_uncertainty_score":0.0028725266},"labels":[],"label_agreement":null},{"id":"W2019726944","doi":"10.3109/10428190903297531","title":"Decreased major histocompatibility complex class II expression in diffuse large B-cell lymphoma does not correlate with CpG methylation of class II transactivator promoters III and IV","year":2009,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"National Cancer Institute; University of Arizona; American Cancer Society","keywords":"Methylation; CIITA; CpG site; Transactivation; Lymphoma; Promoter; Diffuse large B-cell lymphoma; DNA methylation; Biology; Cancer research; Major histocompatibility complex; CD74; Immunology; MHC class II; Gene; Genetics; Gene expression","score_opus":0.01056275874558213,"score_gpt":0.2278023158749936,"score_spread":0.21723955712941148,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2019726944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5665181,0.009061725,0.0025702314,0.3383239,0.0068756295,0.0001416959,0.00062420656,0.00046019215,0.07542432],"genre_scores_gemma":[0.93302476,0.0036096666,0.00081103295,0.0435228,0.008591225,0.000059071433,0.00025343255,0.000054418586,0.010073615],"study_design_codex":"case_report","study_design_gemma":"observational","domain_scores_codex":[0.99958485,0.00014563413,0.00004166102,0.000077991295,0.00007760712,0.00007227751],"domain_scores_gemma":[0.99873966,0.0007118998,0.0001279658,0.000114005794,0.00017394521,0.00013250203],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044157103,0.00031664848,0.0006652723,0.0003443013,0.00052073336,0.00052839826,0.00043584846,0.0036443884,0.003774271],"category_scores_gemma":[0.0035835837,0.0002233431,0.00021922728,0.00039267706,0.00089175865,0.00057510124,0.0001597612,0.0022708413,0.0020375194],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031835912,0.0006524388,0.16795053,0.00060126523,0.00011384993,0.3881648,0.00064003584,0.0010904174,0.033609707,0.0033455894,0.24465258,0.15599526],"study_design_scores_gemma":[0.00083418435,0.0015600751,0.20683707,0.00022418945,0.00015176219,0.6623156,0.00060346484,0.0053054057,0.006400902,0.0064286427,0.10924044,0.0000982637],"about_ca_topic_score_codex":0.0011009228,"about_ca_topic_score_gemma":0.0014156234,"teacher_disagreement_score":0.003774271,"about_ca_system_score_codex":0.0008648616,"about_ca_system_score_gemma":0.0003256233,"threshold_uncertainty_score":0.012626231},"labels":[],"label_agreement":null},{"id":"W2022022610","doi":"10.3109/10428190009113379","title":"Matrix Metalloproteinases and Their Tissue Inhibitors - Expression, Role and Regulation in Human Malignant Non-Hodgkin's Lymphomas","year":2000,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Protease and Inhibitor Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Blood Services; Calgary Laboratory Services; University of Alberta; University of Calgary","funders":"Medical Research Council Canada; Ulster University; Canadian Blood Services","keywords":"Matrix metalloproteinase; Cancer research; Lymphoma; Medicine; Biology; Pathology; Internal medicine","score_opus":0.008402614704211088,"score_gpt":0.257436462538045,"score_spread":0.2490338478338339,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022022610","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002706037,0.99874496,0.000111649904,0.00009102282,0.00008948584,0.000002916346,0.000008800062,0.000004357776,0.0006762513],"genre_scores_gemma":[0.0010968354,0.99782145,0.00015652098,0.000073352,0.00009039263,0.000004566092,0.000021126563,6.7725153e-7,0.00073516864],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99985576,0.000019210576,0.000022039068,0.000024215156,0.00006606404,0.0000126596915],"domain_scores_gemma":[0.9998741,0.000041986907,0.000024754469,0.0000046128084,0.00003970614,0.000014816062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030696392,0.00061223324,0.0010488335,0.0016151252,0.0002144301,0.00071352767,0.00055116427,0.00078478444,0.0014678611],"category_scores_gemma":[0.0003414558,0.00020217011,0.00022219105,0.0021802224,0.00031875717,0.0009930473,0.0003410649,0.0008108322,0.001711644],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011960244,0.00008547552,0.00054810627,0.00949877,0.00005774392,0.00070184097,0.00010352564,0.0003741296,0.008302407,0.0026374578,0.01776912,0.9598018],"study_design_scores_gemma":[0.00003390349,0.00017400594,0.003676346,0.0018419415,0.000103356266,0.0068779774,0.00012050038,0.00012682258,0.0020442286,0.002974663,0.9820046,0.000021697053],"about_ca_topic_score_codex":0.00077377446,"about_ca_topic_score_gemma":0.0010975975,"teacher_disagreement_score":0.0016151252,"about_ca_system_score_codex":0.00048168187,"about_ca_system_score_gemma":0.0006270966,"threshold_uncertainty_score":0.004910469},"labels":[],"label_agreement":null},{"id":"W2025152396","doi":"10.1080/10428190802653776","title":"Anti-tumor immunity in a model of acute myeloid leukemia","year":2009,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Asthma and Lung UK","keywords":"Cytotoxic T cell; Immunology; Immune system; Myeloid leukemia; Myeloid; Biology; Cancer research; T cell; Leukemia; Antigen; Immunotherapy; In vitro","score_opus":0.009572915527247736,"score_gpt":0.22961908880687595,"score_spread":0.22004617327962822,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025152396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98196054,0.0017138699,0.009132504,0.00046219575,0.0003517843,0.0010367658,0.0008612181,0.0003097137,0.004171431],"genre_scores_gemma":[0.97742385,0.0018577407,0.008397989,0.0002507799,0.000101099744,0.0010583376,0.0011233465,0.000047237358,0.009739562],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999313,0.00019963938,0.000068479996,0.00013216415,0.00013992583,0.00014669195],"domain_scores_gemma":[0.99980134,0.00003334945,0.000049430724,0.00004008466,0.000013981776,0.000061888364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051547424,0.001181758,0.00071226916,0.0009159222,0.00038777431,0.00059541955,0.0007335142,0.0009896575,0.0020461348],"category_scores_gemma":[0.00016919895,0.0002857208,0.00041048072,0.00040142672,0.0006378201,0.000586388,0.00040747016,0.0025027702,0.00092213537],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017315006,0.003745656,0.00030088553,0.00015981814,0.000014137225,0.00047486482,0.00011156116,0.0009047643,0.9861167,0.0017700728,0.0003076084,0.004362507],"study_design_scores_gemma":[0.00069869735,0.024795694,0.0019435597,0.00005209764,0.000059444683,0.0018304054,0.00010789623,0.006422767,0.9462409,0.00089562946,0.01692665,0.000026265281],"about_ca_topic_score_codex":0.00037106214,"about_ca_topic_score_gemma":0.00037712615,"teacher_disagreement_score":0.0020461348,"about_ca_system_score_codex":0.00071105687,"about_ca_system_score_gemma":0.00043313162,"threshold_uncertainty_score":0.0068449974},"labels":[],"label_agreement":null},{"id":"W2027026214","doi":"10.1080/10428190310001617286","title":"Hyperthyroidism Six Years Post-BMT for Acute Myeloblastic Leukemia in a Patient on Long-Term Lithium Therapy for Bipolar Affective Disorder","year":2003,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Bipolar Disorder and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; The Scarborough Hospital","funders":"","keywords":"Lithium (medication); Bipolar disorder; Medicine; Thyroid function; Pediatrics; Acute myeloblastic leukemia; Affect (linguistics); Thyroid; Complication; Psychiatry; Internal medicine; Leukemia; Psychology","score_opus":0.007616627718722317,"score_gpt":0.24758517585429643,"score_spread":0.2399685481355741,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027026214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9716258,0.0022953306,0.00078142446,0.00885117,0.0004267092,0.00017825075,0.00023216885,0.00008956081,0.015519605],"genre_scores_gemma":[0.99408466,0.0009345157,0.0003380638,0.0021796993,0.0003872837,0.00002203945,0.00008352864,0.0000116702095,0.0019585628],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9997633,0.00003881139,0.00002717564,0.000039100985,0.0000431544,0.00008845491],"domain_scores_gemma":[0.99925405,0.00015379945,0.00012695894,0.000022248829,0.000052578493,0.00039035495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018869955,0.00064740225,0.00057971117,0.0013011935,0.0027572028,0.00059766136,0.000496892,0.0025726075,0.002691522],"category_scores_gemma":[0.0013894876,0.0005005517,0.0006894272,0.0007755099,0.00071154354,0.001028594,0.00047412855,0.0028707709,0.0005499321],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013038344,0.00014927895,0.034806784,0.00003237643,0.000014901004,0.9594046,0.0006237774,0.00006283209,0.0014019735,0.00016762991,0.0006890293,0.0025164578],"study_design_scores_gemma":[0.000039302013,0.0005974156,0.065718845,0.000046627276,0.000035071203,0.9304479,0.00079899677,0.00023867485,0.00048476466,0.00022839678,0.0013372502,0.000026797225],"about_ca_topic_score_codex":0.0065264986,"about_ca_topic_score_gemma":0.01188646,"teacher_disagreement_score":0.0065264986,"about_ca_system_score_codex":0.001332253,"about_ca_system_score_gemma":0.00090347644,"threshold_uncertainty_score":0.012977004},"labels":[],"label_agreement":null},{"id":"W2027091982","doi":"10.3109/10428194.2011.594193","title":"Is there a role for consolidative radiation therapy for aggressive B-cell lymphoma in the rituximab era?","year":2011,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Rituximab; Lymphoma; Medicine; Radiation therapy; Aggressive lymphoma; Oncology; Chemotherapy; Radioimmunotherapy; Internal medicine; Immunology; Monoclonal antibody; Antibody","score_opus":0.01890653494419384,"score_gpt":0.26031343238437393,"score_spread":0.2414068974401801,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027091982","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019227586,0.018729886,0.00017671623,0.96723896,0.007603828,0.000019687863,0.000088805726,0.000033024655,0.004186425],"genre_scores_gemma":[0.020175127,0.029062226,0.00090311817,0.86387587,0.08187246,0.000071538896,0.00020191418,0.00003757918,0.0038001873],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99808925,0.0007910393,0.00027798273,0.00017936312,0.00044274944,0.00021962954],"domain_scores_gemma":[0.9887582,0.007484811,0.00079371803,0.00021377734,0.0012719567,0.0014775113],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027680078,0.00044542897,0.0018126796,0.00060421706,0.0013798986,0.001890746,0.0016560467,0.019276245,0.012913311],"category_scores_gemma":[0.01621112,0.00033877674,0.0013444108,0.0007369256,0.0023442796,0.0035415746,0.00061208743,0.01385678,0.0059196632],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030857264,0.00031695166,0.0049849544,0.001123763,0.00016814275,0.0043860674,0.0001021878,0.00055938115,0.0014456764,0.008115128,0.7605057,0.21520637],"study_design_scores_gemma":[0.004833432,0.0015955863,0.008946763,0.0036891515,0.00037719237,0.008144528,0.00059789256,0.0012173783,0.0007267291,0.029919771,0.93982005,0.00013150494],"about_ca_topic_score_codex":0.0024834117,"about_ca_topic_score_gemma":0.0066021853,"teacher_disagreement_score":0.019276245,"about_ca_system_score_codex":0.0033493598,"about_ca_system_score_gemma":0.0028919505,"threshold_uncertainty_score":0.04319936},"labels":[],"label_agreement":null},{"id":"W2027093999","doi":"10.1080/1042819021000016087","title":"Allogeneic Bone Marrow Transplantation in the Management of Chronic Neutrophilic Leukemia","year":2002,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; University of Toronto; Health Sciences Centre; University Health Network","funders":"","keywords":"Medicine; Leukocytosis; Leukemia; Myeloproliferative Disorders; Disease; Chronic myelogenous leukemia; Bone marrow; Stage (stratigraphy); Transplantation; Immunology; Internal medicine; Oncology; Pathology; Biology","score_opus":0.015940342000825072,"score_gpt":0.24849738086645873,"score_spread":0.23255703886563367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027093999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8561878,0.10741822,0.009372986,0.006201786,0.0010920536,0.00019945782,0.00006534687,0.00016847304,0.019293852],"genre_scores_gemma":[0.98113626,0.014999655,0.001002581,0.0009507896,0.0009971356,0.000027666403,0.000044208085,0.0000085716,0.000833212],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9998944,0.000041511492,0.000009924928,0.000009856618,0.000019868521,0.000024441706],"domain_scores_gemma":[0.9998215,0.000048841055,0.00004222756,0.000007970658,0.000007868111,0.00007162812],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034650194,0.0003209674,0.00028598626,0.00022650542,0.00046826134,0.0002441839,0.0002655329,0.0006131127,0.0008642286],"category_scores_gemma":[0.0006052921,0.000058405443,0.00021451761,0.00016392516,0.00036392195,0.000255414,0.00024651003,0.0007740588,0.00023393457],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00448017,0.0017553024,0.09103685,0.0012318552,0.0002628202,0.21416384,0.0007361793,0.0027481914,0.03136331,0.0064456547,0.010587004,0.6351889],"study_design_scores_gemma":[0.0016082466,0.013034546,0.14739008,0.00077940454,0.0003715507,0.7316479,0.00078976527,0.003846726,0.010173703,0.008245698,0.08204805,0.00006428395],"about_ca_topic_score_codex":0.00020210419,"about_ca_topic_score_gemma":0.00048579235,"teacher_disagreement_score":0.0008642286,"about_ca_system_score_codex":0.00015622214,"about_ca_system_score_gemma":0.0002947356,"threshold_uncertainty_score":0.002891183},"labels":[],"label_agreement":null},{"id":"W2027904581","doi":"10.3109/10428194.2011.635863","title":"Blood, sex and tears: speculations on the gender imbalance in hematologic malignancies","year":2011,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Prenatal Screening and Diagnostics","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; University of Calgary; Calgary Laboratory Services","funders":"","keywords":"Medicine; Hematologic Neoplasms; Tears; Internal medicine; Dermatology; Immunology; Cancer","score_opus":0.026055523896818797,"score_gpt":0.23219880358617595,"score_spread":0.20614327968935714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027904581","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0075045973,0.018678054,0.000366861,0.95844823,0.009995634,0.000008646746,0.000065174674,0.000027521422,0.004905312],"genre_scores_gemma":[0.17860915,0.0280954,0.0007498081,0.5582828,0.22826461,0.000037581834,0.00009936076,0.000033593493,0.005827584],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99822694,0.000872275,0.00020989013,0.0002161636,0.00033522953,0.00013953111],"domain_scores_gemma":[0.99485624,0.0038717133,0.00038449658,0.00014807006,0.00047188872,0.0002675338],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002318757,0.000526295,0.0010291826,0.000770219,0.0017805208,0.0010753318,0.0012480137,0.014777846,0.0037055272],"category_scores_gemma":[0.015875848,0.00041142863,0.00058204896,0.00067815173,0.003685625,0.003973085,0.00084126886,0.0106686745,0.0020528163],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00068215176,0.00015094371,0.02829732,0.0003572577,0.000091922855,0.06311951,0.0013162011,0.00037878784,0.0019499983,0.033027556,0.78303283,0.08759562],"study_design_scores_gemma":[0.0006093488,0.0006408675,0.019833615,0.0016475847,0.00023665639,0.20264792,0.004100431,0.002391637,0.0019153242,0.123161554,0.6426008,0.00021428154],"about_ca_topic_score_codex":0.0015344672,"about_ca_topic_score_gemma":0.0016140698,"teacher_disagreement_score":0.014777846,"about_ca_system_score_codex":0.002451184,"about_ca_system_score_gemma":0.0010219106,"threshold_uncertainty_score":0.017784655},"labels":[],"label_agreement":null},{"id":"W2028310887","doi":"10.1080/1042819031000119208","title":"Improved Therapeutic Outcome Following Combination Immunogene Vaccination Therapy in Murine Myeloma","year":2003,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital; Ontario Institute for Cancer Research","funders":"","keywords":"CD80; Immunology; Vaccination; Antigen; Immunotherapy; Multiple myeloma; Medicine; Genetic enhancement; Minimal residual disease; Cytotoxic T cell; Cancer research; Immune system; Biology; CD40; In vitro; Bone marrow; Gene","score_opus":0.012800592667473002,"score_gpt":0.2473516002169836,"score_spread":0.2345510075495106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028310887","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99037313,0.0036593776,0.002647237,0.00016126287,0.00010837565,0.0001303274,0.00018537184,0.00019746434,0.0025373625],"genre_scores_gemma":[0.9956299,0.0012762717,0.0012405722,0.00005859439,0.00004682426,0.000066160625,0.00032763835,0.000024557461,0.0013293782],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996557,0.00007013749,0.0000195369,0.000051148247,0.00008260859,0.000120843026],"domain_scores_gemma":[0.99981743,0.00003794769,0.000046159774,0.000030087827,0.000012338591,0.000056071774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031844006,0.0005442558,0.00085191906,0.000551809,0.00016638555,0.000475451,0.0003074941,0.00063962315,0.001175462],"category_scores_gemma":[0.00024246414,0.00014961768,0.00026039514,0.0002779162,0.0003243641,0.00030854187,0.00033354101,0.0010097616,0.00041673597],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033713453,0.002541363,0.0011405984,0.00021412926,0.00009304362,0.00027755927,0.000086018794,0.0024909966,0.9340104,0.0005315535,0.0005813758,0.054661587],"study_design_scores_gemma":[0.0010335866,0.046368204,0.012156499,0.000046006164,0.0002767281,0.0019527687,0.000042660362,0.0056274664,0.92337996,0.00039371825,0.008693457,0.000028892406],"about_ca_topic_score_codex":0.000280627,"about_ca_topic_score_gemma":0.00037805972,"teacher_disagreement_score":0.001175462,"about_ca_system_score_codex":0.00031823915,"about_ca_system_score_gemma":0.00021112387,"threshold_uncertainty_score":0.003932297},"labels":[],"label_agreement":null},{"id":"W2029150962","doi":"10.1080/10428190902943069","title":"Targeting the Bcl-2 family of proteins in Hodgkin lymphoma:<b><i>in vitro</i></b>cytotoxicity, target modulation and drug combination studies of the Bcl-2 homology 3 mimetic ABT-737","year":2009,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital","funders":"","keywords":"Survivin; Lymphoma; Cancer research; Cytotoxicity; Bcl-2 family; Apoptosis; In vitro; Medicine; Pharmacology; Drug; Growth inhibition; Biology; Oncology; Immunology; Programmed cell death; Biochemistry","score_opus":0.007915829360495305,"score_gpt":0.22810931968809678,"score_spread":0.22019349032760147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029150962","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98457277,0.010644398,0.002088672,0.00018304675,0.000053020383,0.00006256343,0.00013047249,0.00008062277,0.002184485],"genre_scores_gemma":[0.99314535,0.004414669,0.001387002,0.00003719942,0.000035045483,0.00003480882,0.00015920043,0.000010902495,0.0007758074],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998265,0.00007829838,0.000011517399,0.000013019931,0.000039684677,0.00003092645],"domain_scores_gemma":[0.9999137,0.000029131239,0.000010697974,0.000010794329,0.000013959378,0.000021720673],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003177444,0.00023791369,0.00035780572,0.0003369485,0.00023090772,0.00031677436,0.00017645214,0.0001596928,0.0011118948],"category_scores_gemma":[0.0001700724,0.00011660737,0.00019459853,0.00024714708,0.00025612875,0.0002244155,0.00011481584,0.0005156602,0.00023983087],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015692047,0.0007832171,0.0009845092,0.00025997518,0.00004769881,0.0001708939,0.00005664898,0.0010632863,0.9626903,0.0004572878,0.0004973481,0.031419586],"study_design_scores_gemma":[0.00020655211,0.0061342297,0.0028081348,0.000010066157,0.0000913794,0.0007405269,0.000028589362,0.0017567254,0.98391163,0.00009092606,0.0042141248,0.0000071378645],"about_ca_topic_score_codex":0.001126253,"about_ca_topic_score_gemma":0.0018004983,"teacher_disagreement_score":0.001126253,"about_ca_system_score_codex":0.0003536538,"about_ca_system_score_gemma":0.00038215125,"threshold_uncertainty_score":0.0037196875},"labels":[],"label_agreement":null},{"id":"W2029440792","doi":"10.1080/10428190500301231","title":"Generation of<i>in vitro</i>B-CLL specific HLA class I restricted CTL responses using autologous dendritic cells pulsed with necrotictumor lysate","year":2005,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre","funders":"Leukemia Research Foundation","keywords":"CTL*; In vitro; Dendritic cell; Immunology; Cancer research; Lysis; Human leukocyte antigen; Class (philosophy); Chemistry; Biology; Molecular biology; Immune system; Cytotoxic T cell; Antigen; Biochemistry; Computer science","score_opus":0.034461594973760036,"score_gpt":0.2773981374998455,"score_spread":0.24293654252608546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029440792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940499,0.00076328457,0.0035465236,0.00008223344,0.000025533202,0.00006497736,0.00011983131,0.00007895471,0.0012687847],"genre_scores_gemma":[0.9963594,0.00053910847,0.0020969734,0.000058400474,0.000017513928,0.00004410734,0.00037517364,0.000016643371,0.0004927341],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99986243,0.000045431705,0.000011996922,0.000022311473,0.000023334374,0.00003441294],"domain_scores_gemma":[0.9999106,0.000033610424,0.00001903032,0.000012632164,0.000009938027,0.000014132061],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019992709,0.00024457628,0.00026168037,0.00008687254,0.0000823673,0.0002943989,0.000093053866,0.00021206039,0.0010909317],"category_scores_gemma":[0.00017565796,0.000087819484,0.00020173838,0.00006927215,0.00014479429,0.00013535819,0.00013863269,0.00051276985,0.00047682715],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004027832,0.00022378487,0.0013378343,0.00009241274,0.000008923268,0.000058631413,0.00002961027,0.00024051833,0.9907844,0.0000585294,0.000121633064,0.006640918],"study_design_scores_gemma":[0.00015490408,0.004314415,0.003092212,0.000013426193,0.000043671374,0.0009243255,0.000034821474,0.0012451292,0.9878349,0.000058709848,0.002279343,0.0000042725583],"about_ca_topic_score_codex":0.00012259517,"about_ca_topic_score_gemma":0.000106099345,"teacher_disagreement_score":0.0010909317,"about_ca_system_score_codex":0.0001496181,"about_ca_system_score_gemma":0.00011267332,"threshold_uncertainty_score":0.0036495924},"labels":[],"label_agreement":null},{"id":"W2030216096","doi":"10.3109/10428194.2010.528095","title":"Study of specific genetic and epigenetic variables in multiple myeloma","year":2010,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Methylenetetrahydrofolate reductase; Methylation; Genotype; CpG site; Single-nucleotide polymorphism; DNA methylation; Epigenetics; CDKN2A; Internal medicine; Biology; Cancer research; Medicine; Genetics; Cancer; Gene; Gene expression","score_opus":0.010377033726410058,"score_gpt":0.22723472910517695,"score_spread":0.2168576953787669,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030216096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99582976,0.0026517506,0.00054541236,0.000058939535,0.000008340347,0.0000113007845,0.00025855607,0.0000071907416,0.00062886166],"genre_scores_gemma":[0.9981652,0.0007642457,0.0004426917,0.000039769064,0.000022417531,0.000009083764,0.00016180954,0.0000030538836,0.00039179897],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999793,0.0000535513,0.00001764517,0.00006823666,0.00004805153,0.000019555708],"domain_scores_gemma":[0.9996933,0.00008335735,0.0001256272,0.000019515994,0.000036652564,0.0000415122],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035390997,0.00013276844,0.00025696403,0.0007707091,0.00019327231,0.00019950814,0.0001794087,0.00024313245,0.0008656081],"category_scores_gemma":[0.00069701904,0.000094439114,0.00016608708,0.0012476856,0.00016602121,0.00018389992,0.00016375691,0.00022400015,0.00013199943],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00064980605,0.000088455025,0.94265026,0.00014116711,0.00024113506,0.0007203523,0.00017940634,0.00020522677,0.029859658,0.0001560259,0.00013711893,0.024971407],"study_design_scores_gemma":[0.000006901408,0.00016280607,0.99598855,0.000006112612,0.00005442581,0.0008469745,0.00006568832,0.00019054572,0.001928104,0.00008757261,0.0006591682,0.0000031104028],"about_ca_topic_score_codex":0.0011985404,"about_ca_topic_score_gemma":0.0013322523,"teacher_disagreement_score":0.0011985404,"about_ca_system_score_codex":0.00019508284,"about_ca_system_score_gemma":0.00017838574,"threshold_uncertainty_score":0.0028957725},"labels":[],"label_agreement":null},{"id":"W2030504196","doi":"10.3109/10428190109064590","title":"Outpatient Supportive Care Following Chemotherapy for Acute Myeloblastic Leukemia","year":2001,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Health Sciences Centre; University of Toronto; Women's College Hospital","funders":"","keywords":"Medicine; Febrile neutropenia; Chemotherapy; Induction chemotherapy; Cytarabine; Neutropenia; Sepsis; Outpatient clinic; Internal medicine; Surgery","score_opus":0.0098518977143296,"score_gpt":0.27482453568250925,"score_spread":0.26497263796817966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030504196","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8836767,0.098029435,0.0019316637,0.0012610832,0.0003153084,0.00038039923,0.0006630473,0.00010486215,0.013637511],"genre_scores_gemma":[0.9610136,0.032503977,0.0019919556,0.0012105921,0.0003564557,0.0001427597,0.0009968806,0.000020557996,0.0017633499],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9991647,0.0003543535,0.000106472544,0.000046125064,0.00024882404,0.00007949717],"domain_scores_gemma":[0.9969117,0.0010900776,0.0012902113,0.00007468637,0.0003490561,0.00028431558],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005751098,0.00012209098,0.00020085931,0.0005720407,0.00033337506,0.0003905242,0.00022372161,0.00019212031,0.0018321257],"category_scores_gemma":[0.005368628,0.000055042383,0.00014381747,0.00073154137,0.00016727686,0.00018808326,0.00025827345,0.00029996762,0.0002887917],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001024333,0.00020130993,0.4619318,0.003116337,0.00013061591,0.008530863,0.0011524048,0.00013277405,0.0034073263,0.0003351536,0.010911226,0.5091258],"study_design_scores_gemma":[0.00013257918,0.0018282854,0.8782084,0.0011800111,0.00022883699,0.035565056,0.0011867485,0.00018739772,0.0022342473,0.00026372756,0.07896664,0.000018025152],"about_ca_topic_score_codex":0.0012093374,"about_ca_topic_score_gemma":0.003142013,"teacher_disagreement_score":0.0018321257,"about_ca_system_score_codex":0.00033281615,"about_ca_system_score_gemma":0.0007067194,"threshold_uncertainty_score":0.006129086},"labels":[],"label_agreement":null},{"id":"W2031912770","doi":"10.3109/10428194.2014.900763","title":"Sunitinib malate in patients with intermediate-2 or high-risk myelodysplastic syndrome or chronic myelomonocytic leukemia","year":2014,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Chronic myelomonocytic leukemia; Sunitinib malate; Myelodysplastic syndromes; Medicine; Internal medicine; Oncology; Cancer research; Gastroenterology; Sunitinib; Cancer; Bone marrow","score_opus":0.01136352221495713,"score_gpt":0.23605733998542885,"score_spread":0.22469381777047173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031912770","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21492627,0.07956634,0.0013395168,0.5990991,0.014589511,0.00013946962,0.000591301,0.00032172233,0.08942676],"genre_scores_gemma":[0.81286806,0.023245543,0.0010669994,0.12461443,0.02297914,0.000080467136,0.0005361839,0.000037420938,0.014571794],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99980766,0.00005307973,0.000018181263,0.000024921685,0.000045672397,0.000050519066],"domain_scores_gemma":[0.9997167,0.00010664583,0.00003311531,0.000010497426,0.000027030406,0.00010589485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020437241,0.00029942073,0.00060563313,0.00035270146,0.00076352,0.00048289393,0.00036597863,0.0033037583,0.0030277802],"category_scores_gemma":[0.0012882664,0.000116097,0.00043742365,0.00034936678,0.00036571236,0.00066317193,0.00021665126,0.0022588917,0.0013182635],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025593806,0.00042209227,0.06961848,0.0005805325,0.00020782967,0.3254653,0.00025679328,0.00119166,0.0061923284,0.0048895553,0.3912152,0.19740091],"study_design_scores_gemma":[0.0012702473,0.0021365592,0.072575144,0.0006899809,0.00035164034,0.5723306,0.00066260784,0.0051971995,0.0031016339,0.015323894,0.3262424,0.000118102515],"about_ca_topic_score_codex":0.0012090771,"about_ca_topic_score_gemma":0.0036243827,"teacher_disagreement_score":0.0033037583,"about_ca_system_score_codex":0.0011311054,"about_ca_system_score_gemma":0.0005594456,"threshold_uncertainty_score":0.010128915},"labels":[],"label_agreement":null},{"id":"W2032055037","doi":"10.1080/10428190802064941","title":"Treatment of relapsed and refractory myeloma","year":2008,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Dalhousie University; Saskatchewan Cancer Agency; Queen Elizabeth II Health Sciences Centre; University of Alberta; University of Saskatchewan; London Health Sciences Centre; St. Paul's Hospital; Centre hospitalier universitaire de Québec; Ottawa Hospital; University of British Columbia","funders":"","keywords":"Lenalidomide; Thalidomide; Medicine; Multiple myeloma; Bortezomib; Refractory (planetary science); Salvage therapy; Oncology; Internal medicine; Clinical trial; Pomalidomide; Malignancy; Chemotherapy; Intensive care medicine; Biology","score_opus":0.037678915989462464,"score_gpt":0.3176391694733303,"score_spread":0.2799602534838679,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032055037","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015232603,0.99866915,0.00006680244,0.00018073438,0.00009481448,0.000004275236,0.00000882023,0.0000056641825,0.0008173531],"genre_scores_gemma":[0.0007751556,0.9983675,0.00014321177,0.00017022803,0.00010526583,0.000005566178,0.000022064813,9.107253e-7,0.00041005824],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99973065,0.00006298586,0.000033500575,0.000038715083,0.00011545497,0.00001864195],"domain_scores_gemma":[0.9998035,0.00007236934,0.000052495543,0.000007794318,0.000045129345,0.000018748859],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053032045,0.0006120256,0.0016158413,0.0019014088,0.00023922864,0.000573228,0.001038969,0.00088185613,0.002830389],"category_scores_gemma":[0.0006356397,0.00017342834,0.00047357386,0.0016285109,0.00038584744,0.00068015716,0.00045390037,0.0012781036,0.00234553],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005799272,0.00006751941,0.00014096552,0.008835129,0.000096936856,0.0002605948,0.000040254596,0.00017059481,0.0010232945,0.001011233,0.02184905,0.9664464],"study_design_scores_gemma":[0.000064826,0.00019002102,0.0018984932,0.0064766,0.00015625637,0.004276075,0.00008060828,0.00009156363,0.0006106288,0.0017451918,0.98439306,0.000016661448],"about_ca_topic_score_codex":0.0008924098,"about_ca_topic_score_gemma":0.0018263663,"teacher_disagreement_score":0.002830389,"about_ca_system_score_codex":0.000539717,"about_ca_system_score_gemma":0.00067681196,"threshold_uncertainty_score":0.009468555},"labels":[],"label_agreement":null},{"id":"W2036791873","doi":"10.1080/10428190802140873","title":"Cardiac morbidity following modern treatment for Hodgkin lymphoma: Supra-additive cardiotoxicity of doxorubicin and radiation therapy","year":2008,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":170,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; Princess Margaret Cancer Centre; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Cardiotoxicity; Doxorubicin; Lymphoma; Chemotherapy; Internal medicine; Radiation therapy; Population; Incidence (geometry); Gastroenterology; Disease; Cardiac toxicity; Oncology; Cardiology; Surgery","score_opus":0.02346052667657797,"score_gpt":0.2627539482421572,"score_spread":0.23929342156557923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2036791873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966433,0.0022474881,0.00026452687,0.00006703766,0.000004163215,0.0000058394025,0.00002601134,0.0000037339862,0.0007378698],"genre_scores_gemma":[0.9994703,0.00032259137,0.000078260404,0.000021204667,0.000012450326,0.0000016703991,0.000030841755,6.0970535e-7,0.00006207206],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99948585,0.00026044078,0.000041345178,0.000032895354,0.00011816847,0.000061254854],"domain_scores_gemma":[0.9985593,0.00056225975,0.00059764826,0.00008276752,0.00006506236,0.00013291431],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078338315,0.00010027233,0.00023033493,0.0002763844,0.00011469219,0.00031400507,0.000105014486,0.00013427756,0.0010312948],"category_scores_gemma":[0.0019986103,0.000099481076,0.0003986322,0.00028208192,0.00017743577,0.00021194435,0.00042439866,0.00024230978,0.000075048774],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007252688,0.000044211924,0.97057444,0.000040010083,0.0001708922,0.0003420433,0.000049265174,0.00045798306,0.0011082488,0.000077732846,0.00008395063,0.026325827],"study_design_scores_gemma":[0.0000128865095,0.0006093431,0.996801,0.000011139068,0.00009765593,0.0012561562,0.00003999971,0.00032925233,0.00047907303,0.00008347228,0.00027682178,0.0000030177175],"about_ca_topic_score_codex":0.00043652765,"about_ca_topic_score_gemma":0.001285696,"teacher_disagreement_score":0.0010312948,"about_ca_system_score_codex":0.00035107293,"about_ca_system_score_gemma":0.00022928973,"threshold_uncertainty_score":0.0041429996},"labels":[],"label_agreement":null},{"id":"W2039165844","doi":"10.1080/10428190600923157","title":"Unusual fluid retention with imatinib therapy for chronic myeloid leukemia","year":2006,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Imatinib; Myeloid leukemia; Medicine; Oncology; Cancer research; Internal medicine","score_opus":0.014858361213849139,"score_gpt":0.24383367669860398,"score_spread":0.22897531548475483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2039165844","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.44410506,0.025933905,0.008671945,0.34252402,0.015971107,0.0007045462,0.0007263826,0.0015095422,0.15985349],"genre_scores_gemma":[0.89222014,0.0051429574,0.0037268999,0.059868332,0.025581835,0.00013133632,0.00021827861,0.00016896646,0.01294139],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99900705,0.00020660595,0.00016205138,0.00010879595,0.0002322488,0.000283314],"domain_scores_gemma":[0.9970337,0.0013706068,0.0006617413,0.00014339795,0.00012625917,0.0006643192],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006599837,0.0014809325,0.0015427059,0.001770931,0.002238426,0.0017355748,0.001319007,0.013873359,0.0053081405],"category_scores_gemma":[0.007048938,0.0008687365,0.0022075074,0.001187173,0.0017070759,0.0033173535,0.0012568843,0.010193869,0.0014862189],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016178533,0.00005014625,0.001961415,0.00006839977,0.000019875592,0.98810774,0.00006604896,0.0001243743,0.00049069826,0.0006753926,0.005589041,0.002684979],"study_design_scores_gemma":[0.0001943493,0.00025045042,0.003483976,0.0000757255,0.0000547256,0.982511,0.00011836455,0.0015220473,0.0011099483,0.0010429038,0.009607721,0.00002875891],"about_ca_topic_score_codex":0.001632862,"about_ca_topic_score_gemma":0.0030797762,"teacher_disagreement_score":0.013873359,"about_ca_system_score_codex":0.002734045,"about_ca_system_score_gemma":0.0014940654,"threshold_uncertainty_score":0.019837022},"labels":[],"label_agreement":null},{"id":"W2039431106","doi":"10.1080/10428190400015022","title":"Allogeneic stem cell transplantation for mantle cell lymphoma--does it deserve a better look?","year":2004,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Mantle cell lymphoma; Medicine; Transplantation; Lymphoma; Stem cell; Population; Autologous stem-cell transplantation; Internal medicine; Surgery; Oncology; Biology","score_opus":0.01109129190567764,"score_gpt":0.23112762485023536,"score_spread":0.2200363329445577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2039431106","genre_codex":"review","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1628312,0.43902984,0.0036499805,0.35359162,0.025940273,0.00014419318,0.00022697517,0.00018630503,0.014399652],"genre_scores_gemma":[0.5937849,0.22002569,0.004368019,0.110729635,0.061095938,0.00017230022,0.00038544892,0.00008886054,0.009349184],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99968016,0.00012923378,0.00005550553,0.000024086266,0.00005150428,0.000059478585],"domain_scores_gemma":[0.99873537,0.0004656307,0.00015590838,0.000106523265,0.00015313172,0.00038339326],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015021225,0.000327534,0.00095447665,0.0004015991,0.00045079915,0.0008994712,0.00050470815,0.0033103938,0.0051305247],"category_scores_gemma":[0.0023515162,0.0001473844,0.00076348434,0.0004155641,0.0010198021,0.0020289556,0.00028273647,0.00195973,0.0010919357],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056813643,0.0008478041,0.048401088,0.0018764153,0.00034364258,0.02403474,0.00037890553,0.0008419541,0.005225915,0.008443479,0.07240618,0.8315185],"study_design_scores_gemma":[0.0052577313,0.022143498,0.14073284,0.007559041,0.0013330837,0.1975475,0.0066861575,0.0025109667,0.005617196,0.046014443,0.5642415,0.00035605932],"about_ca_topic_score_codex":0.00047807596,"about_ca_topic_score_gemma":0.0014989603,"teacher_disagreement_score":0.0051305247,"about_ca_system_score_codex":0.00036736834,"about_ca_system_score_gemma":0.00079009146,"threshold_uncertainty_score":0.017163336},"labels":[],"label_agreement":null},{"id":"W2040039314","doi":"10.3109/10428190109097717","title":"A Multicentric Study of 41 Cases of B-Prolymphocytic Leukemia: Two Evolutive Forms: The Groupe Français d'Hématologie Cellulaire","year":2001,"lang":"fr","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Prolymphocytic leukemia; Medicine; Chronic lymphocytic leukemia; Internal medicine; Immunophenotyping; Univariate analysis; Leukemia; CD5; Gastroenterology; Anemia; Concordance; Multivariate analysis; Immunology; Lymphoma; Antigen","score_opus":0.022949868926353215,"score_gpt":0.28775321473783533,"score_spread":0.2648033458114821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040039314","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9995498,0.00013038947,0.00007848212,0.00001385104,0.000002514821,0.000014802979,0.000056645542,0.0000024326598,0.00015110288],"genre_scores_gemma":[0.99931,0.00013124723,0.00010530403,0.00002272777,0.00001531375,0.000016444146,0.00021464411,0.0000024180517,0.00018175099],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992403,0.00017737606,0.00006806464,0.00021524426,0.00009137618,0.00020772057],"domain_scores_gemma":[0.9986811,0.00035288496,0.0003616136,0.000116330506,0.00011857684,0.00036954423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007339407,0.0006219012,0.00045650106,0.0017133835,0.000953045,0.00048728526,0.00031903962,0.000596623,0.0019073125],"category_scores_gemma":[0.0019940748,0.0004239484,0.00035995155,0.0009720344,0.00078809995,0.00045176732,0.0007972935,0.00031270107,0.00044977697],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022360888,0.00009366495,0.98527414,0.000029704428,0.00004581237,0.0070257997,0.0006623205,0.00007288959,0.0012419944,0.000034871795,0.00017671636,0.0051184953],"study_design_scores_gemma":[0.000051645184,0.0006162285,0.95847523,0.000013984318,0.000044722,0.037234467,0.0011983498,0.00019197831,0.00044386985,0.000049450835,0.0016579081,0.000022177372],"about_ca_topic_score_codex":0.0028565913,"about_ca_topic_score_gemma":0.001957355,"teacher_disagreement_score":0.0028565913,"about_ca_system_score_codex":0.00042109817,"about_ca_system_score_gemma":0.00028413412,"threshold_uncertainty_score":0.0063806176},"labels":[],"label_agreement":null},{"id":"W2040343471","doi":"10.3109/10428190009059279","title":"Accumulation of Sestamibi in Lymphoma Cell Lines<i>In Vitro</i>","year":2000,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Drug Transport and Resistance Mechanisms","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto","funders":"","keywords":"Depolarization; Membrane potential; Hyperpolarization (physics); Cell culture; In vitro; Mitochondrion; Valinomycin; Intracellular; Biology; Lymphoma; Inner mitochondrial membrane; Chemistry; Biophysics; Biochemistry; Immunology","score_opus":0.013964985479915138,"score_gpt":0.2524795333093819,"score_spread":0.23851454782946674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040343471","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97328895,0.007663826,0.010636912,0.00026783557,0.000093126044,0.00017165263,0.0017812845,0.00029519034,0.005801238],"genre_scores_gemma":[0.9774958,0.003139574,0.012243839,0.00017885657,0.0000377842,0.00022302664,0.0031694123,0.00009200761,0.0034197741],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99950004,0.00018807189,0.00006251609,0.00007590282,0.000094057345,0.000079394646],"domain_scores_gemma":[0.9996985,0.00010005596,0.000042056752,0.000054884258,0.000076678116,0.000027812108],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052951835,0.00047256652,0.0005888467,0.00029812526,0.00024419787,0.0006155566,0.00029394563,0.0005096042,0.0012402654],"category_scores_gemma":[0.00027728948,0.00023098457,0.000353597,0.00038187814,0.00018535012,0.00026185805,0.00021564448,0.00058307784,0.00084986375],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020099635,0.00006429715,0.00050410436,0.00008509544,0.000014909961,0.00007563826,0.00007032647,0.00010162373,0.9966558,0.00006113479,0.00013795674,0.0020281519],"study_design_scores_gemma":[0.000011847626,0.0005809419,0.0022927634,0.0000062469408,0.00002255483,0.00020937507,0.00004458941,0.0007630758,0.9945322,0.000014646771,0.0015165186,0.000005290891],"about_ca_topic_score_codex":0.0026503883,"about_ca_topic_score_gemma":0.0027867747,"teacher_disagreement_score":0.0026503883,"about_ca_system_score_codex":0.0005086142,"about_ca_system_score_gemma":0.0002268365,"threshold_uncertainty_score":0.005269885},"labels":[],"label_agreement":null},{"id":"W2041968741","doi":"10.1080/10428190290026295","title":"The Development of Marked Elevation in White Blood Cell Count Does Not Predict Inferior Outcome in Chronic Lymphocytic Leukemia","year":2002,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; White blood cell; Internal medicine; Stage (stratigraphy); Gastroenterology; Clinical significance; Leukemia; Surgery","score_opus":0.02907200730900288,"score_gpt":0.3000358864022648,"score_spread":0.2709638790932619,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2041968741","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99925405,0.00038096402,0.00003921222,0.000023787588,0.0000041034937,0.0000022659547,0.00003347691,0.0000017147934,0.00026046083],"genre_scores_gemma":[0.9997186,0.00009044787,0.000031777785,0.000013768268,0.000010407821,0.0000022360587,0.00008974041,8.579528e-7,0.000042214513],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995326,0.00014728228,0.00006684776,0.000065115164,0.00006955079,0.00011862238],"domain_scores_gemma":[0.99612445,0.0012102028,0.0016349591,0.0001384433,0.00023198914,0.0006599935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007825882,0.00022425104,0.00032125763,0.0007877268,0.00032525748,0.00053223106,0.00028877793,0.0005524081,0.0011875757],"category_scores_gemma":[0.0043531796,0.00015421787,0.00013445757,0.00062538066,0.00060107093,0.00046194674,0.00034927574,0.00030495154,0.00027608473],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017682608,0.000013770816,0.9975539,0.0000069075363,0.0000070400815,0.00021033573,0.000026004831,0.000025111845,0.0003718881,0.0000091748025,0.00004130754,0.0015578701],"study_design_scores_gemma":[0.000016275899,0.0002618938,0.99703896,0.000011836148,0.00001819457,0.0020092325,0.00011844487,0.00014817149,0.00015202895,0.00004551739,0.00017598318,0.0000034238954],"about_ca_topic_score_codex":0.0010046681,"about_ca_topic_score_gemma":0.0014815384,"teacher_disagreement_score":0.0011875757,"about_ca_system_score_codex":0.00028279255,"about_ca_system_score_gemma":0.00026360777,"threshold_uncertainty_score":0.0041388273},"labels":[],"label_agreement":null},{"id":"W2045667534","doi":"10.3109/10428194.2014.1003057","title":"Absolute lymphocyte count as predictor of overall survival for patients with multiple myeloma treated with single autologous stem cell transplant","year":2015,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Multiple myeloma; Internal medicine; Autologous stem-cell transplantation; Multivariate analysis; Oncology; Lymphocyte; Surrogate endpoint; Overall survival; Gastroenterology; Stem cell; Surgery; Urology","score_opus":0.016522998800905204,"score_gpt":0.2301193305084677,"score_spread":0.21359633170756248,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045667534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99915755,0.00044782946,0.000053075877,0.000041108586,0.000006457781,0.0000023881582,0.00006868247,0.0000041145277,0.00021876613],"genre_scores_gemma":[0.9997131,0.000060364535,0.000025312886,0.0000118508615,0.000008497632,0.0000018782105,0.0001069094,7.2654814e-7,0.00007134222],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99988174,0.000029263347,0.000016791806,0.000019106928,0.000026896,0.00002610086],"domain_scores_gemma":[0.99907565,0.00027992518,0.0003478729,0.000032264375,0.000069358466,0.00019497084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040282708,0.00012400109,0.00025895325,0.00040654422,0.00017577925,0.0003941215,0.0001605994,0.00024411734,0.001321812],"category_scores_gemma":[0.0014858765,0.00007743148,0.00028286807,0.0004139482,0.00016946909,0.00028567857,0.00024696477,0.00048822368,0.00017581899],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038589013,0.000023509656,0.9963815,0.000006117106,0.000023403087,0.00006180162,0.000015837919,0.00010899301,0.00032606523,0.0000075628295,0.00007105099,0.0025883373],"study_design_scores_gemma":[0.000012386945,0.00043127104,0.9979506,0.0000061123123,0.000054574233,0.0005230798,0.000063621825,0.00052149716,0.00018443483,0.000032902855,0.00021610975,0.0000033855692],"about_ca_topic_score_codex":0.00059952185,"about_ca_topic_score_gemma":0.000837269,"teacher_disagreement_score":0.001321812,"about_ca_system_score_codex":0.00017273931,"about_ca_system_score_gemma":0.00023500269,"threshold_uncertainty_score":0.0044219494},"labels":[],"label_agreement":null},{"id":"W2046562935","doi":"10.3109/10428190009148399","title":"Clinical Significance of the t(14;18) And<i>BCL2</i>Overexpression in Follicular Large Cell Lymphoma","year":2000,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute; U.S. Department of Health and Human Services","keywords":"Follicular lymphoma; Lymphoma; Anthracycline; Trisomy; Medicine; Oncology; Internal medicine; Chemotherapy; Diffuse large B-cell lymphoma; Cancer research; Biology; Cancer; Breast cancer","score_opus":0.01216047175015825,"score_gpt":0.263319022229649,"score_spread":0.2511585504794907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046562935","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99926347,0.0002528993,0.000043544143,0.00004760683,0.0000021524966,0.0000033919603,0.00002811861,0.0000027412013,0.00035601045],"genre_scores_gemma":[0.9998363,0.00003666704,0.000029249491,0.00001583134,0.0000073046012,0.0000021744138,0.000026350503,7.1398046e-7,0.000045361943],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998342,0.000051455652,0.000018751956,0.000027481776,0.000024020055,0.000044097436],"domain_scores_gemma":[0.9990163,0.00032633066,0.00035371276,0.000035089903,0.00005637297,0.00021224009],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025322856,0.00015536159,0.00021244289,0.00042235726,0.00026494067,0.00038033532,0.00014292232,0.0002969667,0.0010931472],"category_scores_gemma":[0.0015127849,0.0001281902,0.00008022207,0.00028150217,0.0004763694,0.0002596482,0.00017583894,0.00026532135,0.00016042784],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00068403233,0.000034801196,0.9846719,0.000016770375,0.000014817515,0.0023577013,0.00007507523,0.000114862836,0.0065283338,0.00003258801,0.00013735972,0.0053316606],"study_design_scores_gemma":[0.00005900185,0.00064516003,0.9814068,0.000007850867,0.000048261652,0.014892959,0.00021236078,0.000395252,0.0015371523,0.00014519792,0.0006399831,0.0000100340785],"about_ca_topic_score_codex":0.0005638355,"about_ca_topic_score_gemma":0.00079691183,"teacher_disagreement_score":0.0010931472,"about_ca_system_score_codex":0.00019958938,"about_ca_system_score_gemma":0.00015775002,"threshold_uncertainty_score":0.0036569238},"labels":[],"label_agreement":null},{"id":"W2048529382","doi":"10.3109/10428194.2011.567317","title":"Death receptor 4 is preferentially recruited to lipid rafts in chronic lymphocytic leukemia cells contributing to tumor necrosis related apoptosis inducing ligand-induced synergistic apoptotic responses","year":2011,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Chronic lymphocytic leukemia; Apoptosis; Fludarabine; Cancer research; Lipid raft; Chlorambucil; Leukemia; Programmed cell death; Cell culture; Immunology; Receptor; Biology; Medicine; Internal medicine; Chemotherapy; Biochemistry","score_opus":0.021245522603849393,"score_gpt":0.24108168273102867,"score_spread":0.21983616012717927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048529382","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970047,0.0009093153,0.00095006044,0.000057611192,0.00000783021,0.000010505523,0.0000954611,0.000026147289,0.00093838584],"genre_scores_gemma":[0.9964701,0.00059873523,0.00072844676,0.000033882494,0.0000072451076,0.00002518764,0.0002950053,0.0000068775435,0.0018344412],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99989486,0.000020351767,0.0000060881976,0.000015666972,0.000021573072,0.000041487565],"domain_scores_gemma":[0.9999505,0.0000059742597,0.000012830552,0.0000074808836,0.000010763927,0.000012424547],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009075989,0.00020896735,0.00017457696,0.00025600937,0.00025088282,0.00034607097,0.00010889597,0.00018002868,0.0016918627],"category_scores_gemma":[0.00011692437,0.00014991529,0.00016641903,0.00014562313,0.00012531923,0.00018857923,0.0002618728,0.00019796549,0.00087072246],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011872307,0.0000088986935,0.0004949104,0.000020795245,0.000003358388,0.000095580705,0.000015664622,0.00002234835,0.9983176,0.00006838764,0.000036020574,0.0007977161],"study_design_scores_gemma":[0.00008674706,0.00024390098,0.023120651,0.00001194028,0.000032001513,0.0014729073,0.00020881502,0.0011856963,0.9661899,0.00023000388,0.007206002,0.000011387315],"about_ca_topic_score_codex":0.0005621963,"about_ca_topic_score_gemma":0.0007259841,"teacher_disagreement_score":0.0016918627,"about_ca_system_score_codex":0.000356546,"about_ca_system_score_gemma":0.00013993011,"threshold_uncertainty_score":0.0056598186},"labels":[],"label_agreement":null},{"id":"W2048790475","doi":"10.3109/10428194.2014.985673","title":"Structural genomic alterations in primary mediastinal large B-cell lymphoma","year":2014,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia","funders":"BC Cancer Agency; Canadian Institutes of Health Research","keywords":"Lymphoma; CIITA; Cancer research; Somatic cell; Biology; Breakpoint; Chromothripsis; Pathogenesis; Computational biology; Genetics; Gene; Genome instability; Immunology; DNA; Chromosomal translocation; DNA damage","score_opus":0.01713303286461503,"score_gpt":0.2728314617455311,"score_spread":0.25569842888091604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048790475","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012273228,0.9990225,0.0000511179,0.00013748575,0.00006631557,0.0000024482806,0.000017804887,0.000004291997,0.0005753326],"genre_scores_gemma":[0.00081982545,0.9985121,0.00009800808,0.00013718702,0.00007099874,0.0000029979435,0.000034103407,8.459636e-7,0.00032387194],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998932,0.000019158913,0.00001999702,0.0000210321,0.000036006208,0.000010536824],"domain_scores_gemma":[0.99980706,0.00008495988,0.000038770544,0.0000050161357,0.000048610564,0.000015669588],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002980255,0.00053850503,0.0010309558,0.002199369,0.00018012931,0.0005700054,0.00051793107,0.00059618533,0.0029497044],"category_scores_gemma":[0.00054945145,0.00021791646,0.0003835515,0.0021028735,0.00028035583,0.00071227254,0.00039439963,0.00081612426,0.0013485015],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007230445,0.00003587501,0.00026312744,0.01703677,0.00010512903,0.00033775295,0.00004360884,0.0002663868,0.0012157181,0.0011664862,0.023771942,0.95568496],"study_design_scores_gemma":[0.000024893945,0.00009702147,0.002062598,0.0053271996,0.00028444518,0.004946137,0.0000763324,0.00007253847,0.0006637667,0.0015733264,0.98485094,0.000020747211],"about_ca_topic_score_codex":0.0012437328,"about_ca_topic_score_gemma":0.0021496273,"teacher_disagreement_score":0.0029497044,"about_ca_system_score_codex":0.00048281287,"about_ca_system_score_gemma":0.00074397644,"threshold_uncertainty_score":0.009867787},"labels":[],"label_agreement":null},{"id":"W2049281518","doi":"10.3109/10428194.2014.961013","title":"A simplified scoring system to document variant patterns in nodular lymphocyte predominant Hodgkin lymphoma","year":2014,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Terry Fox Foundation","keywords":"Lymphoma; Stage (stratigraphy); Medicine; Multivariate analysis; Lymphocyte; Internal medicine; Pathology; Disease; Scoring system; Hodgkin lymphoma; Overall survival; Oncology; Multivariate statistics; Proportional hazards model; Biology; Computer science","score_opus":0.00739729284019881,"score_gpt":0.2310635807097419,"score_spread":0.2236662878695431,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049281518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8987358,0.0036522148,0.082519434,0.00046185497,0.00035297126,0.0016615682,0.0026059092,0.0006715167,0.009338686],"genre_scores_gemma":[0.88966966,0.00096738123,0.10351854,0.0001171709,0.00011677633,0.00062517106,0.0027644413,0.000057478148,0.00216338],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980557,0.0007900658,0.00034341431,0.00011048816,0.0005683932,0.00013199435],"domain_scores_gemma":[0.9967518,0.00084051886,0.0006922015,0.0002455253,0.0012288811,0.0002410905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034564934,0.00072322745,0.00063177524,0.003929757,0.0002816807,0.0008889075,0.0005851564,0.0003299441,0.001826594],"category_scores_gemma":[0.007287056,0.00019269179,0.00052038534,0.0017283323,0.00034809796,0.00088644156,0.0010633401,0.0004980877,0.00060617336],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017934537,0.0003039475,0.58531606,0.0004688696,0.00043471693,0.00054316793,0.00044382838,0.005721406,0.025376301,0.0016844901,0.0077251173,0.37018853],"study_design_scores_gemma":[0.000509361,0.0039615487,0.88896567,0.0002345805,0.00059563905,0.0093324855,0.0009377911,0.059047002,0.012578302,0.0025055015,0.021093484,0.00023860978],"about_ca_topic_score_codex":0.002574338,"about_ca_topic_score_gemma":0.0043496923,"teacher_disagreement_score":0.003929757,"about_ca_system_score_codex":0.0005429661,"about_ca_system_score_gemma":0.00067954784,"threshold_uncertainty_score":0.01827985},"labels":[],"label_agreement":null},{"id":"W2050123377","doi":"10.3109/10428194.2014.982641","title":"Mixed fields on RhD typing as an indication of loss of heterozygosity on chromosome 1p in acute myeloid leukemia","year":2014,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Blood groups and transfusion","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Myeloid leukemia; Loss of heterozygosity; Leukemia; Myeloid; Typing; Medicine; Oncology; Biology; Internal medicine; Library science; Genetics; Gene; Allele","score_opus":0.014090964404205299,"score_gpt":0.24229266119246923,"score_spread":0.22820169678826394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050123377","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6825176,0.015548677,0.0027481816,0.17444871,0.00497454,0.00019377694,0.00040936482,0.0003673835,0.11879184],"genre_scores_gemma":[0.96156055,0.0030226125,0.0007800135,0.019255178,0.0046918187,0.000026399042,0.000176829,0.000032250377,0.01045445],"study_design_codex":"case_report","study_design_gemma":"observational","domain_scores_codex":[0.9991763,0.0002753473,0.00009110972,0.00009620004,0.00020082686,0.00016016186],"domain_scores_gemma":[0.99891365,0.00057952857,0.00015414052,0.00005429553,0.00012372421,0.00017471157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006210802,0.0004068988,0.000336855,0.0010481087,0.0007316233,0.00078982796,0.00061470387,0.0037154497,0.0031034476],"category_scores_gemma":[0.003796825,0.00034341327,0.00023838619,0.0006762204,0.0012983475,0.0006985974,0.00036500633,0.0019156549,0.0017305111],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00090873725,0.00017027119,0.13765298,0.00015794407,0.000043334207,0.73183316,0.00046428433,0.0005112013,0.0053775604,0.0019195752,0.09014471,0.030816274],"study_design_scores_gemma":[0.00023191608,0.0005441644,0.10882696,0.00046083637,0.000122043944,0.8253279,0.0009435318,0.00487365,0.0037356522,0.0032670388,0.051615454,0.000050823786],"about_ca_topic_score_codex":0.002103329,"about_ca_topic_score_gemma":0.0020783145,"teacher_disagreement_score":0.0037154497,"about_ca_system_score_codex":0.001606723,"about_ca_system_score_gemma":0.00039805993,"threshold_uncertainty_score":0.011657596},"labels":[],"label_agreement":null},{"id":"W2052603677","doi":"10.1080/10428190500080595","title":"N-Benzoylstaurosporine (PKC412) inhibits Akt kinase inducing apoptosis in multiple myeloma cells","year":2005,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Cancer Institute; Case Western Reserve University","keywords":"Protein kinase B; Apoptosis; Multiple myeloma; Cancer research; Kinase; Cell biology; Biology; Immunology; Biochemistry","score_opus":0.017821172388109048,"score_gpt":0.25637748407831695,"score_spread":0.2385563116902079,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052603677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98847044,0.004357739,0.0027438556,0.0001398131,0.000073775744,0.00013679384,0.00067949557,0.00021393821,0.0031840985],"genre_scores_gemma":[0.988193,0.004746796,0.0020612113,0.00007068926,0.000021868582,0.00010073093,0.0011576852,0.000023741924,0.0036243468],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999002,0.0000143776415,0.000013431631,0.000015805228,0.00003223224,0.000023923792],"domain_scores_gemma":[0.9999491,0.000007592899,0.0000146247285,0.000010594224,0.000007895184,0.000010190232],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000113998176,0.00041264348,0.00027896508,0.00022831786,0.00014429686,0.00016785285,0.00020375018,0.00020316684,0.0009887547],"category_scores_gemma":[0.00006883235,0.00011803912,0.0002448544,0.00031951995,0.00012867663,0.00012928358,0.00013470178,0.0005703801,0.0004659671],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013986956,0.000093892515,0.00011481791,0.000050672283,0.000009340412,0.000032217493,0.000006976864,0.00012776666,0.9969848,0.000058117555,0.0000890438,0.002292411],"study_design_scores_gemma":[0.000085924024,0.000869428,0.0029073963,0.000006108614,0.00001970928,0.00020274686,0.000009589956,0.0005565138,0.991852,0.000026859301,0.0034606138,0.000002978617],"about_ca_topic_score_codex":0.000629824,"about_ca_topic_score_gemma":0.0012642829,"teacher_disagreement_score":0.0009887547,"about_ca_system_score_codex":0.00029458167,"about_ca_system_score_gemma":0.0003219779,"threshold_uncertainty_score":0.0033077002},"labels":[],"label_agreement":null},{"id":"W2053328285","doi":"10.1080/10428190600572582","title":"Yttrium 90 ibritumomab tiuxetan in lymphoma","year":2006,"lang":"pl","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre; Sunnybrook Health Science Centre; Cancer Care Ontario; Health Sciences Centre","funders":"European Commission; Government of Ontario; GlaxoSmithKline","keywords":"Ibritumomab tiuxetan; Medicine; Rituximab; Radioimmunotherapy; Refractory (planetary science); Follicular lymphoma; Lymphoma; Oncology; Non-Hodgkin's lymphoma; Internal medicine; CD20; Nuclear medicine; Monoclonal antibody; Immunology; Antibody","score_opus":0.01923111208947437,"score_gpt":0.27481083829889047,"score_spread":0.2555797262094161,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2053328285","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006488641,0.99909914,0.000025884014,0.00005604362,0.000021383505,0.000016177934,0.000021398499,0.0000017083661,0.000109389664],"genre_scores_gemma":[0.0119510805,0.98740166,0.00016122752,0.00025524,0.00003741154,0.000045093115,0.00004348975,0.000001445769,0.00010338419],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984219,0.00064598187,0.0005382864,0.00012050548,0.00022545639,0.0000478836],"domain_scores_gemma":[0.99717015,0.0018902823,0.00066526106,0.000038138784,0.000192829,0.000043448614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021657539,0.00049605535,0.0027421582,0.0024869873,0.0001774258,0.0010166682,0.0005354796,0.00067727396,0.0012690834],"category_scores_gemma":[0.0052703833,0.00033083835,0.0024060258,0.003338287,0.00039994653,0.0007173048,0.0005744031,0.00055120944,0.00013943437],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012417786,0.000047344267,0.0013829876,0.65824485,0.0074270936,0.00016384982,0.00016296109,0.00033476282,0.0009372855,0.0004124332,0.0028532022,0.32679152],"study_design_scores_gemma":[0.0018533854,0.0021948356,0.021520207,0.7093231,0.1040133,0.001895074,0.00045082605,0.0004218221,0.0017131772,0.0017705234,0.15478128,0.00006245037],"about_ca_topic_score_codex":0.0033444627,"about_ca_topic_score_gemma":0.007277841,"teacher_disagreement_score":0.0033444627,"about_ca_system_score_codex":0.0011973464,"about_ca_system_score_gemma":0.0025353006,"threshold_uncertainty_score":0.011453688},"labels":[],"label_agreement":null},{"id":"W2055043352","doi":"10.3109/10428190009053554","title":"Development of a Biologically Distinct EBV-Related Lymphoproliferative Disorder Following Autologous Bone Marrow Transplantation for an EBV-Negative Post-Renal Allograft Burkitt's Lymphoma","year":2000,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Immunosuppression; Lymphoproliferative disorders; Transplantation; Lymphoma; Bone marrow; Pathology; Cyclophosphamide; Immunology; Gastroenterology; Chemotherapy; Internal medicine","score_opus":0.009213515329400344,"score_gpt":0.2465969674826883,"score_spread":0.23738345215328796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2055043352","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99747616,0.00048553722,0.00041883974,0.00014613061,0.000015639993,0.000028069548,0.000022871121,0.0000273837,0.0013791942],"genre_scores_gemma":[0.99948573,0.00011438435,0.000103116734,0.00008264355,0.000029639135,0.000005966331,0.000024397817,0.000002246058,0.00015177688],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9997942,0.000038448492,0.000025820484,0.00003400324,0.00003773372,0.000069758666],"domain_scores_gemma":[0.99924684,0.00022848848,0.00021833713,0.000059553928,0.000043657015,0.0002032391],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028030263,0.00039905615,0.00037590973,0.00046360723,0.0005967413,0.00044047923,0.0003115572,0.0008800711,0.0007851102],"category_scores_gemma":[0.0016728218,0.00025426256,0.00031684866,0.00023369736,0.00048045404,0.00038146132,0.00043479187,0.0010004729,0.00033414224],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004526978,0.00017454303,0.086405106,0.000058794318,0.000020660844,0.8950047,0.0005480437,0.0001559749,0.011107463,0.00024491374,0.0001885197,0.0056385705],"study_design_scores_gemma":[0.00006218202,0.0007509685,0.08198093,0.000019232895,0.00003342873,0.91287905,0.0001987691,0.0005443098,0.0025753465,0.00013506124,0.0008103288,0.000010405333],"about_ca_topic_score_codex":0.00052098633,"about_ca_topic_score_gemma":0.0007254245,"teacher_disagreement_score":0.0008800711,"about_ca_system_score_codex":0.00041467827,"about_ca_system_score_gemma":0.0002499786,"threshold_uncertainty_score":0.0030087829},"labels":[],"label_agreement":null},{"id":"W2055699311","doi":"10.1080/10428190903015628","title":"pY-STAT3 and p53 expression predict outcome for poor prognosis diffuse large B-cell lymphoma treated with high dose chemotherapy and autologous stem cell transplantation","year":2009,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Etoposide; Vincristine; Oncology; Diffuse large B-cell lymphoma; Internal medicine; Autologous stem-cell transplantation; International Prognostic Index; Transplantation; Cyclophosphamide; Lymphoma; Chemotherapy; Melphalan; Cancer research","score_opus":0.008825021794675286,"score_gpt":0.2302343601438441,"score_spread":0.22140933834916882,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2055699311","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.999516,0.00021468998,0.000101640486,0.00001626764,0.0000025870067,0.000004689631,0.000026674847,0.0000018559236,0.000115580435],"genre_scores_gemma":[0.9997825,0.000033976063,0.000053890093,0.0000134929305,0.0000053079025,0.0000030032525,0.00007581363,4.742681e-7,0.000031616306],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999819,0.00007800666,0.000020592559,0.000026980475,0.000027302885,0.000028161272],"domain_scores_gemma":[0.99920434,0.00027382985,0.0002682064,0.000041485808,0.00005490172,0.00015723016],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005949002,0.00023558416,0.0003487023,0.0003147805,0.00015771198,0.00033071692,0.0001330621,0.00023815039,0.00046952086],"category_scores_gemma":[0.0011518816,0.00010262795,0.00026671248,0.00022388868,0.00022059437,0.00023094362,0.00022394612,0.00028525727,0.00011824404],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025924328,0.00008186398,0.98866326,0.000011774308,0.00005209441,0.00011524048,0.00002657869,0.00040264943,0.002168845,0.000011009686,0.00004388329,0.0058304593],"study_design_scores_gemma":[0.00013266539,0.0022532272,0.99308187,0.000008556176,0.00011200423,0.00087449176,0.000057816553,0.0019648469,0.0012056241,0.00006091708,0.00024196746,0.0000060809434],"about_ca_topic_score_codex":0.00034443755,"about_ca_topic_score_gemma":0.0007360041,"teacher_disagreement_score":0.0005949002,"about_ca_system_score_codex":0.0002023946,"about_ca_system_score_gemma":0.0001680242,"threshold_uncertainty_score":0.0031461716},"labels":[],"label_agreement":null},{"id":"W2057060618","doi":"10.3109/10428194.2012.704998","title":"Effect of acute graft-versus-host disease on the outcome of second allogeneic hematopoietic stem cell transplant in children","year":2012,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto; SickKids Foundation","funders":"","keywords":"Graft-versus-host disease; Hematopoietic stem cell transplantation; Stem cell; Medicine; Haematopoiesis; Disease; Hematopoietic stem cell; Outcome (game theory); Hematopoietic cell; Savior sibling; Transplantation; Oncology; Immunology; Internal medicine; Biology; Genetics","score_opus":0.010236432079492598,"score_gpt":0.24487552649720018,"score_spread":0.23463909441770758,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057060618","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99874085,0.0008454751,0.000044308705,0.0000411139,0.000005722132,0.0000021246972,0.00007291336,0.000002018849,0.00024546077],"genre_scores_gemma":[0.99956685,0.00021729348,0.000025609228,0.0000118809,0.000007266182,0.0000022294807,0.00012039989,0.0000017085694,0.000046799003],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99938357,0.00020410764,0.000057301273,0.0000794741,0.00013780578,0.00013768519],"domain_scores_gemma":[0.99714977,0.00085999636,0.0012683611,0.000101398604,0.000111016874,0.0005095164],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093249517,0.0002876538,0.0003854695,0.00039160548,0.00020241295,0.00045024155,0.00017121251,0.00027136618,0.0007573203],"category_scores_gemma":[0.003191362,0.000097131706,0.00083418004,0.00039982362,0.0003204617,0.00032399077,0.0003800399,0.0005500889,0.000115672665],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00060763047,0.000028468721,0.9948177,0.000020349578,0.00009387454,0.00029573086,0.00007882137,0.00015750607,0.00024245534,0.000033567583,0.00007254167,0.0035512233],"study_design_scores_gemma":[0.000017356178,0.00081059075,0.99685895,0.000023063829,0.00010043515,0.0013301468,0.00012652823,0.00016769797,0.00026057925,0.00004254051,0.00025662524,0.000005404206],"about_ca_topic_score_codex":0.0013467143,"about_ca_topic_score_gemma":0.001715913,"teacher_disagreement_score":0.0013467143,"about_ca_system_score_codex":0.0004080661,"about_ca_system_score_gemma":0.00046777658,"threshold_uncertainty_score":0.004931569},"labels":[],"label_agreement":null},{"id":"W2057310034","doi":"10.1080/1042819021000055066","title":"Vascular Events Associated with Alpha Interferon Therapy","year":2003,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Eosinophilic Disorders and Syndromes","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Discontinuation; Alpha interferon; Context (archaeology); Vasculitis; Adverse effect; Concomitant; Thrombotic thrombocytopenic purpura; Melanoma; Internal medicine; Immunology; Surgery; Interferon; Platelet","score_opus":0.02666636327888802,"score_gpt":0.277149466108012,"score_spread":0.250483102829124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057310034","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008495146,0.9970878,0.0001153377,0.000104188686,0.000100656034,0.00000474238,0.000008681516,0.000008500004,0.0017206544],"genre_scores_gemma":[0.007964457,0.9904544,0.00015485709,0.00016948624,0.00021276147,0.00000875352,0.000027953085,0.000001460415,0.0010059015],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9997954,0.000051049155,0.000028856693,0.00003498937,0.00006704489,0.000022628225],"domain_scores_gemma":[0.99973613,0.000095277275,0.00008202588,0.000008806997,0.0000582446,0.000019514113],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029109267,0.0005656004,0.00094294973,0.0012961631,0.00025200308,0.0006623284,0.00039035597,0.0007208861,0.0023288834],"category_scores_gemma":[0.00060011353,0.00012823603,0.00029099084,0.0016074895,0.0002304777,0.00056965294,0.00030190567,0.00061955454,0.0010087264],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011184755,0.000059156035,0.0015313218,0.007910452,0.00009518232,0.0022146576,0.00007484559,0.00026171256,0.0017565484,0.00071636826,0.013401632,0.97186625],"study_design_scores_gemma":[0.00008996934,0.0005230864,0.018305842,0.008280891,0.0005217985,0.07623218,0.00029103123,0.00033885884,0.0037506504,0.002334924,0.88928145,0.000049351915],"about_ca_topic_score_codex":0.00075408834,"about_ca_topic_score_gemma":0.001090488,"teacher_disagreement_score":0.0023288834,"about_ca_system_score_codex":0.00034466913,"about_ca_system_score_gemma":0.0005095454,"threshold_uncertainty_score":0.0077908635},"labels":[],"label_agreement":null},{"id":"W2057527782","doi":"10.3109/10428194.2010.524325","title":"Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone","year":2010,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Lenalidomide; Thalidomide; Dexamethasone; Multiple myeloma; Bortezomib; Refractory (planetary science); Medicine; Internal medicine; Oncology; Chromosome abnormality; Population; Gastroenterology; Chromosome; Biology; Karyotype; Genetics","score_opus":0.025848618773021297,"score_gpt":0.2825363406879408,"score_spread":0.2566877219149195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057527782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9992834,0.00040236636,0.000028108203,0.000027090262,0.0000022427655,0.0000032412704,0.00003972619,0.0000022982467,0.00021154179],"genre_scores_gemma":[0.9997714,0.00007919385,0.000024369856,0.000014637016,0.000005971088,0.0000023576,0.000069027155,7.5094584e-7,0.000032257823],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99975723,0.000076476375,0.000033008284,0.000037837686,0.000057368416,0.000038131944],"domain_scores_gemma":[0.9992204,0.0002379585,0.00032300196,0.000029902054,0.00004095187,0.00014778957],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000280161,0.00015446085,0.0002924761,0.00027090887,0.00016392219,0.00033187828,0.00015016278,0.00020358473,0.000562281],"category_scores_gemma":[0.001257431,0.000075199714,0.0002846053,0.0002563232,0.00018938721,0.00017424021,0.00021198012,0.00026805187,0.00010413356],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019003778,0.00007760677,0.9826493,0.00002182833,0.00012602961,0.00057100464,0.00007660911,0.00037472998,0.003177953,0.000016452752,0.000079996455,0.010928142],"study_design_scores_gemma":[0.000043200183,0.0010701733,0.99604696,0.000007907204,0.00008317013,0.0015172707,0.00007810459,0.00034079695,0.0005925802,0.000028875973,0.00018623943,0.000004763288],"about_ca_topic_score_codex":0.0008775561,"about_ca_topic_score_gemma":0.001437166,"teacher_disagreement_score":0.0008775561,"about_ca_system_score_codex":0.00028665998,"about_ca_system_score_gemma":0.00020158532,"threshold_uncertainty_score":0.0020798445},"labels":[],"label_agreement":null},{"id":"W2057787725","doi":"10.3109/10428194.2012.701738","title":"Proposal for the clinical detection and management of patients and their family members with familial myelodysplastic syndrome/acute leukemia predisposition syndromes","year":2012,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":97,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Myelodysplastic syndromes; Medicine; Psychosocial; Genetic testing; Cancer; Intensive care medicine; Genetic counseling; Genetic predisposition; Clinical Practice; Acute leukemia; Leukemia; Family medicine; Psychiatry; Immunology; Internal medicine; Disease; Genetics; Bone marrow","score_opus":0.02981002818768919,"score_gpt":0.3052547347914638,"score_spread":0.2754447066037746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057787725","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004720413,0.9141263,0.004093679,0.06967184,0.006658364,0.00020221676,0.00020399313,0.00012645317,0.0044450494],"genre_scores_gemma":[0.003899615,0.94997954,0.023336308,0.015517678,0.0032562667,0.00042930958,0.00058451423,0.000014800307,0.0029819126],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989171,0.0004515197,0.00023987234,0.0000993259,0.00024307283,0.000049184524],"domain_scores_gemma":[0.9974062,0.00081074535,0.00032261666,0.00008578283,0.0011157041,0.0002588938],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043124943,0.000822402,0.001655059,0.0029823128,0.0004440535,0.0011668691,0.0018837155,0.0028601969,0.002731068],"category_scores_gemma":[0.005113656,0.0003306734,0.0010209067,0.0020419173,0.0010009005,0.0025373262,0.0009349612,0.0041398536,0.00301633],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000089567795,0.00015292884,0.00064204383,0.010693799,0.0001039627,0.00088532234,0.00016435639,0.00048432962,0.0006292666,0.0080520315,0.2050129,0.7730895],"study_design_scores_gemma":[0.00013691334,0.00013903402,0.0027382746,0.01319176,0.00031498194,0.004889197,0.00031575398,0.00026743466,0.00023050616,0.009224107,0.96848553,0.00006643511],"about_ca_topic_score_codex":0.0017325092,"about_ca_topic_score_gemma":0.0030765352,"teacher_disagreement_score":0.0043124943,"about_ca_system_score_codex":0.0012957223,"about_ca_system_score_gemma":0.005019194,"threshold_uncertainty_score":0.022806942},"labels":[],"label_agreement":null},{"id":"W2058689898","doi":"10.3109/10428190109097663","title":"Lovastatin Induced Control of Blast Cell Growth in an Elderly Patient with Acute Myeloblastic Leukemia","year":2001,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Ontario Institute for Cancer Research","funders":"","keywords":"Lovastatin; Medicine; Acute myeloblastic leukemia; Chemotherapy; In vitro; Pharmacology; Cell culture; Leukemia; Cancer research; Internal medicine; Immunology; Oncology; Cholesterol; Biology; Biochemistry","score_opus":0.004732354167851583,"score_gpt":0.204580555519027,"score_spread":0.19984820135117543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2058689898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954437,0.0011570988,0.00055548496,0.00048200996,0.00003902695,0.000029236498,0.00006440111,0.000056487945,0.002172577],"genre_scores_gemma":[0.9982097,0.00039196393,0.00019040128,0.00019233745,0.00004452258,0.000003172052,0.000040126477,0.0000054597695,0.00092230015],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99990225,0.0000134330285,0.000012811482,0.00002023987,0.000019314566,0.00003199361],"domain_scores_gemma":[0.999821,0.00003568941,0.0000420538,0.000010031009,0.000015265809,0.00007594442],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007550179,0.00030842598,0.0004397333,0.00050640246,0.00070122816,0.00029561223,0.00014729265,0.0005948761,0.00068653026],"category_scores_gemma":[0.00061973353,0.000164542,0.00020121374,0.00033028115,0.00028134868,0.0002125225,0.00020006552,0.0007099153,0.00022525758],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010936706,0.00019981033,0.07148425,0.00008723516,0.000030547926,0.8691066,0.0013940664,0.00021200397,0.03942545,0.0005422886,0.00068861333,0.015735444],"study_design_scores_gemma":[0.000059231294,0.0012625138,0.08457919,0.000015931688,0.000074326985,0.89597356,0.00043945972,0.0006938643,0.011570981,0.00031947676,0.004983061,0.00002849629],"about_ca_topic_score_codex":0.001707379,"about_ca_topic_score_gemma":0.0024277386,"teacher_disagreement_score":0.001707379,"about_ca_system_score_codex":0.00044313355,"about_ca_system_score_gemma":0.00024853344,"threshold_uncertainty_score":0.0033949018},"labels":[],"label_agreement":null},{"id":"W2058946091","doi":"10.1080/10428190500519311","title":"Liposomal encapsulated doxorubicin (Caelyx) in the treatment of relapsed aggressive non-Hodgkin's lymphoma: A phase II study","year":2006,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; BC Cancer Agency","funders":"","keywords":"Medicine; Lymphoma; Doxorubicin; Non-Hodgkin's lymphoma; Internal medicine; Phases of clinical research; Oncology; Chemotherapy","score_opus":0.010097123899735307,"score_gpt":0.26382400403775796,"score_spread":0.25372688013802264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2058946091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971136,0.0014766494,0.00029956896,0.000059146183,0.000022491082,0.0005374954,0.00011931028,0.000029913,0.00034190124],"genre_scores_gemma":[0.993138,0.0026238663,0.0011776238,0.00027395433,0.000066702574,0.00083299656,0.0006213725,0.000015234925,0.0012503286],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99979275,0.00010119869,0.000011325412,0.000030017269,0.000025375086,0.000039352635],"domain_scores_gemma":[0.99968004,0.00006259251,0.000052810312,0.000030338442,0.000017966964,0.00015626359],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010995221,0.0008147936,0.0012862233,0.00030859656,0.00016589779,0.00052796607,0.00050770165,0.00071878865,0.0010856676],"category_scores_gemma":[0.0003577793,0.0003094439,0.00060277764,0.00029575656,0.00052920275,0.0004183773,0.00022443413,0.0012372513,0.00025696773],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.383129,0.13271874,0.013501552,0.0015699366,0.0020274257,0.00084252044,0.001021733,0.0054303315,0.20422098,0.0005109677,0.0018480037,0.25317886],"study_design_scores_gemma":[0.31712556,0.6450867,0.022979666,0.000047441026,0.0004326722,0.0004751678,0.00010415594,0.002028839,0.009133821,0.00010435807,0.0024428354,0.00003875844],"about_ca_topic_score_codex":0.00069496385,"about_ca_topic_score_gemma":0.0012044304,"teacher_disagreement_score":0.0012862233,"about_ca_system_score_codex":0.00034566093,"about_ca_system_score_gemma":0.0006016699,"threshold_uncertainty_score":0.00581491},"labels":[],"label_agreement":null},{"id":"W2060523101","doi":"10.1080/10428190600733325","title":"First among equals: The cancer cell hierarchy","year":2006,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Cancer Cells and Metastasis","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Hierarchy; Cancer research; Cancer; Medicine; Chemistry; Internal medicine; Oncology; Political science","score_opus":0.02782102938706812,"score_gpt":0.29587710689049834,"score_spread":0.26805607750343025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060523101","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002128332,0.98666406,0.0006169179,0.0033685288,0.0010036353,0.000007991288,0.000014999062,0.000022745722,0.008088209],"genre_scores_gemma":[0.0044937143,0.9852173,0.0005703353,0.0023374963,0.000956403,0.000016005633,0.00003159411,0.0000071776103,0.006370031],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997656,0.000059023972,0.000016127593,0.000043172196,0.000093115355,0.000023018407],"domain_scores_gemma":[0.9997328,0.00009415679,0.00002615842,0.000019493922,0.0000840967,0.000043289103],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057717477,0.00059410697,0.0010503683,0.0012566665,0.00057133747,0.0016149676,0.00096765504,0.0013702033,0.0045007677],"category_scores_gemma":[0.00067764876,0.0001966126,0.00029798885,0.0014684434,0.00192835,0.003088335,0.000997454,0.0020186987,0.0033560186],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000042932643,0.000026605367,0.0002841047,0.0047050314,0.000035923324,0.00023004273,0.00028205646,0.00024574483,0.0012267864,0.044653658,0.077278815,0.87098825],"study_design_scores_gemma":[0.0000049369764,0.000019279501,0.0002134591,0.0006746345,0.000010532537,0.00052918994,0.00007769751,0.000029418232,0.0001679427,0.009430971,0.9888354,0.0000065027903],"about_ca_topic_score_codex":0.0020955538,"about_ca_topic_score_gemma":0.0034339253,"teacher_disagreement_score":0.0045007677,"about_ca_system_score_codex":0.0017838954,"about_ca_system_score_gemma":0.0016468443,"threshold_uncertainty_score":0.01505661},"labels":[],"label_agreement":null},{"id":"W2062082839","doi":"10.3109/10428194.2010.516377","title":"Missing mismatch repair: a key to T cell immortality","year":2010,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"DNA mismatch repair; DNA replication; Genome instability; DNA; DNA repair; Cell biology; Biology; Genome; Nucleotide; Genetics; Computational biology; DNA damage; Cancer research; Gene","score_opus":0.012631034353499866,"score_gpt":0.24789057067486145,"score_spread":0.2352595363213616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2062082839","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017174854,0.011545495,0.00047414732,0.9647696,0.017860433,0.000016069525,0.000030789804,0.00005095399,0.0035350549],"genre_scores_gemma":[0.03934035,0.02874802,0.0014072211,0.7704016,0.14676076,0.0000821754,0.000056738867,0.00004513529,0.013158032],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988605,0.00040114232,0.00011760496,0.00014415501,0.00029906497,0.00017752522],"domain_scores_gemma":[0.9977424,0.001435325,0.0001551685,0.00010478009,0.00026568118,0.0002965457],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015371711,0.0008686723,0.0013158739,0.00041220986,0.0017664875,0.0020205749,0.00076051225,0.018896233,0.004020343],"category_scores_gemma":[0.007391369,0.00042399892,0.00075183134,0.00033509417,0.002704055,0.0032732452,0.0010624025,0.024716903,0.003713669],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003691997,0.00013383839,0.001665035,0.00031087836,0.000042521882,0.02059433,0.0003009189,0.00030530168,0.0036680917,0.01881496,0.8858285,0.067966364],"study_design_scores_gemma":[0.0004112026,0.00033576493,0.0014080501,0.0003481803,0.000043156484,0.030686723,0.00041911396,0.0009504084,0.0015748304,0.04278511,0.92097217,0.0000653146],"about_ca_topic_score_codex":0.00086609734,"about_ca_topic_score_gemma":0.001530794,"teacher_disagreement_score":0.018896233,"about_ca_system_score_codex":0.0021750324,"about_ca_system_score_gemma":0.001246809,"threshold_uncertainty_score":0.015781045},"labels":[],"label_agreement":null},{"id":"W2063207072","doi":"10.3109/10428194.2012.742522","title":"Abundant expression of interleukin-21 receptor in follicular lymphoma cells is associated with more aggressive disease","year":2012,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital; Queen's University","funders":"","keywords":"Follicular lymphoma; Lymphoma; Cancer research; Cytokine; Immunohistochemistry; Interleukin 9; Interleukin; Receptor; Biopsy; Pathology; Biology; Medicine; Immunology; Internal medicine","score_opus":0.008604430355567336,"score_gpt":0.23427686687463076,"score_spread":0.22567243651906344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063207072","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99821645,0.00047157815,0.00029460777,0.000032974043,0.000003298642,0.000007791272,0.000075182215,0.000029972804,0.0008680738],"genre_scores_gemma":[0.9993358,0.00011698401,0.0001672012,0.000010754767,0.00001039715,0.0000043142963,0.0001162968,0.0000040417704,0.00023421415],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99975556,0.00004405689,0.000023833529,0.000054360113,0.000057004665,0.00006523879],"domain_scores_gemma":[0.9990521,0.00015448831,0.00037215586,0.00009498662,0.00010028578,0.0002259837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026048828,0.00019179049,0.00030756943,0.001083884,0.00029335605,0.0004897525,0.00016918573,0.00031638955,0.0028118922],"category_scores_gemma":[0.00067898334,0.00014927296,0.00017940818,0.0005929798,0.00033574217,0.00024740995,0.00026148956,0.00037024627,0.0004383635],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00076569663,0.00008947423,0.72644997,0.00006839454,0.00007513433,0.004075018,0.00020329266,0.00007601079,0.25614142,0.00020941965,0.00028129775,0.011564862],"study_design_scores_gemma":[0.000021610467,0.00021045387,0.97096306,0.0000053945078,0.00004855423,0.018020011,0.0002472432,0.00026888854,0.008381383,0.00020040994,0.0016237827,0.000009200289],"about_ca_topic_score_codex":0.00062012556,"about_ca_topic_score_gemma":0.00082201854,"teacher_disagreement_score":0.0028118922,"about_ca_system_score_codex":0.0002497249,"about_ca_system_score_gemma":0.00015394329,"threshold_uncertainty_score":0.009406686},"labels":[],"label_agreement":null},{"id":"W2065622259","doi":"10.1080/10428190290006189","title":"Antigenic Open Reading Frames from HHV-8 are Present in Multiple Myeloma Patients and Normal Individuals at Similar Frequency","year":2002,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital; Ontario Institute for Cancer Research","funders":"","keywords":"Bone marrow; Antigen; Virology; Biology; Population; ORFS; Multiple myeloma; Molecular biology; Stromal cell; Antibody; Immunology; Open reading frame; Medicine; Genetics; Cancer research; Gene; Peptide sequence","score_opus":0.01686107229999625,"score_gpt":0.23619449483575153,"score_spread":0.21933342253575527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2065622259","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9992028,0.0002545465,0.000079520825,0.000015661713,0.0000042316424,0.0000034448283,0.00009669965,0.0000081371245,0.00033498267],"genre_scores_gemma":[0.9994998,0.00008680325,0.00007863184,0.000017411952,0.000010893201,0.0000042694487,0.0001638572,0.0000027467122,0.00013560396],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99964714,0.000049267146,0.00004199559,0.00012324876,0.00007334864,0.00006495825],"domain_scores_gemma":[0.99945194,0.0001793728,0.00018135588,0.000045600274,0.000047898182,0.00009385247],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017858009,0.0003089722,0.00035053064,0.0011252655,0.00033193524,0.00037637373,0.00022388868,0.0004790656,0.0029746296],"category_scores_gemma":[0.0010587506,0.00015117551,0.00022150464,0.0005185552,0.00025580393,0.00020774243,0.00029761152,0.0002650382,0.00035571674],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010356315,0.0000938464,0.947381,0.00005601789,0.00008600906,0.0024255957,0.0005250769,0.000057287332,0.034719944,0.000113022594,0.00024920344,0.013257374],"study_design_scores_gemma":[0.000017436,0.00024602693,0.98378086,0.000009404195,0.00005278242,0.011525509,0.00028786046,0.00012339585,0.0028415755,0.00010905713,0.00099843,0.0000075194466],"about_ca_topic_score_codex":0.0005850103,"about_ca_topic_score_gemma":0.00031351807,"teacher_disagreement_score":0.0029746296,"about_ca_system_score_codex":0.00015309016,"about_ca_system_score_gemma":0.00008525849,"threshold_uncertainty_score":0.009951115},"labels":[],"label_agreement":null},{"id":"W2065628269","doi":"10.1080/10428190600822128","title":"Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myeloma","year":2006,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canada Research Chairs","keywords":"Chromosomal translocation; Multiple myeloma; Mechanism (biology); Outcome (game theory); Chromosome; Disease; Oncology; Biology; Medicine; Genetics; Internal medicine; Immunology; Gene","score_opus":0.020844550676225513,"score_gpt":0.29712161442013624,"score_spread":0.2762770637439107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2065628269","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008785299,0.993248,0.000090459005,0.004284995,0.0012005257,0.000002841476,0.000018622286,0.000010400787,0.0010563196],"genre_scores_gemma":[0.0005782731,0.99472696,0.0001567183,0.0025030037,0.0010422788,0.0000051187176,0.000020287383,0.0000029094651,0.0009644161],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997036,0.00007450017,0.00004471611,0.000051936193,0.00010088951,0.000024313953],"domain_scores_gemma":[0.9991986,0.0003563202,0.00008799581,0.000026891315,0.00021411398,0.00011603402],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093873567,0.0007608794,0.00213042,0.0019742139,0.0005882764,0.0019491971,0.0011820338,0.0020321647,0.0047027934],"category_scores_gemma":[0.0023115692,0.00027332528,0.00049728126,0.0021543968,0.001164723,0.0047796792,0.0007963603,0.0031017943,0.004313238],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008604592,0.00003945684,0.00038642017,0.008201071,0.00007378824,0.00042146927,0.00022506234,0.0001259408,0.0005054229,0.0032493032,0.115852065,0.8708339],"study_design_scores_gemma":[0.000012324762,0.00004749193,0.0006395051,0.0037183291,0.000053848005,0.0018946574,0.0002892441,0.00002879235,0.00009705415,0.0030485888,0.9901494,0.000020756792],"about_ca_topic_score_codex":0.0027297244,"about_ca_topic_score_gemma":0.0041990764,"teacher_disagreement_score":0.0047027934,"about_ca_system_score_codex":0.0008733211,"about_ca_system_score_gemma":0.0012996893,"threshold_uncertainty_score":0.015732467},"labels":[],"label_agreement":null},{"id":"W2066022953","doi":"10.3109/10428194.2013.848982","title":"Isolated bone marrow Hodgkin lymphoma in a human immunodeficiency virus-negative patient: a second case","year":2013,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Lymphoma; Medicine; Hodgkin lymphoma; Bone marrow; Human immunodeficiency virus (HIV); Cancer; Immunodeficiency; Pathology; Oncology; Cancer research; Internal medicine; Virology; Immunology; Immune system","score_opus":0.020159616710042506,"score_gpt":0.27953799006091146,"score_spread":0.25937837335086894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2066022953","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002362446,0.993551,0.00033666697,0.00076370983,0.00037717645,0.000015531894,0.000050629693,0.000013579161,0.0025292283],"genre_scores_gemma":[0.025544545,0.9694332,0.00066225283,0.00156542,0.00081775594,0.000013556678,0.0001422697,0.000007032119,0.0018139456],"study_design_codex":"design_other","study_design_gemma":"case_report","domain_scores_codex":[0.99984217,0.000023656148,0.000029867037,0.00003744001,0.00004287977,0.000023837729],"domain_scores_gemma":[0.99982506,0.00006536059,0.000040093713,0.000007838092,0.000027465647,0.00003436144],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020994333,0.0006594311,0.0011460547,0.0016079029,0.00042431612,0.0008838779,0.0007337124,0.001648545,0.0024120386],"category_scores_gemma":[0.00048540192,0.00022354208,0.00049301836,0.0014558419,0.0004196791,0.0010579762,0.00044109227,0.0016393656,0.0012391655],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017460744,0.00016469468,0.003826216,0.018089486,0.00026934955,0.20938912,0.00049335446,0.00039966495,0.004531705,0.0027535646,0.051404305,0.7085039],"study_design_scores_gemma":[0.000041522962,0.00012008939,0.0036754208,0.0062348577,0.00040770532,0.7201872,0.00036029157,0.00014184549,0.00083990564,0.0015662415,0.26636603,0.000058960508],"about_ca_topic_score_codex":0.00087594334,"about_ca_topic_score_gemma":0.0027251123,"teacher_disagreement_score":0.0024120386,"about_ca_system_score_codex":0.00038243097,"about_ca_system_score_gemma":0.0006197317,"threshold_uncertainty_score":0.008069098},"labels":[],"label_agreement":null},{"id":"W2067305498","doi":"10.3109/10428194.2011.654339","title":"High baseline serum thymidine kinase 1 level predicts unfavorable outcome in patients with follicular lymphoma","year":2012,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Faculty of Medicine and Dentistry, University of Alberta","keywords":"Medicine; International Prognostic Index; Follicular lymphoma; Hazard ratio; Internal medicine; Lymphoma; Beta-2 microglobulin; Oncology; Proportional hazards model; Lactate dehydrogenase; Chronic lymphocytic leukemia; Rituximab; Stage (stratigraphy); Gastroenterology; Immunology; Leukemia; Confidence interval; Biology","score_opus":0.015060401493968709,"score_gpt":0.23096356657214256,"score_spread":0.21590316507817386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067305498","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9995384,0.00019211852,0.000031685184,0.000030098714,0.0000035868613,0.0000019086265,0.000037296802,0.0000023508926,0.00016253794],"genre_scores_gemma":[0.9997725,0.000062405285,0.00001813304,0.000010948161,0.000008576493,0.0000016476463,0.00007174315,5.501761e-7,0.00005346743],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998776,0.000032946242,0.000011598708,0.000022510343,0.000021715226,0.00003369783],"domain_scores_gemma":[0.99933165,0.0002032362,0.00020249502,0.000030421754,0.00004539408,0.00018678412],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030297544,0.00018346487,0.00023849714,0.00038240108,0.00028258556,0.00042487693,0.00017818701,0.00035208248,0.0011459991],"category_scores_gemma":[0.0012492298,0.00017654135,0.00018529482,0.00034510563,0.0003147199,0.00031979207,0.00020530756,0.00046764355,0.00023371605],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023475284,0.000026798918,0.9981489,0.0000034384984,0.000009007607,0.0000950357,0.000019488429,0.000039638162,0.00037651064,0.00000691831,0.00005479156,0.0009847325],"study_design_scores_gemma":[0.000018552175,0.0002588807,0.9983693,0.0000044998365,0.00002192187,0.0006032028,0.00010890603,0.0003137868,0.00013937225,0.00004633337,0.000111786656,0.0000035179844],"about_ca_topic_score_codex":0.0015541464,"about_ca_topic_score_gemma":0.0018755998,"teacher_disagreement_score":0.0015541464,"about_ca_system_score_codex":0.000246085,"about_ca_system_score_gemma":0.00026163994,"threshold_uncertainty_score":0.0038337111},"labels":[],"label_agreement":null},{"id":"W2068794772","doi":"10.3109/10428194.2010.500046","title":"Prognostic biomarkers in malignant lymphomas","year":2010,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Lymphoma; Tumor microenvironment; Follicular lymphoma; Disease; Translational research; Chemokine; Medicine; Cancer research; Biology; Bioinformatics; Computational biology; Immunology; Pathology; Immune system; Tumor cells","score_opus":0.022238817785007865,"score_gpt":0.2893704191402985,"score_spread":0.2671316013552906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068794772","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00047828438,0.99773395,0.00039248553,0.00046301482,0.00018449665,0.0000074861578,0.0000375884,0.000012718605,0.0006899585],"genre_scores_gemma":[0.008511877,0.9883052,0.0013884593,0.00038231406,0.0005033753,0.000025853988,0.00018472775,0.0000036903064,0.00069456646],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99956363,0.0001298979,0.00006258593,0.0000655686,0.00014760971,0.000030726227],"domain_scores_gemma":[0.99915624,0.00042865291,0.00015982249,0.000020915884,0.00019696992,0.000037382513],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013607667,0.00081637356,0.0019162192,0.0025537603,0.00017606896,0.00093763665,0.0006732425,0.0007303022,0.0016054766],"category_scores_gemma":[0.0021932109,0.00022487732,0.0004209663,0.002264491,0.0004152944,0.00094038725,0.00049356994,0.0013570441,0.0011891503],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013172187,0.00005158076,0.003663634,0.0059121624,0.00012679692,0.0003404574,0.000048486243,0.00027126318,0.002012927,0.0018247998,0.016177379,0.9694389],"study_design_scores_gemma":[0.000112829555,0.00039388897,0.021579364,0.0092270905,0.00095618365,0.010158516,0.00023920804,0.00079415605,0.006594078,0.008777356,0.941079,0.000088358465],"about_ca_topic_score_codex":0.0006689114,"about_ca_topic_score_gemma":0.0007819489,"teacher_disagreement_score":0.0025537603,"about_ca_system_score_codex":0.00057997945,"about_ca_system_score_gemma":0.0006758451,"threshold_uncertainty_score":0.0071965456},"labels":[],"label_agreement":null},{"id":"W2070487917","doi":"10.3109/10428194.2015.1022770","title":"Management of adverse events associated with idelalisib treatment: expert panel opinion","year":2015,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":307,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Gilead Sciences (Canada)","funders":"Gilead Sciences","keywords":"Idelalisib; Medicine; Adverse effect; Internal medicine; Diarrhea; Intensive care medicine; Ibrutinib","score_opus":0.07781209335968814,"score_gpt":0.3511248248391235,"score_spread":0.27331273147943536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070487917","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005208586,0.9627418,0.0015596437,0.025296204,0.0028491989,0.00015872243,0.00030582765,0.000038051738,0.0065296856],"genre_scores_gemma":[0.0046168305,0.9735811,0.0024420447,0.01360493,0.0028963126,0.00013348379,0.00037144127,0.000009478773,0.0023444176],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998014,0.0007074039,0.0004731428,0.00014411584,0.0005783477,0.00008299271],"domain_scores_gemma":[0.99510694,0.0019293408,0.0008282053,0.00006759149,0.0019166576,0.00015127735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045135194,0.00069309,0.0013836168,0.0010654539,0.00031795376,0.0012197195,0.001498956,0.002131157,0.004303499],"category_scores_gemma":[0.008271046,0.00019428093,0.0017514928,0.0010599267,0.00032785485,0.0014271247,0.00064243353,0.0020683352,0.0014896635],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011197016,0.00003418628,0.00043428634,0.024188476,0.00030623248,0.00042992277,0.00011070525,0.00026069098,0.0006738545,0.0012260536,0.17711918,0.79510444],"study_design_scores_gemma":[0.00012880964,0.000109604305,0.0015571505,0.04030741,0.00088147767,0.0024830794,0.00015802436,0.00020945069,0.0005631413,0.0022487938,0.9512977,0.000055291763],"about_ca_topic_score_codex":0.0011697453,"about_ca_topic_score_gemma":0.003344555,"teacher_disagreement_score":0.0045135194,"about_ca_system_score_codex":0.0007747761,"about_ca_system_score_gemma":0.0019356663,"threshold_uncertainty_score":0.02387005},"labels":[],"label_agreement":null},{"id":"W2070685379","doi":"10.3109/10428194.2013.862242","title":"Results of a prospective phase II trial evaluating interim positron emission tomography-guided high dose therapy for poor prognosis diffuse large B-cell lymphoma","year":2013,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Foothills Medical Centre; University of Calgary","funders":"","keywords":"Medicine; Vincristine; Rituximab; Diffuse large B-cell lymphoma; Positron emission tomography; Oncology; Internal medicine; Prednisone; Interim analysis; Lymphoma; Interim; Cyclophosphamide; Chemotherapy; Clinical trial; Nuclear medicine","score_opus":0.024409207622668537,"score_gpt":0.31240700740628746,"score_spread":0.28799779978361895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070685379","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889122,0.0028427073,0.0014570535,0.0006993489,0.00020352767,0.002732636,0.0007176545,0.00009458121,0.0023404222],"genre_scores_gemma":[0.9889101,0.0013942613,0.003114044,0.00093386846,0.00015544565,0.0023343682,0.0018021173,0.00001889882,0.0013367917],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9993905,0.0004313779,0.000027897055,0.000055229164,0.00003623292,0.000058806727],"domain_scores_gemma":[0.99900717,0.00031331848,0.00018062959,0.00008486163,0.000052614003,0.0003614034],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00241834,0.00083472155,0.0011602709,0.00022947213,0.0002775333,0.0005091492,0.00042548426,0.00092812884,0.0022903779],"category_scores_gemma":[0.0014739094,0.00022730482,0.00091835414,0.000249456,0.0006059446,0.00043376812,0.00021883778,0.0022448772,0.00041389454],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.77597475,0.05585237,0.022086369,0.0005216289,0.0015169949,0.00021283036,0.00015496649,0.0023839518,0.02375082,0.00031618273,0.0026364499,0.11459277],"study_design_scores_gemma":[0.46917278,0.5074453,0.016528247,0.0000431743,0.0007412807,0.0001903866,0.000033335604,0.0008858897,0.002748751,0.00019951051,0.001994026,0.000017461587],"about_ca_topic_score_codex":0.00026889401,"about_ca_topic_score_gemma":0.00077065115,"teacher_disagreement_score":0.00241834,"about_ca_system_score_codex":0.00033358106,"about_ca_system_score_gemma":0.0008708514,"threshold_uncertainty_score":0.012789547},"labels":[],"label_agreement":null},{"id":"W2071296119","doi":"10.1080/10428190801895345","title":"Therapeutic targeting of the BCL6 oncogene for diffuse large B-cell lymphomas","year":2008,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research","funders":"National Cancer Institute; Leukemia and Lymphoma Society","keywords":"BCL6; Cancer research; Psychological repression; Biology; Lymphoma; Diffuse large B-cell lymphoma; Repressor; Histone deacetylase; Gene; Genetics; B cell; Transcription factor; Histone; Immunology; Germinal center; Gene expression; Antibody","score_opus":0.02476285182321983,"score_gpt":0.2853888692776675,"score_spread":0.26062601745444763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071296119","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00040636427,0.9971583,0.00032230676,0.00018809816,0.00014238518,0.000010825272,0.000017397355,0.000017742654,0.0017365589],"genre_scores_gemma":[0.0019437367,0.9960454,0.00039224268,0.0001998626,0.00010773596,0.000013589968,0.00005553007,0.000003278817,0.0012386322],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998815,0.000020367788,0.000011645505,0.000020649466,0.000049840753,0.000015987742],"domain_scores_gemma":[0.9998926,0.00003916098,0.000019101653,0.000004978788,0.000026808302,0.000017374414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040582306,0.000841689,0.0014821402,0.0021128282,0.0002619185,0.0005828503,0.0010233232,0.0009296582,0.0038535383],"category_scores_gemma":[0.00032345467,0.00023734433,0.00050484797,0.001615949,0.0004078238,0.0009685978,0.00048748057,0.0019018658,0.0032316074],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000107680324,0.00016331927,0.00012341101,0.0053771944,0.00007365127,0.0003666517,0.000038230293,0.00041971088,0.004204296,0.0019134309,0.019326445,0.9678859],"study_design_scores_gemma":[0.00009048026,0.00022706117,0.0012137512,0.0015057122,0.00010614442,0.003875837,0.00004285098,0.00016729307,0.0017615516,0.0015531873,0.9894354,0.000020855161],"about_ca_topic_score_codex":0.00063647627,"about_ca_topic_score_gemma":0.0013250489,"teacher_disagreement_score":0.0038535383,"about_ca_system_score_codex":0.0005398104,"about_ca_system_score_gemma":0.0004209685,"threshold_uncertainty_score":0.012891352},"labels":[],"label_agreement":null},{"id":"W2071845884","doi":"10.1080/10428190601078126","title":"Development of adapted RECIST criteria to assess response in lymphoma and their comparison to the International Workshop Criteria","year":2007,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Juravinski Cancer Centre; McGill University Health Centre; Princess Margaret Cancer Centre; BC Cancer Agency; Jewish General Hospital; Queen's University; McGill University","funders":"","keywords":"Response Evaluation Criteria in Solid Tumors; Medicine; Concordance; Lymphoma; Hodgkin lymphoma; Concordance correlation coefficient; Nuclear medicine; Clinical trial; Internal medicine; Oncology; Statistics; Mathematics; Phases of clinical research","score_opus":0.2976124603191652,"score_gpt":0.4829481651784053,"score_spread":0.18533570485924006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071845884","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.056923397,0.012696772,0.88016915,0.002600889,0.0014686855,0.016085345,0.006675547,0.0018007708,0.021579495],"genre_scores_gemma":[0.27454954,0.002642986,0.67742765,0.0011399713,0.00046776657,0.03240748,0.0059707616,0.0011243096,0.004269537],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.8494546,0.10125938,0.022363247,0.0049411044,0.020694425,0.0012873553],"domain_scores_gemma":[0.7591074,0.14416759,0.018162757,0.015714353,0.06113734,0.0017105646],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.13461052,0.0015275627,0.0033574975,0.008867193,0.00069412286,0.0033714126,0.002987096,0.0013318267,0.003755772],"category_scores_gemma":[0.30522245,0.0006533966,0.00354145,0.007275575,0.0013462239,0.0023427957,0.0032279368,0.0030115643,0.0013472576],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005069919,0.0003468972,0.057522543,0.003879696,0.0035941799,0.00037884692,0.0014114255,0.045262303,0.001447867,0.039560772,0.046415694,0.7951098],"study_design_scores_gemma":[0.0043320484,0.0075101918,0.24729437,0.004858459,0.0046547754,0.005238386,0.002242933,0.3235739,0.009082909,0.16094741,0.22875996,0.0015046288],"about_ca_topic_score_codex":0.002677948,"about_ca_topic_score_gemma":0.0028161914,"teacher_disagreement_score":0.86538947,"about_ca_system_score_codex":0.0031456084,"about_ca_system_score_gemma":0.004291004,"threshold_uncertainty_score":0.711897},"labels":[],"label_agreement":null},{"id":"W2072259702","doi":"10.1080/1042819031000060573","title":"Acute Myelogenous Leukemia Complicated by Acute Necrotizing Ulcerative Gingivitis Due to Aspergillus terreus","year":2003,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Antifungal resistance and susceptibility","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Aspergillus terreus; Itraconazole; Amphotericin B; Medicine; Leukemia; Chronic myelogenous leukemia; Mortality rate; Internal medicine; Immunology; Dermatology; Chemotherapy; Gastroenterology; Antifungal; Microbiology; Biology","score_opus":0.00975397645633386,"score_gpt":0.2500085407479471,"score_spread":0.24025456429161324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2072259702","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991882,0.0015693528,0.000604182,0.000525732,0.000032521853,0.000067569286,0.00003639202,0.00005251252,0.0052296873],"genre_scores_gemma":[0.99808276,0.0007340425,0.0003143919,0.00023892164,0.0000726753,0.000009139345,0.000027794764,0.000005471083,0.00051488547],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9997068,0.000055848537,0.000031935422,0.000031274994,0.000038793103,0.00013520264],"domain_scores_gemma":[0.9994567,0.00013500122,0.00018271412,0.000039026865,0.000024807456,0.00016177868],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002169183,0.00091562205,0.0005893054,0.00059834536,0.0013212671,0.0006233417,0.0002781447,0.0012388008,0.0015304477],"category_scores_gemma":[0.00155912,0.0003817618,0.00034499707,0.00048441114,0.0008288247,0.00061944884,0.000751364,0.00091218116,0.00043460587],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017917153,0.00007753893,0.04043472,0.000048646336,0.000009452005,0.9515104,0.0003426255,0.000085838656,0.003526272,0.00016120542,0.00020721069,0.0034169082],"study_design_scores_gemma":[0.000033021854,0.00021820549,0.0240664,0.000030632196,0.000020139554,0.97309303,0.00039843758,0.00020887979,0.00095908245,0.00015821993,0.00080514286,0.000008757116],"about_ca_topic_score_codex":0.002345287,"about_ca_topic_score_gemma":0.002812189,"teacher_disagreement_score":0.002345287,"about_ca_system_score_codex":0.00050093903,"about_ca_system_score_gemma":0.00054054457,"threshold_uncertainty_score":0.0051198006},"labels":[],"label_agreement":null},{"id":"W2073210499","doi":"10.3109/10428194.2010.535183","title":"In a patient with biclonal Waldenstrom macroglobulinemia only one clone expands in three-dimensional culture and includes putative cancer stem cells","year":2010,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"clone (Java method); Waldenstrom macroglobulinemia; Bone marrow; Biology; Stem cell; Macroglobulinemia; Molecular biology; Antibody; Immunology; Cancer research; Gene; Multiple myeloma; Cell biology; Lymphoma; Genetics","score_opus":0.010021286159338694,"score_gpt":0.25830142249239174,"score_spread":0.24828013633305304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073210499","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99742883,0.00021758354,0.0013146686,0.000053568336,0.000004715958,0.00002303071,0.00006863633,0.00003147493,0.0008574265],"genre_scores_gemma":[0.9978269,0.0000998553,0.0014637625,0.000041182768,0.0000052142705,0.000011055077,0.00012989674,0.000007719373,0.00041429824],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9999211,0.000010906641,0.000007645161,0.000024093013,0.000018922821,0.000017279579],"domain_scores_gemma":[0.99984396,0.00006796159,0.000027337699,0.000020699083,0.000010021792,0.00003011251],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009582139,0.00023710004,0.00018998967,0.00047160214,0.00020949563,0.00025801404,0.00015482403,0.00031104908,0.00092389423],"category_scores_gemma":[0.0003494236,0.00011744464,0.00012435205,0.00016468218,0.00021047507,0.0001354651,0.00023091192,0.00022786095,0.00026815818],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00066481915,0.000098641794,0.12247127,0.00009305913,0.00002907546,0.073158205,0.00072437036,0.00041076198,0.76980734,0.0006730145,0.00032482715,0.031544633],"study_design_scores_gemma":[0.00006578086,0.0013321172,0.2581437,0.000036268037,0.000094873794,0.44106457,0.0006405442,0.0031528973,0.2858456,0.00075985986,0.0088289585,0.000034896828],"about_ca_topic_score_codex":0.00037183057,"about_ca_topic_score_gemma":0.00057864736,"teacher_disagreement_score":0.00092389423,"about_ca_system_score_codex":0.0001255969,"about_ca_system_score_gemma":0.000069395595,"threshold_uncertainty_score":0.0030907393},"labels":[],"label_agreement":null},{"id":"W2073523783","doi":"10.1080/10428190210173","title":"Diffuse Large B-cell Lymphoma: A Clinicopathologic Analysis of 444 Cases Classified According to the Updated Kiel Classification","year":2002,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute","keywords":"Lymphoma; Medicine; Anaplastic large-cell lymphoma; Diffuse large B-cell lymphoma; Internal medicine; Retrospective cohort study; Stage (stratigraphy); Overall survival; Subtyping; Large cell; Pathology; Gastroenterology; Cancer; Adenocarcinoma; Biology","score_opus":0.039268709251652406,"score_gpt":0.2788327295271943,"score_spread":0.23956402027554188,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073523783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9992843,0.00030884767,0.000073310825,0.000010561184,0.0000036701724,0.0000061177093,0.00014132554,0.0000027285826,0.00016900666],"genre_scores_gemma":[0.99927896,0.00015706084,0.00006602096,0.000007936872,0.000008199122,0.000009844269,0.00038748828,0.0000013280641,0.00008317973],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996164,0.00007583531,0.000047181886,0.00007517106,0.00010242685,0.000082945175],"domain_scores_gemma":[0.99949527,0.000104369465,0.00019551329,0.00005867771,0.00007005778,0.00007612319],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005698932,0.00023601472,0.00026353815,0.0021128564,0.00043980125,0.0005585483,0.0003269472,0.00025989735,0.0012387218],"category_scores_gemma":[0.0017305162,0.00023874309,0.0002951965,0.0012033628,0.0003781392,0.0005127325,0.00062036613,0.00017942289,0.00027158824],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000060190247,0.00000704146,0.99703205,0.0000052294113,0.00002226844,0.00025472147,0.00006040986,0.000032531603,0.00021753307,0.000010551871,0.00006880973,0.0022286691],"study_design_scores_gemma":[0.000009226114,0.00005003956,0.9972306,0.0000069155585,0.000021640293,0.0016279495,0.00021413066,0.00017850845,0.00006472834,0.000020212508,0.0005720406,0.0000040296377],"about_ca_topic_score_codex":0.003441754,"about_ca_topic_score_gemma":0.004675958,"teacher_disagreement_score":0.003441754,"about_ca_system_score_codex":0.0005306837,"about_ca_system_score_gemma":0.00020272603,"threshold_uncertainty_score":0.0068434477},"labels":[],"label_agreement":null},{"id":"W2074583097","doi":"10.1080/10428190802276289","title":"Paraneoplastic lumbosacral axonal polyradiculopathy preceding the diagnosis of nodular lymphocyte predominant Hodgkin lymphoma: a case report","year":2008,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Autoimmune Neurological Disorders and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; University of Toronto","funders":"","keywords":"Medicine; Malignancy; Pathology; Polyradiculopathy; Lymphoma; Lumbosacral joint; Lymphocyte; Immunology; Anatomy","score_opus":0.016115479626238684,"score_gpt":0.23556164416107106,"score_spread":0.21944616453483237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2074583097","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.82590735,0.013099494,0.005361235,0.06286358,0.0047842623,0.00076109753,0.00076241215,0.000603279,0.08585735],"genre_scores_gemma":[0.97395295,0.004265912,0.0017843408,0.0077820355,0.007931201,0.00009935658,0.00017411866,0.00006088613,0.0039491556],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9985006,0.00027689105,0.00016660245,0.0003903935,0.00020744947,0.00045804554],"domain_scores_gemma":[0.99606055,0.0017640949,0.00054448046,0.00033139315,0.00038223734,0.000917343],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009460917,0.002677901,0.001966769,0.003074582,0.005166939,0.002487528,0.0026074427,0.013743957,0.004085766],"category_scores_gemma":[0.007525026,0.0020696959,0.0015853499,0.0025047008,0.0032396952,0.00414919,0.0014481333,0.007960104,0.0018207949],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029975465,0.000039348044,0.00253361,0.00002993073,0.0000069427133,0.9956904,0.00009972239,0.000046680947,0.00016401836,0.00013530142,0.0005985216,0.00062555436],"study_design_scores_gemma":[0.000046971734,0.00009141731,0.0055129356,0.000039430484,0.000022667435,0.9922311,0.00016444793,0.00038155695,0.00014470411,0.0002941588,0.0010514008,0.000019244446],"about_ca_topic_score_codex":0.007360632,"about_ca_topic_score_gemma":0.010896595,"teacher_disagreement_score":0.013743957,"about_ca_system_score_codex":0.0035373482,"about_ca_system_score_gemma":0.002544984,"threshold_uncertainty_score":0.025665343},"labels":[],"label_agreement":null},{"id":"W2074923396","doi":"10.3109/10428190009059283","title":"Bone Marrow Necrosis in Adult Acute Leukemia and Non-Hodgkin's Lymphoma","year":2000,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Bone and Joint Diseases","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Lymphoma; Bone marrow; Leukemia; Acute leukemia; Myeloid leukemia; Pathology; Haematopoiesis; Internal medicine; Oncology; Stem cell","score_opus":0.006072855173703697,"score_gpt":0.22715335457122884,"score_spread":0.22108049939752514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2074923396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92602074,0.06920703,0.00082152995,0.00035810034,0.000050692983,0.00003382837,0.00013394242,0.000029156876,0.003345021],"genre_scores_gemma":[0.9903426,0.008830569,0.0002557987,0.000108868706,0.000086002816,0.000006786718,0.000120632125,0.000002581806,0.00024611884],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995005,0.00016957185,0.00009716116,0.00004823202,0.0001236144,0.000060979706],"domain_scores_gemma":[0.9980008,0.0007328802,0.00087495055,0.0000646644,0.00016600816,0.00016072365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006329601,0.00016419595,0.00028505473,0.001287999,0.00022046505,0.00041646752,0.00019046453,0.00040252553,0.001464202],"category_scores_gemma":[0.003888944,0.0001344081,0.00011540737,0.0010198584,0.000541592,0.0005596869,0.00031224618,0.00023772639,0.00037747683],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002756722,0.000030999166,0.9192174,0.00050655333,0.000045583514,0.02331171,0.00032275883,0.00008778002,0.002369724,0.00021311908,0.0006991982,0.052919526],"study_design_scores_gemma":[0.000022268612,0.00027962512,0.73718816,0.0002957563,0.00009004368,0.25430793,0.00080141367,0.00017698224,0.0013669302,0.00038602436,0.005074267,0.000010594708],"about_ca_topic_score_codex":0.00060167303,"about_ca_topic_score_gemma":0.0008263675,"teacher_disagreement_score":0.001464202,"about_ca_system_score_codex":0.00012324382,"about_ca_system_score_gemma":0.00020757945,"threshold_uncertainty_score":0.0048981905},"labels":[],"label_agreement":null},{"id":"W2075891452","doi":"10.3109/10428194.2011.608449","title":"Genomic stratification of multiple myeloma treated with novel agents","year":2011,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Multiple myeloma; Stratification (seeds); Risk stratification; Computational biology; Medicine; Biology; Oncology; Internal medicine; Cancer research; Bioinformatics","score_opus":0.054621532574841286,"score_gpt":0.30317847664759484,"score_spread":0.24855694407275356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2075891452","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005041987,0.9985593,0.0000811096,0.00021688409,0.00006504313,0.0000038219987,0.000018086319,0.0000033068789,0.00054818817],"genre_scores_gemma":[0.0032447574,0.9958456,0.000264743,0.00015510748,0.00015463751,0.000008812791,0.000056853307,8.8034955e-7,0.00026863554],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99985313,0.000037968814,0.000027991804,0.000023335806,0.000047842797,0.000009783913],"domain_scores_gemma":[0.9998198,0.000066906265,0.000042746484,0.000003709958,0.000053486587,0.000013351093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043135305,0.00047133586,0.001292194,0.0014507668,0.0001089182,0.00044611035,0.0004981324,0.00048620004,0.0010646716],"category_scores_gemma":[0.00062531483,0.00012684814,0.0003686687,0.0012376733,0.00016907945,0.0004005179,0.00028295006,0.00056170515,0.00061700394],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015949817,0.000046608282,0.0017393355,0.0070461496,0.00017748716,0.00038264503,0.000035640445,0.00023051407,0.001121138,0.000589768,0.01358891,0.9748823],"study_design_scores_gemma":[0.0001777647,0.0005498512,0.0369001,0.010394269,0.0013710853,0.011581029,0.00018549376,0.00046622273,0.0022439247,0.0027385615,0.9333265,0.00006522687],"about_ca_topic_score_codex":0.0010320462,"about_ca_topic_score_gemma":0.0018947248,"teacher_disagreement_score":0.0014507668,"about_ca_system_score_codex":0.000399471,"about_ca_system_score_gemma":0.00055103505,"threshold_uncertainty_score":0.003561616},"labels":[],"label_agreement":null},{"id":"W2077488231","doi":"10.1080/10428190701799035","title":"Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia","year":2008,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Toxin Mechanisms and Immunotoxins","field":"Immunology and Microbiology","cited_by":153,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute","keywords":"Medicine; Chills; Diphtheria toxin; Refractory (planetary science); Myeloid leukemia; Gastroenterology; Internal medicine; Hypoalbuminemia; Diphtheria; Leukemia; Surgery; Immunology; Vaccination; Toxin","score_opus":0.01033369051243744,"score_gpt":0.24376718167260625,"score_spread":0.23343349116016882,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077488231","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944171,0.0018366255,0.00064150855,0.00034661026,0.000070873924,0.0011730058,0.00021854953,0.000071422575,0.0012243154],"genre_scores_gemma":[0.99507254,0.0010194036,0.001034062,0.00043238606,0.00006811882,0.0011061649,0.00055612234,0.000015456631,0.0006957894],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99974054,0.000118485026,0.00001100168,0.000035945304,0.000023859733,0.000070277085],"domain_scores_gemma":[0.9996284,0.00006889562,0.00007279722,0.000027928618,0.000020902353,0.00018103138],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008685804,0.00092352333,0.0012970231,0.0002265067,0.000325264,0.0005701385,0.0004549534,0.00076253404,0.0010954834],"category_scores_gemma":[0.00059737294,0.00033199633,0.0006492711,0.00030295202,0.00073201,0.0004539865,0.0002485875,0.0020483912,0.00041233617],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.47139722,0.10135893,0.018837724,0.00084923086,0.0011686116,0.0010632986,0.0010343007,0.0055336636,0.16898823,0.00092513976,0.0060211364,0.22282255],"study_design_scores_gemma":[0.2830077,0.68110275,0.01776325,0.00003800826,0.00036115333,0.0007210103,0.00009213147,0.001698284,0.0097248815,0.00035234506,0.005114741,0.000023719065],"about_ca_topic_score_codex":0.0006168978,"about_ca_topic_score_gemma":0.0010297956,"teacher_disagreement_score":0.0012970231,"about_ca_system_score_codex":0.00070448115,"about_ca_system_score_gemma":0.00095342676,"threshold_uncertainty_score":0.0051113963},"labels":[],"label_agreement":null},{"id":"W2078051582","doi":"10.1080/10428190601175393","title":"Phase II, randomized, multicenter, comparative study of peginterferon–α–2a (40 kD) (Pegasys®)<i>versus</i>interferon α-2a (Roferon®-A) in patients with treatment-naïve, chronic-phase chronic myelogenous leukemia","year":2007,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Gastroenterology; Internal medicine; Chronic myelogenous leukemia; PEG ratio; Philadelphia chromosome; Interferon; Adverse effect; Immunology; Leukemia; Chromosomal translocation; Biology","score_opus":0.018731130442451106,"score_gpt":0.2977675554976269,"score_spread":0.2790364250551758,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078051582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99279696,0.0014694593,0.0007863093,0.00038025028,0.00032776935,0.0026389745,0.0004176428,0.000085828244,0.0010969249],"genre_scores_gemma":[0.98823893,0.0014012811,0.0021860783,0.0010617446,0.0006521996,0.0038674066,0.0009203824,0.00003655333,0.0016354584],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9989987,0.0006425746,0.000043785963,0.00014635547,0.000055214572,0.00011333271],"domain_scores_gemma":[0.9983205,0.0004227537,0.00041980422,0.00015034634,0.000090547,0.0005960478],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027504235,0.0020696684,0.003164124,0.00044205412,0.00046317652,0.0012339642,0.0011860387,0.0017794118,0.003329528],"category_scores_gemma":[0.001992614,0.00095413567,0.0013642495,0.00052225863,0.0017776521,0.0013630645,0.00035722172,0.0032250276,0.0009368999],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9648792,0.018053824,0.0007286794,0.00015472915,0.0003240778,0.000041491487,0.00005211246,0.00033290737,0.0052687465,0.00008524761,0.0004060431,0.009672939],"study_design_scores_gemma":[0.8179444,0.17810157,0.0018515191,0.000010025748,0.00021826204,0.000053879987,0.000023236984,0.00049309985,0.00076967943,0.000088587316,0.0004338983,0.00001179497],"about_ca_topic_score_codex":0.0009278012,"about_ca_topic_score_gemma":0.0014523062,"teacher_disagreement_score":0.003329528,"about_ca_system_score_codex":0.0010803739,"about_ca_system_score_gemma":0.0015815,"threshold_uncertainty_score":0.014545798},"labels":[],"label_agreement":null},{"id":"W2078147862","doi":"10.1080/10428190701344881","title":"CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma","year":2007,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Island Health; BC Cancer Agency; University of British Columbia","funders":"BC Cancer Agency","keywords":"Rituximab; Diffuse large B-cell lymphoma; CHOP; Medicine; Internal medicine; Lymphoma; Oncology; Chemotherapy; Progression-free survival; Retrospective cohort study","score_opus":0.008076986968633092,"score_gpt":0.24277807292535974,"score_spread":0.23470108595672665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078147862","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985898,0.00096447405,0.00012286939,0.00003711985,0.0000033851863,0.0000033525735,0.00002140373,0.00000563356,0.0002520527],"genre_scores_gemma":[0.99948895,0.00021919189,0.000094753406,0.00003272561,0.000011183045,0.0000018954793,0.00007649757,0.0000013927769,0.000073407275],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99981576,0.000072659444,0.00001676649,0.000023940418,0.000034329907,0.000036526195],"domain_scores_gemma":[0.99957794,0.00012642017,0.0001546317,0.000029468443,0.000028213859,0.00008323827],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029866834,0.000102800834,0.0002550283,0.00019986,0.00011493644,0.00025987654,0.00009078984,0.0001424434,0.00042563476],"category_scores_gemma":[0.0010669368,0.00007237654,0.00012508845,0.00022399865,0.00013119658,0.00018894873,0.000149394,0.00023685761,0.00011323891],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004377655,0.0003177649,0.81511134,0.00008639607,0.00020167077,0.0019921444,0.00015511226,0.00059056113,0.040661804,0.00007100616,0.0007408292,0.13569376],"study_design_scores_gemma":[0.00017152517,0.004232171,0.9785784,0.000014446643,0.00014897306,0.008531124,0.00009309383,0.00095112046,0.004910353,0.00007757027,0.0022835326,0.000007742457],"about_ca_topic_score_codex":0.00024113298,"about_ca_topic_score_gemma":0.0005534189,"teacher_disagreement_score":0.00042563476,"about_ca_system_score_codex":0.000096854325,"about_ca_system_score_gemma":0.00009783372,"threshold_uncertainty_score":0.0015795231},"labels":[],"label_agreement":null},{"id":"W2078254962","doi":"10.1080/10428190290021632","title":"A Literature Review of Single Agent Treatment of Multiply Relapsed Aggressive Non-Hodgkin's Lymphoma","year":2002,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Inimex Pharmaceuticals (Canada)","funders":"","keywords":"Medicine; Vinorelbine; Etoposide; Oncology; Population; Internal medicine; Clinical trial; Lymphoma; Aggressive lymphoma; Vincristine; Inclusion and exclusion criteria; Rituximab; Chemotherapy; Pathology; Alternative medicine; Cyclophosphamide","score_opus":0.028927631738162974,"score_gpt":0.2899046831440661,"score_spread":0.2609770514059031,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078254962","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00033075584,0.9991579,0.000052233205,0.000053601816,0.000053083288,0.000012379503,0.000023664521,0.000003671437,0.0003126827],"genre_scores_gemma":[0.0015657673,0.9978994,0.0002451069,0.000105631916,0.00004446097,0.000014508018,0.00003335465,8.962094e-7,0.00009084],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99933213,0.00018775862,0.00023022619,0.00008268856,0.00014332472,0.000023853192],"domain_scores_gemma":[0.9985252,0.00095889077,0.00024879476,0.000025522642,0.00020092429,0.00004064404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010863319,0.00073416386,0.0024311151,0.0042536883,0.0003287353,0.000822957,0.001147812,0.0007094226,0.0034042927],"category_scores_gemma":[0.0024490464,0.0003022605,0.0008376122,0.0071389116,0.0003341056,0.0012059836,0.00035979616,0.00044402576,0.00056505244],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002503369,0.00006960972,0.000410897,0.2589789,0.000517622,0.0010357302,0.00018046265,0.00028014006,0.00093747285,0.0004915196,0.012914316,0.72393304],"study_design_scores_gemma":[0.00029241128,0.0012707498,0.012628595,0.23533083,0.008730543,0.015881537,0.00068014214,0.0003631457,0.0021769842,0.0016268473,0.72092855,0.0000895982],"about_ca_topic_score_codex":0.0018145269,"about_ca_topic_score_gemma":0.0043200483,"teacher_disagreement_score":0.0042536883,"about_ca_system_score_codex":0.00074413634,"about_ca_system_score_gemma":0.0019812088,"threshold_uncertainty_score":0.011388481},"labels":[],"label_agreement":null},{"id":"W2079214894","doi":"10.1080/1042819031000060582","title":"Posterior Leukoencephalopathy in Association with the Tumour Lysis Syndrome in Acute Lymphoblastic Leukaemia--A Case with Clinicopathological Correlation","year":2003,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Neurological Complications and Syndromes","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Medicine; Autopsy; Leukoencephalopathy; Malignancy; Tumor lysis syndrome; Pathology; Cortical blindness; Chemotherapy; Internal medicine; Blindness; Disease","score_opus":0.010407605167652795,"score_gpt":0.23538475436949485,"score_spread":0.22497714920184206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079214894","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98608255,0.0041508693,0.0018625787,0.0006869952,0.000096714444,0.00010819053,0.00014893376,0.000089084686,0.0067740306],"genre_scores_gemma":[0.99725527,0.0013634071,0.00048710423,0.00015885409,0.0002021963,0.000025792571,0.000080492595,0.000009062129,0.00041781776],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99954236,0.00006952474,0.000055218912,0.00009540936,0.00006121995,0.00017633018],"domain_scores_gemma":[0.99824166,0.0005487316,0.00053297734,0.0002453189,0.0001021384,0.0003291727],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041857615,0.0015592084,0.00069608074,0.002135523,0.0015412081,0.0015213744,0.00083955994,0.002378058,0.002393651],"category_scores_gemma":[0.0031760505,0.0012185142,0.00050185,0.0015652686,0.002245562,0.0018074973,0.0015758983,0.0019854824,0.0009240074],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006835558,0.00003630552,0.019329177,0.000041579016,0.00001194469,0.9778982,0.00016991125,0.000047540187,0.0008072943,0.00015805993,0.00013937413,0.0012922615],"study_design_scores_gemma":[0.0000181763,0.00003606518,0.005939008,0.0000064755222,0.00001272012,0.9932973,0.00005803185,0.00007028936,0.00020713602,0.00010976996,0.00023969379,0.0000052771193],"about_ca_topic_score_codex":0.0015498734,"about_ca_topic_score_gemma":0.0014913105,"teacher_disagreement_score":0.002393651,"about_ca_system_score_codex":0.0006142609,"about_ca_system_score_gemma":0.000638844,"threshold_uncertainty_score":0.008007586},"labels":[],"label_agreement":null},{"id":"W2079335457","doi":"10.1080/10428190902756578","title":"Incidence and risk factors for second cancers after autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma","year":2009,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"University Health Network","keywords":"Medicine; Internal medicine; Etoposide; Transplantation; Melphalan; Chemotherapy; Oncology; Lymphoma; Cumulative incidence; Cancer; Total body irradiation; Population; Hematopoietic stem cell transplantation; Surgery; Cyclophosphamide","score_opus":0.006591239452566481,"score_gpt":0.24115905153030998,"score_spread":0.2345678120777435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079335457","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99936515,0.0003271012,0.00006835568,0.000020652662,0.0000023796188,0.0000022338616,0.000040387968,0.0000036209015,0.00017007068],"genre_scores_gemma":[0.9996768,0.000090005095,0.00003720068,0.000009406665,0.000008452894,0.0000021333472,0.00008597639,0.0000010368487,0.00008889239],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997613,0.00007523806,0.000026619835,0.00003414764,0.000053980097,0.000048825026],"domain_scores_gemma":[0.99873036,0.0002987612,0.000620047,0.00005953791,0.000063942076,0.00022738615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032207766,0.0001392295,0.00017502547,0.0004692584,0.0001996368,0.00043475025,0.0001748932,0.0003172235,0.0014174788],"category_scores_gemma":[0.0011427446,0.00014738356,0.00029238465,0.00041923666,0.00020126575,0.00020234288,0.0002626642,0.000519244,0.00017623592],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000052643256,0.000016430415,0.998626,0.0000025996396,0.000014303569,0.00009145117,0.000013903149,0.00002045046,0.00009306396,0.0000071787385,0.000040390823,0.0010216142],"study_design_scores_gemma":[0.0000049097907,0.00010380392,0.9983165,0.0000030053304,0.000019943642,0.0011240173,0.000043716398,0.00014822588,0.00010716296,0.000014057673,0.000112846275,0.0000019548993],"about_ca_topic_score_codex":0.00097624527,"about_ca_topic_score_gemma":0.0013852326,"teacher_disagreement_score":0.0014174788,"about_ca_system_score_codex":0.00020821796,"about_ca_system_score_gemma":0.00019748475,"threshold_uncertainty_score":0.0047419667},"labels":[],"label_agreement":null},{"id":"W2079909815","doi":"10.3109/10428194.2015.1061189","title":"Co-existent B-cell and plasma cell neoplasms: a case series providing novel clinical insight","year":2015,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Amyloidosis: Diagnosis, Treatment, Outcomes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Plasma cell; Concomitant; Multiple myeloma; Medicine; Plasma Cell Myeloma; B cell; Amyloidosis; Group B; Plasma cell leukemia; Lymphocytosis; Chronic lymphocytic leukemia; Monoclonal; Bortezomib; Internal medicine; Pathology; Monoclonal antibody; Antibody; Immunology; Leukemia","score_opus":0.025561715507290264,"score_gpt":0.27568026052508066,"score_spread":0.2501185450177904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079909815","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927014,0.001190786,0.0013278585,0.00028989947,0.00005365875,0.000047604943,0.00006958862,0.000036204703,0.004283054],"genre_scores_gemma":[0.9981664,0.00044573966,0.00065691886,0.00009287797,0.00019025308,0.000015465554,0.000054141976,0.0000096173535,0.00036860968],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9990963,0.00016063191,0.00014416978,0.00023450062,0.00014121771,0.00022326324],"domain_scores_gemma":[0.99740833,0.00091165357,0.00063006097,0.00037070015,0.00016430403,0.0005149151],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065049436,0.0009279069,0.00060205767,0.0023595316,0.0016921044,0.0015550005,0.00072012015,0.0014066524,0.0029271925],"category_scores_gemma":[0.0034543902,0.0008164264,0.00045838126,0.0012019216,0.0015379047,0.0013837954,0.0015576532,0.0011065492,0.00090425846],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001404715,0.00017108732,0.2479225,0.00005414105,0.000047396097,0.739569,0.0008378467,0.00011760116,0.0024897046,0.00049894484,0.0005746052,0.0075766635],"study_design_scores_gemma":[0.000010688125,0.000059077895,0.017859513,0.000010641665,0.000018978184,0.98035586,0.00037129654,0.00013624514,0.00041074588,0.0001407283,0.00061763014,0.000008490888],"about_ca_topic_score_codex":0.0011034113,"about_ca_topic_score_gemma":0.00167544,"teacher_disagreement_score":0.0029271925,"about_ca_system_score_codex":0.00042492835,"about_ca_system_score_gemma":0.00056073535,"threshold_uncertainty_score":0.0097923875},"labels":[],"label_agreement":null},{"id":"W2080392453","doi":"10.3109/10428190009065824","title":"TALE Homeoproteins as HOX11-Interacting Partners in T-cell Leukemia","year":2000,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Canadian Blood Services; Women's College Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Leukemia; Cancer research; Medicine; Chemistry; Biology; Genetics","score_opus":0.017937619855348606,"score_gpt":0.28701320237827754,"score_spread":0.26907558252292896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080392453","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877166,0.003511072,0.006032673,0.00011078664,0.000013037527,0.000023067942,0.00017697815,0.00012315164,0.0022926384],"genre_scores_gemma":[0.99459654,0.0007679384,0.0015967874,0.00003140723,0.000004223941,0.000012335592,0.00023841679,0.000009203773,0.0027432542],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99992394,0.000017062166,0.0000040110244,0.000015472793,0.000023673205,0.000015782152],"domain_scores_gemma":[0.9999703,0.000003928865,0.00000864777,0.0000024053575,0.0000025503466,0.0000121746725],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013434773,0.00022853914,0.000111009,0.00019043384,0.00022415441,0.0003261014,0.0001303413,0.00017979332,0.0011933441],"category_scores_gemma":[0.000058724,0.000090381,0.0001237745,0.00014947138,0.00018178363,0.00016010707,0.00025775636,0.00021443542,0.0005720668],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000085391126,0.000019764606,0.00049825874,0.000027387156,0.0000057543853,0.00020989221,0.000021994114,0.00014804806,0.99662364,0.00050199596,0.00008124202,0.0017766098],"study_design_scores_gemma":[0.00001720631,0.000097587916,0.0061916765,0.000004458164,0.000016776228,0.0009877249,0.000044953522,0.0018080645,0.98360175,0.00021529777,0.007009317,0.00000515596],"about_ca_topic_score_codex":0.0002846756,"about_ca_topic_score_gemma":0.00041066567,"teacher_disagreement_score":0.0011933441,"about_ca_system_score_codex":0.0002619125,"about_ca_system_score_gemma":0.000089869645,"threshold_uncertainty_score":0.0039921403},"labels":[],"label_agreement":null},{"id":"W2080486808","doi":"10.1080/10428190400019867","title":"Bcl-2 and c-Myc co-operate in the Epstein – Barr virus-immortalized human B-cell line GM607 but do not confer tumorigenicity","year":2005,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Immortalised cell line; Biology; Lymphoblast; Cancer research; Cell culture; Neoplastic transformation; Epstein–Barr virus; Oncogene; Transformation (genetics); Virus; Lymphoma; Malignant transformation; Cell growth; Virology; Carcinogenesis; Cell; Cancer; Immunology; Cell cycle; Genetics; Gene","score_opus":0.012855520724554625,"score_gpt":0.24607210437897276,"score_spread":0.23321658365441814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080486808","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916182,0.0024131907,0.002790268,0.000104764506,0.00003441383,0.00004274591,0.00025840348,0.00009947902,0.0026386266],"genre_scores_gemma":[0.99302363,0.00087380776,0.0021566078,0.000050231243,0.000014634222,0.00006067747,0.0011096661,0.000025169082,0.0026854638],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99924964,0.00016687585,0.00007515022,0.000079407844,0.0003242203,0.00010461303],"domain_scores_gemma":[0.9995184,0.00015250457,0.00005940349,0.00011021113,0.000051727482,0.00010777705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045047508,0.00034278084,0.00035493224,0.0004146057,0.0002095194,0.00051329995,0.00024590464,0.00033160156,0.0014911991],"category_scores_gemma":[0.00047326973,0.0003459766,0.0003132665,0.00032000008,0.00022619766,0.00027424516,0.0006159111,0.0005849774,0.00082942675],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000101131365,0.000043558368,0.00046483596,0.000021753827,0.0000084338735,0.000139509,0.000025289664,0.00004434024,0.9979963,0.0001388787,0.000030976975,0.0009849689],"study_design_scores_gemma":[0.00004011905,0.0005224176,0.0070985164,0.000010549774,0.000029639654,0.0017412875,0.000039129718,0.001274153,0.98294467,0.000112192414,0.0061812093,0.00000614301],"about_ca_topic_score_codex":0.0006616602,"about_ca_topic_score_gemma":0.0008002224,"teacher_disagreement_score":0.0014911991,"about_ca_system_score_codex":0.0002553468,"about_ca_system_score_gemma":0.00037142102,"threshold_uncertainty_score":0.004988551},"labels":[],"label_agreement":null},{"id":"W2080925567","doi":"10.3109/10428190109057962","title":"Fludarabine in Alkylator-Resistant Follicular Non-Hodgkin's Lymphoma","year":2001,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Canadian Blood Services; Sunnybrook Health Science Centre; Western University","funders":"","keywords":"Fludarabine; Medicine; Chemotherapy; Transplantation; Follicular lymphoma; Salvage therapy; Oncology; Internal medicine; Surgery; Lymphoma; Cyclophosphamide","score_opus":0.009063964940791711,"score_gpt":0.24025947942153852,"score_spread":0.23119551448074682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080925567","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93878466,0.058629163,0.00045633563,0.00021692505,0.000028843788,0.00007518803,0.0001777081,0.000012133831,0.00161895],"genre_scores_gemma":[0.98970395,0.009486738,0.0002472989,0.00016971628,0.00004966122,0.000018618446,0.00013443305,0.0000035401774,0.00018589484],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991955,0.00042760657,0.00013401246,0.00007169019,0.00010005732,0.00007115366],"domain_scores_gemma":[0.9986811,0.0007900398,0.00034750212,0.000045422927,0.00006649947,0.00006936859],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012510188,0.00011320393,0.00038127974,0.00067410985,0.00021498652,0.0003734578,0.00022727056,0.00039379028,0.0006182613],"category_scores_gemma":[0.0029988864,0.00010585681,0.0002477423,0.0010385499,0.0002729901,0.00025238423,0.00017220844,0.00021266095,0.00012905215],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003031884,0.00011886164,0.83868116,0.0012198589,0.00019629966,0.012119523,0.0004803143,0.00035027956,0.0041637486,0.00023196157,0.00092461956,0.13848153],"study_design_scores_gemma":[0.00029842037,0.0038952602,0.9152812,0.00049430714,0.00075621594,0.056302235,0.0010061042,0.0005859466,0.0029775687,0.00033107025,0.01804791,0.000023841534],"about_ca_topic_score_codex":0.0015952558,"about_ca_topic_score_gemma":0.0025960084,"teacher_disagreement_score":0.0015952558,"about_ca_system_score_codex":0.00029016583,"about_ca_system_score_gemma":0.00036681592,"threshold_uncertainty_score":0.006616056},"labels":[],"label_agreement":null},{"id":"W2085000409","doi":"10.1080/10428190601043138","title":"Overexpression of SOCS-2 and SOCS-3 genes reverses erythroid overgrowth and IGF-I hypersensitivity of primary polycythemia vera (PV) cells","year":2007,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto; Health Sciences Centre; Mount Sinai Hospital; Sunnybrook Health Science Centre","funders":"Canadian Institutes of Health Research","keywords":"Polycythemia vera; Haematopoiesis; Progenitor cell; Myeloid; Biology; Immunology; Cancer research; Peripheral blood mononuclear cell; Population; Cytokine; Stem cell; Cell biology; Medicine; Genetics; In vitro","score_opus":0.009433284318129924,"score_gpt":0.22828275624695313,"score_spread":0.2188494719288232,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2085000409","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950296,0.0010817245,0.0017495718,0.00013255455,0.00006909545,0.000031319727,0.00032878824,0.00013979443,0.0014373678],"genre_scores_gemma":[0.99644744,0.00031756848,0.0009954314,0.000055520282,0.000016063894,0.00002499354,0.00048451428,0.000017475513,0.0016409871],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99986017,0.000024793626,0.000015676385,0.000020625741,0.00003226438,0.00004636355],"domain_scores_gemma":[0.99983954,0.00003366674,0.000043666,0.000018467355,0.000012591372,0.00005206188],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010139286,0.00030455407,0.0001904571,0.00018269433,0.00008863615,0.0002873372,0.000112477304,0.0001886758,0.0010642111],"category_scores_gemma":[0.00015288696,0.00010730729,0.00020570161,0.000109222005,0.0002566164,0.00011618294,0.00012602938,0.00056507206,0.0002920804],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008872619,0.000029367651,0.00012601231,0.000017852346,0.0000030786148,0.000045894307,0.000008401961,0.000043127242,0.99868935,0.00007045061,0.000041561896,0.0008361726],"study_design_scores_gemma":[0.00009577129,0.0008746807,0.0061471113,0.0000084668445,0.000028459663,0.00064767065,0.00005689205,0.0018662576,0.9854124,0.00007461863,0.004780858,0.000006795299],"about_ca_topic_score_codex":0.00041281484,"about_ca_topic_score_gemma":0.000779359,"teacher_disagreement_score":0.0010642111,"about_ca_system_score_codex":0.00023743871,"about_ca_system_score_gemma":0.00018851379,"threshold_uncertainty_score":0.0035601258},"labels":[],"label_agreement":null},{"id":"W2085950913","doi":"10.1080/10428190500102555","title":"Troglitazone overcomes doxorubicin-resistance in resistant K562 leukemia cells","year":2005,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Peptidase Inhibition and Analysis","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"Canadian Institutes of Health Research","keywords":"Troglitazone; K562 cells; Doxorubicin; Leukemia; Cancer research; Resistance (ecology); Medicine; Biology; Internal medicine; Chemotherapy; Receptor","score_opus":0.008235208502196396,"score_gpt":0.23514582218768065,"score_spread":0.22691061368548426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2085950913","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99484295,0.0015284092,0.0012410596,0.00010668362,0.000038599283,0.000071466726,0.00041249755,0.0001745494,0.0015838094],"genre_scores_gemma":[0.9922867,0.0013004149,0.0020531868,0.000056708774,0.000013617921,0.000055107474,0.0010415544,0.000043258435,0.0031496102],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99988246,0.000018563323,0.000017390532,0.000024070563,0.000027846101,0.000029636256],"domain_scores_gemma":[0.9999391,0.0000073587107,0.00001587677,0.000014155476,0.000007361322,0.000016156228],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009637819,0.00034251233,0.00056173914,0.0003303215,0.00017234216,0.00026349997,0.00022380802,0.00021141254,0.0011128421],"category_scores_gemma":[0.00010846155,0.00012596487,0.00024912372,0.00023097532,0.00014087853,0.00014724309,0.00016105793,0.0005497364,0.00050791755],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017999898,0.000059993563,0.00017026301,0.00003186623,0.000007116423,0.000054115946,0.0000173827,0.0000877076,0.9966461,0.000053897926,0.000087750435,0.0026037549],"study_design_scores_gemma":[0.00010003251,0.0009993482,0.004502079,0.000005463363,0.000019534144,0.0003332131,0.000022655853,0.0005413744,0.9894804,0.000026574187,0.0039639706,0.0000054266707],"about_ca_topic_score_codex":0.00084690214,"about_ca_topic_score_gemma":0.0018872495,"teacher_disagreement_score":0.0011128421,"about_ca_system_score_codex":0.00023966607,"about_ca_system_score_gemma":0.00018642242,"threshold_uncertainty_score":0.0037228465},"labels":[],"label_agreement":null},{"id":"W2088824526","doi":"10.1080/10428190802353617","title":"Catalase activity and arsenic sensitivity in acute leukemia","year":2008,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Retinoids in leukemia and cellular processes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Catalase; Acute promyelocytic leukemia; Arsenic trioxide; Myeloid leukemia; Reactive oxygen species; Leukemia; Chemistry; Glutathione peroxidase; Cancer research; Glutathione; Apoptosis; Immunology; Biochemistry; Biology; Enzyme","score_opus":0.007209639999661714,"score_gpt":0.21852901100757016,"score_spread":0.21131937100790846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088824526","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99665415,0.0023687973,0.00038499024,0.000045562912,0.00000476154,0.000007764336,0.00010482564,0.000023075061,0.0004060334],"genre_scores_gemma":[0.99868315,0.00059754687,0.00016734269,0.000012042412,0.0000026984067,0.000005053138,0.00011226642,0.0000022469017,0.00041748965],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997936,0.0000728938,0.000023391318,0.0000278316,0.000051101862,0.000031155174],"domain_scores_gemma":[0.9996984,0.000060409428,0.00010654801,0.000021294385,0.00006211116,0.00005128324],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023368688,0.00016773093,0.00022427157,0.00040629238,0.000082343664,0.00032944404,0.00011564411,0.00022549952,0.0009804907],"category_scores_gemma":[0.0003648397,0.00012483321,0.00013558645,0.00034319673,0.00021452786,0.00012889117,0.0001554459,0.00030454417,0.00028582106],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010128648,0.00011325432,0.024386382,0.000077290206,0.000044438966,0.00029423964,0.000078885976,0.00019107248,0.9688164,0.00012784106,0.00007454138,0.0047828136],"study_design_scores_gemma":[0.000040105064,0.0017569155,0.19168402,0.000015983087,0.00010900377,0.0038597567,0.00021045719,0.0013352574,0.7973777,0.00039683006,0.003193033,0.00002088639],"about_ca_topic_score_codex":0.0005866194,"about_ca_topic_score_gemma":0.0004561802,"teacher_disagreement_score":0.0009804907,"about_ca_system_score_codex":0.00031020507,"about_ca_system_score_gemma":0.00013333111,"threshold_uncertainty_score":0.0032801032},"labels":[],"label_agreement":null},{"id":"W2088941610","doi":"10.1080/10428190802023715","title":"Targeting the follicular lymphoma microenvironment – Ready for prime-time?","year":2008,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Follicular lymphoma; Prime time; Lymphoma; Medicine; Prime (order theory); Cancer research; Oncology; Follicular phase; Internal medicine; Computer science","score_opus":0.02287477505465715,"score_gpt":0.27518199615586886,"score_spread":0.25230722110121173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088941610","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007914417,0.9985831,0.000084530846,0.00037770587,0.00028255684,0.0000036091938,0.000008682141,0.0000062808676,0.0005744804],"genre_scores_gemma":[0.0005309728,0.99821955,0.000123521,0.00034565723,0.00015757466,0.000006163176,0.000018420526,9.670673e-7,0.0005970961],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998555,0.000026784257,0.000015509939,0.000020897312,0.00006107034,0.00002022418],"domain_scores_gemma":[0.99983287,0.00006024391,0.000036650865,0.00000458991,0.00004727255,0.000018203236],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055510626,0.0008375994,0.0013561144,0.0010837596,0.00020847222,0.0007158246,0.0010195499,0.0010831413,0.002668591],"category_scores_gemma":[0.00048122846,0.00028997887,0.00042005494,0.001203655,0.0004407602,0.0013164437,0.0005242647,0.0018068985,0.0022725295],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011652924,0.000063672705,0.00013377675,0.008777127,0.00006435553,0.00019685694,0.000034747314,0.00023892311,0.0023683477,0.0024549959,0.077840574,0.9077101],"study_design_scores_gemma":[0.000050952265,0.0001064319,0.00049911847,0.0018984796,0.00009845398,0.001888591,0.0000444539,0.000076480974,0.00086870545,0.0010334507,0.9934208,0.000014067466],"about_ca_topic_score_codex":0.0013068134,"about_ca_topic_score_gemma":0.0031738007,"teacher_disagreement_score":0.002668591,"about_ca_system_score_codex":0.00069795497,"about_ca_system_score_gemma":0.0007870751,"threshold_uncertainty_score":0.008927345},"labels":[],"label_agreement":null},{"id":"W2090218255","doi":"10.3109/10428194.2013.878934","title":"Initial transfusion intensity predicts survival in myelodysplastic syndrome","year":2014,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"Canadian Institutes of Health Research; Aplastic Anemia and Myelodysplasia Association of Canada; Celgene","keywords":"Medicine; Myelodysplastic syndromes; International Prognostic Scoring System; Internal medicine; Blood transfusion; Overall survival; Myeloid leukemia; Myeloid; Leukemia; Gastroenterology; Surgery; Bone marrow","score_opus":0.0135262473141188,"score_gpt":0.2563653017870442,"score_spread":0.2428390544729254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2090218255","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99965715,0.00016217913,0.000028654747,0.000014920997,0.000001877937,0.0000019843537,0.000020423313,0.0000014502192,0.000111309826],"genre_scores_gemma":[0.99980325,0.000042011885,0.00003520765,0.000007969995,0.00000649996,0.0000018767826,0.000059962986,6.9500254e-7,0.00004244286],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998197,0.00006875493,0.000023755134,0.000020442145,0.000028336972,0.000039096256],"domain_scores_gemma":[0.99847716,0.00037414135,0.00070282957,0.000057017733,0.000089805646,0.00029909651],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003667257,0.0002256176,0.00026886453,0.0003908473,0.00021238596,0.00031442748,0.0001490204,0.0003189505,0.0007837987],"category_scores_gemma":[0.002146509,0.00013963887,0.00022405184,0.00036700044,0.00024554733,0.0002520221,0.0002598587,0.00042498286,0.00019460132],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043886606,0.000033532884,0.9964799,0.0000037742022,0.000017080176,0.00010254392,0.00004012014,0.00009669069,0.0006974668,0.000007433805,0.000039240873,0.00204333],"study_design_scores_gemma":[0.000017240518,0.00048188644,0.9980394,0.000005831076,0.000030470392,0.0006223286,0.00007229169,0.00037675415,0.00022243403,0.000026987964,0.00009948956,0.000004766635],"about_ca_topic_score_codex":0.0007243887,"about_ca_topic_score_gemma":0.00085537235,"teacher_disagreement_score":0.0007837987,"about_ca_system_score_codex":0.00021417571,"about_ca_system_score_gemma":0.00015067915,"threshold_uncertainty_score":0.002622068},"labels":[],"label_agreement":null},{"id":"W2090784428","doi":"10.1080/10428190500158797","title":"Cyclin D expression in chronic lymphocytic leukemia","year":2005,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; University of Manitoba","funders":"University of Manitoba; Leukemia and Lymphoma Society","keywords":"Cyclin D2; Cyclin D1; Cyclin D3; Chronic lymphocytic leukemia; Biology; Cyclin B; Cyclin D; Cyclin; Cancer research; Cyclin A2; Cell cycle; Cyclin A; Molecular biology; Immunology; Leukemia; Cell; Genetics","score_opus":0.014543074738468446,"score_gpt":0.2814525180491777,"score_spread":0.26690944331070926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2090784428","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99144053,0.0065524927,0.0003778826,0.00006040922,0.000009796145,0.0000075775165,0.00034899698,0.000015667083,0.0011866475],"genre_scores_gemma":[0.9971209,0.0014983901,0.00032426722,0.00003579225,0.000007691478,0.000009351137,0.00031108432,0.0000033538506,0.0006890133],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9999497,0.000007603265,0.000004570845,0.000015527872,0.000010735419,0.000011901785],"domain_scores_gemma":[0.99992037,0.000020418134,0.000025554938,0.0000048698366,0.000014835367,0.00001405245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010366553,0.000108451415,0.00009868806,0.00064702996,0.00021775175,0.0002958984,0.00005138152,0.00011077215,0.00078169006],"category_scores_gemma":[0.000201937,0.00007239062,0.00008161422,0.0003381575,0.00019467331,0.0001001377,0.000121240235,0.00011289175,0.00012012891],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013474419,0.00003193625,0.1801236,0.00022847975,0.000040244126,0.00085660024,0.00039421255,0.0003591938,0.7828919,0.00045845826,0.0004946347,0.032773286],"study_design_scores_gemma":[0.000114989874,0.00050666474,0.7610486,0.000058502836,0.000070424016,0.0052662245,0.0005343083,0.0009832749,0.19851841,0.0007193066,0.0321475,0.000031736265],"about_ca_topic_score_codex":0.001798994,"about_ca_topic_score_gemma":0.0020482498,"teacher_disagreement_score":0.001798994,"about_ca_system_score_codex":0.00043293307,"about_ca_system_score_gemma":0.00017458345,"threshold_uncertainty_score":0.0035770535},"labels":[],"label_agreement":null},{"id":"W2092467128","doi":"10.1080/10428190601043278","title":"What is the role of rituximab in salvage treatment for patients with diffuse large B-cell lymphoma?","year":2006,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Rituximab; Diffuse large B-cell lymphoma; Salvage therapy; Lymphoma; Medicine; Internal medicine; Ibrutinib; Oncology; Cancer research; Leukemia; Chronic lymphocytic leukemia; Chemotherapy","score_opus":0.005676256751926217,"score_gpt":0.213364026246244,"score_spread":0.2076877694943178,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2092467128","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013932439,0.06528746,0.0007004056,0.87855214,0.014318073,0.000077922436,0.0002436169,0.00014961386,0.026738293],"genre_scores_gemma":[0.14276446,0.08138868,0.0036974505,0.590093,0.16188294,0.00023650369,0.0003939094,0.00012110461,0.019421916],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988889,0.00042179902,0.00019095995,0.00009934147,0.00025745455,0.00014150869],"domain_scores_gemma":[0.99517524,0.0025171998,0.00042897303,0.00011968666,0.000817984,0.0009408637],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017051315,0.00053592917,0.0023578461,0.0008274466,0.0012477303,0.0019105723,0.0016104631,0.014681103,0.007806868],"category_scores_gemma":[0.0120137045,0.0003883109,0.0014743156,0.00063369167,0.0013409862,0.0033741982,0.00033978588,0.0089766225,0.004387318],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038482738,0.0007414732,0.018987399,0.0015714724,0.0004671581,0.03231224,0.00020771436,0.0014524811,0.0017581941,0.0034234894,0.6297212,0.30550888],"study_design_scores_gemma":[0.0056844265,0.0029240723,0.045254584,0.0062568355,0.0016252965,0.1031746,0.0016508345,0.0074077803,0.002473139,0.019387918,0.80375624,0.00040434478],"about_ca_topic_score_codex":0.0026812865,"about_ca_topic_score_gemma":0.0066680913,"teacher_disagreement_score":0.014681103,"about_ca_system_score_codex":0.002500419,"about_ca_system_score_gemma":0.0016957936,"threshold_uncertainty_score":0.02611655},"labels":[],"label_agreement":null},{"id":"W2092568922","doi":"10.1080/10428190902912478","title":"Early stage gastric diffuse large B-cell lymphomas: results of a randomised trial comparing chemotherapy alone<i>versus</i>chemotherapy + involved field radiotherapy","year":2009,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Chemotherapy; Stage (stratigraphy); Internal medicine; Radiation therapy; Induction chemotherapy; Lymphoma; Anthracycline; Clinical trial; Gastroenterology; Incidence (geometry); Oncology; Radiology; Cancer","score_opus":0.014246067083915251,"score_gpt":0.2543617198471192,"score_spread":0.24011565276320396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2092568922","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98904383,0.005205278,0.0005850908,0.0006873968,0.00057892926,0.0026315453,0.0002741478,0.000034955814,0.0009587708],"genre_scores_gemma":[0.9904974,0.0025144948,0.0014772208,0.0008431303,0.00065361033,0.0022269066,0.00043544985,0.000014384989,0.0013373441],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99758613,0.0018018956,0.00016818577,0.0001802282,0.00008631164,0.00017731223],"domain_scores_gemma":[0.99731255,0.0012633465,0.00052098336,0.00019717128,0.00010038297,0.0006056125],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038300196,0.0012546177,0.0030527448,0.00045147777,0.0004157939,0.00087477226,0.0007702227,0.002150723,0.003505012],"category_scores_gemma":[0.004091764,0.00060620805,0.0021471821,0.0004385714,0.0014781076,0.00097471033,0.00044888817,0.002597951,0.0005440289],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9882224,0.0027051196,0.00038696718,0.0002642414,0.0005012857,0.0000291494,0.000022930348,0.00015182573,0.0016039253,0.000040193805,0.00012289011,0.005949067],"study_design_scores_gemma":[0.891543,0.1058378,0.001094388,0.000023515773,0.0006848932,0.000034041706,0.000011336965,0.00012941721,0.0002942205,0.00007825065,0.000259945,0.000009303459],"about_ca_topic_score_codex":0.00063842034,"about_ca_topic_score_gemma":0.0012019102,"teacher_disagreement_score":0.0038300196,"about_ca_system_score_codex":0.0007104794,"about_ca_system_score_gemma":0.0008552782,"threshold_uncertainty_score":0.020255327},"labels":[],"label_agreement":null},{"id":"W2093350079","doi":"10.1080/10428190601071717","title":"Zidovudine and interferon-α treatment induces a high response rate and reduces HTLV-1 proviral load and VEGF plasma levels in patients with adult T-cell leukemia from North East Iran","year":2007,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"T-cell and Retrovirus Studies","field":"Immunology and Microbiology","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Nautical Research Society","funders":"","keywords":"Zidovudine; Medicine; Immunology; Leukemia; Chemotherapy; Adult T-cell leukemia/lymphoma; Immunosuppression; Human T-lymphotropic virus 1; Virology; Internal medicine; Virus; T-cell leukemia; Viral disease","score_opus":0.008662121771244423,"score_gpt":0.19467052715843247,"score_spread":0.18600840538718805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2093350079","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986523,0.00093677046,0.00007791838,0.000043010514,0.000009219508,0.000016132466,0.000014812725,0.000010597349,0.00023933765],"genre_scores_gemma":[0.9993957,0.00022821393,0.00012527556,0.00004850857,0.000020430127,0.000009454613,0.000047651058,0.0000014426032,0.0001234283],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9999031,0.000031210897,0.000009190149,0.000014448209,0.000021409,0.000020558226],"domain_scores_gemma":[0.99987805,0.000033501616,0.000033010885,0.000007457619,0.000011999707,0.0000358698],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020260565,0.00018501887,0.00043198367,0.0002023479,0.0001353693,0.000143898,0.00009657359,0.00015591292,0.00028881346],"category_scores_gemma":[0.0003983078,0.00009140828,0.00020188828,0.0001449034,0.00008844526,0.000079744,0.000055343233,0.00027792892,0.000076982375],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01968678,0.004017512,0.5063182,0.0003554586,0.00048653354,0.0042846343,0.0014607628,0.0015390153,0.24794601,0.00015418939,0.0016429343,0.21210797],"study_design_scores_gemma":[0.0015938942,0.018194245,0.9545986,0.000021564534,0.00032246593,0.005694582,0.00030578743,0.0015106152,0.013622533,0.000083125095,0.0040335297,0.000019033392],"about_ca_topic_score_codex":0.0008347577,"about_ca_topic_score_gemma":0.0010640615,"teacher_disagreement_score":0.0008347577,"about_ca_system_score_codex":0.000189505,"about_ca_system_score_gemma":0.0001433256,"threshold_uncertainty_score":0.0016598105},"labels":[],"label_agreement":null},{"id":"W2093514907","doi":"10.1080/1042819031000067918","title":"Intermediate Dose Thalidomide (200 mg Daily) has Comparable Efficacy and Less Toxicity than Higher Doses in Relapsed Multiple Myeloma","year":2003,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Thalidomide; Discontinuation; Medicine; Multiple myeloma; Toxicity; Internal medicine; Gastroenterology; Retrospective cohort study","score_opus":0.0664127587477917,"score_gpt":0.3197220966819115,"score_spread":0.2533093379341198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2093514907","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00063652894,0.9983346,0.000051028455,0.000067857705,0.000026767399,0.000004399262,0.00001425925,0.00000500468,0.0008595591],"genre_scores_gemma":[0.0032076798,0.99604416,0.00014484698,0.000087744615,0.000033760236,0.000006202477,0.000032891745,9.908623e-7,0.00044178788],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998523,0.000029702733,0.000026621345,0.000029589133,0.000050952836,0.0000108967],"domain_scores_gemma":[0.9998062,0.00008261251,0.000048108202,0.0000066112166,0.00004185916,0.000014573745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045604978,0.00044568576,0.0014960442,0.0015522134,0.00017264974,0.0005904878,0.0006518268,0.00048082194,0.0031481453],"category_scores_gemma":[0.0004822584,0.0001366565,0.00039738923,0.00200637,0.0002448222,0.00056078506,0.00021791956,0.0003982736,0.0013557115],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001365664,0.000044973494,0.00044992194,0.014437025,0.000108987864,0.00029494887,0.000039058745,0.000113137765,0.0017444204,0.00041961262,0.0058649504,0.9763464],"study_design_scores_gemma":[0.00018908404,0.0008653989,0.012154543,0.008472823,0.0008692733,0.01124163,0.0002008226,0.00012758063,0.0025609327,0.0012719291,0.9620168,0.000029098755],"about_ca_topic_score_codex":0.00094060414,"about_ca_topic_score_gemma":0.0022709602,"teacher_disagreement_score":0.0031481453,"about_ca_system_score_codex":0.000372316,"about_ca_system_score_gemma":0.0006290544,"threshold_uncertainty_score":0.010531545},"labels":[],"label_agreement":null},{"id":"W2094252783","doi":"10.3109/10428194.2013.827785","title":"Preservation of lower incidence of chronic lymphocytic leukemia in Chinese residents in British Columbia: a 26-year survey from 1983 to 2008","year":2013,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Paul's Hospital; Vancouver General Hospital; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Chronic lymphocytic leukemia; Incidence (geometry); Demography; Medicine; Cancer registry; Cancer incidence; Population; Standardized rate; Chinese population; Leukemia; Internal medicine; Biology; Genetics","score_opus":0.010671169226739606,"score_gpt":0.2565736229097232,"score_spread":0.24590245368298358,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2094252783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965732,0.00024013482,0.000034378456,0.00008871416,0.0000035428989,0.000008680844,0.0018734994,0.000005907594,0.0011719934],"genre_scores_gemma":[0.9982445,0.00018654818,0.00003758035,0.000036235437,0.000002486378,0.000007347557,0.000792088,0.0000017622234,0.0006913453],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99971026,0.00003585701,0.000028962224,0.000066344524,0.00007818243,0.00008034781],"domain_scores_gemma":[0.9989737,0.00005160403,0.00021045821,0.00004944796,0.0004841972,0.00023059928],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029976034,0.0001625269,0.00022812896,0.0010127211,0.00083816267,0.00053635304,0.00046940276,0.0002506153,0.0011690658],"category_scores_gemma":[0.00089276064,0.00018662162,0.0001760562,0.0024927065,0.00033306563,0.0002265998,0.00031485522,0.00030436713,0.00024807535],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027347412,0.000010401668,0.99751294,0.000011917886,0.000014692952,0.00004372589,0.00032314387,0.000021176565,0.0001539539,0.0000077098675,0.00033108884,0.0015420722],"study_design_scores_gemma":[5.8726204e-7,0.000004129196,0.99951077,0.0000029119208,0.0000038609032,0.000019652347,0.00023866593,0.000017082593,0.000019157816,0.0000011287356,0.00018116446,9.57026e-7],"about_ca_topic_score_codex":0.90753853,"about_ca_topic_score_gemma":0.9356151,"teacher_disagreement_score":0.09246147,"about_ca_system_score_codex":0.0036632488,"about_ca_system_score_gemma":0.0034491331,"threshold_uncertainty_score":0.18601191},"labels":[],"label_agreement":null},{"id":"W2094394948","doi":"10.1080/10428190701824544","title":"Aurora A kinase RNAi and small molecule inhibition of Aurora kinases with VE-465 induce apoptotic death in multiple myeloma cells","year":2008,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Microtubule and mitosis dynamics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Aurora inhibitor; Aurora A kinase; Aurora kinase; Centrosome; Kinase; Cancer research; Multiple myeloma; Programmed cell death; Apoptosis; Cell biology; Biology; Cell cycle; Immunology; Genetics","score_opus":0.011075464239785416,"score_gpt":0.19913231274955057,"score_spread":0.18805684850976515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2094394948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916471,0.001545595,0.0026082054,0.000119319,0.00004651702,0.00004794514,0.0007702204,0.00018803657,0.0030271355],"genre_scores_gemma":[0.9937028,0.0007589724,0.0016287726,0.000051932177,0.0000056027193,0.000042554908,0.0007518314,0.000019824683,0.0030375768],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999795,0.00001814888,0.000029061244,0.000039294893,0.00006978368,0.000048613456],"domain_scores_gemma":[0.9999157,0.000016569475,0.000022028666,0.000011964699,0.000008254284,0.000025519117],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010290166,0.0002680299,0.000362975,0.00019859921,0.000165755,0.00028204455,0.00022124544,0.00024039017,0.0015191993],"category_scores_gemma":[0.000069567795,0.00012955235,0.00032654504,0.00022896161,0.00016700607,0.00016031682,0.00016289864,0.00068973575,0.00037136595],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017381574,0.000052162482,0.00011746614,0.00002947745,0.000010579295,0.00005907402,0.000013223702,0.00010607567,0.99774796,0.00013012772,0.000081314676,0.0014788011],"study_design_scores_gemma":[0.00003136729,0.00035480666,0.0029026507,0.000003843726,0.0000126092,0.00019882522,0.000019423118,0.0009540835,0.9940671,0.000037407885,0.00141522,0.0000027376245],"about_ca_topic_score_codex":0.0010612134,"about_ca_topic_score_gemma":0.0015218294,"teacher_disagreement_score":0.0015191993,"about_ca_system_score_codex":0.0003629456,"about_ca_system_score_gemma":0.00021537059,"threshold_uncertainty_score":0.0050822496},"labels":[],"label_agreement":null},{"id":"W2095058829","doi":"10.1080/10428190500062932","title":"Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: Potential implications for future prophylaxis recommendations","year":2005,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Hepatitis B Virus Studies","field":"Medicine","cited_by":125,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Hepatitis B; HBsAg; Lamivudine; Hepatitis B virus; Rituximab; Chemotherapy; Vincristine; Immunology; Hepatitis; Internal medicine; Lymphoma; Gastroenterology; Cyclophosphamide; Virus","score_opus":0.011375562699313314,"score_gpt":0.27604664583183325,"score_spread":0.2646710831325199,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095058829","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.78213185,0.1032649,0.0029094783,0.08111571,0.0013574804,0.00010781853,0.00009735698,0.00007772086,0.028937725],"genre_scores_gemma":[0.97525465,0.01616063,0.00071335665,0.0051327427,0.0016172794,0.000013623215,0.00004854939,0.0000039759293,0.0010553139],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.99934584,0.0004332886,0.00008022535,0.00002238364,0.000061865714,0.000056463887],"domain_scores_gemma":[0.9964528,0.0023012883,0.00045529715,0.000121675395,0.00037016807,0.00029873842],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011608204,0.00016694749,0.0002701884,0.00025484478,0.00041020085,0.00059647404,0.0003241091,0.0016596256,0.0014664815],"category_scores_gemma":[0.0064152633,0.00010411649,0.0002396126,0.0001808992,0.00043234453,0.00084944797,0.00018706665,0.000842164,0.00031491078],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018006382,0.000698717,0.49530807,0.0007848706,0.00016612152,0.18849848,0.0011429866,0.0010991136,0.0026703838,0.005487812,0.015632566,0.2867103],"study_design_scores_gemma":[0.00089404057,0.0062897163,0.24863975,0.0030355242,0.0006761411,0.600717,0.007140636,0.006114782,0.0055419113,0.018638551,0.10213142,0.0001805346],"about_ca_topic_score_codex":0.0005192967,"about_ca_topic_score_gemma":0.00081385655,"teacher_disagreement_score":0.0016596256,"about_ca_system_score_codex":0.00032626092,"about_ca_system_score_gemma":0.0004777739,"threshold_uncertainty_score":0.00613904},"labels":[],"label_agreement":null},{"id":"W2095225241","doi":"10.3109/10428190309178811","title":"Cost-effectiveness of a Transplantation Strategy Compared to Melphalan and Prednisone in Younger Patients with Multiple Myeloma","year":2003,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Joseph’s Healthcare Hamilton; Hamilton Health Sciences; Hamilton Regional Laboratory Medicine Program; Cancer Care Ontario; McMaster University","funders":"Hamilton Health Sciences","keywords":"Melphalan; Medicine; Prednisone; Multiple myeloma; Autologous stem-cell transplantation; Transplantation; Internal medicine; Cost effectiveness; Surgery; Oncology","score_opus":0.022135308889808858,"score_gpt":0.2778753257788484,"score_spread":0.2557400168890395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095225241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965855,0.0020839581,0.00015350507,0.0004670701,0.000020518271,0.000038740785,0.00012668135,0.000005767603,0.0005182548],"genre_scores_gemma":[0.99916494,0.00046654258,0.00013093652,0.00005899324,0.000010805643,0.00001002545,0.000089032284,8.991551e-7,0.00006782133],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998955,0.0006915603,0.000055858396,0.00005026501,0.00013185624,0.000115463576],"domain_scores_gemma":[0.9976829,0.0014409607,0.00043462048,0.000049245,0.000083694715,0.00030851894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018706741,0.0005396249,0.00060787605,0.0005709738,0.00029812212,0.00068176375,0.0004422906,0.0005775575,0.0014765756],"category_scores_gemma":[0.00721549,0.00023525557,0.0019164745,0.0007152931,0.00038829018,0.00048534406,0.0004961724,0.0005901499,0.000054468746],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14448176,0.0033039455,0.36091372,0.0015233431,0.009905298,0.002963115,0.00043407906,0.22350447,0.004588947,0.0030935095,0.0030967414,0.24219108],"study_design_scores_gemma":[0.01739211,0.044317164,0.7069839,0.00083498826,0.013768123,0.002792472,0.000999131,0.20075327,0.0041174376,0.0044114953,0.003419585,0.00021023027],"about_ca_topic_score_codex":0.047347315,"about_ca_topic_score_gemma":0.06309069,"teacher_disagreement_score":0.047347315,"about_ca_system_score_codex":0.006135815,"about_ca_system_score_gemma":0.002153327,"threshold_uncertainty_score":0.09414345},"labels":[],"label_agreement":null},{"id":"W2095357289","doi":"10.3109/10428190903370387","title":"State-of-the-art in the management of chronic myelogenous leukemia in the era of the tyrosine kinase inhibitors: evolutionary trends in diagnosis, monitoring and treatment","year":2009,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Nilotinib; Dasatinib; Imatinib; Medicine; Chronic myelogenous leukemia; Myeloid leukemia; Tyrosine kinase; Tyrosine-kinase inhibitor; Disease; Imatinib mesylate; Intensive care medicine; Oncology; Internal medicine; Leukemia","score_opus":0.019624493807393912,"score_gpt":0.27948932661892767,"score_spread":0.2598648328115338,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095357289","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000073881994,0.99905175,0.00006477918,0.00032204812,0.00008393432,0.0000019664471,0.000004268878,0.0000035833377,0.0003936876],"genre_scores_gemma":[0.00039341667,0.99895716,0.00019547551,0.00016125523,0.0001388378,0.0000029254404,0.000009548595,7.7306856e-7,0.00014050625],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.999501,0.00012658078,0.00008570015,0.00006688543,0.00019012304,0.000029653753],"domain_scores_gemma":[0.9989675,0.0005599401,0.0001535133,0.000024535251,0.00023323597,0.00006122636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014272389,0.0007071772,0.0016699639,0.0022811834,0.00029243788,0.0010455631,0.0011941019,0.0013523857,0.0022513599],"category_scores_gemma":[0.0015060976,0.0002465192,0.0004859093,0.0035099054,0.000674634,0.0017377349,0.0005385667,0.0018696854,0.0019447727],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004603864,0.000041082792,0.00019218196,0.008375696,0.000053091517,0.00016174551,0.00004454454,0.00025126382,0.0004256366,0.0012558285,0.013383813,0.9757691],"study_design_scores_gemma":[0.000033747845,0.00017228619,0.0021276332,0.0077208574,0.00016803057,0.0030635695,0.00015984336,0.00018094135,0.0003212575,0.0022404878,0.98378193,0.000029457802],"about_ca_topic_score_codex":0.0014133314,"about_ca_topic_score_gemma":0.0024041554,"teacher_disagreement_score":0.0022811834,"about_ca_system_score_codex":0.00082238833,"about_ca_system_score_gemma":0.0011907496,"threshold_uncertainty_score":0.007548034},"labels":[],"label_agreement":null},{"id":"W2097324482","doi":"10.3109/10428194.2011.624227","title":"Double high-dose therapy with dose-intensive cyclophosphamide, etoposide, cisplatin (DICEP) followed by high-dose melphalan and autologous stem cell transplantation for relapsed/refractory Hodgkin lymphoma","year":2011,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; University of Calgary","funders":"","keywords":"Medicine; Melphalan; Etoposide; Internal medicine; Autologous stem-cell transplantation; Cyclophosphamide; Oncology; Progression-free survival; Gastroenterology; Transplantation; Carmustine; Refractory (planetary science); Stem cell; Salvage therapy; Chemotherapy; Urology; Surgery","score_opus":0.014815767357193631,"score_gpt":0.2296442179792584,"score_spread":0.21482845062206476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097324482","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957094,0.0033067358,0.000397527,0.000036882197,0.000011185576,0.000048592472,0.000028994591,0.000009554073,0.00045117034],"genre_scores_gemma":[0.99825996,0.0008210435,0.00052441977,0.00008019116,0.000034887922,0.000023717757,0.00012484522,0.0000027458334,0.0001281962],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997044,0.00011928617,0.000038653787,0.000046866633,0.000046230678,0.000044580618],"domain_scores_gemma":[0.99960977,0.00014710415,0.0001138917,0.000039517585,0.000018020422,0.000071753566],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004789691,0.000179381,0.00042883327,0.00022255318,0.00018809956,0.00024128224,0.00020594044,0.00022083492,0.00044800353],"category_scores_gemma":[0.00082958094,0.000094173374,0.00023380655,0.00022979859,0.0002677045,0.0001629872,0.00024293968,0.0002638167,0.00012256268],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014927814,0.0011594262,0.5695875,0.0010444812,0.0007287615,0.009514056,0.00058039604,0.0025682768,0.052933324,0.00016068059,0.0015063921,0.3452889],"study_design_scores_gemma":[0.0016125066,0.02273615,0.90119445,0.00013133524,0.00055640686,0.042635947,0.00036071928,0.0012007189,0.019903589,0.00014974986,0.009492691,0.000025674923],"about_ca_topic_score_codex":0.00026076037,"about_ca_topic_score_gemma":0.0009628045,"teacher_disagreement_score":0.0004789691,"about_ca_system_score_codex":0.00038131152,"about_ca_system_score_gemma":0.0002891209,"threshold_uncertainty_score":0.0027666092},"labels":[],"label_agreement":null},{"id":"W2097752354","doi":"10.1080/10428190310001638832","title":"Detection of Chromosome 13q Deletions and IgH Translocations in Patients with Multiple Myeloma by FISH: Comparison with Karyotype Analysis","year":2004,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Karyotype; Chromosomal translocation; Multiple myeloma; Fish <Actinopterygii>; Biology; Genetics; Chromosome; Chromosome analysis; Cytogenetics; Molecular biology; Gene; Immunology; Fishery","score_opus":0.0070428659838574215,"score_gpt":0.22985836820092523,"score_spread":0.2228155022170678,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097752354","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998755,0.00038217328,0.00030368427,0.000034081073,0.0000035178066,0.00000649182,0.00007171478,0.000014035094,0.00042922146],"genre_scores_gemma":[0.9993678,0.00015926623,0.00028656467,0.000020710704,0.000006811283,0.000006823272,0.000070152935,0.0000036337308,0.00007842899],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996625,0.00006120565,0.000050440205,0.00008848126,0.00008611301,0.000051247323],"domain_scores_gemma":[0.999474,0.00024237015,0.00009988944,0.000036006182,0.00007683912,0.00007091516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041496495,0.0004127192,0.0003720905,0.0019355705,0.0001859839,0.00030671235,0.00020440631,0.0005955941,0.0013511652],"category_scores_gemma":[0.0018688844,0.00022684992,0.0001733328,0.0007554488,0.00031578686,0.00041921547,0.0003801537,0.00022081596,0.00033340527],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00065198465,0.00003456701,0.9534506,0.000040052375,0.00003631571,0.0042217695,0.00027365066,0.00022119224,0.029727578,0.000033893928,0.00010090468,0.011207371],"study_design_scores_gemma":[0.000038100858,0.0004112027,0.9692094,0.000013319696,0.00007743084,0.022264106,0.00029391437,0.0011546519,0.005696391,0.000098982106,0.0007268137,0.000015653508],"about_ca_topic_score_codex":0.0010722098,"about_ca_topic_score_gemma":0.0007015928,"teacher_disagreement_score":0.0019355705,"about_ca_system_score_codex":0.000252055,"about_ca_system_score_gemma":0.00013405917,"threshold_uncertainty_score":0.0045201182},"labels":[],"label_agreement":null},{"id":"W2098205907","doi":"10.3109/10428194.2013.824077","title":"Expression of microRNA-1234 related signal transducer and activator of transcription 3 in patients with diffuse large B-cell lymphoma of activated B-cell like type from high and low infectious disease areas","year":2013,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network","funders":"National Cancer Institute","keywords":"STAT3; microRNA; STAT protein; Cancer research; Lymphoma; Carcinogenesis; Diffuse large B-cell lymphoma; Biology; Transfection; Medicine; Signal transduction; Immunology; Cell culture; Gene; Cell biology; Genetics","score_opus":0.003196871236730002,"score_gpt":0.178234416654029,"score_spread":0.175037545417299,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098205907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99960476,0.00013755499,0.000033016127,0.000012435043,0.0000017287617,0.0000020023526,0.00004756218,0.0000021628841,0.00015873455],"genre_scores_gemma":[0.9996885,0.00004136184,0.00005851731,0.000013556897,0.000002464848,0.000002856924,0.00008721033,8.7754034e-7,0.00010464421],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999887,0.000024765837,0.000015176073,0.000026853544,0.00002174907,0.000024500054],"domain_scores_gemma":[0.99985397,0.00003585437,0.00005271699,0.000005739347,0.000022507815,0.000029226447],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000121825935,0.00018857329,0.00023804438,0.00064338354,0.0002555823,0.00039492163,0.00010960115,0.00027349265,0.0010688296],"category_scores_gemma":[0.0004214915,0.0001798988,0.00019163219,0.00044423554,0.00017440841,0.00013389897,0.00014558037,0.00025674608,0.0001489995],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010986052,0.000050598526,0.97837913,0.000029352346,0.000058999776,0.0014244238,0.0001927624,0.00006327066,0.015317877,0.000034489338,0.00013125285,0.0032191763],"study_design_scores_gemma":[0.000044426968,0.00021233865,0.9921875,0.0000068456607,0.00008257439,0.003797685,0.00039100114,0.00045123254,0.0023694902,0.00004679124,0.00040331343,0.000006732013],"about_ca_topic_score_codex":0.0011068918,"about_ca_topic_score_gemma":0.0013060799,"teacher_disagreement_score":0.0011068918,"about_ca_system_score_codex":0.0002723402,"about_ca_system_score_gemma":0.00012518797,"threshold_uncertainty_score":0.003575623},"labels":[],"label_agreement":null},{"id":"W2098380899","doi":"10.3109/10428190903388376","title":"Improved survival using an intensive, pediatric-based chemotherapy regimen in adults with T-cell acute lymphoblastic leukemia","year":2009,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Regimen; Asparaginase; Internal medicine; Chemotherapy; Oncology; Overall survival; Multivariate analysis; Lymphoblastic Leukemia; Leukemia","score_opus":0.01097828439615595,"score_gpt":0.2549455362204758,"score_spread":0.24396725182431983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098380899","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990127,0.00064730266,0.000052679563,0.000017526987,0.0000018435716,0.0000049871323,0.000061148596,0.0000016765769,0.00020016458],"genre_scores_gemma":[0.999418,0.00026372014,0.00007842785,0.000018831157,0.0000065498525,0.000004727239,0.00018862155,6.7608704e-7,0.000020439664],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996475,0.00014265774,0.000046226636,0.000041507177,0.000068060624,0.000054091954],"domain_scores_gemma":[0.99876237,0.00030134732,0.00070815376,0.000043511267,0.000059478523,0.00012504487],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044527935,0.00012453788,0.00029194678,0.0003000328,0.00015184368,0.00027923888,0.00011183156,0.00017576352,0.00039850816],"category_scores_gemma":[0.0019901386,0.00006854839,0.00018265653,0.0006372595,0.00016773684,0.0002858715,0.00019733398,0.00022589699,0.000049531543],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009057327,0.000058580867,0.9855745,0.000021709822,0.000059475242,0.0002807206,0.000050017687,0.00021687381,0.0006386317,0.000022221433,0.000091507296,0.012079909],"study_design_scores_gemma":[0.000054507836,0.0012658009,0.9953686,0.00001186785,0.000092874674,0.0019689698,0.00008235886,0.00026466517,0.00025407952,0.000030610994,0.00060219935,0.000003615495],"about_ca_topic_score_codex":0.00064846687,"about_ca_topic_score_gemma":0.0014752622,"teacher_disagreement_score":0.00064846687,"about_ca_system_score_codex":0.00029092564,"about_ca_system_score_gemma":0.00027169054,"threshold_uncertainty_score":0.0023548603},"labels":[],"label_agreement":null},{"id":"W2099220112","doi":"10.3109/10428194.2011.639018","title":"Non-relapse mortality in pediatric acute lymphoblastic leukemia: a systematic review and meta-analysis","year":2011,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Institute for Clinical Evaluative Sciences; University of Toronto; SickKids Foundation; Public Health Ontario; Hospital for Sick Children","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Lymphoblastic Leukemia; Meta-analysis; Internal medicine; Complete remission; Pediatrics; Mortality rate; Leukemia; Chemotherapy","score_opus":0.047082088209867874,"score_gpt":0.32497771594731656,"score_spread":0.2778956277374487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099220112","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0048103305,0.99422073,0.00027517413,0.00010221634,0.00006881683,0.00012801986,0.00027687306,0.000011405628,0.00010640806],"genre_scores_gemma":[0.12392611,0.8727969,0.001602781,0.00031376918,0.00014471236,0.0005503909,0.00049533247,0.000012079386,0.00015787013],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99301916,0.0036798446,0.0018006829,0.0006078267,0.0007115223,0.00018091024],"domain_scores_gemma":[0.982623,0.013107287,0.0025812523,0.00037432453,0.0011052968,0.00020883582],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.010480547,0.0021663392,0.014080093,0.0058147586,0.00044898747,0.0018723694,0.0015848435,0.0014050563,0.002199411],"category_scores_gemma":[0.026898311,0.0012892822,0.02487349,0.0070674014,0.00040157288,0.001235189,0.0010856289,0.0012829443,0.00019719367],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019814624,0.00003462661,0.0084933,0.37619326,0.5912867,0.0002229294,0.000087572036,0.00059352524,0.00021122368,0.00011261771,0.0008032426,0.01997956],"study_design_scores_gemma":[0.00058864005,0.00025800677,0.006370446,0.0221457,0.96826583,0.00020355995,0.00005101243,0.00021864926,0.000132425,0.0001462686,0.0016002186,0.000019246061],"about_ca_topic_score_codex":0.0053207255,"about_ca_topic_score_gemma":0.014272102,"teacher_disagreement_score":0.9859199,"about_ca_system_score_codex":0.002103622,"about_ca_system_score_gemma":0.0026915376,"threshold_uncertainty_score":0.055427134},"labels":[],"label_agreement":null},{"id":"W2099980739","doi":"10.3109/10428194.2014.918972","title":"Is there a role for omacetaxine in the management of chronic myelogenous leukemia in the era of the tyrosine kinase inhibitors?","year":2014,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"","keywords":"Chronic myelogenous leukemia; Tyrosine kinase; Medicine; Cancer research; Leukemia; CD135; Immunology; Internal medicine; Receptor","score_opus":0.012325001069235906,"score_gpt":0.2414652612103483,"score_spread":0.2291402601411124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099980739","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00089149177,0.006032472,0.00012985876,0.9804387,0.0075442083,0.000011223006,0.000036467944,0.000022106946,0.0048934026],"genre_scores_gemma":[0.011723418,0.014613681,0.00076604646,0.90622884,0.05851482,0.00003504127,0.000054562148,0.000019972236,0.00804357],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99905616,0.00027851618,0.00014585642,0.00009210056,0.00027745575,0.00014978324],"domain_scores_gemma":[0.99751306,0.0012620873,0.00031669345,0.00006518694,0.0003394143,0.000503643],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010012058,0.00044444305,0.0012923152,0.0004486698,0.0016903124,0.0018530205,0.001158223,0.02523435,0.006739701],"category_scores_gemma":[0.0077144667,0.00030951615,0.0012935664,0.00045162567,0.0017727804,0.0034164705,0.000739048,0.021041322,0.003694955],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056418753,0.00031385597,0.0035243786,0.00032988327,0.00007130532,0.01717405,0.00014298756,0.000467013,0.0010634351,0.010399332,0.8538797,0.11206986],"study_design_scores_gemma":[0.00071263994,0.00046638653,0.0024969564,0.00092947995,0.000076439545,0.019139435,0.00038246685,0.00086093455,0.00054828235,0.021782564,0.95251673,0.00008769564],"about_ca_topic_score_codex":0.0029229424,"about_ca_topic_score_gemma":0.007480942,"teacher_disagreement_score":0.02523435,"about_ca_system_score_codex":0.0027764828,"about_ca_system_score_gemma":0.00250594,"threshold_uncertainty_score":0.02254659},"labels":[],"label_agreement":null},{"id":"W2100198173","doi":"10.3109/10428194.2012.710907","title":"Role of radiotherapy in patients with early-stage diffuse large B-cell lymphoma of Waldeyer's ring in remission after anthracycline-containing chemotherapy","year":2012,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Anthracycline; Chemotherapy; Stage (stratigraphy); Lymphoma; Internal medicine; Radiation therapy; Gastroenterology; Surgery; Diffuse large B-cell lymphoma; Induction chemotherapy; Oncology; Cancer; Breast cancer","score_opus":0.004290189130809547,"score_gpt":0.22056401710279658,"score_spread":0.21627382797198702,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100198173","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907017,0.0085076215,0.00009146069,0.00013269547,0.000023359371,0.000033122782,0.00006852127,0.000010331649,0.00043119784],"genre_scores_gemma":[0.99835867,0.0011999019,0.00009451745,0.000072522904,0.000038874467,0.000016801316,0.00014296747,0.000001894629,0.000073798925],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996505,0.00021307229,0.000029040477,0.000042010633,0.000030868177,0.00003449698],"domain_scores_gemma":[0.9990747,0.00037751382,0.00028983934,0.000051251198,0.000042344484,0.00016427995],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078286487,0.00023574663,0.0010000952,0.00025570052,0.00019768257,0.00039775213,0.00030483236,0.0004439612,0.000637556],"category_scores_gemma":[0.0022727987,0.000099011195,0.00043823165,0.0005124564,0.00020340331,0.0002571187,0.00018371781,0.00039656102,0.000099330646],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.051924802,0.0009042946,0.768663,0.00056604744,0.00078129524,0.0007613189,0.00025859056,0.001875528,0.005584193,0.000081642276,0.00069375517,0.16790561],"study_design_scores_gemma":[0.0020265586,0.015482475,0.97763515,0.000099742865,0.00072625757,0.00090078556,0.00008034951,0.0010091456,0.0004926394,0.0000691451,0.0014629826,0.000014774417],"about_ca_topic_score_codex":0.0009357558,"about_ca_topic_score_gemma":0.002212979,"teacher_disagreement_score":0.0010000952,"about_ca_system_score_codex":0.00028533643,"about_ca_system_score_gemma":0.00032370025,"threshold_uncertainty_score":0.004140198},"labels":[],"label_agreement":null},{"id":"W2100242421","doi":"10.3109/10428194.2014.963082","title":"Pulmonary tuberculosis reactivation following ruxolitinib treatment in a patient with primary myelofibrosis","year":2014,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Héma-Québec","funders":"","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Tuberculosis; Pulmonary tuberculosis; Internal medicine; Oncology; Bone marrow; Pathology","score_opus":0.010706398558013006,"score_gpt":0.22411892115910517,"score_spread":0.21341252260109217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100242421","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.73071855,0.016213503,0.0029505317,0.18186124,0.0050139087,0.00028348964,0.0005452568,0.00033620163,0.06207739],"genre_scores_gemma":[0.9698972,0.0030764998,0.00075402326,0.017689688,0.0053483834,0.000027658936,0.0001308247,0.00002893296,0.003046679],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99920636,0.00020029103,0.00008888191,0.00012459715,0.00012136987,0.00025853794],"domain_scores_gemma":[0.9979869,0.0009854615,0.00027458605,0.00012176712,0.00014628397,0.00048495358],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006522624,0.0007468488,0.00097131514,0.0009347898,0.0018373319,0.0014864914,0.0009328363,0.008178652,0.0019272637],"category_scores_gemma":[0.004859582,0.0005868722,0.0009044842,0.00075588515,0.0010014871,0.0013162186,0.00067117676,0.004773498,0.0009279404],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000113678754,0.00007998818,0.011283833,0.00004624992,0.000016515263,0.97929126,0.00023355482,0.00016313823,0.0005147157,0.0003756155,0.004330441,0.003550944],"study_design_scores_gemma":[0.000090405396,0.00025908856,0.013583312,0.00016466723,0.00006182346,0.977689,0.0004345779,0.0017296935,0.0005448297,0.0010220361,0.0043935785,0.000026912816],"about_ca_topic_score_codex":0.0031657594,"about_ca_topic_score_gemma":0.0047071124,"teacher_disagreement_score":0.008178652,"about_ca_system_score_codex":0.0022340945,"about_ca_system_score_gemma":0.0010190444,"threshold_uncertainty_score":0.016209602},"labels":[],"label_agreement":null},{"id":"W2100660242","doi":"10.3109/10428194.2012.711828","title":"Limited-stage mantle cell lymphoma: treatment outcomes at the Princess Margaret Hospital","year":2012,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Blastoid; Mantle cell lymphoma; Stage (stratigraphy); Internal medicine; Univariate analysis; Chemoradiotherapy; Radiation therapy; Lymphoma; Surgery; Oncology; Gastroenterology; Multivariate analysis","score_opus":0.013008611068373449,"score_gpt":0.24576594878896707,"score_spread":0.23275733772059362,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100660242","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99798113,0.00052425975,0.000058096794,0.00041842123,0.0000061421024,0.000018262932,0.00026657197,0.0000071548893,0.00072003383],"genre_scores_gemma":[0.99845874,0.0002622597,0.000057741618,0.00020984579,0.000034167177,0.000016765927,0.00037949398,0.0000057084226,0.00057540153],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997726,0.000056202563,0.000019069857,0.000042851483,0.000048772155,0.000060507784],"domain_scores_gemma":[0.99936014,0.000069107286,0.00024304083,0.000018813338,0.000064268854,0.00024468414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021037455,0.0001707075,0.00022088314,0.000396971,0.00039036098,0.0004976388,0.0002257816,0.00044446596,0.0024504284],"category_scores_gemma":[0.0011200636,0.00017658056,0.00023594203,0.0006216102,0.00022710138,0.00046142988,0.00041081215,0.00041097408,0.0004905482],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011391017,0.000374347,0.96622336,0.000088518864,0.000111231224,0.0020784049,0.0005191889,0.0006567805,0.0015354331,0.0000489489,0.0022439046,0.024980737],"study_design_scores_gemma":[0.00011933579,0.0011145438,0.9950552,0.00003911144,0.000042061372,0.0016795775,0.00017883134,0.00041016107,0.00027220818,0.000092028684,0.0009804011,0.000016578051],"about_ca_topic_score_codex":0.0045793904,"about_ca_topic_score_gemma":0.0086423755,"teacher_disagreement_score":0.0045793904,"about_ca_system_score_codex":0.0009350044,"about_ca_system_score_gemma":0.0003590714,"threshold_uncertainty_score":0.009105504},"labels":[],"label_agreement":null},{"id":"W2100969937","doi":"10.3109/10428194.2013.773996","title":"Medical emergency team involvement in patients hospitalized with acute myeloid leukemia","year":2013,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Sepsis Diagnosis and Treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canada Research Chairs; Alberta Innovates - Health Solutions","keywords":"Medicine; Myeloid leukemia; Incidence (geometry); Confidence interval; Internal medicine; Intensive care unit; Retrospective cohort study; Emergency medicine; Emergency department; Pediatrics","score_opus":0.012272568152495247,"score_gpt":0.25154227164907006,"score_spread":0.2392697034965748,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100969937","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99935144,0.00018581576,0.00004025329,0.000058893893,0.000007861068,0.00000534271,0.00013632157,0.0000024142348,0.0002116678],"genre_scores_gemma":[0.999481,0.00012621253,0.000045727236,0.00003599641,0.000016819946,0.000005666328,0.00023329111,0.0000010342233,0.000054256525],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991253,0.00022259301,0.00012864158,0.00013628292,0.00017698306,0.00021022152],"domain_scores_gemma":[0.9972767,0.00036745126,0.0017201741,0.000075809774,0.00014231696,0.0004175431],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000526295,0.00023165041,0.00033077243,0.0007407364,0.000639384,0.0009248987,0.0003690008,0.0005235224,0.001408301],"category_scores_gemma":[0.003158106,0.0003611639,0.0004437721,0.00096169795,0.0002726236,0.0008734575,0.00081411755,0.00088589935,0.0002036447],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004238262,0.000017364606,0.99914134,0.000004257271,0.000014994944,0.000140211,0.00004177308,0.000018447086,0.00003451741,0.000008565735,0.00006438795,0.0004716405],"study_design_scores_gemma":[0.000009951891,0.00014401013,0.99736565,0.000012812942,0.000019936582,0.0014975478,0.00046808747,0.00025297402,0.000053358763,0.00003767542,0.00013194309,0.000006100847],"about_ca_topic_score_codex":0.0024473602,"about_ca_topic_score_gemma":0.0033325553,"teacher_disagreement_score":0.0024473602,"about_ca_system_score_codex":0.0003733556,"about_ca_system_score_gemma":0.00040822697,"threshold_uncertainty_score":0.0048662424},"labels":[],"label_agreement":null},{"id":"W2101109518","doi":"10.3109/10428194.2011.555888","title":"High response rate and improvement of long-term survival with combined treatment modalities in patients with poor-risk primary thyroid diffuse large B-cell lymphoma: an International Extranodal Lymphoma Study Group and Intergruppo Italiano Linfomi study","year":2011,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Provincia autonoma di Bolzano - Alto Adige","keywords":"Medicine; Lymphoma; Radiation therapy; Internal medicine; Modalities; Chemotherapy; Survival rate; Thyroid; Oncology; Diffuse large B-cell lymphoma; Surgery; Gastroenterology","score_opus":0.008709439332276173,"score_gpt":0.21736576793321233,"score_spread":0.20865632860093616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101109518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99870026,0.0008726178,0.000055797464,0.00002660919,0.0000047608114,0.00001836387,0.00006984668,0.0000029654464,0.0002487907],"genre_scores_gemma":[0.99944776,0.00015224676,0.000049457132,0.000030225652,0.000021019121,0.000022599159,0.00017132165,0.0000013046482,0.000104176164],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995577,0.00019935016,0.000038658505,0.00007166189,0.000064669235,0.00006802187],"domain_scores_gemma":[0.9992894,0.0002427401,0.00019380133,0.00007248798,0.000038780196,0.0001626874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009873888,0.00022955354,0.0005141111,0.00039230965,0.00019083792,0.00041111084,0.00020970845,0.0003846564,0.0007460788],"category_scores_gemma":[0.001129797,0.00014566757,0.0005558451,0.0003526179,0.00022591832,0.00024923895,0.00021639443,0.00033827536,0.00015396721],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021505808,0.0013107865,0.9385435,0.0001322844,0.00077495654,0.0003463705,0.0002258868,0.0005815753,0.006398024,0.000023409024,0.0003101708,0.029847262],"study_design_scores_gemma":[0.0009931,0.009049288,0.98666114,0.000012231152,0.00040562055,0.0008104786,0.00007357879,0.00046809262,0.00074406655,0.000026654876,0.0007452895,0.000010449813],"about_ca_topic_score_codex":0.0004743896,"about_ca_topic_score_gemma":0.00065305736,"teacher_disagreement_score":0.0009873888,"about_ca_system_score_codex":0.00033305993,"about_ca_system_score_gemma":0.00017677918,"threshold_uncertainty_score":0.0052219033},"labels":[],"label_agreement":null},{"id":"W2101740016","doi":"10.3109/10428194.2014.909039","title":"A single institution experience of extranodal natural killer/T cell lymphoma of nasal type","year":2014,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; CHOP; Vincristine; Prednisone; Internal medicine; Lymphoma; Cyclophosphamide; Gastroenterology; Nasal cavity; Radiation therapy; Stage (stratigraphy); Chemotherapy; International Prognostic Index; B symptoms; Surgery; Oncology","score_opus":0.010408843332424539,"score_gpt":0.2336162705908109,"score_spread":0.22320742725838635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101740016","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99725693,0.00055129273,0.00027543123,0.00013103304,0.0000150237365,0.000029019056,0.00007576563,0.000014815323,0.001650828],"genre_scores_gemma":[0.99859077,0.0004107984,0.0003234588,0.000119948054,0.00002187746,0.000010628172,0.00011826527,0.000008013672,0.00039617624],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.99954444,0.00007924605,0.00005645158,0.00007917036,0.00011297603,0.00012767222],"domain_scores_gemma":[0.99865025,0.00014111886,0.00033260917,0.00010515706,0.00019775289,0.0005731186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036364433,0.00029419686,0.00024138165,0.00031290954,0.0009936582,0.0007687535,0.00035357493,0.00027814417,0.0017041893],"category_scores_gemma":[0.001220908,0.00017165516,0.0003241066,0.00076840975,0.00042168924,0.00032195117,0.0005958501,0.00038474056,0.00033913023],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026355957,0.00024367259,0.94602096,0.00010154191,0.00008801702,0.02066346,0.0013246271,0.00026770978,0.0026338308,0.00009396421,0.0011634113,0.027135279],"study_design_scores_gemma":[0.00007908986,0.0016807996,0.8498338,0.00010381057,0.00016027884,0.13462223,0.004622643,0.0007383704,0.001657703,0.00013612278,0.006314416,0.000050694947],"about_ca_topic_score_codex":0.026022263,"about_ca_topic_score_gemma":0.08807491,"teacher_disagreement_score":0.026022263,"about_ca_system_score_codex":0.0021937515,"about_ca_system_score_gemma":0.0020816203,"threshold_uncertainty_score":0.0517416},"labels":[],"label_agreement":null},{"id":"W2103254744","doi":"10.3109/10428194.2012.660631","title":"Phase 1 trial of linifanib (ABT-869) in patients with refractory or relapsed acute myeloid leukemia","year":2012,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Princess Margaret Cancer Centre","funders":"Takeda Oncology","keywords":"Cytarabine; Medicine; Myeloid leukemia; Neutropenia; Refractory (planetary science); Fms-Like Tyrosine Kinase 3; Phases of clinical research; Internal medicine; Pharmacology; Clinical trial; Chemotherapy; Chemistry; Biology","score_opus":0.016781957473714398,"score_gpt":0.2891959538203783,"score_spread":0.2724139963466639,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103254744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99152815,0.0027782882,0.00050889037,0.00062678626,0.00013632288,0.001812132,0.00073460455,0.00012546369,0.00174941],"genre_scores_gemma":[0.98676026,0.0025353166,0.001991039,0.0011793714,0.00024858868,0.002071871,0.002141807,0.000026496355,0.0030452393],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99975306,0.00014065336,0.000009762728,0.00003525776,0.000017875213,0.00004334823],"domain_scores_gemma":[0.99964786,0.00006544729,0.00006808617,0.000020000161,0.000015415728,0.00018322427],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011018845,0.0014965315,0.0014249982,0.00031603925,0.0003707402,0.0005652404,0.0005226339,0.0008088467,0.0025582463],"category_scores_gemma":[0.00067609706,0.00040380325,0.0006244944,0.0002651365,0.0006617186,0.0005069079,0.0002945561,0.0019259105,0.00068046746],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7098265,0.05244707,0.008627488,0.0009987019,0.0010363742,0.00059231825,0.0003782664,0.0031898902,0.049807347,0.00047319662,0.008261156,0.16436167],"study_design_scores_gemma":[0.6332979,0.34478799,0.012783236,0.000039610815,0.00029576206,0.0003958119,0.00003982057,0.0016935584,0.003046047,0.0003212847,0.0032748338,0.000024050203],"about_ca_topic_score_codex":0.00065833906,"about_ca_topic_score_gemma":0.002001156,"teacher_disagreement_score":0.0025582463,"about_ca_system_score_codex":0.0005431266,"about_ca_system_score_gemma":0.00084200624,"threshold_uncertainty_score":0.008558214},"labels":[],"label_agreement":null},{"id":"W2103379333","doi":"10.3109/10428194.2015.1004170","title":"Methylenetetrahydrofolate reductase<i>C677T</i>and<i>A1298C</i>polymorphism and susceptibility to acute lymphoblastic leukemia in a cohort of Egyptian children","year":2015,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Methylenetetrahydrofolate reductase; Genotype; Genetics; Haplotype; Allele; Restriction fragment length polymorphism; Cohort; Medicine; Polymorphism (computer science); Internal medicine; Biology; Gene","score_opus":0.012244770635397247,"score_gpt":0.26354154470093216,"score_spread":0.2512967740655349,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103379333","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99975103,0.00006138023,0.000039610262,0.000009028882,0.0000011341676,0.0000053802514,0.00004766118,0.0000011294992,0.0000836479],"genre_scores_gemma":[0.9994844,0.00009005156,0.00010908726,0.000018008714,0.0000046183995,0.00000914526,0.00011126767,0.0000018869739,0.00017145068],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999694,0.00006671664,0.000026580045,0.00007818019,0.000057652338,0.00007690817],"domain_scores_gemma":[0.9995498,0.00008051347,0.00015820458,0.000058676662,0.000050255523,0.000102429694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046447618,0.00046216763,0.00039622036,0.0008365733,0.000712736,0.000537501,0.00034383175,0.0003517126,0.0011911301],"category_scores_gemma":[0.0009828269,0.0004496398,0.00045661832,0.0008388818,0.0003609434,0.00028152738,0.0003255612,0.00045749973,0.00015326442],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024126748,0.00007619772,0.9969242,0.000008218507,0.00006418946,0.0003595516,0.0002514709,0.000024339906,0.001082847,0.00002975018,0.000041878327,0.00089609734],"study_design_scores_gemma":[0.000036060166,0.00038352114,0.9967079,0.000006234415,0.0000983831,0.0015549836,0.00034877277,0.000115454284,0.00036492263,0.000027441738,0.00035191962,0.000004330636],"about_ca_topic_score_codex":0.010953894,"about_ca_topic_score_gemma":0.009137498,"teacher_disagreement_score":0.010953894,"about_ca_system_score_codex":0.00041273475,"about_ca_system_score_gemma":0.00041682078,"threshold_uncertainty_score":0.021780312},"labels":[],"label_agreement":null},{"id":"W2105993077","doi":"10.3109/10428194.2011.619605","title":"Genetic variability in<i>N-acetyltransferase 2</i>gene determines susceptibility to childhood lymphoid or myeloid leukemia in Brazil","year":2011,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro; Conselho Nacional de Desenvolvimento Científico e Tecnológico; DNA Genotek","keywords":"Odds ratio; Haplotype; Myeloid leukemia; Single-nucleotide polymorphism; Leukemia; Genotype; SNP; Tag SNP; Confidence interval; Oncology; Internal medicine; Logistic regression; Acute lymphocytic leukemia; Biology; Medicine; Genetics; Immunology; Lymphoblastic Leukemia; Gene","score_opus":0.016166005579840263,"score_gpt":0.25961122452996854,"score_spread":0.24344521895012827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105993077","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990582,0.00015537224,0.0001006814,0.000025469331,0.0000012443072,0.0000068827458,0.0001510087,0.0000029812966,0.00049828336],"genre_scores_gemma":[0.999526,0.0001346309,0.000117962554,0.0000105784475,0.0000011216149,0.0000039444567,0.000117433534,0.000002215133,0.00008611982],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997545,0.00006974606,0.000022752,0.00006799771,0.00004288783,0.00004210791],"domain_scores_gemma":[0.9994665,0.00013066115,0.00026262156,0.000043377484,0.00004877843,0.000048132413],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004608747,0.00024892192,0.00023426712,0.00048013724,0.00018980588,0.00032664373,0.00019800098,0.00015528798,0.0011828538],"category_scores_gemma":[0.0013179943,0.000258524,0.00028518902,0.00062010606,0.00034994967,0.000083914136,0.0002354555,0.00018652805,0.00014431585],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000768595,0.000012166089,0.99433064,0.000018312541,0.000049124865,0.00011754967,0.00027674396,0.00003891378,0.0026097896,0.00010030479,0.000050717572,0.0023188763],"study_design_scores_gemma":[0.000010587236,0.000062597,0.9983217,0.000015643773,0.000041130486,0.0004565604,0.00018022099,0.00016436433,0.00029799686,0.00008088772,0.00036526693,0.00000301028],"about_ca_topic_score_codex":0.03410778,"about_ca_topic_score_gemma":0.033027794,"teacher_disagreement_score":0.03410778,"about_ca_system_score_codex":0.00039136835,"about_ca_system_score_gemma":0.0002803328,"threshold_uncertainty_score":0.06781846},"labels":[],"label_agreement":null},{"id":"W2106860974","doi":"10.3109/10428194.2011.601475","title":"Lower incidence of plasma cell neoplasm is maintained in migrant Chinese to British Columbia: findings from a 30-year survey","year":2011,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; Leukemia & Lymphoma Society of Canada; University of British Columbia","funders":"","keywords":"Incidence (geometry); Confidence interval; Demography; Ethnic group; Medicine; Standardized rate; Etiology; Population; Plasma cell neoplasm; Ethnic chinese; Epidemiology; Multiple myeloma; Internal medicine; Plasmacytoma","score_opus":0.013042410612530931,"score_gpt":0.23766761615937296,"score_spread":0.22462520554684204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106860974","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99866843,0.0002268639,0.000023718074,0.00006147713,0.0000028256588,0.000005048391,0.00052150385,0.0000036305091,0.00048639605],"genre_scores_gemma":[0.9992091,0.00018010304,0.0000245173,0.000040349132,0.000002708121,0.0000041345925,0.0003346026,0.000001664709,0.00020288365],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996828,0.00005015132,0.000029484772,0.000068898575,0.000086689826,0.000082073704],"domain_scores_gemma":[0.99876785,0.000086132495,0.00033362687,0.00006817046,0.00043641066,0.0003078666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026836255,0.00022527152,0.00029465047,0.0011160674,0.0008996046,0.00060790323,0.00056294136,0.0003264171,0.0011869395],"category_scores_gemma":[0.0011345661,0.00022855899,0.00022229487,0.0021107432,0.00039598776,0.00021224245,0.0003985893,0.0003798125,0.00021100133],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022812446,0.000009969081,0.99835676,0.000009146877,0.00002019849,0.000073930656,0.0002815214,0.000015617801,0.00013729432,0.0000047037142,0.00016771052,0.00090044586],"study_design_scores_gemma":[7.427103e-7,0.0000045742113,0.99959785,0.0000031307854,0.0000041241287,0.000042475403,0.00023872839,0.000021774425,0.0000088770275,0.0000013707148,0.00007526407,0.0000011128126],"about_ca_topic_score_codex":0.8368799,"about_ca_topic_score_gemma":0.86113304,"teacher_disagreement_score":0.16312009,"about_ca_system_score_codex":0.002028473,"about_ca_system_score_gemma":0.001985677,"threshold_uncertainty_score":0.32816142},"labels":[],"label_agreement":null},{"id":"W2107376308","doi":"10.3109/10428194.2014.889825","title":"Effectiveness and safety of thiotepa as conditioning treatment prior to stem cell transplant in patients with central nervous system lymphoma","year":2014,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"CNS Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Ottawa Hospital","funders":"","keywords":"ThioTEPA; Medicine; Oncology; Hematopoietic stem cell transplantation; Internal medicine; Lymphoma; Transplantation; Meta-analysis; Surgery; Chemotherapy; Cyclophosphamide","score_opus":0.007150088999730191,"score_gpt":0.23561258928012294,"score_spread":0.22846250028039275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107376308","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014859193,0.9982097,0.000027719461,0.00006766027,0.000032617092,0.00001948417,0.000035422738,0.0000016957378,0.00011969915],"genre_scores_gemma":[0.03659213,0.96265596,0.00025636813,0.00021656264,0.00006338819,0.000050483613,0.000087931694,0.0000022177883,0.000075024844],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99824524,0.0008434344,0.0004823454,0.00013586532,0.00024004203,0.00005317138],"domain_scores_gemma":[0.99575555,0.0030466642,0.000792234,0.000045535817,0.00027673037,0.00008339834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002507967,0.00063333637,0.0041364245,0.0022667118,0.00023633064,0.0009912461,0.00090842095,0.0011009234,0.0023027686],"category_scores_gemma":[0.008913068,0.0004079362,0.005391234,0.0022769903,0.00029860882,0.0007009392,0.00041915794,0.00093493634,0.00012885738],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042717713,0.00010157823,0.0021819621,0.7085579,0.04088598,0.00015595683,0.0001440641,0.00044246152,0.00061010214,0.00034622903,0.00252281,0.23977923],"study_design_scores_gemma":[0.0054053916,0.0043080645,0.02602574,0.46399355,0.44756487,0.001624884,0.0004403549,0.000638731,0.0013970874,0.0009636337,0.047550097,0.00008767275],"about_ca_topic_score_codex":0.0041501024,"about_ca_topic_score_gemma":0.009424147,"teacher_disagreement_score":0.0041501024,"about_ca_system_score_codex":0.0012720525,"about_ca_system_score_gemma":0.0020521912,"threshold_uncertainty_score":0.013263583},"labels":[],"label_agreement":null},{"id":"W2110932840","doi":"10.3109/10428190109097658","title":"Establishment of a Cytokine-Producing Anaplastic Large-Cell Lymphoma Cell Line Containing the t(2;5) Translocation: Potential Role of Cytokines in Clinical Manifestations","year":2001,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre; Hospital for Sick Children","funders":"","keywords":"Anaplastic large-cell lymphoma; Cytokine; Neutrophilia; Biology; CD30; Immunology; Immunophenotyping; Bone marrow; T cell; Cancer research; Lymphoma; Flow cytometry; Immune system","score_opus":0.009658542660796693,"score_gpt":0.238479385698005,"score_spread":0.22882084303720832,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110932840","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967805,0.00051336014,0.0016028398,0.000045104163,0.000013471211,0.00006342855,0.00045382272,0.000038746744,0.00048867794],"genre_scores_gemma":[0.9947339,0.0003584499,0.0030499802,0.000032552533,0.000021262766,0.00007006567,0.0013951526,0.000011624408,0.00032710444],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99967337,0.00008907921,0.00004675072,0.000054195698,0.000079836376,0.000056871617],"domain_scores_gemma":[0.999647,0.00012739233,0.000050222272,0.00008674503,0.00003009762,0.000058515325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003511002,0.000300879,0.00031478168,0.00032721474,0.00019785813,0.00037137003,0.0002871006,0.00033206597,0.00074842153],"category_scores_gemma":[0.0003694394,0.00015919855,0.00022948615,0.0002933446,0.00022828151,0.00018333075,0.00021672295,0.00056701485,0.0004912056],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013428315,0.00008719467,0.002194837,0.00003596252,0.0000046718947,0.00048759943,0.00006558878,0.00008929436,0.99546033,0.00013103157,0.000052228435,0.0012570194],"study_design_scores_gemma":[0.0002620747,0.0041464143,0.046469294,0.000028494682,0.00006978837,0.014012392,0.00017480097,0.0043014544,0.9230113,0.00012806518,0.0073720845,0.000023936416],"about_ca_topic_score_codex":0.00040834254,"about_ca_topic_score_gemma":0.0005778108,"teacher_disagreement_score":0.00074842153,"about_ca_system_score_codex":0.00017383364,"about_ca_system_score_gemma":0.00014428463,"threshold_uncertainty_score":0.0025037527},"labels":[],"label_agreement":null},{"id":"W2111128439","doi":"10.3109/10428194.2013.816700","title":"Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404)","year":2013,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"National Cancer Institute","keywords":"Medicine; Internal medicine; Vincristine; Gastroenterology; Bevacizumab; Neutropenia; Regimen; CHOP; Prednisone; Surgery; Chemotherapy; Cyclophosphamide","score_opus":0.00647058112068715,"score_gpt":0.23524904892706575,"score_spread":0.2287784678063786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111128439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959629,0.0022417863,0.0001386912,0.00015913373,0.000030013078,0.00028540593,0.00015029541,0.000013911372,0.0010178904],"genre_scores_gemma":[0.9953557,0.0016287442,0.0006495605,0.00020728359,0.00009438804,0.00036839079,0.00059902325,0.0000046534087,0.001092223],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99961215,0.00022612333,0.00002146229,0.00003920129,0.00005791106,0.000043213557],"domain_scores_gemma":[0.99975175,0.00005174933,0.000059265072,0.00001155512,0.000015181229,0.00011058983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009307501,0.0005975813,0.0007537521,0.00027465913,0.00019165943,0.00038307297,0.00036930034,0.00040586598,0.001293392],"category_scores_gemma":[0.0005300352,0.00029251236,0.0005074271,0.0002965678,0.00024258622,0.00030447333,0.00016773045,0.0007308111,0.00020685454],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3549479,0.04282097,0.12400884,0.0011826521,0.0045258407,0.0011473562,0.00033462507,0.0044214763,0.056603882,0.0003993273,0.0069103567,0.4026968],"study_design_scores_gemma":[0.21105927,0.44073102,0.3134558,0.00012830558,0.0019875239,0.00227289,0.00010750206,0.004194971,0.0060091997,0.00028117746,0.01971877,0.000053549575],"about_ca_topic_score_codex":0.0007506154,"about_ca_topic_score_gemma":0.003154807,"teacher_disagreement_score":0.001293392,"about_ca_system_score_codex":0.00062672945,"about_ca_system_score_gemma":0.0006612902,"threshold_uncertainty_score":0.00492239},"labels":[],"label_agreement":null},{"id":"W2112068705","doi":"10.3109/10428194.2015.1068306","title":"Silibinin suppresses NPM-ALK, potently induces apoptosis and enhances chemosensitivity in ALK-positive anaplastic large cell lymphoma","year":2015,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Silymarin and Mushroom Poisoning","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Silibinin; Anaplastic lymphoma kinase; Cancer research; Anaplastic large-cell lymphoma; Survivin; Protein kinase B; Chemistry; Cell growth; Apoptosis; Biology; Lymphoma; Medicine; Immunology; Biochemistry; Pathology","score_opus":0.012672692621934774,"score_gpt":0.24135518206545545,"score_spread":0.22868248944352068,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112068705","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99470115,0.0024052327,0.0009908305,0.00006784766,0.000019359995,0.000022879101,0.00009438094,0.00005819806,0.0016401106],"genre_scores_gemma":[0.9972525,0.0008809572,0.00061327976,0.000029080404,0.000010547231,0.000015598653,0.00014621284,0.000005651435,0.0010460942],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999683,0.000007666257,0.0000037525401,0.0000043161244,0.000008176658,0.000007759524],"domain_scores_gemma":[0.9999747,0.000004032619,0.000008012703,0.0000028459822,0.0000029459327,0.0000074118393],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000705537,0.00022712564,0.00016521126,0.00018626271,0.00010539006,0.00013838874,0.0000904498,0.00012813543,0.00075137295],"category_scores_gemma":[0.00007682455,0.00006278296,0.00014017089,0.00010563808,0.0001308877,0.00015947933,0.00009654036,0.00028162618,0.0001657095],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030335615,0.000087398235,0.00022622426,0.00003146781,0.000004858999,0.00006449636,0.000011800653,0.000058921283,0.9958461,0.000039284634,0.000043860135,0.0032822967],"study_design_scores_gemma":[0.00004447749,0.0010223868,0.0042772787,0.00000333731,0.000015797017,0.0003221186,0.000022363278,0.0007746979,0.9920283,0.000029692577,0.0014572396,0.0000023468015],"about_ca_topic_score_codex":0.00032980827,"about_ca_topic_score_gemma":0.0010635357,"teacher_disagreement_score":0.00075137295,"about_ca_system_score_codex":0.00014179779,"about_ca_system_score_gemma":0.00011912361,"threshold_uncertainty_score":0.0025135875},"labels":[],"label_agreement":null},{"id":"W2112529529","doi":"10.3109/10428194.2013.790968","title":"Comparison of outcomes among patients aged 80 and over and younger patients with diffuse large B-cell lymphoma: a population based study","year":2013,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"","keywords":"Medicine; Internal medicine; Diffuse large B-cell lymphoma; Confidence interval; International Prognostic Index; Retrospective cohort study; Lymphoma; Comorbidity; Cohort; Performance status; Population; Overall survival","score_opus":0.007458380733081112,"score_gpt":0.24030235645578002,"score_spread":0.2328439757226989,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112529529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99967873,0.000074349264,0.00002551122,0.0000096583235,0.0000026005143,0.000004333296,0.00009178545,8.546431e-7,0.00011226436],"genre_scores_gemma":[0.99951684,0.0000654414,0.000030154435,0.000028575521,0.000010082733,0.00000777412,0.00028426616,0.0000012878111,0.000055487253],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995059,0.000112099144,0.000053043874,0.00014524149,0.000080522055,0.00010324871],"domain_scores_gemma":[0.999032,0.00018345486,0.00033333598,0.000078067416,0.00008559787,0.00028749363],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006532388,0.0003233181,0.00064344273,0.0009715895,0.00053963676,0.0006949195,0.00023306161,0.00048224692,0.0009496784],"category_scores_gemma":[0.001749354,0.0003301351,0.00052532315,0.00094178197,0.00032446402,0.00077476836,0.0005123753,0.000546763,0.00023598345],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013694049,0.00003527877,0.9989864,0.0000037555112,0.000057431545,0.00009576001,0.00007643914,0.000017203127,0.00012873278,0.000007323464,0.000029764877,0.00042492256],"study_design_scores_gemma":[0.000018825485,0.0003138248,0.9985739,0.0000033766012,0.000048139627,0.00046944784,0.00030761198,0.000076379736,0.00002906098,0.00001823143,0.00013619952,0.000004990274],"about_ca_topic_score_codex":0.0035684502,"about_ca_topic_score_gemma":0.0040459726,"teacher_disagreement_score":0.0035684502,"about_ca_system_score_codex":0.000346213,"about_ca_system_score_gemma":0.00026614196,"threshold_uncertainty_score":0.007095337},"labels":[],"label_agreement":null},{"id":"W2112626326","doi":"10.3109/10428194.2013.858154","title":"The problem with cyclophosphamide, doxorubicin, vincristine and prednisone for the treatment of peripheral T-cell lymphoma","year":2013,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Prednisone; Vincristine; Cyclophosphamide; Medicine; Doxorubicin; Peripheral; Lymphoma; Peripheral T-cell lymphoma; Chemotherapy; Oncology; Internal medicine; Immunology; T cell; Immune system","score_opus":0.008534077756637998,"score_gpt":0.21878022310359987,"score_spread":0.21024614534696187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112626326","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09032921,0.039628085,0.003116607,0.77827007,0.014664255,0.00017823391,0.00019938932,0.00017039619,0.073443696],"genre_scores_gemma":[0.46346095,0.029762093,0.00424437,0.37431562,0.093639456,0.00017894739,0.00018484784,0.000068708614,0.034144975],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992867,0.0002581342,0.00009781378,0.00011003092,0.00016594915,0.000081443184],"domain_scores_gemma":[0.9990368,0.000480967,0.00011730377,0.00006019847,0.0001402144,0.00016454748],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006391817,0.0003984882,0.00046972343,0.00048405066,0.0010441312,0.00083759543,0.00040962876,0.0036086193,0.0036618817],"category_scores_gemma":[0.0028863954,0.00023830052,0.00059377693,0.00058806484,0.00091869815,0.00089206593,0.0003402209,0.004177544,0.0031032292],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054400624,0.00049605576,0.048238724,0.0010523598,0.00017913546,0.23099124,0.00055116287,0.0013686108,0.0059533054,0.0060182903,0.44587332,0.25873378],"study_design_scores_gemma":[0.00029691265,0.0005384131,0.026736744,0.0006429526,0.00008419523,0.54999435,0.00045059068,0.001928249,0.0013984898,0.010564456,0.40731683,0.00004787729],"about_ca_topic_score_codex":0.0009848891,"about_ca_topic_score_gemma":0.0036835945,"teacher_disagreement_score":0.0036618817,"about_ca_system_score_codex":0.0013963591,"about_ca_system_score_gemma":0.0006614279,"threshold_uncertainty_score":0.012250185},"labels":[],"label_agreement":null},{"id":"W2113262521","doi":"10.3109/10428194.2011.576791","title":"Bone marrow stromal cells protect myeloma cells from bortezomib induced apoptosis by suppressing microRNA-15a expression","year":2011,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":113,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"Tianjin Science and Technology Program; Natural Science Foundation of Tianjin City; National Natural Science Foundation of China; Peking Union Medical College; Academy of Medical Sciences","keywords":"Bortezomib; Stromal cell; Multiple myeloma; Bone marrow; microRNA; Cancer research; Transfection; Apoptosis; Vascular endothelial growth factor; Medicine; Immunology; Chemistry; Biology; Cell culture; VEGF receptors","score_opus":0.020943145627392513,"score_gpt":0.2422504560969769,"score_spread":0.22130731046958438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113262521","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99156344,0.004261719,0.0020276047,0.00020338224,0.00006597385,0.000038591683,0.00040370427,0.000105930725,0.0013296673],"genre_scores_gemma":[0.993152,0.0017537831,0.0022803496,0.00011699554,0.000017671875,0.000045858953,0.00067266024,0.00001450046,0.001946292],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999881,0.000022596929,0.000015766791,0.000019666377,0.000034766905,0.00002618194],"domain_scores_gemma":[0.99994385,0.0000100300895,0.000018285698,0.000005566594,0.000008769332,0.000013496111],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016498425,0.00021974124,0.00031093287,0.0001907646,0.00017253388,0.00032502436,0.00009387651,0.00016234074,0.0014352349],"category_scores_gemma":[0.000093477116,0.00015140213,0.00026534463,0.00014585812,0.00014807591,0.000101255566,0.0001995306,0.00043156196,0.00030385627],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016082826,0.000027916007,0.00029621125,0.000038618662,0.0000117374575,0.000028183616,0.000016663704,0.000031919266,0.99715143,0.00006496667,0.00006885427,0.0021027464],"study_design_scores_gemma":[0.00005628413,0.0005515742,0.006310684,0.000008726161,0.000033055876,0.00019890313,0.00005024792,0.0005282584,0.9868024,0.00005862343,0.0053968932,0.000004355657],"about_ca_topic_score_codex":0.00051252457,"about_ca_topic_score_gemma":0.0012338973,"teacher_disagreement_score":0.0014352349,"about_ca_system_score_codex":0.0001552991,"about_ca_system_score_gemma":0.00027777025,"threshold_uncertainty_score":0.0048012733},"labels":[],"label_agreement":null},{"id":"W2113301890","doi":"10.3109/10428191003802340","title":"Human leukocyte antigen class I alleles and the risk of chronic myelogenous leukemia: a meta-analysis","year":2010,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Odds ratio; Chronic myelogenous leukemia; Human leukocyte antigen; Meta-analysis; Allele; Immunology; Medicine; Context (archaeology); Population; Leukemia; Oncology; Biology; Genetics; Internal medicine; Antigen; Environmental health; Gene","score_opus":0.03427095306676008,"score_gpt":0.2982893996736653,"score_spread":0.2640184466069052,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113301890","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0042349417,0.99469453,0.00034979428,0.0001500502,0.00007483141,0.00006276643,0.00021304032,0.000013786164,0.00020623738],"genre_scores_gemma":[0.09054329,0.90669656,0.0014324543,0.00029329822,0.00012916801,0.00019551479,0.00038079207,0.000009552227,0.0003193771],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99781406,0.0013155383,0.0003301529,0.00022432898,0.00023675634,0.00007917294],"domain_scores_gemma":[0.9950819,0.0038774973,0.00048841664,0.00011793223,0.0003463921,0.00008788569],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004480051,0.0017616441,0.007871987,0.002746364,0.00029697662,0.0012541089,0.0013381215,0.0012950259,0.0031412079],"category_scores_gemma":[0.008302427,0.0008097447,0.014764931,0.005079314,0.00020750189,0.0005816815,0.00059829373,0.0009935267,0.000261512],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004550933,0.000084097774,0.011305159,0.24522735,0.67191225,0.00045168353,0.00008223086,0.0023372073,0.00067346176,0.00032184937,0.003145329,0.059908483],"study_design_scores_gemma":[0.0008635494,0.0003723675,0.010372762,0.014942177,0.967131,0.0003147836,0.00004448608,0.0007013453,0.00027584383,0.00038437423,0.0045700497,0.000027260945],"about_ca_topic_score_codex":0.0050613596,"about_ca_topic_score_gemma":0.010118141,"teacher_disagreement_score":0.007871987,"about_ca_system_score_codex":0.0013011489,"about_ca_system_score_gemma":0.0013664822,"threshold_uncertainty_score":0.023693025},"labels":[],"label_agreement":null},{"id":"W2114541062","doi":"10.3109/10428194.2013.770151","title":"Patterns of use of 18-fluoro-2-deoxy-D-glucose positron emission tomography for initial staging of grade 1–2 follicular lymphoma and its impact on initial treatment strategy in the National Comprehensive Cancer Network Non-Hodgkin Lymphoma Outcomes database","year":2013,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre de Santé et de Services Sociaux de Chicoutimi","funders":"National Comprehensive Cancer Network","keywords":"Medicine; Positron emission tomography; Follicular lymphoma; Stage (stratigraphy); Lymphoma; Nuclear medicine; Radiation therapy; Radiology; Internal medicine","score_opus":0.043497121389043866,"score_gpt":0.33806455552479425,"score_spread":0.2945674341357504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2114541062","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953927,0.0006952357,0.0001289798,0.00015633786,0.0000045673046,0.000016977623,0.0029769733,0.000006009835,0.00062232383],"genre_scores_gemma":[0.9971306,0.00026939262,0.0001506011,0.000043397777,0.00000526526,0.00001620891,0.0023080918,0.0000037221805,0.00007283615],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981902,0.00061320834,0.00032514974,0.00031940677,0.00035164144,0.00020049555],"domain_scores_gemma":[0.9926018,0.0017823143,0.0042838617,0.00030574837,0.0006600972,0.0003661196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013072249,0.00012225326,0.00035703514,0.0013043886,0.00016299715,0.00059168495,0.00044439035,0.0002957687,0.00061629486],"category_scores_gemma":[0.0059146425,0.00018676546,0.0002988059,0.0022306438,0.00017689317,0.00047977534,0.00050709926,0.0003343197,0.00010891935],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005989663,0.000006777504,0.99826837,0.000008954833,0.000021183247,0.000027324988,0.000031582033,0.000038303362,0.000054587028,0.0000091699885,0.00013667524,0.0013370999],"study_design_scores_gemma":[0.000005830552,0.000020234898,0.99894375,0.0000123765885,0.00001340208,0.00022180207,0.0001270004,0.00027355386,0.000059356717,0.000011987579,0.00030731122,0.000003367623],"about_ca_topic_score_codex":0.013679045,"about_ca_topic_score_gemma":0.029971642,"teacher_disagreement_score":0.013679045,"about_ca_system_score_codex":0.00081045256,"about_ca_system_score_gemma":0.00045666663,"threshold_uncertainty_score":0.027198851},"labels":[],"label_agreement":null},{"id":"W2115374164","doi":"10.1080/10428190701706410","title":"David A. G. Galton: a personal perspective","year":2007,"lang":"sv","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Academic and Historical Perspectives in Psychology","field":"Psychology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Galton's problem; Perspective (graphical); Genealogy; Medicine; Environmental ethics; Biology; Computer science; History; Philosophy; Mathematics; Statistics; Artificial intelligence","score_opus":0.015434343030066466,"score_gpt":0.30857361458260396,"score_spread":0.2931392715525375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115374164","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00056144636,0.08881626,0.00063717726,0.8721163,0.022788567,0.0000037764355,0.000042226588,0.00003052128,0.015003642],"genre_scores_gemma":[0.043618914,0.21137623,0.0017750862,0.567441,0.05765364,0.000026457421,0.00005593851,0.00011704965,0.11793578],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.999041,0.00035151618,0.00004380749,0.00016895407,0.00030694104,0.000087803564],"domain_scores_gemma":[0.996564,0.0013309824,0.00015920366,0.000085563384,0.0008308941,0.001029428],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002078182,0.00054977596,0.0006246298,0.0013932481,0.0028529237,0.0039024092,0.00094193325,0.0044717095,0.015944669],"category_scores_gemma":[0.005245891,0.00021394099,0.00023497759,0.0012984112,0.0039259456,0.0051713362,0.0017838929,0.008387716,0.0050906665],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013137371,0.000018668978,0.00030369847,0.000081360195,0.000005102763,0.00015733206,0.0006208094,0.000039655308,0.00007013493,0.02549619,0.95066404,0.022529865],"study_design_scores_gemma":[0.000005596504,0.000011288807,0.00034554495,0.00025126524,0.0000028638606,0.00078878173,0.0014805464,0.00004699863,0.00009185875,0.018678082,0.97828203,0.000015228087],"about_ca_topic_score_codex":0.0028907573,"about_ca_topic_score_gemma":0.0053944215,"teacher_disagreement_score":0.015944669,"about_ca_system_score_codex":0.0016986696,"about_ca_system_score_gemma":0.0016416266,"threshold_uncertainty_score":0.053340197},"labels":[],"label_agreement":null},{"id":"W2118057314","doi":"10.3109/10428194.2012.682314","title":"Sudden blast crisis in chronic myeloid leukemia treated with tyrosine kinase inhibitors","year":2012,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Blast Crisis; Imatinib; Imatinib mesylate; Myeloid leukemia; Internal medicine; Immunology; Oncology","score_opus":0.010599954824801078,"score_gpt":0.2298835276421774,"score_spread":0.21928357281737632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118057314","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93181586,0.044535827,0.001182883,0.0057224934,0.0004596523,0.00039332896,0.00061773695,0.00007389506,0.015198314],"genre_scores_gemma":[0.98807436,0.006758301,0.00051951164,0.002314451,0.00056864513,0.00007183671,0.00068104145,0.0000067124092,0.0010050785],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.99982065,0.000051199833,0.000021420143,0.00001798473,0.000047654543,0.000041058614],"domain_scores_gemma":[0.999699,0.000067406094,0.00010024837,0.000007929485,0.000029953833,0.00009552757],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023469592,0.0001458929,0.0005159889,0.00027625586,0.00031076898,0.00022793635,0.00015536381,0.0003714766,0.0013046794],"category_scores_gemma":[0.0012322864,0.00006727432,0.00020233441,0.00046074597,0.00019994481,0.00026402102,0.00025559304,0.0006585245,0.00019969427],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009829452,0.0008010733,0.5384707,0.0015816693,0.00025445753,0.07532441,0.00089772925,0.00091505126,0.012627518,0.0029265727,0.027030367,0.32934088],"study_design_scores_gemma":[0.0015985117,0.0042934357,0.78140944,0.0012002967,0.00037972472,0.13817358,0.00066694565,0.0028841426,0.002000508,0.0058475537,0.061467662,0.000078137644],"about_ca_topic_score_codex":0.0007997204,"about_ca_topic_score_gemma":0.0013848144,"teacher_disagreement_score":0.0013046794,"about_ca_system_score_codex":0.00033704823,"about_ca_system_score_gemma":0.00043149287,"threshold_uncertainty_score":0.0043646097},"labels":[],"label_agreement":null},{"id":"W2118461306","doi":"10.1080/10428190500032273","title":"Prolonged treatment response in aggressive natural killer cell leukemia","year":2005,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Cytopenia; Medicine; Hepatosplenomegaly; Bone marrow; Spleen; Splenectomy; Pentostatin; Immunology; Immunosuppression; Leukemia; Pathology; Disease; Lymphoma","score_opus":0.006797536973110428,"score_gpt":0.2207631312537711,"score_spread":0.21396559428066067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118461306","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9830489,0.0077310796,0.0013019312,0.0007059796,0.000079292084,0.0000615762,0.00008923895,0.00008197387,0.0068999436],"genre_scores_gemma":[0.99836737,0.00038209528,0.0001236593,0.00034253622,0.0000892647,0.000022630538,0.000078278266,0.000008468035,0.00058567186],"study_design_codex":"design_other","study_design_gemma":"case_report","domain_scores_codex":[0.99977475,0.00008103087,0.000020112228,0.00003205226,0.000036480134,0.000055579752],"domain_scores_gemma":[0.9989477,0.00049223617,0.00026698085,0.000059351518,0.000050439336,0.00018330594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003524981,0.00020968688,0.00037751626,0.00019788605,0.00039268215,0.00024387865,0.00015194318,0.0006308766,0.0019339656],"category_scores_gemma":[0.0019836861,0.000068940935,0.00018913692,0.0001840185,0.00021033385,0.00023690592,0.00019056661,0.0007913494,0.00042590045],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010254265,0.0017789146,0.22898254,0.0011651362,0.00027469915,0.21259229,0.002786064,0.0027775057,0.15022328,0.0028228518,0.005288407,0.38105398],"study_design_scores_gemma":[0.00075811247,0.017511614,0.367674,0.0001389631,0.00031757713,0.52131057,0.00040530897,0.0021650281,0.022724468,0.0019481715,0.06497662,0.00006960753],"about_ca_topic_score_codex":0.0002080814,"about_ca_topic_score_gemma":0.00028520098,"teacher_disagreement_score":0.0019339656,"about_ca_system_score_codex":0.00037077698,"about_ca_system_score_gemma":0.000114690214,"threshold_uncertainty_score":0.0064697266},"labels":[],"label_agreement":null},{"id":"W2118515712","doi":"10.3109/10428194.2015.1018248","title":"A phase I trial of two sequence-specific schedules of decitabine and vorinostat in patients with acute myeloid leukemia","year":2015,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Decitabine; Vorinostat; Medicine; Myeloid leukemia; Schedule; Myeloid; Internal medicine; Phases of clinical research; Oncology; Clinical trial; Biology","score_opus":0.027536819723377324,"score_gpt":0.29850660911470805,"score_spread":0.2709697893913307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118515712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991608,0.0015582079,0.00085556804,0.00026505793,0.00015455268,0.0033066508,0.00045189375,0.000083012485,0.0017170833],"genre_scores_gemma":[0.9837091,0.0019360019,0.004432941,0.00054292707,0.0001869577,0.00522485,0.0014727636,0.000022194017,0.0024722891],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99971,0.00011438798,0.00001876546,0.000062089144,0.000035376986,0.00005940554],"domain_scores_gemma":[0.99954164,0.00006853918,0.000093073904,0.000043585187,0.000019801993,0.0002334408],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010865311,0.0014774336,0.0015573981,0.00053712813,0.00030118233,0.00046620079,0.0007868921,0.0008939945,0.0028426852],"category_scores_gemma":[0.0008246727,0.0004904703,0.00077762123,0.00046550538,0.0007189918,0.00062506035,0.00038328924,0.0021596618,0.00041562095],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.66705567,0.08600191,0.0035203893,0.001025258,0.0008148952,0.0002462072,0.00027974957,0.00549274,0.059606906,0.0009342941,0.002978852,0.17204309],"study_design_scores_gemma":[0.55963427,0.429269,0.0033963022,0.000026344818,0.00020825477,0.00017707759,0.000030735162,0.0014636724,0.003607871,0.00025099103,0.0019123987,0.000023059165],"about_ca_topic_score_codex":0.0006839741,"about_ca_topic_score_gemma":0.0017866157,"teacher_disagreement_score":0.0028426852,"about_ca_system_score_codex":0.0007367521,"about_ca_system_score_gemma":0.0013929331,"threshold_uncertainty_score":0.009509742},"labels":[],"label_agreement":null},{"id":"W2119879346","doi":"10.3109/10428194.2013.796046","title":"Granulocyte colony-stimulating factor as secondary prophylaxis of febrile neutropenia in the management of advanced-stage Hodgkin lymphoma treated with adriamycin, bleomycin, vinblastine and dacarbazine chemotherapy: a decision analysis","year":2013,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; ABVD; Dacarbazine; Febrile neutropenia; Vinblastine; Neutropenia; Internal medicine; Lymphoma; Granulocyte colony-stimulating factor; Bleomycin; Oncology; Chemotherapy; Vincristine; Cyclophosphamide","score_opus":0.006334859424107247,"score_gpt":0.24027529736222186,"score_spread":0.23394043793811461,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119879346","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95113844,0.010777258,0.026374023,0.003643112,0.00021207477,0.0016572183,0.0011332292,0.00006906868,0.004995747],"genre_scores_gemma":[0.9929472,0.0011843871,0.0042648977,0.00045540943,0.000043290285,0.00022993589,0.00022953472,0.000009397712,0.0006358613],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.98793286,0.010541698,0.00028630596,0.0003632168,0.0003928005,0.00048315356],"domain_scores_gemma":[0.9581841,0.038149603,0.0018606856,0.00035326937,0.00047677063,0.00097545166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015082109,0.0012918882,0.002600071,0.0012733454,0.0002640719,0.0015745515,0.0011853521,0.0015035657,0.0038003414],"category_scores_gemma":[0.030717643,0.0007246234,0.007358347,0.0006678212,0.00061481347,0.0012090286,0.0010641448,0.0023082967,0.0001430899],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031332955,0.0010390539,0.014415368,0.0013205452,0.008980246,0.00027793663,0.00007439896,0.89968866,0.00057081453,0.0057946774,0.0009814339,0.035523977],"study_design_scores_gemma":[0.009275111,0.012256179,0.0073013464,0.0005310014,0.013289166,0.0002413752,0.00013372378,0.94095784,0.001038475,0.012775776,0.0021179083,0.000082073035],"about_ca_topic_score_codex":0.0049712,"about_ca_topic_score_gemma":0.0042791595,"teacher_disagreement_score":0.015082109,"about_ca_system_score_codex":0.0032602095,"about_ca_system_score_gemma":0.0036058242,"threshold_uncertainty_score":0.07976276},"labels":[],"label_agreement":null},{"id":"W2119915366","doi":"10.3109/10428190009148856","title":"The Use of Archival Bone Marrow Specimens in Detecting B-Cell Non-Hodgkin's Lymphomas Using Polymerase Chain Reaction Methods","year":2000,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital; Alberta Hospital Edmonton","funders":"","keywords":"Lymphoma; Bone marrow; Pathology; Polymerase chain reaction; Biopsy; Non-Hodgkin's lymphoma; Monoclonal; Medicine; Biology; Molecular biology; Monoclonal antibody; Antibody; Gene; Immunology","score_opus":0.026970797353493493,"score_gpt":0.2842633691387643,"score_spread":0.2572925717852708,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119915366","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9162513,0.008379875,0.0703089,0.000107955304,0.000090247624,0.00050739537,0.00050256285,0.00030150235,0.0035502545],"genre_scores_gemma":[0.8504448,0.0064838664,0.13943562,0.00027383107,0.000087594075,0.00051801273,0.0010996686,0.00004783897,0.0016088637],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977902,0.00054386514,0.00029366446,0.00071328424,0.0005075979,0.00015141368],"domain_scores_gemma":[0.99765575,0.0011603913,0.00032661867,0.0003806876,0.00036961428,0.00010698893],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023378013,0.00085068896,0.00042035515,0.001643983,0.00027214346,0.0010328409,0.0006792536,0.0007642366,0.0009391288],"category_scores_gemma":[0.00460371,0.0004457556,0.00026982007,0.00060815766,0.0011724097,0.00049071026,0.00052050216,0.00067359133,0.0009759138],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005982046,0.00017115672,0.13925533,0.0004155605,0.000065766144,0.0012068719,0.00063906354,0.000243421,0.7887651,0.00023176943,0.0001229494,0.06828484],"study_design_scores_gemma":[0.00012687936,0.005053945,0.21384169,0.00027447482,0.000687866,0.022163115,0.0019232195,0.006152296,0.73529357,0.0011182083,0.013284569,0.000080135986],"about_ca_topic_score_codex":0.00058103295,"about_ca_topic_score_gemma":0.0010191493,"teacher_disagreement_score":0.0023378013,"about_ca_system_score_codex":0.0001795985,"about_ca_system_score_gemma":0.00034322523,"threshold_uncertainty_score":0.012363613},"labels":[],"label_agreement":null},{"id":"W2120309731","doi":"10.3109/10428194.2014.970548","title":"Development and characterization of a Mantle Cell Lymphoma Cell Bank in the American Type Culture Collection","year":2014,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Mantle cell lymphoma; Lymphoma; Cell culture; Medicine; Malignancy; Disease; Cancer research; Biology; Pathology; Genetics","score_opus":0.007498928054494789,"score_gpt":0.2181362960515551,"score_spread":0.21063736799706032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120309731","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.19801916,0.0147031,0.5100725,0.0068553,0.004359984,0.046800453,0.11209378,0.0050188927,0.10207684],"genre_scores_gemma":[0.16865928,0.013601439,0.48578903,0.0024313098,0.0007388559,0.027927272,0.25413555,0.0009349612,0.045782316],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99506265,0.00090761244,0.00076815253,0.00046710615,0.0024310728,0.000363286],"domain_scores_gemma":[0.99468505,0.0004995462,0.0001733238,0.0014124311,0.002660378,0.00056922686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005024355,0.0009265393,0.0012380743,0.0040568765,0.0027250722,0.0019320798,0.0044818847,0.0011844558,0.013620811],"category_scores_gemma":[0.0027129876,0.00077436725,0.0011017319,0.0035646101,0.00072915544,0.0010004,0.001620985,0.003138162,0.012306383],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015551421,0.0034157755,0.013932244,0.00090208295,0.00022333763,0.0022770585,0.0011564266,0.0026098604,0.7944977,0.015399136,0.08051822,0.08351295],"study_design_scores_gemma":[0.00085382233,0.0022122927,0.038869634,0.0006048323,0.000584604,0.0039300164,0.0005794792,0.012768213,0.37729463,0.0016948963,0.5603535,0.0002540116],"about_ca_topic_score_codex":0.010313127,"about_ca_topic_score_gemma":0.023479318,"teacher_disagreement_score":0.013620811,"about_ca_system_score_codex":0.0012254646,"about_ca_system_score_gemma":0.003919622,"threshold_uncertainty_score":0.0455662},"labels":[],"label_agreement":null},{"id":"W2120629149","doi":"10.3109/10428194.2012.737917","title":"A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186","year":2012,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Cancer Centre; Princess Margaret Cancer Centre; University Health Network; McGill University; Jewish General Hospital; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Cytarabine; Internal medicine; Sorafenib; Myeloid leukemia; Myelodysplastic syndromes; Oncology; Rash; Cancer; Leukemia; Bone marrow","score_opus":0.03020316122113193,"score_gpt":0.3264832382603513,"score_spread":0.2962800770392194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120629149","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917944,0.0022026547,0.00033895802,0.000524478,0.0001135561,0.002654308,0.0010189909,0.000048888192,0.0013037199],"genre_scores_gemma":[0.98609656,0.002577306,0.0015628245,0.0009091656,0.00018507354,0.003239375,0.002116312,0.000019486917,0.0032939527],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99974114,0.00012126944,0.00001385566,0.00003794209,0.000024188379,0.00006159178],"domain_scores_gemma":[0.9995951,0.00004568961,0.000059846767,0.000021881717,0.00002633528,0.00025114074],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011532716,0.0012927344,0.0014605124,0.00039713754,0.00038193638,0.00062408415,0.0005650667,0.0008230064,0.0035827085],"category_scores_gemma":[0.0006360336,0.00046561344,0.00093600445,0.0003804131,0.0006780722,0.00042387162,0.00024913915,0.0018219305,0.00067672844],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85426897,0.045374874,0.0055946317,0.00080937677,0.0010187749,0.00034931948,0.00021746015,0.0014963215,0.026959863,0.0002896003,0.0056599877,0.05796079],"study_design_scores_gemma":[0.83533144,0.15280329,0.0075386264,0.00001978989,0.00020098421,0.00013293003,0.000033378612,0.0005976409,0.0010597344,0.000089102636,0.0021752052,0.00001791351],"about_ca_topic_score_codex":0.0019886086,"about_ca_topic_score_gemma":0.0055826833,"teacher_disagreement_score":0.9980114,"about_ca_system_score_codex":0.00076749054,"about_ca_system_score_gemma":0.0017754413,"threshold_uncertainty_score":0.011985362},"labels":[],"label_agreement":null},{"id":"W2121142323","doi":"10.3109/10428194.2015.1010079","title":"Barriers to enrollment of patients with recurrent diffuse large B-cell lymphoma onto clinical trials","year":2015,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"","keywords":"Diffuse large B-cell lymphoma; Lymphoma; Medicine; Internal medicine; Oncology; Refractory (planetary science); Clinical trial; Biology","score_opus":0.03231703514413337,"score_gpt":0.31077920280161025,"score_spread":0.2784621676574769,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121142323","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007964523,0.005885156,0.0016859242,0.9620764,0.005969328,0.001262263,0.00047394042,0.00010005383,0.014582509],"genre_scores_gemma":[0.07431215,0.0063361432,0.0057646004,0.8603869,0.04509178,0.0036580353,0.0006695917,0.000100531,0.003680332],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9443149,0.0376263,0.007633413,0.0023093114,0.0060634273,0.002052584],"domain_scores_gemma":[0.86906177,0.088548854,0.0076342616,0.004743445,0.0078102355,0.022201432],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.04060446,0.00043737446,0.001739404,0.0006203103,0.0022403148,0.0065370104,0.0030584403,0.014548351,0.017118493],"category_scores_gemma":[0.117661856,0.0007994708,0.0017382982,0.0012495016,0.002372404,0.0049680946,0.0045167427,0.0138913235,0.0074716397],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004770424,0.0012138137,0.01247063,0.0013007505,0.00024279677,0.0019691312,0.0009752518,0.00074824685,0.0025108948,0.013951102,0.661044,0.29880288],"study_design_scores_gemma":[0.010975547,0.004736171,0.026231425,0.004226728,0.0003023359,0.004381813,0.0011879505,0.0029793272,0.0012459771,0.055406407,0.8881678,0.00015853698],"about_ca_topic_score_codex":0.0014700784,"about_ca_topic_score_gemma":0.00400415,"teacher_disagreement_score":0.9593955,"about_ca_system_score_codex":0.0026372445,"about_ca_system_score_gemma":0.008345949,"threshold_uncertainty_score":0.21473944},"labels":[],"label_agreement":null},{"id":"W2121252697","doi":"10.1080/10428190410001673409","title":"Intracranial Presentation of Systemic Hodgkin's Disease","year":2004,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"CNS Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cape Breton University; Dalhousie University; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Presentation (obstetrics); Medicine; Disease; Pathology; Radiology","score_opus":0.01975733090592726,"score_gpt":0.2954856302587458,"score_spread":0.27572829935281856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121252697","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001939953,0.99389327,0.00012436952,0.00019631322,0.0001312417,0.000008570162,0.000034979614,0.00001692428,0.003654385],"genre_scores_gemma":[0.021064652,0.97682494,0.00025945817,0.00039722474,0.00021765029,0.000012673757,0.00007567171,0.0000030111971,0.0011447301],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997929,0.000041309155,0.00004535824,0.0000334466,0.000063239924,0.00002365153],"domain_scores_gemma":[0.99954045,0.00023951761,0.00009981505,0.000017272407,0.00007398274,0.0000289809],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022923991,0.000458205,0.001440161,0.0022784176,0.000292972,0.00074111315,0.00037856644,0.0006956411,0.003171754],"category_scores_gemma":[0.0010848845,0.00016301875,0.00037427418,0.0026240428,0.00035709795,0.00069694396,0.00028426634,0.0004287554,0.001523964],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000081000304,0.000047754053,0.006789308,0.032347098,0.00018556739,0.025057213,0.00024900786,0.000105530526,0.002408549,0.0005570856,0.025071736,0.9071],"study_design_scores_gemma":[0.0000668108,0.00031849463,0.039420627,0.024129359,0.0011074931,0.388173,0.0009784723,0.00012450774,0.00172035,0.001343092,0.54256904,0.0000486364],"about_ca_topic_score_codex":0.0014023802,"about_ca_topic_score_gemma":0.0038184368,"teacher_disagreement_score":0.003171754,"about_ca_system_score_codex":0.0003035473,"about_ca_system_score_gemma":0.0010184777,"threshold_uncertainty_score":0.010610521},"labels":[],"label_agreement":null},{"id":"W2122782874","doi":"10.3109/10428190109097657","title":"Seroprevalence of Helicobacter Pylori Infection in Patients with Lymphoma","year":2001,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Helicobacter pylori-related gastroenterology studies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Seroprevalence; Helicobacter pylori infection; Medicine; Helicobacter pylori; Lymphoma; Internal medicine; Helicobacter Infections; Immunology; Gastroenterology; Serology; Antibody","score_opus":0.008118880540723683,"score_gpt":0.221649423264312,"score_spread":0.21353054272358832,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122782874","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9993075,0.00020015454,0.000020187397,0.000030158759,0.000003049016,0.0000026022176,0.00005408893,0.000002531834,0.00037963828],"genre_scores_gemma":[0.9997135,0.00007730683,0.000030566713,0.000030538828,0.000007634321,0.0000028686234,0.00006387306,5.370337e-7,0.00007312476],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997874,0.00007675642,0.000031151383,0.000025953326,0.000042505824,0.00003631499],"domain_scores_gemma":[0.9992823,0.00016585903,0.00028747352,0.00002552283,0.00009435386,0.00014454167],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025502758,0.00012479168,0.00021377255,0.0006999093,0.00025214898,0.00033497502,0.00011920998,0.00029111016,0.0014554787],"category_scores_gemma":[0.0011208758,0.00016840208,0.00014020337,0.00054305827,0.00018085368,0.00027946525,0.00018246035,0.0002768515,0.00020871048],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023751603,0.000014336041,0.99904877,0.0000044404337,0.000008619539,0.000063267704,0.00004330906,0.000007676758,0.00017698032,0.0000033009958,0.000040676674,0.00056469504],"study_design_scores_gemma":[0.0000025668623,0.00006584702,0.9990081,0.000003770518,0.000007909192,0.0006085468,0.00010601818,0.000055330478,0.000046479676,0.0000059408767,0.00008841473,0.0000011583269],"about_ca_topic_score_codex":0.0018949492,"about_ca_topic_score_gemma":0.0023022154,"teacher_disagreement_score":0.0018949492,"about_ca_system_score_codex":0.00013658172,"about_ca_system_score_gemma":0.00011393493,"threshold_uncertainty_score":0.0048691034},"labels":[],"label_agreement":null},{"id":"W2123670570","doi":"10.3109/10428191003729741","title":"Mutations in ABL kinase domain are associated with inferior progression-free survival","year":2010,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Terry Fox Foundation","keywords":"Imatinib mesylate; ABL; Point mutation; Fusion gene; Cancer research; Imatinib; Protein kinase domain; Mutation; Myeloid leukemia; Biology; Medicine; Tyrosine kinase; Gene; Genetics; Mutant; Receptor","score_opus":0.009334364910513348,"score_gpt":0.2532084003162289,"score_spread":0.24387403540571553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123670570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99905246,0.00056053704,0.00007256368,0.000031498694,0.0000036682047,0.0000021738326,0.000041698,0.0000042827005,0.0002311124],"genre_scores_gemma":[0.9996954,0.00008775841,0.000034811143,0.000020768333,0.000007036186,0.0000021132767,0.00006767825,0.0000013575434,0.00008307436],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997656,0.00004697282,0.00002429307,0.000048323825,0.00004711913,0.00006768842],"domain_scores_gemma":[0.99891424,0.0003024427,0.0004461002,0.00005194242,0.000056560362,0.00022871107],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037463862,0.0001530458,0.00039862006,0.0002770099,0.00015716313,0.0002708283,0.00013382085,0.00042770198,0.0017057023],"category_scores_gemma":[0.0014285519,0.000094581774,0.00022118114,0.0002453992,0.000204842,0.00018884768,0.00019119361,0.00034054636,0.00021641608],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050251107,0.00022239624,0.92534554,0.00008495658,0.000271874,0.0021518052,0.00018829398,0.00068737735,0.031784084,0.00022113555,0.00057065935,0.033446807],"study_design_scores_gemma":[0.00010638384,0.0016648559,0.9860184,0.000015627611,0.00013034134,0.0076198746,0.00005751859,0.00085419277,0.0020585584,0.0002649959,0.0011967001,0.000012575305],"about_ca_topic_score_codex":0.00017211998,"about_ca_topic_score_gemma":0.00022260136,"teacher_disagreement_score":0.0017057023,"about_ca_system_score_codex":0.00015684261,"about_ca_system_score_gemma":0.00013396844,"threshold_uncertainty_score":0.0057061315},"labels":[],"label_agreement":null},{"id":"W2123817338","doi":"10.1080/10428190410001697395","title":"Improved Outcome of Human Immunodeficiency Virus-Associated Plasmablastic Lymphoma of the Oral Cavity in the Era of Highly Active Antiretroviral Therapy: A Report of Two Cases","year":2004,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver; BC Cancer Agency; University of British Columbia","funders":"","keywords":"Plasmablastic lymphoma; Medicine; Lymphoma; CHOP; Internal medicine; Chemotherapy; Viral load; Human immunodeficiency virus (HIV); Gastroenterology; Immunology","score_opus":0.015793737149852626,"score_gpt":0.27670560593632115,"score_spread":0.26091186878646855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123817338","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99389863,0.0020458857,0.000594247,0.00019986441,0.000055515273,0.000065932494,0.00006989509,0.00005263012,0.0030173475],"genre_scores_gemma":[0.9983341,0.000579792,0.00023058991,0.0001226614,0.00012681073,0.000022012664,0.000064286374,0.000009559089,0.0005100613],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9994717,0.000054360382,0.00005849469,0.0001250671,0.00006356385,0.0002268081],"domain_scores_gemma":[0.99902594,0.00020584207,0.00024145698,0.00011859153,0.00007531008,0.00033301525],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003060948,0.0013053699,0.00078877306,0.0013157593,0.0014670828,0.0015164235,0.00082799,0.0024592914,0.0011421188],"category_scores_gemma":[0.0022792558,0.00073431706,0.00071779615,0.00066779763,0.0012753189,0.000931564,0.0010813243,0.0012759609,0.0005830564],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013661782,0.00013630016,0.053555507,0.00004785548,0.000025929105,0.9397195,0.0005598687,0.00008956327,0.0015113557,0.00010131489,0.00019348765,0.0039227987],"study_design_scores_gemma":[0.000023421526,0.00016148189,0.028192502,0.000012475955,0.000028107386,0.97025865,0.0001736863,0.00015200593,0.0004378984,0.000048747013,0.0004949257,0.000016029895],"about_ca_topic_score_codex":0.0016538957,"about_ca_topic_score_gemma":0.0014359192,"teacher_disagreement_score":0.0024592914,"about_ca_system_score_codex":0.00084878656,"about_ca_system_score_gemma":0.00041645556,"threshold_uncertainty_score":0.0061584115},"labels":[],"label_agreement":null},{"id":"W2127063344","doi":"10.1080/00268970500096616","title":"Malignant pleural effusions in lymphoproliferative disorders","year":2005,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Pleural and Pulmonary Diseases","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dartmouth General Hospital; Dalhousie University; University of Saskatchewan","funders":"","keywords":"Lymphoproliferative disorders; Medicine; Hematological disorders; Pleural effusion; Pathology; Dermatology; Immunology; Lymphoma; Internal medicine","score_opus":0.009058763380532296,"score_gpt":0.24037587551305445,"score_spread":0.23131711213252215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127063344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99886405,0.00070436153,0.00008074771,0.000025111829,0.0000056394624,0.0000058982305,0.00007036334,0.0000026538466,0.00024123212],"genre_scores_gemma":[0.9995478,0.00020257013,0.00006658518,0.000012947936,0.00001735612,0.0000053509652,0.00010970587,6.187603e-7,0.000036938178],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994118,0.00018632476,0.00008439068,0.00007053527,0.00013270137,0.000114288225],"domain_scores_gemma":[0.99722916,0.0006661435,0.0014701667,0.0000753252,0.00016848835,0.00039078124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058612844,0.0002632634,0.00032851944,0.00097210065,0.0003492739,0.00047075978,0.00021706684,0.00036271955,0.0010483649],"category_scores_gemma":[0.0034507494,0.00024124335,0.00026580723,0.00089105417,0.00037319103,0.0004773904,0.000381597,0.00046664343,0.0001788067],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000048651822,0.00001108796,0.99882597,0.00000748945,0.000010963455,0.00031573544,0.000016278722,0.0000128872825,0.00009079462,0.000006724752,0.000022313909,0.00063116115],"study_design_scores_gemma":[0.000008667875,0.00015924891,0.99186397,0.00001307726,0.0000215161,0.007370062,0.00010855794,0.00014413954,0.000113931594,0.00002661829,0.00016734534,0.0000029047953],"about_ca_topic_score_codex":0.0005852247,"about_ca_topic_score_gemma":0.0006832031,"teacher_disagreement_score":0.0010483649,"about_ca_system_score_codex":0.00015804783,"about_ca_system_score_gemma":0.0002183882,"threshold_uncertainty_score":0.0035070777},"labels":[],"label_agreement":null},{"id":"W2128096360","doi":"10.1080/1042819021000015989-1","title":"Molecular Analysis of a New Variant of the CBFβ - MYH11 Gene Fusion","year":2002,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Fusion gene; Chromosomal inversion; Molecular biology; Biology; Breakpoint; Gene; Genetics; Chromosome; Karyotype","score_opus":0.01559876478246606,"score_gpt":0.24700998108138367,"score_spread":0.23141121629891762,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128096360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981933,0.00016569423,0.0008361017,0.000055705572,0.0000074381546,0.00001886706,0.00012109277,0.000019135245,0.00058253494],"genre_scores_gemma":[0.99815315,0.00011320116,0.0010240428,0.000029505682,0.000008142869,0.000011861009,0.00029632312,0.0000042200554,0.0003595303],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.999828,0.000012563986,0.000015568254,0.000052845935,0.00003694452,0.000053997905],"domain_scores_gemma":[0.99980956,0.000059486512,0.00004961083,0.000015311503,0.0000133384465,0.00005267821],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008953869,0.0002937868,0.00019224767,0.000549967,0.0003111366,0.00030645862,0.00023086106,0.00059000676,0.0013863326],"category_scores_gemma":[0.000589404,0.00018490036,0.00023921017,0.0002545529,0.00040718378,0.0001790826,0.00035180146,0.00036083677,0.0002074305],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045368983,0.00012644703,0.08893295,0.00007184042,0.000036944253,0.10612143,0.0005712458,0.00038472953,0.7850363,0.0011477193,0.00024303068,0.016873611],"study_design_scores_gemma":[0.00013843605,0.0009939213,0.22654745,0.000028880395,0.0001222814,0.523887,0.0005772781,0.0028661333,0.23149516,0.001043865,0.01225014,0.0000495204],"about_ca_topic_score_codex":0.0006506416,"about_ca_topic_score_gemma":0.00040607693,"teacher_disagreement_score":0.0013863326,"about_ca_system_score_codex":0.00027994392,"about_ca_system_score_gemma":0.00016015304,"threshold_uncertainty_score":0.004637778},"labels":[],"label_agreement":null},{"id":"W2128185159","doi":"10.3109/10428194.2011.553001","title":"Paired box gene 5 may modulate Proviral Integration of Moloney virus2gene and protein expression in mature B-cells","year":2011,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Cancer Mechanisms and Therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Atlantic Cancer Research Institute","funders":"Canadian Institutes of Health Research","keywords":"Gene isoform; Molecular biology; Biology; HEK 293 cells; Transfection; Transcription factor; Western blot; Gene; Cell culture; Gene expression; Carcinogenesis; Cancer research; Genetics","score_opus":0.015910921200222087,"score_gpt":0.2265344543100825,"score_spread":0.21062353310986043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128185159","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965264,0.000976504,0.0012336159,0.00003499641,0.00001584977,0.00001239072,0.00011580452,0.000023492588,0.0010609641],"genre_scores_gemma":[0.99693155,0.0004967729,0.00088876794,0.000037849422,0.000010235306,0.00001702633,0.00030139793,0.000007963399,0.001308328],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998927,0.000027388092,0.000006797453,0.000017445496,0.000025640113,0.000030066454],"domain_scores_gemma":[0.9999368,0.000016564296,0.00001755545,0.000004430897,0.0000058621476,0.000018774854],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013317216,0.00019525479,0.00011180929,0.00017011052,0.00009172926,0.0002880259,0.000089888585,0.00016379001,0.0015595134],"category_scores_gemma":[0.00014470886,0.00009271039,0.00014910851,0.000084914056,0.00011649567,0.00019953573,0.00019271346,0.0003202253,0.00030123262],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008439003,0.000010760785,0.0002538929,0.000011542204,0.0000017119116,0.000042949443,0.000010025468,0.000019513995,0.9988438,0.0000886911,0.000015091806,0.0006176818],"study_design_scores_gemma":[0.000017883083,0.00047405047,0.016566254,0.000006235131,0.000014264682,0.00031559166,0.000064434964,0.0008113753,0.9794998,0.00012099786,0.0021051397,0.00000395547],"about_ca_topic_score_codex":0.00012534707,"about_ca_topic_score_gemma":0.0001704453,"teacher_disagreement_score":0.0015595134,"about_ca_system_score_codex":0.00016389311,"about_ca_system_score_gemma":0.000080604405,"threshold_uncertainty_score":0.005217135},"labels":[],"label_agreement":null},{"id":"W2129504146","doi":"10.3109/10428194.2014.951848","title":"Single nucleotide polymorphisms in non-coding region of the glucocorticoid receptor gene and prednisone response in childhood acute lymphoblastic leukemia","year":2015,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Education and Early Childhood Development","funders":"First Hospital of Jilin University","keywords":"Prednisone; Single-nucleotide polymorphism; Haplotype; Odds ratio; Allele; Glucocorticoid; Medicine; Glucocorticoid receptor; Internal medicine; Oncology; Gene; Genetics; Biology; Immunology; Genotype","score_opus":0.014379983887584697,"score_gpt":0.24005891617737168,"score_spread":0.225678932289787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129504146","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9995227,0.00028139682,0.000037998314,0.000020176962,0.0000021166288,0.0000016676502,0.00005009979,0.0000017123091,0.00008222906],"genre_scores_gemma":[0.9996742,0.00011054076,0.000043441647,0.000012066093,0.000004127344,0.000002158213,0.000079605394,8.707071e-7,0.000072898234],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997111,0.00008349966,0.000031739357,0.00006800787,0.000064085856,0.000041574393],"domain_scores_gemma":[0.9995659,0.00011002881,0.00020489248,0.000028026121,0.000024810166,0.00006631483],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032031874,0.0002305507,0.00025215236,0.00039229656,0.00016446263,0.00030807627,0.00019390136,0.00018550234,0.0010421507],"category_scores_gemma":[0.00085985335,0.000103066435,0.00028567231,0.00066090585,0.00023676752,0.00010068096,0.0001871596,0.00026428144,0.00011327499],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033776017,0.00003294056,0.9910251,0.000026637332,0.00013933225,0.00021771558,0.000084649226,0.00010905517,0.0030947297,0.0000321087,0.00007005437,0.004829943],"study_design_scores_gemma":[0.000013840212,0.00006870517,0.9987112,0.0000053505983,0.00009299249,0.00027083055,0.00004425169,0.00017042879,0.00043574403,0.000027129703,0.00015737153,0.0000020913596],"about_ca_topic_score_codex":0.0037443477,"about_ca_topic_score_gemma":0.00449699,"teacher_disagreement_score":0.0037443477,"about_ca_system_score_codex":0.00027986147,"about_ca_system_score_gemma":0.00032386786,"threshold_uncertainty_score":0.007445097},"labels":[],"label_agreement":null},{"id":"W2130198817","doi":"10.3109/10428194.2012.697560","title":"Incidence, predictors and significance of severe toxicity in patients with human immunodeficiency virus-associated Hodgkin lymphoma","year":2012,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver; St. Michael's Hospital; University of Toronto; Sunnybrook Health Science Centre; St. Paul's Hospital; Health Sciences Centre; University of British Columbia","funders":"","keywords":"Lymphoma; Medicine; Incidence (geometry); Human immunodeficiency virus (HIV); Hodgkin lymphoma; Oncology; Toxicity; Internal medicine; Immunology; Virology","score_opus":0.00703833338773078,"score_gpt":0.22090101145416002,"score_spread":0.21386267806642925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130198817","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978126,0.0015983401,0.00006159044,0.0000502263,0.0000051876104,0.000004896117,0.00008154912,0.000004662765,0.00038086966],"genre_scores_gemma":[0.9995838,0.00023021807,0.00003414955,0.000016539823,0.000013931782,0.0000022249071,0.000085451225,9.543033e-7,0.00003274083],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995053,0.00017389885,0.00009726231,0.000063912834,0.00010019291,0.0000594294],"domain_scores_gemma":[0.9973086,0.00089177134,0.0010385959,0.00011894583,0.00024148736,0.00040064438],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005918237,0.00019031948,0.00032899927,0.0008210439,0.00033330577,0.00061935803,0.00029910603,0.000498707,0.00074344565],"category_scores_gemma":[0.0039693825,0.00023040742,0.0002846338,0.0011073912,0.00036557592,0.0005479525,0.00035565454,0.00052027125,0.00014305415],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005954613,0.0000061472692,0.99887496,0.00000513772,0.000011200226,0.00011311913,0.000010060876,0.000023944729,0.00004602114,0.0000033399722,0.000023094255,0.0008234558],"study_design_scores_gemma":[0.0000057639,0.00010032763,0.9976044,0.0000052559594,0.000022751774,0.0018635204,0.00007589025,0.00016254603,0.00003938148,0.000020552025,0.00009699275,0.000002552532],"about_ca_topic_score_codex":0.0013609254,"about_ca_topic_score_gemma":0.0013159271,"teacher_disagreement_score":0.0013609254,"about_ca_system_score_codex":0.00025584808,"about_ca_system_score_gemma":0.00026285663,"threshold_uncertainty_score":0.003129959},"labels":[],"label_agreement":null},{"id":"W2130798268","doi":"10.3109/10428194.2012.664843","title":"Association between obesity at diagnosis and weight change during induction and survival in pediatric acute lymphoblastic leukemia","year":2012,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; SickKids Foundation; Hospital for Sick Children","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Hazard ratio; Confidence interval; Internal medicine; Univariate analysis; Obesity; Weight change; Weight gain; Gastroenterology; Weight loss; Body weight; Multivariate analysis","score_opus":0.021269748749087162,"score_gpt":0.25982361407088067,"score_spread":0.2385538653217935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130798268","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9991351,0.00057097705,0.000053815867,0.000037035177,0.000004304684,0.0000018133675,0.000085028856,0.0000014714901,0.00011054596],"genre_scores_gemma":[0.9994203,0.00026268457,0.00005872755,0.000011186095,0.000009287522,0.0000033592964,0.00017662352,0.0000012328757,0.000056674297],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997205,0.00010348818,0.0000266003,0.0000364478,0.0000567591,0.000056180663],"domain_scores_gemma":[0.99764806,0.0006437154,0.0013577711,0.00006311679,0.00006325508,0.00022402681],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071292656,0.00018332811,0.00019097462,0.00037048812,0.00014167264,0.00036074856,0.00020465594,0.0002571795,0.0008255663],"category_scores_gemma":[0.0024825365,0.0001175791,0.00035130075,0.0006508143,0.00016743563,0.00027783858,0.00022701091,0.0005878581,0.00008568501],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018852222,0.000017064933,0.99818903,0.000005648673,0.000032032684,0.000026779222,0.000012785495,0.00003709742,0.000059063,0.0000055798296,0.000023708746,0.0014027255],"study_design_scores_gemma":[0.000004908579,0.0001023165,0.9994636,0.000004455787,0.000029464227,0.0001280135,0.000029084269,0.00012459251,0.00003579047,0.000010690019,0.00006565045,0.0000014645724],"about_ca_topic_score_codex":0.0013866838,"about_ca_topic_score_gemma":0.0024636479,"teacher_disagreement_score":0.0013866838,"about_ca_system_score_codex":0.00023898017,"about_ca_system_score_gemma":0.00021667872,"threshold_uncertainty_score":0.003770411},"labels":[],"label_agreement":null},{"id":"W2131163045","doi":"10.3109/10428194.2014.994178","title":"Very late relapse of Philadelphia chromosome positive acute megakaryoblastic leukemia","year":2014,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Acute megakaryoblastic leukemia; Medicine; Philadelphia chromosome; Acute leukemia; Oncology; Internal medicine; Leukemia; Cancer research; Biology; Chromosomal translocation; Genetics; Gene","score_opus":0.010564894281328053,"score_gpt":0.23509868296768516,"score_spread":0.2245337886863571,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131163045","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.26603845,0.01648417,0.0032764853,0.54640055,0.020871853,0.00023564699,0.0007883657,0.00041312238,0.14549142],"genre_scores_gemma":[0.7281568,0.005001556,0.0016014636,0.20416106,0.038288433,0.000058739988,0.0004745706,0.00013336222,0.022123994],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9994228,0.0001655219,0.000056229637,0.000060733542,0.000110015986,0.00018481986],"domain_scores_gemma":[0.99868244,0.0005013854,0.00019936867,0.000087831664,0.00014109151,0.00038786168],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005503044,0.0005808674,0.0009987735,0.0006389749,0.0015878803,0.0015026783,0.000922189,0.009145039,0.002944709],"category_scores_gemma":[0.0051836306,0.00036822123,0.0009953011,0.00052948605,0.00080766826,0.0011869011,0.0006931152,0.007188246,0.0014406135],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035697524,0.00018986089,0.014084837,0.00010806739,0.000049800943,0.87436575,0.0001956788,0.00033625562,0.001438961,0.0034057363,0.08932612,0.016142031],"study_design_scores_gemma":[0.00028454355,0.0005215694,0.01634456,0.00021597935,0.0001042725,0.92406064,0.00040504243,0.0022105055,0.0008974936,0.004827484,0.050075464,0.000052356056],"about_ca_topic_score_codex":0.0014893877,"about_ca_topic_score_gemma":0.0030084234,"teacher_disagreement_score":0.009145039,"about_ca_system_score_codex":0.0018663753,"about_ca_system_score_gemma":0.0008374773,"threshold_uncertainty_score":0.01354152},"labels":[],"label_agreement":null},{"id":"W2131395115","doi":"10.3109/10428194.2011.643404","title":"Salvage chemotherapy and autologous stem cell transplant in primary refractory diffuse large B-cell lymphoma: outcomes and prognostic factors","year":2011,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Vincristine; Rituximab; Internal medicine; Etoposide; Salvage therapy; Oncology; CHOP; DHAP; Diffuse large B-cell lymphoma; Autologous stem-cell transplantation; Chemotherapy; Gemcitabine; Surgery; Cyclophosphamide; Lymphoma; Chemistry","score_opus":0.012257883743986255,"score_gpt":0.21361873074930124,"score_spread":0.20136084700531498,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131395115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953113,0.0041028913,0.00007788303,0.000060085164,0.0000061031915,0.000008938889,0.00011781372,0.0000032987205,0.0003117693],"genre_scores_gemma":[0.9988965,0.0007616212,0.000041944855,0.00002734758,0.00001742145,0.0000042918277,0.00019430427,9.771229e-7,0.000055580513],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996673,0.00011893325,0.00004485958,0.000055244676,0.00007129338,0.00004251799],"domain_scores_gemma":[0.99872583,0.0003854018,0.00057236536,0.000051045437,0.00008840948,0.00017693812],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005916909,0.00012538557,0.0003396991,0.00047484995,0.00015894751,0.0004007591,0.0002171072,0.00028883436,0.0007484376],"category_scores_gemma":[0.0022301779,0.00009576577,0.00025532537,0.00070680794,0.00023450579,0.0002441632,0.00019170748,0.00022846225,0.00022877262],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048283784,0.000036094887,0.98834527,0.00004236945,0.00007110219,0.0009389323,0.000046174428,0.00007818229,0.0002979101,0.000009892272,0.0001499245,0.009501405],"study_design_scores_gemma":[0.000049117338,0.0006419061,0.9917001,0.00004174884,0.00013066866,0.0060829017,0.00015812763,0.0002846737,0.0002918089,0.00004578069,0.00056903774,0.0000041594303],"about_ca_topic_score_codex":0.0008319122,"about_ca_topic_score_gemma":0.0015155216,"teacher_disagreement_score":0.0008319122,"about_ca_system_score_codex":0.00031053825,"about_ca_system_score_gemma":0.0002582343,"threshold_uncertainty_score":0.0031292439},"labels":[],"label_agreement":null},{"id":"W2131790261","doi":"10.1080/10428190310001593184","title":"Isolated Central Nervous System Relapse in Lymphoid Blast Crisis Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia in Patients on Imatinib Therapy","year":2003,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Imatinib; Medicine; Myeloid leukemia; Cytarabine; Imatinib mesylate; Methotrexate; Philadelphia chromosome; Bone marrow; Leukemia; Internal medicine; Oncology; Immunology; Chromosomal translocation; Biology","score_opus":0.0067067921439944445,"score_gpt":0.21897548995774901,"score_spread":0.21226869781375457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131790261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99683964,0.00040421888,0.00008823552,0.00018279269,0.000008237638,0.00003453781,0.00003444052,0.000008588538,0.0023993263],"genre_scores_gemma":[0.99916697,0.00022493328,0.00009143477,0.00010609836,0.000057178106,0.000011399982,0.000058215443,0.0000034358463,0.00028043712],"study_design_codex":"case_report","study_design_gemma":"observational","domain_scores_codex":[0.99984765,0.000027847549,0.000015480142,0.000023780005,0.000023334564,0.000061806655],"domain_scores_gemma":[0.99953806,0.00009987965,0.00013577608,0.000020905389,0.000028966904,0.00017654395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016978917,0.00034756624,0.00048120736,0.00072031753,0.00089172984,0.00052845845,0.00042390637,0.0007723604,0.0020956444],"category_scores_gemma":[0.0010320187,0.00020264159,0.00022351417,0.00046465598,0.00058703753,0.0004550167,0.00050082133,0.00068526017,0.00029950097],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001292159,0.00030969802,0.48545888,0.00008743089,0.00004600707,0.48778045,0.0008964897,0.00018245743,0.007202759,0.00026557056,0.0008311065,0.015646992],"study_design_scores_gemma":[0.00014199657,0.0010564337,0.38409784,0.000036414003,0.000087510256,0.6099479,0.00073429703,0.00049629254,0.001618482,0.00029233217,0.0014674027,0.00002294431],"about_ca_topic_score_codex":0.001368398,"about_ca_topic_score_gemma":0.0028834338,"teacher_disagreement_score":0.0020956444,"about_ca_system_score_codex":0.0004429361,"about_ca_system_score_gemma":0.0003873138,"threshold_uncertainty_score":0.0070106387},"labels":[],"label_agreement":null},{"id":"W2132862303","doi":"10.3109/10428194.2014.939969","title":"Hyperhemolysis associated with marginal zone lymphoma","year":2014,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Blood groups and transfusion","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Hemolysis; Medicine; Lymphoma; Marginal zone; Autologous blood; Immunology; Blood transfusion; Intensive care medicine; Surgery; Antibody; B cell","score_opus":0.009615132713618295,"score_gpt":0.2060630755283149,"score_spread":0.1964479428146966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132862303","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12841846,0.02210058,0.0033645541,0.71702075,0.020762777,0.0002865123,0.00032811196,0.0005412699,0.10717701],"genre_scores_gemma":[0.6815715,0.011843901,0.0019905064,0.22238992,0.059764493,0.00013588497,0.0001872548,0.000082744526,0.02203387],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9989635,0.00031780367,0.00008497016,0.0001248435,0.00026515,0.00024358583],"domain_scores_gemma":[0.99844944,0.0006461343,0.00019747531,0.00009500267,0.00024144103,0.00037049936],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00084660365,0.00084295834,0.0009376607,0.0011274124,0.002023737,0.0013935189,0.0011465444,0.0099207815,0.0030868526],"category_scores_gemma":[0.006549868,0.0005322306,0.0010390878,0.0009814776,0.0017858241,0.0018330511,0.00087874883,0.0074030138,0.0017706697],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025882994,0.00019455809,0.014351028,0.00020775723,0.000072873336,0.84977835,0.00037449156,0.0004689172,0.001734289,0.004952977,0.10845949,0.01914651],"study_design_scores_gemma":[0.00028463427,0.0002588263,0.011496576,0.0005116835,0.00012960317,0.90839875,0.0006162074,0.0027469902,0.0009866777,0.0093820505,0.065119006,0.000068943664],"about_ca_topic_score_codex":0.0038963472,"about_ca_topic_score_gemma":0.005504096,"teacher_disagreement_score":0.0099207815,"about_ca_system_score_codex":0.0031725108,"about_ca_system_score_gemma":0.0014450592,"threshold_uncertainty_score":0.0230183},"labels":[],"label_agreement":null},{"id":"W2132959953","doi":"10.1080/10428194310001593193","title":"The High Rate of Bone Resorption in Multiple Myeloma is due to RANK (Receptor Activator of Nuclear Factor-κB) and RANK Ligand Expression","year":2004,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"RANKL; Osteoclast; Bone resorption; RANK Ligand; Osteoprotegerin; Osteolysis; Multiple myeloma; Cancer research; Stromal cell; Receptor; Chemistry; Internal medicine; Medicine; Bone remodeling; Endocrinology; Activator (genetics)","score_opus":0.02358573838970978,"score_gpt":0.2861738569402019,"score_spread":0.26258811855049213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132959953","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002652341,0.99765563,0.00017141612,0.00015937896,0.00008523785,0.0000039423467,0.000017703962,0.000010240836,0.0016312237],"genre_scores_gemma":[0.0015079034,0.9963142,0.0002568517,0.00014092751,0.00009137549,0.000007349522,0.00003434937,0.000001630982,0.0016454108],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99984694,0.000021491851,0.000016637228,0.000033534234,0.00006846824,0.000012930041],"domain_scores_gemma":[0.99983406,0.000054018838,0.00003843155,0.0000063528546,0.00005049603,0.00001657084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028056625,0.00067753217,0.0012307597,0.0018097924,0.00025349428,0.00078593177,0.000492398,0.00091666257,0.0040618484],"category_scores_gemma":[0.00026923802,0.00023538704,0.0002784833,0.0024224722,0.00040676206,0.000882347,0.0003590158,0.0008761353,0.0039707776],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000071008275,0.00006085365,0.00027338418,0.0075872284,0.00005810618,0.00034511436,0.000041365114,0.00017712945,0.0065400233,0.0014160676,0.012455158,0.9709746],"study_design_scores_gemma":[0.000023383685,0.00017099852,0.0023719457,0.001447001,0.00009269734,0.0046058474,0.00009304409,0.00005034588,0.0022419852,0.0014404719,0.9874464,0.000016064736],"about_ca_topic_score_codex":0.00086724403,"about_ca_topic_score_gemma":0.0016445724,"teacher_disagreement_score":0.0040618484,"about_ca_system_score_codex":0.00046061972,"about_ca_system_score_gemma":0.0006710066,"threshold_uncertainty_score":0.01358825},"labels":[],"label_agreement":null},{"id":"W2133838536","doi":"10.3109/10428194.2012.723211","title":"Analysis of microsatellite instability in gastric mucosa-associated lymphoid tissue lymphoma","year":2012,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Microsatellite instability; Lymphoma; Pathology; Medicine; General surgery; Biology; Microsatellite; Genetics","score_opus":0.013175636823694601,"score_gpt":0.25968089328242355,"score_spread":0.24650525645872895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133838536","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.999233,0.00035109217,0.00018832584,0.000008234132,0.0000012620588,0.0000047638096,0.000055368113,0.000008593464,0.00014924194],"genre_scores_gemma":[0.99946207,0.00010544227,0.00022764715,0.000006135486,0.0000025474415,0.0000041734693,0.00008905401,0.000001882002,0.00010120305],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998325,0.000033022894,0.000025140514,0.00003907801,0.000044326054,0.000025930127],"domain_scores_gemma":[0.9996624,0.00006494327,0.00013369204,0.000016059874,0.00005442149,0.000068473826],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018973803,0.00017817665,0.00017337658,0.0016122612,0.00014864559,0.00024312227,0.00012871639,0.00021401056,0.000728447],"category_scores_gemma":[0.00062922284,0.00011265925,0.000117664014,0.0006012995,0.00017633442,0.00012427133,0.00020973566,0.000113488735,0.00023429125],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006086258,0.000035920002,0.74762994,0.00006279136,0.000044950266,0.003806804,0.00034023952,0.00014534305,0.23673235,0.000061451916,0.00008125752,0.010450249],"study_design_scores_gemma":[0.000027893457,0.00065931946,0.94146276,0.00001247858,0.000081340615,0.020909563,0.0003245304,0.0009343423,0.034086447,0.00009614899,0.0013952883,0.000009950035],"about_ca_topic_score_codex":0.0005076303,"about_ca_topic_score_gemma":0.0005365108,"teacher_disagreement_score":0.0016122612,"about_ca_system_score_codex":0.00015009235,"about_ca_system_score_gemma":0.00008368759,"threshold_uncertainty_score":0.002436936},"labels":[],"label_agreement":null},{"id":"W2133983117","doi":"10.1080/10428190290016935","title":"Bcl-3/IgH translocation (14;19)(q32;q13) in Non-Hodgkin's Lymphomas","year":2002,"lang":"zh","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Chromosomal translocation; Lymphoma; Chronic lymphocytic leukemia; Medicine; Pathology; Abnormality; Non-Hodgkin's lymphoma; Leukemia; Internal medicine; Biology; Gene","score_opus":0.02022337419519823,"score_gpt":0.26642772729422054,"score_spread":0.2462043530990223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133983117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99830127,0.00069981767,0.00028917586,0.000047538946,0.0000063188922,0.000011301929,0.00002318784,0.000015248897,0.0006060681],"genre_scores_gemma":[0.9995505,0.00016922234,0.00013111728,0.000017489909,0.000014939354,0.0000043339837,0.000032706565,0.0000025746026,0.000077094875],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996395,0.00009416085,0.00005949852,0.00006989371,0.0000700556,0.00006683038],"domain_scores_gemma":[0.9993788,0.00019950065,0.00020518515,0.000053111533,0.000051409614,0.00011198488],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037944966,0.00024530094,0.00023924714,0.0012574142,0.00052836176,0.0005028112,0.0003904594,0.00059352315,0.0010478701],"category_scores_gemma":[0.0019054663,0.00024678846,0.00012208422,0.0007970747,0.00074275275,0.00040831568,0.00056704594,0.0002893945,0.00022505749],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038245445,0.00007482097,0.90818864,0.000089451,0.000035550453,0.050457735,0.0005309922,0.0002710357,0.011186079,0.00016837852,0.0004532942,0.028161455],"study_design_scores_gemma":[0.00010376293,0.0005673425,0.5691752,0.000031515978,0.00009877984,0.42175156,0.0007572893,0.0007885196,0.0034195886,0.0007257314,0.0025567715,0.00002396457],"about_ca_topic_score_codex":0.0007101921,"about_ca_topic_score_gemma":0.00087754143,"teacher_disagreement_score":0.0012574142,"about_ca_system_score_codex":0.000234289,"about_ca_system_score_gemma":0.00026307022,"threshold_uncertainty_score":0.003505528},"labels":[],"label_agreement":null},{"id":"W2134740705","doi":"10.3109/10428194.2014.883072","title":"A single-institution analysis of the utility of pre-induction ejection fraction measurement in patients newly diagnosed with acute myeloid leukemia","year":2014,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Ejection fraction; Medicine; Myeloid leukemia; Induction chemotherapy; Single Center; Internal medicine; Retrospective cohort study; Chemotherapy; Intensive care medicine; Acute leukemia; Cardiac function curve; Oncology; Leukemia; Cardiology; Heart failure","score_opus":0.012025073621952246,"score_gpt":0.22398278206855174,"score_spread":0.2119577084465995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2134740705","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99924207,0.00020075697,0.00011045852,0.000034379485,0.0000030910007,0.00001467475,0.00023340867,0.0000061641367,0.00015498081],"genre_scores_gemma":[0.9993554,0.0000701003,0.0001725865,0.000039388837,0.000011158478,0.00000838508,0.00030458576,0.0000033106612,0.000035106503],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99851805,0.00047614274,0.00022619637,0.00039995983,0.00024471566,0.00013490608],"domain_scores_gemma":[0.99078417,0.0026765051,0.004047066,0.00085283373,0.0006964022,0.0009430853],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013054432,0.00031663457,0.00059478567,0.00084153906,0.0004936332,0.0010578582,0.00054163433,0.00045903237,0.0010569219],"category_scores_gemma":[0.008292783,0.00039697895,0.0005876351,0.0013048378,0.00053412875,0.00057924533,0.0006387496,0.00058263424,0.00022483552],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006771908,0.00007168064,0.99611783,0.000015920154,0.00011289687,0.0001234356,0.000046177334,0.00010568313,0.00028873773,0.0000121950025,0.00010437351,0.0023238454],"study_design_scores_gemma":[0.00011165068,0.00079639617,0.99618345,0.000014161042,0.00021434588,0.00095600175,0.00019386232,0.00086655247,0.00037459223,0.000023493418,0.00025047362,0.000015189423],"about_ca_topic_score_codex":0.004539828,"about_ca_topic_score_gemma":0.007329274,"teacher_disagreement_score":0.004539828,"about_ca_system_score_codex":0.0011627277,"about_ca_system_score_gemma":0.0009370231,"threshold_uncertainty_score":0.009026766},"labels":[],"label_agreement":null},{"id":"W2134806292","doi":"10.3109/10428194.2011.602771","title":"Treatment of Hodgkin lymphoma with adriamycin, bleomycin, vinblastine and dacarbazine without routine granulocyte-colony stimulating factor support does not increase the risk of febrile neutropenia: a prospective cohort study","year":2011,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"ABVD; Medicine; Dacarbazine; Neutropenia; Febrile neutropenia; Vinblastine; Internal medicine; Granulocyte colony-stimulating factor; Chemotherapy; Surgery; Lymphoma; Gastroenterology; Vincristine; Cyclophosphamide","score_opus":0.012524684018580885,"score_gpt":0.2424399040712438,"score_spread":0.2299152200526629,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2134806292","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9992225,0.00041414303,0.000059546117,0.000020836278,0.000007089869,0.00002679049,0.000080107886,0.0000020002835,0.00016696045],"genre_scores_gemma":[0.9989926,0.000414952,0.00008844786,0.00006372969,0.000028334816,0.000028975264,0.0002426502,0.0000032033947,0.00013711894],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985921,0.0006118832,0.00015340513,0.00023705713,0.00023449337,0.00017101962],"domain_scores_gemma":[0.9958851,0.0011244434,0.0013823059,0.00066557626,0.0002736176,0.00066884625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019129161,0.00046968853,0.0006573785,0.00042162152,0.00060378475,0.0009629205,0.00043266342,0.0006111509,0.0016541824],"category_scores_gemma":[0.0053521283,0.0005683616,0.0010306671,0.0006414197,0.00055435015,0.00065283116,0.00039170744,0.0009536462,0.0004115602],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009873613,0.0025834993,0.9753355,0.00006014324,0.00074014824,0.000571922,0.00024130134,0.00013014115,0.0008494869,0.00004709878,0.00037159535,0.009195639],"study_design_scores_gemma":[0.0027484046,0.03674892,0.9502225,0.000056003322,0.0009711308,0.0049552238,0.00052467553,0.0008443988,0.00087250833,0.00011796837,0.0018878566,0.000050374518],"about_ca_topic_score_codex":0.0018638534,"about_ca_topic_score_gemma":0.0021039366,"teacher_disagreement_score":0.0019129161,"about_ca_system_score_codex":0.0004809636,"about_ca_system_score_gemma":0.00070925965,"threshold_uncertainty_score":0.010116637},"labels":[],"label_agreement":null},{"id":"W2135057615","doi":"10.3109/10428190903585286","title":"A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study","year":2010,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Medicine; Sorafenib; Internal medicine; Myeloid leukemia; Refractory (planetary science); Regimen; Myelodysplastic syndromes; Oncology; Population; Phases of clinical research; Chemotherapy; Leukemia; Clinical trial; Gastroenterology; Bone marrow","score_opus":0.053731407724228554,"score_gpt":0.3961122256343599,"score_spread":0.3423808179101313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135057615","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98283017,0.002543389,0.0007850064,0.001049763,0.0005479261,0.007843942,0.0017538618,0.000108932,0.0025368922],"genre_scores_gemma":[0.9721182,0.0024053694,0.0025128415,0.0019112189,0.0005707268,0.01288679,0.0028392687,0.00003556187,0.004720123],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9993548,0.0003068978,0.000031932213,0.00011988756,0.000057024543,0.00012949183],"domain_scores_gemma":[0.99877805,0.00019840767,0.00021814939,0.00010240889,0.00006835409,0.00063468906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019938764,0.0017707143,0.003006299,0.00048130366,0.00053333177,0.001089811,0.00092798163,0.0015565709,0.007660537],"category_scores_gemma":[0.0016938677,0.00079745,0.0016192765,0.0004722364,0.001216942,0.0011097842,0.0004537427,0.003050254,0.0011499095],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9642474,0.016055873,0.0008256792,0.00030145992,0.0005544025,0.000058874823,0.000053325897,0.00042489113,0.002899778,0.00017955918,0.0014735814,0.012925229],"study_design_scores_gemma":[0.95605856,0.04172472,0.0011491529,0.00000822821,0.00011833384,0.000024775398,0.000013127444,0.00020425906,0.00012328688,0.0000943221,0.00047278067,0.000008513594],"about_ca_topic_score_codex":0.0013744779,"about_ca_topic_score_gemma":0.003687259,"teacher_disagreement_score":0.007660537,"about_ca_system_score_codex":0.0011240055,"about_ca_system_score_gemma":0.0020602047,"threshold_uncertainty_score":0.025627077},"labels":[],"label_agreement":null},{"id":"W2136508030","doi":"10.3109/10428194.2014.915544","title":"Intermittent granulocyte colony-stimulating factor for neutropenia management in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone","year":2014,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Lenalidomide; Medicine; Neutropenia; Dexamethasone; Granulocyte colony-stimulating factor; Multiple myeloma; Internal medicine; Refractory (planetary science); Absolute neutrophil count; Gastroenterology; Febrile neutropenia; Toxicity; Surgery; Chemotherapy","score_opus":0.016324495911819753,"score_gpt":0.25568155543578397,"score_spread":0.23935705952396422,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136508030","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99571276,0.0030279937,0.00015723443,0.0002786466,0.00001861147,0.00006307219,0.00004099261,0.00001564343,0.00068500044],"genre_scores_gemma":[0.9983699,0.0008434681,0.0003936835,0.00015821235,0.000042921412,0.00002483987,0.00007400251,0.0000022431057,0.00009063995],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999871,0.00004358903,0.000021502026,0.000015281734,0.000026170646,0.0000224104],"domain_scores_gemma":[0.9997391,0.00005636993,0.00008723621,0.000008909735,0.000010102446,0.00009819658],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025458226,0.00015243905,0.00035984913,0.00028815417,0.00029319612,0.00029674114,0.00023107689,0.00019388879,0.0004060059],"category_scores_gemma":[0.0008421166,0.000084298714,0.00026899143,0.0003399231,0.00013923972,0.00019321077,0.00018089126,0.00036315725,0.00006986158],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011138764,0.0022022217,0.64612377,0.00045616494,0.00032184532,0.009748894,0.00070377765,0.0012668573,0.014579582,0.00018623674,0.003047288,0.31022462],"study_design_scores_gemma":[0.0033514318,0.025959685,0.9273457,0.00027750662,0.0006435249,0.02465358,0.00062152906,0.0032782778,0.0053831628,0.00047983608,0.007966234,0.000039547424],"about_ca_topic_score_codex":0.0008192971,"about_ca_topic_score_gemma":0.0026564824,"teacher_disagreement_score":0.0008192971,"about_ca_system_score_codex":0.00040142192,"about_ca_system_score_gemma":0.0006110045,"threshold_uncertainty_score":0.0029125214},"labels":[],"label_agreement":null},{"id":"W2136559095","doi":"10.3109/10428194.2013.866662","title":"Pregnancy outcomes in patients with chronic myeloid leukemia treated with imatinib mesylate: short report from a developing country","year":2013,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital","funders":"","keywords":"Medicine; Myeloid leukemia; Imatinib mesylate; Pregnancy; Adverse effect; Imatinib; Fetus; Pediatrics; Obstetrics; Internal medicine","score_opus":0.007434360182514351,"score_gpt":0.22280724291478163,"score_spread":0.2153728827322673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136559095","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99847275,0.00084043905,0.00004707688,0.00009473763,0.0000045969828,0.000006082201,0.00009895201,0.0000016340883,0.00043362178],"genre_scores_gemma":[0.9989278,0.0007970793,0.00003597817,0.00006363403,0.000009752743,0.000006534183,0.000095870615,0.0000010169359,0.00006234067],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99973065,0.000100113866,0.000044328975,0.0000322336,0.000049383503,0.00004328455],"domain_scores_gemma":[0.99885476,0.00034670596,0.0005352332,0.000039615912,0.00006958328,0.00015417069],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000410453,0.00013444283,0.00022515065,0.00044341496,0.00043381733,0.00037274678,0.00012356213,0.0002685041,0.0005488636],"category_scores_gemma":[0.001906709,0.00015772597,0.00020857202,0.0006745488,0.00028018508,0.00021860778,0.00035075797,0.0003446854,0.00008390726],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000096506614,0.000022001155,0.99446905,0.00001783877,0.000027172853,0.0013855447,0.00033699445,0.000038317598,0.00017293173,0.000017748327,0.00011044644,0.0033053674],"study_design_scores_gemma":[0.00001699015,0.00032029333,0.98736143,0.000028441478,0.00006525617,0.009729212,0.0013084299,0.000118963064,0.0001801602,0.00002915054,0.00083156483,0.000010179561],"about_ca_topic_score_codex":0.0029739903,"about_ca_topic_score_gemma":0.0023878396,"teacher_disagreement_score":0.0029739903,"about_ca_system_score_codex":0.00026542484,"about_ca_system_score_gemma":0.000274728,"threshold_uncertainty_score":0.005913377},"labels":[],"label_agreement":null},{"id":"W2136631504","doi":"10.1080/10428190701528491","title":"Guanosine acts intracellularly to initiate apoptosis in NB4 cells: A role for nucleoside transport","year":2007,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Adenosine and Purinergic Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"National Cancer Institute; Natural Sciences and Engineering Research Council of Canada; U.S. Department of Health and Human Services","keywords":"Guanosine; Apoptosis; Nucleoside; Cell biology; Programmed cell death; Intracellular; Nucleoside transporter; Viability assay; Cell cycle; Cell cycle checkpoint; Cell growth; Chemistry; Biology; Transporter; Biochemistry; Gene","score_opus":0.0076918730028687115,"score_gpt":0.23056611370479163,"score_spread":0.2228742407019229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136631504","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99008685,0.0034589337,0.0037992108,0.00026262735,0.000031599353,0.000037268732,0.00020378984,0.00008915357,0.0020305796],"genre_scores_gemma":[0.99398464,0.0010971887,0.0029372112,0.000035677258,0.000007971735,0.000032101805,0.0001600323,0.000010538165,0.0017346271],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999341,0.00001724112,0.000006316902,0.000010401688,0.000013742504,0.00001822841],"domain_scores_gemma":[0.99994934,0.000008064414,0.000010603243,0.000008571207,0.000011068411,0.000012382941],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001228586,0.00027063885,0.00025173175,0.00013517324,0.00016740004,0.0002296908,0.00016880222,0.0002750388,0.0009936639],"category_scores_gemma":[0.000093696566,0.00008496193,0.00017587935,0.00010330918,0.00023353251,0.00032650272,0.00018870208,0.00034025477,0.00026093394],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000968069,0.0000063812536,0.00012615228,0.000023182836,0.0000016935008,0.00009092024,0.000013101039,0.000022498438,0.99884284,0.00012251645,0.000013281829,0.0006406425],"study_design_scores_gemma":[0.000033013792,0.00031595657,0.0032107073,0.000007867651,0.000010099798,0.0004067029,0.000050350107,0.00067037606,0.9926963,0.000118163814,0.0024767597,0.0000038286644],"about_ca_topic_score_codex":0.0011881771,"about_ca_topic_score_gemma":0.0015595662,"teacher_disagreement_score":0.0011881771,"about_ca_system_score_codex":0.00040055494,"about_ca_system_score_gemma":0.0002157934,"threshold_uncertainty_score":0.003324151},"labels":[],"label_agreement":null},{"id":"W2137344646","doi":"10.3109/10428194.2014.982638","title":"Tumor suppressors in follicular lymphoma","year":2014,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Biology; Epigenetics; Somatic cell; Follicular lymphoma; Cancer research; Suppressor; DNA methylation; Lymphoma; Chromosomal translocation; Gene silencing; Gene; Genetics; Immunology; Gene expression","score_opus":0.01861678396511938,"score_gpt":0.2871781545044321,"score_spread":0.2685613705393127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137344646","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019217256,0.99891794,0.00007559235,0.000109281194,0.00006530478,0.0000031146965,0.000017506032,0.0000059870904,0.00061308837],"genre_scores_gemma":[0.0017919904,0.9973231,0.00013484657,0.00011200559,0.00008388527,0.0000047856565,0.00004742122,0.0000014035697,0.00050064875],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.999882,0.00002008726,0.000020356416,0.000019983985,0.00004507336,0.000012544538],"domain_scores_gemma":[0.99985504,0.00006285088,0.000029099821,0.0000041657877,0.00003344868,0.00001538932],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033850165,0.0005414911,0.0008538508,0.0021258865,0.00020944708,0.0006643596,0.0005042994,0.00070307974,0.0028312234],"category_scores_gemma":[0.00044118814,0.00016910477,0.00034528528,0.0016148307,0.00030457962,0.0005997965,0.0004910925,0.0010681968,0.001467943],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007055493,0.00005298237,0.00034559952,0.012885987,0.00009353179,0.00039698748,0.00007141881,0.00035464493,0.003371669,0.0027399661,0.016304925,0.96331185],"study_design_scores_gemma":[0.00002029523,0.00007984242,0.0010956771,0.0023090506,0.00011854594,0.0034544053,0.000055880464,0.00006135741,0.0011086297,0.0015835569,0.99009854,0.000014354027],"about_ca_topic_score_codex":0.0008488715,"about_ca_topic_score_gemma":0.0012499051,"teacher_disagreement_score":0.0028312234,"about_ca_system_score_codex":0.00042829785,"about_ca_system_score_gemma":0.0006253401,"threshold_uncertainty_score":0.009471357},"labels":[],"label_agreement":null},{"id":"W2137372268","doi":"10.3109/10428194.2010.500051","title":"The value of positron emission tomography in prognosis and response assessment in non-Hodgkin lymphoma","year":2010,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Peter MacCallum Cancer Centre; National Cancer Research Institute","keywords":"Medicine; Positron emission tomography; Lymphoma; Interim; Hodgkin lymphoma; Medical physics; Grading (engineering); Oncology; Nuclear medicine; Internal medicine","score_opus":0.01110885524102844,"score_gpt":0.30170028290951584,"score_spread":0.2905914276684874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137372268","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000109835695,0.9994411,0.00006155398,0.00008783454,0.000036065274,0.0000020798277,0.0000053113295,0.0000018746703,0.00025443512],"genre_scores_gemma":[0.0012183274,0.99838245,0.00014108208,0.000067525456,0.000062617764,0.0000039140837,0.0000130181,7.7200883e-7,0.00011021939],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996327,0.00012678596,0.000061019073,0.00005154827,0.00010693985,0.000020992718],"domain_scores_gemma":[0.99916947,0.0005468684,0.00008896496,0.000021858574,0.00015224676,0.000020637259],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014797407,0.0006755296,0.0017825756,0.002247566,0.00013232545,0.0007638001,0.0007447259,0.00083272235,0.0011178976],"category_scores_gemma":[0.0018012465,0.0003011413,0.00058361184,0.0025197878,0.00047449002,0.0010555922,0.0004076217,0.0010463494,0.000760944],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000897436,0.000031296015,0.0007154158,0.011342254,0.0001683752,0.00023765664,0.00004164372,0.00035405,0.00071374583,0.00090508,0.0070579425,0.9783427],"study_design_scores_gemma":[0.000111308065,0.0003935056,0.01629813,0.015371805,0.0012294048,0.010603486,0.00023732522,0.0008034065,0.002291397,0.0046618646,0.94789565,0.00010275834],"about_ca_topic_score_codex":0.001731181,"about_ca_topic_score_gemma":0.0023316282,"teacher_disagreement_score":0.002247566,"about_ca_system_score_codex":0.000734246,"about_ca_system_score_gemma":0.0008128456,"threshold_uncertainty_score":0.007825732},"labels":[],"label_agreement":null},{"id":"W2137508909","doi":"10.3109/10428194.2014.882507","title":"Molecular relapse after allogeneic hematopoietic cell transplant for chronic myeloid leukemia: some long-term survivors appear to tolerate even lack of major molecular response","year":2014,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Myeloid leukemia; Hematopoietic cell; Medicine; Immunology; Haematopoiesis; Myeloid; Hematopoietic stem cell transplantation; Leukemia; Transplantation; Oncology; Cancer research; Stem cell; Internal medicine; Biology; Genetics","score_opus":0.012048295225232536,"score_gpt":0.24854209005624414,"score_spread":0.2364937948310116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137508909","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08347528,0.004006368,0.000941972,0.84085876,0.008514855,0.00008229106,0.0001831874,0.00022787538,0.06170947],"genre_scores_gemma":[0.39723006,0.007352443,0.0016368082,0.50346905,0.03357885,0.00008108891,0.00031043877,0.00012025458,0.05622107],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99973553,0.000055109787,0.000030017383,0.000033849374,0.000066843735,0.00007860059],"domain_scores_gemma":[0.9994172,0.00019124635,0.00009274053,0.00003112444,0.00006715658,0.0002005537],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002679198,0.00033911792,0.0005200112,0.00028775306,0.0013052056,0.0009866167,0.0006018537,0.007444799,0.0045857984],"category_scores_gemma":[0.0019105215,0.0001753559,0.0005827845,0.0003667388,0.0007654845,0.00095768075,0.00033346025,0.005096012,0.0024255568],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006464289,0.00056684774,0.036571994,0.00015642625,0.00008537431,0.319386,0.0004372153,0.0005778256,0.004197805,0.0066672266,0.54601026,0.08469656],"study_design_scores_gemma":[0.00061358657,0.0015382125,0.039489612,0.0003682153,0.00019332267,0.5325438,0.0013055512,0.0030799166,0.0028552131,0.0128735425,0.4050338,0.00010531301],"about_ca_topic_score_codex":0.0019211199,"about_ca_topic_score_gemma":0.0044717644,"teacher_disagreement_score":0.007444799,"about_ca_system_score_codex":0.0016533935,"about_ca_system_score_gemma":0.000746747,"threshold_uncertainty_score":0.0153410435},"labels":[],"label_agreement":null},{"id":"W2138573874","doi":"10.3109/10428194.2014.939967","title":"Classification of non-Hodgkin lymphoma in Algeria according to the World Health Organization classification","year":2014,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Lymphoma; Mantle cell lymphoma; Follicular lymphoma; Hodgkin lymphoma; Medicine; Classical Hodgkin lymphoma; Oncology; Internal medicine","score_opus":0.015628852843106826,"score_gpt":0.27578041283930294,"score_spread":0.2601515599961961,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138573874","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9846681,0.005278498,0.0009254365,0.00034512114,0.00007058437,0.00010167979,0.001847783,0.00002355036,0.00673925],"genre_scores_gemma":[0.99197793,0.0024238809,0.002071765,0.0001298314,0.000044654065,0.000060554645,0.002381849,0.000007099504,0.0009024113],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99944276,0.00016405924,0.00010576572,0.000059541355,0.00012139511,0.00010644735],"domain_scores_gemma":[0.99940956,0.000052812335,0.00027193228,0.000031553347,0.00018196717,0.00005228833],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008188222,0.0001723956,0.0001648883,0.0025765626,0.00026252551,0.00045109104,0.00024130779,0.0001223462,0.0010710423],"category_scores_gemma":[0.0012262494,0.0000636096,0.0001859527,0.0018265296,0.0002647306,0.00026348012,0.00029801414,0.000116985924,0.0001907986],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012051127,0.000023078574,0.9615891,0.000067867935,0.000053631455,0.00030014096,0.00038038904,0.00016942431,0.0007165658,0.00032216462,0.0017264313,0.03453076],"study_design_scores_gemma":[0.0000063349007,0.000037542297,0.99196845,0.000053693686,0.000023194987,0.0013335955,0.0005711776,0.00022168609,0.00017861984,0.00013871821,0.005461255,0.000005783404],"about_ca_topic_score_codex":0.011876091,"about_ca_topic_score_gemma":0.0071302443,"teacher_disagreement_score":0.011876091,"about_ca_system_score_codex":0.0006694034,"about_ca_system_score_gemma":0.00052343233,"threshold_uncertainty_score":0.02361393},"labels":[],"label_agreement":null},{"id":"W2139199450","doi":"10.3109/10428194.2010.548535","title":"Expression and prognostic significance of Oct2 and Bob1 in multiple myeloma: implications for targeted therapeutics","year":2011,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Saint John Regional Hospital; University of Calgary; University of Alberta","funders":"Alberta Cancer Foundation","keywords":"Multiple myeloma; Medicine; Oncology; Cancer research; Internal medicine","score_opus":0.04494350580488436,"score_gpt":0.28597660667642627,"score_spread":0.2410331008715419,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139199450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95536226,0.039662134,0.0011995863,0.0015613113,0.000022972441,0.000015165376,0.0002225539,0.00001713837,0.0019369178],"genre_scores_gemma":[0.9946831,0.0041531357,0.0005939628,0.00007239122,0.0000471309,0.000008115543,0.000115645,0.000002963766,0.0003237244],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998554,0.000061189676,0.000008724015,0.000017894834,0.00003294017,0.000023913573],"domain_scores_gemma":[0.9995609,0.00016101665,0.00014952928,0.00001514327,0.000036765538,0.00007652402],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067785574,0.00014832617,0.00042475338,0.00037039822,0.0001762465,0.00043347277,0.00016173662,0.00022428439,0.0008910126],"category_scores_gemma":[0.0011207733,0.00012435063,0.00011947047,0.00060880865,0.00025785444,0.00040388774,0.00021578291,0.00034303157,0.000131526],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005495609,0.00016230873,0.77771205,0.0002944081,0.00018370971,0.00086875993,0.000078502344,0.002153647,0.043756396,0.0007097648,0.0013046395,0.16728021],"study_design_scores_gemma":[0.00015043373,0.00083464966,0.96930605,0.00009110111,0.0002671028,0.0036414408,0.0002716275,0.0065532685,0.011932522,0.001747544,0.0051728664,0.000031428237],"about_ca_topic_score_codex":0.0009344105,"about_ca_topic_score_gemma":0.0016627468,"teacher_disagreement_score":0.0009344105,"about_ca_system_score_codex":0.0005001456,"about_ca_system_score_gemma":0.00029643773,"threshold_uncertainty_score":0.0036287904},"labels":[],"label_agreement":null},{"id":"W2139569200","doi":"10.3109/10428194.2012.666662","title":"Association of interleukin-6 and interleukin-8 with poor prognosis in elderly patients with chronic lymphocytic leukemia","year":2012,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research Institute in Oncology and Hematology; University of Manitoba; CancerCare Manitoba; Research Manitoba","funders":"Canadian Institutes of Health Research","keywords":"Chronic lymphocytic leukemia; Medicine; Cohort; Immunology; Internal medicine; Beta-2 microglobulin; Interleukin 6; Interleukin; Stromal cell; Population; Tumor necrosis factor alpha; Leukemia; Oncology; Cytokine","score_opus":0.006982895544242365,"score_gpt":0.23207738180895285,"score_spread":0.22509448626471049,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139569200","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.999188,0.00049208634,0.000052701274,0.000028063256,0.0000055365595,0.0000018655822,0.000060782073,0.0000016400569,0.0001693264],"genre_scores_gemma":[0.99970776,0.00010037236,0.00003699786,0.0000143150355,0.000012713807,0.0000022032011,0.000062597755,4.3254425e-7,0.00006261041],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99983394,0.000056085802,0.00002345253,0.000025002017,0.000028281813,0.00003316493],"domain_scores_gemma":[0.99911124,0.00020470536,0.00039281452,0.000041898773,0.00010611642,0.00014325259],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032011693,0.00014667682,0.00022238221,0.00048012874,0.0001948449,0.000262683,0.00008822835,0.00023560597,0.0006324846],"category_scores_gemma":[0.001312757,0.000078661105,0.00013102705,0.00044870426,0.00014325044,0.00021946486,0.00017650095,0.00028026494,0.000101279424],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012799914,0.000009565692,0.99845886,0.0000047505455,0.0000132212035,0.000065643144,0.000035603785,0.000017530207,0.00023093059,0.000005995404,0.000031375737,0.0009984563],"study_design_scores_gemma":[0.000006790297,0.00011016754,0.99900585,0.0000036504348,0.000017561517,0.00038269057,0.000105578234,0.00008133865,0.00005971283,0.000021897284,0.00020251088,0.0000022758356],"about_ca_topic_score_codex":0.00083329703,"about_ca_topic_score_gemma":0.0012811213,"teacher_disagreement_score":0.00083329703,"about_ca_system_score_codex":0.000096190975,"about_ca_system_score_gemma":0.000105827436,"threshold_uncertainty_score":0.0021159053},"labels":[],"label_agreement":null},{"id":"W2140486815","doi":"10.3109/10428194.2013.873537","title":"Oligoclonal and monoclonal bands after single autologous stem cell transplant in patients with multiple myeloma: impact on overall survival and progression-free survival","year":2013,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Autologous stem-cell transplantation; Multiple myeloma; Internal medicine; Oncology; Multivariate analysis; Overall survival; Progression-free survival; clone (Java method); Stem cell; Monoclonal; Monoclonal antibody; Immunology; Antibody; Biology","score_opus":0.008659674165426144,"score_gpt":0.23120845890660932,"score_spread":0.22254878474118317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140486815","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99943084,0.00028379774,0.00004249237,0.000033105087,0.0000041046546,0.0000018512898,0.000032596003,0.0000020831155,0.00016917674],"genre_scores_gemma":[0.9998192,0.00005328469,0.000022673847,0.000011648244,0.00000847642,0.0000011895086,0.00004498808,4.515834e-7,0.000038028553],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99980277,0.000052911877,0.000018812196,0.000029382622,0.00004992493,0.00004622165],"domain_scores_gemma":[0.9985586,0.00035605035,0.00065570325,0.00003634587,0.00007878467,0.0003146105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000443534,0.0001706271,0.00029275758,0.00035881103,0.00022739476,0.0004200229,0.00013936193,0.00022384922,0.00089725124],"category_scores_gemma":[0.0015451896,0.00008355411,0.00029352447,0.00038717224,0.0002056818,0.00038317798,0.0002671446,0.00045095928,0.000118095864],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004906814,0.000042429067,0.99434423,0.00000678641,0.000032878288,0.00016737786,0.000022200467,0.00010669585,0.00048524278,0.000009921696,0.000050372262,0.004241212],"study_design_scores_gemma":[0.000012889534,0.0005864934,0.9974107,0.000005378561,0.000053159165,0.0009531955,0.00006887355,0.000470412,0.00027630356,0.000037369202,0.00012152922,0.0000037188508],"about_ca_topic_score_codex":0.00049855106,"about_ca_topic_score_gemma":0.00092320784,"teacher_disagreement_score":0.00089725124,"about_ca_system_score_codex":0.00022055126,"about_ca_system_score_gemma":0.00020701597,"threshold_uncertainty_score":0.0030016303},"labels":[],"label_agreement":null},{"id":"W2140652862","doi":"10.1080/10428190310001593120","title":"The Spectrum of Lymphoma with 8q24 Aberrations: A Clinical, Pathological and Cytogenetic Study of 87 Consecutive Cases","year":2003,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Croucher Foundation","keywords":"Lymphoma; Mantle cell lymphoma; Follicular lymphoma; Medicine; Chromosomal translocation; Pathology; Burkitt's lymphoma; Internal medicine; Gastroenterology; Oncology; Biology","score_opus":0.027477785139627432,"score_gpt":0.2930685879245135,"score_spread":0.26559080278488606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140652862","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.999225,0.0002661798,0.0001311011,0.000012313406,0.0000015149207,0.000018396908,0.00008156648,0.000005008685,0.00025899513],"genre_scores_gemma":[0.9992066,0.00018050411,0.0001768932,0.000018124678,0.000010064868,0.000025325891,0.00027285554,0.0000031199734,0.000106657295],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994972,0.00006630003,0.00006963083,0.0001243033,0.00012480386,0.00011790775],"domain_scores_gemma":[0.9992404,0.00018408292,0.0002196919,0.0000725098,0.00011291625,0.00017043324],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000426304,0.0003250526,0.0003866273,0.0011680818,0.0005248939,0.0003665651,0.00034036525,0.00037994303,0.0011619827],"category_scores_gemma":[0.001707296,0.00034544597,0.00021907056,0.0008562094,0.0004547169,0.0004133754,0.00061294384,0.0002846197,0.0004528098],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012431254,0.000050431572,0.9840746,0.00001936058,0.000014079199,0.008225641,0.00040738465,0.00006201858,0.0017315135,0.000020917614,0.0001230601,0.005146589],"study_design_scores_gemma":[0.0000150432425,0.00022174146,0.96673733,0.000010933989,0.000019812553,0.031197079,0.00046162627,0.0001982069,0.0004002845,0.00003178413,0.0006981695,0.00000794858],"about_ca_topic_score_codex":0.0021185926,"about_ca_topic_score_gemma":0.002066584,"teacher_disagreement_score":0.0021185926,"about_ca_system_score_codex":0.0003520823,"about_ca_system_score_gemma":0.00030493233,"threshold_uncertainty_score":0.0042124987},"labels":[],"label_agreement":null},{"id":"W2140880663","doi":"10.1080/10428190701321277","title":"Clinical progression and outcome of patients with monoclonal B-cell lymphocytosis","year":2007,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Lymphocytosis; Chronic lymphocytic leukemia; Medicine; Stage (stratigraphy); Internal medicine; Organomegaly; Gastroenterology; Immunophenotyping; Fludarabine; Monoclonal; Leukemia; Immunology; Disease; Cyclophosphamide; Chemotherapy; Monoclonal antibody; Antigen; Antibody","score_opus":0.017757468983474342,"score_gpt":0.32059903198838025,"score_spread":0.3028415630049059,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140880663","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99888486,0.00050107396,0.00004007156,0.000033936758,0.00000533335,0.000004719191,0.00010656522,0.0000050711965,0.00041842746],"genre_scores_gemma":[0.9994398,0.00009758659,0.000017321969,0.000027377828,0.000010244953,0.000005945314,0.00028944848,0.000001177175,0.000111021254],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997565,0.00006164808,0.000021173168,0.00004411769,0.000035496854,0.000080987906],"domain_scores_gemma":[0.9990227,0.00019448568,0.00032828428,0.000041929114,0.00009685988,0.0003156558],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032927134,0.00018779331,0.00037356513,0.00034405602,0.00038439615,0.0005759493,0.000208082,0.00041587756,0.0006366601],"category_scores_gemma":[0.0020290387,0.000116895484,0.00032768364,0.00037830722,0.00025874397,0.00032594538,0.0002359643,0.00044942272,0.000286818],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016261073,0.00010824294,0.98830986,0.000014159292,0.00005644833,0.0007173309,0.000117512405,0.00025254875,0.0008975833,0.000028231203,0.00028313723,0.0075889225],"study_design_scores_gemma":[0.000096858086,0.0017651967,0.9932653,0.000014762047,0.000063416555,0.003307581,0.00011720277,0.00047284592,0.0002465939,0.00010118851,0.00053626316,0.000012852793],"about_ca_topic_score_codex":0.001132549,"about_ca_topic_score_gemma":0.0010492456,"teacher_disagreement_score":0.001132549,"about_ca_system_score_codex":0.00035295877,"about_ca_system_score_gemma":0.0002046897,"threshold_uncertainty_score":0.0025609732},"labels":[],"label_agreement":null},{"id":"W2141079126","doi":"10.3109/10428191003695652","title":"Gastrointestinal complications in children with acute myeloid leukemia","year":2010,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; SickKids Foundation; Hospital for Sick Children","funders":"","keywords":"Medicine; Etiology; Gastrointestinal cancer; Necrotizing enterocolitis; Gastrointestinal bleeding; Enterocolitis; Myeloid leukemia; Internal medicine; Randomized controlled trial; Intensive care medicine; Natural history; Pediatrics; Colorectal cancer; Cancer","score_opus":0.01586547505808435,"score_gpt":0.28214479965224043,"score_spread":0.2662793245941561,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141079126","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001754605,0.9996363,0.0000065473355,0.00003408936,0.000019923269,0.000003109167,0.000011399377,9.990233e-7,0.00011219442],"genre_scores_gemma":[0.0012410267,0.99855727,0.00004190075,0.00006490767,0.000026859681,0.0000058077558,0.000015136723,2.9183335e-7,0.000046794376],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99946314,0.00013079186,0.00018383375,0.000054583554,0.00013692054,0.000030784406],"domain_scores_gemma":[0.9985808,0.0008083548,0.00043567526,0.000014602627,0.00012378296,0.000036782214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068623683,0.0006672035,0.0021738613,0.0040884134,0.00026265343,0.0008612079,0.00056151993,0.0008112566,0.0024821882],"category_scores_gemma":[0.0024995487,0.0003103974,0.0010226186,0.005835367,0.00035059347,0.0010725023,0.00052810047,0.00064089574,0.0003575171],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021753836,0.00004415595,0.0030044995,0.27195254,0.00085827307,0.0008146995,0.00023649806,0.00015095857,0.00041353953,0.00050964527,0.0127166305,0.709081],"study_design_scores_gemma":[0.00032602626,0.00057636143,0.051295344,0.37079564,0.00979141,0.026350025,0.0012149841,0.0001721454,0.0007570874,0.0012352259,0.5373966,0.00008924315],"about_ca_topic_score_codex":0.0034480237,"about_ca_topic_score_gemma":0.007280292,"teacher_disagreement_score":0.0040884134,"about_ca_system_score_codex":0.00069250143,"about_ca_system_score_gemma":0.0017097043,"threshold_uncertainty_score":0.008303702},"labels":[],"label_agreement":null},{"id":"W2141117691","doi":"10.3109/10428190903308064","title":"Early detection of patients with poor risk diffuse large B-cell lymphoma","year":2009,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Rituximab; Medicine; Diffuse large B-cell lymphoma; Vincristine; International Prognostic Index; Prednisone; Internal medicine; Lymphoma; Oncology; Context (archaeology); CHOP; Cyclophosphamide; Clinical trial; Chemotherapy; Biology","score_opus":0.008167993805071017,"score_gpt":0.23357155439725139,"score_spread":0.22540356059218036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141117691","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019009267,0.9989592,0.000085443775,0.00016651547,0.000070589034,0.000004019379,0.000014498322,0.000005419436,0.0005041854],"genre_scores_gemma":[0.0012428426,0.9981142,0.00017253432,0.00012477936,0.0000580097,0.0000058296114,0.000035280962,9.969448e-7,0.00024547527],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998337,0.000048877202,0.0000264882,0.000028385999,0.000048706574,0.000013804289],"domain_scores_gemma":[0.9997397,0.00011969378,0.000045638688,0.000007961635,0.00006461394,0.000022372866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053432275,0.0007214335,0.0021604192,0.0017018223,0.00014881066,0.0005775162,0.0008409406,0.0007438435,0.00305416],"category_scores_gemma":[0.00087144086,0.00020844876,0.00044305561,0.0015356761,0.0003358904,0.00087910896,0.00038464135,0.0008836005,0.0020403487],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008614967,0.00003619219,0.0005033205,0.0122742085,0.00008778232,0.00025916018,0.000034231256,0.00011455645,0.0006166844,0.0005185505,0.017606549,0.96786267],"study_design_scores_gemma":[0.00014112871,0.00027463524,0.010370651,0.015069523,0.0006987234,0.009896312,0.00021972285,0.00015025781,0.0010688332,0.0020844396,0.9599843,0.00004136415],"about_ca_topic_score_codex":0.0010623271,"about_ca_topic_score_gemma":0.001851276,"teacher_disagreement_score":0.00305416,"about_ca_system_score_codex":0.00036039966,"about_ca_system_score_gemma":0.00067374605,"threshold_uncertainty_score":0.010217249},"labels":[],"label_agreement":null},{"id":"W2141817010","doi":"10.3109/10428194.2013.850685","title":"Early deaths in pediatric acute leukemia: a population-based study","year":2013,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; Hospital for Sick Children; Pediatric Oncology Group; University of Toronto","funders":"Canadian Institutes of Health Research; McMaster University","keywords":"Medicine; Myeloid leukemia; Incidence (geometry); Pediatrics; Retrospective cohort study; Population; Acute leukemia; Leukemia; Lymphoblastic Leukemia; Cohort; Internal medicine","score_opus":0.009866601174023082,"score_gpt":0.2582252562685282,"score_spread":0.24835865509450514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141817010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99791867,0.00022800619,0.000056379165,0.000043524957,0.0000025154773,0.000020903966,0.0013167758,0.0000028944958,0.00041029885],"genre_scores_gemma":[0.9981413,0.0004222874,0.000087762484,0.000028921404,0.000006631167,0.00002153025,0.0011626097,0.0000016787094,0.00012731427],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99952257,0.00005288232,0.000036556736,0.00008306935,0.00015399256,0.0001509657],"domain_scores_gemma":[0.99920505,0.00006866288,0.0003849114,0.00003910212,0.00015679245,0.00014562682],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003814533,0.0002802123,0.00030601397,0.0009912986,0.0006296181,0.00059099286,0.0005228307,0.00032001227,0.0009515597],"category_scores_gemma":[0.0011754027,0.00027776256,0.0003637123,0.0021760727,0.00028352713,0.00052423845,0.00043415907,0.00047546756,0.00014135729],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001750537,0.000011186099,0.9992061,0.0000059359254,0.000012018926,0.000048984984,0.00008309145,0.000022225919,0.000032953896,0.000007890537,0.00007193051,0.00048001396],"study_design_scores_gemma":[0.0000032191335,0.000024212724,0.9993882,0.000005631573,0.0000071096124,0.00011138797,0.00019540064,0.000045250683,0.000012069938,0.0000053117074,0.00020025797,0.0000018679324],"about_ca_topic_score_codex":0.45377833,"about_ca_topic_score_gemma":0.6093296,"teacher_disagreement_score":0.45377833,"about_ca_system_score_codex":0.003075858,"about_ca_system_score_gemma":0.0027001128,"threshold_uncertainty_score":0.9022741},"labels":[],"label_agreement":null},{"id":"W2141969313","doi":"10.3109/10428194.2010.499978","title":"Proton therapy for Hodgkin lymphoma: does a case report make the case?","year":2010,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Advanced Radiotherapy Techniques","field":"Physics and Astronomy","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Public Health Ontario","funders":"","keywords":"Hodgkin lymphoma; Proton therapy; Medicine; Lymphoma; Oncology; Internal medicine; Cancer research; Radiation therapy","score_opus":0.009408159501526216,"score_gpt":0.2614440209089707,"score_spread":0.25203586140744444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141969313","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.20389327,0.050011147,0.008606117,0.61124194,0.03162002,0.00047418266,0.0006680523,0.00087624055,0.09260911],"genre_scores_gemma":[0.74449354,0.029192252,0.0077382587,0.10273112,0.09765643,0.00024380148,0.00032514072,0.00019120837,0.01742822],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99867517,0.0002831575,0.00017167199,0.0002915739,0.00021584466,0.0003625199],"domain_scores_gemma":[0.9960096,0.0019889094,0.00066201866,0.0003679881,0.00037750718,0.00059398235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011711306,0.0022062308,0.0019038544,0.0022884563,0.003742139,0.003099797,0.0029678138,0.029895894,0.006533908],"category_scores_gemma":[0.009493516,0.0014234532,0.0025743076,0.0017964852,0.0029987865,0.008399114,0.0016629694,0.011320578,0.0041715833],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024476372,0.00003737052,0.0012273801,0.000060518047,0.000012430026,0.98948646,0.00011332935,0.000076372955,0.00016101466,0.0006878006,0.0060990257,0.0020137518],"study_design_scores_gemma":[0.000022953582,0.00003029902,0.00072594034,0.000052321517,0.00001910179,0.9933342,0.00023143044,0.0002781788,0.00008715858,0.0010817971,0.004119712,0.000016757731],"about_ca_topic_score_codex":0.0025981958,"about_ca_topic_score_gemma":0.003388886,"teacher_disagreement_score":0.029895894,"about_ca_system_score_codex":0.002767926,"about_ca_system_score_gemma":0.0012815197,"threshold_uncertainty_score":0.021858156},"labels":[],"label_agreement":null},{"id":"W2142330668","doi":"10.3109/10428194.2014.894190","title":"Prolonged progression-free survival and preserved quality of life in the Canadian prospective study of tositumomab and iodine<sup>131</sup>-tositumomab for previously treated, rituximab-exposed, indolent non-Hodgkin lymphoma","year":2014,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; London Health Sciences Centre; University of Calgary; GlaxoSmithKline (Canada); Centre Hospitalier de l’Université de Montréal","funders":"GlaxoSmithKline","keywords":"Medicine; Internal medicine; Rituximab; Radioimmunotherapy; Oncology; Adverse effect; Lymphoma; Gastroenterology; Immunology; Antibody; Monoclonal antibody","score_opus":0.021871265829693374,"score_gpt":0.27748041892764,"score_spread":0.25560915309794663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142330668","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99942136,0.00017263164,0.000016967027,0.00003528962,0.0000023124867,0.000012893071,0.00013224341,0.0000014932315,0.00020492285],"genre_scores_gemma":[0.99944836,0.000059690305,0.000029641053,0.000045049816,0.0000040369246,0.0000051426355,0.0002924,9.1526044e-7,0.00011477409],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99961615,0.000051990417,0.000019619585,0.000042732558,0.00012957117,0.00013996802],"domain_scores_gemma":[0.999151,0.0000614383,0.00023673198,0.000030643005,0.00017286281,0.0003473435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006134663,0.00033545456,0.00034990197,0.0003516732,0.0010124355,0.00074088713,0.00044468677,0.00036734436,0.00067779724],"category_scores_gemma":[0.0010005758,0.000231238,0.00048232672,0.0007554096,0.0004184583,0.0002357102,0.00031014383,0.00063388166,0.00008286774],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013219818,0.00015649301,0.9942363,0.00001436264,0.000091676775,0.00018231235,0.0001851507,0.00008380415,0.0007803558,0.000020285383,0.00018621174,0.0027412365],"study_design_scores_gemma":[0.000059194706,0.0003639072,0.99876285,0.000003560921,0.00003700786,0.00016976292,0.00009062523,0.00013930546,0.00006041751,0.000007357236,0.00030132823,0.000004717315],"about_ca_topic_score_codex":0.4079562,"about_ca_topic_score_gemma":0.49641138,"teacher_disagreement_score":0.59204376,"about_ca_system_score_codex":0.00340017,"about_ca_system_score_gemma":0.0036336482,"threshold_uncertainty_score":0.8111633},"labels":[],"label_agreement":null},{"id":"W2142822429","doi":"10.1080/1042819031000067530","title":"Intravascular Lymphoma Presenting with Bone Marrow Involvement and Leukemic Phase","year":2003,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"CNS Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Pancytopenia; Bone marrow; Pathology; Medicine; CD5; Lymphoma; Intravascular large B-cell lymphoma; Leukemia; Immunocytochemistry; Immunology","score_opus":0.011142118670850744,"score_gpt":0.2396114841933541,"score_spread":0.22846936552250335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142822429","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9773926,0.004997856,0.0021366628,0.0010401476,0.00015348938,0.0001455383,0.00022211483,0.00016328359,0.0137481615],"genre_scores_gemma":[0.9959894,0.0013288027,0.00064654433,0.00048449045,0.0002832856,0.000018690005,0.000095808646,0.000012004685,0.001141051],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9997961,0.00002208067,0.0000145155345,0.000045918845,0.00002266247,0.00009872757],"domain_scores_gemma":[0.9995789,0.0000966011,0.000105893785,0.000031955795,0.00002685823,0.00015982623],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015646902,0.0014194571,0.00068254065,0.0012135751,0.0011214713,0.00084387575,0.00046043776,0.0020394868,0.0027562014],"category_scores_gemma":[0.0011986821,0.0005528735,0.00031861468,0.0010075629,0.0005815479,0.0008528726,0.00088867755,0.001313114,0.001082771],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000057071535,0.00003800812,0.011527558,0.000030596122,0.0000047795024,0.9848579,0.00013899175,0.00003946449,0.0009983414,0.00014567446,0.00021388961,0.001947671],"study_design_scores_gemma":[0.000018989764,0.000075215205,0.0047221864,0.000010629925,0.000010719776,0.9938897,0.00008598477,0.00012306064,0.00023435112,0.00014297957,0.00068123976,0.0000049056766],"about_ca_topic_score_codex":0.0013203191,"about_ca_topic_score_gemma":0.0018408614,"teacher_disagreement_score":0.0027562014,"about_ca_system_score_codex":0.00032298907,"about_ca_system_score_gemma":0.00041181647,"threshold_uncertainty_score":0.009220421},"labels":[],"label_agreement":null},{"id":"W2143651540","doi":"10.3109/10428194.2015.1034699","title":"Isolated<i>MYC</i>cytogenetic abnormalities in diffuse large B-cell lymphoma do not predict an adverse clinical outcome","year":2015,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"BCL6; Fluorescence in situ hybridization; Lymphoma; Diffuse large B-cell lymphoma; Internal medicine; Medicine; Oncology; Cancer research; Biology; B cell; Immunology; Gene; Genetics","score_opus":0.03735700249744781,"score_gpt":0.3056437599755823,"score_spread":0.26828675747813446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143651540","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99960345,0.00009604971,0.000057349964,0.000011774987,0.000002369442,0.0000013758787,0.000036706286,0.000002010971,0.00018898644],"genre_scores_gemma":[0.9998332,0.000022881242,0.000023346201,0.000007647959,0.000004188511,9.470192e-7,0.00007783834,7.8790725e-7,0.000029036562],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998246,0.00003626038,0.000020794047,0.000039945196,0.000035528366,0.000042989694],"domain_scores_gemma":[0.99883384,0.0002948873,0.00044204883,0.00006734448,0.000093123905,0.0002687136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026852943,0.00017402136,0.00021483796,0.00043144825,0.00020468306,0.00036212217,0.00015386844,0.00026405274,0.0010267666],"category_scores_gemma":[0.0014748697,0.00010955183,0.0001382587,0.0002593847,0.00031350585,0.00024329686,0.00021693691,0.00027005424,0.00020571829],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014775031,0.000008368245,0.997526,0.0000030262174,0.000011902674,0.00015864738,0.000016808768,0.000032937005,0.0009591653,0.000005990722,0.000025285293,0.0011041126],"study_design_scores_gemma":[0.000008636938,0.00017678071,0.99683666,0.0000027446445,0.000022371152,0.0021829954,0.00009182499,0.0001842395,0.0003215352,0.000031661137,0.00013790902,0.0000025519912],"about_ca_topic_score_codex":0.00074475893,"about_ca_topic_score_gemma":0.0011501274,"teacher_disagreement_score":0.0010267666,"about_ca_system_score_codex":0.000102848586,"about_ca_system_score_gemma":0.00012631128,"threshold_uncertainty_score":0.0034348965},"labels":[],"label_agreement":null},{"id":"W2145001558","doi":"10.3109/10428194.2012.719615","title":"Treatment response and overall outcome of patients with relapsed and refractory peripheral T-cell lymphoma compared to diffuse large B-cell lymphoma","year":2012,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Etoposide; Lymphoma; Diffuse large B-cell lymphoma; Cytarabine; Chemotherapy; Autologous stem-cell transplantation; Gastroenterology; Peripheral T-cell lymphoma; Cohort; Oncology; Salvage therapy; Immunology; T cell","score_opus":0.010972065217812627,"score_gpt":0.2393099212090804,"score_spread":0.22833785599126777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145001558","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9995999,0.00019594144,0.000029154997,0.00001182906,0.0000017224603,0.0000035536048,0.00005231884,0.000001778814,0.000103901686],"genre_scores_gemma":[0.99965644,0.00005047397,0.00002124785,0.00001913517,0.000008851062,0.0000050007175,0.0001972024,0.0000011488307,0.000040485786],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999617,0.00013396802,0.000050110153,0.000093062365,0.00005164819,0.000054218897],"domain_scores_gemma":[0.998971,0.00027383037,0.0004425955,0.00006541371,0.00007918653,0.00016796468],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005498876,0.00019858067,0.00048328508,0.00059332914,0.00017865961,0.00041319634,0.00021234082,0.00037011728,0.0006246137],"category_scores_gemma":[0.001950355,0.000090112415,0.00033623737,0.00045295144,0.0002361741,0.00030378762,0.0002928553,0.00028703245,0.00020062238],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001202579,0.000070807335,0.99215066,0.000018223214,0.0001011854,0.00029347485,0.00009641035,0.00018630768,0.0011882472,0.00000954977,0.00006359277,0.0046188985],"study_design_scores_gemma":[0.000049531038,0.001146495,0.99596405,0.0000067327683,0.000065618464,0.0017324539,0.0001451138,0.00046818095,0.0002373283,0.000021621592,0.00015696094,0.000005922695],"about_ca_topic_score_codex":0.0005551748,"about_ca_topic_score_gemma":0.00061153056,"teacher_disagreement_score":0.0006246137,"about_ca_system_score_codex":0.00025707358,"about_ca_system_score_gemma":0.0001223441,"threshold_uncertainty_score":0.0029081106},"labels":[],"label_agreement":null},{"id":"W2145186497","doi":"10.3109/10428194.2015.1026901","title":"Treatment of patients with secondary central nervous system lymphoma with high-dose busulfan/thiotepa-based conditioning and autologous stem cell transplant","year":2015,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"CNS Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; University of Calgary","funders":"","keywords":"ThioTEPA; Busulfan; Medicine; Regimen; Cyclophosphamide; Surgery; Melphalan; Rituximab; Autologous stem-cell transplantation; Chemotherapy; Lymphoma; Internal medicine; Oncology","score_opus":0.0074405407810333515,"score_gpt":0.19377833841580097,"score_spread":0.18633779763476763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145186497","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99768627,0.00068763795,0.00032666477,0.00008951733,0.000008404255,0.000038578844,0.000029008883,0.000015825479,0.0011180119],"genre_scores_gemma":[0.99889165,0.0002513079,0.00040888588,0.000070484835,0.000019843279,0.000017332623,0.0001678378,0.000002384642,0.00017027289],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99991846,0.00002423807,0.000006273123,0.000011008634,0.000019058458,0.000020933578],"domain_scores_gemma":[0.99984324,0.000026283371,0.00004080192,0.000010657366,0.000012831305,0.000066216555],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017536542,0.00014979269,0.00027014076,0.0002047022,0.00026063484,0.00022489339,0.0001525433,0.00012657302,0.00082669547],"category_scores_gemma":[0.00042698113,0.000056110326,0.00019803458,0.00024364622,0.0002696719,0.00009957779,0.00021776608,0.00026819913,0.0001588245],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034047146,0.0009905285,0.8508518,0.000109346154,0.00015729516,0.0035447555,0.00038841146,0.0011742844,0.02064039,0.00011229442,0.0009815154,0.11764469],"study_design_scores_gemma":[0.0005797271,0.008752216,0.9660881,0.00004175148,0.00014810586,0.011862307,0.00032920213,0.0015460185,0.0064975885,0.00018752123,0.0039560716,0.000011345359],"about_ca_topic_score_codex":0.00406028,"about_ca_topic_score_gemma":0.015579778,"teacher_disagreement_score":0.00406028,"about_ca_system_score_codex":0.00053101365,"about_ca_system_score_gemma":0.0007413978,"threshold_uncertainty_score":0.00807327},"labels":[],"label_agreement":null},{"id":"W2146054188","doi":"10.3109/10428194.2014.944519","title":"Skeletal, neuromuscular and fitness impairments among children with newly diagnosed acute lymphoblastic leukemia","year":2014,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":111,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto","funders":"National Cancer Institute","keywords":"Medicine; Percentile; Confidence interval; Bone mineral; Rehabilitation; Weakness; Physical therapy; Quality of life (healthcare); Internal medicine; Lymphoblastic Leukemia; Body mass index; Logistic regression; Pediatrics; Surgery; Leukemia; Osteoporosis","score_opus":0.006386891828701512,"score_gpt":0.23106590579247213,"score_spread":0.22467901396377063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146054188","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99945897,0.00024140113,0.000019499477,0.000020282901,0.0000024159733,0.0000024461172,0.0001385547,0.000002025774,0.00011438805],"genre_scores_gemma":[0.99947935,0.00017195792,0.00002701448,0.000010195766,0.000005051729,0.0000038274693,0.0002498301,8.779946e-7,0.000051915133],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999501,0.00010707811,0.000060244707,0.00007667196,0.0001348124,0.00012015303],"domain_scores_gemma":[0.99887997,0.00021041477,0.0006215206,0.00003278755,0.000085503845,0.00016972116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049579464,0.00035009047,0.0003748083,0.0008406018,0.00033447242,0.0005576956,0.0002982532,0.00033418203,0.00051249407],"category_scores_gemma":[0.0018659693,0.00018671613,0.00036110933,0.00080177636,0.00039514044,0.00050709175,0.0005837632,0.00045316928,0.00012399943],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027263226,0.000011346194,0.99917823,0.000004748019,0.000010356633,0.00006377339,0.000036118046,0.000025845904,0.000033903303,0.0000028820307,0.000024644676,0.00058094773],"study_design_scores_gemma":[0.0000021581618,0.00006572369,0.9993723,0.0000028878628,0.000008773945,0.0003530923,0.00009832347,0.000033468164,0.00001690113,0.0000035833289,0.00004166424,0.0000011423215],"about_ca_topic_score_codex":0.007968596,"about_ca_topic_score_gemma":0.009491508,"teacher_disagreement_score":0.007968596,"about_ca_system_score_codex":0.00044536233,"about_ca_system_score_gemma":0.00030336302,"threshold_uncertainty_score":0.015844464},"labels":[],"label_agreement":null},{"id":"W2146651952","doi":"10.3109/10428194.2012.731599","title":"Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies","year":2012,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network","funders":"","keywords":"Chronic lymphocytic leukemia; Medicine; ROR1; Cancer research; Follicular lymphoma; Lymphoma; Mantle cell lymphoma; Leukemia; Internal medicine; Receptor; Platelet-derived growth factor receptor","score_opus":0.020076497107328888,"score_gpt":0.27465724116146906,"score_spread":0.25458074405414016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146651952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88657176,0.1079272,0.00083786837,0.00042953526,0.00003529371,0.000014772897,0.00013640776,0.00002932779,0.004017915],"genre_scores_gemma":[0.9861545,0.012052314,0.00053363084,0.000065214386,0.00007349375,0.000009779654,0.00015369228,0.0000033766491,0.00095393084],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998385,0.000052792897,0.000014856847,0.000028449986,0.000031360327,0.0000340305],"domain_scores_gemma":[0.99988914,0.000025251033,0.00004285341,0.000009340129,0.000013165502,0.00002019395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028894728,0.00015620174,0.00018249097,0.00064115395,0.00016153764,0.00034480257,0.00013134492,0.0002876894,0.00095866347],"category_scores_gemma":[0.00036574618,0.00009161186,0.00012617199,0.0004704366,0.00026776706,0.00029878796,0.00025264831,0.00027898155,0.00020154305],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018479296,0.000121421326,0.42363706,0.001002254,0.00013478713,0.0071945726,0.000621445,0.0010621564,0.33133295,0.0019003708,0.0018909638,0.22925408],"study_design_scores_gemma":[0.00009263587,0.00082712906,0.8756215,0.00023679592,0.00023153482,0.04056547,0.00063999876,0.0015118873,0.031056946,0.0011778217,0.048007086,0.00003122916],"about_ca_topic_score_codex":0.0010455955,"about_ca_topic_score_gemma":0.0010151404,"teacher_disagreement_score":0.0010455955,"about_ca_system_score_codex":0.0002958093,"about_ca_system_score_gemma":0.00019227882,"threshold_uncertainty_score":0.003207028},"labels":[],"label_agreement":null},{"id":"W2147655719","doi":"10.3109/10428194.2012.723210","title":"Emergence of carbapenem-resistant Enterobacteriaceae as causes of bloodstream infections in patients with hematologic malignancies","year":2012,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Antibiotic Resistance in Bacteria","field":"Biochemistry, Genetics and Molecular Biology","cited_by":123,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; National Institutes of Health; Sick Kids Foundation","keywords":"Klebsiella pneumoniae; Carbapenem-resistant enterobacteriaceae; Pulsed-field gel electrophoresis; Enterobacter cloacae; Microbiology; Population; Medicine; Fungemia; Carbapenem; Biology; Antibiotics; Genotype; Escherichia coli; Gene","score_opus":0.0047940171867644965,"score_gpt":0.21038817693394263,"score_spread":0.20559415974717812,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147655719","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998418,0.0010535754,0.00008783211,0.0000679635,0.000005559849,0.0000058980595,0.000057438076,0.0000054372895,0.00029828434],"genre_scores_gemma":[0.9994043,0.00029847393,0.00008784002,0.00004440847,0.000021335682,0.0000029771122,0.00008661949,0.0000016456139,0.00005247008],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994916,0.00010528772,0.00007229876,0.00010028293,0.00010534949,0.00012518605],"domain_scores_gemma":[0.9975169,0.00047221358,0.001220625,0.00010272749,0.00022945082,0.0004580069],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004606463,0.00024006882,0.00038982547,0.00073903997,0.00047195744,0.00089816615,0.00026396263,0.0005414883,0.0011398136],"category_scores_gemma":[0.00280917,0.0002251485,0.00028836605,0.0010710434,0.00037544165,0.000769525,0.00041830173,0.0006222127,0.00022989567],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000048304588,0.000013155798,0.9968375,0.00000811055,0.000007687238,0.0007566659,0.00008931605,0.000021699037,0.00030013532,0.000010403729,0.000046841997,0.0018601087],"study_design_scores_gemma":[0.0000073960664,0.00016052468,0.9927079,0.000019452249,0.000024701472,0.005770419,0.00044324037,0.00020500035,0.00022078988,0.00003194103,0.00040210877,0.000006561932],"about_ca_topic_score_codex":0.0018504056,"about_ca_topic_score_gemma":0.0013492403,"teacher_disagreement_score":0.0018504056,"about_ca_system_score_codex":0.00042256428,"about_ca_system_score_gemma":0.00042484413,"threshold_uncertainty_score":0.003813088},"labels":[],"label_agreement":null},{"id":"W2148047768","doi":"10.3109/10428194.2012.740558","title":"Clinical characteristics and outcome associated with pandemic (2009) H1N1 influenza infection in patients with hematologic malignancies: a retrospective cohort study","year":2012,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Influenza Virus Research Studies","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Mount Sinai Hospital; University of Toronto","funders":"","keywords":"Medicine; Hematologic malignancy; Malignancy; Internal medicine; Retrospective cohort study; Hematological malignancy; Cohort; Immunology; Gastroenterology","score_opus":0.0409784437075487,"score_gpt":0.33538123134180386,"score_spread":0.29440278763425515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148047768","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9994954,0.000106180305,0.000028592409,0.00001100699,0.0000031420454,0.000009438294,0.00017372558,0.0000012826282,0.00017125336],"genre_scores_gemma":[0.99955314,0.000066187305,0.000030212295,0.000014843772,0.000006961822,0.000009808561,0.00027662996,0.0000011099859,0.00004111251],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995154,0.00009078082,0.000075317526,0.00012704046,0.00009016047,0.000101213074],"domain_scores_gemma":[0.99884427,0.00017227497,0.00046738042,0.00009572228,0.00012319055,0.00029712642],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047778917,0.00026937484,0.00055774185,0.0007727001,0.0005634028,0.0006410051,0.00030962154,0.00053187733,0.0011583809],"category_scores_gemma":[0.001508162,0.0003819058,0.0005433091,0.001047165,0.00030561863,0.00060929713,0.0004946742,0.00061311125,0.00023901957],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006367891,0.000024052999,0.99941397,0.0000031308127,0.000018514327,0.0001424875,0.000034031145,0.000010776388,0.000097431664,0.0000038891794,0.000025881876,0.00016209096],"study_design_scores_gemma":[0.0000064674628,0.00018036358,0.9986696,0.000003841849,0.000017099532,0.000757898,0.00019477177,0.000058868645,0.000030762956,0.0000063443977,0.00007065274,0.0000033884448],"about_ca_topic_score_codex":0.003797182,"about_ca_topic_score_gemma":0.003179363,"teacher_disagreement_score":0.003797182,"about_ca_system_score_codex":0.00037997618,"about_ca_system_score_gemma":0.00036065193,"threshold_uncertainty_score":0.0075501204},"labels":[],"label_agreement":null},{"id":"W2148153235","doi":"10.1080/1042819031000139774","title":"Rescue of Interferon Induced Bone Marrow Aplasia in a Patient with Chronic Myeloid Leukemia by Allogeneic Bone Marrow Transplant","year":2003,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Markham Stouffville Hospital; University Health Network; University of Toronto","funders":"","keywords":"Medicine; Bone marrow; Aplasia; Prednisone; Bone Marrow Aplasia; Complication; Hypoplasia; Myeloid leukemia; Immunology; Chronic myelogenous leukemia; Philadelphia chromosome; Leukemia; Gastroenterology; Internal medicine; Chromosomal translocation; Biology","score_opus":0.008472961117209849,"score_gpt":0.2164746803923874,"score_spread":0.20800171927517755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148153235","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939107,0.0011309711,0.0007527012,0.0011234274,0.000089060515,0.000040174313,0.00004901985,0.000043727574,0.0028601782],"genre_scores_gemma":[0.99812037,0.000338386,0.00026961995,0.00032768887,0.00006972003,0.000010224736,0.00007089283,0.000007642638,0.0007854028],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99991786,0.000019611549,0.000011710524,0.00001019876,0.000012890106,0.000027819668],"domain_scores_gemma":[0.9997675,0.000072598574,0.00003679766,0.000023986267,0.0000119774695,0.00008725224],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020044454,0.0003247447,0.00033931553,0.00019104035,0.0004955298,0.00029921214,0.00020427849,0.0008185293,0.00085063744],"category_scores_gemma":[0.0010405965,0.0001446123,0.00032289178,0.00012497876,0.0002126143,0.00018690155,0.00023247839,0.0011454364,0.00033290565],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004057833,0.0009688617,0.070216484,0.00019279649,0.00013006965,0.8019384,0.0011204992,0.0009854822,0.057468824,0.0016613703,0.0021253768,0.059133977],"study_design_scores_gemma":[0.0011546159,0.0056205303,0.064812355,0.000069479276,0.00015413447,0.8966037,0.00019741472,0.0027678807,0.018427344,0.0010110058,0.009156164,0.000025269323],"about_ca_topic_score_codex":0.00035541286,"about_ca_topic_score_gemma":0.0005755841,"teacher_disagreement_score":0.00085063744,"about_ca_system_score_codex":0.00029228124,"about_ca_system_score_gemma":0.00027264262,"threshold_uncertainty_score":0.0028457046},"labels":[],"label_agreement":null},{"id":"W2148893624","doi":"10.3109/10428190903275586","title":"Lysophosphatidic acid receptor expression in chronic lymphocytic leukemia leads to cell survival mediated though vascular endothelial growth factor expression","year":2009,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba; Research Manitoba","funders":"CancerCare Manitoba Foundation; Manitoba Health Research Council; Friedreich's Ataxia Research Alliance","keywords":"Lysophosphatidic acid; Autocrine signalling; Chronic lymphocytic leukemia; Apoptosis; Receptor; Cancer research; Biology; Vascular endothelial growth factor; Endocrinology; Internal medicine; Leukemia; Immunology; Medicine; VEGF receptors; Biochemistry","score_opus":0.012765486987522282,"score_gpt":0.2597939234841367,"score_spread":0.24702843649661443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148893624","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982322,0.00088448875,0.00025824498,0.000044257344,0.00000712039,0.000004512079,0.00007984728,0.00001819959,0.00047112393],"genre_scores_gemma":[0.99832326,0.00047402977,0.00020022149,0.000020823583,0.0000052399605,0.000010619348,0.00023229822,0.0000033030055,0.000730222],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99987304,0.000028420598,0.0000108919385,0.000014574454,0.000021923839,0.000051209747],"domain_scores_gemma":[0.9999298,0.00001909016,0.000017292357,0.000007783624,0.000006147637,0.000019878493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013907345,0.00017291466,0.00013381218,0.00019364344,0.00014237835,0.00033031328,0.00008825864,0.00020809924,0.0021570318],"category_scores_gemma":[0.0001468778,0.00012428283,0.00014981469,0.00014236559,0.00016495814,0.00016585001,0.00013464977,0.000321799,0.00047598584],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034840824,0.00005228928,0.002303097,0.000040360923,0.000008829835,0.0002478972,0.000026563637,0.00003800887,0.99472934,0.00011391397,0.0001171446,0.0019742227],"study_design_scores_gemma":[0.00029559623,0.0020924313,0.06966992,0.00002917914,0.00010295281,0.005649236,0.00028049469,0.0018956254,0.90982753,0.00027778733,0.009865332,0.000013964567],"about_ca_topic_score_codex":0.00056940806,"about_ca_topic_score_gemma":0.0008548855,"teacher_disagreement_score":0.0021570318,"about_ca_system_score_codex":0.00029972632,"about_ca_system_score_gemma":0.00012431364,"threshold_uncertainty_score":0.0072159767},"labels":[],"label_agreement":null},{"id":"W2149077277","doi":"10.3109/10428194.2014.947607","title":"<i>DNMT3A</i>mutations and prognostic significance in childhood acute lymphoblastic leukemia","year":2014,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ministry of Education and Child Care","funders":"","keywords":"Exon; Mutation; Minimal residual disease; Intron; Coding region; Medicine; Lymphoblastic Leukemia; Biology; Cancer research; Genetics; Internal medicine; Leukemia; Molecular biology; Oncology; Gene","score_opus":0.0073971769516722515,"score_gpt":0.24177743551813394,"score_spread":0.2343802585664617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149077277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990552,0.0006335913,0.000041317628,0.000025653573,0.000001661455,0.000001425842,0.00009139874,0.0000031059196,0.00014668696],"genre_scores_gemma":[0.99940825,0.0003139873,0.00007414628,0.000009233159,0.000005164693,0.0000017199291,0.00014298968,0.0000018021075,0.00004262929],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997998,0.00005661817,0.000026303744,0.00003586734,0.00003966527,0.000041717973],"domain_scores_gemma":[0.9988431,0.00048251371,0.00041055752,0.00004353936,0.000057235062,0.00016305452],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036707794,0.00018942513,0.00024254207,0.0008906323,0.00025589296,0.00038497226,0.00015286102,0.00028023636,0.0007844536],"category_scores_gemma":[0.0018319321,0.00015785369,0.00013005092,0.00091495056,0.00038741317,0.00032371873,0.00021173107,0.00029337563,0.00018242748],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036680646,0.000008883589,0.99077296,0.000017999451,0.000026219286,0.00028428284,0.000060466726,0.000110789355,0.0025738473,0.000022097181,0.00007917124,0.005676468],"study_design_scores_gemma":[0.0000139457325,0.000100243466,0.995262,0.000010280242,0.000044424647,0.0025272134,0.00009781352,0.00025398788,0.0012515899,0.000069034046,0.0003648016,0.000004604915],"about_ca_topic_score_codex":0.002082832,"about_ca_topic_score_gemma":0.0027131566,"teacher_disagreement_score":0.002082832,"about_ca_system_score_codex":0.00031066086,"about_ca_system_score_gemma":0.0002257168,"threshold_uncertainty_score":0.0041413903},"labels":[],"label_agreement":null},{"id":"W2151599813","doi":"10.3109/10428194.2012.661854","title":"Bcl2-interacting killer CpG methylation in multiple myeloma: a potential predictor of relapsed/refractory disease with therapeutic implications","year":2012,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Methylation; CpG site; DNA methylation; Multiple myeloma; Disease; Medicine; Stage (stratigraphy); Gene silencing; Internal medicine; Cancer research; Epigenetics; Oncology; Immunology; Gastroenterology; Biology; Gene; Gene expression; Genetics","score_opus":0.020197574919612844,"score_gpt":0.275966272670074,"score_spread":0.2557686977504612,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151599813","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99882966,0.00077769597,0.000138508,0.000041737472,0.0000024938668,0.0000034624009,0.000056477907,0.0000044296776,0.00014545111],"genre_scores_gemma":[0.9996785,0.000115033734,0.00007148904,0.000010269843,0.0000072286803,0.0000017742286,0.000048803766,8.481352e-7,0.00006611875],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999864,0.000045812823,0.000013536098,0.000026743748,0.0000304618,0.000019322559],"domain_scores_gemma":[0.999483,0.00014096742,0.0002105926,0.000027408481,0.000039539187,0.00009851966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000401553,0.0001846266,0.00026568357,0.0005647242,0.00016572609,0.00022175466,0.00020035189,0.00030620716,0.0011632096],"category_scores_gemma":[0.00089977897,0.00011937606,0.00017497908,0.00057705655,0.00018838063,0.00017985626,0.00019351313,0.00032466793,0.00016875297],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00051836466,0.000023527135,0.9899469,0.00002028042,0.000029138624,0.00020098653,0.00004172462,0.00009179981,0.0034215103,0.000011833356,0.00005673255,0.0056370646],"study_design_scores_gemma":[0.000012513834,0.0002137615,0.99647254,0.000006672155,0.00004918413,0.0014316199,0.00008314127,0.00078564027,0.00063937035,0.000061004168,0.00024107836,0.0000034664467],"about_ca_topic_score_codex":0.00086426805,"about_ca_topic_score_gemma":0.00093493453,"teacher_disagreement_score":0.0011632096,"about_ca_system_score_codex":0.00011734132,"about_ca_system_score_gemma":0.00015502598,"threshold_uncertainty_score":0.0038913488},"labels":[],"label_agreement":null},{"id":"W2153978703","doi":"10.3109/10428194.2010.504872","title":"Prognostic implications of extranodal involvement in patients with diffuse large B-cell lymphoma treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone","year":2010,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Vincristine; Rituximab; Prednisone; International Prognostic Index; Internal medicine; Cyclophosphamide; CHOP; B symptoms; Diffuse large B-cell lymphoma; Lymphoma; Oncology; Anthracycline; Gastroenterology; Doxorubicin; Chemotherapy; Cancer","score_opus":0.004040064221313318,"score_gpt":0.2000309562857332,"score_spread":0.19599089206441989,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2153978703","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990433,0.00065395184,0.000030197372,0.000043103788,0.0000044113485,0.0000019931767,0.000030172183,0.0000021889723,0.0001906688],"genre_scores_gemma":[0.9996458,0.00013095746,0.000044734465,0.000021198483,0.000020172021,0.0000022554898,0.0000897926,9.892296e-7,0.000044081557],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996445,0.00012654187,0.00003891021,0.000056361478,0.000060847844,0.00007270798],"domain_scores_gemma":[0.9977652,0.00055039977,0.0010553972,0.00007489338,0.00011185803,0.0004422949],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042439156,0.00021799207,0.00037903374,0.0004934601,0.00021031198,0.0004507126,0.00037173383,0.0005230044,0.00062272476],"category_scores_gemma":[0.0023647905,0.00020499087,0.00026067285,0.00049791683,0.0004107665,0.00038979054,0.00030020135,0.0005248582,0.0001312191],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025763462,0.000015451857,0.9974477,0.000005305683,0.000019143905,0.00039389875,0.000019085664,0.000074117226,0.00033012044,0.0000049653595,0.000044724307,0.0013878094],"study_design_scores_gemma":[0.000020397261,0.00011782024,0.996375,0.000005317215,0.000027715232,0.0028531677,0.000058410522,0.00028543719,0.00010920372,0.00001634268,0.00012761718,0.0000035719343],"about_ca_topic_score_codex":0.0012447722,"about_ca_topic_score_gemma":0.0025171284,"teacher_disagreement_score":0.0012447722,"about_ca_system_score_codex":0.00034713015,"about_ca_system_score_gemma":0.00026678902,"threshold_uncertainty_score":0.0025186539},"labels":[],"label_agreement":null},{"id":"W2154423235","doi":"10.1080/10428190801910912","title":"Noxa mediates bortezomib induced apoptosis in both sensitive and intrinsically resistant mantle cell lymphoma cells and this effect is independent of constitutive activity of the AKT and NF-<b>kappa</b>B pathways","year":2008,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Institutes of Health","keywords":"Bortezomib; Proteasome inhibitor; Mantle cell lymphoma; Apoptosis; Protein kinase B; Cancer research; Proteasome; Downregulation and upregulation; Chemistry; Cell culture; Biology; Lymphoma; Multiple myeloma; Immunology; Biochemistry; Gene","score_opus":0.008174629035748681,"score_gpt":0.2006906936547852,"score_spread":0.19251606461903653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154423235","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98892933,0.00495596,0.0030804186,0.00008089035,0.0000276487,0.000044217948,0.00050314964,0.000103110564,0.0022751554],"genre_scores_gemma":[0.9937973,0.0016008067,0.0014783858,0.00006131395,0.000014984487,0.00005370098,0.0012271673,0.000017503027,0.0017489444],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99965394,0.00006834492,0.000039558134,0.000043384174,0.00013141354,0.000063322506],"domain_scores_gemma":[0.9998915,0.000015011255,0.000029028706,0.000022759872,0.000014348846,0.000027292683],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023299408,0.00030980428,0.0004075327,0.00025977375,0.00016375237,0.0003979146,0.0002284193,0.0002052739,0.0017899086],"category_scores_gemma":[0.00014015271,0.00021592533,0.00036557275,0.00021197143,0.00015190797,0.0002327687,0.0002777178,0.00051131763,0.00058487087],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008486588,0.000032626078,0.00047768553,0.00003778106,0.000013956122,0.000032051285,0.00001687559,0.000035870893,0.9974721,0.00007116655,0.00004104069,0.0016840512],"study_design_scores_gemma":[0.000034532484,0.0006238926,0.017886039,0.000010005756,0.000029180917,0.00072883174,0.000045877783,0.00073201023,0.9753253,0.000076531585,0.00450121,0.0000064935125],"about_ca_topic_score_codex":0.0003647397,"about_ca_topic_score_gemma":0.00076631684,"teacher_disagreement_score":0.0017899086,"about_ca_system_score_codex":0.00029161823,"about_ca_system_score_gemma":0.00014487191,"threshold_uncertainty_score":0.005987823},"labels":[],"label_agreement":null},{"id":"W2155791176","doi":"10.3109/10428194.2013.840889","title":"Genetic risk of chronic lymphocytic leukemia: a tale of two cities","year":2013,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Chronic lymphocytic leukemia; Genetics; Family aggregation; Allele; Population; Disease; Biology; Medicine; Leukemia; Gene; Internal medicine","score_opus":0.011787878781792348,"score_gpt":0.2531573642100715,"score_spread":0.24136948542827916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155791176","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1542965,0.1254865,0.006211271,0.65295917,0.0081676645,0.0001754705,0.0032547524,0.00041578745,0.04903293],"genre_scores_gemma":[0.69656736,0.12779947,0.009541561,0.12958921,0.008942582,0.00038140843,0.0027065352,0.00037819784,0.024093678],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9975535,0.0007657349,0.00016680006,0.00056164764,0.0006379092,0.00031436607],"domain_scores_gemma":[0.9969494,0.00075630425,0.00026729662,0.00035932244,0.0006644309,0.0010032646],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003599643,0.0010193397,0.0014227871,0.0039677294,0.005686683,0.0064695617,0.0019059877,0.0048086205,0.010180516],"category_scores_gemma":[0.0074955253,0.00081431,0.0014279404,0.0045293346,0.0050237207,0.005277162,0.0075296815,0.00631789,0.0011968139],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016822402,0.00048513498,0.24965788,0.0012408498,0.0025271727,0.0033702436,0.02153523,0.001389957,0.004813943,0.16172382,0.26041973,0.2911538],"study_design_scores_gemma":[0.0004507188,0.00071406906,0.31610155,0.004373544,0.002380356,0.0035696405,0.03174845,0.0017412467,0.0010039476,0.18963417,0.44769123,0.0005911223],"about_ca_topic_score_codex":0.045388248,"about_ca_topic_score_gemma":0.046564918,"teacher_disagreement_score":0.045388248,"about_ca_system_score_codex":0.0030857096,"about_ca_system_score_gemma":0.003477522,"threshold_uncertainty_score":0.09024811},"labels":[],"label_agreement":null},{"id":"W2157783814","doi":"10.3109/10428194.2011.633250","title":"Upfront thiotepa, busulfan, cyclophosphamide, and autologous stem cell transplantation for primary CNS lymphoma: a single centre experience","year":2011,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"CNS Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; ThioTEPA; Busulfan; Primary central nervous system lymphoma; Cyclophosphamide; Internal medicine; Autologous stem-cell transplantation; Oncology; Vincristine; Surgery; Chemotherapy; Regimen; Performance status","score_opus":0.014925888919821618,"score_gpt":0.21909359956061303,"score_spread":0.20416771064079142,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157783814","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962333,0.002089002,0.0006616866,0.00008088025,0.000028266577,0.00010037173,0.000045624925,0.000025050826,0.0007358123],"genre_scores_gemma":[0.99595803,0.0022255923,0.00076793943,0.00012167891,0.00012469257,0.000068344794,0.00020457567,0.000013347886,0.0005159135],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9995252,0.00018545627,0.000047604313,0.00007434387,0.00007079148,0.00009653034],"domain_scores_gemma":[0.999485,0.00010303556,0.00006810657,0.00004662976,0.00002854427,0.000268518],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006360821,0.0009828378,0.00063956797,0.00032453766,0.00073428696,0.0007125397,0.00073122943,0.0005429219,0.0013312319],"category_scores_gemma":[0.0011996576,0.00027385532,0.000815575,0.00046863934,0.00050587225,0.00033602072,0.00054871663,0.00066327624,0.0005725086],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022464432,0.0320733,0.24554513,0.0010455167,0.0015346687,0.057878535,0.0068445993,0.008450324,0.054885417,0.0003718213,0.0045984313,0.5643078],"study_design_scores_gemma":[0.017525872,0.22915503,0.5554861,0.00035963632,0.0019493062,0.13406074,0.0019726893,0.0080746,0.031536493,0.00065624656,0.018965274,0.00025805546],"about_ca_topic_score_codex":0.002029254,"about_ca_topic_score_gemma":0.0032170636,"teacher_disagreement_score":0.002029254,"about_ca_system_score_codex":0.0007672433,"about_ca_system_score_gemma":0.0006911522,"threshold_uncertainty_score":0.005566776},"labels":[],"label_agreement":null},{"id":"W2157797828","doi":"10.3109/10428190109064600","title":"BAD Induces Apoptosis in Cells Over-Expressing Bcl-2 or Bcl-xL without Loss of Mitochondrial Membrane Potential","year":2001,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Transfection; Bcl-xL; Apoptosis; Programmed cell death; Cell biology; Cell culture; Biology; Leukemia; Cancer research; Chemistry; Immunology; Biochemistry; Genetics","score_opus":0.007304111917981187,"score_gpt":0.2289915247457736,"score_spread":0.22168741282779242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157797828","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.984346,0.0036555482,0.00781859,0.0002337851,0.00015064375,0.00003876075,0.0005066055,0.00022513447,0.0030249427],"genre_scores_gemma":[0.987932,0.00232574,0.0037086224,0.00013048886,0.000020878495,0.000042973985,0.0013280156,0.000024857774,0.004486466],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997814,0.000043886306,0.000024815115,0.000034630026,0.000067056615,0.000048178816],"domain_scores_gemma":[0.9999025,0.00002412547,0.000018554916,0.000018302091,0.000010234869,0.000026272095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021867343,0.00029940932,0.00028587176,0.0002624214,0.00019441289,0.00040224913,0.000093685405,0.00020560024,0.0017147763],"category_scores_gemma":[0.0001241027,0.00013311046,0.00024597754,0.0002653793,0.0002657031,0.00026569422,0.00022093495,0.00060799567,0.00070375414],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013810881,0.00003216488,0.000174502,0.000036983507,0.00000508221,0.00003783113,0.000016337237,0.000025069272,0.99812275,0.00020241679,0.000053567528,0.0011550891],"study_design_scores_gemma":[0.000044846467,0.0004745066,0.0019326535,0.000004455103,0.000014324649,0.000311154,0.000030459712,0.0004902138,0.9928242,0.00013799359,0.0037313367,0.0000037621853],"about_ca_topic_score_codex":0.00016049118,"about_ca_topic_score_gemma":0.0002794016,"teacher_disagreement_score":0.0017147763,"about_ca_system_score_codex":0.00023263514,"about_ca_system_score_gemma":0.00017238801,"threshold_uncertainty_score":0.00573647},"labels":[],"label_agreement":null},{"id":"W2157912932","doi":"10.3109/10428194.2014.971407","title":"The deregulated promoter methylation of the<i>Polo-like kinases</i>as a potential biomarker in hematological malignancies","year":2014,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Windsor Regional Hospital; University of Windsor","funders":"Windsor Cancer Centre Foundation","keywords":"Polo-like kinase; Methylation; DNA methylation; Carcinogenesis; PLK1; Biology; Cancer research; Leukemia; Kinase; Biomarker; Myelodysplastic syndromes; Bone marrow; Molecular biology; Cancer; Genetics; Immunology; DNA; Gene; Cell cycle; Gene expression","score_opus":0.011268430685235196,"score_gpt":0.2545168655827003,"score_spread":0.24324843489746512,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157912932","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99380857,0.0032392521,0.001862134,0.000058354264,0.000007226211,0.000019646175,0.00024723235,0.000034225297,0.00072335167],"genre_scores_gemma":[0.9978315,0.0006160546,0.0010190137,0.000020935677,0.0000068576965,0.000012113405,0.00022986205,0.0000032313983,0.0002603521],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99986994,0.000040563275,0.000012501441,0.00002768236,0.000027168171,0.000022069291],"domain_scores_gemma":[0.9998535,0.000036944224,0.00006310857,0.000009214273,0.00001704836,0.000020282472],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029913455,0.00021161884,0.00015306156,0.0007389826,0.00011936741,0.00031565953,0.00015738778,0.0002066042,0.00071255805],"category_scores_gemma":[0.00036924414,0.000121848825,0.000095866366,0.00045006172,0.00022461115,0.00023334112,0.00015448543,0.00025126225,0.00015160655],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008218786,0.00004887372,0.16575451,0.00015137334,0.00005350862,0.00025291633,0.000093422466,0.00023754555,0.8196464,0.00012404897,0.00008329223,0.01273225],"study_design_scores_gemma":[0.000021699743,0.0006705729,0.5354369,0.00002395446,0.00012083851,0.002525932,0.0002366992,0.0017114062,0.456623,0.00037498501,0.0022416152,0.000012445759],"about_ca_topic_score_codex":0.0004662219,"about_ca_topic_score_gemma":0.0005198105,"teacher_disagreement_score":0.0007389826,"about_ca_system_score_codex":0.00014855491,"about_ca_system_score_gemma":0.00010913404,"threshold_uncertainty_score":0.002383709},"labels":[],"label_agreement":null},{"id":"W2158664264","doi":"10.3109/10428194.2012.722217","title":"Correlation of the microculture-kinetic drug-induced apoptosis assay with patient outcomes in initial treatment of adult acute myelocytic leukemia","year":2012,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Semtech (Canada)","funders":"Leukemia and Lymphoma Society","keywords":"Idarubicin; Microculture; Apoptosis; Medicine; Daunorubicin; Myeloid leukemia; Chemotherapy; Internal medicine; Leukemia; Oncology; Pharmacology; Immunology; Cytarabine; Biology; Cell culture; Biochemistry","score_opus":0.010439009679549102,"score_gpt":0.2573961836601869,"score_spread":0.2469571739806378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158664264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9993237,0.0002994629,0.00014235784,0.000020499185,0.0000030894114,0.000004760591,0.000052499185,0.000004448328,0.00014919642],"genre_scores_gemma":[0.99961746,0.00006126672,0.00012556856,0.000009554788,0.000004791642,0.000005499195,0.00012373268,8.46301e-7,0.00005128892],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99967515,0.00010977983,0.000051796414,0.00004474662,0.00007999329,0.00003848889],"domain_scores_gemma":[0.99817145,0.0006969452,0.0007679327,0.00007070403,0.00011945338,0.00017347277],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005623477,0.00017231719,0.00025071568,0.00039960528,0.00016379751,0.00034291061,0.00015584558,0.00023164753,0.0005090269],"category_scores_gemma":[0.003113047,0.00011405515,0.00011481025,0.00034793923,0.00023722011,0.00022976441,0.00024465116,0.0003781661,0.0001722426],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070118887,0.000047183123,0.9922144,0.000010861644,0.000020978418,0.00007724748,0.000035730576,0.00016817286,0.0016922123,0.0000108843315,0.00006646517,0.0049547805],"study_design_scores_gemma":[0.000023024024,0.0009430195,0.9947818,0.000004113589,0.00003350423,0.00092570635,0.000056594792,0.00096399704,0.001975751,0.000045952085,0.00024105569,0.0000054744146],"about_ca_topic_score_codex":0.00037010707,"about_ca_topic_score_gemma":0.0007963432,"teacher_disagreement_score":0.0005623477,"about_ca_system_score_codex":0.00029802124,"about_ca_system_score_gemma":0.00017195725,"threshold_uncertainty_score":0.0029740334},"labels":[],"label_agreement":null},{"id":"W2160932375","doi":"10.3109/10428194.2014.927457","title":"Shelf-life extension of azacitidine: waste and cost reduction in the treatment of myelodysplastic syndromes","year":2014,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Azacitidine; Myelodysplastic syndromes; Reduction (mathematics); Medicine; Extension (predicate logic); Oncology; Internal medicine; Computer science; Biology; Genetics","score_opus":0.02607203243919772,"score_gpt":0.27239053465651586,"score_spread":0.24631850221731813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160932375","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0038042336,0.009717582,0.00024049092,0.9776163,0.0039764894,0.000009958256,0.00002690073,0.000025800155,0.004582257],"genre_scores_gemma":[0.044385623,0.017028632,0.0013428688,0.87255615,0.056832854,0.00004658676,0.00005674365,0.00003149844,0.007719131],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99825174,0.00061441347,0.00027160402,0.00013452275,0.00059049536,0.00013725553],"domain_scores_gemma":[0.99564654,0.0024447043,0.00051837595,0.00015626175,0.00078623235,0.00044796205],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023999629,0.0003406386,0.0008195349,0.00043837787,0.001379716,0.0017685681,0.0009988672,0.016090112,0.0026016603],"category_scores_gemma":[0.012470265,0.00026222633,0.0007300287,0.0005339027,0.0015668126,0.0021436561,0.00072227593,0.011660081,0.0019939335],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007899467,0.00020291803,0.0060639624,0.00040317452,0.00006125809,0.011490302,0.00037579567,0.00061793625,0.002860577,0.0079959715,0.73411363,0.2350245],"study_design_scores_gemma":[0.0003977178,0.00082565116,0.007088315,0.0008208342,0.000116498675,0.025744174,0.0005992627,0.0013110489,0.0018332351,0.024202157,0.9369865,0.0000745445],"about_ca_topic_score_codex":0.0022363907,"about_ca_topic_score_gemma":0.0069925883,"teacher_disagreement_score":0.016090112,"about_ca_system_score_codex":0.003126954,"about_ca_system_score_gemma":0.002198354,"threshold_uncertainty_score":0.022687733},"labels":[],"label_agreement":null},{"id":"W2161794113","doi":"10.3109/10428194.2011.652108","title":"Long-term follow-up of patients with chronic myeloid leukemia in chronic phase developing sudden blast phase on imatinib therapy","year":2011,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Imatinib; Cumulative incidence; Internal medicine; Imatinib mesylate; Myeloid leukemia; Incidence (geometry); Oncology; Dasatinib; Tyrosine-kinase inhibitor; Nilotinib; Pediatrics; Transplantation; Cancer","score_opus":0.023020625815163804,"score_gpt":0.2731842722756763,"score_spread":0.25016364646051253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2161794113","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.999411,0.00020034236,0.000047686837,0.000031331852,0.000003459236,0.000005266522,0.000079280064,0.0000014530223,0.00022015501],"genre_scores_gemma":[0.99953794,0.00007815256,0.000031865537,0.000027999424,0.000009682083,0.0000054056454,0.00021891686,6.718589e-7,0.00008941633],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997222,0.000061794184,0.000034965124,0.00004527526,0.00005555097,0.00008031031],"domain_scores_gemma":[0.99851483,0.0003050531,0.0005723221,0.00008518687,0.00016250054,0.00036011738],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005027899,0.0001640914,0.00038843142,0.0005184868,0.0005852286,0.00046102892,0.00020980087,0.00048380363,0.00057930936],"category_scores_gemma":[0.0021785744,0.00014397856,0.00031210005,0.0005353244,0.00024036334,0.00044560968,0.00033092228,0.00059228163,0.00020603885],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003229856,0.00006202506,0.9949963,0.000007167764,0.000027285158,0.0007025314,0.00012511759,0.00007079311,0.0006143128,0.000013942369,0.00008154246,0.0029759808],"study_design_scores_gemma":[0.000023072582,0.00078754517,0.9954661,0.000009500954,0.0000670512,0.0024406963,0.00018177749,0.00025744445,0.00028693012,0.000038961374,0.00043181027,0.000009056661],"about_ca_topic_score_codex":0.0013956837,"about_ca_topic_score_gemma":0.0017109758,"teacher_disagreement_score":0.0013956837,"about_ca_system_score_codex":0.00029015532,"about_ca_system_score_gemma":0.00022187222,"threshold_uncertainty_score":0.0027751327},"labels":[],"label_agreement":null},{"id":"W2162410017","doi":"10.3109/10428194.2014.971409","title":"Comparative effectiveness analysis of different salvage therapy intensities used for diffuse large B-cell lymphoma in Northern or Southern Alberta: an instrumental variable analysis","year":2014,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services; University of Alberta; University of Calgary","funders":"Alberta Health Services","keywords":"Salvage therapy; Medicine; Internal medicine; Refractory (planetary science); Oncology; Chemotherapy; Lymphoma; Diffuse large B-cell lymphoma; Population; Surgery; Biology","score_opus":0.013599289130931717,"score_gpt":0.2619701770272454,"score_spread":0.24837088789631367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162410017","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977449,0.00085557986,0.0006119772,0.000058081496,0.000006475045,0.00008150557,0.00006945852,0.0000060269736,0.0005660215],"genre_scores_gemma":[0.99919087,0.00015410656,0.00037938784,0.000037731956,0.0000069465736,0.000027224029,0.00009716922,0.000001682139,0.00010495323],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965587,0.002513613,0.0001225768,0.00016572625,0.00042916526,0.00021004034],"domain_scores_gemma":[0.9965676,0.002154958,0.00070345163,0.00014043911,0.00017862997,0.00025487755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0047039413,0.00032886787,0.000644796,0.0005123287,0.00018467501,0.00047083767,0.00051107496,0.000298725,0.000793762],"category_scores_gemma":[0.0075269067,0.00008836534,0.00085440505,0.00053083553,0.0005908782,0.00020674177,0.00041494638,0.00039347296,0.00003547649],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19865818,0.0032170226,0.5493856,0.000761034,0.010003384,0.0002255836,0.00049892056,0.04608233,0.004856232,0.0018124001,0.00065656373,0.1838428],"study_design_scores_gemma":[0.00889832,0.052368555,0.8921859,0.00010943064,0.008441815,0.00020394404,0.00071511127,0.03142496,0.0029243282,0.0009478,0.0017216012,0.000058130427],"about_ca_topic_score_codex":0.054916695,"about_ca_topic_score_gemma":0.071838975,"teacher_disagreement_score":0.054916695,"about_ca_system_score_codex":0.0038764495,"about_ca_system_score_gemma":0.0025770406,"threshold_uncertainty_score":0.10919404},"labels":[],"label_agreement":null},{"id":"W2163004538","doi":"10.3109/10428194.2014.964699","title":"Risk and prophylaxis strategy of hepatitis B virus reactivation in patients with lymphoma undergoing chemotherapy with or without rituximab","year":2014,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Hepatitis B Virus Studies","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Héma-Québec","funders":"","keywords":"Medicine; Rituximab; HBsAg; Hepatitis B virus; Chemotherapy; Fulminant hepatitis; Lymphoma; Internal medicine; Hepatitis B; Asymptomatic; Gastroenterology; Viremia; Immunology; Hepatitis; Antibody; Virus","score_opus":0.013079890692348512,"score_gpt":0.26004543575576455,"score_spread":0.24696554506341603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163004538","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021972222,0.99950504,0.0000150595715,0.00006939437,0.00002088441,0.0000030205208,0.000010174852,9.0073684e-7,0.00015579523],"genre_scores_gemma":[0.0017655006,0.99799573,0.00006585273,0.00007413503,0.00002773962,0.0000061427722,0.000014802774,3.276312e-7,0.000049702743],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996623,0.00010555717,0.000110097455,0.000036175126,0.0000712127,0.000014671865],"domain_scores_gemma":[0.99924386,0.000492543,0.00016356702,0.000009096348,0.00007405748,0.00001692846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006281997,0.00046266618,0.001213618,0.0020800726,0.00018582844,0.000619559,0.0005969398,0.00061775063,0.0018710544],"category_scores_gemma":[0.002031279,0.00020021058,0.00094557804,0.0016895295,0.00019816625,0.00063854357,0.00029079782,0.0005167811,0.00023111829],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002342005,0.00006009801,0.0021345145,0.13442543,0.0010197461,0.00033014384,0.00013925208,0.0001826103,0.00040578324,0.00072920887,0.008518412,0.85182065],"study_design_scores_gemma":[0.00033511885,0.00077697745,0.02805584,0.27205485,0.015531452,0.015016059,0.00062313816,0.00032973645,0.0013918016,0.0020532855,0.66374207,0.00008973989],"about_ca_topic_score_codex":0.0013480873,"about_ca_topic_score_gemma":0.0023704085,"teacher_disagreement_score":0.0020800726,"about_ca_system_score_codex":0.00049815915,"about_ca_system_score_gemma":0.0010908492,"threshold_uncertainty_score":0.0062592626},"labels":[],"label_agreement":null},{"id":"W2164257516","doi":"10.3109/10428194.2014.893304","title":"Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for the treatment of secondary plasma cell leukemia","year":2014,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Lenalidomide; Bortezomib; Plasma cell leukemia; Dexamethasone; Medicine; Multiple myeloma; Pharmacology; Leukemia; Oncology; Internal medicine","score_opus":0.024237332105817144,"score_gpt":0.2679509948797453,"score_spread":0.24371366277392814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164257516","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.022419242,0.028859554,0.0020627447,0.86033696,0.023753354,0.00026058554,0.00031327998,0.00030225384,0.061692107],"genre_scores_gemma":[0.23384248,0.044607867,0.0045086187,0.5749326,0.072240375,0.00023280393,0.0004255637,0.0001253919,0.069084354],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994634,0.00013649165,0.000058565318,0.0000721942,0.00017577797,0.00009362924],"domain_scores_gemma":[0.9995689,0.00015545357,0.000050875955,0.000021598436,0.00006707709,0.00013615307],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036870668,0.0005784142,0.0007013782,0.0005178393,0.0015378087,0.0008691682,0.0009015421,0.0063232477,0.00436973],"category_scores_gemma":[0.0020996889,0.00024121048,0.0007833115,0.00054155436,0.0009547021,0.0013204028,0.0005121029,0.007708088,0.0038676583],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037757042,0.0003323168,0.006092289,0.00040176604,0.000070009424,0.2355722,0.00025617407,0.0005523006,0.0032961217,0.007742194,0.64538664,0.09992042],"study_design_scores_gemma":[0.000436359,0.0005798743,0.005025381,0.00063707994,0.0000697153,0.36166587,0.00030251298,0.001959432,0.001336203,0.011636618,0.6162949,0.000056003937],"about_ca_topic_score_codex":0.0022073844,"about_ca_topic_score_gemma":0.0063176984,"teacher_disagreement_score":0.0063232477,"about_ca_system_score_codex":0.002745048,"about_ca_system_score_gemma":0.0013328589,"threshold_uncertainty_score":0.019916832},"labels":[],"label_agreement":null},{"id":"W2165807556","doi":"10.3109/10428194.2012.738365","title":"Patients with activated B-cell like diffuse large B-cell lymphoma in high and low infectious disease areas have different inflammatory gene signatures","year":2012,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Toronto General Hospital","funders":"Karolinska Institutet","keywords":"Diffuse large B-cell lymphoma; Lymphoma; Anaplastic lymphoma kinase; Biology; Gene expression; Cancer research; STAT protein; Pathogenesis; Gene expression profiling; Real-time polymerase chain reaction; Lymph node; STAT3; Gene; Pathology; Immunology; Medicine; Genetics","score_opus":0.0033394312183381014,"score_gpt":0.18860214547219378,"score_spread":0.18526271425385568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165807556","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99964285,0.00008155422,0.00005390575,0.000008701622,8.131727e-7,0.000001755589,0.00003094345,0.0000019934832,0.00017738846],"genre_scores_gemma":[0.9996542,0.000043102016,0.00008193199,0.000015389529,0.0000027496421,0.0000023497594,0.00010226323,0.0000014445059,0.00009652898],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998653,0.000026565944,0.000015293615,0.00003761564,0.000020630569,0.00003463858],"domain_scores_gemma":[0.9998461,0.0000351478,0.000057695048,0.000007929458,0.000018033485,0.00003510948],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010446237,0.00020438508,0.00023942786,0.00064247637,0.00032580682,0.0003672958,0.000080225516,0.00022223702,0.0014566836],"category_scores_gemma":[0.00030388843,0.00010720993,0.00013300237,0.0004829556,0.00027419627,0.00014659851,0.00015859703,0.00017853157,0.00020826937],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00080797443,0.00007675657,0.9405741,0.000039421768,0.000058115096,0.0015839637,0.0004307442,0.00006123648,0.051688556,0.0000593337,0.00006750019,0.00455225],"study_design_scores_gemma":[0.000017732742,0.00019361875,0.99222565,0.0000046421696,0.000046040834,0.0039725807,0.0005135715,0.000060847142,0.002604378,0.000060335988,0.00029648666,0.000004104796],"about_ca_topic_score_codex":0.00051733706,"about_ca_topic_score_gemma":0.0009248723,"teacher_disagreement_score":0.0014566836,"about_ca_system_score_codex":0.00012378489,"about_ca_system_score_gemma":0.00007131054,"threshold_uncertainty_score":0.004873097},"labels":[],"label_agreement":null},{"id":"W2168354819","doi":"10.3109/10428194.2014.935368","title":"Human immunodeficiency virus-associated multicentric Castleman disease refractory to antiretroviral therapy: clinical features, treatment and outcome","year":2014,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; St. Paul's Hospital","funders":"","keywords":"Medicine; Lymphoma; Refractory (planetary science); Chemotherapy; Castleman disease; Viral load; Internal medicine; Human immunodeficiency virus (HIV); Immunotherapy; Antiretroviral therapy; Virus; Immunology; Gastroenterology; Disease; Cancer","score_opus":0.023639807940394206,"score_gpt":0.3122604062879047,"score_spread":0.28862059834751047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168354819","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99701995,0.0015717449,0.000097151555,0.00006333382,0.000008781562,0.000038735765,0.00014731288,0.0000052678997,0.0010477221],"genre_scores_gemma":[0.99901974,0.00027463466,0.00010169694,0.00006339843,0.000049559963,0.000025618994,0.0003013247,0.0000015074561,0.00016255511],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.99978584,0.00006131041,0.000021787848,0.00003872778,0.000021970127,0.00007034021],"domain_scores_gemma":[0.99936324,0.00019992513,0.00013213852,0.000032835873,0.000026310017,0.00024560763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032749187,0.00041284354,0.00053817435,0.00024076129,0.00071476464,0.0004730742,0.00023631194,0.0006775754,0.0009417349],"category_scores_gemma":[0.0010524407,0.00012092353,0.00023302918,0.000360072,0.00031231434,0.00026331263,0.00022574929,0.00048688456,0.00021800913],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055076233,0.001627673,0.9165251,0.00019538663,0.00018574655,0.020780629,0.0002595861,0.000895201,0.0053734146,0.00019267488,0.0012325483,0.047224376],"study_design_scores_gemma":[0.0006551724,0.008936006,0.94129425,0.00008364916,0.00008052835,0.04500937,0.0002957438,0.001325629,0.00058782735,0.00028467836,0.0014127681,0.000034425208],"about_ca_topic_score_codex":0.0008125261,"about_ca_topic_score_gemma":0.0011225952,"teacher_disagreement_score":0.0009417349,"about_ca_system_score_codex":0.00032362647,"about_ca_system_score_gemma":0.0002768729,"threshold_uncertainty_score":0.0031504035},"labels":[],"label_agreement":null},{"id":"W2168366051","doi":"10.3109/10428194.2010.500072","title":"Targeting the microenvironment","year":2010,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Tumor microenvironment; Stromal cell; Bystander effect; Cancer research; Carcinogenesis; Immune system; Cancer; Medicine; Function (biology); Biology; Tumor cells; Immunology; Cell biology; Internal medicine","score_opus":0.009931421058738251,"score_gpt":0.24448532256989608,"score_spread":0.23455390151115782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168366051","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002959355,0.99442613,0.0007295111,0.0005299179,0.00031014095,0.000008760062,0.000023647453,0.000020419351,0.0036555633],"genre_scores_gemma":[0.0026528782,0.9940258,0.00042047308,0.0003032771,0.00018749994,0.000015559812,0.00004353744,0.0000038590297,0.0023470789],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99986994,0.000020160212,0.000009053539,0.00002715864,0.000054454697,0.00001918357],"domain_scores_gemma":[0.999881,0.000039191385,0.000021532898,0.0000075562357,0.000029315113,0.000021338124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030784137,0.0008894196,0.0011243921,0.0012010399,0.00033562232,0.0010994991,0.00092200225,0.0013361528,0.003274481],"category_scores_gemma":[0.00028102295,0.00020059713,0.00032829275,0.0009935616,0.00068094005,0.0013578753,0.0008765871,0.0017090702,0.0029872186],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000813957,0.000075878466,0.0002970524,0.007649387,0.00007332628,0.00042188267,0.00009394507,0.00050172536,0.018319711,0.015066107,0.041387092,0.91603243],"study_design_scores_gemma":[0.000010976928,0.00004716791,0.00039311935,0.0005695228,0.000027928421,0.001467499,0.00003952099,0.00008998201,0.0028219381,0.0026376203,0.991884,0.0000106855905],"about_ca_topic_score_codex":0.0010218049,"about_ca_topic_score_gemma":0.0016477932,"teacher_disagreement_score":0.003274481,"about_ca_system_score_codex":0.00083446625,"about_ca_system_score_gemma":0.000667227,"threshold_uncertainty_score":0.010954201},"labels":[],"label_agreement":null},{"id":"W2169038235","doi":"10.3109/10428194.2011.605188","title":"Oral fludarabine and rituximab as initial therapy for chronic lymphocytic leukemia or small lymphocytic lymphoma: population-based experience matches clinical trials","year":2011,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; Vancouver General Hospital; BC Cancer Agency; University of British Columbia","funders":"BC Cancer Agency; University of British Columbia","keywords":"Fludarabine; Medicine; Chronic lymphocytic leukemia; Rituximab; Internal medicine; Discontinuation; Oncology; Clinical trial; Population; Lymphoma; Gastroenterology; Leukemia; Chemotherapy; Cyclophosphamide","score_opus":0.16902655781496087,"score_gpt":0.4110555117732854,"score_spread":0.24202895395832455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169038235","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9606333,0.03215422,0.00075428357,0.0006422922,0.00007303039,0.001836723,0.00032830736,0.000042592725,0.003535268],"genre_scores_gemma":[0.97973835,0.015154575,0.0017766138,0.00079090043,0.00016418484,0.0011283269,0.0006348882,0.0000107165015,0.00060149113],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99209213,0.005944961,0.00038524598,0.00045524773,0.00080422894,0.0003183104],"domain_scores_gemma":[0.99414706,0.0028456883,0.0011308555,0.00042765067,0.00058549125,0.00086329045],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013114426,0.0005005863,0.001701154,0.00041261755,0.0004151062,0.0009667796,0.0005492278,0.0010375438,0.0012482135],"category_scores_gemma":[0.012800458,0.00027927454,0.0007752687,0.0009800713,0.0010796527,0.0005915989,0.00038803834,0.0013082374,0.00023437214],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33417925,0.018956896,0.06505356,0.0015845305,0.0039337706,0.00030068328,0.0010338532,0.0009541547,0.0062681017,0.00037786242,0.0032264376,0.56413084],"study_design_scores_gemma":[0.31060284,0.46942168,0.18516727,0.00070975715,0.0047052912,0.0011219135,0.0006547903,0.0009055076,0.0034477313,0.0005747887,0.022589598,0.00009871121],"about_ca_topic_score_codex":0.003878984,"about_ca_topic_score_gemma":0.0076128547,"teacher_disagreement_score":0.013114426,"about_ca_system_score_codex":0.0011347813,"about_ca_system_score_gemma":0.0022967195,"threshold_uncertainty_score":0.0693565},"labels":[],"label_agreement":null},{"id":"W2169096446","doi":"10.3109/10428191003661860","title":"Multiple myeloma may include microvessel endothelial cells of malignant origin","year":2010,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"clone (Java method); Paracrine signalling; Progenitor cell; Biology; Autocrine signalling; Pathology; Population; Bone marrow; Malignancy; Pericyte; Cancer research; Neovascularization; Endothelium; Cancer cell; Cancer; Angiogenesis; Stem cell; Endothelial stem cell; Immunology; Medicine; Cell biology; Cell culture; Genetics; Gene; Receptor","score_opus":0.029841449146530356,"score_gpt":0.3123519019111376,"score_spread":0.28251045276460723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169096446","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00035454845,0.996747,0.00022729022,0.00031228334,0.00016373818,0.0000055038577,0.00001303344,0.000011247406,0.002165323],"genre_scores_gemma":[0.003308237,0.99408495,0.0003348137,0.00029458787,0.00026005172,0.00000991041,0.000053277563,0.000001850009,0.0016522589],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998838,0.000023084005,0.000016384909,0.000022826602,0.00004008651,0.00001388996],"domain_scores_gemma":[0.9998221,0.00008245106,0.00003058934,0.000007242492,0.00004168005,0.000015915146],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035854583,0.00063416385,0.0009667239,0.0016306124,0.0002077761,0.0006997915,0.00044667715,0.00092778186,0.0022479016],"category_scores_gemma":[0.0003125276,0.00019822805,0.0002640072,0.0012062346,0.0005269495,0.0011903476,0.00037738724,0.00110058,0.0019408291],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007195326,0.00006376104,0.0006881164,0.004922711,0.000051729116,0.0009245805,0.0000444535,0.00018107104,0.0036940179,0.0030249332,0.019805776,0.9665268],"study_design_scores_gemma":[0.000026633348,0.000102317616,0.002440663,0.0014505208,0.00008955881,0.010636317,0.000065735425,0.00009259711,0.0018441258,0.0014644788,0.98176885,0.000018161138],"about_ca_topic_score_codex":0.00081486226,"about_ca_topic_score_gemma":0.0016858758,"teacher_disagreement_score":0.0022479016,"about_ca_system_score_codex":0.00042107483,"about_ca_system_score_gemma":0.00048680892,"threshold_uncertainty_score":0.0075199604},"labels":[],"label_agreement":null},{"id":"W2169395626","doi":"10.3109/10428194.2010.531409","title":"Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (&lt;12 months)","year":2010,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Vancouver Hospital and Health Sciences Centre","funders":"Celgene","keywords":"Lenalidomide; Medicine; Thalidomide; Bortezomib; Multiple myeloma; Internal medicine; Cohort; Oncology; Population; Autologous stem-cell transplantation; Surgery","score_opus":0.010861604291262782,"score_gpt":0.23001383547196608,"score_spread":0.2191522311807033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169395626","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943246,0.0046348837,0.00015079847,0.00014831392,0.000025139523,0.000009476204,0.00005272584,0.00001516996,0.00063883426],"genre_scores_gemma":[0.99804795,0.0011956014,0.00019553819,0.00013070113,0.00006900384,0.0000053948443,0.00012807648,0.0000019042145,0.00022576282],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99992776,0.000022418213,0.000010746338,0.000010795881,0.000012833062,0.000015374757],"domain_scores_gemma":[0.9997013,0.00005440944,0.00014046792,0.00001027531,0.00001878193,0.000074576696],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034637362,0.0001411025,0.00031055484,0.00019210768,0.00015251974,0.0002811323,0.000095999276,0.00016010784,0.000996508],"category_scores_gemma":[0.0006187609,0.000041911982,0.00021083982,0.00017054382,0.000102292826,0.00025873756,0.0001884189,0.00032485617,0.00014554607],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055351635,0.00095383596,0.754413,0.00020165427,0.0002634683,0.0005159428,0.00021314462,0.00064571074,0.009855021,0.00010177016,0.001113474,0.2261878],"study_design_scores_gemma":[0.00023984433,0.011292267,0.97895515,0.00006313547,0.00027347152,0.0018426009,0.00015119667,0.00065765466,0.0021195083,0.00020289177,0.0041921227,0.000010073901],"about_ca_topic_score_codex":0.00023142062,"about_ca_topic_score_gemma":0.0007061001,"teacher_disagreement_score":0.000996508,"about_ca_system_score_codex":0.00015991558,"about_ca_system_score_gemma":0.00011894529,"threshold_uncertainty_score":0.0033336282},"labels":[],"label_agreement":null},{"id":"W2169400635","doi":"10.1080/10428190601136163","title":"Acute promyelocytic leukemia: A novel<i>PML/RARα</i>fusion that generates a frameshift in the RARα transcript and ATRA resistance","year":2007,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Retinoids in leukemia and cellular processes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Capital District Health Authority; Dalhousie University","funders":"","keywords":"Acute promyelocytic leukemia; Promyelocyte; Cancer research; Leukemia; Fusion transcript; Cytarabine; Promyelocytic leukemia protein; Fusion gene; Medicine; Frameshift mutation; Biology; Retinoic acid; Exon; Immunology; Genetics; Gene","score_opus":0.008408581974120337,"score_gpt":0.22523637538504357,"score_spread":0.21682779341092323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169400635","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915746,0.00080009934,0.0028603773,0.00049365795,0.000028962024,0.00004344362,0.00014964362,0.00016484581,0.0038844019],"genre_scores_gemma":[0.99570185,0.00030831297,0.0015042197,0.0001414214,0.000030180561,0.000013009942,0.00014104252,0.000018733246,0.0021412806],"study_design_codex":"case_report","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998691,0.000014232614,0.000012963653,0.000032865373,0.00002528373,0.000045529858],"domain_scores_gemma":[0.99984646,0.000028136465,0.000049492486,0.000014653969,0.000007923465,0.000053376876],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000093855386,0.0004372104,0.00021748056,0.00027002543,0.00031144524,0.00037721207,0.0001801903,0.0006822967,0.0014325299],"category_scores_gemma":[0.00030259034,0.00020709926,0.00021502524,0.00022757784,0.0005109137,0.00027704635,0.0002200866,0.0005327038,0.0006500983],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007307657,0.0002126033,0.025932528,0.00018599523,0.000037469425,0.4708279,0.0005446029,0.0005192588,0.47035822,0.004628609,0.0012380191,0.02478403],"study_design_scores_gemma":[0.000087104294,0.0005126165,0.018374318,0.000016169413,0.000050183386,0.90075916,0.00010983012,0.0006328285,0.06792366,0.00076142396,0.010759382,0.000013358946],"about_ca_topic_score_codex":0.00035022933,"about_ca_topic_score_gemma":0.0004908412,"teacher_disagreement_score":0.0014325299,"about_ca_system_score_codex":0.0004089717,"about_ca_system_score_gemma":0.0002788837,"threshold_uncertainty_score":0.0047923326},"labels":[],"label_agreement":null},{"id":"W2171081863","doi":"10.1080/10428190701694186","title":"Phase II study of denileukin diftitox for previously treated indolent non-Hodgkin lymphoma: Final results of E1497","year":2007,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Mycobacterium research and diagnosis","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Hodgkin lymphoma; Lymphoma; Medicine; Internal medicine; Oncology","score_opus":0.025739308410309865,"score_gpt":0.318033629001405,"score_spread":0.29229432059109517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171081863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915182,0.0020841989,0.0009902621,0.0002333669,0.0000996091,0.0020767853,0.0008590105,0.00009195351,0.0020465336],"genre_scores_gemma":[0.98354983,0.0018673493,0.0018186312,0.0010867199,0.0001337528,0.0024758137,0.004061554,0.000042432774,0.004963814],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99976414,0.000110902125,0.000011549611,0.000027342478,0.000025998648,0.000060073282],"domain_scores_gemma":[0.9996575,0.000043176176,0.000050136754,0.000033882,0.000023950053,0.00019128686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00084049127,0.00077386486,0.0011892398,0.00020384947,0.00021004124,0.0005994987,0.0005974028,0.00092022505,0.0029916312],"category_scores_gemma":[0.0004238108,0.00029007648,0.000636476,0.00014929062,0.00041046826,0.0003208236,0.00026190226,0.0014102652,0.00094609935],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.461468,0.13409775,0.017534224,0.0006368582,0.0014625008,0.0013746944,0.00046468113,0.004807178,0.1454707,0.0006478862,0.010526697,0.22150883],"study_design_scores_gemma":[0.35473403,0.5927736,0.025443222,0.00004399975,0.00037158854,0.00087880506,0.000084871215,0.0021961643,0.0145766735,0.00027419766,0.008584521,0.0000383664],"about_ca_topic_score_codex":0.00052592513,"about_ca_topic_score_gemma":0.0009825816,"teacher_disagreement_score":0.0029916312,"about_ca_system_score_codex":0.00030237375,"about_ca_system_score_gemma":0.00061119435,"threshold_uncertainty_score":0.0100079775},"labels":[],"label_agreement":null},{"id":"W2171440950","doi":"10.3109/10428194.2014.970550","title":"Combining MYC, BCL2 and TP53 gene and protein expression alterations improves risk stratification in diffuse large B-cell lymphoma","year":2014,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Chromosomal translocation; Fluorescence in situ hybridization; Immunohistochemistry; Lymphoma; Internal medicine; Cancer research; Gene expression; Oncology; Gene; Risk stratification; Progression-free survival; Biology; Medicine; Overall survival; Genetics","score_opus":0.006580176482716248,"score_gpt":0.2217849288754741,"score_spread":0.21520475239275785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171440950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9994578,0.00024318536,0.0001660846,0.00001757137,0.000001422914,0.0000035502205,0.000010160234,0.000005156533,0.00009513319],"genre_scores_gemma":[0.9996092,0.00007089127,0.00021880513,0.000006880712,0.00000450265,0.0000017956448,0.00003879893,0.0000011933635,0.000047947175],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995819,0.00018350892,0.000038109152,0.00006541689,0.00008452345,0.000046604666],"domain_scores_gemma":[0.99949884,0.00014491174,0.00015027937,0.000034488887,0.00004264222,0.00012881662],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008646309,0.00040935315,0.00038672463,0.0005402809,0.00019202178,0.00044528273,0.00015559731,0.00020558081,0.00040165865],"category_scores_gemma":[0.001381791,0.0001522804,0.00018514453,0.00036628914,0.00018272012,0.0003000643,0.00032445625,0.0002529038,0.00010561492],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022976839,0.00011636929,0.9499372,0.000018354125,0.000090514826,0.00019180821,0.000060568014,0.00046127572,0.014450194,0.000017712355,0.000062686486,0.03229545],"study_design_scores_gemma":[0.00013199523,0.0031852669,0.9840687,0.000007684655,0.0002489374,0.0016979262,0.00012775324,0.0031106183,0.006810375,0.00014711278,0.00044986466,0.000013685513],"about_ca_topic_score_codex":0.00047214463,"about_ca_topic_score_gemma":0.0012421352,"teacher_disagreement_score":0.0008646309,"about_ca_system_score_codex":0.00021089632,"about_ca_system_score_gemma":0.00016309695,"threshold_uncertainty_score":0.00457263},"labels":[],"label_agreement":null},{"id":"W2171830805","doi":"10.3109/10428194.2014.953152","title":"Aggressive congenital juvenile myelomonocytic leukemia associated with somatic<i>KRAS</i>p.G13D mutation and concurrent germline<i>IGF1R</i>duplication","year":2014,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"","keywords":"Juvenile myelomonocytic leukemia; Germline mutation; Germline; KRAS; Cancer research; Gene duplication; Mutation; Biology; Somatic cell; Genetics; Medicine; Gene; Haematopoiesis","score_opus":0.015535477822808326,"score_gpt":0.2567419644317981,"score_spread":0.24120648660898977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171830805","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.35960716,0.023975112,0.006002717,0.46322724,0.020831963,0.0005057796,0.0009502769,0.000978039,0.123921685],"genre_scores_gemma":[0.85495806,0.0100076515,0.0042761434,0.08172495,0.028603787,0.000093590046,0.00030652015,0.00010084891,0.019928487],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99936384,0.000114271184,0.000057740137,0.00014993057,0.00015402406,0.00016017832],"domain_scores_gemma":[0.9990896,0.00027848964,0.0001395183,0.00006579408,0.00011342196,0.00031331682],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004060165,0.0009041068,0.000834188,0.0009241056,0.0016253515,0.0011415004,0.0009975386,0.0061086193,0.003766451],"category_scores_gemma":[0.0025644896,0.00038206656,0.0007609142,0.00080281385,0.0014421187,0.0019976413,0.00077351835,0.0057628034,0.0017933352],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000072560055,0.0000636303,0.008898752,0.00008710105,0.000016385902,0.9504608,0.00018716777,0.00012515023,0.0012685849,0.0020081974,0.028859172,0.007952499],"study_design_scores_gemma":[0.000045810884,0.000077195255,0.0044722264,0.00010495961,0.00002115733,0.97546005,0.0002534705,0.0006498106,0.0003482243,0.0015780893,0.016968234,0.000020782052],"about_ca_topic_score_codex":0.002945769,"about_ca_topic_score_gemma":0.0053434814,"teacher_disagreement_score":0.0061086193,"about_ca_system_score_codex":0.0024547498,"about_ca_system_score_gemma":0.0011613478,"threshold_uncertainty_score":0.017810464},"labels":[],"label_agreement":null},{"id":"W2216590292","doi":"10.3109/10428194.2015.1115032","title":"Allogeneic Hematopoietic Stem Cell Transplantions in Blastic Plasmacytoid Dendritic Cell Neoplasm in first complete remission: an effective therapy for a rare disease","year":2015,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Cutaneous lymphoproliferative disorders research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Disease; Neoplasm; Stem cell; Myeloproliferative neoplasm; Haematopoiesis; Complete remission; Hematopoietic stem cell; Cancer research; Oncology; Internal medicine; Immunology; Pathology; Bone marrow; Chemotherapy; Biology; Myelofibrosis; Genetics","score_opus":0.02325502392348319,"score_gpt":0.26783664146040326,"score_spread":0.24458161753692007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2216590292","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4978345,0.032523744,0.009476255,0.38968727,0.016748946,0.0003640654,0.00045019682,0.00066393585,0.052251015],"genre_scores_gemma":[0.8826179,0.011207456,0.0022993784,0.07105503,0.016454458,0.00011816746,0.00030669267,0.00005680707,0.015884046],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9998418,0.000044286495,0.000013374301,0.000024306071,0.000033591,0.00004264823],"domain_scores_gemma":[0.9996586,0.00013629586,0.000030419897,0.00003042451,0.00002375955,0.000120564226],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024466234,0.00030622206,0.00058328017,0.00031260448,0.0008155746,0.00047730556,0.00042390413,0.0042666905,0.0012108877],"category_scores_gemma":[0.0011146044,0.00013157618,0.00047355448,0.00025356218,0.0005994247,0.00069171254,0.0003273539,0.0032606171,0.00070755],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011288214,0.00050846714,0.009317539,0.00026430766,0.00006098371,0.8436832,0.00026046069,0.0007351215,0.008343617,0.0059788986,0.060171206,0.069547355],"study_design_scores_gemma":[0.0008187776,0.0011541594,0.013752104,0.00017641117,0.00009149089,0.88112235,0.00021781503,0.0034347519,0.0039769183,0.007607891,0.08760763,0.00003978986],"about_ca_topic_score_codex":0.00041499583,"about_ca_topic_score_gemma":0.0008564656,"teacher_disagreement_score":0.0042666905,"about_ca_system_score_codex":0.00094059604,"about_ca_system_score_gemma":0.00037200874,"threshold_uncertainty_score":0.0068244934},"labels":[],"label_agreement":null},{"id":"W2216707999","doi":"10.3109/10428194.2014.974043","title":"The risk of secondary primary malignancies after therapy for multiple myeloma","year":2015,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Lenalidomide; Multiple myeloma; Medicine; Context (archaeology); Malignancy; Incidence (geometry); Disease; Oncology; Maintenance therapy; Internal medicine; Hematologic malignancy; Cancer; Intensive care medicine; Chemotherapy","score_opus":0.028808453546756495,"score_gpt":0.30089248121573137,"score_spread":0.2720840276689749,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2216707999","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016287534,0.9991461,0.000033608692,0.00016910919,0.00005349231,0.0000020483221,0.000013401702,0.0000023559567,0.0004169674],"genre_scores_gemma":[0.0017004714,0.9977742,0.00006747633,0.00012980653,0.00010148058,0.0000036027259,0.000027444961,8.4809284e-7,0.0001947631],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99959916,0.00010247305,0.000068471774,0.00006467377,0.00013799885,0.000027197879],"domain_scores_gemma":[0.99931645,0.00038107048,0.00014827038,0.0000147039445,0.00010660435,0.00003290603],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069544616,0.00040908615,0.0012515361,0.001793938,0.00021253912,0.00083182106,0.00054165215,0.0008674159,0.0028765013],"category_scores_gemma":[0.0015991894,0.00018188922,0.00081115257,0.0016500101,0.0002865523,0.00062234676,0.00048836775,0.0010243576,0.0007099928],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000116815216,0.00005223293,0.0017545449,0.035169195,0.0006265737,0.00049644784,0.000104059225,0.0002300411,0.0006770265,0.0015150559,0.018307105,0.9409509],"study_design_scores_gemma":[0.00005085371,0.00024160717,0.010060684,0.021778505,0.0013616428,0.011066653,0.00020200727,0.000116530806,0.0008462365,0.0022811699,0.9519554,0.000038666214],"about_ca_topic_score_codex":0.0011874292,"about_ca_topic_score_gemma":0.001824763,"teacher_disagreement_score":0.0028765013,"about_ca_system_score_codex":0.00048242186,"about_ca_system_score_gemma":0.0010669495,"threshold_uncertainty_score":0.009622812},"labels":[],"label_agreement":null},{"id":"W2220816567","doi":"10.3109/10428194.2015.1091929","title":"Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a meta-analysis","year":2015,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":92,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; McMaster University","funders":"","keywords":"Nilotinib; Bosutinib; Dasatinib; Medicine; Ponatinib; Imatinib; Internal medicine; Tyrosine kinase; Myeloid leukemia; Tyrosine-kinase inhibitor; Imatinib mesylate; Incidence (geometry); Oncology; Cancer","score_opus":0.024971778580207896,"score_gpt":0.26893631047231953,"score_spread":0.24396453189211165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2220816567","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0050509395,0.99343264,0.00037653637,0.00015672648,0.000102128295,0.00007092149,0.00052136247,0.000013572688,0.00027512547],"genre_scores_gemma":[0.17750274,0.81853133,0.0013356141,0.0006438639,0.00020552964,0.00024740072,0.0011002945,0.000020618032,0.00041264648],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9967709,0.0016722126,0.00072741485,0.0003739092,0.0003407485,0.00011466482],"domain_scores_gemma":[0.99430907,0.0043071415,0.0007467479,0.00016050537,0.00038520282,0.00009128835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0054276567,0.0017477659,0.008397931,0.0031910995,0.00031344697,0.0015161717,0.0010991802,0.0011605794,0.002896599],"category_scores_gemma":[0.0100612175,0.00087172445,0.02400736,0.004490217,0.00023869233,0.00078080595,0.0008299193,0.0013833598,0.00021838007],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029866893,0.000026874306,0.0075939074,0.17831242,0.7877946,0.00017240718,0.000045058816,0.0010033369,0.00028220654,0.00018700886,0.0013126777,0.020282833],"study_design_scores_gemma":[0.00047538453,0.00014132223,0.005990401,0.008773483,0.98097515,0.00012733231,0.000022285594,0.00027359792,0.00012635152,0.00024300489,0.0028341794,0.00001752023],"about_ca_topic_score_codex":0.004902283,"about_ca_topic_score_gemma":0.011238991,"teacher_disagreement_score":0.008397931,"about_ca_system_score_codex":0.0012673917,"about_ca_system_score_gemma":0.001152042,"threshold_uncertainty_score":0.028704524},"labels":[],"label_agreement":null},{"id":"W2223535813","doi":"10.3109/10428194.2016.1138292","title":"Investigating the synergistic mechanism between ibrutinib and daunorubicin in acute myeloid leukemia cells","year":2016,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Ibrutinib; Bruton's tyrosine kinase; Daunorubicin; Myeloid leukemia; Tyrosine kinase; Cancer research; Leukemia; Tyrosine-kinase inhibitor; Cytotoxic T cell; Medicine; Pharmacology; Immunology; Chemistry; Internal medicine; Receptor; Chronic lymphocytic leukemia; Biochemistry; Cancer","score_opus":0.018939623820719117,"score_gpt":0.26311155212537624,"score_spread":0.24417192830465712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2223535813","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.28278086,0.07756179,0.0033738548,0.5631711,0.018353969,0.0003375993,0.0005669877,0.0003131196,0.053540688],"genre_scores_gemma":[0.7851091,0.042985696,0.004240937,0.116440974,0.015930124,0.00030197445,0.00043348718,0.000038338032,0.03451928],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99970907,0.00009146623,0.000024313043,0.000032578162,0.000090540394,0.000052016334],"domain_scores_gemma":[0.99976426,0.00010301198,0.000023641585,0.000024152701,0.00004115634,0.000043851167],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048064004,0.00029324586,0.0005518913,0.00015850604,0.00068148144,0.000757176,0.0005316143,0.004059823,0.0027896704],"category_scores_gemma":[0.00095011195,0.0001570415,0.00040015494,0.00025512924,0.00042676384,0.0006591976,0.0002882833,0.003206454,0.001880285],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005611674,0.0011760453,0.012229234,0.0015250277,0.00018256449,0.08013521,0.00089767214,0.0013851584,0.1672966,0.019327272,0.40794238,0.30229115],"study_design_scores_gemma":[0.001625866,0.0032934656,0.011782628,0.00022689493,0.00031025583,0.09927801,0.00092450366,0.0047308435,0.10777119,0.018484917,0.7515084,0.000063013],"about_ca_topic_score_codex":0.00043901143,"about_ca_topic_score_gemma":0.0008466089,"teacher_disagreement_score":0.004059823,"about_ca_system_score_codex":0.0012478504,"about_ca_system_score_gemma":0.0003702062,"threshold_uncertainty_score":0.009332418},"labels":[],"label_agreement":null},{"id":"W2226640202","doi":"10.3109/10428194.2015.1128542","title":"Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients","year":2016,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital","funders":"","keywords":"Medicine; Multiple myeloma; Skin biopsy; Biopsy; Infiltration (HVAC); Immunohistochemistry; Pathology; Retrospective cohort study; Internal medicine","score_opus":0.02067668219786432,"score_gpt":0.2621880326709159,"score_spread":0.24151135047305158,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2226640202","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99926025,0.00026517213,0.0000829998,0.000012996211,0.0000021955925,0.000010254421,0.0001170025,0.0000032913294,0.00024584457],"genre_scores_gemma":[0.99958175,0.00012761455,0.000064370826,0.000018901828,0.000008185119,0.000009621049,0.00013548917,0.0000021410274,0.000051998646],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999582,0.00009169057,0.000062486644,0.00012909374,0.0000661417,0.00006869363],"domain_scores_gemma":[0.99886924,0.00020356862,0.000534704,0.000096892305,0.00008304498,0.00021253919],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047963727,0.00035514883,0.0004985328,0.00087387674,0.00067893515,0.0006376769,0.00028767763,0.00038890142,0.001571594],"category_scores_gemma":[0.0012600158,0.00044094303,0.00032007543,0.001162179,0.00033932074,0.00060237333,0.0005587802,0.00037564302,0.00031122292],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009129596,0.000035816134,0.99734384,0.000010238553,0.00003247503,0.0009512813,0.00009461941,0.000029121118,0.00030953376,0.000008182198,0.00004510883,0.0010485182],"study_design_scores_gemma":[0.000020002703,0.0003134926,0.9912806,0.000014442941,0.00006650555,0.007164446,0.0004160779,0.00014512424,0.00020624427,0.000020384465,0.00034380404,0.000009000281],"about_ca_topic_score_codex":0.002095102,"about_ca_topic_score_gemma":0.0019225588,"teacher_disagreement_score":0.002095102,"about_ca_system_score_codex":0.00033381837,"about_ca_system_score_gemma":0.00024065987,"threshold_uncertainty_score":0.0052574873},"labels":[],"label_agreement":null},{"id":"W2257900942","doi":"10.3109/10428194.2015.1088652","title":"A comparison of discharge strategies after chemotherapy completion in pediatric patients with acute myeloid leukemia: a report from the Children’s Oncology Group","year":2016,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Cancer Institute; National Institutes of Health","keywords":"Medicine; Chemotherapy; Myeloid leukemia; Induction chemotherapy; Bacteremia; Hypoxia (environmental); Internal medicine; Oncology; Antibiotics","score_opus":0.008103024406947731,"score_gpt":0.26274451110494745,"score_spread":0.25464148669799974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2257900942","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975504,0.0016568175,0.000101871825,0.00013773677,0.000006216266,0.000017650209,0.00019280837,0.0000022536917,0.00033431803],"genre_scores_gemma":[0.9980453,0.0013351429,0.00014743907,0.00007788395,0.000011027873,0.000018473285,0.0003186917,0.0000019906674,0.000043957665],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99876034,0.00050724903,0.00018600826,0.00010035388,0.00028954455,0.00015652398],"domain_scores_gemma":[0.9934409,0.0029745724,0.0025745062,0.00015807757,0.0005031712,0.00034871703],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016090063,0.00013754376,0.00027505663,0.00042770524,0.00023802304,0.00043715455,0.00020440866,0.000236891,0.0004900131],"category_scores_gemma":[0.008776711,0.000086352775,0.0006039995,0.000943555,0.00018535454,0.00034244457,0.00036005126,0.00040923263,0.00005843096],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005253489,0.00006443492,0.9836715,0.00007165013,0.00014777221,0.00008396344,0.00031594685,0.00013783411,0.00009809527,0.000036404625,0.00030782164,0.0145393],"study_design_scores_gemma":[0.00005487874,0.0005518445,0.9975514,0.000050510735,0.00009513418,0.00019666369,0.00066111324,0.00013573232,0.00013631409,0.000014686375,0.0005458261,0.0000059193176],"about_ca_topic_score_codex":0.0075346255,"about_ca_topic_score_gemma":0.010127194,"teacher_disagreement_score":0.0075346255,"about_ca_system_score_codex":0.00092269346,"about_ca_system_score_gemma":0.0010181507,"threshold_uncertainty_score":0.014981508},"labels":[],"label_agreement":null},{"id":"W2275216622","doi":"10.3109/10428194.2015.1117609","title":"Granulocyte colony-stimulating factor in secondary prophylaxis for advanced-stage Hodgkin lymphoma treated with ABVD chemotherapy: a cost-effectiveness analysis","year":2016,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Public Health Ontario; Grand River Hospital; Princess Margaret Cancer Centre; University of Toronto; Health Sciences Centre; Mount Sinai Hospital; Sunnybrook Health Science Centre","funders":"","keywords":"ABVD; Medicine; Neutropenia; Granulocyte colony-stimulating factor; Oncology; Internal medicine; Febrile neutropenia; Lymphoma; Chemotherapy; Quality-adjusted life year; Intensive care medicine; Cost effectiveness; Cyclophosphamide","score_opus":0.014681539980273708,"score_gpt":0.2786988909212562,"score_spread":0.2640173509409825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2275216622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92738456,0.020314652,0.026447132,0.003256284,0.00019975379,0.0030010985,0.004876286,0.00016494539,0.014355299],"genre_scores_gemma":[0.98960984,0.0025969,0.005693068,0.00026338876,0.000028326007,0.00035292772,0.0008071011,0.000013977011,0.00063442625],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.99701947,0.0021709832,0.000092881026,0.00014130205,0.00025793322,0.0003175033],"domain_scores_gemma":[0.99388087,0.005153941,0.00029762142,0.00007560757,0.00030221662,0.00028966932],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00485301,0.0015672313,0.0027411687,0.0021482194,0.00036858086,0.0019827264,0.0014023407,0.0012471884,0.0039656176],"category_scores_gemma":[0.013299581,0.00081973633,0.0049485895,0.001494742,0.00047981425,0.0010375481,0.00081145565,0.0015373708,0.00014004759],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008900859,0.0009295323,0.008956505,0.0014288268,0.0047499095,0.00027258426,0.000050907263,0.9368836,0.00046125002,0.0036551598,0.0012287209,0.03248209],"study_design_scores_gemma":[0.0036661364,0.003807256,0.007085497,0.0005200051,0.009535084,0.00027381798,0.00015141783,0.96883214,0.0005046308,0.003613481,0.0019226419,0.00008792372],"about_ca_topic_score_codex":0.098594695,"about_ca_topic_score_gemma":0.07458103,"teacher_disagreement_score":0.098594695,"about_ca_system_score_codex":0.012274669,"about_ca_system_score_gemma":0.009022488,"threshold_uncertainty_score":0.19604164},"labels":[],"label_agreement":null},{"id":"W2283880462","doi":"10.3109/10428194.2016.1140161","title":"B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL)","year":2016,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Medicine; Bortezomib; Internal medicine; Refractory (planetary science); Chemotherapy; Transplantation; Autologous stem-cell transplantation; Lymphoma; Gastroenterology; Oncology; Clinical endpoint; Randomized controlled trial; Multiple myeloma","score_opus":0.010912618588100553,"score_gpt":0.25292783276751835,"score_spread":0.2420152141794178,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2283880462","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99598783,0.0020565868,0.00027561642,0.00023345933,0.00016395819,0.0005974821,0.00015151438,0.000047450725,0.00048611645],"genre_scores_gemma":[0.99456394,0.0015050778,0.00084131234,0.0005067113,0.00025964412,0.0008632276,0.00043459653,0.000013454373,0.0010119765],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9994536,0.00035414918,0.000023417151,0.000060074788,0.000031305088,0.000077345794],"domain_scores_gemma":[0.99934167,0.00019334754,0.00014892602,0.000041078263,0.000018507018,0.00025655876],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015189064,0.0010500867,0.001912225,0.0003807877,0.00020544347,0.00081110926,0.00083605445,0.0013479925,0.002471212],"category_scores_gemma":[0.0010508683,0.00040335886,0.0010074783,0.00034181392,0.00082790793,0.00061213726,0.00038052537,0.0022225853,0.00040685304],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9614142,0.009582798,0.0009453414,0.00022810239,0.0006273767,0.000037563368,0.000035396246,0.00052994443,0.0044516576,0.00009004137,0.0003962939,0.021661239],"study_design_scores_gemma":[0.7554804,0.23797545,0.0033044522,0.000025687892,0.00049807684,0.00007725644,0.000022579428,0.0007124256,0.0011695785,0.00014434643,0.0005765859,0.000013256024],"about_ca_topic_score_codex":0.00061651337,"about_ca_topic_score_gemma":0.0013436147,"teacher_disagreement_score":0.002471212,"about_ca_system_score_codex":0.0006128069,"about_ca_system_score_gemma":0.0005697289,"threshold_uncertainty_score":0.008267045},"labels":[],"label_agreement":null},{"id":"W2294536664","doi":"10.3109/10428194.2016.1146950","title":"Impact of ruxolitinib treatment on the hemoglobin dynamics and the negative prognosis of anemia in patients with myelofibrosis","year":2016,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Myelofibrosis; Ruxolitinib; Medicine; Anemia; Hemoglobin; Internal medicine; Oncology; Bone marrow","score_opus":0.007914056492146979,"score_gpt":0.22774553025526542,"score_spread":0.21983147376311846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2294536664","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4025691,0.048113007,0.0006573415,0.49940953,0.004537904,0.00007073914,0.0006922022,0.00010351251,0.04384668],"genre_scores_gemma":[0.91790843,0.008754387,0.00069741765,0.0570297,0.012438299,0.000029925568,0.00030192785,0.000013353951,0.00282663],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99960774,0.00015135352,0.000046154102,0.00003469815,0.00011046028,0.00004968731],"domain_scores_gemma":[0.99884415,0.0005103102,0.00019329866,0.00003387943,0.00015926933,0.00025903076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041513273,0.00014627275,0.0005600442,0.0003051266,0.00043175044,0.0005254413,0.00027157218,0.0015884005,0.0011727733],"category_scores_gemma":[0.0046966155,0.000074487085,0.00022812224,0.0003886557,0.00029191727,0.0004357776,0.00018491357,0.0018457357,0.00055110885],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063468446,0.00064050016,0.32539475,0.00030638208,0.00020656666,0.059066474,0.0003395101,0.0011321489,0.006341114,0.0043206825,0.19612765,0.39977738],"study_design_scores_gemma":[0.0017799211,0.004270707,0.5944985,0.001790286,0.00081154786,0.17016427,0.0010345327,0.00889984,0.0037412874,0.0227501,0.1900423,0.00021658879],"about_ca_topic_score_codex":0.0011286583,"about_ca_topic_score_gemma":0.003124991,"teacher_disagreement_score":0.0015884005,"about_ca_system_score_codex":0.0010052751,"about_ca_system_score_gemma":0.0006130987,"threshold_uncertainty_score":0.0072938204},"labels":[],"label_agreement":null},{"id":"W2296118977","doi":"10.3109/10428194.2015.1128540","title":"Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial*","year":2016,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"National Cancer Institute","keywords":"Lenalidomide; Medicine; Tolerability; Neutropenia; Internal medicine; Discontinuation; Refractory (planetary science); Chronic lymphocytic leukemia; Adverse effect; Gastroenterology; Oncology; Surgery; Leukemia; Chemotherapy; Multiple myeloma","score_opus":0.01989551389267892,"score_gpt":0.3024081237141699,"score_spread":0.282512609821491,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2296118977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98951906,0.005121273,0.00070433324,0.0003613388,0.0001482896,0.0024787341,0.0005848496,0.00007861988,0.0010035916],"genre_scores_gemma":[0.990373,0.0020440824,0.002077271,0.00085695816,0.0003028452,0.00278587,0.00085026695,0.000031629468,0.0006780749],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978873,0.0014590401,0.0001866088,0.00021563469,0.00012053714,0.00013086341],"domain_scores_gemma":[0.9974081,0.00095024455,0.00068319053,0.00029154023,0.0001576718,0.0005092277],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0048954603,0.0013478262,0.0028216587,0.0003793721,0.0005021053,0.0011200925,0.0008462061,0.0016046499,0.002400928],"category_scores_gemma":[0.003345771,0.0006158659,0.0019246149,0.00048806643,0.0012162878,0.0010154678,0.00031242304,0.002381665,0.0004877102],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9481549,0.012372162,0.0021439774,0.00034685762,0.0010437155,0.000025487476,0.00007492599,0.0003309726,0.006089524,0.000043291944,0.00037608962,0.028998017],"study_design_scores_gemma":[0.8292229,0.16486128,0.00339211,0.000028071843,0.00061814836,0.00003648018,0.000020493877,0.00032693404,0.0008665605,0.000067162364,0.00054229185,0.000017653856],"about_ca_topic_score_codex":0.0004958653,"about_ca_topic_score_gemma":0.0011689173,"teacher_disagreement_score":0.0048954603,"about_ca_system_score_codex":0.0008769451,"about_ca_system_score_gemma":0.0011225106,"threshold_uncertainty_score":0.025889993},"labels":[],"label_agreement":null},{"id":"W2296287591","doi":"10.3109/10428194.2016.1153089","title":"STAT3 inhibitor has potent antitumor activity in B-lineage acute lymphoblastic leukemia cells overexpressing the high mobility group A1 (HMGA1)–STAT3 pathway","year":2016,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Cancer Institute","keywords":"Malignancy; Cancer research; Lymphoblastic Leukemia; Medicine; Acute leukemia; Cancer; STAT3; Leukemia; Immunology; Internal medicine; Apoptosis; Biology","score_opus":0.01465642014332335,"score_gpt":0.24176507810135878,"score_spread":0.22710865795803542,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2296287591","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.44898218,0.09494089,0.0042638043,0.32760686,0.01856609,0.00038812682,0.0017375986,0.0013434639,0.10217092],"genre_scores_gemma":[0.82029665,0.043587353,0.0032412573,0.08530731,0.009081561,0.000174105,0.0015008947,0.00010252533,0.036708288],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998739,0.000028056153,0.0000093409135,0.000015362204,0.00003903124,0.00003446003],"domain_scores_gemma":[0.9998387,0.00006286171,0.000018954455,0.000011256114,0.00002139054,0.000046848036],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002722992,0.00026081654,0.00050460815,0.00021894861,0.0003154865,0.00036717663,0.00031914853,0.001919476,0.0026753538],"category_scores_gemma":[0.00037418996,0.00010950043,0.00033319616,0.00028775664,0.00032738945,0.00026779898,0.00013994893,0.0021035771,0.001441052],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063160467,0.0012843962,0.009276934,0.0011988432,0.00010785854,0.04047278,0.00024975388,0.0011192065,0.1324057,0.007787883,0.4528903,0.34689033],"study_design_scores_gemma":[0.0026705088,0.00903145,0.020416806,0.00026383158,0.0001863547,0.06805231,0.00021487825,0.005257814,0.11002334,0.0054053883,0.77838606,0.00009134581],"about_ca_topic_score_codex":0.0005648534,"about_ca_topic_score_gemma":0.0017585367,"teacher_disagreement_score":0.0026753538,"about_ca_system_score_codex":0.0007298903,"about_ca_system_score_gemma":0.0003123906,"threshold_uncertainty_score":0.008949935},"labels":[],"label_agreement":null},{"id":"W2299133976","doi":"10.3109/10428194.2016.1157878","title":"Pre- and post-treatment serum ferritin levels in patients with higher risk myelodysplastic syndromes receiving azacitidine","year":2016,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Myelodysplastic syndromes; Azacitidine; Medicine; Myeloid leukemia; Internal medicine; Serum ferritin; Anemia; Oncology; Ferritin; Myeloid; Bone marrow; Gene","score_opus":0.011453141841531444,"score_gpt":0.23782365249906168,"score_spread":0.22637051065753022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2299133976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5435942,0.020600049,0.0006702023,0.37294528,0.0040773153,0.00007805271,0.0002984721,0.00009415323,0.05764228],"genre_scores_gemma":[0.9276345,0.004748817,0.00062438543,0.05555971,0.007225364,0.000028538547,0.00016372274,0.000015145525,0.003999736],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996119,0.00012374861,0.000042781718,0.0000506566,0.0000845397,0.000086389635],"domain_scores_gemma":[0.9989766,0.00041522027,0.00015004151,0.000041302203,0.00011905163,0.00029774816],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003679654,0.0002073846,0.00043619509,0.0005027477,0.00094339723,0.00055315526,0.00042331783,0.0036488755,0.0023617528],"category_scores_gemma":[0.003383362,0.0001466174,0.00029375489,0.0005616428,0.00057529344,0.00063818187,0.00019652114,0.0024351475,0.00057762937],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024092596,0.0005385506,0.46966356,0.00021957845,0.000090754314,0.32860792,0.001000536,0.0005172182,0.0043658335,0.0028078528,0.09018525,0.0995938],"study_design_scores_gemma":[0.00052101526,0.0016370367,0.36369473,0.0009653245,0.00025721165,0.5532548,0.002447145,0.002959325,0.0012904338,0.012553595,0.06030341,0.00011608716],"about_ca_topic_score_codex":0.0031399585,"about_ca_topic_score_gemma":0.0051395185,"teacher_disagreement_score":0.0036488755,"about_ca_system_score_codex":0.0011806227,"about_ca_system_score_gemma":0.00066152407,"threshold_uncertainty_score":0.008566022},"labels":[],"label_agreement":null},{"id":"W2301625000","doi":"10.3109/10428194.2016.1160084","title":"Azacitidine in the treatment of blastic plasmacytoid dendritic cell neoplasm: a report of 3 cases","year":2016,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Cutaneous lymphoproliferative disorders research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Azacitidine; Medicine; Neoplasm; Cancer research; Myeloproliferative neoplasm; Plasmacytoid dendritic cell; Internal medicine; Immunology; Bone marrow; Biology; Pathology; Dendritic cell; Genetics; Antigen; Myelofibrosis; Gene","score_opus":0.020069063602651687,"score_gpt":0.2746700720578132,"score_spread":0.2546010084551615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2301625000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88043547,0.0488969,0.006927406,0.018874168,0.001899443,0.00039758062,0.00053041923,0.00044341738,0.041595027],"genre_scores_gemma":[0.976715,0.010214708,0.0022125824,0.004699951,0.0022291194,0.000074264724,0.00027778995,0.000052433665,0.0035240573],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99946624,0.000085278945,0.00007692417,0.00012374026,0.00009258989,0.0001551833],"domain_scores_gemma":[0.9993413,0.00020246166,0.00012085803,0.00007646081,0.000055391018,0.00020353493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031074023,0.0010035124,0.00093148724,0.0012931586,0.0017665714,0.0012005463,0.0010058575,0.0059123216,0.0014816759],"category_scores_gemma":[0.0017018124,0.0005123433,0.0008383564,0.0011871674,0.000925354,0.0011022027,0.0007680045,0.0026546118,0.0008959959],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000056410234,0.00004252074,0.0046854164,0.00004296948,0.000012465171,0.98897845,0.000113527356,0.0000801414,0.0010640755,0.00015652645,0.0007919794,0.003975551],"study_design_scores_gemma":[0.000021249136,0.00004611316,0.002362176,0.000013718046,0.00001997832,0.99502003,0.000054131422,0.00015820462,0.00034779523,0.00011801737,0.0018318231,0.0000067711944],"about_ca_topic_score_codex":0.0018674432,"about_ca_topic_score_gemma":0.002448879,"teacher_disagreement_score":0.0059123216,"about_ca_system_score_codex":0.0013392919,"about_ca_system_score_gemma":0.00068455096,"threshold_uncertainty_score":0.009717226},"labels":[],"label_agreement":null},{"id":"W2344741804","doi":"10.1080/10428194.2016.1177772","title":"A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation","year":2016,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Celgene","keywords":"Lenalidomide; Multiple myeloma; Medicine; Thalidomide; Oncology; Internal medicine; Autologous stem-cell transplantation; Bortezomib; Melphalan; Transplantation; Progression-free survival; Meta-analysis; Surgery; Chemotherapy","score_opus":0.033855129194133374,"score_gpt":0.30208937127960067,"score_spread":0.2682342420854673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2344741804","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0020713718,0.9957408,0.0003852839,0.0002174383,0.00011149267,0.00023684102,0.00086485245,0.0000135982555,0.00035847002],"genre_scores_gemma":[0.070299074,0.9254103,0.0015092087,0.00069271785,0.00013079829,0.000715331,0.0009942887,0.000017682658,0.00023067363],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9933227,0.0032254169,0.0019377671,0.0006287764,0.000689083,0.00019635382],"domain_scores_gemma":[0.9884759,0.008779398,0.0015815897,0.0002569198,0.0007657191,0.00014045268],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008563203,0.0021482867,0.012053029,0.006563553,0.0005060259,0.00227645,0.001567017,0.0014572797,0.0047539137],"category_scores_gemma":[0.02467288,0.00090940465,0.022936665,0.008621072,0.00045896647,0.0013872465,0.0012431868,0.0015963947,0.00034202923],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001156344,0.000028317745,0.002065182,0.6489086,0.32247278,0.00012443161,0.000075839045,0.00062364613,0.0001627235,0.00028036453,0.0013399243,0.022761846],"study_design_scores_gemma":[0.00060410897,0.00015877304,0.0033709374,0.06565692,0.9234904,0.00013500168,0.00005151549,0.00020649789,0.00010577644,0.00046177264,0.005731266,0.000027072558],"about_ca_topic_score_codex":0.009562813,"about_ca_topic_score_gemma":0.022058714,"teacher_disagreement_score":0.012053029,"about_ca_system_score_codex":0.0028903766,"about_ca_system_score_gemma":0.0047420906,"threshold_uncertainty_score":0.045287073},"labels":[],"label_agreement":null},{"id":"W2377143140","doi":"10.1080/10428194.2016.1180685","title":"Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS)","year":2016,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Hotel Dieu Hospital","funders":"","keywords":"Pomalidomide; Medicine; Dexamethasone; Lenalidomide; Randomization; Multiple myeloma; Internal medicine; Refractory (planetary science); Gastroenterology; Phases of clinical research; Randomized controlled trial; Progressive disease; Surgery; Clinical trial; Chemotherapy","score_opus":0.018214258481873274,"score_gpt":0.2731410443367429,"score_spread":0.2549267858548696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2377143140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99589986,0.0025053096,0.00009545367,0.0003083331,0.00006787049,0.00015086315,0.00037534066,0.000020539206,0.00057638274],"genre_scores_gemma":[0.9966543,0.0006969286,0.0003563982,0.0004160102,0.00012023365,0.00023820366,0.0010267557,0.000007883622,0.00048314902],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.999393,0.00041729343,0.000029209295,0.000060698032,0.000046534533,0.00005318507],"domain_scores_gemma":[0.9992409,0.00020734129,0.00023061123,0.000042839558,0.000022720043,0.00025560858],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022518677,0.0004390418,0.0009590221,0.00019270096,0.0002110649,0.0007801132,0.00042014703,0.000622474,0.001386421],"category_scores_gemma":[0.0015300354,0.00015658142,0.00091930485,0.0002847733,0.00034140292,0.0003546885,0.00029762232,0.0013638688,0.00018574376],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90435433,0.00422145,0.039937783,0.00028871628,0.0014401808,0.00006361512,0.00008196256,0.0010259271,0.0043173074,0.00014337516,0.0022226393,0.041902732],"study_design_scores_gemma":[0.5701617,0.19097532,0.22561887,0.00015002416,0.0019380272,0.000306734,0.00009277984,0.0044958172,0.0018671216,0.0006987309,0.003646867,0.000048050533],"about_ca_topic_score_codex":0.00084889936,"about_ca_topic_score_gemma":0.0019560605,"teacher_disagreement_score":0.0022518677,"about_ca_system_score_codex":0.0006523283,"about_ca_system_score_gemma":0.00071874354,"threshold_uncertainty_score":0.011909127},"labels":[],"label_agreement":null},{"id":"W2397442087","doi":"10.1080/10428194.2016.1179295","title":"Validation of the NCCN-IPI in both <i>de novo</i> and transformed diffuse large B cell lymphoma","year":2016,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Diffuse large B-cell lymphoma; International Prognostic Index; Medicine; Lymphoma; Risk stratification; Internal medicine; Oncology","score_opus":0.0074482426832511335,"score_gpt":0.21808160447531527,"score_spread":0.21063336179206413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2397442087","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15445349,0.00931559,0.0029608048,0.76184034,0.015435266,0.00020704225,0.0009947718,0.00016350298,0.054629162],"genre_scores_gemma":[0.7472032,0.004106234,0.006697578,0.2113406,0.018668875,0.00025803357,0.0014048824,0.00007978374,0.010240881],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99702173,0.0011813616,0.00047977993,0.00020707131,0.0007968364,0.00031325215],"domain_scores_gemma":[0.9908263,0.0036484643,0.00046740822,0.00073878514,0.003689094,0.0006300095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00522155,0.00022514592,0.00050512154,0.00042073824,0.00078051956,0.001355359,0.000700068,0.003875916,0.0013576658],"category_scores_gemma":[0.020491656,0.00019373708,0.0003630866,0.0004167622,0.001144343,0.000950461,0.00040733308,0.0042125066,0.002400245],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011824146,0.00028739445,0.26907623,0.00032229928,0.000080248064,0.027896058,0.0014544752,0.0007549194,0.00992866,0.007486076,0.45350197,0.22802927],"study_design_scores_gemma":[0.0004295466,0.0014736186,0.1482458,0.0013058165,0.00022367941,0.10506187,0.0034012662,0.010157531,0.016435113,0.020154795,0.6929438,0.00016720222],"about_ca_topic_score_codex":0.0041446136,"about_ca_topic_score_gemma":0.006188604,"teacher_disagreement_score":0.00522155,"about_ca_system_score_codex":0.0018049955,"about_ca_system_score_gemma":0.0013537762,"threshold_uncertainty_score":0.027614474},"labels":[],"label_agreement":null},{"id":"W2399783955","doi":"10.3109/10428194.2016.1171861","title":"Next-generation sequencing identifies a novel<i>ELAVL1–TYK2</i>fusion gene in MOLM-16, an AML cell line highly sensitive to the PIM kinase inhibitor AZD1208","year":2016,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Cancer Mechanisms and Therapy","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Institute for Health and Care Research","keywords":"Fusion gene; Gene; Biology; Kinase; DNA sequencing; Cancer research; Genetics; Computational biology","score_opus":0.029012575121624855,"score_gpt":0.24390346093335952,"score_spread":0.21489088581173466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2399783955","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.69454205,0.005770967,0.0067342254,0.244487,0.0062293974,0.00025107522,0.0015318173,0.0008220613,0.039631397],"genre_scores_gemma":[0.94024426,0.0020994633,0.0029864828,0.03793105,0.0035886185,0.00006953206,0.000505705,0.00009546173,0.012479421],"study_design_codex":"case_report","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996805,0.00004614575,0.000029575445,0.00007207036,0.00008335597,0.00008844421],"domain_scores_gemma":[0.9995034,0.00022496287,0.000052290045,0.00003516096,0.000064985965,0.000119276854],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027352784,0.0004767712,0.00059881713,0.0003692475,0.000695957,0.0009049609,0.0005731548,0.00492508,0.0019669272],"category_scores_gemma":[0.0010258474,0.00022310046,0.00041274895,0.00025320536,0.0007207724,0.00044765134,0.00021204057,0.0033035525,0.001225226],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013870246,0.0002965824,0.024352347,0.00024905268,0.00009021398,0.7143017,0.0005249356,0.00086057826,0.10395811,0.004093862,0.09860368,0.051281907],"study_design_scores_gemma":[0.00036562522,0.00086699525,0.03870298,0.0001340973,0.00023147189,0.7675633,0.0007699183,0.012072705,0.058382075,0.00755093,0.11328368,0.00007616611],"about_ca_topic_score_codex":0.0014276108,"about_ca_topic_score_gemma":0.0019241641,"teacher_disagreement_score":0.00492508,"about_ca_system_score_codex":0.0012087852,"about_ca_system_score_gemma":0.00032731707,"threshold_uncertainty_score":0.008770347},"labels":[],"label_agreement":null},{"id":"W2404590269","doi":"10.1080/10428194.2016.1180681","title":"Chemotherapeutic treatment is associated with Notch1 induction in cutaneous T-cell lymphoma","year":2016,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Cutaneous lymphoproliferative disorders research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Gemcitabine; Etoposide; Cancer research; Chemotherapy; Doxorubicin; Notch signaling pathway; Downregulation and upregulation; Gene knockdown; Lymphoma; Medicine; Biology; Cell culture; Immunology; Internal medicine; Receptor; Gene","score_opus":0.01645850853920417,"score_gpt":0.25578618355007976,"score_spread":0.2393276750108756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2404590269","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966505,0.0014986412,0.00045585437,0.000034679768,0.000007884916,0.000022798382,0.000141478,0.000034101042,0.0011540285],"genre_scores_gemma":[0.99845874,0.00043055016,0.00019552991,0.000021901662,0.0000033544327,0.000020476225,0.00016563624,0.0000036327115,0.0007001994],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999089,0.000022857892,0.000009358584,0.000014560544,0.00002309923,0.000021060932],"domain_scores_gemma":[0.9998971,0.000018317567,0.000041678566,0.000012029371,0.0000104434175,0.000020274732],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006174362,0.000116197116,0.00017333114,0.00016939298,0.00009907589,0.00019197345,0.000062069674,0.00014103793,0.0018750072],"category_scores_gemma":[0.00012208993,0.00007074902,0.0001318437,0.00017042254,0.000084770945,0.000086886044,0.00011553509,0.00021831616,0.00026589163],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020064673,0.00006266056,0.0023219436,0.000049300004,0.0000064445344,0.00023471922,0.0000172216,0.00003846488,0.99408096,0.000040776995,0.000067577144,0.0028794091],"study_design_scores_gemma":[0.00005136552,0.0012802534,0.114741616,0.00001410612,0.00004812229,0.0021026512,0.00008167348,0.00090362295,0.8775451,0.00006287125,0.0031628625,0.000005851797],"about_ca_topic_score_codex":0.00027128364,"about_ca_topic_score_gemma":0.00037007584,"teacher_disagreement_score":0.0018750072,"about_ca_system_score_codex":0.00020369812,"about_ca_system_score_gemma":0.000082954706,"threshold_uncertainty_score":0.0062725544},"labels":[],"label_agreement":null},{"id":"W2406330856","doi":"10.1080/10428194.2016.1180684","title":"Increased protein processing gene signature in HDACi-resistant cells predicts response to proteasome inhibitors","year":2016,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"National Cancer Institute; Doris Duke Charitable Foundation; Roche; Canadian Institutes of Health Research; Novartis; American Society of Hematology; Samuel Waxman Cancer Research Foundation","keywords":"Histone deacetylase; Cancer research; Gene signature; Proteasome; Histone; HDAC11; Histone deacetylase inhibitor; Gene; Proteasome inhibitor; Biology; Chemistry; Gene expression; Cell biology; Genetics","score_opus":0.005991476028193569,"score_gpt":0.22485079635543084,"score_spread":0.21885932032723726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2406330856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6407252,0.009484039,0.007041399,0.2578055,0.009352272,0.0003865989,0.0014896161,0.0006883889,0.07302705],"genre_scores_gemma":[0.93635136,0.003237658,0.0024781374,0.03842199,0.006361892,0.00012751229,0.0004319177,0.00007075003,0.012518668],"study_design_codex":"case_report","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996562,0.00008738767,0.000043803837,0.00005389809,0.00009535419,0.00006330067],"domain_scores_gemma":[0.9989938,0.00052701787,0.00011520188,0.000121749166,0.00013171257,0.0001105318],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036715422,0.00027579034,0.0004862932,0.0003269216,0.00033858413,0.0005150624,0.00031371543,0.0017827267,0.002914076],"category_scores_gemma":[0.0019203777,0.00012297172,0.0002550052,0.00031822216,0.00048631243,0.0003340626,0.00014084844,0.0016933243,0.001773454],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007260754,0.0007854472,0.18075183,0.0004230401,0.000120792436,0.23866817,0.00059503096,0.0010415965,0.16116436,0.005809488,0.2265123,0.17686707],"study_design_scores_gemma":[0.000739182,0.002585871,0.2833868,0.00026601797,0.0001884532,0.4200928,0.0008710631,0.0102690505,0.058302566,0.015981974,0.20720817,0.00010799718],"about_ca_topic_score_codex":0.00025845057,"about_ca_topic_score_gemma":0.00044351915,"teacher_disagreement_score":0.002914076,"about_ca_system_score_codex":0.00051387126,"about_ca_system_score_gemma":0.00013478441,"threshold_uncertainty_score":0.0097485185},"labels":[],"label_agreement":null},{"id":"W2409070542","doi":"10.1080/10428194.2016.1177181","title":"Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials","year":2016,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital; Vancouver General Hospital","funders":"Celgene","keywords":"Pomalidomide; Medicine; Dexamethasone; Multiple myeloma; Internal medicine; Clinical trial; Urology; Renal function; Refractory (planetary science); Creatinine; Dosing; Surgery; Lenalidomide; Gastroenterology","score_opus":0.034032644198169676,"score_gpt":0.3138947330508331,"score_spread":0.2798620888526634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2409070542","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.36568096,0.6216179,0.0024643748,0.0008277529,0.00053125515,0.0019552761,0.0041036694,0.00014305221,0.0026758076],"genre_scores_gemma":[0.94334936,0.049977995,0.0016950483,0.00085076253,0.00032898784,0.00092924177,0.0024461406,0.00003016425,0.00039236667],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9902041,0.00603861,0.0017448493,0.00089198747,0.0008854554,0.0002349433],"domain_scores_gemma":[0.99326706,0.0029966114,0.0025761137,0.00044332596,0.0004540814,0.00026285177],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.014828201,0.0014113656,0.0062814876,0.0016786898,0.00027333517,0.002188344,0.0007012402,0.0009908061,0.001201604],"category_scores_gemma":[0.01290995,0.0005905655,0.014537757,0.0025374277,0.0004308172,0.00084158394,0.00089423306,0.0009939839,0.00015305777],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1980167,0.00022268589,0.024964465,0.021764474,0.7124927,0.00012102835,0.00008659542,0.0013990838,0.0013920557,0.00012841253,0.0013354154,0.03807631],"study_design_scores_gemma":[0.08734886,0.010756073,0.07361387,0.0020564063,0.818695,0.00031762777,0.000118738535,0.001226457,0.00076847937,0.00054200774,0.0044680513,0.000088352324],"about_ca_topic_score_codex":0.0011970539,"about_ca_topic_score_gemma":0.002835346,"teacher_disagreement_score":0.9937185,"about_ca_system_score_codex":0.0008933656,"about_ca_system_score_gemma":0.0009957872,"threshold_uncertainty_score":0.07841998},"labels":[],"label_agreement":null},{"id":"W2411938662","doi":"10.1080/10428194.2016.1185785","title":"Novel regimens prior to autologous stem cell transplantation for the management of adults with relapsed/refractory non-Hodgkin lymphoma and Hodgkin lymphoma: alternatives to BEAM conditioning","year":2016,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Fluidigm (Canada)","funders":"","keywords":"Carmustine; Melphalan; Medicine; Etoposide; Bendamustine; Oncology; Busulfan; Tolerability; Lymphoma; Internal medicine; Regimen; Brentuximab vedotin; Transplantation; Cyclophosphamide; Chemotherapy; Surgery; Hodgkin lymphoma; Rituximab","score_opus":0.015033059829724846,"score_gpt":0.27165723905321304,"score_spread":0.2566241792234882,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2411938662","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014842194,0.99931204,0.0000488103,0.00007104418,0.00004611093,0.00000564261,0.000008666996,0.0000026143232,0.0003567857],"genre_scores_gemma":[0.0012354127,0.9981407,0.00018199111,0.00013107077,0.000058439637,0.0000085548545,0.000028223742,0.0000011195242,0.00021441258],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998159,0.00004367317,0.000037729176,0.000033298547,0.0000566044,0.000012830267],"domain_scores_gemma":[0.9998204,0.000095555755,0.000041557018,0.0000049288114,0.000027312195,0.000010253625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004040959,0.0005472095,0.0012280921,0.001681534,0.00019079025,0.00059352285,0.0006897338,0.0007507456,0.0035265724],"category_scores_gemma":[0.0005905393,0.000182519,0.00077965093,0.0011331431,0.00027962704,0.00086266577,0.0003687805,0.0013400965,0.0010585332],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013543211,0.00010841163,0.0001569327,0.040221725,0.0002009247,0.00016240914,0.0000499091,0.00020148962,0.0013310318,0.0010516474,0.008371567,0.94800854],"study_design_scores_gemma":[0.00016215918,0.00042414514,0.0026029013,0.01967488,0.0008753803,0.004067288,0.00011791527,0.00012567766,0.0011833925,0.0013266318,0.9694084,0.00003122597],"about_ca_topic_score_codex":0.00084875344,"about_ca_topic_score_gemma":0.002029283,"teacher_disagreement_score":0.0035265724,"about_ca_system_score_codex":0.00030391014,"about_ca_system_score_gemma":0.0005268498,"threshold_uncertainty_score":0.011797547},"labels":[],"label_agreement":null},{"id":"W2419412633","doi":"10.1080/10428194.2016.1187274","title":"Effect of the addition of rituximab to salvage chemotherapy prior to autologous stem cell transplant in aggressive CD20+ lymphoma: a cohort comparison from the NCIC Clinical Trials Group Study LY.12<sup>*</sup>","year":2016,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of Manitoba; Princess Margaret Cancer Centre; Sunnybrook Health Science Centre; London Health Sciences Centre; Queen's University; Juravinski Hospital; Queen Elizabeth II Health Sciences Centre; Health Sciences Centre","funders":"Canadian Cancer Society Research Institute","keywords":"Medicine; Rituximab; CHOP; Internal medicine; Cohort; Oncology; Autologous stem-cell transplantation; Transplantation; Chemotherapy; Surgery; Salvage therapy; Lymphoma; Gastroenterology","score_opus":0.022262845710548543,"score_gpt":0.3168151131251936,"score_spread":0.2945522674146451,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2419412633","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99718386,0.0020319163,0.00008077281,0.00007257454,0.000033898872,0.00009482689,0.00023815119,0.0000053575227,0.00025868134],"genre_scores_gemma":[0.9979603,0.0006867742,0.00016773058,0.00017118124,0.00008093605,0.00013103086,0.0006469921,0.000006161046,0.00014898235],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9972289,0.0017350256,0.00029506808,0.00033890078,0.00019960872,0.00020252523],"domain_scores_gemma":[0.99604404,0.001456499,0.0011591642,0.0005068788,0.00020079885,0.0006326602],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004974803,0.0007614343,0.0016821895,0.00044031994,0.00033152066,0.001176965,0.00060122646,0.0010548126,0.0013014823],"category_scores_gemma":[0.0058379094,0.00035821187,0.0029976063,0.0006129748,0.00048947276,0.0005900571,0.0005168277,0.0012265216,0.0002519548],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8467816,0.003401453,0.10462523,0.00033420758,0.011293295,0.00019868618,0.00022017778,0.0007596467,0.004548738,0.00006817993,0.00076790334,0.027000885],"study_design_scores_gemma":[0.16517302,0.27290657,0.52762324,0.00020526708,0.023874277,0.0006491556,0.0004706126,0.0019607334,0.0034838656,0.00028677442,0.0032364652,0.00012998287],"about_ca_topic_score_codex":0.0017971122,"about_ca_topic_score_gemma":0.00354956,"teacher_disagreement_score":0.004974803,"about_ca_system_score_codex":0.0008278283,"about_ca_system_score_gemma":0.00088478636,"threshold_uncertainty_score":0.02630955},"labels":[],"label_agreement":null},{"id":"W2460247604","doi":"10.1080/10428194.2016.1193852","title":"Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed/refractory diffuse large B-cell lymphoma and Hodgkin lymphoma","year":2016,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Gemcitabine; Salvage therapy; Medicine; Internal medicine; Regimen; Oncology; Diffuse large B-cell lymphoma; Refractory (planetary science); Lymphoma; Dexamethasone; Chemotherapy; Surgery; Biology","score_opus":0.009841282103977077,"score_gpt":0.2455668701614619,"score_spread":0.2357255880574848,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2460247604","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98752105,0.010360017,0.00019364874,0.00022737066,0.00001130756,0.000059184298,0.00020319155,0.00002154373,0.0014025974],"genre_scores_gemma":[0.9943157,0.0043563345,0.00028816392,0.00015262181,0.000023843348,0.000014346073,0.00044014433,0.0000031446589,0.00040570932],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9998658,0.000048659385,0.000017348004,0.0000169182,0.000034147753,0.000017196102],"domain_scores_gemma":[0.99977905,0.00004886931,0.00006390498,0.000018942086,0.000015663456,0.00007368681],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022156611,0.000117702824,0.0004294092,0.0002990761,0.00019928646,0.00028343013,0.00017731923,0.00012583785,0.00061595597],"category_scores_gemma":[0.0005003838,0.00007937089,0.00010497083,0.00043613563,0.00016248785,0.00014026114,0.0001625235,0.0002171925,0.00016930595],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045301705,0.0007067889,0.49777195,0.00041890275,0.00018152724,0.0028006078,0.00017640796,0.0007526542,0.01755265,0.00009633615,0.0034293004,0.47158265],"study_design_scores_gemma":[0.00075515814,0.0071137585,0.9455962,0.00017357971,0.00024641494,0.01405268,0.00030734763,0.0012581727,0.008318218,0.00019277983,0.021967424,0.000018300821],"about_ca_topic_score_codex":0.0018149664,"about_ca_topic_score_gemma":0.011420283,"teacher_disagreement_score":0.0018149664,"about_ca_system_score_codex":0.0004996972,"about_ca_system_score_gemma":0.0005203764,"threshold_uncertainty_score":0.0036255717},"labels":[],"label_agreement":null},{"id":"W2470838233","doi":"10.1080/10428194.2016.1196815","title":"FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS study","year":2016,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Queen's University; BC Cancer Agency; Princess Margaret Cancer Centre; Kingston General Hospital; University of Toronto","funders":"F. Hoffmann-La Roche; Roche","keywords":"Medicine; Follicular lymphoma; Internal medicine; Hazard ratio; Oncology; Positron emission tomography; Lymphoma; Obinutuzumab; Nuclear medicine; Standardized uptake value; Rituximab; Progression-free survival; Prospective cohort study; PET-CT; Overall survival; Confidence interval","score_opus":0.013231878525028678,"score_gpt":0.2600789023359821,"score_spread":0.2468470238109534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2470838233","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9996178,0.00014279097,0.000040523893,0.0000118566495,7.0802355e-7,0.0000057673374,0.000070728194,0.0000023126236,0.00010733223],"genre_scores_gemma":[0.9996555,0.000026544925,0.00006647858,0.000011605005,0.0000037981822,0.000005105698,0.00019055653,0.0000018794353,0.00003845706],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994198,0.00034973575,0.000033528504,0.00007993001,0.00006381139,0.000053257056],"domain_scores_gemma":[0.9985373,0.00054652605,0.00038868058,0.00021495832,0.00009257762,0.00021990758],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019189682,0.00034358795,0.00056763424,0.00045548496,0.00019683281,0.00071738375,0.0003463751,0.00036916812,0.0007355214],"category_scores_gemma":[0.0027410814,0.00021877626,0.0006150259,0.00036602054,0.00038013505,0.0003161634,0.0004879666,0.00038827502,0.00018292372],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048061735,0.00006594582,0.9899159,0.000012748469,0.00020861301,0.0001584934,0.00008113686,0.00015499505,0.0015531792,0.000021940916,0.00008925369,0.0029316545],"study_design_scores_gemma":[0.00026163887,0.001016797,0.9963325,0.000007242878,0.00025233458,0.00050999684,0.00012431857,0.0006973321,0.00036001223,0.00006877923,0.00036091977,0.000007947466],"about_ca_topic_score_codex":0.00069811265,"about_ca_topic_score_gemma":0.00077674177,"teacher_disagreement_score":0.0019189682,"about_ca_system_score_codex":0.00024678282,"about_ca_system_score_gemma":0.0001959271,"threshold_uncertainty_score":0.010148585},"labels":[],"label_agreement":null},{"id":"W2508095929","doi":"10.1080/10428194.2016.1218005","title":"The mitochondria target drug avocatin B synergizes with induction chemotherapeutics to induce leukemia cell death","year":2016,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Centre for Drug Research and Development; University of Waterloo","funders":"","keywords":"Drug; Leukemia; Programmed cell death; Cancer research; Mitochondrion; Apoptosis; Biology; Medicine; Pharmacology; Immunology; Cell biology; Biochemistry","score_opus":0.013085849444078186,"score_gpt":0.24691204312996085,"score_spread":0.23382619368588267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2508095929","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12746637,0.06803909,0.006177347,0.66965204,0.027809307,0.0003817252,0.00055335974,0.001491839,0.09842891],"genre_scores_gemma":[0.6441534,0.0480452,0.0034356613,0.23680948,0.03907496,0.00028172633,0.0005446163,0.00014278741,0.027512204],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99946123,0.00013885343,0.000034700875,0.00006362589,0.00022234616,0.00007926772],"domain_scores_gemma":[0.9993235,0.0003339271,0.00008574788,0.000045049044,0.00007129782,0.00014059371],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004610012,0.00034191576,0.0006554239,0.00035373977,0.00067832525,0.00068939995,0.00057389576,0.0035986546,0.0025733807],"category_scores_gemma":[0.0018040144,0.00015392566,0.00042523022,0.00029411275,0.0007790122,0.0007030429,0.00056692923,0.004107192,0.0022970003],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020214557,0.00048352528,0.0041669332,0.00080805994,0.00012348293,0.027011456,0.00029063175,0.00083635363,0.044252258,0.01627218,0.5592256,0.34450805],"study_design_scores_gemma":[0.0012133338,0.0024977815,0.004883412,0.00035102802,0.00009661698,0.062220056,0.00024022876,0.0028496643,0.033198956,0.017457947,0.8749112,0.00007982612],"about_ca_topic_score_codex":0.00027002746,"about_ca_topic_score_gemma":0.0008690507,"teacher_disagreement_score":0.0035986546,"about_ca_system_score_codex":0.0014060878,"about_ca_system_score_gemma":0.00042188607,"threshold_uncertainty_score":0.010201931},"labels":[],"label_agreement":null},{"id":"W2508313410","doi":"10.1080/10428194.2016.1222376","title":"Comparison of a pediatric-inspired treatment protocol versus standard-intensity chemotherapy for young adults with standard-risk BCR-ABL negative acute lymphoblastic leukemia","year":2016,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Vancouver General Hospital","funders":"BC Cancer Agency","keywords":"Medicine; Lymphoblastic Leukemia; Retrospective cohort study; Cohort; Chemotherapy; Pediatrics; Young adult; Internal medicine; Complete remission; Overall survival; Acute lymphocytic leukemia; Oncology; Leukemia","score_opus":0.017547924228737764,"score_gpt":0.306720113224732,"score_spread":0.2891721889959943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2508313410","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99672014,0.0010133279,0.00056969747,0.00010696752,0.000019272313,0.00054515497,0.000089376495,0.0000064754868,0.0009295915],"genre_scores_gemma":[0.99413127,0.0013815121,0.0028231333,0.0001927813,0.000037697064,0.0009210643,0.0003761291,0.0000040928417,0.00013219839],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9988551,0.00082066853,0.00010038666,0.000060136805,0.00011610823,0.000047569676],"domain_scores_gemma":[0.99847084,0.0004901539,0.0005560711,0.000106761676,0.00012447244,0.00025164586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018848268,0.00016912622,0.00030881408,0.00026803015,0.00017255577,0.0002745544,0.0002877029,0.00021696917,0.00061730476],"category_scores_gemma":[0.004787525,0.00008587666,0.00029636853,0.0004060018,0.00017725669,0.00032521065,0.00032466327,0.0003333668,0.00007102699],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.114814095,0.010226,0.33910477,0.0011209117,0.0012165689,0.0005345636,0.001103583,0.009211478,0.009133299,0.0017063085,0.0023080497,0.5095205],"study_design_scores_gemma":[0.026211167,0.4389009,0.50300074,0.00035843017,0.0012350072,0.001790025,0.0010426282,0.0063705454,0.0051312186,0.00082738546,0.015082808,0.000049203045],"about_ca_topic_score_codex":0.00075583655,"about_ca_topic_score_gemma":0.0020816391,"teacher_disagreement_score":0.0018848268,"about_ca_system_score_codex":0.00082625524,"about_ca_system_score_gemma":0.0014679709,"threshold_uncertainty_score":0.009968042},"labels":[],"label_agreement":null},{"id":"W2515657367","doi":"10.1080/10428194.2016.1204657","title":"Leukocytoclastic vasculitis following lenalidomide during the treatment of follicular lymphoma","year":2016,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Lenalidomide; Thalidomide; Medicine; Multiple myeloma; Follicular lymphoma; Lymphoma; Dermatology; Oncology; Internal medicine","score_opus":0.014584976461774424,"score_gpt":0.2546905278786067,"score_spread":0.24010555141683226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2515657367","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6213235,0.035181157,0.0067058755,0.22370279,0.009645343,0.0007733531,0.00043422237,0.0006538379,0.101579934],"genre_scores_gemma":[0.9479302,0.0049519967,0.000996715,0.032463364,0.008249354,0.000047938254,0.000101295765,0.000034706507,0.0052243415],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99904114,0.00025160046,0.00010868548,0.000113865564,0.00019277819,0.00029176645],"domain_scores_gemma":[0.9978497,0.0008156829,0.00036202188,0.00013242789,0.00024297337,0.0005971479],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009713989,0.0007751764,0.0010098399,0.0009217085,0.001983233,0.001484256,0.0009869203,0.005912316,0.0014043248],"category_scores_gemma":[0.0053956546,0.0004508993,0.0010565957,0.0007964214,0.0011570735,0.0012211163,0.0005369948,0.005255789,0.00068663625],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032355424,0.000111736874,0.008962928,0.00012652563,0.000052685817,0.9732676,0.0002995994,0.000261233,0.0009563748,0.0010813845,0.006118114,0.008438196],"study_design_scores_gemma":[0.00027226357,0.0005058061,0.015839256,0.00028297707,0.00013175415,0.9604097,0.00063395884,0.0023220077,0.000995904,0.0024451446,0.016117277,0.000043927663],"about_ca_topic_score_codex":0.00550988,"about_ca_topic_score_gemma":0.009893117,"teacher_disagreement_score":0.005912316,"about_ca_system_score_codex":0.004223911,"about_ca_system_score_gemma":0.0014873714,"threshold_uncertainty_score":0.030646801},"labels":[],"label_agreement":null},{"id":"W2521333572","doi":"10.1080/10428194.2016.1213825","title":"Chest CT scans are frequently abnormal in asymptomatic patients with newly diagnosed acute myeloid leukemia","year":2016,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Mount Sinai Hospital; Institute for Clinical Evaluative Sciences; University Health Network; University of Toronto","funders":"University Health Network","keywords":"Asymptomatic; Medicine; Radiology; Myeloid leukemia; Pneumonia; Febrile neutropenia; Neutropenia; Internal medicine","score_opus":0.006568723383776506,"score_gpt":0.21871192484718555,"score_spread":0.21214320146340904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2521333572","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971506,0.0011773569,0.00017262205,0.000110765905,0.0000123678,0.000013311019,0.00014741972,0.000019654126,0.0011959958],"genre_scores_gemma":[0.9992181,0.0003161433,0.00014974053,0.000060247876,0.000028637192,0.0000034599607,0.00012883068,0.0000028200811,0.00009195057],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995278,0.000098902055,0.00007949792,0.00006427276,0.00015461157,0.00007488086],"domain_scores_gemma":[0.99703526,0.00067617773,0.0015563897,0.00007461781,0.00027788148,0.00037968135],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037364633,0.0002640792,0.00036789523,0.00088718766,0.00030238155,0.00055186474,0.00023820168,0.000495638,0.0012865829],"category_scores_gemma":[0.004105661,0.00024054493,0.00015168333,0.00072427094,0.0003308478,0.0006125202,0.00026646722,0.00033617343,0.00031627194],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008105311,0.00002285894,0.9902428,0.000024526636,0.00001002018,0.0053330907,0.00009994807,0.000028489138,0.0012587175,0.000013707957,0.00018295694,0.0027018555],"study_design_scores_gemma":[0.000006264437,0.0001395663,0.9703945,0.000021049187,0.000024825951,0.028209029,0.0002379341,0.00010949473,0.00034333146,0.000023503395,0.0004848757,0.000005510733],"about_ca_topic_score_codex":0.0016992674,"about_ca_topic_score_gemma":0.0031215155,"teacher_disagreement_score":0.0016992674,"about_ca_system_score_codex":0.00020610957,"about_ca_system_score_gemma":0.0002688758,"threshold_uncertainty_score":0.004304111},"labels":[],"label_agreement":null},{"id":"W2531543939","doi":"10.1080/10428194.2016.1243680","title":"Incidence rates of treatment-emergent adverse events and related hospitalization are reduced with azacitidine compared with conventional care regimens in older patients with acute myeloid leukemia","year":2016,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Azacitidine; Incidence (geometry); Myeloid leukemia; Adverse effect; Internal medicine; Randomization; Clinical trial; Emergency medicine","score_opus":0.007809037247689415,"score_gpt":0.2445108173246626,"score_spread":0.23670178007697318,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2531543939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970221,0.00216449,0.000120408506,0.000066660534,0.000007945476,0.0000072894823,0.0000671345,0.000007225041,0.0005367006],"genre_scores_gemma":[0.99905246,0.0005144881,0.00015240398,0.00004381322,0.000016900249,0.0000043844,0.00009906878,8.1433876e-7,0.00011565637],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997485,0.00010516755,0.00003554355,0.00003314733,0.000060268707,0.000017297998],"domain_scores_gemma":[0.9993305,0.00021872869,0.00028913905,0.000047913287,0.000037787144,0.000075916214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049313164,0.00008381642,0.0002540074,0.00016783252,0.00008128591,0.00017361464,0.00008030022,0.00015765018,0.00072833564],"category_scores_gemma":[0.001973436,0.00005928793,0.00026559544,0.00020208608,0.000087655746,0.0001723558,0.0001146126,0.0002579447,0.000069099166],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01400191,0.0005483286,0.8086133,0.0003019333,0.0008209229,0.00019430467,0.00021872985,0.00066278863,0.012095658,0.00010206505,0.00065648096,0.1617836],"study_design_scores_gemma":[0.00021912469,0.0026614664,0.9946143,0.000013625985,0.00019156007,0.00024450486,0.000040744126,0.00044083592,0.0007995475,0.000052127347,0.00071812223,0.0000039056863],"about_ca_topic_score_codex":0.0007677455,"about_ca_topic_score_gemma":0.0023618608,"teacher_disagreement_score":0.0007677455,"about_ca_system_score_codex":0.00016516777,"about_ca_system_score_gemma":0.00013932446,"threshold_uncertainty_score":0.0026080012},"labels":[],"label_agreement":null},{"id":"W2559063049","doi":"10.1080/10428194.2016.1207765","title":"A common ancestral DNMT3A-mutated preleukemic clone giving rise to AML and MDS in an adolescent girl","year":2016,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Gene; clone (Java method); Myeloid leukemia; Mutation; Myeloid; Genetics; Biology; Methyltransferase; Cancer research; Medicine; Methylation","score_opus":0.01909827924751811,"score_gpt":0.2877261521024222,"score_spread":0.2686278728549041,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559063049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8847449,0.0064896103,0.0027530452,0.073857546,0.0026686625,0.00025910937,0.0006436486,0.0002773644,0.028306127],"genre_scores_gemma":[0.9728584,0.003713929,0.0021012437,0.012326079,0.0038553416,0.00005279199,0.00018200777,0.00006624327,0.0048439205],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.999463,0.00008578872,0.000051045325,0.00018524606,0.000086344815,0.00012860286],"domain_scores_gemma":[0.998958,0.0003493079,0.00016499207,0.00006799442,0.000087883556,0.00037181575],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031855635,0.0011209549,0.0010329551,0.0014658358,0.0021897315,0.0010478765,0.0010059491,0.0065232287,0.0024543526],"category_scores_gemma":[0.003083928,0.000933296,0.00075704395,0.00082121993,0.0011453719,0.0017269013,0.0010135073,0.005368618,0.0009673841],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000044137807,0.000032762855,0.0069640325,0.000029105613,0.000007230624,0.98775196,0.00017930909,0.000081186576,0.0006474076,0.00073448365,0.001928811,0.0015995248],"study_design_scores_gemma":[0.000019733061,0.00006707293,0.005071469,0.00003785134,0.000012682747,0.9911726,0.00016527364,0.00035568714,0.00025412833,0.0005062628,0.002326811,0.00001039415],"about_ca_topic_score_codex":0.0028471586,"about_ca_topic_score_gemma":0.0036771863,"teacher_disagreement_score":0.0065232287,"about_ca_system_score_codex":0.0020761192,"about_ca_system_score_gemma":0.0007660143,"threshold_uncertainty_score":0.015063345},"labels":[],"label_agreement":null},{"id":"W2560764121","doi":"10.1080/10428194.2016.1265115","title":"Severe inflammatory myositis in a patient receiving concurrent nivolumab and azacitidine","year":2016,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Nivolumab; Azacitidine; Medicine; Myositis; Nilotinib; Internal medicine; Ipilimumab; Oncology; Dermatology; Immunotherapy; Cancer; Myeloid leukemia","score_opus":0.007861848712363367,"score_gpt":0.2188114789362649,"score_spread":0.21094963022390154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560764121","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.32267871,0.02629432,0.005300768,0.5260597,0.021679917,0.00064233295,0.0006986329,0.0005869243,0.09605875],"genre_scores_gemma":[0.86186016,0.0064236466,0.0026570926,0.094450176,0.023392955,0.0000842597,0.0002169536,0.00007235723,0.010842386],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9987797,0.00027509624,0.000107970955,0.0003635795,0.00018337162,0.00029021312],"domain_scores_gemma":[0.9987733,0.00049568346,0.00014613963,0.000071914845,0.00012970215,0.0003833983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006353826,0.001285344,0.0013747318,0.0009852983,0.0027105995,0.0016387127,0.0010825972,0.011857164,0.0028162918],"category_scores_gemma":[0.0043537463,0.0007959112,0.001179197,0.0010382754,0.0015949475,0.002417819,0.00082884484,0.009996219,0.0013813477],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018149284,0.00010787782,0.0071282964,0.00009098919,0.000028903609,0.9697286,0.00023306721,0.00015545727,0.0009949162,0.00079586264,0.01596881,0.0045858044],"study_design_scores_gemma":[0.0001372092,0.00035990673,0.009048956,0.000204085,0.000068114634,0.9707809,0.0003755409,0.0014771706,0.0005217883,0.0022068974,0.014771614,0.000047853202],"about_ca_topic_score_codex":0.0042846324,"about_ca_topic_score_gemma":0.008260661,"teacher_disagreement_score":0.011857164,"about_ca_system_score_codex":0.0031095566,"about_ca_system_score_gemma":0.0013453722,"threshold_uncertainty_score":0.02256155},"labels":[],"label_agreement":null},{"id":"W2614736655","doi":"10.1080/10428194.2017.1307980","title":"Bleomycin pulmonary toxicity does not adversely affect the outcome of patients with Hodgkin lymphoma","year":2017,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of British Columbia","funders":"","keywords":"Bleomycin; Medicine; ABVD; Dacarbazine; Vinblastine; Internal medicine; Pulmonary toxicity; Lymphoma; Oncology; Discontinuation; Incidence (geometry); Gastroenterology; Chemotherapy; Toxicity; Hodgkin's lymphoma; Surgery; Cyclophosphamide; Vincristine","score_opus":0.013137404206686028,"score_gpt":0.25038566945046503,"score_spread":0.237248265243779,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2614736655","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99587244,0.0023332622,0.00012557086,0.00012263183,0.0000098967785,0.000006517702,0.00013209859,0.000005433714,0.0013922557],"genre_scores_gemma":[0.9994518,0.00027986482,0.00002236638,0.000034485456,0.000015201777,0.000001578107,0.00010667595,0.0000012846644,0.00008668204],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996164,0.00015068542,0.000054167293,0.00003502336,0.0000857906,0.00005784187],"domain_scores_gemma":[0.99762493,0.0008394036,0.0009954312,0.00010726637,0.0001917138,0.00024130975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005058441,0.00009605697,0.0002280857,0.00032735546,0.00018278824,0.0005011826,0.00009652839,0.00020090358,0.000964821],"category_scores_gemma":[0.004651338,0.00007825335,0.00022855941,0.00042746376,0.00020889204,0.00040962917,0.00021307926,0.00023406172,0.0002402859],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001825725,0.000014466902,0.9898505,0.000022664844,0.00004864848,0.00027228924,0.000041424795,0.000076506774,0.0002727274,0.000013920647,0.00011973626,0.009084513],"study_design_scores_gemma":[0.000013939554,0.0002783103,0.99675936,0.000015557905,0.00006398121,0.0018409481,0.0000784529,0.00014018457,0.00015380091,0.000054095777,0.0005989904,0.0000024875683],"about_ca_topic_score_codex":0.00078159914,"about_ca_topic_score_gemma":0.0017838606,"teacher_disagreement_score":0.000964821,"about_ca_system_score_codex":0.00023728391,"about_ca_system_score_gemma":0.00016998437,"threshold_uncertainty_score":0.0032276511},"labels":[],"label_agreement":null},{"id":"W2614912162","doi":"10.1080/10428194.2017.1318439","title":"Use of minimal residual disease assessment in the treatment of chronic lymphocytic leukemia","year":2017,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Roche (Canada); University of Calgary; McGill University; Jewish General Hospital; Queen Elizabeth II Health Sciences Centre; Fluidigm (Canada); Foothills Medical Centre","funders":"","keywords":"Medicine; Minimal residual disease; Oncology; Clinical trial; Chronic lymphocytic leukemia; Clinical endpoint; Surrogate endpoint; Internal medicine; Complete remission; Leukemia; Intensive care medicine; Chemotherapy","score_opus":0.11134316876918608,"score_gpt":0.38885895669780457,"score_spread":0.2775157879286185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2614912162","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000062298604,0.99942636,0.000055101675,0.00011334912,0.00004683126,0.0000049073474,0.000007870374,0.0000015816407,0.00028174187],"genre_scores_gemma":[0.0010798292,0.99839324,0.00018487491,0.00015938474,0.00006295093,0.000007958293,0.000017234051,9.855885e-7,0.000093600735],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99923766,0.00024557937,0.00017552305,0.00008853952,0.00022027598,0.000032399308],"domain_scores_gemma":[0.9987835,0.0008346739,0.00016489373,0.000022634185,0.00016202379,0.000032263924],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018566701,0.00056617375,0.0021039846,0.003179863,0.00022735856,0.0010954291,0.0011134571,0.001055472,0.0019149238],"category_scores_gemma":[0.0024271563,0.0002735641,0.0010515066,0.0023968597,0.0007590627,0.0013393603,0.0007013876,0.0019304721,0.00064344273],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011394519,0.000044965804,0.00029366498,0.03415717,0.000258368,0.0001144371,0.00006756136,0.0003176469,0.0004951159,0.0031460302,0.007851215,0.9531399],"study_design_scores_gemma":[0.00011098234,0.00030084522,0.0028823784,0.030044729,0.0009634634,0.0022978946,0.00015380287,0.00025075432,0.00078137714,0.0042393464,0.95791376,0.000060622275],"about_ca_topic_score_codex":0.0014718904,"about_ca_topic_score_gemma":0.0024669312,"teacher_disagreement_score":0.003179863,"about_ca_system_score_codex":0.0007826027,"about_ca_system_score_gemma":0.0012517716,"threshold_uncertainty_score":0.00981915},"labels":[],"label_agreement":null},{"id":"W2616989782","doi":"10.3109/10428194.2010.532893","title":"Mantle cell lymphoma: report of the 2010 Mantle Cell Lymphoma Consortium Workshop","year":2010,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Penn State Hershey Cancer Institute; National Institutes of Health; University of Rochester; Moffitt Cancer Center; University of Virginia; Lymphoma Research Foundation","keywords":"Mantle cell lymphoma; Cyclin D1; Lymphoma; Medicine; Cancer research; Epigenetics; Bioinformatics; Biology; Cell cycle; Immunology; Internal medicine; Cancer; Gene; Genetics","score_opus":0.020294859893623795,"score_gpt":0.27303801513273673,"score_spread":0.25274315523911295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2616989782","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0023872468,0.96221703,0.00036905633,0.013677327,0.011508581,0.00010795203,0.00025427766,0.000033334865,0.009445193],"genre_scores_gemma":[0.008331155,0.95848423,0.0008220336,0.0060261255,0.005041544,0.000094297466,0.0007865691,0.0000140065795,0.020400094],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997255,0.000046158963,0.000032955748,0.000039819075,0.000118349984,0.000037089027],"domain_scores_gemma":[0.99961746,0.000044416756,0.000040236562,0.0000062429503,0.0001946872,0.00009684078],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010856434,0.00078764046,0.0007449332,0.0011899179,0.00023473374,0.0007926762,0.0006650353,0.0020203257,0.0028310404],"category_scores_gemma":[0.0008277099,0.00027189837,0.00044118732,0.0010541225,0.0001869454,0.0007099684,0.0007187664,0.0010809221,0.0028273156],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019773503,0.00013225451,0.00077704125,0.004355418,0.00008471572,0.0018073256,0.00013762448,0.00026768338,0.0026974347,0.0010686204,0.39763787,0.59083617],"study_design_scores_gemma":[0.000047532514,0.00011985156,0.0015130428,0.0012529762,0.000079854944,0.0024706412,0.00008841524,0.000057500143,0.0007760954,0.00018907264,0.9933876,0.00001733418],"about_ca_topic_score_codex":0.0034482172,"about_ca_topic_score_gemma":0.0076110037,"teacher_disagreement_score":0.0034482172,"about_ca_system_score_codex":0.0010309839,"about_ca_system_score_gemma":0.0026930585,"threshold_uncertainty_score":0.009470761},"labels":[],"label_agreement":null},{"id":"W2619012808","doi":"10.1080/10428194.2017.1326034","title":"Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus","year":2017,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"Janssen Research and Development","keywords":"Ibrutinib; Mantle cell lymphoma; Temsirolimus; Medicine; Quality of life (healthcare); Internal medicine; Oncology; Clinical trial; Lymphoma; Phases of clinical research; Randomized controlled trial; Leukemia; Discovery and development of mTOR inhibitors; Chronic lymphocytic leukemia","score_opus":0.07370496193561728,"score_gpt":0.3693687295541824,"score_spread":0.2956637676185651,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2619012808","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99207157,0.002648087,0.00036420068,0.00024177847,0.00006759393,0.0010061745,0.0024571253,0.000018026929,0.0011253945],"genre_scores_gemma":[0.9914527,0.0008058849,0.00054558454,0.00040143068,0.00008750455,0.0015214259,0.004736444,0.000009125169,0.00043994896],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99767846,0.0016159669,0.00018494704,0.00016616438,0.00018294773,0.00017159521],"domain_scores_gemma":[0.99664766,0.0009963871,0.0010613375,0.00026974667,0.0002376294,0.0007873022],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004936032,0.00071994826,0.0017712084,0.0004116687,0.0004137602,0.0007858887,0.00056075805,0.0008394403,0.0026724786],"category_scores_gemma":[0.0030338275,0.00029061627,0.0022647304,0.00072072813,0.00070097094,0.0008631331,0.00044579047,0.0019844924,0.00031532417],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91899335,0.01565931,0.027321069,0.0005800856,0.0062912083,0.00005978617,0.00015117977,0.0009756055,0.0052838908,0.00013046736,0.0014021943,0.023151845],"study_design_scores_gemma":[0.5977524,0.25619316,0.13562591,0.0001014883,0.004504807,0.00014318178,0.00015085097,0.0010415792,0.001938717,0.00017001767,0.002322686,0.000055240882],"about_ca_topic_score_codex":0.00065078086,"about_ca_topic_score_gemma":0.0011728482,"teacher_disagreement_score":0.004936032,"about_ca_system_score_codex":0.0004914054,"about_ca_system_score_gemma":0.0006997032,"threshold_uncertainty_score":0.02610451},"labels":[],"label_agreement":null},{"id":"W2703436965","doi":"10.1080/10428194.2017.1334125","title":"Long-term health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma receiving lenalidomide and dexamethasone","year":2017,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"Celgene","keywords":"Medicine; Lenalidomide; Dexamethasone; Multiple myeloma; Quality of life (healthcare); Internal medicine; Confidence interval; Pediatrics; Oncology","score_opus":0.027634969815474822,"score_gpt":0.2933253349468921,"score_spread":0.2656903651314173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2703436965","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990614,0.0005384882,0.00008546947,0.00007768833,0.000006329659,0.0000103355405,0.00007951685,0.0000028717077,0.00013793055],"genre_scores_gemma":[0.9996208,0.000099328216,0.00007222024,0.00003252115,0.0000066336024,0.000007113682,0.00012378053,4.011114e-7,0.000037017653],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99956936,0.00023718415,0.000033891192,0.000051749365,0.000047875492,0.000059905982],"domain_scores_gemma":[0.99878687,0.00039047806,0.0005082595,0.00006270714,0.000036037403,0.00021554192],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015289504,0.00020747655,0.0004899017,0.00016968542,0.00019829006,0.0005899059,0.00024681553,0.00023661292,0.00040654713],"category_scores_gemma":[0.0024089862,0.00011567068,0.00059097115,0.00027962704,0.00020122968,0.00035812633,0.0003541447,0.00067095034,0.000063241736],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021503273,0.0015719135,0.93171674,0.00008697707,0.00046567968,0.00010088314,0.0001375502,0.0018054392,0.00091888837,0.000068149595,0.0003295321,0.041295093],"study_design_scores_gemma":[0.0017631814,0.014881165,0.976848,0.00003864737,0.00040973775,0.00018198405,0.00012231634,0.0043486794,0.00059809285,0.0001808805,0.0006116179,0.000015750631],"about_ca_topic_score_codex":0.0012899055,"about_ca_topic_score_gemma":0.0024687285,"teacher_disagreement_score":0.0015289504,"about_ca_system_score_codex":0.00056849787,"about_ca_system_score_gemma":0.00044536803,"threshold_uncertainty_score":0.008085966},"labels":[],"label_agreement":null},{"id":"W2765329477","doi":"10.1080/10428194.2017.1387904","title":"Improved survival outcomes with the addition of rituximab to initial therapy for chronic lymphocytic leukemia: a comparative effectiveness analysis in the province of British Columbia, Canada","year":2017,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Paul's Hospital; St. John’s Health Sciences Centre; Vancouver General Hospital; BC Cancer Agency; University of British Columbia","funders":"","keywords":"Chemoimmunotherapy; Rituximab; Medicine; Chronic lymphocytic leukemia; Internal medicine; Oncology; Chemotherapy; Cohort; Population; Clinical trial; Purine analogue; Leukemia; Immunology; Lymphoma","score_opus":0.01682509996718804,"score_gpt":0.2938357957084521,"score_spread":0.277010695741264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765329477","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99099475,0.0063914205,0.00007734909,0.0002900064,0.000016738702,0.00012562194,0.0007590658,0.000005518838,0.0013394839],"genre_scores_gemma":[0.99761486,0.0015457992,0.00011600676,0.000090722686,0.000009673598,0.000030412588,0.00044096992,0.0000018908987,0.00014974497],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99636036,0.0017028766,0.0002810879,0.00022559288,0.0008424402,0.00058755017],"domain_scores_gemma":[0.99369836,0.0022234512,0.0013181404,0.00023690451,0.0013035528,0.0012196584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036365138,0.00031868546,0.0007214061,0.0008901067,0.0007244111,0.0011459237,0.00073491316,0.00044295212,0.00097652944],"category_scores_gemma":[0.012060618,0.0001766833,0.0011812707,0.0019466811,0.0007368294,0.00024834514,0.0005136641,0.0005477003,0.000049271915],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07313925,0.0015452841,0.7852141,0.001582167,0.0075455387,0.00023354554,0.00062094483,0.003825682,0.0014084356,0.000463841,0.0027391335,0.121681996],"study_design_scores_gemma":[0.007163908,0.0063365586,0.9755197,0.00037135129,0.005024562,0.00016278261,0.00068474264,0.0020073738,0.00042694196,0.000119535805,0.0021268164,0.000055813212],"about_ca_topic_score_codex":0.8926567,"about_ca_topic_score_gemma":0.94685745,"teacher_disagreement_score":0.107343316,"about_ca_system_score_codex":0.022390814,"about_ca_system_score_gemma":0.023037259,"threshold_uncertainty_score":0.2159509},"labels":[],"label_agreement":null},{"id":"W2781752934","doi":"10.1080/10428194.2017.1416364","title":"Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in the HELIOS study","year":2018,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"Johnson and Johnson; Astellas Pharma; Celgene; Gilead Sciences","keywords":"Bendamustine; Ibrutinib; Medicine; Chronic lymphocytic leukemia; Internal medicine; Placebo; Quality of life (healthcare); Rituximab; Clinical endpoint; Oncology; Clinical trial; Lymphoma; Leukemia; Pathology","score_opus":0.0091424588777352,"score_gpt":0.24512924548105156,"score_spread":0.23598678660331635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2781752934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99847883,0.00084184116,0.000047463767,0.000046208406,0.000016117103,0.00010532809,0.00019373556,0.0000053426184,0.00026520467],"genre_scores_gemma":[0.99845743,0.00031045917,0.00008829734,0.0001014524,0.00005549313,0.00020795074,0.0004995406,0.0000019098416,0.0002774339],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99929166,0.00041915552,0.000053485415,0.0000778491,0.0000796217,0.000078209036],"domain_scores_gemma":[0.9994184,0.00013834334,0.00016763141,0.00004784891,0.00003560155,0.00019215628],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022659397,0.0006939638,0.0013883031,0.0002665015,0.00021915435,0.00053205807,0.00033323112,0.0005679246,0.0013831167],"category_scores_gemma":[0.0012877672,0.00034557725,0.0011488742,0.00026644283,0.0003823495,0.0004917085,0.00040179497,0.0009697155,0.00023346973],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7622584,0.02138928,0.1437766,0.0006637002,0.006005866,0.00014685123,0.00042486188,0.0010335937,0.013824181,0.00007323892,0.0015381596,0.048865307],"study_design_scores_gemma":[0.24692205,0.30707923,0.43651754,0.00007999551,0.0033482045,0.00019461603,0.00021721944,0.0013003525,0.0021335655,0.000089577305,0.0020720602,0.000045656852],"about_ca_topic_score_codex":0.0005880292,"about_ca_topic_score_gemma":0.0011849117,"teacher_disagreement_score":0.0022659397,"about_ca_system_score_codex":0.00034263427,"about_ca_system_score_gemma":0.00041974173,"threshold_uncertainty_score":0.011983633},"labels":[],"label_agreement":null},{"id":"W2793121285","doi":"10.1080/10428194.2017.1365855","title":"Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the randomized, phase 3 LYM-3002 study","year":2018,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Rituximab; Vincristine; Mantle cell lymphoma; Internal medicine; Bortezomib; Hazard ratio; Prednisone; CHOP; Neutropenia; Gastroenterology; Cyclophosphamide; Autologous stem-cell transplantation; Transplantation; Bendamustine; Surgery; Oncology; Lymphoma; Chemotherapy; Confidence interval; Multiple myeloma","score_opus":0.010090361013395142,"score_gpt":0.27379315675973653,"score_spread":0.26370279574634137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793121285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99853146,0.00090222986,0.000064939,0.00006365982,0.000022048578,0.00009391666,0.0001066613,0.000008237851,0.00020670502],"genre_scores_gemma":[0.9988508,0.00028651755,0.00011391979,0.00013455073,0.000049689526,0.00009689265,0.00030302742,0.0000034448829,0.00016107161],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.998926,0.0007740312,0.000050686474,0.000103734434,0.00006264677,0.000082841034],"domain_scores_gemma":[0.9988397,0.00038848474,0.0003198988,0.000108007305,0.000052830666,0.00029109957],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027926513,0.0008457558,0.001347264,0.00027745633,0.00023169811,0.0008200141,0.00051509676,0.00064415415,0.00089928147],"category_scores_gemma":[0.0016064874,0.0003697833,0.0017143274,0.00022948044,0.0004993056,0.0004829692,0.0002988629,0.0013287783,0.00019996655],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9383959,0.005144942,0.023663035,0.0002904547,0.00247067,0.000110940775,0.00009742848,0.0006566042,0.006473551,0.000047645237,0.0006185272,0.022030383],"study_design_scores_gemma":[0.5488815,0.2988818,0.13952024,0.000071835195,0.0046798163,0.00039317398,0.000114308146,0.0024547856,0.003163983,0.00029213948,0.0014955365,0.000050959676],"about_ca_topic_score_codex":0.00045487515,"about_ca_topic_score_gemma":0.0015595232,"teacher_disagreement_score":0.0027926513,"about_ca_system_score_codex":0.00060065347,"about_ca_system_score_gemma":0.00067678356,"threshold_uncertainty_score":0.014769137},"labels":[],"label_agreement":null},{"id":"W2796416879","doi":"10.1080/10428194.2018.1452208","title":"Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi","year":2018,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; McGill University; Jewish General Hospital","funders":"","keywords":"Panobinostat; Medicine; Internal medicine; Refractory (planetary science); Diffuse large B-cell lymphoma; Lymphoma; Oncology; Overall survival; Gastroenterology; Biology","score_opus":0.04424755085223389,"score_gpt":0.31793521721302564,"score_spread":0.2736876663607918,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2796416879","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997389,0.0017619076,0.00019403509,0.000057588182,0.00000912661,0.00013241044,0.00012711948,0.000015498112,0.0003133326],"genre_scores_gemma":[0.99774724,0.00074808946,0.00043824906,0.00011568197,0.00002977494,0.00010398523,0.00052762346,0.000005388273,0.00028396264],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99976796,0.00012246094,0.000014033916,0.000034590015,0.000032384858,0.000028517681],"domain_scores_gemma":[0.9996661,0.0000920707,0.00006936089,0.000024427643,0.000019134077,0.00012884164],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008520948,0.0005270218,0.0007754992,0.0003543441,0.00015792024,0.0002475381,0.00024809426,0.00043120832,0.0007442041],"category_scores_gemma":[0.0005684919,0.00016899112,0.00036124533,0.000262802,0.00029248558,0.00026646085,0.0001569828,0.00054841285,0.0002071265],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18475117,0.021349961,0.21351464,0.0009570384,0.002076231,0.0018797531,0.0005761817,0.0067112837,0.15920122,0.00015934442,0.0018047446,0.40701845],"study_design_scores_gemma":[0.042978674,0.5357233,0.38501355,0.000062652405,0.001264264,0.0035707797,0.00015297836,0.0052314433,0.02056957,0.00020814761,0.0051748757,0.000049685124],"about_ca_topic_score_codex":0.00040189247,"about_ca_topic_score_gemma":0.0009636791,"teacher_disagreement_score":0.0008520948,"about_ca_system_score_codex":0.0003057658,"about_ca_system_score_gemma":0.00022948635,"threshold_uncertainty_score":0.0045063496},"labels":[],"label_agreement":null},{"id":"W2811117276","doi":"10.1080/10428194.2018.1473576","title":"Autologous transplantation improves survival rates for follicular lymphoma patients who relapse within two years of chemoimmunotherapy: a multi-center retrospective analysis of consecutively treated patients in the real world","year":2018,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Calgary","funders":"Alberta Cancer Foundation","keywords":"Chemoimmunotherapy; Medicine; Retrospective cohort study; Transplantation; Single Center; Surgery; Follicular lymphoma; Lymphoma; Internal medicine; Rituximab; Oncology","score_opus":0.011123329664823167,"score_gpt":0.2756643720021961,"score_spread":0.26454104233737297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2811117276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9995784,0.00024124309,0.00004398985,0.000014867906,0.0000015672496,0.0000020335578,0.000033696357,0.0000020548853,0.0000820829],"genre_scores_gemma":[0.99985754,0.00005000853,0.000018930245,0.000009050432,0.0000029102846,0.0000013769057,0.0000441768,5.611404e-7,0.000015528321],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996228,0.00014279535,0.000048276765,0.00006909137,0.00006078319,0.000056180103],"domain_scores_gemma":[0.9985493,0.0003515699,0.00073657365,0.000103912316,0.00008582963,0.00017281475],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053487765,0.000110031746,0.0002344099,0.00047811653,0.0002485849,0.00042779392,0.0001586235,0.00025611214,0.0006690568],"category_scores_gemma":[0.0021403611,0.00012867221,0.00027878402,0.00043302652,0.00024006286,0.00029821764,0.00019692817,0.0002612989,0.00012934956],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019158685,0.000024383844,0.9978327,0.000004494005,0.000025520683,0.00010089141,0.000036578,0.000038038183,0.00028910025,0.000005594854,0.000034171266,0.0014168988],"study_design_scores_gemma":[0.000016916123,0.00043561135,0.99691916,0.000005530713,0.000055547305,0.0016101744,0.00014353388,0.00028675405,0.00030882415,0.00001486423,0.00019834819,0.0000047864246],"about_ca_topic_score_codex":0.00084455387,"about_ca_topic_score_gemma":0.0011500113,"teacher_disagreement_score":0.00084455387,"about_ca_system_score_codex":0.00019379787,"about_ca_system_score_gemma":0.00016937555,"threshold_uncertainty_score":0.0028287172},"labels":[],"label_agreement":null},{"id":"W2897571764","doi":"10.1080/10428194.2018.1515937","title":"A phase I study of romidepsin, gemcitabine, dexamethasone and cisplatin combination therapy in the treatment of peripheral T-cell and diffuse large B-cell lymphoma; the Canadian cancer trials group LY.15 study†","year":2018,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; Sunnybrook Health Science Centre; BC Cancer Agency; Princess Margaret Cancer Centre; Health Sciences Centre; Saint John Regional Hospital; Dalhousie University; University of New Brunswick","funders":"","keywords":"Romidepsin; Gemcitabine; Medicine; Internal medicine; Cisplatin; Lymphoma; Dexamethasone; Peripheral T-cell lymphoma; Cancer; Phases of clinical research; Chemotherapy; Oncology; Gastroenterology; Chemistry; Immunology; T cell","score_opus":0.03095222513590106,"score_gpt":0.31236087569468546,"score_spread":0.2814086505587844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897571764","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9664655,0.007092741,0.001024638,0.0016169373,0.0003927895,0.011304578,0.004527633,0.00021757417,0.0073576816],"genre_scores_gemma":[0.97213405,0.005565697,0.0037694243,0.0017716016,0.000274024,0.005529014,0.004473454,0.00006134066,0.0064213574],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995054,0.00020807394,0.000016349868,0.00006896378,0.00006781229,0.00013348518],"domain_scores_gemma":[0.99936575,0.000060378734,0.00007326758,0.000035128636,0.000047137,0.00041834114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020307358,0.0019452659,0.0023031826,0.00055419304,0.0006750106,0.000938239,0.001237905,0.0010131327,0.003731511],"category_scores_gemma":[0.0007279526,0.0005598035,0.0011453294,0.00066004065,0.0012960562,0.0005326064,0.00034620822,0.0031969503,0.0008107268],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.70378935,0.083407484,0.006345358,0.0015721403,0.002093319,0.00043726258,0.00047915982,0.0034609458,0.034179587,0.0007343436,0.020957392,0.1425437],"study_design_scores_gemma":[0.6839763,0.29084545,0.010229084,0.000044394248,0.0006872739,0.00024389793,0.00006621666,0.0010387814,0.0021868187,0.00020746996,0.010431515,0.000042844116],"about_ca_topic_score_codex":0.027670868,"about_ca_topic_score_gemma":0.09036575,"teacher_disagreement_score":0.027670868,"about_ca_system_score_codex":0.0032472548,"about_ca_system_score_gemma":0.006687961,"threshold_uncertainty_score":0.055019617},"labels":[],"label_agreement":null},{"id":"W2909446572","doi":"10.1080/10428194.2018.1562180","title":"Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study","year":2019,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Internal medicine; Gastroenterology; Refractory (planetary science); Chronic lymphocytic leukemia; Adverse effect; Syk; Phases of clinical research; Leukemia; Oncology; Chemotherapy; Tyrosine kinase; Receptor","score_opus":0.008657355297071786,"score_gpt":0.25424940007524544,"score_spread":0.24559204477817365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2909446572","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965922,0.0020443934,0.00010248048,0.00011643277,0.00002498697,0.00023224157,0.00029281777,0.000017529801,0.00057686603],"genre_scores_gemma":[0.99562365,0.0019018069,0.00031071203,0.00026223954,0.000086234395,0.0002492183,0.0010561312,0.000007663685,0.00050243986],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99959105,0.00022980187,0.00002930773,0.000049657494,0.000041529143,0.000058596263],"domain_scores_gemma":[0.9994838,0.00011364604,0.00011538783,0.00003591315,0.000038427508,0.00021276978],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014937894,0.0008550953,0.0018268983,0.0002981534,0.00026667307,0.00064214336,0.00038506475,0.000561669,0.0011741918],"category_scores_gemma":[0.0007114236,0.0002968869,0.00085856963,0.00034560787,0.0003351555,0.0006172824,0.00020489923,0.0010803208,0.00033434998],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.59909046,0.038914673,0.06642594,0.0012488212,0.0043503814,0.0011052336,0.0005383161,0.0037096268,0.06471236,0.00018389859,0.0038449396,0.21587545],"study_design_scores_gemma":[0.34389848,0.49407682,0.14525154,0.000092259565,0.0017225676,0.0012803404,0.0001828452,0.0030257327,0.004818648,0.0001307761,0.005450775,0.00006928015],"about_ca_topic_score_codex":0.0007748031,"about_ca_topic_score_gemma":0.0029551731,"teacher_disagreement_score":0.0018268983,"about_ca_system_score_codex":0.0005771668,"about_ca_system_score_gemma":0.00068838825,"threshold_uncertainty_score":0.007900059},"labels":[],"label_agreement":null},{"id":"W2910383185","doi":"10.1080/10428194.2018.1563691","title":"Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis","year":2019,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Hospital; University of Calgary; Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"National Cancer Institute","keywords":"Medicine; Internal medicine; Oncology; Autologous stem-cell transplantation; Lymphoma; Randomized controlled trial; Transplantation; Aggressive lymphoma; Randomization; Subgroup analysis; Gastroenterology; Surgery; Rituximab; Confidence interval","score_opus":0.005829918759344031,"score_gpt":0.24275891050548834,"score_spread":0.23692899174614432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2910383185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95609933,0.032154344,0.0019396289,0.0011038063,0.000866086,0.0017974803,0.0024241165,0.000119457574,0.0034956082],"genre_scores_gemma":[0.99214655,0.0023072704,0.0008737352,0.00077384844,0.00033411494,0.0013259335,0.0011820148,0.000035830162,0.0010206567],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.997743,0.0014444274,0.00027605132,0.00021615237,0.00013883921,0.00018161593],"domain_scores_gemma":[0.9986236,0.00061872555,0.00025945238,0.00026309595,0.00008588368,0.00014935574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043711513,0.0012318334,0.0034476942,0.00056330365,0.0002433414,0.0012534364,0.00064398535,0.00091554277,0.002354113],"category_scores_gemma":[0.0034405948,0.00029866805,0.007254195,0.0007126887,0.0003491126,0.000716458,0.00046443674,0.0015308514,0.00027416673],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.882647,0.00070688245,0.014234388,0.0024474247,0.05912469,0.00022318456,0.00010614665,0.0017406081,0.0040817517,0.0004093856,0.002679013,0.031599652],"study_design_scores_gemma":[0.72684693,0.053941008,0.057151362,0.00061959104,0.14199562,0.0005498064,0.00029620525,0.0067017796,0.0026163803,0.0031270385,0.006051661,0.00010254749],"about_ca_topic_score_codex":0.00076688925,"about_ca_topic_score_gemma":0.0019465329,"teacher_disagreement_score":0.0043711513,"about_ca_system_score_codex":0.0005797606,"about_ca_system_score_gemma":0.00076866057,"threshold_uncertainty_score":0.023117125},"labels":[],"label_agreement":null},{"id":"W2912598520","doi":"10.1080/10428194.2018.1498490","title":"Improving CD20 antibody therapy: obinutuzumab in lymphoproliferative disorders","year":2019,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Obinutuzumab; Rituximab; Medicine; Chronic lymphocytic leukemia; CD20; Follicular lymphoma; Lymphoma; Immunology; Antibody; Monoclonal antibody; Lymphoproliferative disorders; Oncology; Internal medicine; Leukemia","score_opus":0.03349201169399164,"score_gpt":0.34155322463289023,"score_spread":0.3080612129388986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912598520","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000052078212,0.99941516,0.00002968428,0.00012513423,0.00009126101,0.0000020860466,0.000005002191,0.0000026524006,0.00027683008],"genre_scores_gemma":[0.00041963134,0.9990169,0.00006758492,0.00015075253,0.000100043915,0.0000030971344,0.00001369382,8.535228e-7,0.00022742947],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997708,0.000056273206,0.000034721095,0.000031196385,0.000083131985,0.000023881079],"domain_scores_gemma":[0.99975115,0.000118251824,0.000044609747,0.000006645676,0.000057879468,0.000021445387],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060118665,0.00070247625,0.0013341404,0.002707944,0.00022486167,0.00090115174,0.000951454,0.0010597818,0.0031992793],"category_scores_gemma":[0.0007581287,0.00020806534,0.0006039505,0.0021041387,0.00034669988,0.0010736536,0.0006447186,0.0017535975,0.00124065],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000082638864,0.000049060858,0.00010512733,0.021123188,0.0001405516,0.00013713831,0.000050000788,0.00025961385,0.00063903054,0.0018276424,0.029811908,0.945774],"study_design_scores_gemma":[0.00004830137,0.000090905494,0.00073584873,0.011220471,0.0002618926,0.0014518147,0.00005016349,0.00009839807,0.00030053634,0.0019223131,0.9838054,0.00001390057],"about_ca_topic_score_codex":0.0009874287,"about_ca_topic_score_gemma":0.002058872,"teacher_disagreement_score":0.0031992793,"about_ca_system_score_codex":0.0006454902,"about_ca_system_score_gemma":0.0008223057,"threshold_uncertainty_score":0.01070267},"labels":[],"label_agreement":null},{"id":"W2930076345","doi":"10.1080/10428194.2019.1576872","title":"Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia","year":2019,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Kite Pharma; Celgene; Regeneron Pharmaceuticals; Novartis; Servier; Amgen; Pfizer; Roche","keywords":"Blinatumomab; Salvage therapy; Medicine; Chemotherapy; Hematopoietic stem cell transplantation; Refractory (planetary science); Internal medicine; Lymphoblastic Leukemia; Oncology; Leukemia; Transplantation; Biology","score_opus":0.012450703097188843,"score_gpt":0.2686966968504686,"score_spread":0.2562459937532798,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2930076345","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.976928,0.015753483,0.00043474432,0.00092816364,0.00036140144,0.0009318817,0.00078937184,0.000053888034,0.0038191115],"genre_scores_gemma":[0.9893161,0.0058510923,0.0007056008,0.0005721794,0.00018157404,0.001000585,0.0005513374,0.00001416918,0.0018074055],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995096,0.00029936407,0.0000395508,0.000050138613,0.00004276763,0.000058623118],"domain_scores_gemma":[0.9992083,0.0002411372,0.00030246272,0.00004492767,0.000022697213,0.00018045036],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00088377146,0.00029868257,0.0009237679,0.0003164532,0.00016795483,0.00046640122,0.00036423918,0.0005375394,0.004835019],"category_scores_gemma":[0.001715222,0.00013550722,0.0008534075,0.00031508043,0.00026677758,0.00055764907,0.0002410153,0.0014924805,0.000488335],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7751313,0.0059992936,0.003920286,0.001159783,0.0007986043,0.00011894443,0.000113994065,0.0006082461,0.00421279,0.0004267169,0.0017171674,0.20579278],"study_design_scores_gemma":[0.37356442,0.5624218,0.035423182,0.0009860421,0.002522234,0.00048752798,0.00021063387,0.0017780075,0.006048319,0.0016009447,0.014905954,0.000050964016],"about_ca_topic_score_codex":0.00034958753,"about_ca_topic_score_gemma":0.0017946595,"teacher_disagreement_score":0.004835019,"about_ca_system_score_codex":0.0006218413,"about_ca_system_score_gemma":0.0005333137,"threshold_uncertainty_score":0.016174734},"labels":[],"label_agreement":null},{"id":"W2945425711","doi":"10.1080/10428194.2019.1613539","title":"Management of cardiovascular health in acute leukemia: a national survey","year":2019,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Leukemia & Lymphoma Society of Canada; Vancouver General Hospital","funders":"","keywords":"Medicine; Cardiotoxicity; Comorbidity; Intensive care medicine; Internal medicine; Disease; Health care; Hematology; Multidisciplinary approach; Anthracycline; Chemotherapy; Cancer","score_opus":0.015152967176642013,"score_gpt":0.2615875773783027,"score_spread":0.24643461020166066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2945425711","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9819479,0.00039994498,0.0001587375,0.000568482,0.000010817356,0.00015646486,0.013894259,0.0000152017055,0.0028482294],"genre_scores_gemma":[0.98979795,0.00068602856,0.00029806726,0.00057348644,0.000014465609,0.00013036928,0.00802902,0.00000424534,0.00046633722],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989976,0.00020738418,0.00021799935,0.00011034338,0.00032398492,0.00014253156],"domain_scores_gemma":[0.99809676,0.00016338548,0.0009049421,0.00009981746,0.00038398796,0.00035107142],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009911064,0.0001155968,0.00028785184,0.00061125227,0.00031131995,0.0003715942,0.00033330577,0.0003476718,0.0010709469],"category_scores_gemma":[0.0021070053,0.00019562973,0.00030903376,0.0016648085,0.00013637298,0.0004926682,0.00062231,0.00061381113,0.00024848038],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028036586,0.000049508824,0.9974504,0.000022932254,0.000026488897,0.000015240044,0.00005784587,0.00003652265,0.00006877115,0.000011107666,0.00080479827,0.001428436],"study_design_scores_gemma":[0.000003210381,0.000024178298,0.99940836,0.000009474707,0.0000056681592,0.000027405546,0.00011407092,0.00004482329,0.000010589949,0.000004215063,0.0003466271,0.0000015781831],"about_ca_topic_score_codex":0.06440136,"about_ca_topic_score_gemma":0.083347954,"teacher_disagreement_score":0.06440136,"about_ca_system_score_codex":0.001013586,"about_ca_system_score_gemma":0.0011001235,"threshold_uncertainty_score":0.12805301},"labels":[],"label_agreement":null},{"id":"W2948560683","doi":"10.1080/10428194.2019.1620940","title":"Anti-leukemia effect of vitamin K3 is mediated through mitochondrial complexes I and II","year":2019,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Retinoids in leukemia and cellular processes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Guelph","funders":"University of Guelph","keywords":"Leukemia; Cancer research; Mitochondrion; Chemistry; Medicine; Internal medicine; Biochemistry","score_opus":0.00586690514693654,"score_gpt":0.2236275928983494,"score_spread":0.21776068775141286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2948560683","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005860722,0.040122278,0.0011627477,0.9052101,0.0262045,0.00003819796,0.00017925909,0.00017989858,0.021042421],"genre_scores_gemma":[0.18880378,0.08280963,0.0023032916,0.59724563,0.07348377,0.00018274806,0.00026994108,0.00010009328,0.05480108],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992968,0.00023101333,0.000063178544,0.00009649235,0.00020727658,0.0001052408],"domain_scores_gemma":[0.9985922,0.0007128316,0.00014580981,0.0001312319,0.00029455798,0.000123336],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008361601,0.00042871592,0.0006397668,0.00028618483,0.0010986776,0.0014086263,0.0006273856,0.006987916,0.004185653],"category_scores_gemma":[0.0035724144,0.00021649308,0.00043892732,0.00021332991,0.0016687709,0.001040476,0.0006197539,0.007204305,0.005595316],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014600893,0.0001300547,0.00205762,0.00046266217,0.000078487756,0.0069291065,0.00015278047,0.00017601938,0.02334082,0.025033604,0.79310936,0.14706941],"study_design_scores_gemma":[0.00042041246,0.00025036072,0.0017520894,0.00019301612,0.000036804835,0.0065960484,0.00017631431,0.0006287271,0.01261745,0.026753234,0.95053333,0.00004222046],"about_ca_topic_score_codex":0.0012557374,"about_ca_topic_score_gemma":0.0020080532,"teacher_disagreement_score":0.006987916,"about_ca_system_score_codex":0.0021936607,"about_ca_system_score_gemma":0.0009033801,"threshold_uncertainty_score":0.015916169},"labels":[],"label_agreement":null},{"id":"W2955661053","doi":"10.1080/10428194.2019.1620941","title":"Risk factors for skin cancer and solid tumors in newly diagnosed patients with chronic lymphocytic leukemia and the impact of skin surveillance on survival","year":2019,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"CancerCare Manitoba Foundation; Manitoba Health Research Council","keywords":"Medicine; Chronic lymphocytic leukemia; Skin cancer; Chemotherapy; Internal medicine; Cancer; Incidence (geometry); Leukemia; Oncology; Dermatology","score_opus":0.007728653774308125,"score_gpt":0.26915934534176517,"score_spread":0.261430691567457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955661053","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99911684,0.00047132454,0.000037000045,0.000020419653,0.0000029928153,0.00000307575,0.0001387922,0.0000017000764,0.0002078592],"genre_scores_gemma":[0.99960667,0.00011678116,0.000027337574,0.00000981165,0.0000065875256,0.0000029131504,0.00016957305,6.2261125e-7,0.00005976829],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996898,0.00009655407,0.00003412417,0.000047267185,0.00006129663,0.00007103072],"domain_scores_gemma":[0.9984394,0.0004208596,0.00067690725,0.00006188527,0.00010564524,0.0002952812],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038735886,0.00016275364,0.00024419182,0.0006195652,0.00024519596,0.00039043446,0.00012957942,0.00025586662,0.000980217],"category_scores_gemma":[0.0019013417,0.00019261811,0.00039626134,0.000673938,0.0001818065,0.00038364073,0.0002294916,0.00035193027,0.000107768035],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000050846553,0.000006619196,0.9993913,0.0000020662844,0.000012982976,0.0000311874,0.000011080639,0.000015604433,0.000032870008,0.000002442178,0.000015790692,0.00042704618],"study_design_scores_gemma":[0.000004341265,0.00008538184,0.99936575,0.0000035584217,0.00001540698,0.0002969772,0.000046467812,0.00007778777,0.000025033676,0.000005438036,0.000072375195,0.0000014040108],"about_ca_topic_score_codex":0.0044514216,"about_ca_topic_score_gemma":0.0060239756,"teacher_disagreement_score":0.0044514216,"about_ca_system_score_codex":0.00020752425,"about_ca_system_score_gemma":0.00023119476,"threshold_uncertainty_score":0.008851051},"labels":[],"label_agreement":null},{"id":"W2975621535","doi":"10.1080/10428194.2019.1660977","title":"Granulocyte transfusions – bridging to allogeneic hematopoietic stem cell transplantation","year":2019,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Antifungal resistance and susceptibility","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; BC Cancer Agency","funders":"","keywords":"Neutropenia; Medicine; Hematopoietic stem cell transplantation; Bridging (networking); Haematopoiesis; Granulocyte; Transplantation; Stem cell; Chemotherapy; Disease; Intensive care medicine; Immunology; Internal medicine; Biology","score_opus":0.0119281698805527,"score_gpt":0.23265665868198396,"score_spread":0.22072848880143126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2975621535","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014120174,0.007878208,0.00054102275,0.9389033,0.017166004,0.00004440367,0.000065710854,0.000054114167,0.021227172],"genre_scores_gemma":[0.11861088,0.009303728,0.0008947849,0.7867282,0.06607752,0.000058208418,0.000105175895,0.000036254238,0.018185262],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99924445,0.00031328833,0.00008799465,0.000085181346,0.0001599963,0.00010908947],"domain_scores_gemma":[0.9990754,0.00049597415,0.000097075754,0.000033159024,0.00010234671,0.00019600643],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006709286,0.0004686188,0.00054824195,0.00047354275,0.0016561152,0.0011969352,0.0006404094,0.011834648,0.0029158902],"category_scores_gemma":[0.0038780698,0.00023481836,0.0008479192,0.00042703422,0.0011730532,0.0011911641,0.00062932447,0.009207038,0.0017751922],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005707318,0.0002831251,0.007228029,0.00022786052,0.00008959455,0.1628221,0.00042658346,0.0008489205,0.0025624607,0.012945943,0.73975855,0.072236225],"study_design_scores_gemma":[0.00065392494,0.0006297806,0.0092796935,0.001478258,0.0001255452,0.24390544,0.0010292835,0.003769317,0.0025193496,0.044557415,0.69192886,0.00012315215],"about_ca_topic_score_codex":0.002055387,"about_ca_topic_score_gemma":0.0044893413,"teacher_disagreement_score":0.011834648,"about_ca_system_score_codex":0.0019420534,"about_ca_system_score_gemma":0.0011508124,"threshold_uncertainty_score":0.014090657},"labels":[],"label_agreement":null},{"id":"W2981763967","doi":"10.1080/10428194.2019.1675879","title":"Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study","year":2019,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":150,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"Bristol-Myers Squibb","keywords":"Dasatinib; Discontinuation; Medicine; Myeloid leukemia; Internal medicine; Imatinib; Tyrosine-kinase inhibitor; Adverse effect; Tyrosine kinase; Oncology; Gastroenterology; Cancer; Receptor","score_opus":0.005489341495418336,"score_gpt":0.237756561886154,"score_spread":0.23226722039073566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981763967","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99535924,0.002670515,0.00016181252,0.00014985162,0.000035042132,0.00015691725,0.0006446019,0.000008958897,0.0008131965],"genre_scores_gemma":[0.9969104,0.0012061901,0.00015308546,0.00022781035,0.000069748436,0.00011265467,0.00086615543,0.0000035125622,0.00045038172],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99946123,0.00029474095,0.000041582123,0.00005743178,0.00007390917,0.00007113024],"domain_scores_gemma":[0.99929976,0.00017856198,0.00022836248,0.000073738,0.000041019775,0.00017862346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015365698,0.0005771222,0.0010428275,0.00018777342,0.00022862785,0.0006080765,0.0002859661,0.0005330802,0.0012966718],"category_scores_gemma":[0.0011323032,0.00023487456,0.0008969594,0.00040626043,0.00034231448,0.00050528627,0.00032629917,0.0009536144,0.0002977134],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5831775,0.007433548,0.24439903,0.0016617205,0.0059752087,0.0006843822,0.0004878002,0.0015921516,0.017810026,0.000455152,0.004571265,0.13175233],"study_design_scores_gemma":[0.37675482,0.15658379,0.4401156,0.00013498176,0.0030007318,0.0014204171,0.00025789163,0.0014861672,0.0027328308,0.00057923835,0.016858103,0.00007537417],"about_ca_topic_score_codex":0.0005331036,"about_ca_topic_score_gemma":0.0013374137,"teacher_disagreement_score":0.0015365698,"about_ca_system_score_codex":0.00031297278,"about_ca_system_score_gemma":0.0005207408,"threshold_uncertainty_score":0.008126199},"labels":[],"label_agreement":null},{"id":"W2990938107","doi":"10.1080/10428194.2019.1688320","title":"Consolidation outcomes in CPX-351 versus cytarabine/daunorubicin-treated older patients with high-risk/secondary acute myeloid leukemia","year":2019,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada","funders":"","keywords":"Medicine; Cytarabine; Daunorubicin; Internal medicine; Myeloid leukemia; Population; Leukemia; Surgery; Oncology","score_opus":0.006292642361575587,"score_gpt":0.23580892617668242,"score_spread":0.22951628381510683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990938107","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99654216,0.002669699,0.000097249664,0.0001424255,0.0000408909,0.00003316278,0.000079238394,0.000004745642,0.00039032125],"genre_scores_gemma":[0.998777,0.00057356566,0.00007101271,0.00014680732,0.000059279664,0.00001942398,0.00020309047,0.0000012980607,0.00014860513],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995401,0.0002043151,0.00003975713,0.000082175844,0.00005025829,0.00008334687],"domain_scores_gemma":[0.99892956,0.00023934132,0.00036546672,0.000058098685,0.00004371793,0.00036384855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012700417,0.00023752725,0.0007058969,0.00015246143,0.00017492537,0.00045414423,0.00022174238,0.00037625284,0.0011519294],"category_scores_gemma":[0.0018971964,0.00009309709,0.0010235211,0.00021760001,0.00022526766,0.00047004592,0.00039611896,0.0010128214,0.0001665419],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4104098,0.0034119207,0.37758067,0.00079228706,0.003926355,0.00047783938,0.00048329428,0.0020778591,0.01015202,0.00048225909,0.0020942837,0.18811144],"study_design_scores_gemma":[0.019669201,0.1808123,0.7790788,0.00028215887,0.004324143,0.0008648475,0.00041989057,0.0055196104,0.0030648613,0.0008314358,0.0050899955,0.00004271112],"about_ca_topic_score_codex":0.00086251245,"about_ca_topic_score_gemma":0.0018706413,"teacher_disagreement_score":0.0012700417,"about_ca_system_score_codex":0.00049080333,"about_ca_system_score_gemma":0.000509356,"threshold_uncertainty_score":0.0067166686},"labels":[],"label_agreement":null},{"id":"W2993163009","doi":"10.1080/10428194.2019.1697877","title":"The option of treatment and outcomes for patients with AIDS-related diffuse large B-cell lymphoma from a resource-limited setting in China","year":2019,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Cart; Lymphoma; Antiretroviral therapy; Medicine; Human immunodeficiency virus (HIV); Diffuse large B-cell lymphoma; China; Intensive care medicine; Oncology; Internal medicine; Virology; Viral load; Political science; Geography","score_opus":0.004419475394368583,"score_gpt":0.20793332043203167,"score_spread":0.2035138450376631,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2993163009","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5853199,0.0057309424,0.00011817742,0.39050016,0.0010002531,0.00003902634,0.0005643599,0.000016779066,0.016710432],"genre_scores_gemma":[0.9364049,0.003155099,0.00014475435,0.0544763,0.0014120188,0.000031279837,0.00035831862,0.000007894501,0.0040095104],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995908,0.00012515501,0.00003808359,0.00002738907,0.000047600355,0.00017098917],"domain_scores_gemma":[0.9987546,0.00024097507,0.00017919843,0.000031112173,0.00021584393,0.00057826214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005384558,0.00009410694,0.00029904646,0.000348472,0.0014824247,0.00067802146,0.00033236938,0.0014113535,0.0029467973],"category_scores_gemma":[0.0029156294,0.000089485766,0.00022035681,0.0007401021,0.00043944689,0.0004677436,0.00036590887,0.0014948209,0.00029550373],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070280745,0.00032581072,0.80405223,0.00015592056,0.000059548758,0.020890456,0.0015711746,0.0003923253,0.00067367475,0.0018249103,0.116644315,0.052706793],"study_design_scores_gemma":[0.00041731738,0.00047883554,0.8892381,0.0008133384,0.00015317924,0.026712222,0.00873783,0.0027862936,0.00039992284,0.0065576616,0.0635868,0.000118549855],"about_ca_topic_score_codex":0.049743317,"about_ca_topic_score_gemma":0.08537265,"teacher_disagreement_score":0.049743317,"about_ca_system_score_codex":0.003603129,"about_ca_system_score_gemma":0.0035508533,"threshold_uncertainty_score":0.09890759},"labels":[],"label_agreement":null},{"id":"W3012118048","doi":"10.1080/10428194.2020.1734594","title":"IND.216: a phase II study of buparlisib and associated biomarkers, raptor and p70S6K, in patients with relapsed and refractory chronic lymphocytic leukemia","year":2020,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Princess Margaret Cancer Centre; University Health Network; McGill University; University of Alberta; Queen Elizabeth II Health Sciences Centre; CancerCare Manitoba; Jewish General Hospital","funders":"","keywords":"Medicine; Internal medicine; Chronic lymphocytic leukemia; Toxicity; Gastroenterology; Oncology; Leukemia","score_opus":0.012710099089056265,"score_gpt":0.25567834900218644,"score_spread":0.24296824991313018,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012118048","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848008,0.00400881,0.0006969659,0.00074660056,0.00013166256,0.0019300326,0.0026180018,0.00026765314,0.004799386],"genre_scores_gemma":[0.97832686,0.0031424996,0.00253916,0.0015676658,0.00021359084,0.0025303643,0.006290072,0.000043613665,0.0053462777],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99983585,0.000059411766,0.000013852956,0.00002710891,0.000027446098,0.000036376678],"domain_scores_gemma":[0.99982494,0.000015459285,0.00003777189,0.000017227372,0.0000136416265,0.000091008944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005298844,0.0009565932,0.0013129577,0.00046381916,0.00027689373,0.0005481612,0.0005663742,0.00079025404,0.0036175924],"category_scores_gemma":[0.00029578307,0.00030256642,0.00083047064,0.00045444176,0.00038290847,0.00049731706,0.00032548205,0.0014264209,0.0012658951],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29687208,0.07565207,0.019507619,0.002264543,0.0013851549,0.00085234275,0.00024629003,0.0033374643,0.18583368,0.00053827226,0.012989941,0.4005206],"study_design_scores_gemma":[0.39451683,0.5278924,0.038443316,0.00008239795,0.0006975928,0.002562465,0.00007287589,0.00261253,0.019059619,0.0003661417,0.013610813,0.00008309776],"about_ca_topic_score_codex":0.00029919646,"about_ca_topic_score_gemma":0.00084284594,"teacher_disagreement_score":0.0036175924,"about_ca_system_score_codex":0.00032032546,"about_ca_system_score_gemma":0.0006363328,"threshold_uncertainty_score":0.012102008},"labels":[],"label_agreement":null},{"id":"W3020462214","doi":"10.1080/10428194.2020.1749607","title":"Healthcare resource utilization in myeloproliferative neoplasms: a population-based study from Ontario, Canada","year":2020,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; Entomological Society of Canada; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Polycythemia vera; Myelofibrosis; Population; Cohort; Health care; Comorbidity; Venous thrombosis; Internal medicine; Essential thrombocythemia; Thrombosis; Emergency medicine; Surgery; Environmental health","score_opus":0.02424562514465522,"score_gpt":0.25278177620426145,"score_spread":0.22853615105960623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3020462214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99011457,0.00096614595,0.00008747942,0.00028185136,0.0000104149585,0.000066620625,0.0069919233,0.0000067377487,0.0014743076],"genre_scores_gemma":[0.99643314,0.00066831097,0.00011347295,0.00013243956,0.0000072989596,0.000028780723,0.0021365818,0.000003464251,0.00047652677],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991073,0.000054827957,0.00008560775,0.00015650298,0.0003135735,0.0002821638],"domain_scores_gemma":[0.99814963,0.000090754176,0.00052040524,0.00006885448,0.00073244097,0.000437812],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052637944,0.000418097,0.00053771905,0.0014688175,0.0022329786,0.0013510302,0.0010343139,0.0005135493,0.0014816999],"category_scores_gemma":[0.0016038723,0.0005146428,0.0007999414,0.005807593,0.0006893747,0.0005356623,0.0008692966,0.00060230185,0.00018781604],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004423234,0.0000280556,0.997127,0.000035974186,0.000059075217,0.00006702671,0.0003629022,0.00006439961,0.000074890035,0.000050032308,0.0008079578,0.0012784925],"study_design_scores_gemma":[0.000009043184,0.000015052617,0.99868053,0.00002718022,0.000024649673,0.00004562944,0.0005059642,0.00017740302,0.000015946884,0.000011797314,0.00048005575,0.0000067404394],"about_ca_topic_score_codex":0.99248534,"about_ca_topic_score_gemma":0.99515474,"teacher_disagreement_score":0.031288054,"about_ca_system_score_codex":0.031288054,"about_ca_system_score_gemma":0.025948627,"threshold_uncertainty_score":0.2270118},"labels":[],"label_agreement":null},{"id":"W3028254761","doi":"10.1080/10428194.2020.1765234","title":"Changes in primary outcome and sample size measures after initiation of accrual among trials supporting approval of drugs for hematological malignancies by the US food and drug administration","year":2020,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Sample size determination; Medicine; Accrual; Clinical trial; Internal medicine; Food and drug administration; Pharmacology; Accounting","score_opus":0.16665121526340146,"score_gpt":0.3539382664629288,"score_spread":0.18728705119952735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028254761","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"reporting","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":"reporting","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.29422355,0.32394683,0.14822811,0.028150208,0.015360743,0.09779915,0.050031986,0.0022694422,0.039990008],"genre_scores_gemma":[0.7893695,0.012606066,0.06792845,0.008803407,0.001508432,0.10666019,0.00992365,0.00059714005,0.0026032217],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.4902766,0.2834475,0.16385466,0.0140600335,0.046117038,0.0022441593],"domain_scores_gemma":[0.34985408,0.49473262,0.095821194,0.032705393,0.0252912,0.0015955631],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.39035636,0.0012425451,0.0045321262,0.0063365554,0.00093662454,0.0048926645,0.0021322048,0.0028774024,0.0053605726],"category_scores_gemma":[0.61717546,0.00097298046,0.011392017,0.0076367045,0.0025971024,0.0056884605,0.0029542756,0.0045885853,0.0009401324],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12112696,0.0011180356,0.12656218,0.12136898,0.11501608,0.0007060571,0.003837174,0.0038241886,0.00556719,0.0135579,0.034232102,0.45308316],"study_design_scores_gemma":[0.060692757,0.029590556,0.45533314,0.03324008,0.1252785,0.002112223,0.0013769722,0.006377639,0.026710339,0.053960435,0.20428075,0.001046568],"about_ca_topic_score_codex":0.00050556666,"about_ca_topic_score_gemma":0.0008101847,"teacher_disagreement_score":0.60964364,"about_ca_system_score_codex":0.0031988306,"about_ca_system_score_gemma":0.003674982,"threshold_uncertainty_score":0.75179917},"labels":[],"label_agreement":null},{"id":"W3032936560","doi":"10.1080/10428194.2020.1772472","title":"Characteristics and outcomes of patients with relapsed follicular lymphoma following retreatment with second-line rituximab-containing chemotherapy","year":2020,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Spinal Cord Injury BC; Health Sciences Centre; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; Hôpital Maisonneuve-Rosemont; University of Toronto","funders":"","keywords":"Follicular lymphoma; Rituximab; Medicine; Oncology; Internal medicine; Chemotherapy; Lymphoma; Follicular phase; Stage (stratigraphy)","score_opus":0.007847507902116808,"score_gpt":0.21658497532236864,"score_spread":0.20873746742025184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032936560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989121,0.00029589527,0.000025261723,0.00006127887,0.000006714821,0.000005380937,0.00018317149,0.0000023947116,0.00050781766],"genre_scores_gemma":[0.9994137,0.00007325042,0.000010031543,0.00003988022,0.000013364865,0.0000057957873,0.0003111907,8.949931e-7,0.00013184309],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997706,0.000037796788,0.000032257394,0.000044095344,0.000036945323,0.000078286605],"domain_scores_gemma":[0.99928194,0.00012842599,0.00030447164,0.000035847184,0.00006336375,0.00018597941],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030036768,0.00009921979,0.00026555697,0.0004040595,0.00022522899,0.0004530084,0.0002444956,0.0003656543,0.0011462829],"category_scores_gemma":[0.0018051603,0.000085061074,0.00037171965,0.0005729978,0.00018526301,0.00043242742,0.00024659702,0.00036420967,0.0002431051],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000587762,0.00007747814,0.9943811,0.000007188873,0.00004731625,0.0003533352,0.000085445776,0.00011450265,0.0003408143,0.000028754232,0.00023252367,0.0037436483],"study_design_scores_gemma":[0.000024704455,0.00053381675,0.99747914,0.0000071197765,0.0000344016,0.0010037024,0.00023530649,0.00020096738,0.000059400292,0.000050860457,0.00036442306,0.000006056478],"about_ca_topic_score_codex":0.0025991697,"about_ca_topic_score_gemma":0.0024510568,"teacher_disagreement_score":0.0025991697,"about_ca_system_score_codex":0.0003869944,"about_ca_system_score_gemma":0.00023721287,"threshold_uncertainty_score":0.0051680803},"labels":[],"label_agreement":null},{"id":"W3041025600","doi":"10.1080/10428194.2020.1789626","title":"Severe infections following treatment for childhood cancer: a report from CYP-C","year":2020,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; SickKids Foundation; Institute for Clinical Evaluative Sciences; University of Toronto","funders":"Canadian Institutes of Health Research; Public Health Agency of Canada","keywords":"Medicine; Leukemia; Hazard ratio; Internal medicine; Confidence interval; Cancer; Cumulative incidence; Population; Incidence (geometry); Childhood leukemia; Cohort; Multivariate analysis; Univariate analysis; Proportional hazards model; Oncology; Lymphoblastic Leukemia; Environmental health","score_opus":0.024315173166287982,"score_gpt":0.29210512193379096,"score_spread":0.26778994876750295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3041025600","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954829,0.002554163,0.00011757641,0.00016933665,0.0000133726,0.00002085036,0.0004574657,0.0000055089477,0.0011787348],"genre_scores_gemma":[0.9973246,0.0020271789,0.000060730894,0.00011042153,0.00003078749,0.0000075047697,0.00028396145,0.0000027918925,0.00015211964],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99955827,0.00009760338,0.00005450167,0.00007047748,0.00011798638,0.00010124059],"domain_scores_gemma":[0.99798644,0.00045110914,0.0009332956,0.00016767404,0.00019814834,0.0002632786],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042985068,0.00018529534,0.0002717584,0.0006948162,0.0005746547,0.0006881324,0.00015408969,0.00030284317,0.0009490118],"category_scores_gemma":[0.0016612975,0.00014795044,0.00041726866,0.0013707144,0.00043941318,0.00019412022,0.00038091317,0.00047393766,0.00012294357],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009608611,0.000023904862,0.9904759,0.00006456455,0.00005925421,0.0012730998,0.0005608495,0.000047072026,0.00028741738,0.000038710798,0.0005267684,0.0065463264],"study_design_scores_gemma":[0.0000058013898,0.00009573905,0.99407816,0.000033116772,0.00003713733,0.003780911,0.00031760146,0.00004906623,0.0001269705,0.0000129009795,0.0014544572,0.000008076167],"about_ca_topic_score_codex":0.027503552,"about_ca_topic_score_gemma":0.016971884,"teacher_disagreement_score":0.027503552,"about_ca_system_score_codex":0.00068635325,"about_ca_system_score_gemma":0.001014584,"threshold_uncertainty_score":0.054686904},"labels":[],"label_agreement":null},{"id":"W3045653281","doi":"10.1080/10428194.2020.1795161","title":"Prolonged progression free survival in a subset of responders to the combination of brentuximab vedotin and bendamustine in heavily treated patients with relapsed or refractory Hodgkin lymphoma: updated results from an international multi-center phase I/II experience","year":2020,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; Princess Margaret Cancer Centre; University of Toronto","funders":"H. Lundbeck A/S; Seattle Genetics; AstraZeneca","keywords":"Brentuximab vedotin; Bendamustine; Medicine; Oncology; Internal medicine; Refractory (planetary science); Lymphoma; Malignancy; Hodgkin lymphoma; Biology; Rituximab","score_opus":0.020722327468934282,"score_gpt":0.2885611615219742,"score_spread":0.26783883405303993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3045653281","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9697683,0.011302037,0.00057739665,0.009290824,0.00038221502,0.00007898412,0.0006605368,0.000056336674,0.007883505],"genre_scores_gemma":[0.98795474,0.0035123168,0.00047091025,0.0048498223,0.00057033804,0.000056898716,0.0009571019,0.000014237857,0.0016136146],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9998276,0.000061308536,0.000014941913,0.000025790636,0.00003054296,0.000039842744],"domain_scores_gemma":[0.9995647,0.00019102391,0.00007182928,0.000019332974,0.00003437271,0.00011872488],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034205383,0.00020058086,0.00047622318,0.00018597751,0.00024220257,0.00040507322,0.00027612183,0.00054094556,0.0009906099],"category_scores_gemma":[0.0008027087,0.000074312404,0.00026735812,0.00028407748,0.00014214056,0.0003139563,0.0001262891,0.0006297568,0.00024809688],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02765188,0.00142813,0.40123203,0.00045002904,0.000349464,0.018437378,0.0006745719,0.0025387702,0.028032904,0.0005497961,0.04527959,0.47337553],"study_design_scores_gemma":[0.0037850176,0.023338245,0.8641502,0.0002912865,0.0008361125,0.040179573,0.00053614785,0.004776821,0.0047874195,0.0017001154,0.055538822,0.000080116864],"about_ca_topic_score_codex":0.00060625107,"about_ca_topic_score_gemma":0.0020261246,"teacher_disagreement_score":0.0009906099,"about_ca_system_score_codex":0.00044277022,"about_ca_system_score_gemma":0.00024220145,"threshold_uncertainty_score":0.003313899},"labels":[],"label_agreement":null},{"id":"W3048067521","doi":"10.1080/10428194.2020.1795159","title":"Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma","year":2020,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"National Cancer Institute","keywords":"Ibrutinib; Bendamustine; Medicine; Chronic lymphocytic leukemia; Internal medicine; Rituximab; Ofatumumab; Placebo; Hazard ratio; Alemtuzumab; Oncology; Lymphoma; Gastroenterology; Leukemia; Confidence interval; Transplantation; Pathology","score_opus":0.02279744231098206,"score_gpt":0.2582515279847478,"score_spread":0.23545408567376575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3048067521","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8991213,0.029302254,0.0024250667,0.0027946,0.0006116029,0.0032405208,0.049624283,0.0002054373,0.012674956],"genre_scores_gemma":[0.90156627,0.00523236,0.0024360085,0.003375306,0.00050284556,0.0028038046,0.07835006,0.00008668383,0.0056466637],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99811244,0.0010171273,0.00014007185,0.00015620422,0.0003255622,0.00024861156],"domain_scores_gemma":[0.99732167,0.00073114136,0.0007540425,0.00020081573,0.00039439995,0.0005980574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007902329,0.001132501,0.0021685853,0.00044184242,0.000493983,0.0014520668,0.00078735186,0.0010263675,0.0030373195],"category_scores_gemma":[0.0033147929,0.0003644992,0.0041531287,0.00072759576,0.0003228416,0.00081151165,0.0007784119,0.0021510075,0.0007392192],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.74740916,0.006135631,0.07857556,0.0029593066,0.02277497,0.0005122961,0.0003110316,0.004004108,0.010437209,0.00037017092,0.030786468,0.095724076],"study_design_scores_gemma":[0.33505347,0.12549357,0.4652851,0.00052574347,0.03140162,0.000661549,0.00026932338,0.0013499969,0.0046390044,0.0009018671,0.0342643,0.00015450448],"about_ca_topic_score_codex":0.0017914344,"about_ca_topic_score_gemma":0.005614587,"teacher_disagreement_score":0.007902329,"about_ca_system_score_codex":0.0010523334,"about_ca_system_score_gemma":0.001452672,"threshold_uncertainty_score":0.041791975},"labels":[],"label_agreement":null},{"id":"W3080882593","doi":"10.1080/10428194.2020.1791846","title":"Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy","year":2020,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"","keywords":"Medicine; Neutropenia; Brentuximab vedotin; Internal medicine; Febrile neutropenia; Dacarbazine; Vinblastine; Adverse effect; Lymphoma; Chemotherapy; Gastroenterology; Surgery; Oncology; Hodgkin lymphoma","score_opus":0.0064694461906447676,"score_gpt":0.20612635667743887,"score_spread":0.1996569104867941,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3080882593","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952028,0.003117655,0.00009874475,0.00043436917,0.00007055757,0.00003355596,0.00007496567,0.000016526456,0.0009508645],"genre_scores_gemma":[0.99901056,0.00047313425,0.000063055486,0.00018624819,0.000052340583,0.00000933819,0.000068486625,0.0000012281605,0.00013553888],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9996872,0.00015670601,0.000023931905,0.000033611184,0.000034968503,0.00006369699],"domain_scores_gemma":[0.99915254,0.00029522003,0.00019088543,0.000032720585,0.000034380337,0.000294105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063800794,0.00017168855,0.00053339964,0.00014876187,0.00014251024,0.00037085687,0.00019760134,0.0002587447,0.0011816449],"category_scores_gemma":[0.0018233756,0.000079274156,0.000533555,0.00017871415,0.000156585,0.00030520806,0.00020478437,0.0006749778,0.000095714815],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15410008,0.0067955083,0.3816768,0.00054889714,0.0026750446,0.0004089798,0.00021300098,0.0024128614,0.0048062354,0.0003131709,0.005449568,0.4406],"study_design_scores_gemma":[0.014374916,0.06783842,0.908797,0.00018072635,0.0014883011,0.00049982587,0.000105355735,0.0020789765,0.0012022868,0.00046132295,0.002957346,0.00001559095],"about_ca_topic_score_codex":0.0006823159,"about_ca_topic_score_gemma":0.0022559531,"teacher_disagreement_score":0.0011816449,"about_ca_system_score_codex":0.00030231208,"about_ca_system_score_gemma":0.00040765785,"threshold_uncertainty_score":0.00395298},"labels":[],"label_agreement":null},{"id":"W3081847310","doi":"10.1080/10428194.2020.1808206","title":"Classic Hodgkin lymphoma post-transplant lymphoproliferative disorders (PTLD) are often preceded by discordant PTLD subtypes","year":2020,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Post-transplant lymphoproliferative disorder; Lymphoproliferative disorders; Internal medicine; Medicine; Incidence (geometry); Medical microbiology; Lymphoma; Gastroenterology; Pathology; Immunology; Rituximab","score_opus":0.008089078092508206,"score_gpt":0.22072056191069214,"score_spread":0.21263148381818395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3081847310","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99752444,0.0006018736,0.00017479669,0.000032111653,0.0000057298703,0.000008889013,0.00009954297,0.00002093594,0.0015316829],"genre_scores_gemma":[0.99947506,0.00013216781,0.000096966694,0.000023004983,0.00000942169,0.000002394003,0.00012013594,0.0000031562229,0.00013772641],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997392,0.000039521274,0.00004156926,0.000045022163,0.0000631653,0.000071442744],"domain_scores_gemma":[0.99892116,0.00024842224,0.000523027,0.00007391194,0.000062624604,0.0001709328],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019233182,0.00013471437,0.00019981636,0.0004598147,0.00029288267,0.00042935723,0.00017849208,0.00018490425,0.002743825],"category_scores_gemma":[0.0017324301,0.00012034756,0.00013539291,0.0004994246,0.00026008772,0.00031776982,0.0003815401,0.00026777652,0.0003267789],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031907565,0.0000254975,0.9764708,0.00005280137,0.000024469127,0.0071232654,0.00019858658,0.00005822387,0.0027036828,0.00012354886,0.00033430185,0.012565676],"study_design_scores_gemma":[0.000013967888,0.000121393496,0.9125372,0.000021970298,0.00003029028,0.08359192,0.000277992,0.00015831112,0.0016593409,0.00016175235,0.00141921,0.00000659151],"about_ca_topic_score_codex":0.00068932807,"about_ca_topic_score_gemma":0.0011608487,"teacher_disagreement_score":0.002743825,"about_ca_system_score_codex":0.00020999879,"about_ca_system_score_gemma":0.00020634044,"threshold_uncertainty_score":0.0091789365},"labels":[],"label_agreement":null},{"id":"W3088246524","doi":"10.1080/10428194.2020.1817445","title":"Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review","year":2020,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre","funders":"Pfizer","keywords":"Medicine; Cytarabine; Myeloid leukemia; Concomitant; Oncology; Adverse effect; Internal medicine; Intensive care medicine","score_opus":0.01785343812651554,"score_gpt":0.278385460990264,"score_spread":0.2605320228637485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088246524","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00028154583,0.9950262,0.00021342945,0.001960011,0.00030527925,0.000050366587,0.0001399459,0.00000849907,0.0020146808],"genre_scores_gemma":[0.0018695988,0.9953898,0.00053649815,0.0013184092,0.00021417184,0.000044719247,0.00019163961,0.0000033383835,0.000431744],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99936646,0.00021589524,0.00016251788,0.000065136766,0.0001582157,0.000031804455],"domain_scores_gemma":[0.99829143,0.0008733352,0.00027738643,0.000022238846,0.00048260516,0.00005297528],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020270785,0.0005686737,0.0014194221,0.001188296,0.00021116555,0.00074475503,0.00111001,0.0010248149,0.0033326596],"category_scores_gemma":[0.004510741,0.00021799291,0.0013725198,0.0011802887,0.00018554126,0.00071012945,0.00047750009,0.0010477703,0.0010450259],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015792008,0.00003400522,0.0006062988,0.060382314,0.0005337583,0.00018289688,0.00010740034,0.00040233746,0.00060641597,0.0010793937,0.065272115,0.87063515],"study_design_scores_gemma":[0.00013990232,0.00017688378,0.0030502838,0.10754304,0.002175516,0.0015366136,0.00014292283,0.00017415574,0.0005152206,0.001238826,0.88326144,0.000045332046],"about_ca_topic_score_codex":0.0017337335,"about_ca_topic_score_gemma":0.005145693,"teacher_disagreement_score":0.0033326596,"about_ca_system_score_codex":0.00061017665,"about_ca_system_score_gemma":0.0016542587,"threshold_uncertainty_score":0.01114881},"labels":[],"label_agreement":null},{"id":"W3104232645","doi":"10.1080/10428194.2020.1845334","title":"Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study","year":2020,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; Princess Margaret Cancer Centre","funders":"AOP Orphan; Incyte; Sierra Oncology; European Hematology Association; Celgene; Novartis Pharmaceuticals Corporation; Pfizer","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Internal medicine; Jump; Phase (matter); Oncology; Physics; Bone marrow","score_opus":0.016623192033264837,"score_gpt":0.2876019261148819,"score_spread":0.27097873408161705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3104232645","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975458,0.00054912595,0.00008237992,0.00006980061,0.0000078477315,0.000038486985,0.0014500582,0.000005961819,0.00025058162],"genre_scores_gemma":[0.99445623,0.00016150084,0.00019968896,0.00007489129,0.00003689537,0.00007088624,0.004810072,0.000005222581,0.00018474816],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990213,0.000550966,0.000070051814,0.00013577916,0.00014555398,0.000076377306],"domain_scores_gemma":[0.9966329,0.0012076969,0.0011739614,0.0003098156,0.00021793219,0.00045778693],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026811438,0.00037598732,0.0008126039,0.00038046043,0.00019113037,0.0006486304,0.0005495986,0.0005226613,0.0013662486],"category_scores_gemma":[0.0032037878,0.00020835796,0.00084478647,0.0006404793,0.00018307309,0.0004257289,0.0004684372,0.00079079944,0.00020607696],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034365077,0.00043357402,0.9528679,0.00015962355,0.0011694375,0.00013333626,0.000048361984,0.0005097751,0.0014776902,0.0000544194,0.0014093468,0.0073714545],"study_design_scores_gemma":[0.00218571,0.0020444028,0.9926111,0.000024775805,0.0005547962,0.0001808911,0.000048694532,0.0013871485,0.00024669862,0.00007432029,0.000627192,0.000014309902],"about_ca_topic_score_codex":0.00051669026,"about_ca_topic_score_gemma":0.0011615504,"teacher_disagreement_score":0.0026811438,"about_ca_system_score_codex":0.00018357336,"about_ca_system_score_gemma":0.00032613997,"threshold_uncertainty_score":0.014179468},"labels":[],"label_agreement":null},{"id":"W3110487414","doi":"10.1080/10428194.2020.1850718","title":"Investigating the gut microbial community and genes in children with differing levels of change in serum asparaginase activity during pegaspargase treatment for acute lymphoblastic leukemia","year":2020,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Izaak Walton Killam Health Centre; Dalhousie University","funders":"IWK Health Centre; Nova Scotia Health Research Foundation; Crohn's and Colitis Foundation","keywords":"Asparaginase; Lymphoblastic Leukemia; Medicine; Microbiome; Metagenomics; Gene; Escherichia coli; Bacteroides; Microbial population biology; Microbiology; Immunology; Biology; Leukemia; Bacteria; Bioinformatics; Biochemistry; Genetics","score_opus":0.044493276827956056,"score_gpt":0.2871279467115785,"score_spread":0.24263466988362242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3110487414","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990331,0.00023757269,0.00016640937,0.00003513731,0.0000045836236,0.000009558952,0.00035667795,0.0000048172533,0.0001522209],"genre_scores_gemma":[0.99825245,0.0002816311,0.0005158485,0.00007442758,0.0000075254757,0.000027501908,0.0005609643,0.0000064652354,0.00027311774],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995745,0.000077110104,0.000027732463,0.00012176651,0.00007084305,0.00012803113],"domain_scores_gemma":[0.9996093,0.000052385934,0.00017352926,0.000018826071,0.00005536193,0.00009058386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025378857,0.00032525376,0.00047486354,0.00055284635,0.00036444917,0.0006283146,0.00017163323,0.00038765086,0.00087825913],"category_scores_gemma":[0.00090068014,0.0002259502,0.00038014917,0.0007283366,0.00029485195,0.0004290606,0.00047510373,0.00059159106,0.00019751677],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00079325587,0.00010017891,0.97670424,0.000052339463,0.000053948905,0.0003309199,0.0006007518,0.00010091313,0.013865623,0.000040407827,0.00017961732,0.007177769],"study_design_scores_gemma":[0.0000082370525,0.00039395972,0.9951094,0.000013022255,0.00003995244,0.0005013615,0.0011027183,0.00020330954,0.002087935,0.00003820204,0.0004949361,0.000007033131],"about_ca_topic_score_codex":0.0037715167,"about_ca_topic_score_gemma":0.004977093,"teacher_disagreement_score":0.0037715167,"about_ca_system_score_codex":0.000561085,"about_ca_system_score_gemma":0.00030030383,"threshold_uncertainty_score":0.007499099},"labels":[],"label_agreement":null},{"id":"W3112812645","doi":"10.1080/10428194.2020.1849674","title":"Evaluation of the effect of prospective biomarker testing on progression-free survival in diffuse large B-cell lymphoma","year":2020,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"F. Hoffmann-La Roche","keywords":"Biomarker; Diffuse large B-cell lymphoma; Lymphoma; Medicine; Oncology; Chemotherapy; Internal medicine; Cancer research; Biology","score_opus":0.021800845148916583,"score_gpt":0.275620091838249,"score_spread":0.2538192466893324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3112812645","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4594896,0.066943265,0.003567808,0.4151778,0.008531195,0.0004299494,0.0021727842,0.00026853633,0.04341895],"genre_scores_gemma":[0.8980492,0.009182653,0.0030898328,0.07745504,0.0069783623,0.00028782958,0.00078532525,0.00003790464,0.0041339006],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99693716,0.0020271742,0.00022605696,0.00023533008,0.00042387258,0.00015043799],"domain_scores_gemma":[0.9777805,0.017173825,0.0009404549,0.0007640006,0.0021012202,0.0012399375],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0066136005,0.0003473347,0.0009741556,0.0004457864,0.00047991466,0.0011421901,0.00054667314,0.0028583724,0.0015153735],"category_scores_gemma":[0.024786986,0.00015993617,0.00063622394,0.0006581916,0.0006368424,0.00079865,0.0002761487,0.0022481198,0.00079164124],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04767997,0.0015513398,0.27823684,0.0004961786,0.00058155635,0.0053401585,0.00027611357,0.002756057,0.005367316,0.0029914551,0.097075365,0.55764765],"study_design_scores_gemma":[0.008265724,0.05253359,0.6382143,0.0013249397,0.0032343275,0.019915072,0.0006337124,0.022988055,0.016094021,0.022543173,0.2138948,0.0003583748],"about_ca_topic_score_codex":0.0014730513,"about_ca_topic_score_gemma":0.0026721747,"teacher_disagreement_score":0.0066136005,"about_ca_system_score_codex":0.0022439673,"about_ca_system_score_gemma":0.0010518157,"threshold_uncertainty_score":0.034976482},"labels":[],"label_agreement":null},{"id":"W3117683236","doi":"10.1080/10428194.2020.1861277","title":"Evolving management strategies for lymphomas during the COVID-19 pandemic","year":2020,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Pandemic; Medicine; Coronavirus disease 2019 (COVID-19); Population; Quality (philosophy); Adaptation (eye); Intensive care medicine; Psychology; Disease; Pathology; Environmental health","score_opus":0.05738243624992581,"score_gpt":0.3307174995746764,"score_spread":0.27333506332475055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3117683236","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.041408826,0.060748644,0.006864737,0.83671355,0.0035836147,0.00025967244,0.00015901851,0.00017907772,0.050082922],"genre_scores_gemma":[0.5979991,0.12178571,0.024398725,0.23747419,0.008732969,0.0006150848,0.0005070084,0.00015644185,0.008330876],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9929716,0.003967812,0.0005488216,0.00030920247,0.00090164255,0.0013009843],"domain_scores_gemma":[0.99462694,0.0014531859,0.00083124114,0.0001113432,0.00096395495,0.002013284],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009231376,0.0003746772,0.00042413798,0.0010981001,0.0035643613,0.005292034,0.0014313646,0.0030593406,0.004652212],"category_scores_gemma":[0.019334732,0.00022638947,0.0005919233,0.0006145624,0.0020111573,0.0035836536,0.00761091,0.005932683,0.0008439187],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026193305,0.0005452218,0.047256526,0.0022619201,0.00016404956,0.0067782514,0.021045567,0.0028483858,0.0018855421,0.0639935,0.26470605,0.5882531],"study_design_scores_gemma":[0.00009243568,0.0006386455,0.021124156,0.009610727,0.0001481914,0.004871734,0.059395734,0.00150525,0.0012452153,0.05939191,0.84181964,0.00015641862],"about_ca_topic_score_codex":0.006540455,"about_ca_topic_score_gemma":0.012802247,"teacher_disagreement_score":0.009231376,"about_ca_system_score_codex":0.0050026644,"about_ca_system_score_gemma":0.010817708,"threshold_uncertainty_score":0.048820734},"labels":[],"label_agreement":null},{"id":"W3133799417","doi":"10.1080/10428194.2021.1889536","title":"The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study","year":2021,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Dasatinib; Myeloid leukemia; Medicine; Nivolumab; Nilotinib; Oncology; Internal medicine; Leukemia; Immunotherapy; Cancer; Imatinib","score_opus":0.011044376472123788,"score_gpt":0.24454907450342167,"score_spread":0.2335046980312979,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3133799417","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08885228,0.027781567,0.00072052167,0.8131677,0.011664529,0.0004059309,0.004070891,0.00023906387,0.053097527],"genre_scores_gemma":[0.27647752,0.012205241,0.0017762284,0.6513677,0.0221605,0.0005321611,0.003193579,0.000102509395,0.03218453],"study_design_codex":"not_applicable","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9988219,0.00040726026,0.00015824988,0.000112018366,0.0003625341,0.0001380147],"domain_scores_gemma":[0.99835014,0.0006676547,0.00019811114,0.000055078992,0.00034466054,0.0003843055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001569806,0.00032819042,0.0009162657,0.00024209984,0.0008943715,0.0009889869,0.000608242,0.0065669743,0.0029525582],"category_scores_gemma":[0.0034235744,0.00022698275,0.0005545198,0.00048321256,0.00050473964,0.000591334,0.00031012495,0.0036939725,0.0032256623],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006329086,0.0008084265,0.017301934,0.0003208739,0.00013333221,0.009190947,0.0001705732,0.0006491497,0.0071105356,0.0016356242,0.78641194,0.1699376],"study_design_scores_gemma":[0.013574486,0.005810086,0.046823844,0.00045546077,0.00026779383,0.020766204,0.0002661623,0.0039795614,0.0050448054,0.0053057964,0.89759624,0.00010956759],"about_ca_topic_score_codex":0.0025439458,"about_ca_topic_score_gemma":0.008129948,"teacher_disagreement_score":0.0065669743,"about_ca_system_score_codex":0.0026801901,"about_ca_system_score_gemma":0.0013289878,"threshold_uncertainty_score":0.019446313},"labels":[],"label_agreement":null},{"id":"W3143688388","doi":"10.1080/10428194.2021.1910688","title":"Inferior outcomes with reduced intensity conditioning followed by allogeneic hematopoietic cell transplantation in fit individuals with acute lymphoblastic leukemia: a Canadian single-center study and a comparison to registry data","year":2021,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; University of Manitoba; Princess Margaret Cancer Centre; CancerCare Manitoba; BC Children's Hospital; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Hematopoietic cell; Transplantation; Single Center; Internal medicine; Hematopoietic stem cell transplantation; Conditioning; Acute leukemia; Lymphoblastic Leukemia; Multivariate analysis; Retrospective cohort study; Oncology; Leukemia; Gastroenterology; Surgery; Haematopoiesis; Stem cell","score_opus":0.0215223810949936,"score_gpt":0.26363405859038924,"score_spread":0.24211167749539564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3143688388","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986842,0.00026936043,0.000061069644,0.0000684668,0.0000033786298,0.000011269266,0.00042834625,0.0000024838507,0.00047150094],"genre_scores_gemma":[0.99918693,0.00016523556,0.0000466183,0.000041197432,0.0000039104707,0.000004147225,0.0004812804,0.0000022994548,0.00006839617],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989114,0.00016242437,0.00007108758,0.00023953288,0.00034829316,0.0002672677],"domain_scores_gemma":[0.9982444,0.00016858494,0.00069790933,0.00018323996,0.000409275,0.00029657863],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011091797,0.00030225905,0.00035755595,0.00087718613,0.0010792583,0.0009305505,0.00069227646,0.00039218177,0.0009206832],"category_scores_gemma":[0.0026846651,0.0002203022,0.0005873456,0.0023503855,0.00057689677,0.00026775303,0.00057105353,0.00051396457,0.00007352392],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015556166,0.00001986707,0.99767727,0.00000965065,0.00008239911,0.000045164983,0.00010605996,0.00006377817,0.00016102298,0.00005379447,0.00012571184,0.001499643],"study_design_scores_gemma":[0.000025453579,0.00007186982,0.9986821,0.000010774229,0.00010103972,0.00013196148,0.00026980616,0.00023768566,0.000079267884,0.000028462784,0.0003535506,0.000008122939],"about_ca_topic_score_codex":0.77255505,"about_ca_topic_score_gemma":0.8215482,"teacher_disagreement_score":0.22744495,"about_ca_system_score_codex":0.00680543,"about_ca_system_score_gemma":0.007597783,"threshold_uncertainty_score":0.45756882},"labels":[],"label_agreement":null},{"id":"W3162249178","doi":"10.1080/10428194.2021.1919658","title":"A 10-color flow cytometry panel for diagnosis and minimal residual disease in chronic lymphocytic leukemia","year":2021,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"Canadian Institutes of Health Research","keywords":"Chronic lymphocytic leukemia; Minimal residual disease; Immunophenotyping; Medicine; Flow cytometry; Multilocus sequence typing; clone (Java method); Leukemia; Immunology; Oncology; Biology","score_opus":0.02986774142796106,"score_gpt":0.2905386127932589,"score_spread":0.2606708713652978,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3162249178","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.81809795,0.0048023094,0.14849499,0.0015121949,0.00043078524,0.0010219453,0.002439692,0.002738936,0.020461185],"genre_scores_gemma":[0.8320465,0.0011593167,0.15536892,0.00082331756,0.00011613345,0.00066183123,0.0034468374,0.000121763704,0.006255351],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99860555,0.0005470074,0.00012896296,0.00017320464,0.00040764062,0.00013775431],"domain_scores_gemma":[0.99902797,0.00038281752,0.00008907783,0.000114215465,0.00026450062,0.00012147637],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022844274,0.00052491244,0.00029394397,0.0017632935,0.00025535846,0.0006479069,0.0007178488,0.0006406805,0.004100504],"category_scores_gemma":[0.0023113296,0.0002765489,0.00029322042,0.00051407923,0.00035664137,0.00049956195,0.00043647707,0.0006517271,0.0013139228],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024005086,0.00043272763,0.09314605,0.00019986228,0.00007426262,0.00070824934,0.00033056704,0.0016631549,0.7564924,0.0020265172,0.0075479303,0.1349778],"study_design_scores_gemma":[0.00048515433,0.004379872,0.21648748,0.00025619604,0.00026079602,0.010624243,0.00020114986,0.061121363,0.6247488,0.0019734497,0.07927495,0.00018649665],"about_ca_topic_score_codex":0.0014142138,"about_ca_topic_score_gemma":0.0027592266,"teacher_disagreement_score":0.004100504,"about_ca_system_score_codex":0.0007033797,"about_ca_system_score_gemma":0.0005031464,"threshold_uncertainty_score":0.013717532},"labels":[],"label_agreement":null},{"id":"W3164483329","doi":"10.1080/10428194.2021.1933472","title":"Hsa-miR-372-5p regulates the NIMA related kinase 7 and IL-1β release in NK/T-cell lymphoma","year":2021,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Basic and Applied Basic Research Foundation of Guangdong Province; Applied Basic Research Foundation of Yunnan Province; Canadian Network for Research and Innovation in Machining Technology, Natural Sciences and Engineering Research Council of Canada; National Natural Science Foundation of China","keywords":"Mononucleosis; Lymphoma; microRNA; Biology; Cancer research; Epstein–Barr virus; Immunology; Downregulation and upregulation; Virus; Virology; Gene; Genetics","score_opus":0.0063253099479392855,"score_gpt":0.21608363143746917,"score_spread":0.2097583214895299,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3164483329","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899323,0.0046097226,0.0020706782,0.000100149795,0.00006758571,0.000027589644,0.0012191839,0.00013268426,0.001840129],"genre_scores_gemma":[0.9955824,0.00068965816,0.0011771265,0.00007845688,0.000011315629,0.00003280002,0.0012379431,0.000027352282,0.0011629915],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99976677,0.000029880708,0.000020339403,0.00006498622,0.00006948586,0.00004855153],"domain_scores_gemma":[0.99993527,0.000010667459,0.000020994026,0.0000069919215,0.00001208348,0.000014018419],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020657862,0.00025163696,0.0003297768,0.00031460228,0.00021600151,0.0005350255,0.000114010356,0.00020746372,0.0011050797],"category_scores_gemma":[0.00024410314,0.00018175086,0.0003491775,0.00020250425,0.00021415773,0.00020608875,0.00027422528,0.00038098852,0.0004297495],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012070705,0.000050830102,0.009313324,0.00017071405,0.00008710884,0.0002962473,0.00010415427,0.00042223695,0.97964156,0.0002580285,0.00048148804,0.007967201],"study_design_scores_gemma":[0.000114188064,0.00052948657,0.11532158,0.00003935212,0.0003037176,0.0014894424,0.00028228713,0.007917071,0.85734683,0.00054006133,0.016087675,0.00002829889],"about_ca_topic_score_codex":0.0005893304,"about_ca_topic_score_gemma":0.00097638665,"teacher_disagreement_score":0.0011050797,"about_ca_system_score_codex":0.00033407594,"about_ca_system_score_gemma":0.00027738386,"threshold_uncertainty_score":0.0036967993},"labels":[],"label_agreement":null},{"id":"W3165356648","doi":"10.1080/10428194.2021.1910685","title":"Mitochondrial metabolism: powering new directions in acute myeloid leukemia","year":2021,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute; University of British Columbia","funders":"BC Cancer Foundation; University of British Columbia; Canadian Institutes of Health Research; Leukemia and Lymphoma Society of Canada","keywords":"Myeloid leukemia; Leukemia; Mitochondrion; Context (archaeology); Cancer research; Oxidative phosphorylation; Myeloid; Biology; Stem cell; Medicine; Immunology; Cell biology; Biochemistry","score_opus":0.024508357642982058,"score_gpt":0.3126004999898599,"score_spread":0.28809214234687786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3165356648","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000037874346,0.9989666,0.000050764484,0.0004294666,0.0001742308,0.0000012610149,0.0000055720684,0.0000038789913,0.00033036846],"genre_scores_gemma":[0.00031411333,0.99900323,0.00006668517,0.00021712706,0.00018867347,0.0000015890898,0.000010672863,8.058954e-7,0.00019713822],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998229,0.000039935072,0.000027710852,0.000026556712,0.00006082111,0.000022188773],"domain_scores_gemma":[0.99969494,0.00013223029,0.000037849153,0.000008575566,0.00009299119,0.000033419157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006709484,0.000609761,0.001261488,0.0018086133,0.00032802275,0.001255909,0.0008021566,0.0013113011,0.0026965288],"category_scores_gemma":[0.0007955741,0.00022525477,0.0004177016,0.0017553555,0.0006120437,0.0022485775,0.0008988656,0.0024565847,0.0018794317],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000091134796,0.000049942413,0.00015183029,0.014303368,0.00006828917,0.00025243958,0.00008767816,0.00034142745,0.0009991742,0.009105449,0.04106142,0.9334879],"study_design_scores_gemma":[0.0000130134495,0.000077780816,0.0003904091,0.003154016,0.00005454042,0.0009382609,0.00007628869,0.000074041316,0.00019814371,0.004208111,0.9908014,0.000014001289],"about_ca_topic_score_codex":0.0010434998,"about_ca_topic_score_gemma":0.0018719559,"teacher_disagreement_score":0.0026965288,"about_ca_system_score_codex":0.00082438433,"about_ca_system_score_gemma":0.0011302001,"threshold_uncertainty_score":0.009020746},"labels":[],"label_agreement":null},{"id":"W3172578726","doi":"10.1080/10428194.2021.1938029","title":"Prognostic value of disease risk score versus gait speed in older adults with lymphoma","year":2021,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Dana-Farber Cancer Institute","keywords":"Medicine; Gait; Internal medicine; Lymphoma; Cohort; Disease; Preferred walking speed; Oncology; Physical medicine and rehabilitation","score_opus":0.013297063889686184,"score_gpt":0.25933042327733996,"score_spread":0.24603335938765378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172578726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99916244,0.0004074572,0.00005798103,0.000029890654,0.0000068786017,0.0000032911862,0.00009596551,0.0000022376914,0.00023389632],"genre_scores_gemma":[0.9996364,0.00009178077,0.00005134177,0.000013544432,0.000013998014,0.000002119439,0.000121120014,6.858837e-7,0.00006909738],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997955,0.00008282967,0.000026149482,0.000033475982,0.00002570286,0.000036422352],"domain_scores_gemma":[0.9988926,0.0003284485,0.00041475694,0.00006421838,0.00010021031,0.00019970351],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062191597,0.00028518683,0.00036421785,0.00064360653,0.00015341531,0.00042657877,0.00014699141,0.00036526623,0.0009361874],"category_scores_gemma":[0.0034535893,0.00010001955,0.00029531418,0.0006000549,0.00014892848,0.00039976148,0.00037231972,0.00033571862,0.00015590712],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003075456,0.00001565342,0.99703395,0.0000057873212,0.000032273976,0.000031182928,0.00001457592,0.000049630464,0.00011278731,0.0000075663743,0.00003232551,0.0023566838],"study_design_scores_gemma":[0.0000120748455,0.00033957852,0.99869674,0.000007819249,0.00004781614,0.00017663692,0.000046710393,0.00046594007,0.000065176784,0.0000417866,0.00009607467,0.0000036609792],"about_ca_topic_score_codex":0.0009422483,"about_ca_topic_score_gemma":0.0015607888,"teacher_disagreement_score":0.0009422483,"about_ca_system_score_codex":0.00012654418,"about_ca_system_score_gemma":0.000109061315,"threshold_uncertainty_score":0.003289044},"labels":[],"label_agreement":null},{"id":"W3175217849","doi":"10.1080/10428194.2021.1941936","title":"Impact of initial biopsy type on the time to final diagnostic biopsy in patients with follicular lymphoma and suspected histologic transformation","year":2021,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"National Cancer Institute","keywords":"Biopsy; Medicine; Radiology; Follicular lymphoma; Fine-needle aspiration; Lymphoma; Positron emission tomography; Gold standard (test); Pathology","score_opus":0.01065069518265316,"score_gpt":0.25027051749929746,"score_spread":0.2396198223166443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3175217849","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99772376,0.0008986383,0.00014108208,0.00014237274,0.000022878086,0.0000087346225,0.00006668976,0.000006671117,0.0009891556],"genre_scores_gemma":[0.99964976,0.00008862563,0.00007518297,0.00004100015,0.000016007958,0.0000033560136,0.00007203158,0.000003151081,0.00005102546],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988977,0.00041253495,0.0001296614,0.0001296839,0.00017343451,0.00025705175],"domain_scores_gemma":[0.9887129,0.00629799,0.0024697294,0.00027620606,0.00067093724,0.0015722866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012433052,0.00017857787,0.00038346447,0.0005381118,0.00046263353,0.0010397983,0.00034882536,0.0004534467,0.0018938222],"category_scores_gemma":[0.014172127,0.00018415399,0.00052805163,0.00047658468,0.00030655213,0.00063898345,0.00037160094,0.00082941493,0.00025474033],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011512998,0.00008138433,0.9922849,0.000009125488,0.00003343655,0.0005750625,0.0000639561,0.00016079497,0.0003155734,0.000023406788,0.0001487794,0.005152208],"study_design_scores_gemma":[0.00004123798,0.00069957395,0.9933849,0.000035387267,0.00010371478,0.0028865093,0.0006070065,0.0013381547,0.00044441002,0.000072309296,0.0003721145,0.000014734202],"about_ca_topic_score_codex":0.0035244683,"about_ca_topic_score_gemma":0.0043378384,"teacher_disagreement_score":0.0035244683,"about_ca_system_score_codex":0.0006824073,"about_ca_system_score_gemma":0.0006243245,"threshold_uncertainty_score":0.0070079565},"labels":[],"label_agreement":null},{"id":"W3182533416","doi":"10.1080/10428194.2021.1938027","title":"A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies","year":2021,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Ibrutinib; Bruton's tyrosine kinase; Diffuse large B-cell lymphoma; Refractory (planetary science); Medicine; Cancer research; Pharmacodynamics; Pharmacology; Internal medicine; Oncology; Lymphoma; Pharmacokinetics; Tyrosine kinase; Chronic lymphocytic leukemia; Biology; Leukemia; Receptor","score_opus":0.00943998338930477,"score_gpt":0.2521259848472878,"score_spread":0.24268600145798305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3182533416","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9836611,0.0031509541,0.0010108562,0.0006657608,0.00016959787,0.005462454,0.0015666021,0.00013960921,0.00417305],"genre_scores_gemma":[0.9788012,0.002706864,0.003582271,0.0012773431,0.00020492877,0.005346394,0.002862158,0.000053850355,0.005165071],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995376,0.00022936943,0.000019221576,0.000081216414,0.000044775934,0.00008791341],"domain_scores_gemma":[0.9996624,0.00004144162,0.00004679169,0.000026374675,0.000030180492,0.00019279783],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013288023,0.0013392855,0.0015669732,0.000526388,0.000383862,0.0009958887,0.00067448773,0.0011841964,0.0036860819],"category_scores_gemma":[0.0006514902,0.0005908914,0.001110662,0.00039929966,0.00064545206,0.0006195327,0.00027392714,0.0023555188,0.0010407655],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.52664465,0.1567479,0.0070165084,0.0010594293,0.001652252,0.0006361412,0.00046374544,0.0035727178,0.10108213,0.000713282,0.0074556805,0.19295543],"study_design_scores_gemma":[0.50396323,0.4751149,0.008919765,0.000037321573,0.00042683535,0.00034434538,0.00005919839,0.0016330726,0.0039300323,0.00024368985,0.0052954364,0.000032216627],"about_ca_topic_score_codex":0.0011449368,"about_ca_topic_score_gemma":0.0032036984,"teacher_disagreement_score":0.0036860819,"about_ca_system_score_codex":0.0008727388,"about_ca_system_score_gemma":0.0013818219,"threshold_uncertainty_score":0.012331128},"labels":[],"label_agreement":null},{"id":"W3183715267","doi":"10.1080/10428194.2021.1957865","title":"Effectiveness of brentuximab vedotin monotherapy in relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis","year":2021,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Brentuximab vedotin; Medicine; Internal medicine; Neutropenia; Adverse effect; Confidence interval; Oncology; Meta-analysis; Anemia; Lymphoma; Observational study; Gastroenterology; Hodgkin lymphoma; Chemotherapy","score_opus":0.04153131334834914,"score_gpt":0.3275803715179592,"score_spread":0.28604905816961007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3183715267","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017188261,0.99713933,0.00020460786,0.00011505922,0.000074732205,0.00007603319,0.0003640251,0.000013432088,0.00029387596],"genre_scores_gemma":[0.060817692,0.93668157,0.0007281124,0.0005818749,0.00012399335,0.00020770247,0.00055225194,0.000015108724,0.0002918067],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99796885,0.0008074697,0.00061963004,0.00024118493,0.00027752115,0.00008539564],"domain_scores_gemma":[0.99598664,0.0028928497,0.00057492894,0.00009547009,0.0003705716,0.000079522455],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049079433,0.001665281,0.010161689,0.003701412,0.00037839328,0.0018101637,0.0010975908,0.0011562929,0.004383375],"category_scores_gemma":[0.008773679,0.0008161822,0.0191453,0.0048419368,0.0003322376,0.0011957656,0.0008047915,0.0012749679,0.00039221504],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016868596,0.000029134104,0.0023987493,0.58264637,0.36478382,0.00017169208,0.00007651849,0.0005199824,0.0004418369,0.00019375236,0.0022385023,0.044812776],"study_design_scores_gemma":[0.0006326976,0.00016854687,0.0041256417,0.042541645,0.9454264,0.00016718867,0.000043725133,0.0001537923,0.00015583562,0.0002144758,0.0063470015,0.00002294826],"about_ca_topic_score_codex":0.004989094,"about_ca_topic_score_gemma":0.01621983,"teacher_disagreement_score":0.010161689,"about_ca_system_score_codex":0.0013206394,"about_ca_system_score_gemma":0.0018889388,"threshold_uncertainty_score":0.025956035},"labels":[],"label_agreement":null},{"id":"W3186223954","doi":"10.1080/10428194.2021.1953006","title":"Gut bacterial gene changes following pegaspargase treatment in pediatric patients with acute lymphoblastic leukemia","year":2021,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Izaak Walton Killam Health Centre; Dalhousie University","funders":"IWK Health Centre; Nova Scotia Health Research Foundation","keywords":"Asparaginase; Asparagine; Glutamine; Lymphoblastic Leukemia; Asparagine synthetase; Gut microbiome; Gene; Medicine; Microbiome; Biology; Amino acid; Gut flora; Microbiology; Leukemia; Biochemistry; Internal medicine; Bioinformatics","score_opus":0.010383390874948967,"score_gpt":0.24175526932241911,"score_spread":0.23137187844747015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3186223954","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987436,0.0005043584,0.00009391009,0.000048703096,0.0000052248624,0.0000070089227,0.00034287618,0.000005102033,0.0002491491],"genre_scores_gemma":[0.9986243,0.0003975673,0.0002176155,0.000060120616,0.0000058632754,0.000013972696,0.00043133917,0.0000031953196,0.00024607594],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998479,0.000028282207,0.000011647424,0.00003118844,0.00003211467,0.000048888764],"domain_scores_gemma":[0.9998222,0.000039102546,0.000076813354,0.000006972494,0.000019572864,0.000035492212],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008647342,0.00015036108,0.0003237675,0.0003874824,0.00020947825,0.00033766896,0.00007997399,0.00022017033,0.0007266406],"category_scores_gemma":[0.0003837446,0.000087727334,0.00017858826,0.00077043666,0.00019213918,0.00013968736,0.00016413114,0.00034219,0.00010190922],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004038254,0.00014330403,0.92273533,0.00011234157,0.000093380266,0.0025107206,0.000464348,0.0003367555,0.04680209,0.00007578379,0.00041121204,0.022276511],"study_design_scores_gemma":[0.000015940273,0.00047920668,0.9908343,0.00001061592,0.00006330999,0.0015943324,0.0005412973,0.00023398653,0.005258087,0.000050433886,0.00091291976,0.000005615465],"about_ca_topic_score_codex":0.0015701596,"about_ca_topic_score_gemma":0.0018661862,"teacher_disagreement_score":0.0015701596,"about_ca_system_score_codex":0.00039343192,"about_ca_system_score_gemma":0.0001662758,"threshold_uncertainty_score":0.0031220317},"labels":[],"label_agreement":null},{"id":"W3202324403","doi":"10.1080/10428194.2021.1961233","title":"Infections in secondary immunodeficiency patients treated with Privigen<sup>®</sup>or Hizentra<sup>®</sup>: a retrospective US administrative claims study in patients with hematological malignancies","year":2021,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Pneumocystis jirovecii pneumonia detection and treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"CSL Behring","keywords":"Retrospective cohort study; Medicine; Internal medicine","score_opus":0.009488305154979077,"score_gpt":0.23316239576098807,"score_spread":0.22367409060600899,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202324403","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9991002,0.00017356087,0.000030169647,0.00001987483,0.000003294693,0.0000058131527,0.0004227205,0.0000018926869,0.00024235484],"genre_scores_gemma":[0.99946696,0.00007168662,0.00001620333,0.000020925321,0.000004587018,0.0000042542542,0.00030835136,7.8488176e-7,0.00010633284],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996203,0.000098333534,0.000060542545,0.00008197916,0.000067553425,0.000071268696],"domain_scores_gemma":[0.99903226,0.0001337771,0.0005544515,0.00006656544,0.000056848698,0.00015610472],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004358019,0.00019022786,0.00023844006,0.00070439087,0.00037003384,0.00080188183,0.00026955083,0.0004603783,0.0018503916],"category_scores_gemma":[0.0013856845,0.00044374054,0.0004913997,0.0009568207,0.00023043422,0.0004245767,0.0004203197,0.000663896,0.0003139856],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001512514,0.000041772462,0.99921525,0.0000053439844,0.000032024367,0.000041204497,0.000037644673,0.000015218137,0.00007786126,0.000009608967,0.000059145554,0.0003136552],"study_design_scores_gemma":[0.000014221954,0.00014518849,0.99908686,0.0000061715314,0.000026488691,0.00025042915,0.00015417548,0.0001461547,0.00004719495,0.000012420164,0.00010762742,0.0000030631818],"about_ca_topic_score_codex":0.006346534,"about_ca_topic_score_gemma":0.006886217,"teacher_disagreement_score":0.006346534,"about_ca_system_score_codex":0.00033264232,"about_ca_system_score_gemma":0.00027517782,"threshold_uncertainty_score":0.012619138},"labels":[],"label_agreement":null},{"id":"W3203935034","doi":"10.1080/10428194.2021.1948026","title":"Anticipation in multiple-case lymphoid cancer families after controlling for ascertainment biases","year":2021,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"DNA Repair Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; Canada's Michael Smith Genome Sciences Centre; University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Anticipation (artificial intelligence); Inheritance (genetic algorithm); Disease; Cancer; Medicine; Oncology; Biology; Genetics; Internal medicine; Gene","score_opus":0.019825228264423077,"score_gpt":0.2570912003199949,"score_spread":0.23726597205557182,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203935034","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8982455,0.004195218,0.026834702,0.056523386,0.0025059034,0.00010020078,0.001646667,0.0002896962,0.009658765],"genre_scores_gemma":[0.9853006,0.00089641556,0.0038698132,0.004894251,0.0021916414,0.000059720584,0.00024249729,0.00003552894,0.0025095516],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99704355,0.0017694739,0.0001484276,0.0006127473,0.00021960688,0.00020612872],"domain_scores_gemma":[0.9815801,0.013801507,0.0021217894,0.0014404978,0.00053945417,0.0005166491],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0053637973,0.0004114398,0.00070052914,0.00085053814,0.0009009668,0.00065004104,0.0006716589,0.0020633216,0.0021014682],"category_scores_gemma":[0.028201934,0.00032009132,0.0003876884,0.0012299628,0.0006012348,0.0007808923,0.000461032,0.0013807524,0.0005416782],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002434099,0.00009805808,0.8497203,0.00010980036,0.00036074087,0.05396959,0.00054609776,0.0016498344,0.003846314,0.0036654316,0.024459166,0.059140515],"study_design_scores_gemma":[0.0003032022,0.000972718,0.68053347,0.00025296575,0.0009057217,0.20197435,0.0009385947,0.037718635,0.0032923103,0.045368806,0.027536355,0.00020286419],"about_ca_topic_score_codex":0.0033510348,"about_ca_topic_score_gemma":0.005875504,"teacher_disagreement_score":0.0053637973,"about_ca_system_score_codex":0.00046993996,"about_ca_system_score_gemma":0.00038659945,"threshold_uncertainty_score":0.028366804},"labels":[],"label_agreement":null},{"id":"W3209446816","doi":"10.1080/10428194.2021.1992761","title":"Risk factors for severe infections in secondary immunodeficiency: a retrospective US administrative claims study in patients with hematological malignancies","year":2021,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Pneumocystis jirovecii pneumonia detection and treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"CSL Behring","keywords":"Medicine; Multivariate analysis; Retrospective cohort study; Internal medicine; Receiver operating characteristic; Psychological intervention; Primary immunodeficiency; Intensive care medicine; Pediatrics; Disease","score_opus":0.010680148477638452,"score_gpt":0.2458394867161154,"score_spread":0.23515933823847696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3209446816","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99895144,0.00013347254,0.00008176001,0.000030653453,0.0000026763037,0.000011293479,0.00060574804,0.0000024852097,0.00018048813],"genre_scores_gemma":[0.9993987,0.00004692255,0.00005363882,0.000017517179,0.000005126437,0.000006170015,0.00044433173,6.3597224e-7,0.000026875421],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992207,0.00026268748,0.00013859208,0.00012032675,0.00017214377,0.000085442436],"domain_scores_gemma":[0.99734527,0.00052687497,0.001448981,0.0002460978,0.00018227042,0.00025056448],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010132911,0.00019469002,0.00031252732,0.0007883587,0.00029020928,0.00070086773,0.0003039539,0.0003808213,0.00072653464],"category_scores_gemma":[0.003416224,0.00034860277,0.00040723503,0.0013659137,0.00024143964,0.00042125673,0.00046388214,0.0005512362,0.0001268577],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006028186,0.000025677664,0.9994948,0.0000037401508,0.00001977625,0.000025874122,0.000017275015,0.000027794427,0.000036720397,0.0000098493065,0.000042729243,0.00023538164],"study_design_scores_gemma":[0.000010908178,0.000098767014,0.9988782,0.000005998591,0.000019527419,0.00028095668,0.00009932288,0.00045073504,0.000045369976,0.000015450201,0.00009154234,0.000003159685],"about_ca_topic_score_codex":0.0050971676,"about_ca_topic_score_gemma":0.0050005503,"teacher_disagreement_score":0.0050971676,"about_ca_system_score_codex":0.00034109887,"about_ca_system_score_gemma":0.00042120833,"threshold_uncertainty_score":0.010134995},"labels":[],"label_agreement":null},{"id":"W3210219109","doi":"10.1080/10428194.2021.1999445","title":"Risk of thyroid disorders in adult and childhood Hodgkin lymphoma survivors 40 years after treatment","year":2021,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Cancer Research UK","keywords":"Medicine; Radiation therapy; Thyroid; Pediatrics; Disease; Thyroid cancer; Chemotherapy; Internal medicine; Proportional hazards model; Oncology","score_opus":0.005786720895113386,"score_gpt":0.23441941803492367,"score_spread":0.22863269713981027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3210219109","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99946743,0.0002740232,0.000012370861,0.000019129837,9.89608e-7,9.6193e-7,0.0001078783,7.510755e-7,0.00011646617],"genre_scores_gemma":[0.9996107,0.00014954929,0.000011905434,0.0000064836286,0.0000032473947,0.000001461584,0.00013229257,4.833372e-7,0.000083908424],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99977845,0.000046709374,0.00002332485,0.000031986117,0.00004902716,0.0000705076],"domain_scores_gemma":[0.9989447,0.00015874428,0.00058781594,0.000038571918,0.00005564366,0.00021455705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037305517,0.00009141088,0.00017261732,0.0004835611,0.00016230327,0.000309755,0.00016917604,0.00021852128,0.0011963785],"category_scores_gemma":[0.0014789052,0.0001288032,0.00031366816,0.0007135179,0.00014434077,0.00019596839,0.00030176152,0.00027545265,0.000084906766],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006556492,0.000004709662,0.9989625,0.0000026074538,0.000017555749,0.00004051962,0.000058691698,0.000023961196,0.000041437695,0.0000073728193,0.000026213904,0.0007488824],"study_design_scores_gemma":[0.0000022298555,0.00004813478,0.9995166,0.0000040055834,0.000010062145,0.0001581043,0.00010173966,0.000042543907,0.000020683548,0.000008626626,0.000085820415,0.0000014369678],"about_ca_topic_score_codex":0.008290724,"about_ca_topic_score_gemma":0.0080357725,"teacher_disagreement_score":0.008290724,"about_ca_system_score_codex":0.00030600408,"about_ca_system_score_gemma":0.0002777157,"threshold_uncertainty_score":0.016484976},"labels":[],"label_agreement":null},{"id":"W4200502803","doi":"10.1080/10428194.2021.2012667","title":"Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes","year":2021,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Myelodysplastic syndromes; Myeloid leukemia; Refractory (planetary science); Demethylase; Medicine; Internal medicine; Leukemia; Oncology; Cancer research; Biology; Gene; Bone marrow; Biochemistry","score_opus":0.020733444090083104,"score_gpt":0.2678499167161682,"score_spread":0.2471164726260851,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200502803","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.091359176,0.02006202,0.0012345344,0.8152573,0.02724248,0.0004792268,0.001960708,0.0002316393,0.042172935],"genre_scores_gemma":[0.2881004,0.011470232,0.0025870996,0.6107455,0.033163942,0.00067270495,0.0014917698,0.00009675304,0.051671516],"study_design_codex":"not_applicable","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997017,0.000108604676,0.00002864821,0.000037697824,0.00007112029,0.0000522717],"domain_scores_gemma":[0.999308,0.0003618675,0.000064630454,0.000021510587,0.000050878203,0.00019306925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00084629067,0.00036017416,0.0006633069,0.00018178814,0.0004857208,0.0007348827,0.0005749818,0.005496797,0.0027948073],"category_scores_gemma":[0.0014916912,0.0001707596,0.0004539404,0.0001995308,0.00043638534,0.0005791851,0.00020465185,0.0035857842,0.0010684202],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0135629205,0.0013965897,0.006838397,0.0003700501,0.00020490572,0.012468359,0.00015265832,0.001340453,0.010675187,0.004768517,0.7373028,0.21091914],"study_design_scores_gemma":[0.03677149,0.011291667,0.02324497,0.0003990065,0.00041655957,0.017800098,0.00031551704,0.008161271,0.010204349,0.019939275,0.8713505,0.00010534013],"about_ca_topic_score_codex":0.00085466757,"about_ca_topic_score_gemma":0.003944352,"teacher_disagreement_score":0.005496797,"about_ca_system_score_codex":0.0011435596,"about_ca_system_score_gemma":0.00066832587,"threshold_uncertainty_score":0.009349525},"labels":[],"label_agreement":null},{"id":"W4210829474","doi":"10.1080/10428194.2022.2030477","title":"Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2 MM-014 trial","year":2022,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Vancouver General Hospital; McGill University Health Centre","funders":"Bristol-Myers Squibb","keywords":"Lenalidomide; Pomalidomide; Medicine; Daratumumab; Dexamethasone; Multiple myeloma; Internal medicine; Neutropenia; Oncology; Chemotherapy","score_opus":0.0279549313468648,"score_gpt":0.29230793487169454,"score_spread":0.26435300352482977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210829474","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96767825,0.024464116,0.00033531463,0.0009561207,0.0003471198,0.0008819056,0.0017356976,0.00007807738,0.0035234413],"genre_scores_gemma":[0.98153853,0.008823102,0.0013006763,0.0013597335,0.00034869183,0.00093641586,0.003953386,0.00001734942,0.0017220943],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9994041,0.00033244086,0.000040750132,0.00007092311,0.00008805504,0.00006375162],"domain_scores_gemma":[0.9994161,0.00013270447,0.00021672825,0.000035697107,0.00003848516,0.00016028206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015959333,0.0005645087,0.0011889735,0.00027148987,0.00026026485,0.0008259947,0.00048985897,0.0005571109,0.0018669919],"category_scores_gemma":[0.0013628529,0.00021280577,0.0012901704,0.00038489775,0.00027921944,0.00058218156,0.00036313303,0.0022450052,0.0003340734],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6913451,0.010753551,0.01704728,0.0015358394,0.004979495,0.0001670347,0.00015228668,0.0018497284,0.0076241004,0.00032210755,0.007006851,0.25721657],"study_design_scores_gemma":[0.73128927,0.17164639,0.073066995,0.0004483788,0.004165326,0.00055631716,0.00012856648,0.0016469924,0.0027005936,0.00061251933,0.013672276,0.000066415996],"about_ca_topic_score_codex":0.0007601992,"about_ca_topic_score_gemma":0.0025299594,"teacher_disagreement_score":0.0018669919,"about_ca_system_score_codex":0.00058953994,"about_ca_system_score_gemma":0.0007237183,"threshold_uncertainty_score":0.0084401965},"labels":[],"label_agreement":null},{"id":"W4213044498","doi":"10.1080/10428194.2022.2042689","title":"Enhanced cytotoxicity of bisantrene when combined with venetoclax, panobinostat, decitabine and olaparib in acute myeloid leukemia cells","year":2022,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Institutes of Health","keywords":"Decitabine; Panobinostat; Cancer research; PARP1; Olaparib; Azacitidine; Myeloid leukemia; Cytotoxicity; Pharmacology; PI3K/AKT/mTOR pathway; Poly ADP ribose polymerase; Chemistry; Leukemia; Vorinostat; Apoptosis; Histone deacetylase; Medicine; DNA methylation; In vitro; Immunology; Histone; Polymerase; Biochemistry; DNA","score_opus":0.008695234625414798,"score_gpt":0.2345867560039069,"score_spread":0.2258915213784921,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213044498","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99331445,0.003342163,0.00065284286,0.00006628324,0.000047075475,0.000035193334,0.00032544555,0.000053030388,0.0021633448],"genre_scores_gemma":[0.99489826,0.001392693,0.0012314577,0.00002353994,0.000018699126,0.00003298256,0.00048961234,0.000007655254,0.0019050739],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99987125,0.00003811324,0.00001546292,0.000023154334,0.000029022138,0.000023029956],"domain_scores_gemma":[0.9999213,0.000018767762,0.000014974342,0.000013130278,0.000010132831,0.000021670106],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013095597,0.0003681296,0.00036724593,0.00028924496,0.00013737468,0.00022731998,0.00015220244,0.00018496613,0.0010111883],"category_scores_gemma":[0.00012181908,0.00009378068,0.00022564903,0.00028068852,0.00012706121,0.00017797374,0.00016330082,0.0003465419,0.00022381848],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006990317,0.00011416424,0.00039240986,0.000076752964,0.00001438755,0.00007435975,0.000026263933,0.0001647237,0.99287283,0.000061470164,0.00007901321,0.00542449],"study_design_scores_gemma":[0.00006597188,0.0020403708,0.0055228076,0.0000078803,0.000037641123,0.00035093148,0.000016615099,0.00057127076,0.9886135,0.000024202716,0.0027440183,0.0000048475836],"about_ca_topic_score_codex":0.0008963917,"about_ca_topic_score_gemma":0.0014554815,"teacher_disagreement_score":0.0010111883,"about_ca_system_score_codex":0.00016202094,"about_ca_system_score_gemma":0.00025756893,"threshold_uncertainty_score":0.003382802},"labels":[],"label_agreement":null},{"id":"W4220688343","doi":"10.1080/10428194.2022.2043299","title":"Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia","year":2022,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Genetics; National Cancer Institute; Celgene; CLL Global Research Foundation","keywords":"Lenalidomide; Chronic lymphocytic leukemia; Chimeric antigen receptor; CD23; Cancer research; T cell; Antigen; Immunology; Leukemia; Medicine; Immune system; Multiple myeloma; Immunoglobulin E; Antibody","score_opus":0.01615558200279773,"score_gpt":0.26819361320453683,"score_spread":0.2520380312017391,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220688343","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9864694,0.006606616,0.0017206715,0.00015618849,0.000058140657,0.00012548757,0.00024012994,0.00014312065,0.004480258],"genre_scores_gemma":[0.9948782,0.0017700666,0.0012511305,0.0000464635,0.000019977455,0.000040251023,0.00017414754,0.000017291504,0.0018024158],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998555,0.000033022898,0.000009212999,0.000018493152,0.00003333886,0.00005044465],"domain_scores_gemma":[0.99996316,0.000005404959,0.000007402175,0.00000475999,0.0000037560258,0.000015488045],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000153552,0.00032599416,0.00034343684,0.0003118377,0.00014849528,0.0004922403,0.0002463923,0.00023580574,0.0009982445],"category_scores_gemma":[0.00007178041,0.000101730286,0.00019051047,0.00021877229,0.00018341729,0.0002116019,0.00022843653,0.0005197793,0.00031235188],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001713488,0.001023106,0.0011260629,0.00019953198,0.000043411856,0.00022917613,0.00009513479,0.0017386617,0.94568545,0.0009378119,0.0008484569,0.04635976],"study_design_scores_gemma":[0.0006635954,0.0087771695,0.007602838,0.000018725894,0.0001391079,0.0014079437,0.000055010965,0.0037666617,0.94625723,0.0001929604,0.031097008,0.000021846447],"about_ca_topic_score_codex":0.0018732053,"about_ca_topic_score_gemma":0.0036904276,"teacher_disagreement_score":0.0018732053,"about_ca_system_score_codex":0.0005162371,"about_ca_system_score_gemma":0.00037159317,"threshold_uncertainty_score":0.0037455559},"labels":[],"label_agreement":null},{"id":"W4220970057","doi":"10.1080/10428194.2022.2047674","title":"Long-term follow up of relapsed/refractory non-Hodgkin lymphoma patients treated with single-agent selinexor – a retrospective, single center study","year":2022,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Single Center; Refractory (planetary science); Lymphoma; Internal medicine; Adverse effect; Retrospective cohort study; Oncology; Cohort; Gastroenterology; Surgery","score_opus":0.012991366514394826,"score_gpt":0.23037435745385598,"score_spread":0.21738299093946115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220970057","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99861693,0.00077185046,0.00004730141,0.000023381219,0.000005023063,0.000011723094,0.00018536604,0.0000023479975,0.00033621403],"genre_scores_gemma":[0.9992737,0.00019196016,0.000027765129,0.000036341735,0.000014235349,0.000009275758,0.00033336415,0.0000017384909,0.0001115237],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995427,0.000111585425,0.00007834426,0.00011568299,0.0000651731,0.00008659911],"domain_scores_gemma":[0.9987184,0.00022655915,0.0005149909,0.00010959174,0.00015399241,0.00027656349],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006846289,0.00022386327,0.0006388662,0.0007045037,0.00069082715,0.0006523463,0.00032248753,0.0006175196,0.0011488124],"category_scores_gemma":[0.0011019921,0.00026019214,0.0006536137,0.00076907635,0.0003363108,0.00072851544,0.00035017994,0.00065083825,0.00037209954],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008445144,0.00010662791,0.99545056,0.000021805316,0.00015417322,0.00062760327,0.00011283815,0.000046287176,0.00038717157,0.000010769499,0.0000883753,0.0021491405],"study_design_scores_gemma":[0.000049167833,0.0011571121,0.9959086,0.000015621847,0.00020441243,0.0017011277,0.00023440359,0.00011982375,0.00012610394,0.000020585961,0.0004519368,0.000011052602],"about_ca_topic_score_codex":0.0016243553,"about_ca_topic_score_gemma":0.0016833688,"teacher_disagreement_score":0.0016243553,"about_ca_system_score_codex":0.00038333584,"about_ca_system_score_gemma":0.00022462552,"threshold_uncertainty_score":0.0038431883},"labels":[],"label_agreement":null},{"id":"W4221042673","doi":"10.1080/10428194.2021.2002321","title":"Real-world treatment patterns and clinical outcomes in patients with AML unfit for first-line intensive chemotherapy <sup>*</sup>","year":2022,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"AbbVie","keywords":"Medicine; Cytarabine; Internal medicine; Myeloid leukemia; Retrospective cohort study; Oncology; Chemotherapy","score_opus":0.019842773664186884,"score_gpt":0.3008118159603816,"score_spread":0.2809690422961947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221042673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998659,0.00032978583,0.000055014807,0.00005675472,0.0000021081505,0.0000054403663,0.00047717922,0.0000029382013,0.00041182974],"genre_scores_gemma":[0.9994523,0.00010171739,0.00003734113,0.000017330116,0.0000037430034,0.000003556962,0.00035690947,9.5150796e-7,0.000026191614],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995635,0.00013992035,0.00008902415,0.00007603298,0.00006124834,0.00007026826],"domain_scores_gemma":[0.9972921,0.00047276315,0.0017777202,0.000089532325,0.00014381904,0.00022398916],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005350003,0.00007870658,0.0001758049,0.0007385063,0.00024964087,0.0005720603,0.00014916426,0.00020395544,0.00088890025],"category_scores_gemma":[0.0030901325,0.00008264456,0.00016740148,0.0013078076,0.00024214026,0.00045354266,0.00026014328,0.00022972585,0.00013046006],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000050171664,0.000007930804,0.99854445,0.0000044090325,0.00001113529,0.000038395054,0.00003594259,0.000040286162,0.000039247316,0.000015371068,0.00006060169,0.0011520631],"study_design_scores_gemma":[0.000003883005,0.000054469638,0.9989203,0.0000064329424,0.000010116569,0.00030414033,0.00023278476,0.00016323237,0.000054288856,0.000026503201,0.00022001147,0.0000038237304],"about_ca_topic_score_codex":0.0042279405,"about_ca_topic_score_gemma":0.004485737,"teacher_disagreement_score":0.0042279405,"about_ca_system_score_codex":0.00045880314,"about_ca_system_score_gemma":0.00027748148,"threshold_uncertainty_score":0.008406639},"labels":[],"label_agreement":null},{"id":"W4221096818","doi":"10.1080/10428194.2022.2043304","title":"Momelotinib reduces transfusion requirements in patients with myelofibrosis","year":2022,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Sierra Oncology","keywords":"Myelofibrosis; Medicine; Blood transfusion; Intensive care medicine; Hematologic Neoplasms; Internal medicine; Cancer; Bone marrow","score_opus":0.011677659078381407,"score_gpt":0.22856058992765435,"score_spread":0.21688293084927293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221096818","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11947827,0.034968738,0.0011321707,0.694896,0.009415071,0.0001293898,0.00080397894,0.00024915737,0.13892722],"genre_scores_gemma":[0.71107274,0.019385913,0.0018579075,0.21069811,0.023165867,0.00012089583,0.0008784398,0.00006728866,0.03275291],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997789,0.000075451,0.000024926649,0.000016217327,0.00006300295,0.000041408486],"domain_scores_gemma":[0.9993111,0.0003079075,0.000095865886,0.000020404757,0.00008872151,0.00017593769],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030539755,0.00016188873,0.00036954417,0.0002972097,0.0004674911,0.00050278293,0.00026231358,0.0015716441,0.0056132562],"category_scores_gemma":[0.0034123722,0.00006893002,0.00021234284,0.00031899396,0.00017361845,0.00030078265,0.00017005003,0.0015183896,0.0013377743],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024203404,0.00050523155,0.021660006,0.0002509411,0.00007850145,0.019706624,0.00018856139,0.0009685545,0.0032050651,0.0046871873,0.6286235,0.31770557],"study_design_scores_gemma":[0.0029153547,0.002784083,0.06970145,0.0012359819,0.00019190743,0.083069265,0.00056635943,0.004632467,0.0041811895,0.023804935,0.8068468,0.000070246344],"about_ca_topic_score_codex":0.0010209962,"about_ca_topic_score_gemma":0.0029387511,"teacher_disagreement_score":0.0056132562,"about_ca_system_score_codex":0.0007585052,"about_ca_system_score_gemma":0.00059521414,"threshold_uncertainty_score":0.018778265},"labels":[],"label_agreement":null},{"id":"W4225252886","doi":"10.1080/10428194.2022.2057484","title":"A phase 1b study of atezolizumab in combination with guadecitabine for the treatment of acute myeloid leukemia","year":2022,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Roche","keywords":"Atezolizumab; Medicine; Internal medicine; Cohort; Myeloid leukemia; Adverse effect; Myeloid; Gastroenterology; Phases of clinical research; Oncology; Clinical trial; Cancer","score_opus":0.018746075209494596,"score_gpt":0.29706529832496653,"score_spread":0.2783192231154719,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225252886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99121815,0.0039838743,0.0008571865,0.00035053462,0.00008955625,0.0017373305,0.00064929924,0.0000632803,0.001050866],"genre_scores_gemma":[0.98871034,0.0033466746,0.0025066186,0.0006185901,0.000117166484,0.0013455879,0.0013588149,0.00002253152,0.001973592],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99976045,0.00013253732,0.00001690413,0.00003730754,0.000019331064,0.00003351103],"domain_scores_gemma":[0.999666,0.00006443589,0.00009383543,0.00002638247,0.000023679446,0.0001257067],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010188882,0.0009797711,0.0012785991,0.0003136981,0.00021648461,0.00047873514,0.00048940163,0.0007921944,0.0017600022],"category_scores_gemma":[0.00063951284,0.0003331012,0.0006816955,0.0002346711,0.00037333302,0.00039402215,0.00023245266,0.0019246552,0.00043013002],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.45903024,0.07442877,0.009719686,0.0018348289,0.001660184,0.0005966138,0.00035152113,0.003651278,0.16208825,0.00053183694,0.003943463,0.28216332],"study_design_scores_gemma":[0.36300364,0.6020351,0.014684174,0.00007559475,0.0004052876,0.0008216575,0.000046958132,0.0014328839,0.011053096,0.00018241725,0.006224229,0.00003483942],"about_ca_topic_score_codex":0.00036897656,"about_ca_topic_score_gemma":0.0010970248,"teacher_disagreement_score":0.0017600022,"about_ca_system_score_codex":0.0003684135,"about_ca_system_score_gemma":0.00069710275,"threshold_uncertainty_score":0.0058878064},"labels":[],"label_agreement":null},{"id":"W4225305158","doi":"10.1080/10428194.2022.2064981","title":"Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL","year":2022,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Blinatumomab; Medicine; Chemotherapy; Oncology; Internal medicine; Leukemia; Lymphoblastic Leukemia","score_opus":0.009542903617033152,"score_gpt":0.2629823416724143,"score_spread":0.25343943805538116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225305158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916466,0.001952963,0.00083462364,0.00035093172,0.00015423857,0.003124669,0.00073603215,0.000096053,0.0011038382],"genre_scores_gemma":[0.986302,0.001733948,0.0023807648,0.001013692,0.0002727995,0.0041247904,0.0015591697,0.000029295608,0.002583559],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997129,0.00014581539,0.000013598587,0.00004564116,0.000024685745,0.000057355806],"domain_scores_gemma":[0.99946636,0.000080916696,0.000120122175,0.000042846284,0.000042950032,0.0002468553],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012969441,0.0011201244,0.001631496,0.00031559422,0.0003594437,0.0007494786,0.0006622959,0.0010762033,0.003071679],"category_scores_gemma":[0.00074071594,0.00047472122,0.0007303892,0.00025462644,0.0006100792,0.0008961922,0.0003186022,0.002546156,0.0008214762],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.71312284,0.13786308,0.0054043,0.0007299723,0.00070852763,0.00029736155,0.0003010283,0.0011864869,0.034111127,0.00030540224,0.0036412256,0.10232867],"study_design_scores_gemma":[0.5403528,0.44616875,0.0067637945,0.00003206642,0.00016670836,0.00022936743,0.000052529347,0.0010381734,0.0023455394,0.00014725365,0.002684914,0.000018114122],"about_ca_topic_score_codex":0.0004638446,"about_ca_topic_score_gemma":0.0016525176,"teacher_disagreement_score":0.003071679,"about_ca_system_score_codex":0.00056580175,"about_ca_system_score_gemma":0.0011587549,"threshold_uncertainty_score":0.010275722},"labels":[],"label_agreement":null},{"id":"W4229005543","doi":"10.1080/10428194.2022.2060505","title":"Radioimmunotherapy for orbital marginal zone lymphoma: a retrospective review","year":2022,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Spinal Cord Injury BC; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine","score_opus":0.029441916850048464,"score_gpt":0.30669290550330847,"score_spread":0.27725098865326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229005543","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002208005,0.99666685,0.00008927461,0.00008566685,0.00005819729,0.00004585219,0.00033910281,0.0000062073314,0.0005008552],"genre_scores_gemma":[0.013241446,0.9850852,0.00034247918,0.00043505334,0.00008839395,0.000043245327,0.0005096884,0.0000071759505,0.0002474001],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.999127,0.00009936762,0.00041837044,0.00014167989,0.0001648196,0.000048750888],"domain_scores_gemma":[0.9981712,0.0009235271,0.00054120686,0.00006478075,0.00024260982,0.000056643046],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086799386,0.000577478,0.002197984,0.004571147,0.00031495822,0.0011029036,0.0009960942,0.00071013416,0.0037592242],"category_scores_gemma":[0.0023721727,0.00044082367,0.0019702765,0.005746099,0.00054292136,0.001380968,0.0004894298,0.0008575872,0.00078273355],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016156482,0.0002044841,0.02363037,0.3851597,0.009336545,0.006679362,0.00049187604,0.00033868203,0.0049289716,0.00069688115,0.036135815,0.5307816],"study_design_scores_gemma":[0.0010481287,0.001319941,0.119727716,0.25544402,0.08573445,0.0861419,0.0012950131,0.00029523027,0.0032914376,0.00079239265,0.4446167,0.00029309958],"about_ca_topic_score_codex":0.0016657417,"about_ca_topic_score_gemma":0.0042924797,"teacher_disagreement_score":0.004571147,"about_ca_system_score_codex":0.0007326328,"about_ca_system_score_gemma":0.0014837664,"threshold_uncertainty_score":0.012575865},"labels":[],"label_agreement":null},{"id":"W4246681679","doi":"10.1080/10428190210192","title":"Results of a Randomized Phase III Trial in Children and Adolescents with Advanced Stage Diffuse Large Cell Non-Hodgkin's Lymphoma: A Pediatric Oncology Group Study","year":2002,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Cancer Institute; National Institutes of Health","keywords":"Medicine; Vincristine; Prednisone; Cyclophosphamide; Internal medicine; Working Formulation; Lymphoma; Diffuse large B-cell lymphoma; Stage (stratigraphy); Methotrexate; Randomized controlled trial; Oncology; Lymphoblastic lymphoma; Chemotherapy; Gastroenterology; Surgery; Non-Hodgkin's lymphoma; Immunology; T cell","score_opus":0.007457312578628314,"score_gpt":0.2532243498802955,"score_spread":0.2457670373016672,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4246681679","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98917586,0.00416282,0.0004444366,0.0010395752,0.0003450347,0.0029446722,0.00068766,0.000047466325,0.0011524451],"genre_scores_gemma":[0.9818008,0.0037962736,0.0019585665,0.0016946926,0.000483915,0.0074231545,0.0012473312,0.0000241191,0.0015710143],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9987011,0.00096226716,0.000056527915,0.00010257146,0.000069926056,0.00010758545],"domain_scores_gemma":[0.99772197,0.00072497566,0.00053667056,0.00016520744,0.000098750585,0.0007525093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026245709,0.001061581,0.0022505738,0.00025399265,0.00036699956,0.00090846326,0.00067422877,0.0014431084,0.004450065],"category_scores_gemma":[0.0032757793,0.00050650287,0.0014663943,0.00035891365,0.0010842775,0.0007549421,0.00034262516,0.0029494942,0.0005259369],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9664111,0.0075703245,0.0035199353,0.00044119425,0.0013133998,0.0001059057,0.000082480314,0.00049804366,0.001475801,0.00018271086,0.0013858369,0.017013198],"study_design_scores_gemma":[0.9483414,0.04704124,0.002884057,0.000035690988,0.00044162676,0.00005634845,0.000021684977,0.00021623178,0.00018056265,0.00010453324,0.00067068706,0.0000059159283],"about_ca_topic_score_codex":0.000642425,"about_ca_topic_score_gemma":0.0013811396,"teacher_disagreement_score":0.004450065,"about_ca_system_score_codex":0.0006825884,"about_ca_system_score_gemma":0.0016529339,"threshold_uncertainty_score":0.014886916},"labels":[],"label_agreement":null},{"id":"W4280597826","doi":"10.1080/10428194.2022.2076848","title":"Differential use of the hematopoietic cell transplantation-comorbidity index among adult and pediatric transplant physicians","year":2022,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; Office of Naval Research; AbbVie Canada; Sanofi Genzyme; Genentech; Health Resources and Services Administration; CytoSen Therapeutics; MorphoSys; Kyowa Hakko Kirin; Vertex Pharmaceuticals; Omeros Corporation; Bristol-Myers Squibb; Instituto Nacional de Cancerología; Adaptive Biotechnologies; Incyte; Kiadis Pharma; bluebird bio; Medical College of Wisconsin; StemCyte; CSL Behring; Karyopharm Therapeutics; National Cancer Institute; Gilead Sciences; CareDx; National Heart, Lung, and Blood Institute; Novartis Pharmaceuticals Corporation; Daiichi-Sankyo; Accenture; Merck; GlaxoSmithKline; Be The Match Foundation; Seagen; Astellas Pharma US; Medac; Jazz Pharmaceuticals; National Marrow Donor Program","keywords":"Medicine; Family medicine; Health care; Management; Business; Political science; Law","score_opus":0.010881083615651724,"score_gpt":0.20822707808181493,"score_spread":0.1973459944661632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280597826","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.934794,0.0043410948,0.0006678024,0.0034621218,0.00017591841,0.00005400789,0.008057731,0.000107051244,0.048340224],"genre_scores_gemma":[0.99448967,0.0011151949,0.0003087207,0.00032773818,0.00011396279,0.000032043008,0.0021528974,0.0000221422,0.001437715],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997112,0.00004284452,0.000028251225,0.000043729404,0.00009284411,0.00008115061],"domain_scores_gemma":[0.9987968,0.0003704961,0.00041761642,0.000028541244,0.00010878146,0.0002776865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021389427,0.00012876808,0.00018776662,0.0009314013,0.00023688041,0.0005337938,0.0002650185,0.00033708182,0.02237043],"category_scores_gemma":[0.0028309824,0.00009074925,0.00025787557,0.00094493234,0.00012094475,0.0005267871,0.00043744972,0.00053394574,0.0012775498],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017246153,0.000028905277,0.9632458,0.000045190307,0.000029180728,0.00034839485,0.00008283401,0.00009897363,0.00016306264,0.0003601386,0.014273355,0.02115178],"study_design_scores_gemma":[0.000012416059,0.000030682222,0.99379236,0.00011211355,0.000021395981,0.0021352482,0.0002550232,0.000513339,0.00010239392,0.00023460251,0.0027813043,0.000009040761],"about_ca_topic_score_codex":0.004273363,"about_ca_topic_score_gemma":0.0074612475,"teacher_disagreement_score":0.02237043,"about_ca_system_score_codex":0.00029272772,"about_ca_system_score_gemma":0.00030047307,"threshold_uncertainty_score":0.07483655},"labels":[],"label_agreement":null},{"id":"W4283259643","doi":"10.1080/10428194.2022.2086251","title":"Optimizing pegaspargase therapy in patients with hypersensitivity reactions","year":2022,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Eosinophilic Esophagitis","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Izaak Walton Killam Health Centre","funders":"","keywords":"Medicine; Intensive care medicine; Pharmacology","score_opus":0.010771804502194603,"score_gpt":0.2161162079237528,"score_spread":0.20534440342155819,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283259643","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01676814,0.008314053,0.0013670747,0.8775447,0.011969239,0.00012913161,0.00011823008,0.00032367744,0.083465695],"genre_scores_gemma":[0.17590041,0.012476874,0.0042534326,0.68593466,0.07973749,0.00017707556,0.00020326067,0.00018926295,0.04112748],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99958986,0.00011168449,0.00006270383,0.000035468503,0.00010714698,0.00009323084],"domain_scores_gemma":[0.9989195,0.0004306523,0.00013260172,0.000034416993,0.00015041158,0.0003323551],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039882644,0.0004965672,0.0006671631,0.00044727218,0.001000493,0.0013993537,0.00045441964,0.008421721,0.009618915],"category_scores_gemma":[0.0052413545,0.0002543622,0.00082813954,0.00023664135,0.0004919457,0.001026172,0.00052263564,0.006517974,0.00453628],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003697419,0.00039404846,0.010482611,0.00019156435,0.00005143882,0.054502804,0.00013850717,0.0006076528,0.002122426,0.0022423372,0.8410546,0.08784222],"study_design_scores_gemma":[0.0011782398,0.0011974582,0.021631204,0.0013009597,0.00017853998,0.14573024,0.0005619968,0.0047363555,0.0028071466,0.013732436,0.80682313,0.00012226975],"about_ca_topic_score_codex":0.0014445247,"about_ca_topic_score_gemma":0.003073036,"teacher_disagreement_score":0.009618915,"about_ca_system_score_codex":0.001325584,"about_ca_system_score_gemma":0.0009955913,"threshold_uncertainty_score":0.03217846},"labels":[],"label_agreement":null},{"id":"W4285027377","doi":"10.1080/10428194.2022.2095624","title":"PET-CR as a potential surrogate endpoint in untreated DLBCL: meta-analysis and implications for clinical trial design","year":2022,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Janssen Biotech; Chugai Pharmaceutical; H. Lundbeck A/S; Servier; Incyte; AbbVie; Takeda Pharmaceutical Company; Teva Pharmaceutical Industries; Sandoz; MorphoSys; Celgene; Seattle Genetics; Karyopharm Therapeutics; Gilead Sciences; Merck; TG Therapeutics; Amgen","keywords":"Chemoimmunotherapy; Hazard ratio; Medicine; Internal medicine; Clinical trial; Diffuse large B-cell lymphoma; Clinical endpoint; Oncology; Meta-analysis; Progression-free survival; Sample size determination; Surrogate endpoint; Proportional hazards model; Overall survival; Confidence interval; Lymphoma; Nuclear medicine; Rituximab; Statistics","score_opus":0.206374533336237,"score_gpt":0.4167294272308164,"score_spread":0.2103548938945794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285027377","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013650225,0.9952402,0.0020732072,0.000564284,0.00018209865,0.00015340051,0.000118719174,0.000023244564,0.00027984104],"genre_scores_gemma":[0.16110747,0.82497644,0.008437978,0.0023758772,0.00062665524,0.001399677,0.0005751828,0.000065943364,0.00043481056],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9725468,0.023351027,0.0022787347,0.0007974053,0.0008370339,0.0001889851],"domain_scores_gemma":[0.9407324,0.054506037,0.0023350513,0.0011753195,0.0010139258,0.00023726953],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.044510193,0.0018425111,0.011756467,0.002336554,0.00023068459,0.0030081717,0.0017597249,0.0021095804,0.0023307954],"category_scores_gemma":[0.07351994,0.00089453126,0.020575963,0.0027644036,0.00046259956,0.0016225065,0.00089435314,0.0025749942,0.0002426804],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005412405,0.000052749994,0.0037586363,0.2216784,0.6626626,0.00011145746,0.00007116359,0.0038508645,0.00028295515,0.0016596925,0.0022040752,0.09825498],"study_design_scores_gemma":[0.0032072635,0.00061947264,0.003834976,0.030254977,0.9427082,0.00016305024,0.000052491374,0.0029452043,0.00031905243,0.0067440835,0.009099513,0.00005155706],"about_ca_topic_score_codex":0.0020416258,"about_ca_topic_score_gemma":0.0036425502,"teacher_disagreement_score":0.044510193,"about_ca_system_score_codex":0.0016570978,"about_ca_system_score_gemma":0.002238347,"threshold_uncertainty_score":0.23539525},"labels":[],"label_agreement":null},{"id":"W4285077352","doi":"10.1080/10428194.2022.2095628","title":"Pediatric cancer and hematopoietic stem cell transplantation patients requiring renal replacement therapy: results of the retrospective nationwide AIEOP study","year":2022,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Kidney Injury Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's & Women's Health Centre of British Columbia","funders":"","keywords":"Medicine; Renal replacement therapy; Hematopoietic stem cell transplantation; Retrospective cohort study; Acute kidney injury; Dialysis; Transplantation; Mortality rate; Survival rate; Internal medicine; Cohort; Surgery; Pediatrics","score_opus":0.013548722463097303,"score_gpt":0.26259608006275537,"score_spread":0.24904735759965807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285077352","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99919707,0.00014186953,0.000032576198,0.00001470474,0.0000022338074,0.0000071727673,0.00044728804,0.0000014647977,0.00015556494],"genre_scores_gemma":[0.9988288,0.00018280424,0.00005052697,0.000016866841,0.000007320305,0.000013515317,0.0008490286,0.0000020363884,0.000049045888],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99933773,0.00015480861,0.00008376081,0.00015646042,0.00013105288,0.00013620417],"domain_scores_gemma":[0.9983872,0.0002337815,0.00089138316,0.00014731749,0.00014176455,0.00019857305],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086131704,0.00030616077,0.00040345656,0.0009385872,0.00032933665,0.0007499905,0.00033402437,0.0003641369,0.0007819511],"category_scores_gemma":[0.0020338546,0.0003510952,0.00048333046,0.001698343,0.00028747445,0.00063623703,0.00066664035,0.0004898847,0.0001742437],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000039310264,0.000012428777,0.9995309,0.0000033079853,0.00001870243,0.00004558292,0.000026009222,0.0000110575465,0.00003062488,0.0000040672153,0.000029201905,0.0002488806],"study_design_scores_gemma":[0.0000053809154,0.00004053329,0.99941206,0.000002995916,0.00002056091,0.00022680193,0.00012768149,0.000040570336,0.000022134775,0.000003941642,0.00009572264,0.0000015435692],"about_ca_topic_score_codex":0.006112735,"about_ca_topic_score_gemma":0.0076172156,"teacher_disagreement_score":0.006112735,"about_ca_system_score_codex":0.00038648394,"about_ca_system_score_gemma":0.0005105016,"threshold_uncertainty_score":0.012154281},"labels":[],"label_agreement":null},{"id":"W4285389858","doi":"10.1080/10428194.2022.2092853","title":"Phase 1b, open-label study evaluating the safety and pharmacokinetics of atezolizumab (anti–PD-L1 antibody) administered in combination with Hu5F9-G4 to patients with relapsed and/or refractory acute myeloid leukemia","year":2022,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"F. Hoffmann-La Roche","keywords":"Atezolizumab; Medicine; Myeloid leukemia; Refractory (planetary science); Pharmacokinetics; Antibody; Oncology; Pharmacology; Internal medicine; Immunology; Cancer; Immunotherapy; Nivolumab","score_opus":0.039697565353864255,"score_gpt":0.3630186783913506,"score_spread":0.32332111303748634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285389858","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9710764,0.005140556,0.0016517453,0.009909914,0.0015404646,0.0017827608,0.0021885012,0.00017156941,0.0065380335],"genre_scores_gemma":[0.9784985,0.001577684,0.0019815783,0.009156489,0.00092301297,0.0010998799,0.0016460575,0.00004309174,0.0050737085],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996712,0.00016062935,0.000016577782,0.000063335916,0.000033796237,0.000054472282],"domain_scores_gemma":[0.9993445,0.00022025585,0.00009169677,0.00004358295,0.00004105226,0.00025875575],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009668483,0.00080595195,0.0018241649,0.00017686399,0.0004235735,0.00094975537,0.0006809014,0.0024965426,0.002908799],"category_scores_gemma":[0.0011450223,0.0003976721,0.00084007287,0.0002751933,0.0005881461,0.0007809001,0.00017337032,0.004352326,0.00091979775],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6620615,0.044204343,0.012068452,0.0008306926,0.0016365163,0.0038300809,0.00045142786,0.0036864665,0.047320258,0.0012845108,0.032259073,0.19036667],"study_design_scores_gemma":[0.65626085,0.2911764,0.016569467,0.000063796026,0.0005058127,0.0023291206,0.000106598156,0.0048098397,0.0048000906,0.0010515464,0.022270888,0.000055518838],"about_ca_topic_score_codex":0.0007541444,"about_ca_topic_score_gemma":0.0022055935,"teacher_disagreement_score":0.002908799,"about_ca_system_score_codex":0.0013674241,"about_ca_system_score_gemma":0.00091058906,"threshold_uncertainty_score":0.009921372},"labels":[],"label_agreement":null},{"id":"W4294844962","doi":"10.1080/10428194.2022.2118536","title":"Prognostic factors and outcomes of infant acute lymphoblastic leukemia (ALL), hypodiploid ALL, and mixed-phenotype acute leukemia (MPAL) in Canada: a report from CYP-C","year":2022,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Children's Hospital; Izaak Walton Killam Health Centre; Dalhousie University; BC Children's Hospital; Centre Hospitalier Universitaire Sainte-Justine; McMaster Children's Hospital; Université Laval; Université de Montréal","funders":"","keywords":"Lymphoblastic Leukemia; Medicine; Phenotype; Internal medicine; Oncology; Leukemia; Acute lymphocytic leukemia; Acute leukemia; Pediatrics; Cancer research; Biology; Gene; Genetics","score_opus":0.011892839809546652,"score_gpt":0.24647278469254,"score_spread":0.23457994488299336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294844962","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933468,0.0007165969,0.00007710294,0.00014423612,0.000003787001,0.000020824575,0.0044578994,0.000009120587,0.0012236995],"genre_scores_gemma":[0.9972735,0.00054831494,0.00006958021,0.000034210207,0.0000033096173,0.000007529698,0.0018015825,0.0000029651208,0.00025906035],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995098,0.000027517437,0.00003401114,0.000069074405,0.00018698335,0.00017273783],"domain_scores_gemma":[0.998601,0.00006579044,0.0003486563,0.00005356928,0.00062523596,0.0003057272],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030931085,0.0002900903,0.00025430328,0.0012706963,0.0012166254,0.00087416655,0.00064373895,0.0002577033,0.00094664044],"category_scores_gemma":[0.0012077568,0.0002498516,0.00031952848,0.0033483831,0.000515704,0.00021587776,0.00061270787,0.0004243918,0.00013066996],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000036619404,0.000006171715,0.9971642,0.000011178804,0.000018047223,0.000065511456,0.00013967704,0.00007321307,0.00008680415,0.000027243845,0.00038563288,0.001985687],"study_design_scores_gemma":[0.0000044065173,0.000010098264,0.9985898,0.000014108388,0.000017284045,0.00018210252,0.0004181519,0.00016267633,0.000062350955,0.000009739955,0.0005243197,0.0000048481675],"about_ca_topic_score_codex":0.9840971,"about_ca_topic_score_gemma":0.9868274,"teacher_disagreement_score":0.01671123,"about_ca_system_score_codex":0.01671123,"about_ca_system_score_gemma":0.016822658,"threshold_uncertainty_score":0.12124902},"labels":[],"label_agreement":null},{"id":"W4294908193","doi":"10.1080/10428194.2022.2109157","title":"Development of a distributed international patient data registry for hairy cell leukemia","year":2022,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre; Queen's University; University of Manitoba; Research Institute in Oncology and Hematology","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; National Institutes of Health; Cancer Research UK; Hairy Cell Leukemia Foundation","keywords":"Hairy cell leukemia; Excellence; Medicine; Disease registry; Leukemia; Disease; Pathology; Internal medicine; Political science","score_opus":0.03041926185656664,"score_gpt":0.2864874881111542,"score_spread":0.2560682262545876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294908193","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13035697,0.0017455671,0.44053906,0.021695703,0.003095039,0.03402274,0.22539644,0.030101964,0.113046534],"genre_scores_gemma":[0.19510353,0.0011146313,0.50353295,0.0027673545,0.0008195788,0.020213233,0.25983268,0.0020153737,0.014600655],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9841055,0.006155911,0.0030921465,0.002504553,0.0032017517,0.0009400712],"domain_scores_gemma":[0.92725194,0.011865388,0.0064974558,0.018610138,0.02615735,0.009617694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.040370516,0.00053660106,0.0010492902,0.0059661004,0.0014173216,0.0034174628,0.0037033116,0.0007454775,0.016735215],"category_scores_gemma":[0.04614665,0.00055905007,0.00089180836,0.006688269,0.0005556163,0.005578084,0.005348147,0.002235681,0.007779657],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022932778,0.00190353,0.14969869,0.00082457636,0.0002746209,0.0004904343,0.0019187934,0.0045112534,0.004525421,0.024927225,0.24797873,0.56065345],"study_design_scores_gemma":[0.0024375573,0.0018141911,0.12271325,0.0011123632,0.00042664318,0.0010451659,0.002641219,0.021959258,0.01182766,0.008652373,0.82507294,0.0002973412],"about_ca_topic_score_codex":0.007324328,"about_ca_topic_score_gemma":0.0057353755,"teacher_disagreement_score":0.040370516,"about_ca_system_score_codex":0.002542574,"about_ca_system_score_gemma":0.017272474,"threshold_uncertainty_score":0.21350223},"labels":[],"label_agreement":null},{"id":"W4295423248","doi":"10.1080/10428194.2022.2109154","title":"A natural history of lower-risk myelodysplastic syndromes with ring sideroblasts: an analysis of the MDS-CAN registry","year":2022,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"EVERSANA (Canada); Bristol-Myers Squibb (Canada); Dalhousie University; Hamilton Health Sciences; Hôpital de l'Enfant-Jésus; Juravinski Cancer Centre; Dr. Georges-L.-Dumont University Hospital Centre; St. Paul's Hospital; University of British Columbia; McGill University Health Centre; University of Ottawa; Sunnybrook Health Science Centre; Jewish General Hospital; University of Alberta; CancerCare Manitoba; Health Sciences Centre; University Health Network; Ottawa Hospital; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Myelodysplastic syndromes; Medicine; Natural history; International Prognostic Scoring System; Internal medicine; Clinical trial; Myeloid leukemia; Natural history study; Pediatrics; Bone marrow","score_opus":0.009955952144202041,"score_gpt":0.22864631906547972,"score_spread":0.2186903669212777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295423248","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942561,0.0001612538,0.000084287465,0.000053310825,0.0000025561242,0.000035643432,0.004912067,0.0000056831045,0.0004890897],"genre_scores_gemma":[0.9934596,0.00012422662,0.00012972447,0.00003181167,0.0000062722074,0.00003704573,0.0060426206,0.0000046821906,0.00016402699],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985983,0.0003878005,0.00016326785,0.00027820276,0.00036532772,0.00020699386],"domain_scores_gemma":[0.9940269,0.00080003834,0.0028142368,0.00079773366,0.0009845343,0.00057664234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020206566,0.00016755829,0.00037363174,0.0010851125,0.00047110298,0.0007238966,0.00064596004,0.0002478699,0.0009801437],"category_scores_gemma":[0.0051474683,0.00020893269,0.00041306124,0.0024396123,0.00030308115,0.0004719014,0.00083754276,0.00040595015,0.00019470227],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016068216,0.000010795311,0.99875236,0.0000072471316,0.00004468562,0.000019282861,0.00004075635,0.00004715958,0.000025723884,0.000021448124,0.00023717275,0.0006327596],"study_design_scores_gemma":[0.00002272245,0.000050584273,0.998777,0.000010202864,0.000052068885,0.0000900754,0.00016224106,0.0002901822,0.00003874926,0.0000144026235,0.00048533865,0.000006385228],"about_ca_topic_score_codex":0.121688314,"about_ca_topic_score_gemma":0.20115022,"teacher_disagreement_score":0.121688314,"about_ca_system_score_codex":0.001626017,"about_ca_system_score_gemma":0.002473149,"threshold_uncertainty_score":0.24195999},"labels":[],"label_agreement":null},{"id":"W4297338547","doi":"10.1080/10428194.2022.2123226","title":"Clinical utility of interim CT scans in patients receiving chemoimmuntherapy for first line treatment of follicular lymphoma","year":2022,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Princess Margaret Cancer Foundation","keywords":"Chemoimmunotherapy; Medicine; Asymptomatic; Follicular lymphoma; Biopsy; Radiology; Malignancy; Lymphoma; Interim; Internal medicine; Surgery; Oncology; Rituximab","score_opus":0.026550311206926063,"score_gpt":0.2996931429276785,"score_spread":0.27314283172075243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297338547","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967398,0.0011946665,0.0001349713,0.00009575655,0.0000070330952,0.000011433578,0.00016159684,0.000010065609,0.0016447727],"genre_scores_gemma":[0.99937755,0.00019729635,0.000118205935,0.000026363892,0.000012998468,0.000004707325,0.00018793679,0.0000021193712,0.000072846095],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99974555,0.00008685094,0.000037508617,0.00002621927,0.000055652064,0.000048169644],"domain_scores_gemma":[0.9977729,0.0007078585,0.0009106496,0.00009332249,0.00026397817,0.00025135273],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006219747,0.00014905848,0.00023460508,0.0007550371,0.00018525808,0.00053779053,0.00021751726,0.0003268048,0.00082844537],"category_scores_gemma":[0.005021836,0.000108507484,0.0001976686,0.000531323,0.00026475757,0.0003824718,0.00017268598,0.00038355385,0.00019995282],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027352644,0.000013010049,0.9928208,0.000008910537,0.000009419071,0.00047223084,0.000034553956,0.00006732627,0.00029433952,0.000009320724,0.0001065077,0.0058899918],"study_design_scores_gemma":[0.000014256974,0.00038560998,0.99234277,0.000025225594,0.000051159663,0.005412269,0.00014630696,0.00046984956,0.0005735302,0.00003628985,0.0005366436,0.0000061226506],"about_ca_topic_score_codex":0.0013209424,"about_ca_topic_score_gemma":0.0020626395,"teacher_disagreement_score":0.0013209424,"about_ca_system_score_codex":0.00037000066,"about_ca_system_score_gemma":0.00020022143,"threshold_uncertainty_score":0.003289342},"labels":[],"label_agreement":null},{"id":"W4297988839","doi":"10.1080/10428194.2022.2126282","title":"Subtherapeutic concentrations of posaconazole tablet: determining risk factors and effectiveness of a standardized dose adjustment in hematology inpatients","year":2022,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Antifungal resistance and susceptibility","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surrey Memorial Hospital","funders":"","keywords":"Posaconazole; Medicine; Hematology; Internal medicine; Therapeutic drug monitoring; Gastroenterology; Pharmacology; Antifungal; Pharmacokinetics; Voriconazole","score_opus":0.010899608130516722,"score_gpt":0.2568458399961135,"score_spread":0.24594623186559678,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297988839","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99952185,0.0001629888,0.00005090365,0.00003465998,0.0000021605483,0.0000042080505,0.00004733222,0.0000015581361,0.00017438269],"genre_scores_gemma":[0.99981743,0.00005265989,0.000034868623,0.000015459273,0.0000037229534,0.000001943271,0.000046265726,6.8417785e-7,0.000026924758],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991334,0.00025975224,0.00015124188,0.00012433251,0.00017751445,0.00015377956],"domain_scores_gemma":[0.99691087,0.000695764,0.0018424153,0.00013610958,0.00016285709,0.0002520644],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006854946,0.00013540854,0.00028463188,0.00029727689,0.00020860425,0.000633675,0.00021931781,0.0002999004,0.0007419349],"category_scores_gemma":[0.0047288565,0.00012735694,0.00029999678,0.000644347,0.00018425798,0.00037494858,0.00029345255,0.00046252666,0.00013639053],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023303143,0.00006106285,0.9974349,0.000005043488,0.000014738184,0.000045918176,0.000031295203,0.000027507047,0.0001418613,0.000008721573,0.000039180126,0.0019566545],"study_design_scores_gemma":[0.0000068271543,0.00035964468,0.99852884,0.00000724873,0.000023561084,0.00020707148,0.00020192061,0.00027188807,0.00027071498,0.0000138091955,0.00010610616,0.0000024072149],"about_ca_topic_score_codex":0.0018578051,"about_ca_topic_score_gemma":0.0022209403,"teacher_disagreement_score":0.0018578051,"about_ca_system_score_codex":0.00042271052,"about_ca_system_score_gemma":0.00047170647,"threshold_uncertainty_score":0.0036939979},"labels":[],"label_agreement":null},{"id":"W4308365535","doi":"10.1080/10428194.2022.2136968","title":"Expression of TCF3 target genes defines a subclass of diffuse large B-cell lymphoma characterized by up-regulation of MYC target genes and poor clinical outcome following R-CHOP therapy","year":2022,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Department of Pathology and Laboratory Medicine, University of North Carolina School of Medicine; Leukemia and Lymphoma Society of Canada","keywords":"Diffuse large B-cell lymphoma; CHOP; Gene; Lymphoma; Biology; Cancer research; Transcription factor; Oncology; Internal medicine; Bioinformatics; Genetics; Medicine; Immunology","score_opus":0.018983383939383654,"score_gpt":0.27462303849781894,"score_spread":0.2556396545584353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308365535","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99951196,0.00005336553,0.00019453157,0.000005822136,5.31803e-7,0.000004254734,0.00006595265,0.0000044476,0.00015919095],"genre_scores_gemma":[0.9996462,0.000016771097,0.00010252216,0.0000047880653,0.00000121411,0.0000038256335,0.00017085568,0.0000017483952,0.000052116982],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99987626,0.000021812646,0.000010181796,0.00003384891,0.000022089454,0.00003591208],"domain_scores_gemma":[0.9998529,0.00003954771,0.00004269925,0.000018895762,0.00001441653,0.00003156945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001574112,0.00012323278,0.00019972169,0.0005957289,0.00018440367,0.00027161828,0.00010014619,0.00018529252,0.00048890157],"category_scores_gemma":[0.00037772075,0.000051609968,0.00014339079,0.00037860396,0.00021481153,0.000077447876,0.00013712837,0.00016940237,0.00011987237],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001484026,0.00011862112,0.73245597,0.000028898425,0.00006322974,0.0005573548,0.0002618134,0.0006467023,0.24530216,0.00010830717,0.0001508036,0.018822238],"study_design_scores_gemma":[0.000019645704,0.00016289167,0.9859015,0.000004085297,0.00002608828,0.0014797951,0.00022486363,0.0020726977,0.00963097,0.00014372481,0.00032946473,0.0000043305668],"about_ca_topic_score_codex":0.0013586994,"about_ca_topic_score_gemma":0.0020796421,"teacher_disagreement_score":0.0013586994,"about_ca_system_score_codex":0.00022748584,"about_ca_system_score_gemma":0.00014370398,"threshold_uncertainty_score":0.0027015805},"labels":[],"label_agreement":null},{"id":"W4309287965","doi":"10.1080/10428194.2022.2136956","title":"Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 study","year":2022,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Cohort; Internal medicine; Lenalidomide; Oncology; Lymphoma; Refractory (planetary science); Clinical endpoint; Adverse effect; Multiple myeloma; Cancer; Clinical trial; Immunotherapy","score_opus":0.008453224238700503,"score_gpt":0.2541884000132351,"score_spread":0.2457351757745346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309287965","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9805235,0.006941533,0.00072868913,0.00093130925,0.0001280408,0.0033221475,0.00410188,0.00008263435,0.0032402342],"genre_scores_gemma":[0.98295444,0.003859118,0.0014393734,0.0019561946,0.0002089491,0.0025832744,0.0050251335,0.000022575909,0.001950859],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995646,0.0002633351,0.000021020456,0.00005488811,0.000043186454,0.000053026604],"domain_scores_gemma":[0.9995745,0.00006801154,0.00012639852,0.000044958113,0.00003247638,0.00015358608],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021680787,0.0007953819,0.00097259023,0.00017979967,0.0002991625,0.00068169355,0.0005752454,0.00077664404,0.003473867],"category_scores_gemma":[0.0010736305,0.00032454383,0.00094382325,0.0003852013,0.00032795084,0.0006288658,0.000348582,0.0016579065,0.0008074409],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.78781104,0.026407415,0.024496403,0.002539792,0.0032303554,0.00040300481,0.00026199402,0.0016178888,0.027488118,0.0004944249,0.009739054,0.115510516],"study_design_scores_gemma":[0.80805284,0.11588437,0.060797516,0.00017036371,0.0017928622,0.0005273267,0.00006810497,0.0009066593,0.0025408873,0.0003780737,0.008849487,0.00003146775],"about_ca_topic_score_codex":0.00065082894,"about_ca_topic_score_gemma":0.0016905674,"teacher_disagreement_score":0.003473867,"about_ca_system_score_codex":0.0007309591,"about_ca_system_score_gemma":0.001124021,"threshold_uncertainty_score":0.011621296},"labels":[],"label_agreement":null},{"id":"W4313431583","doi":"10.1080/10428194.2022.2148221","title":"Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study","year":2023,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Janssen Research and Development","keywords":"Daratumumab; Medicine; Tapering; Refractory (planetary science); Open label; Multicenter study; Multiple myeloma; Phases of clinical research; Oncology; Internal medicine; Clinical trial; Computer science; Materials science; Lenalidomide","score_opus":0.03396421959788129,"score_gpt":0.2982158978671249,"score_spread":0.26425167826924356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313431583","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.950043,0.038738687,0.00093701587,0.002037439,0.0004249823,0.00073170103,0.00093841186,0.00008865885,0.00606027],"genre_scores_gemma":[0.9901877,0.006227772,0.00087431964,0.0009213614,0.00028910142,0.00020658154,0.00062093785,0.000008409748,0.00066390017],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99961936,0.00012708339,0.000038954902,0.000044727523,0.00012580937,0.00004403329],"domain_scores_gemma":[0.99925715,0.00023926391,0.00027042505,0.000040170537,0.000058123554,0.00013483853],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010882004,0.0001933665,0.00080849376,0.00019478955,0.0002272112,0.0005750774,0.0001995072,0.000361759,0.0019753163],"category_scores_gemma":[0.0014516513,0.00014252846,0.0008571355,0.0003389838,0.00020193354,0.00029888964,0.00016849379,0.0009938197,0.0002875759],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23422404,0.00548529,0.07233564,0.0019365583,0.002578945,0.0007610002,0.0002694966,0.00074786064,0.01768022,0.00044649327,0.011589386,0.65194505],"study_design_scores_gemma":[0.20856714,0.19289707,0.5306998,0.0011634813,0.0047714827,0.0035298658,0.00046445915,0.0041262447,0.009418304,0.0014766979,0.042761162,0.00012428219],"about_ca_topic_score_codex":0.00056319707,"about_ca_topic_score_gemma":0.0026163456,"teacher_disagreement_score":0.0019753163,"about_ca_system_score_codex":0.0003791154,"about_ca_system_score_gemma":0.0009055561,"threshold_uncertainty_score":0.0066081285},"labels":[],"label_agreement":null},{"id":"W4313575780","doi":"10.1080/10428194.2022.2156793","title":"The burden of red blood cell transfusions in patients with lower-risk myelodysplastic syndromes and ring sideroblasts: an analysis of the prospective MDS-CAN registry","year":2023,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada); Bristol-Myers Squibb (Canada); Dalhousie University; Hamilton Health Sciences; McGill University Health Centre; University of Ottawa; Dr. Georges-L.-Dumont University Hospital Centre; St. Paul's Hospital; University of British Columbia; Health Sciences Centre; CancerCare Manitoba; University Health Network; Ottawa Hospital; Princess Margaret Cancer Centre; University of Toronto; Juravinski Cancer Centre; Sunnybrook Health Science Centre","funders":"Genentech; Otsuka Pharmaceutical; Astellas Pharma; Jazz Pharmaceuticals; Astex Pharmaceuticals; Taiho Pharmaceutical; F. Hoffmann-La Roche; Alexion Pharmaceuticals; Janssen Pharmaceuticals; Gilead Sciences; Celgene; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer","keywords":"Medicine; Myelodysplastic syndromes; Blood transfusion; Anemia; International Prognostic Scoring System; Internal medicine; Quality of life (healthcare); Pediatrics; Bone marrow","score_opus":0.005771964666928705,"score_gpt":0.21999720375555107,"score_spread":0.21422523908862237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313575780","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99823534,0.00020693502,0.00008328684,0.000029476667,0.000002422425,0.000008456087,0.0012442344,0.0000030493397,0.00018685128],"genre_scores_gemma":[0.99741167,0.00012326939,0.00008957902,0.000020103706,0.000008037752,0.000012442562,0.002270912,0.0000022164506,0.00006166547],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99856204,0.0005240589,0.00029074596,0.00025800386,0.0002318305,0.00013337127],"domain_scores_gemma":[0.9944495,0.00083797233,0.0034839793,0.0005256233,0.0003766124,0.00032626427],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018832298,0.00021703746,0.00038214505,0.0012728549,0.00027231683,0.0008142719,0.0004240832,0.0002937291,0.00078694086],"category_scores_gemma":[0.0044555315,0.00024101231,0.00056456384,0.0026307818,0.00022137733,0.0005749642,0.0008719197,0.00044498083,0.00018690174],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005576824,0.00000813247,0.99941635,0.000003761329,0.000034898538,0.000013200001,0.000014394879,0.000055440418,0.000017593196,0.000011670665,0.000047201378,0.00032152416],"study_design_scores_gemma":[0.000008960631,0.00004377218,0.9989071,0.000006891156,0.00004661391,0.00012193881,0.0000992396,0.0005177748,0.000037220918,0.000018530205,0.00018835923,0.000003718173],"about_ca_topic_score_codex":0.0061620525,"about_ca_topic_score_gemma":0.008233842,"teacher_disagreement_score":0.99383795,"about_ca_system_score_codex":0.00046160258,"about_ca_system_score_gemma":0.00053841725,"threshold_uncertainty_score":0.012252331},"labels":[],"label_agreement":null},{"id":"W4321376636","doi":"10.1080/10428194.2023.2171729","title":"A novel method to investigate drug resistance in the chronic lymphocytic leukemia (CLL) microenvironment: Analysis of CLL Cellular Environment and Response (ACCER)","year":2023,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; CancerCare Manitoba; University of Manitoba","funders":"","keywords":"Chronic lymphocytic leukemia; Ibrutinib; Tumor microenvironment; Stromal cell; Cancer research; Fludarabine; Leukemia; Medicine; Bone marrow; Immunology; Internal medicine; Tumor cells; Chemotherapy","score_opus":0.017058968566526552,"score_gpt":0.2730238147016377,"score_spread":0.25596484613511117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321376636","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8652951,0.0072837314,0.11822928,0.00029935138,0.00014022972,0.00035711922,0.0011978915,0.0007653706,0.0064320345],"genre_scores_gemma":[0.8423066,0.0039856266,0.14084445,0.00028302355,0.000060913713,0.0007946184,0.0011973239,0.00011651208,0.010410856],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997315,0.000059293267,0.000019318633,0.00006089418,0.0000885728,0.00004051811],"domain_scores_gemma":[0.9998524,0.000036384223,0.00003462654,0.000021427644,0.000030892377,0.000024213645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028415336,0.00034969955,0.00022228809,0.0007113056,0.00027771384,0.00026499524,0.00016987404,0.0004086463,0.0018102109],"category_scores_gemma":[0.00010941538,0.00020533928,0.00022560771,0.0003953275,0.00018864918,0.0003128057,0.00027723738,0.0005662833,0.00039506773],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004740846,0.00002328299,0.0007084346,0.00005093525,0.00000496839,0.000054518638,0.000037542148,0.000037185713,0.9964635,0.0000872,0.00005392918,0.0024310995],"study_design_scores_gemma":[0.000023307526,0.00046383037,0.01741547,0.000015499707,0.000035591693,0.0013319046,0.00014339788,0.0019843278,0.9715214,0.00014973292,0.006895207,0.00002042904],"about_ca_topic_score_codex":0.0006080678,"about_ca_topic_score_gemma":0.0015843237,"teacher_disagreement_score":0.0018102109,"about_ca_system_score_codex":0.00019263629,"about_ca_system_score_gemma":0.000158604,"threshold_uncertainty_score":0.0060557723},"labels":[],"label_agreement":null},{"id":"W4366603286","doi":"10.1080/10428194.2023.2196593","title":"Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy","year":2023,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Genentech; Servier; Astellas Pharma; Galecto; Sierra Oncology; CTI Biopharma; Incyte; Pfizer; CareDx; MorphoSys; Celgene; Bristol-Myers Squibb; AstraZeneca; Constellation Pharmaceuticals; Italfarmaco; Menarini Group; Astellas Pharma US; Gilead Sciences; U.S. Department of Defense","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Myeloproliferative neoplasm; Clinical trial; Janus kinase; Expanded access; Internal medicine; Oncology; Bone marrow; Cytokine","score_opus":0.07429801613504322,"score_gpt":0.3947768205150981,"score_spread":0.3204788043800549,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366603286","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013163668,0.9990946,0.000035336776,0.00023213009,0.00012341604,0.0000036123133,0.000024553565,0.0000031094623,0.0003516128],"genre_scores_gemma":[0.0008739728,0.9982621,0.00009599486,0.00039220243,0.00010994703,0.000005748042,0.000043501048,0.0000016948261,0.00021488473],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99964106,0.0000752651,0.00009410767,0.00005979954,0.00010704563,0.000022742717],"domain_scores_gemma":[0.999022,0.000549685,0.00014693761,0.000019104267,0.00021822182,0.000044005046],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011404771,0.0006569248,0.0016139868,0.0024959133,0.00022147721,0.0010405242,0.00079750584,0.0008231555,0.0032428857],"category_scores_gemma":[0.0022167147,0.00029591026,0.0010975202,0.002699865,0.000326574,0.0012461038,0.0005344679,0.0013653147,0.0009017723],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021521273,0.000037648,0.00025189656,0.046171274,0.0003566214,0.00020609827,0.00008413757,0.0003012775,0.0007877561,0.0018867288,0.029077824,0.9206235],"study_design_scores_gemma":[0.00007612807,0.00028407873,0.0020974039,0.03215004,0.0011569364,0.0017350347,0.00012111933,0.00015102986,0.0004327664,0.0012625548,0.96049523,0.000037597172],"about_ca_topic_score_codex":0.0010902783,"about_ca_topic_score_gemma":0.0026261515,"teacher_disagreement_score":0.0032428857,"about_ca_system_score_codex":0.0007412046,"about_ca_system_score_gemma":0.0013595185,"threshold_uncertainty_score":0.010848522},"labels":[],"label_agreement":null},{"id":"W4366757045","doi":"10.1080/10428194.2023.2203286","title":"Hereditary alpha-tryptasemia and complete deletion of exon 8 of the c-kit gene in patients with mast cell activation syndrome","year":2023,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Mast cells and histamine","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Declaration; Medicine; Informed consent; Conflict of interest; Family medicine; Institutional review board; Alternative medicine; Surgery; Political science; Pathology; Law","score_opus":0.005357887550220224,"score_gpt":0.16998631937248498,"score_spread":0.16462843182226475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366757045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99589866,0.0008051733,0.0007579142,0.0002712133,0.000045973768,0.000028194256,0.00016437717,0.000047880618,0.001980645],"genre_scores_gemma":[0.99905807,0.00016560608,0.00018596879,0.00007829194,0.00006751685,0.0000067469887,0.00005746459,0.000006220895,0.0003740596],"study_design_codex":"case_report","study_design_gemma":"observational","domain_scores_codex":[0.9996594,0.000041120686,0.00003516249,0.00010783893,0.000088493885,0.000067921],"domain_scores_gemma":[0.9996032,0.00012500855,0.00009281477,0.000018919005,0.000031814176,0.00012828328],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018512123,0.0012015358,0.00060677767,0.0012978307,0.0007730176,0.00032752965,0.00041820965,0.0011608386,0.0032854383],"category_scores_gemma":[0.0011377026,0.0003838604,0.0003588952,0.0006472033,0.00074567756,0.0004769769,0.00045169066,0.00065108173,0.0004168377],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005568367,0.000167475,0.16625148,0.00008948309,0.000094587645,0.79088783,0.0008723642,0.00038862144,0.0318732,0.00048039694,0.0010255458,0.0073121893],"study_design_scores_gemma":[0.000058348778,0.00033935448,0.19343813,0.000026854328,0.00008517327,0.8017682,0.00020749902,0.00046256132,0.0025627844,0.00027141807,0.00075108005,0.000028577122],"about_ca_topic_score_codex":0.0011977188,"about_ca_topic_score_gemma":0.001006625,"teacher_disagreement_score":0.0032854383,"about_ca_system_score_codex":0.00022400187,"about_ca_system_score_gemma":0.0002776392,"threshold_uncertainty_score":0.010990858},"labels":[],"label_agreement":null},{"id":"W4366759859","doi":"10.1080/10428194.2023.2199340","title":"Population-level impact of ibrutinib for chronic lymphocytic leukemia in British Columbia, Canada","year":2023,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Paul's Hospital; Vancouver General Hospital; University of British Columbia","funders":"AbbVie; Lundbeck Canada; University of British Columbia; GlaxoSmithKline","keywords":"Ibrutinib; Discontinuation; Medicine; Chronic lymphocytic leukemia; Adverse effect; Internal medicine; Population; Oncology; Leukemia","score_opus":0.020516141504062696,"score_gpt":0.28692706116083677,"score_spread":0.2664109196567741,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366759859","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96430314,0.0049860314,0.00022274576,0.0037829727,0.000060616658,0.00008877604,0.01910631,0.000052587777,0.0073968684],"genre_scores_gemma":[0.99373204,0.0015056299,0.00017324033,0.00043811565,0.000017019807,0.000022593193,0.0030064834,0.00001549912,0.0010892776],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985911,0.00016623425,0.00009908935,0.00021651879,0.00037192952,0.00055521756],"domain_scores_gemma":[0.99637765,0.00021332144,0.0006353745,0.00013324361,0.0016166125,0.0010239262],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009786475,0.00033495584,0.00054496643,0.0012355908,0.002084684,0.0018811247,0.001324755,0.000510041,0.0027587595],"category_scores_gemma":[0.002999123,0.00028166268,0.00056431023,0.0049107503,0.0006298568,0.00043266613,0.00092108035,0.00117153,0.00024062362],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021270919,0.000051499635,0.9803122,0.000063032516,0.00019798863,0.00014561974,0.00032104013,0.0005336097,0.00022376204,0.00028997113,0.0059657735,0.011682755],"study_design_scores_gemma":[0.000027305992,0.00004326375,0.9944284,0.00007850372,0.000100610705,0.00012273333,0.0010746715,0.0007069082,0.000079208134,0.00006717802,0.0032450054,0.000026146714],"about_ca_topic_score_codex":0.9961029,"about_ca_topic_score_gemma":0.99793077,"teacher_disagreement_score":0.043953385,"about_ca_system_score_codex":0.043953385,"about_ca_system_score_gemma":0.05102877,"threshold_uncertainty_score":0.31890565},"labels":[],"label_agreement":null},{"id":"W4375864821","doi":"10.1080/10428194.2023.2203790","title":"Single-center retrospective study assessing the efficacy and safety of BeEAM (bendamustine, etoposide, cytarabine, melphalan) as conditioning regimen for autologous hematopoietic stem cell transplantation","year":2023,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital du Sacré-Cœur de Montréal","funders":"","keywords":"Medicine; Bendamustine; Internal medicine; Etoposide; Oncology; Carmustine; Febrile neutropenia; Melphalan; Cytarabine; Autologous stem-cell transplantation; Follicular lymphoma; Mucositis; Hematopoietic stem cell transplantation; Regimen; Transplantation; Surgery; Neutropenia; Lymphoma; Chemotherapy; Rituximab","score_opus":0.01950455767052423,"score_gpt":0.2957316072068995,"score_spread":0.2762270495363753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4375864821","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9991518,0.00037723,0.000098660086,0.00000997954,0.00000521561,0.00005520934,0.00008849443,0.000002187628,0.00021112117],"genre_scores_gemma":[0.999416,0.000104485865,0.00008771631,0.00004941139,0.000016281163,0.000035045978,0.00022392931,0.000001983877,0.00006503521],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99904734,0.00030558687,0.00016751295,0.0002569964,0.0001223093,0.00010017394],"domain_scores_gemma":[0.99796873,0.00052503403,0.0006665072,0.00023566482,0.0002076841,0.00039631705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00130535,0.00032623604,0.0007359199,0.0005553394,0.00057360734,0.00067493756,0.00025315132,0.00046010784,0.0013980943],"category_scores_gemma":[0.0022393675,0.00033997916,0.0006138576,0.000855663,0.0004582037,0.00040846967,0.0003202714,0.00038426352,0.00030768442],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002756284,0.0006902532,0.99161536,0.000055208064,0.0003118802,0.000575848,0.0001420522,0.00006105016,0.0008981277,0.00003350209,0.00010044203,0.0027599204],"study_design_scores_gemma":[0.00097643904,0.015677653,0.97594815,0.00003491714,0.00053074886,0.0036408966,0.00048806358,0.000425229,0.00069951796,0.000059001257,0.0014900778,0.000029358152],"about_ca_topic_score_codex":0.0011627388,"about_ca_topic_score_gemma":0.001328994,"teacher_disagreement_score":0.0013980943,"about_ca_system_score_codex":0.00045119366,"about_ca_system_score_gemma":0.00065945025,"threshold_uncertainty_score":0.0069034696},"labels":[],"label_agreement":null},{"id":"W4376254224","doi":"10.1080/10428194.2023.2209232","title":"Return on investment of the lymphoma diagnostic pathway implementation in Alberta, Canada","year":2023,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Alberta Health; Impact; Alberta Health Services","funders":"","keywords":"Propensity score matching; Return on investment; Medicine; Clinical pathway; Investment (military); Emergency medicine; Health care; Cohort; Medical emergency; Internal medicine; Nursing; Economics","score_opus":0.06703035261450856,"score_gpt":0.32211303332498603,"score_spread":0.25508268071047746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376254224","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9664894,0.0015296229,0.0013276598,0.00822393,0.00008166676,0.00084881537,0.0027285048,0.00010898703,0.018661454],"genre_scores_gemma":[0.99201477,0.00076820987,0.0019479112,0.0005987751,0.000019262612,0.000113566595,0.0012549995,0.000015687328,0.0032668402],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99022865,0.0022555632,0.000267223,0.0003267936,0.00340827,0.003513418],"domain_scores_gemma":[0.9848859,0.0028892446,0.0014555937,0.00031982653,0.00547462,0.0049747773],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007280784,0.00036719482,0.0003661203,0.0015456503,0.0015418791,0.003046337,0.0014934551,0.00068701286,0.0025552788],"category_scores_gemma":[0.019261826,0.0003131665,0.0006183555,0.0024356712,0.0011234531,0.0007266468,0.0020943624,0.001347712,0.00018310992],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003087159,0.0020776116,0.61104953,0.00063240033,0.00040535128,0.00090351916,0.0023582028,0.035236053,0.0014511592,0.011761003,0.020409293,0.3106286],"study_design_scores_gemma":[0.00043226394,0.0015084336,0.9475399,0.00040563394,0.0001919684,0.00019200797,0.0050770002,0.02478632,0.0008841046,0.00093418086,0.017948013,0.000100256104],"about_ca_topic_score_codex":0.9760724,"about_ca_topic_score_gemma":0.97981745,"teacher_disagreement_score":0.13178205,"about_ca_system_score_codex":0.13178205,"about_ca_system_score_gemma":0.2076838,"threshold_uncertainty_score":0.9561502},"labels":[],"label_agreement":null},{"id":"W4378953570","doi":"10.1080/10428194.2023.2216819","title":"Exploring new prognostic biomarkers in Mantle Cell Lymphoma: a comparison of the circSCORE and the MCL35 score","year":2023,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"Novo Nordisk Fonden; Greater Copenhagen Health Science Partners; Lundbeckfonden; Kræftens Bekæmpelse","keywords":"Mantle cell lymphoma; Internal medicine; Oncology; Medicine; Lymphoma; Geology","score_opus":0.055044144537478974,"score_gpt":0.2632539157212679,"score_spread":0.20820977118378892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378953570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99266887,0.003046044,0.0021160033,0.00032135544,0.000046340876,0.00004194714,0.00053402816,0.000023658764,0.0012016844],"genre_scores_gemma":[0.9965155,0.00046780534,0.00157231,0.000105008956,0.00010855505,0.000030618157,0.0009500001,0.000010040988,0.00024006139],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989274,0.00044508363,0.00009210064,0.00017753438,0.00026172528,0.00009615095],"domain_scores_gemma":[0.99747354,0.0011394166,0.00062392786,0.00018650723,0.00027907547,0.0002975271],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034612124,0.00059923937,0.0008648155,0.0014041014,0.00020981646,0.0013062168,0.0004668692,0.00036971015,0.0013437971],"category_scores_gemma":[0.005592961,0.00011711929,0.00078994886,0.001211097,0.0002938767,0.0007729768,0.0009251539,0.00061982364,0.00023799126],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002874703,0.00006667981,0.9520177,0.000091129536,0.0008124026,0.00005486731,0.00007006174,0.0013098946,0.0017128679,0.00029401123,0.00047029663,0.040225487],"study_design_scores_gemma":[0.0003931125,0.0037323309,0.96814764,0.00007820306,0.0016900039,0.0006514881,0.00030672445,0.017116245,0.002131235,0.0015939493,0.0040979795,0.00006106798],"about_ca_topic_score_codex":0.0006484536,"about_ca_topic_score_gemma":0.0014598047,"teacher_disagreement_score":0.0034612124,"about_ca_system_score_codex":0.00043813096,"about_ca_system_score_gemma":0.00043929424,"threshold_uncertainty_score":0.018304884},"labels":[],"label_agreement":null},{"id":"W4381309016","doi":"10.1080/10428194.2023.2226278","title":"Estimating the impact of early bendamustine failure on feasibility of subsequent CAR-T cell therapy in mantle cell lymphoma","year":2023,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Calgary","funders":"","keywords":"Bendamustine; Medicine; Internal medicine; Lymphoma","score_opus":0.03402183222211579,"score_gpt":0.3065968196357071,"score_spread":0.2725749874135913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381309016","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.39363313,0.0063255522,0.003982971,0.5269083,0.006073103,0.00016922662,0.0015777997,0.00025494746,0.061074976],"genre_scores_gemma":[0.9149874,0.0023350974,0.0030844337,0.06500543,0.0070745745,0.000075911834,0.00044770198,0.000073665586,0.006915821],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992482,0.00027400698,0.000095464646,0.00006674162,0.00018224117,0.00013330913],"domain_scores_gemma":[0.99184084,0.005996272,0.0003831689,0.00021645453,0.0010459024,0.0005172746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001380521,0.00023888107,0.00037750328,0.0005801371,0.00043874266,0.0009266417,0.00045060928,0.003181543,0.00329282],"category_scores_gemma":[0.011491259,0.00022064612,0.00039917085,0.00040000604,0.00032578537,0.0005273683,0.00022523504,0.002892003,0.0015143869],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063725896,0.000515065,0.4773626,0.0002518982,0.00017952887,0.057135105,0.00044297794,0.004901276,0.007504522,0.0027652031,0.23299575,0.20957345],"study_design_scores_gemma":[0.0013116379,0.0069800257,0.5309995,0.0007957888,0.0009653236,0.14880128,0.0025329918,0.0510026,0.015594576,0.020154806,0.22058257,0.00027897782],"about_ca_topic_score_codex":0.004775753,"about_ca_topic_score_gemma":0.0065798406,"teacher_disagreement_score":0.004775753,"about_ca_system_score_codex":0.0023237173,"about_ca_system_score_gemma":0.00076204113,"threshold_uncertainty_score":0.01685983},"labels":[],"label_agreement":null},{"id":"W4385620600","doi":"10.1080/10428194.2023.2234528","title":"Comparative effectiveness of salvage chemotherapy regimens and chimeric antigen T-cell receptor therapies in relapsed and refractory diffuse large B cell lymphoma: a network meta-analysis of clinical trials","year":2023,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Oncology; Internal medicine; Rituximab; Gemcitabine; Chimeric antigen receptor; Salvage therapy; Regimen; Clinical trial; Diffuse large B-cell lymphoma; Lymphoma; Chemotherapy regimen; Chemotherapy; Refractory (planetary science); Immunotherapy; Cancer; Biology","score_opus":0.1039930813529429,"score_gpt":0.3912292872957763,"score_spread":0.2872362059428334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385620600","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07481768,0.9185145,0.0025727903,0.00066229946,0.00060883106,0.0004934246,0.001300354,0.000098442724,0.00093174144],"genre_scores_gemma":[0.8678625,0.124591485,0.0030101324,0.0011212261,0.0003992384,0.0008608339,0.0016064201,0.00007879506,0.0004692637],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98388577,0.011492503,0.002063015,0.001435741,0.0007924882,0.000330449],"domain_scores_gemma":[0.9800326,0.015380502,0.002697954,0.00092271867,0.0005828234,0.00038336773],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.021147287,0.0026494775,0.013202126,0.0031459702,0.0003649265,0.0029923138,0.0018555076,0.0019021066,0.002342359],"category_scores_gemma":[0.025763936,0.001118085,0.036044654,0.0035042695,0.0006885592,0.0017232939,0.0013052294,0.0022608538,0.00024383588],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017357493,0.000034493874,0.0046581263,0.022141954,0.94933975,0.000051756113,0.000026609388,0.0011051659,0.00022736298,0.00008217024,0.00026951835,0.0047056666],"study_design_scores_gemma":[0.0037959374,0.00057733885,0.004162691,0.0012330724,0.9883597,0.000040021936,0.000024937694,0.00072306924,0.00013099267,0.00027371998,0.00066240405,0.0000162056],"about_ca_topic_score_codex":0.0027419613,"about_ca_topic_score_gemma":0.004002572,"teacher_disagreement_score":0.021147287,"about_ca_system_score_codex":0.0017433986,"about_ca_system_score_gemma":0.00093502627,"threshold_uncertainty_score":0.11183888},"labels":[],"label_agreement":null},{"id":"W4385683538","doi":"10.1080/10428194.2023.2242990","title":"High sensitivity c-reactive protein and circulating biomarkers of endothelial dysfunction in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors","year":2023,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; McMaster University; Toronto General Hospital; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Nilotinib; Medicine; Ponatinib; Chronic myelogenous leukemia; Myeloid leukemia; Internal medicine; C-reactive protein; Cancer; Oncology; Immunology; Leukemia; Imatinib; Inflammation","score_opus":0.006563382667115001,"score_gpt":0.20799284824514153,"score_spread":0.20142946557802652,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385683538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9992531,0.00037606666,0.00007382391,0.00003157164,0.000005364653,0.0000040086775,0.00010125505,0.0000014813194,0.00015326662],"genre_scores_gemma":[0.99966025,0.00008649316,0.000051147803,0.000025823723,0.000010022838,0.0000036551505,0.00009372398,5.702234e-7,0.00006825664],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995741,0.00014723995,0.000053280008,0.00008520115,0.00007119441,0.00006905218],"domain_scores_gemma":[0.99883205,0.00026253622,0.0005281264,0.00007641456,0.00010670826,0.0001942091],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067157764,0.00025294645,0.0003825706,0.00047348227,0.00023968253,0.0005437422,0.00020324512,0.00043293388,0.00081024447],"category_scores_gemma":[0.0015976445,0.00024699327,0.00032315447,0.00079952116,0.00021650048,0.00037270697,0.0002556837,0.00074906443,0.00012831923],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027722633,0.00004155447,0.99831104,0.0000075858334,0.00006423182,0.000045018856,0.00002182083,0.000031394226,0.00038661325,0.000009735918,0.000031310865,0.00077250676],"study_design_scores_gemma":[0.0000117913005,0.00017092901,0.9990972,0.000003727566,0.000040733932,0.00021353966,0.00006356924,0.00018318028,0.0001030112,0.000018410894,0.0000912828,0.0000026689302],"about_ca_topic_score_codex":0.0010104005,"about_ca_topic_score_gemma":0.0012771605,"teacher_disagreement_score":0.0010104005,"about_ca_system_score_codex":0.00016877372,"about_ca_system_score_gemma":0.00019086484,"threshold_uncertainty_score":0.0035517216},"labels":[],"label_agreement":null},{"id":"W4388033587","doi":"10.1080/10428194.2023.2275529","title":"Re: exposure to phenoxyacetic acids and glyphosate as risk factors for non-Hodgkin lymphoma","year":2023,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Pesticide and Herbicide Environmental Studies","field":"Environmental Science","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Toronto; Carleton University","funders":"","keywords":"Glyphosate; Hodgkin lymphoma; Advice (programming); Law; Lymphoma; Actuarial science; Business; Medicine; Political science; Biotechnology; Computer science; Biology; Internal medicine","score_opus":0.010169848182255298,"score_gpt":0.22980972139863137,"score_spread":0.21963987321637607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388033587","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0066714915,0.09389992,0.0010464141,0.5840314,0.31016445,0.00009366596,0.0013310631,0.000170201,0.0025914006],"genre_scores_gemma":[0.04141912,0.023637282,0.00086598616,0.21805157,0.703292,0.00012111588,0.0006898485,0.00016205845,0.011761086],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9940006,0.0018598279,0.0012719748,0.0010223031,0.0014925194,0.00035279666],"domain_scores_gemma":[0.95333195,0.025587952,0.0048417253,0.0012664202,0.012622129,0.0023497897],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009235224,0.0018063696,0.0032932002,0.002557284,0.0008641947,0.0028521952,0.0031410393,0.00909967,0.0067878678],"category_scores_gemma":[0.04596902,0.000752037,0.0015558181,0.0018688046,0.0010884083,0.0029022319,0.0011891366,0.005476739,0.0025072396],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015575993,0.00009648286,0.013052856,0.0028144252,0.0013522988,0.0025736308,0.0002441802,0.0001397222,0.0012088104,0.0007551459,0.9388615,0.037343312],"study_design_scores_gemma":[0.0010410973,0.0010055588,0.07516241,0.0055496073,0.005121661,0.020486316,0.0011150676,0.0021300595,0.0047063865,0.006544697,0.8767292,0.0004079932],"about_ca_topic_score_codex":0.003390022,"about_ca_topic_score_gemma":0.005935555,"teacher_disagreement_score":0.009235224,"about_ca_system_score_codex":0.0016103988,"about_ca_system_score_gemma":0.0015189325,"threshold_uncertainty_score":0.04884106},"labels":[],"label_agreement":null},{"id":"W4389380274","doi":"10.1080/10428194.2023.2290468","title":"Daratumumab for the treatment of relapsed/refractory AL amyloidosis: experience from the amyloidosis Program of Calgary (APC)","year":2023,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Amyloidosis: Diagnosis, Treatment, Outcomes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Daratumumab; AL amyloidosis; Refractory (planetary science); Amyloidosis; Medicine; Internal medicine; Oncology; Psychology; Multiple myeloma; Immunoglobulin light chain; Immunology; Bortezomib; Materials science","score_opus":0.01602393768162398,"score_gpt":0.2771956226334811,"score_spread":0.2611716849518571,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389380274","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.38002974,0.48751715,0.0033805377,0.0898794,0.0080621485,0.00027408468,0.0010275064,0.0001357958,0.029693766],"genre_scores_gemma":[0.66431606,0.26168117,0.004339163,0.046312623,0.01191863,0.00013573749,0.0012905216,0.00015974029,0.009846322],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9996805,0.00012719387,0.00003471369,0.00003692392,0.00007362981,0.000047027093],"domain_scores_gemma":[0.9986841,0.0005600621,0.00013816316,0.000038568993,0.00018796587,0.00039100353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011626397,0.0004431815,0.00077044225,0.00020668363,0.0004161185,0.0007357663,0.00040911578,0.00067361316,0.0011085739],"category_scores_gemma":[0.002405782,0.00011541122,0.0006518293,0.00035423602,0.00028381625,0.00062521826,0.000261088,0.0024868124,0.00041730326],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007191401,0.0018042834,0.018712098,0.0010308659,0.0007922031,0.011067987,0.0009657642,0.0014124144,0.004046959,0.0012024668,0.11023496,0.84153855],"study_design_scores_gemma":[0.011971867,0.022603417,0.16472137,0.0038142984,0.003018786,0.103846915,0.0011567505,0.0034683112,0.0060310923,0.002785469,0.67635894,0.00022277066],"about_ca_topic_score_codex":0.0010795096,"about_ca_topic_score_gemma":0.0020057382,"teacher_disagreement_score":0.9989205,"about_ca_system_score_codex":0.0004772566,"about_ca_system_score_gemma":0.0004484148,"threshold_uncertainty_score":0.0061486363},"labels":[],"label_agreement":null},{"id":"W4389950858","doi":"10.1080/10428194.2023.2295786","title":"The successful management of acute promyelocytic leukemia during pregnancy: a case report","year":2023,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Retinoids in leukemia and cellular processes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; Discovery Centre; Population Health Research Institute; McMaster University","funders":"Ontario Institute for Cancer Research; Johns Hopkins Children's Center","keywords":"Acute promyelocytic leukemia; Pregnancy; Medicine; Leukemia; Obstetrics; Internal medicine; Biology; Retinoic acid; Genetics","score_opus":0.006557435381448718,"score_gpt":0.23736484786168344,"score_spread":0.23080741248023473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389950858","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.854263,0.051709384,0.02479464,0.033354193,0.0046620313,0.00080971705,0.0008311274,0.00076859246,0.028807439],"genre_scores_gemma":[0.9640743,0.013978735,0.0075266417,0.004132488,0.0052684,0.0001520532,0.00025326508,0.000100937985,0.004513161],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9988531,0.00020093773,0.00015957879,0.00025136126,0.00020112256,0.0003339339],"domain_scores_gemma":[0.9983833,0.00044908948,0.00037834098,0.00013344994,0.00008033534,0.0005754966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005099951,0.0028499626,0.0016608711,0.003380405,0.0039276076,0.002287997,0.0025872507,0.010056152,0.001856405],"category_scores_gemma":[0.004402614,0.0012465002,0.0018745994,0.0020878897,0.0020862562,0.0025653788,0.0024604907,0.0057769096,0.0014045727],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011503824,0.00002818086,0.0009700504,0.000022099508,0.0000043543205,0.9971681,0.00008037603,0.000055325883,0.0002462156,0.00014435202,0.00021797419,0.0010515141],"study_design_scores_gemma":[0.0000042583633,0.00003133592,0.00061707146,0.000014043711,0.000005540764,0.99852127,0.000053201155,0.00011845705,0.0001667135,0.00011550308,0.00034476107,0.000007858059],"about_ca_topic_score_codex":0.0017601204,"about_ca_topic_score_gemma":0.002305497,"teacher_disagreement_score":0.010056152,"about_ca_system_score_codex":0.001846852,"about_ca_system_score_gemma":0.001529283,"threshold_uncertainty_score":0.013399899},"labels":[],"label_agreement":null},{"id":"W4390406598","doi":"10.1080/10428194.2023.2290466","title":"Frontline therapy with bendamustine rituximab (BR) and rituximab cyclophosphamide vincristine prednisone (RCVP) confers similar long-term outcomes in patients with treatment naïve Waldenström macroglobulinemia in a real-world setting: a population-based analysis","year":2023,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia Hospital","funders":"","keywords":"Rituximab; Medicine; Bendamustine; Prednisone; Vincristine; Internal medicine; Waldenstrom macroglobulinemia; Regimen; Cyclophosphamide; Macroglobulinemia; Gastroenterology; Population; Surgery; Chemotherapy; Oncology; Lymphoma; Multiple myeloma","score_opus":0.013781753511820725,"score_gpt":0.2816441447738777,"score_spread":0.267862391262057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390406598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9996972,0.00016327428,0.000031107225,0.000008369275,0.0000016946051,0.0000034332597,0.000028446455,8.208482e-7,0.00006563969],"genre_scores_gemma":[0.99968445,0.000054772067,0.000035525893,0.000018725632,0.000007936587,0.000004923805,0.00016302714,8.402857e-7,0.000029850851],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99918705,0.00038776835,0.000074083226,0.00014952783,0.00010475563,0.00009689828],"domain_scores_gemma":[0.9988558,0.00032231308,0.00046453785,0.00010652352,0.000055959485,0.00019481941],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012266869,0.00023088351,0.0005304246,0.0003874918,0.00022456599,0.00059524504,0.00023817718,0.00046723493,0.00043735732],"category_scores_gemma":[0.0018337537,0.0002085939,0.00070409663,0.00030926723,0.0002948115,0.00040525303,0.0003399832,0.00042855515,0.00011132745],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009649871,0.0003967544,0.9766151,0.00003720958,0.0010430361,0.0003657714,0.00015648692,0.00057416386,0.002443127,0.000028721654,0.00015535341,0.00853438],"study_design_scores_gemma":[0.00084475154,0.005793732,0.98985285,0.000011904466,0.00047081534,0.0009875961,0.00016741185,0.0010498225,0.00040047077,0.000048394042,0.00035708808,0.000015097113],"about_ca_topic_score_codex":0.00082215166,"about_ca_topic_score_gemma":0.001036137,"teacher_disagreement_score":0.0012266869,"about_ca_system_score_codex":0.00037418335,"about_ca_system_score_gemma":0.00018638422,"threshold_uncertainty_score":0.006487429},"labels":[],"label_agreement":null},{"id":"W4390535428","doi":"10.1080/10428194.2023.2300719","title":"Real-world data of the use of rivaroxaban in pediatric patients with hematologic malignancies","year":2024,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Blood Coagulation and Thrombosis Mechanisms","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Rivaroxaban; Medicine; Hematologic malignancy; Hematologic Neoplasms; Intensive care medicine; Internal medicine; Cancer; Atrial fibrillation; Warfarin","score_opus":0.04423736769432415,"score_gpt":0.2669800630131104,"score_spread":0.22274269531878624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390535428","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.70270646,0.049965873,0.0040184744,0.011001874,0.0003781156,0.00016081135,0.21309246,0.00020426793,0.018471653],"genre_scores_gemma":[0.92478305,0.013331893,0.0029036521,0.0021803211,0.00036144265,0.00017390156,0.055599805,0.000049773098,0.0006160144],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99466395,0.0017459132,0.0012298101,0.00075394614,0.0014014606,0.00020490774],"domain_scores_gemma":[0.9693096,0.010019425,0.016465819,0.0012209937,0.0023883244,0.00059575104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022860593,0.00025838602,0.0004568349,0.0013714986,0.00022297415,0.0010624359,0.00037290636,0.00065768,0.004684961],"category_scores_gemma":[0.023423282,0.00027668604,0.0005763038,0.003966968,0.0002342582,0.0008550692,0.000511774,0.0011296166,0.00094440125],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033401712,0.000048615686,0.95583516,0.00048857485,0.0003634366,0.00017864349,0.00014245593,0.00059053354,0.000112982794,0.0004551876,0.016919466,0.024530914],"study_design_scores_gemma":[0.000051167168,0.00012290354,0.96851873,0.0004785677,0.00019470243,0.0017432628,0.00037561904,0.0013479738,0.00026385576,0.00039414948,0.026477244,0.000031866974],"about_ca_topic_score_codex":0.0066064927,"about_ca_topic_score_gemma":0.008174782,"teacher_disagreement_score":0.0066064927,"about_ca_system_score_codex":0.0007655658,"about_ca_system_score_gemma":0.0007424279,"threshold_uncertainty_score":0.015672743},"labels":[],"label_agreement":null},{"id":"W4390976218","doi":"10.1080/10428194.2024.2301738","title":"Management and use of healthcare resources in patients with chronic lymphocytic leukemia initiating venetoclax in routine clinical practice","year":2024,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University; Queen's University; ABB (Canada); University of Alberta; Health Sciences North; Cégep de Rimouski; Moncton Hospital; CancerCare Manitoba; Thunder Bay Regional Health Sciences Centre; Jewish General Hospital; University of Ottawa; University of Manitoba","funders":"AbbVie Canada","keywords":"Venetoclax; Ibrutinib; Medicine; Chronic lymphocytic leukemia; Tumor lysis syndrome; Internal medicine; Rituximab; Lymphoma; Oncology; Observational study; Leukemia; Chemotherapy","score_opus":0.021181746894429886,"score_gpt":0.3121649750153639,"score_spread":0.290983228120934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390976218","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99724954,0.0008613363,0.00003523786,0.0002334256,0.0000049058485,0.000022452483,0.0005932716,0.000004080541,0.0009957849],"genre_scores_gemma":[0.9991767,0.00028879364,0.00006414041,0.00007674385,0.000005971481,0.000008086227,0.00030736235,9.643201e-7,0.00007122633],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992781,0.00015959736,0.00007726079,0.00010062676,0.00017643493,0.00020793873],"domain_scores_gemma":[0.99818784,0.00024235486,0.0010352546,0.00004084297,0.00015849367,0.0003352426],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042472302,0.000114062874,0.00027808984,0.0004548578,0.00061181065,0.00079115405,0.00032453207,0.00029982036,0.0010070244],"category_scores_gemma":[0.0033168774,0.000120991346,0.0002428857,0.0014413807,0.0002509101,0.00035893722,0.00035579596,0.00061925466,0.000076364406],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007676509,0.00005247,0.99589205,0.000017332019,0.000022874732,0.00007192944,0.0001344388,0.000056534085,0.00005919198,0.000019678051,0.00025303714,0.003343797],"study_design_scores_gemma":[0.000011867287,0.00009153984,0.99837863,0.000030029947,0.000017507145,0.0002062003,0.0005438522,0.00025301153,0.00003532526,0.000026710743,0.00039947365,0.0000057787192],"about_ca_topic_score_codex":0.18682387,"about_ca_topic_score_gemma":0.26747337,"teacher_disagreement_score":0.18682387,"about_ca_system_score_codex":0.0025111244,"about_ca_system_score_gemma":0.0028995106,"threshold_uncertainty_score":0.3714729},"labels":[],"label_agreement":null},{"id":"W4391167737","doi":"10.1080/10428194.2024.2306463","title":"The impact of marginalization on diffuse large B-cell lymphoma overall survival: a retrospective cohort study","year":2024,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre; University of Toronto","funders":"Ministry of Long-Term Care; Ministry of Health, Ontario","keywords":"Diffuse large B-cell lymphoma; Retrospective cohort study; Medicine; Lymphoma; Overall survival; Cohort; Oncology; Internal medicine","score_opus":0.008793164795337854,"score_gpt":0.2719263780576062,"score_spread":0.26313321326226835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391167737","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971608,0.00035417036,0.00013281946,0.00006759608,0.0000054976163,0.00003205742,0.0016523125,0.0000045957217,0.0005902631],"genre_scores_gemma":[0.9989729,0.000118036216,0.000087819855,0.000032730433,0.0000043485443,0.000010952317,0.00064814626,0.0000023710656,0.00012265726],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989434,0.00011277034,0.00008289914,0.00025399425,0.00026133738,0.00034562696],"domain_scores_gemma":[0.9984365,0.00011134284,0.00058260135,0.00023022616,0.00035667088,0.00028253856],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010056405,0.00031779165,0.00033525392,0.00093564385,0.0013797415,0.0008623042,0.0008473711,0.00029901197,0.0011288793],"category_scores_gemma":[0.0021003026,0.0002948604,0.0006454441,0.0020617493,0.00068411464,0.00038898204,0.0007431893,0.00053145416,0.00012960006],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000063273736,0.0000073179112,0.9987336,0.000009548088,0.00006272586,0.0000506786,0.00015651964,0.00002370318,0.000089956455,0.000037117126,0.00012160828,0.00064401183],"study_design_scores_gemma":[0.000005376172,0.000038552713,0.9985701,0.000010063417,0.00004983005,0.0001443373,0.00037226448,0.000117192634,0.00003478121,0.000022814858,0.00062814,0.000006596214],"about_ca_topic_score_codex":0.74313617,"about_ca_topic_score_gemma":0.83556265,"teacher_disagreement_score":0.74313617,"about_ca_system_score_codex":0.005775171,"about_ca_system_score_gemma":0.0068097212,"threshold_uncertainty_score":0.5167531},"labels":[],"label_agreement":null},{"id":"W4391692164","doi":"10.1080/10428194.2024.2313626","title":"Stem cell allografting for chronic Myeloid leukemia in the tyrosine kinase era – forgotten but not gone","year":2024,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Myeloid leukemia; Transplantation; Stem cell; Oncology; Tyrosine-kinase inhibitor; Tyrosine kinase; Internal medicine; Intensive care medicine; Cancer; Biology","score_opus":0.01426282834381978,"score_gpt":0.249594515214795,"score_spread":0.23533168687097522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391692164","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003662735,0.9610027,0.0005715647,0.026467133,0.0026783652,0.000018954364,0.000043040873,0.000028982935,0.005526616],"genre_scores_gemma":[0.025284218,0.9484629,0.0016946265,0.016946672,0.003952559,0.000026240106,0.00012438401,0.000018072387,0.0034903327],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99962807,0.00013933546,0.00006270712,0.000020833902,0.000116805044,0.000032296106],"domain_scores_gemma":[0.9992582,0.00030678004,0.00014390043,0.0000304423,0.00014341023,0.00011720116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015140026,0.00013545335,0.0004346779,0.0004930851,0.00023936898,0.0008444336,0.00026463115,0.0005182242,0.0024725986],"category_scores_gemma":[0.0018358645,0.00006750657,0.0003323396,0.00039709214,0.00057995104,0.0012797292,0.00047820355,0.0015065768,0.0009366558],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002457063,0.000069634305,0.0009765755,0.0015731802,0.00007783499,0.00021510124,0.000067744084,0.00007568708,0.0010114644,0.0037574386,0.03323255,0.9586972],"study_design_scores_gemma":[0.0001233885,0.0004925699,0.0038181422,0.006937255,0.00018478151,0.0021208804,0.00024319296,0.00010624324,0.0009873279,0.007081647,0.9778846,0.000020006062],"about_ca_topic_score_codex":0.0004825845,"about_ca_topic_score_gemma":0.0027802244,"teacher_disagreement_score":0.0024725986,"about_ca_system_score_codex":0.00036579222,"about_ca_system_score_gemma":0.0008374183,"threshold_uncertainty_score":0.008271694},"labels":[],"label_agreement":null},{"id":"W4392954109","doi":"10.1080/10428194.2024.2328800","title":"Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial","year":2024,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"GlaxoSmithKline","keywords":"Ruxolitinib; Myelofibrosis; Anemia; Post-hoc analysis; Medicine; Janus kinase; Internal medicine; Hemoglobin; Randomized controlled trial; Janus kinase 2; Clinical trial; Gastroenterology; Receptor; Bone marrow","score_opus":0.01462902550181141,"score_gpt":0.2639739017926614,"score_spread":0.24934487629084998,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392954109","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99253744,0.003461726,0.0002658742,0.0003836233,0.00012818124,0.0006695252,0.00057371135,0.000035519166,0.0019444162],"genre_scores_gemma":[0.99386793,0.0010634012,0.0006567821,0.0006628009,0.00022918734,0.0007821096,0.0013195747,0.000009872583,0.0014084366],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9991817,0.0005070569,0.000057569072,0.00009102094,0.00006126449,0.000101512924],"domain_scores_gemma":[0.99933976,0.0002703982,0.0001881666,0.000053542644,0.000028449875,0.000119746466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020618818,0.0008061251,0.0019904114,0.0002581708,0.00019464604,0.00082310685,0.0003463761,0.0005931259,0.0024543165],"category_scores_gemma":[0.0018514338,0.0002350457,0.0021776957,0.00021303842,0.0003549253,0.0004978525,0.00039787934,0.0013422519,0.00021121287],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96921635,0.002188037,0.0032573747,0.00045571194,0.0021117744,0.000064412234,0.000062569,0.0008184526,0.003082656,0.00026136637,0.0012176471,0.017263686],"study_design_scores_gemma":[0.83847636,0.11789383,0.02801965,0.00014729954,0.0047218497,0.00019677368,0.00012180504,0.0033448508,0.002261278,0.0013037401,0.0034589965,0.000053627376],"about_ca_topic_score_codex":0.00025770452,"about_ca_topic_score_gemma":0.0014566705,"teacher_disagreement_score":0.0024543165,"about_ca_system_score_codex":0.00036168247,"about_ca_system_score_gemma":0.00058243715,"threshold_uncertainty_score":0.010904431},"labels":[],"label_agreement":null},{"id":"W4393274863","doi":"10.1080/10428194.2024.2333451","title":"Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (m <i>IDH1</i> ) acute myeloid leukemia (AML)","year":2024,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Venetoclax; IDH1; Isocitrate dehydrogenase; Myeloid leukemia; Internal medicine; Medicine; Refractory (planetary science); Complete remission; Gastroenterology; Myeloid; Leukemia; Oncology; Chemotherapy; Mutant; Chemistry; Biology; Chronic lymphocytic leukemia; Enzyme","score_opus":0.006680696083015651,"score_gpt":0.2386489908476709,"score_spread":0.23196829476465525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393274863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970824,0.0019104491,0.00014196285,0.00007279749,0.000012602491,0.00002920553,0.000048907354,0.000014315209,0.00068720704],"genre_scores_gemma":[0.9989434,0.00052525796,0.00016315926,0.000055166307,0.000020048778,0.0000105712215,0.000090885966,0.0000016999841,0.00018988817],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9999021,0.00004849581,0.000008641616,0.00001011796,0.000011348481,0.000019350238],"domain_scores_gemma":[0.9998299,0.000048800914,0.00004782403,0.000011724959,0.00000900743,0.00005273372],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002971352,0.00014100673,0.00031586032,0.00011191905,0.0001672569,0.00024731917,0.00011685436,0.00014552915,0.0005726623],"category_scores_gemma":[0.0003599121,0.000074736534,0.00014344262,0.0001390671,0.00015946472,0.00015938097,0.00012175718,0.00056119915,0.00014309741],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09515,0.0060033095,0.17981377,0.00064806006,0.00048168347,0.004151831,0.00095565256,0.0023904885,0.15461466,0.00043634247,0.0036110538,0.5517431],"study_design_scores_gemma":[0.027018206,0.24244982,0.6133093,0.00018778718,0.0009441065,0.01763963,0.00047339537,0.0057631833,0.06530192,0.00047313832,0.026378302,0.000061205705],"about_ca_topic_score_codex":0.0004512846,"about_ca_topic_score_gemma":0.0015418768,"teacher_disagreement_score":0.0005726623,"about_ca_system_score_codex":0.00020810323,"about_ca_system_score_gemma":0.00021073653,"threshold_uncertainty_score":0.0019156933},"labels":[],"label_agreement":null},{"id":"W4394009934","doi":"10.1080/10428194.2024.2336046","title":"Gammopathic dermopathy: characterization of cutaneous MGUS","year":2024,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Skin Diseases and Diabetes","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"","keywords":"Medicine; Monoclonal gammopathy of undetermined significance; Dermatology; Macroglobulinemia; Gammopathy; Monoclonal gammopathy; Monoclonal; Pathology; Multiple myeloma; Immunology; Monoclonal antibody; Antibody","score_opus":0.006898439544060198,"score_gpt":0.2285811013089907,"score_spread":0.2216826617649305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394009934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944674,0.0009746732,0.0005795497,0.000055772634,0.000009306899,0.000047918573,0.000059802216,0.000015662697,0.00378986],"genre_scores_gemma":[0.9992311,0.00016909535,0.00031360573,0.000033154385,0.000013247855,0.000006165763,0.000041927146,0.0000016389783,0.00019007424],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998221,0.00003878703,0.000025559835,0.000035465102,0.000030197896,0.000047980946],"domain_scores_gemma":[0.99976164,0.000057129644,0.000055094984,0.000021200007,0.00003178737,0.000073205934],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023793612,0.0003262765,0.00026042893,0.0009524844,0.0002987951,0.00031359284,0.00013214829,0.00024737907,0.0018039716],"category_scores_gemma":[0.0007534508,0.000109739194,0.00016459488,0.00036184385,0.0002627198,0.00028003473,0.00032717356,0.00025920125,0.000290385],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047555118,0.00018102671,0.8173666,0.00015727048,0.000041054245,0.0869816,0.00047096855,0.00023472485,0.064312086,0.0002912065,0.00036062623,0.02912724],"study_design_scores_gemma":[0.000049702125,0.0006514174,0.540901,0.00004572922,0.00006396204,0.4448651,0.0004867999,0.00094674976,0.009404201,0.00020694196,0.0023652273,0.0000130271355],"about_ca_topic_score_codex":0.00041824093,"about_ca_topic_score_gemma":0.0004915918,"teacher_disagreement_score":0.0018039716,"about_ca_system_score_codex":0.00010876926,"about_ca_system_score_gemma":0.00010949251,"threshold_uncertainty_score":0.006034851},"labels":[],"label_agreement":null},{"id":"W4394854044","doi":"10.1080/10428194.2024.2340052","title":"Prevalence of geriatric impairments and frailty categorization among real-world patients with multiple myeloma: a prospective cohort study (MFRAIL)","year":2024,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Frailty in Older Adults","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Western University; McMaster University; Population Health Research Institute","funders":"Janssen Canada; Hamilton Health Sciences","keywords":"Medicine; Multiple myeloma; Frailty Index; Prospective cohort study; Cohort; Geriatric Depression Scale; Internal medicine; Geriatrics; Physical therapy; Cognition; Gerontology; Psychiatry; Depressive symptoms","score_opus":0.005744017384403465,"score_gpt":0.2337024949837621,"score_spread":0.22795847759935864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394854044","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9996294,0.000074522206,0.000029998513,0.000012810368,0.0000012596921,0.000005701517,0.00016891706,0.0000013071223,0.00007598876],"genre_scores_gemma":[0.9996306,0.000058936417,0.000038790957,0.0000144592805,0.0000043052096,0.000007652537,0.00020225621,6.3921874e-7,0.00004243517],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996575,0.0000899946,0.000047996386,0.000080842685,0.00005662993,0.000067005094],"domain_scores_gemma":[0.9991812,0.00011122151,0.00038972433,0.000095847114,0.000057026602,0.000164871],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082251575,0.00023984368,0.00028567394,0.0009473866,0.0004092006,0.0006849049,0.00026198517,0.0003488586,0.00083095155],"category_scores_gemma":[0.0017306661,0.00021842985,0.00038089207,0.0007688752,0.00026652947,0.00061867596,0.00063967775,0.00040029458,0.00016861368],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004786123,0.000015401241,0.9992316,0.0000033293802,0.000019170226,0.000030430981,0.000058365855,0.0000119225815,0.0000669814,0.0000035005924,0.000022801925,0.00048874406],"study_design_scores_gemma":[0.0000050283934,0.00009907503,0.99942696,0.0000037371838,0.000013352263,0.00020084775,0.00011369497,0.00005183494,0.000023965526,0.00000528027,0.000053511478,0.0000027994327],"about_ca_topic_score_codex":0.004401991,"about_ca_topic_score_gemma":0.005961976,"teacher_disagreement_score":0.004401991,"about_ca_system_score_codex":0.00025826533,"about_ca_system_score_gemma":0.00020806515,"threshold_uncertainty_score":0.008752704},"labels":[],"label_agreement":null},{"id":"W4394932930","doi":"10.1080/10428194.2024.2338851","title":"Management of relapsed/refractory mantle cell lymphoma","year":2024,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Mantle cell lymphoma; Chimeric antigen receptor; Refractory (planetary science); Medicine; Ibrutinib; Lymphoma; Oncology; Internal medicine; Immunotherapy; Biology; Chronic lymphocytic leukemia; Cancer; Leukemia","score_opus":0.020328474560353502,"score_gpt":0.28568424620108385,"score_spread":0.2653557716407303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394932930","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018753251,0.99886,0.00012958582,0.0001340168,0.00007266727,0.0000062275553,0.00001353115,0.000007391492,0.0005890009],"genre_scores_gemma":[0.0012490556,0.9979253,0.0002372461,0.00018718449,0.000121192636,0.0000076125593,0.000042122352,0.0000015383182,0.00022881084],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99983835,0.000039899143,0.000028590111,0.000025621779,0.000052589276,0.000014911239],"domain_scores_gemma":[0.9998512,0.00006911421,0.000036202775,0.0000040044724,0.000025344163,0.000014035112],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046822694,0.00065422355,0.0013028833,0.0017694666,0.00018659049,0.000675516,0.00077897473,0.0006336995,0.0020612727],"category_scores_gemma":[0.0006354053,0.00014698847,0.00046903844,0.0008998043,0.00024058667,0.00066354714,0.00050865806,0.0011449286,0.0011853577],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000059738886,0.000041795687,0.00014647529,0.018304627,0.00012753306,0.0003447898,0.00003835713,0.00032991217,0.0009981105,0.000796402,0.010300131,0.9685121],"study_design_scores_gemma":[0.000082753875,0.00034405367,0.0023554813,0.018355235,0.000577287,0.008619743,0.00015986225,0.0002543921,0.0010126834,0.0022344687,0.96596986,0.000034269255],"about_ca_topic_score_codex":0.0005816194,"about_ca_topic_score_gemma":0.0013181348,"teacher_disagreement_score":0.0020612727,"about_ca_system_score_codex":0.00035469444,"about_ca_system_score_gemma":0.0005376816,"threshold_uncertainty_score":0.0068956614},"labels":[],"label_agreement":null},{"id":"W4394993559","doi":"10.1080/10428194.2024.2344052","title":"Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with <i>FLT3-</i> mutant acute myeloid leukemia","year":2024,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Pharmacyclics; Genentech; Swedish Orphan Biovitrum; Daiichi-Sankyo; Syndax Pharmaceuticals; Sierra Oncology; Incyte; National Center for Advancing Translational Sciences; Agios Pharmaceuticals; Astex Pharmaceuticals; PTC Therapeutics; AstraZeneca; Celgene; Leukemia and Lymphoma Society; Astellas Pharma; Instituto Nacional de Cancerología; TG Therapeutics; Pfizer; Amgen","keywords":"Medicine; Myeloid leukemia; Oncology; Chemotherapy; Internal medicine","score_opus":0.017783905045925752,"score_gpt":0.2946410852356914,"score_spread":0.27685718018976563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394993559","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9818871,0.004330407,0.0037181075,0.0013560517,0.00013754328,0.0006114358,0.0016525417,0.00007485619,0.006231936],"genre_scores_gemma":[0.9979121,0.0005944096,0.0007938301,0.00014147026,0.000012543667,0.000073498864,0.00024106957,0.0000034936336,0.0002275572],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.99846387,0.001067568,0.00006350556,0.00009773958,0.00011534123,0.00019194969],"domain_scores_gemma":[0.9971102,0.0020909153,0.0004345112,0.00005717016,0.00007596478,0.00023123441],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002199843,0.00093565905,0.0009929569,0.0005791906,0.00019111944,0.0010953351,0.0008484178,0.0009320182,0.004134965],"category_scores_gemma":[0.008607715,0.0004048568,0.003565159,0.00049582793,0.00042566928,0.0011063383,0.00074599806,0.0012286935,0.00018398603],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.123815306,0.0024584304,0.01725699,0.0018777618,0.0053034,0.00086248585,0.00009975167,0.7249149,0.0037358396,0.0052211364,0.0030188106,0.1114352],"study_design_scores_gemma":[0.02913536,0.07988039,0.05939198,0.0015285612,0.024152944,0.0023206724,0.00047854334,0.7749842,0.0073698116,0.013529135,0.006939241,0.00028915217],"about_ca_topic_score_codex":0.0067724036,"about_ca_topic_score_gemma":0.0060347007,"teacher_disagreement_score":0.0067724036,"about_ca_system_score_codex":0.002994413,"about_ca_system_score_gemma":0.0022282486,"threshold_uncertainty_score":0.021726131},"labels":[],"label_agreement":null},{"id":"W4398783795","doi":"10.1080/10428194.2024.2353877","title":"Outcomes of patients aged ≥26 years with relapsed or refractory B-cell acute lymphoblastic leukemia in ZUMA-3 and historical trials","year":2024,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Precision Nanosystems (Canada)","funders":"","keywords":"Medicine; Blinatumomab; Refractory (planetary science); Internal medicine; Clinical trial; Lymphoblastic Leukemia; Oncology; Leukemia","score_opus":0.024587027961861088,"score_gpt":0.2825747664574556,"score_spread":0.25798773849559453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398783795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99596596,0.0024964414,0.000071760594,0.00007050604,0.000028841976,0.00009417051,0.0004917411,0.000005263445,0.0007752596],"genre_scores_gemma":[0.9961791,0.0010016857,0.00008276212,0.00015335908,0.000048925995,0.00015754317,0.0020867418,0.0000027146511,0.00028716077],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9994148,0.00032593013,0.000044343,0.00007337174,0.000041667125,0.00009992221],"domain_scores_gemma":[0.99921477,0.00015175501,0.00024397379,0.00005464248,0.00003903953,0.0002958224],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020023086,0.0003316591,0.00083554833,0.0002628927,0.00033252282,0.0006253628,0.00029580845,0.0004376034,0.0013143464],"category_scores_gemma":[0.0013116916,0.00013205483,0.0010803667,0.00039793475,0.0002643006,0.00055071607,0.0005395971,0.00069819076,0.00023177567],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.57300943,0.007195164,0.33130988,0.0006619604,0.0029871988,0.00086467667,0.0005590549,0.0026302568,0.0077741314,0.00051039,0.0031381259,0.069359794],"study_design_scores_gemma":[0.061546348,0.20989871,0.7061316,0.00023757166,0.0027665864,0.001784521,0.0005502103,0.0014901276,0.0030301437,0.000560249,0.011936731,0.00006734921],"about_ca_topic_score_codex":0.00052948575,"about_ca_topic_score_gemma":0.0011429214,"teacher_disagreement_score":0.0020023086,"about_ca_system_score_codex":0.00056846836,"about_ca_system_score_gemma":0.0005137662,"threshold_uncertainty_score":0.010589361},"labels":[],"label_agreement":null},{"id":"W4399367500","doi":"10.1080/10428194.2024.2346733","title":"Safety and efficacy of fedratinib in patients with myelofibrosis previously treated with ruxolitinib: primary analysis of FREEDOM trial","year":2024,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Princess Margaret Cancer Centre","funders":"Agence Nationale de la Recherche","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Clinical endpoint; Adverse effect; Internal medicine; Confidence interval; Randomized controlled trial; Population; Anemia; Phases of clinical research; Clinical trial; Gastroenterology; Bone marrow","score_opus":0.006397220163147106,"score_gpt":0.22620042659871015,"score_spread":0.21980320643556303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399367500","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98689204,0.005069887,0.00046130837,0.0005714288,0.00010519444,0.00097205996,0.0025219715,0.000064171254,0.003341968],"genre_scores_gemma":[0.99440753,0.0007573036,0.0005449732,0.00030933908,0.000121229656,0.00040875014,0.0026967723,0.000006503511,0.00074753835],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9995946,0.00020592193,0.000030659914,0.00006218941,0.000037228852,0.00006942912],"domain_scores_gemma":[0.99931395,0.0001516588,0.00017690343,0.00006549149,0.000053040974,0.0002389806],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018198392,0.0004396214,0.0010690332,0.00018888748,0.00026870947,0.00064718083,0.0002609939,0.00051458174,0.0023955205],"category_scores_gemma":[0.001300973,0.00014755568,0.0011574494,0.00021974857,0.00031067152,0.000413402,0.00025265123,0.0012067219,0.00035820095],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8447836,0.0064019933,0.027970023,0.00061150844,0.0016137989,0.00020716382,0.00012566618,0.00141682,0.008701323,0.00035817368,0.004524444,0.10328552],"study_design_scores_gemma":[0.5342641,0.28993332,0.14862043,0.00025292116,0.0025095914,0.0010647358,0.00010333427,0.0040742303,0.005948133,0.0008955326,0.012251666,0.00008191192],"about_ca_topic_score_codex":0.00047224385,"about_ca_topic_score_gemma":0.0016035044,"teacher_disagreement_score":0.0023955205,"about_ca_system_score_codex":0.00045295228,"about_ca_system_score_gemma":0.0007660865,"threshold_uncertainty_score":0.009624302},"labels":[],"label_agreement":null},{"id":"W4399727620","doi":"10.1080/10428194.2024.2363418","title":"Experience of using venetoclax in relapsed T- cell lymphoma","year":2024,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"AbbVie Canada","keywords":"Venetoclax; Lymphoma; Medicine; Psychology; Oncology; Internal medicine; Leukemia; Chronic lymphocytic leukemia","score_opus":0.023643846805762852,"score_gpt":0.28762061089524205,"score_spread":0.2639767640894792,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399727620","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6607911,0.11050356,0.0064658355,0.120001115,0.00744726,0.0003198427,0.0006271805,0.00028889178,0.093555324],"genre_scores_gemma":[0.89135593,0.044005807,0.0031358537,0.03825717,0.006588322,0.00009367199,0.00053007493,0.000108386106,0.015924802],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9992162,0.0003944468,0.00006187409,0.0000780935,0.0001214769,0.0001279668],"domain_scores_gemma":[0.9986953,0.00066155137,0.00009877822,0.00006797505,0.00008012513,0.00039619431],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010996101,0.00050120533,0.00036834445,0.00035147916,0.0012383125,0.0008975741,0.00060675887,0.002909351,0.002594691],"category_scores_gemma":[0.0036416415,0.0001931929,0.0005615363,0.00067426375,0.00064472045,0.0007677279,0.0005262187,0.003002698,0.0011443583],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034536766,0.00317454,0.056404117,0.00078136806,0.00022249756,0.44486365,0.005503825,0.0014123806,0.008577691,0.005730926,0.08452548,0.38534984],"study_design_scores_gemma":[0.0006504376,0.008439533,0.04403375,0.00072118815,0.00021621415,0.6554085,0.0016184464,0.0016703536,0.0033118739,0.0044064443,0.27940646,0.00011681433],"about_ca_topic_score_codex":0.0012461885,"about_ca_topic_score_gemma":0.002550534,"teacher_disagreement_score":0.002909351,"about_ca_system_score_codex":0.0010497116,"about_ca_system_score_gemma":0.0006221045,"threshold_uncertainty_score":0.008680046},"labels":[],"label_agreement":null},{"id":"W4400195209","doi":"10.1080/10428194.2024.2371474","title":"Cytomegalovirus infection risk with alemtuzumab therapy in hematological malignancies: a retrospective cohort study in the non-transplant setting","year":2024,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Cytomegalovirus and herpesvirus research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Alemtuzumab; Medicine; Retrospective cohort study; Cytomegalovirus infection; Cohort; Internal medicine; Cytomegalovirus; Immunology; Cohort study; Oncology; Human cytomegalovirus; Transplantation; Viral disease; Human immunodeficiency virus (HIV); Herpesviridae; Virus","score_opus":0.012586165988133363,"score_gpt":0.2762413753881765,"score_spread":0.26365520940004317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400195209","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9993012,0.00020397056,0.000068859015,0.000027788064,0.000005065836,0.0000075055436,0.0001692513,0.000002232805,0.00021412718],"genre_scores_gemma":[0.99968827,0.000072143055,0.000031497344,0.000017664299,0.0000062803633,0.000004763985,0.00011238016,0.0000018424358,0.00006524068],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993268,0.00014628701,0.00008759363,0.00021334444,0.000105009756,0.00012108793],"domain_scores_gemma":[0.998662,0.00019649643,0.0005848034,0.00020560742,0.00009944439,0.00025170605],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076948653,0.00021828579,0.00030511554,0.00058125064,0.00042591422,0.00092289696,0.00036112344,0.0004085635,0.0013317303],"category_scores_gemma":[0.0019118221,0.00033044777,0.00056968955,0.0008527044,0.0002556808,0.0005725097,0.00046091335,0.0007152802,0.00022314089],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006715427,0.00001960287,0.99923146,0.0000034528734,0.000037118352,0.000080599195,0.000044226254,0.000014578194,0.00012725948,0.000010435271,0.00004039177,0.0003237778],"study_design_scores_gemma":[0.0000061794044,0.00013886175,0.998497,0.00000556621,0.000040779636,0.00065821933,0.00020730968,0.00013337441,0.000079774916,0.000014661052,0.0002139359,0.000004294913],"about_ca_topic_score_codex":0.0038051775,"about_ca_topic_score_gemma":0.0042465706,"teacher_disagreement_score":0.0038051775,"about_ca_system_score_codex":0.0002821072,"about_ca_system_score_gemma":0.0003923446,"threshold_uncertainty_score":0.0075660944},"labels":[],"label_agreement":null},{"id":"W4400358109","doi":"10.1080/10428194.2024.2373323","title":"Importance of long-term follow-up of autologous stem cell transplantation for mantle cell lymphoma","year":2024,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Calgary","funders":"","keywords":"Mantle cell lymphoma; Transplantation; Stem cell; Autologous stem-cell transplantation; Term (time); Lymphoma; Medicine; Oncology; Internal medicine; Biology; Cell biology; Astronomy; Physics","score_opus":0.01213021060018144,"score_gpt":0.24807137991661388,"score_spread":0.23594116931643244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400358109","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92620456,0.05059448,0.004211761,0.006703682,0.0008040042,0.000085703454,0.0012167826,0.00009865207,0.010080289],"genre_scores_gemma":[0.99463814,0.0022528134,0.0007126562,0.0009004193,0.00036056826,0.000036029855,0.00055799645,0.000006622517,0.0005347379],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99935514,0.00026348233,0.00011523509,0.00005918837,0.00012452554,0.00008254737],"domain_scores_gemma":[0.9950871,0.0021499884,0.0007755105,0.00048660013,0.00090828456,0.00059249264],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039399425,0.00013880504,0.0004523788,0.00042499704,0.00048548752,0.0006463342,0.0003023089,0.0006071086,0.0009814841],"category_scores_gemma":[0.0061652893,0.00005419125,0.00035456647,0.00045013963,0.00021839465,0.0008396147,0.00022278777,0.00096001115,0.00028197168],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006093207,0.00030561248,0.6541211,0.00023517877,0.00024679088,0.0011813014,0.0001660943,0.0008408075,0.0051473915,0.0005124251,0.0032448638,0.32790524],"study_design_scores_gemma":[0.00018066484,0.003292394,0.96502745,0.00054831593,0.00077555026,0.0037754844,0.00040995554,0.0028568294,0.0032313114,0.001613577,0.018233934,0.00005449306],"about_ca_topic_score_codex":0.0018602668,"about_ca_topic_score_gemma":0.0031596904,"teacher_disagreement_score":0.0039399425,"about_ca_system_score_codex":0.0004141568,"about_ca_system_score_gemma":0.00063102477,"threshold_uncertainty_score":0.020836651},"labels":[],"label_agreement":null},{"id":"W4400513282","doi":"10.1080/10428194.2024.2370437","title":"Development and testing of a lymphoma clinical trial-specific frailty index: a secondary analysis of the NCIC-CTG LY.12 clinical trial","year":2024,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Frailty in Older Adults","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Juravinski Hospital; Queen's University; Canadian Cancer Society; Kingston Health Sciences Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical trial; Index (typography); Internal medicine; Oncology; Gerontology; World Wide Web; Computer science","score_opus":0.08956660989390927,"score_gpt":0.3489894354522371,"score_spread":0.25942282555832785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400513282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92805165,0.0023780942,0.027635988,0.00093800924,0.00032563275,0.019642178,0.012869958,0.00024971843,0.007908764],"genre_scores_gemma":[0.95742416,0.00018617851,0.012332312,0.00057180075,0.00014924053,0.019676462,0.008564281,0.00006638665,0.0010291393],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9620229,0.028416174,0.0034399536,0.0023222035,0.0026725964,0.0011261245],"domain_scores_gemma":[0.9340993,0.030764364,0.014795489,0.009763692,0.007989255,0.002587834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.06793113,0.0012380766,0.0018929744,0.0016269579,0.0006980035,0.0017042429,0.0009971214,0.00084722706,0.003273712],"category_scores_gemma":[0.08755776,0.00035504543,0.0036736275,0.001690117,0.0006505551,0.0014145828,0.0016355609,0.0016743068,0.0005958078],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18187663,0.002929194,0.6803482,0.0035834413,0.024289222,0.00022083361,0.0007928281,0.006721538,0.004710922,0.0040899306,0.009735593,0.080701664],"study_design_scores_gemma":[0.0400787,0.0574506,0.8398423,0.0004974294,0.012176798,0.00045243072,0.00025674378,0.021063859,0.004460621,0.0038312217,0.019704392,0.00018493195],"about_ca_topic_score_codex":0.00095525215,"about_ca_topic_score_gemma":0.0015717093,"teacher_disagreement_score":0.06793113,"about_ca_system_score_codex":0.0010101021,"about_ca_system_score_gemma":0.002096613,"threshold_uncertainty_score":0.35925847},"labels":[],"label_agreement":null},{"id":"W4400690992","doi":"10.1080/10428194.2024.2371472","title":"Real-world outcomes with novel therapies in relapsed/refractory diffuse large B-cell lymphoma","year":2024,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Genmab; AbbVie Canada","keywords":"Refractory (planetary science); Diffuse large B-cell lymphoma; Lymphoma; Medicine; Oncology; Internal medicine; Cancer research; Materials science","score_opus":0.015303812571067062,"score_gpt":0.27597024301362166,"score_spread":0.2606664304425546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400690992","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971969,0.00074617635,0.0001303023,0.000065099885,0.000004625556,0.000022110646,0.0012676875,0.0000051305324,0.0005619231],"genre_scores_gemma":[0.9979206,0.00020033224,0.00010924031,0.0000520164,0.000011559811,0.000017498578,0.0016190356,0.0000020284008,0.000067800844],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988348,0.0005805479,0.00013615159,0.00015993573,0.00016227798,0.00012633318],"domain_scores_gemma":[0.9966492,0.00064148963,0.0021014498,0.00015520748,0.00019289908,0.00025961048],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014238314,0.00017291745,0.00034091732,0.0007492454,0.00021742644,0.00093537645,0.0002685023,0.00028242936,0.0006010512],"category_scores_gemma":[0.0032015808,0.00009967317,0.0004262607,0.0009622987,0.0003082546,0.00061232055,0.00053450203,0.00034810742,0.00015153125],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024530136,0.0002857733,0.9809006,0.000079951176,0.00034193127,0.00015699802,0.00013440092,0.0012088466,0.00051505043,0.00008923758,0.0005169127,0.013317256],"study_design_scores_gemma":[0.00025799448,0.0018995719,0.99205047,0.00003778189,0.00023029988,0.00071715825,0.00038848948,0.00162659,0.00057894783,0.000109075794,0.0020818773,0.000021760263],"about_ca_topic_score_codex":0.0033084233,"about_ca_topic_score_gemma":0.0073777167,"teacher_disagreement_score":0.0033084233,"about_ca_system_score_codex":0.0011885053,"about_ca_system_score_gemma":0.00053267466,"threshold_uncertainty_score":0.008623242},"labels":[],"label_agreement":null},{"id":"W4401523698","doi":"10.1080/10428194.2024.2390574","title":"Outcomes of adults with refractory or relapsed acute myeloid leukemia treated with azacitidine and venetoclax compared to other therapies: a multicenter retrospective study","year":2024,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; Université Laval; Université de Montréal; Hôpital Maisonneuve-Rosemont; Centre hospitalier universitaire de Québec","funders":"","keywords":"Medicine; Venetoclax; Ven; Azacitidine; Internal medicine; Myeloid leukemia; Salvage therapy; Neutropenia; Febrile neutropenia; Refractory (planetary science); Acute leukemia; Septic shock; Oncology; Leukemia; Gastroenterology; Sepsis; Chemotherapy","score_opus":0.012312535876723572,"score_gpt":0.27438114018462784,"score_spread":0.26206860430790424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401523698","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.999275,0.00036063633,0.000034211716,0.000014750525,0.0000031534853,0.0000058413248,0.00012022008,0.0000012557917,0.0001849498],"genre_scores_gemma":[0.99949956,0.00013682529,0.00003694612,0.000021880795,0.000015737405,0.000008171781,0.00023853402,0.000001014547,0.00004137852],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99958926,0.00010395886,0.0000697328,0.00010836993,0.00006424779,0.00006442603],"domain_scores_gemma":[0.9989191,0.00014466011,0.0006281604,0.000055735178,0.00007500303,0.00017731127],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043048838,0.00016357431,0.00048344198,0.00046585983,0.00024690825,0.00044734828,0.00013534322,0.00031624569,0.0006092486],"category_scores_gemma":[0.0013632735,0.000115272414,0.00037019563,0.0006737646,0.00018963659,0.00033755213,0.0002514578,0.00025794076,0.00014036443],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003733568,0.00004388531,0.99706405,0.000012747759,0.00006501093,0.00021435111,0.00006189428,0.000035937075,0.00022064384,0.000012555617,0.00005056875,0.0018451156],"study_design_scores_gemma":[0.00004850394,0.001138261,0.9954111,0.000012910544,0.00010794475,0.002177404,0.00025897933,0.00013454696,0.00014527036,0.000022153332,0.00053680287,0.0000061788164],"about_ca_topic_score_codex":0.00079331663,"about_ca_topic_score_gemma":0.00071887433,"teacher_disagreement_score":0.00079331663,"about_ca_system_score_codex":0.00020588408,"about_ca_system_score_gemma":0.00019394889,"threshold_uncertainty_score":0.0022767186},"labels":[],"label_agreement":null},{"id":"W4402927660","doi":"10.1080/10428194.2024.2403668","title":"Intensity of survivin expression linked to features of aggressive relapsed/refractory diffuse large B-cell lymphoma","year":2024,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Sunnybrook Hospital; Health Sciences Centre; Sunnybrook Health Science Centre; Queen Elizabeth II Health Sciences Centre; University Health Network; University of Toronto","funders":"Merck Canada","keywords":"Diffuse large B-cell lymphoma; Survivin; Refractory (planetary science); Lymphoma; Cancer research; Medicine; Intensity (physics); Aggressive lymphoma; Oncology; Internal medicine; Rituximab; Biology; Cancer; Physics; Optics","score_opus":0.00902916657617432,"score_gpt":0.24642681576975697,"score_spread":0.23739764919358267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402927660","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9995832,0.0001145573,0.00005884573,0.000008529562,0.0000010844938,0.000018873556,0.000060697486,0.0000042054603,0.00015007493],"genre_scores_gemma":[0.9996859,0.000024407589,0.00006566661,0.00000896943,0.0000030794126,0.00001292887,0.00010142167,8.8249965e-7,0.00009674107],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99970335,0.00016580759,0.00001773049,0.000044092212,0.000035491987,0.000033453623],"domain_scores_gemma":[0.99950314,0.00010961659,0.00021454232,0.000030355355,0.000039424274,0.0001029027],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010339002,0.00035197005,0.0002912226,0.00036157973,0.0001610071,0.00037490905,0.00020305529,0.0002520204,0.0009696771],"category_scores_gemma":[0.00084593595,0.00020601762,0.0002043537,0.00022808093,0.00023592045,0.00015571012,0.00020471879,0.00028739445,0.0001656749],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022136452,0.0010211145,0.942118,0.000075706055,0.0003060927,0.00021171386,0.00010291949,0.0003938319,0.019213019,0.000034476114,0.00015707647,0.014229578],"study_design_scores_gemma":[0.0009573963,0.014823079,0.98017484,0.000008601635,0.00018529396,0.0005985403,0.000080270205,0.0005977177,0.0022263383,0.0000530702,0.00028758345,0.000007295604],"about_ca_topic_score_codex":0.00030228787,"about_ca_topic_score_gemma":0.00057926076,"teacher_disagreement_score":0.0010339002,"about_ca_system_score_codex":0.00019588358,"about_ca_system_score_gemma":0.00016228811,"threshold_uncertainty_score":0.0054678917},"labels":[],"label_agreement":null},{"id":"W4403036158","doi":"10.1080/10428194.2024.2402814","title":"Real-world outcomes following ibrutinib dose reduction in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma","year":2024,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; AbbVie Canada; Pharmacyclics; GlaxoSmithKline; Pfizer","keywords":"Ibrutinib; Chronic lymphocytic leukemia; Medicine; Lymphoma; Internal medicine; Oncology; Leukemia","score_opus":0.013125910070183586,"score_gpt":0.2702881273349522,"score_spread":0.2571622172647686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403036158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946392,0.00053880864,0.00027978516,0.0001241421,0.000005377531,0.000032413198,0.003886819,0.000009533215,0.000483955],"genre_scores_gemma":[0.99462706,0.00015700878,0.0002826573,0.000075176315,0.000011469148,0.000027974374,0.00476393,0.000002403019,0.000052317966],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99785703,0.0010427419,0.0003707078,0.0003159048,0.0002871325,0.00012648458],"domain_scores_gemma":[0.98913175,0.002813315,0.0066797337,0.0005135608,0.00054678693,0.00031494306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022311192,0.0001976705,0.0004287,0.0010237806,0.00017924217,0.0012191967,0.0003291213,0.00036566268,0.00061011617],"category_scores_gemma":[0.009226916,0.0001493524,0.00059179944,0.0018167702,0.00019700162,0.00073240564,0.00047099136,0.00043929508,0.000113981434],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001165432,0.00013126995,0.9900956,0.00005740855,0.00043179345,0.000064267435,0.0000560751,0.0015452739,0.00013222836,0.00006134821,0.00045358823,0.0058056964],"study_design_scores_gemma":[0.0002546454,0.00074050017,0.98740953,0.000045175428,0.00030885293,0.00057203334,0.00029913074,0.008174693,0.00035426306,0.00014681717,0.0016689737,0.000025385556],"about_ca_topic_score_codex":0.005907251,"about_ca_topic_score_gemma":0.008241946,"teacher_disagreement_score":0.005907251,"about_ca_system_score_codex":0.0009822886,"about_ca_system_score_gemma":0.0004368263,"threshold_uncertainty_score":0.011799455},"labels":[],"label_agreement":null},{"id":"W4403103653","doi":"10.1080/10428194.2024.2408646","title":"Optimizing multiple Myeloma clinical trials: research direction, addressing limitations, and strategies for improvement","year":2024,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Multiple myeloma; Clinical trial; Medicine; Medical physics; Intensive care medicine; Computer science; Internal medicine","score_opus":0.41103464638971776,"score_gpt":0.51015466070124,"score_spread":0.09912001431152229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403103653","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004467265,0.85239965,0.011309045,0.12777466,0.0042080334,0.0016652088,0.0003126677,0.00014902791,0.0017350196],"genre_scores_gemma":[0.0145259425,0.79958814,0.110308826,0.060301542,0.0071267686,0.006790068,0.0004967116,0.00016927261,0.00069271633],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.61666125,0.30454734,0.052502126,0.007606054,0.01592603,0.0027572692],"domain_scores_gemma":[0.17974803,0.72185344,0.033965886,0.015297014,0.044405315,0.0047303606],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.474356,0.0034621877,0.015269536,0.006433657,0.0020564583,0.02006929,0.006998554,0.01083643,0.01105559],"category_scores_gemma":[0.5834297,0.0028030467,0.010519002,0.009777553,0.00743489,0.027198361,0.008026693,0.015149732,0.003208912],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013786819,0.00022752515,0.0019255185,0.31035048,0.005277685,0.00016791442,0.0017623658,0.0022472306,0.00054877537,0.052594356,0.049350612,0.57416886],"study_design_scores_gemma":[0.0021596274,0.00083882274,0.0024178955,0.5978303,0.009493144,0.00032655086,0.0022747214,0.002858468,0.00045872896,0.11764865,0.26346803,0.0002251476],"about_ca_topic_score_codex":0.0056539704,"about_ca_topic_score_gemma":0.010410726,"teacher_disagreement_score":0.525644,"about_ca_system_score_codex":0.011318385,"about_ca_system_score_gemma":0.07724317,"threshold_uncertainty_score":0.6482127},"labels":[],"label_agreement":null},{"id":"W4403738904","doi":"10.1080/10428194.2024.2416577","title":"Matching-adjusted indirect comparisons of zanubrutinib (MAGNOLIA, BGB-3111-AU-003) versus ibrutinib (PCYC-1121) and rituximab (CHRONOS-3) in relapsed/refractory marginal zone lymphoma","year":2024,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Precision Nanosystems (Canada)","funders":"BeiGene","keywords":"Ibrutinib; Rituximab; Refractory (planetary science); Medicine; Lymphoma; Internal medicine; Leukemia; Biology","score_opus":0.02549745069079592,"score_gpt":0.28914271282788556,"score_spread":0.26364526213708966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403738904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9739897,0.005569489,0.013186539,0.0002719083,0.0003358654,0.0025341609,0.0013911665,0.000108123626,0.0026130672],"genre_scores_gemma":[0.9921984,0.00043339876,0.004764212,0.00014984103,0.000038651553,0.0012104666,0.00038759707,0.000013910643,0.00080349244],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.983146,0.014557507,0.00060569134,0.00072204665,0.00052017544,0.00044857574],"domain_scores_gemma":[0.9921578,0.0052330825,0.0014544236,0.0008121548,0.00014863657,0.00019387451],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01717423,0.0013361163,0.001816293,0.0006905962,0.00017421045,0.0007298378,0.0011079984,0.0009490539,0.0040211566],"category_scores_gemma":[0.022140734,0.00043093858,0.006411295,0.0005720747,0.0007558355,0.0008179858,0.0010115693,0.0016137379,0.00023966265],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7820392,0.002461943,0.02082312,0.003532286,0.079321876,0.00015135405,0.0002913027,0.027626446,0.002934507,0.0054411385,0.0012030646,0.074173786],"study_design_scores_gemma":[0.35768557,0.24600255,0.104127266,0.0009715453,0.14148337,0.0005197744,0.00041446782,0.09546678,0.013353472,0.028049499,0.0116287805,0.00029691754],"about_ca_topic_score_codex":0.0010441273,"about_ca_topic_score_gemma":0.0012825204,"teacher_disagreement_score":0.01717423,"about_ca_system_score_codex":0.0009384692,"about_ca_system_score_gemma":0.0008424886,"threshold_uncertainty_score":0.09082711},"labels":[],"label_agreement":null},{"id":"W4403844943","doi":"10.1080/10428194.2024.2419375","title":"Frailty measures in multiple myeloma: evaluating the impact on outcomes and quality-of-life in clinical trials and real-world practice","year":2024,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Frailty in Older Adults","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; Hamilton Health Sciences Foundation; National Institute on Aging; Instituto Nacional de Cancerología; American Society of Hematology","keywords":"Multiple myeloma; Quality of life (healthcare); Clinical Practice; Clinical trial; Medicine; Quality (philosophy); Intensive care medicine; Internal medicine; Family medicine; Nursing","score_opus":0.3352841792584343,"score_gpt":0.5287818209399442,"score_spread":0.1934976416815099,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403844943","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018778225,0.99913675,0.000082382365,0.00020071935,0.00007825741,0.00006850442,0.00006648541,0.0000035709854,0.0001755842],"genre_scores_gemma":[0.003987698,0.9944857,0.0006138383,0.00040100093,0.00011681406,0.0002356603,0.00008900697,0.0000033970214,0.0000669127],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9898323,0.0054059518,0.0024728628,0.0004814765,0.0016266424,0.00018083457],"domain_scores_gemma":[0.949456,0.041802168,0.0049634054,0.0004772682,0.002894401,0.0004066969],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.019611986,0.0012009752,0.007002605,0.0040902756,0.00033432004,0.0025029976,0.0014320797,0.0017980823,0.0032536464],"category_scores_gemma":[0.053643294,0.00048496996,0.0055710077,0.0044044475,0.0006475016,0.0015549798,0.0013306533,0.0017835228,0.00035719122],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008738199,0.000099272824,0.0010712972,0.41830775,0.010756625,0.0000513707,0.00014563049,0.0004876522,0.00023094128,0.0012765923,0.0053981114,0.56130093],"study_design_scores_gemma":[0.0013802964,0.0019788,0.010869445,0.7524215,0.060812484,0.00050325104,0.00031449037,0.0006718107,0.0005154573,0.003364624,0.16703796,0.00012999063],"about_ca_topic_score_codex":0.0026633192,"about_ca_topic_score_gemma":0.005117809,"teacher_disagreement_score":0.019611986,"about_ca_system_score_codex":0.0022932931,"about_ca_system_score_gemma":0.0058199074,"threshold_uncertainty_score":0.10371935},"labels":[],"label_agreement":null},{"id":"W4404203615","doi":"10.1080/10428194.2024.2422844","title":"Improvement in quality of life in MDS patients who become transfusion independent after treatment","year":2024,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Neurological Complications and Syndromes","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Royal Victoria Hospital; Royal Victoria Regional Health Centre; Vancouver General Hospital; Princess Margaret Cancer Centre; Dr. Georges-L.-Dumont University Hospital Centre; St. Paul's Hospital; McGill University Health Centre; University of Ottawa; Queen Elizabeth II Health Sciences Centre; CancerCare Manitoba; University Health Network; University of Alberta Hospital; Health Sciences Centre; Alberta Hospital Edmonton; University of British Columbia; Juravinski Cancer Centre; Jewish General Hospital; Sunnybrook Health Science Centre","funders":"Canadian Institutes of Health Research","keywords":"Quality of life (healthcare); Intensive care medicine; Medicine; Quality (philosophy); Blood transfusion; Internal medicine; Nursing; Philosophy","score_opus":0.01785048394298953,"score_gpt":0.2723172665011397,"score_spread":0.25446678255815014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404203615","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9994079,0.0001938515,0.00002162418,0.00002627556,0.000002954935,0.000005757351,0.00010099422,0.0000014493766,0.00023920737],"genre_scores_gemma":[0.9996737,0.000053130298,0.000026729482,0.000017631257,0.000004133226,0.000005252586,0.00015467986,3.705147e-7,0.000064392036],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997507,0.00008519183,0.000031924217,0.000028509738,0.000044213422,0.00005950741],"domain_scores_gemma":[0.99932003,0.00011138282,0.00031584463,0.00002507164,0.00005303057,0.00017475181],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004077297,0.00012864413,0.00032942207,0.0005102589,0.00030477424,0.000438938,0.0001270732,0.00020270149,0.00071550236],"category_scores_gemma":[0.0017414975,0.00008679553,0.00032127264,0.00065281434,0.00018303888,0.00029961776,0.0002650066,0.00034397782,0.00008755901],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005633216,0.000086804896,0.99445,0.000011357151,0.000053389664,0.000117430216,0.000109579305,0.00009074295,0.00027868312,0.000013266754,0.00011578617,0.0041096783],"study_design_scores_gemma":[0.000030931078,0.0006725975,0.9983438,0.000006497867,0.000031798645,0.00031430984,0.00012170001,0.00016556047,0.000084379004,0.00002245651,0.00020154809,0.000004335453],"about_ca_topic_score_codex":0.0017925706,"about_ca_topic_score_gemma":0.0024400337,"teacher_disagreement_score":0.0017925706,"about_ca_system_score_codex":0.00034439552,"about_ca_system_score_gemma":0.00018574572,"threshold_uncertainty_score":0.0035642385},"labels":[],"label_agreement":null},{"id":"W4404419054","doi":"10.1080/10428194.2024.2424373","title":"Deranged cytokine levels are linked to cancer-related cognitive impairment in lymphoma patients receiving R-CHOP chemotherapy","year":2024,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"CHOP; Medicine; Chemotherapy; Oncology; Lymphoma; Internal medicine; Cognitive impairment; Cytokine; Cancer; Cognition; Disease; Psychiatry","score_opus":0.013883912336277275,"score_gpt":0.27780065090409356,"score_spread":0.2639167385678163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404419054","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9992698,0.00047450888,0.000025626754,0.0000180621,0.0000026012856,0.0000052095747,0.000041160438,0.0000016515031,0.00016134954],"genre_scores_gemma":[0.9996884,0.00011787128,0.000028576256,0.000017678709,0.0000053330095,0.00000400048,0.000053578082,3.9586516e-7,0.0000842813],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998592,0.00003142912,0.000022358603,0.000022655622,0.00003226607,0.000032017568],"domain_scores_gemma":[0.9994611,0.00006777166,0.00031978145,0.000020605263,0.000060389502,0.00007038299],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019393743,0.00016573351,0.00029892958,0.00032742257,0.00020038475,0.0003273077,0.000114560804,0.000194828,0.00052799855],"category_scores_gemma":[0.0008582764,0.000104292165,0.00021969306,0.00038789024,0.000109988636,0.00014620581,0.00014976026,0.00038730956,0.00008528565],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00105384,0.00015458265,0.9901957,0.000027595248,0.000062857514,0.00030107566,0.000118151,0.00007279773,0.0017937787,0.000008755807,0.00008073343,0.006130108],"study_design_scores_gemma":[0.000011414321,0.00041653385,0.9986356,0.0000062024687,0.000037183912,0.00035277146,0.000076973636,0.00010155376,0.00021038254,0.000012427358,0.00013649455,0.0000024594497],"about_ca_topic_score_codex":0.0011697682,"about_ca_topic_score_gemma":0.0019211521,"teacher_disagreement_score":0.0011697682,"about_ca_system_score_codex":0.0001883966,"about_ca_system_score_gemma":0.00013123987,"threshold_uncertainty_score":0.0023258924},"labels":[],"label_agreement":null},{"id":"W4404538329","doi":"10.1080/10428194.2024.2430703","title":"Severe toxicity, but long-term persistence of CAR T cells after immune checkpoint inhibitors in large B-cell lymphoma","year":2024,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"National Cancer Institute; National Institutes of Health","keywords":"Persistence (discontinuity); Lymphoma; Toxicity; Term (time); Immune system; Immune checkpoint; Cancer research; Biology; Immunology; Medicine; Immunotherapy; Internal medicine","score_opus":0.011446509951488564,"score_gpt":0.2485690102953221,"score_spread":0.23712250034383353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404538329","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.021153968,0.1241212,0.002197259,0.53372663,0.30929196,0.00005524093,0.00045440256,0.0002115486,0.008787888],"genre_scores_gemma":[0.106756024,0.06094677,0.001053787,0.24525706,0.56544846,0.00005599543,0.00030583912,0.00012876707,0.020047283],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9994165,0.00014040768,0.00011451154,0.00009064225,0.00016351558,0.00007450292],"domain_scores_gemma":[0.9960459,0.0025792145,0.00032911648,0.00012240311,0.0006585099,0.00026483188],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001740451,0.0005225373,0.0010454785,0.0003807039,0.00056998094,0.001385928,0.0010051788,0.0034118807,0.0019449467],"category_scores_gemma":[0.006816022,0.00026482574,0.00048792918,0.00035687452,0.0008094531,0.0010730942,0.00021649037,0.005425451,0.0015867074],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020190545,0.00013454228,0.0032538685,0.0010647124,0.0002168014,0.013550651,0.00010134054,0.00030500305,0.0031049934,0.0027626827,0.82643,0.14705625],"study_design_scores_gemma":[0.00048386658,0.0009973194,0.010171974,0.00062378077,0.0005564179,0.04122595,0.00016768661,0.0012330388,0.0046525453,0.0036256753,0.93617654,0.00008515727],"about_ca_topic_score_codex":0.0004748975,"about_ca_topic_score_gemma":0.0011678131,"teacher_disagreement_score":0.0034118807,"about_ca_system_score_codex":0.00085684966,"about_ca_system_score_gemma":0.00045675263,"threshold_uncertainty_score":0.009204507},"labels":[],"label_agreement":null},{"id":"W4405757822","doi":"10.1080/10428194.2024.2438807","title":"Navigating AML treatment in vascular Ehlers–Danlos syndrome: achieving deeper remission with oral azacitidine—a first case report","year":2024,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Ehlers–Danlos syndrome; Medicine; Azacitidine; Dermatology; Surgery; Genetics; Biology","score_opus":0.015110241712121391,"score_gpt":0.2871527101170982,"score_spread":0.2720424684049768,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405757822","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9481924,0.00973641,0.005066122,0.010519852,0.0004206741,0.0002098845,0.00031880892,0.00023656039,0.025299286],"genre_scores_gemma":[0.98782814,0.0028992305,0.0022377083,0.0023989163,0.00050099153,0.00002538041,0.00017298305,0.000040507297,0.0038961954],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99979275,0.000032933895,0.000024868394,0.000051549694,0.000034731824,0.00006319242],"domain_scores_gemma":[0.9996879,0.000081035345,0.00007166788,0.00002397288,0.00001558901,0.00011987057],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013931807,0.0006372274,0.00037672906,0.0006041198,0.001050672,0.00074019056,0.0005617991,0.0023657896,0.0021339282],"category_scores_gemma":[0.0009281252,0.00024420858,0.0004677229,0.00047156235,0.0006016194,0.000949091,0.000608723,0.0018387572,0.00072699],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006916312,0.0000762462,0.009617801,0.000043860906,0.000014376247,0.9761121,0.00018892113,0.000111863126,0.0014804214,0.00058316696,0.0013262258,0.010375874],"study_design_scores_gemma":[0.000010101388,0.00005547637,0.002663483,0.000016135646,0.000011490219,0.99441904,0.000089801935,0.00020801905,0.00043035735,0.00029783856,0.0017897551,0.000008597548],"about_ca_topic_score_codex":0.0014110921,"about_ca_topic_score_gemma":0.0026259767,"teacher_disagreement_score":0.0023657896,"about_ca_system_score_codex":0.0007029501,"about_ca_system_score_gemma":0.0005119252,"threshold_uncertainty_score":0.007138729},"labels":[],"label_agreement":null},{"id":"W4406669602","doi":"10.1080/10428194.2025.2455485","title":"Are we maintaining minimal residual disease in myeloma?","year":2025,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Minimal residual disease; Multiple myeloma; Medicine; Oncology; Clinical trial; Disease; Intensive care medicine; Residual; Clinical endpoint; Maintenance therapy; Internal medicine; Chemotherapy; Bone marrow; Computer science","score_opus":0.04017158920676689,"score_gpt":0.3358778949116927,"score_spread":0.2957063057049258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406669602","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000048534344,0.99860114,0.000047440397,0.00095590303,0.00013978936,0.0000014325184,0.000007168244,0.0000022642257,0.00019627636],"genre_scores_gemma":[0.00063615886,0.9983115,0.0000954181,0.0006210911,0.00019043741,0.0000036111278,0.000010670723,9.28827e-7,0.00013015083],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995339,0.00015982588,0.000078431476,0.00006035193,0.00012919863,0.000038421476],"domain_scores_gemma":[0.99917054,0.0005092169,0.00011401593,0.000023381916,0.00014396288,0.00003886944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016629408,0.0004923088,0.0016880688,0.0011878953,0.00028824044,0.0015877851,0.0010431051,0.001628231,0.0020404758],"category_scores_gemma":[0.0024824243,0.0002468873,0.0006925803,0.0013006211,0.0009192295,0.0030794044,0.00067503145,0.0027244864,0.0011107277],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011413991,0.00003433808,0.00024602245,0.026956426,0.00022657128,0.0001482194,0.00015419658,0.00021924928,0.0005983373,0.0069930945,0.026729722,0.9375796],"study_design_scores_gemma":[0.000044383894,0.00015015664,0.0010716174,0.019124256,0.00030676476,0.0013146532,0.00025158978,0.00008498727,0.0002765161,0.009249237,0.968093,0.000032766322],"about_ca_topic_score_codex":0.0014558114,"about_ca_topic_score_gemma":0.0024685182,"teacher_disagreement_score":0.0020404758,"about_ca_system_score_codex":0.0007312413,"about_ca_system_score_gemma":0.0015727145,"threshold_uncertainty_score":0.008794546},"labels":[],"label_agreement":null},{"id":"W4407408419","doi":"10.1080/10428194.2025.2461663","title":"Clozapine is associated with an increased risk of Hodgkin and non-Hodgkin lymphoma","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Hodgkin lymphoma; Clozapine; Lymphoma; Medicine; Oncology; Internal medicine; Psychiatry; Schizophrenia (object-oriented programming)","score_opus":0.00764993146340629,"score_gpt":0.25286658271748363,"score_spread":0.24521665125407735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407408419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99602664,0.0014100171,0.0002052826,0.0001836092,0.000010514915,0.000010354304,0.0006483979,0.000024645204,0.0014805346],"genre_scores_gemma":[0.9989887,0.00035673115,0.00007971112,0.000034230794,0.000010339372,0.0000019915421,0.00018682973,0.0000032933137,0.00033816491],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99940646,0.00020641279,0.000074858355,0.00007182503,0.00017969405,0.000060823204],"domain_scores_gemma":[0.99686915,0.0006478716,0.0019232486,0.00020579256,0.00018105238,0.00017289128],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046916254,0.00015319443,0.00019439323,0.00083756034,0.00016961942,0.00052291196,0.00011145991,0.00019774308,0.0026093284],"category_scores_gemma":[0.0033686305,0.00012487464,0.0006029219,0.00085305504,0.00014749012,0.00015438898,0.00027446094,0.00036084055,0.00014637042],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010099247,0.000024148198,0.98824525,0.00004451779,0.00042818976,0.0003373533,0.000070575654,0.00007763952,0.0015187762,0.000054592314,0.00026512114,0.007924012],"study_design_scores_gemma":[0.000011721954,0.00006013096,0.9980877,0.0000132867945,0.00015486793,0.0005764458,0.000061646926,0.00015053248,0.00028355338,0.000045314056,0.00055071653,0.000004105899],"about_ca_topic_score_codex":0.007712306,"about_ca_topic_score_gemma":0.010547493,"teacher_disagreement_score":0.007712306,"about_ca_system_score_codex":0.00035767068,"about_ca_system_score_gemma":0.00031916922,"threshold_uncertainty_score":0.015334845},"labels":[],"label_agreement":null},{"id":"W4407859877","doi":"10.1080/10428194.2025.2467801","title":"Clinical characteristics and disease outcomes of primary bone lymphoma in the rituximab era: a retrospective study from the Princess Margaret Cancer Center, Toronto, Canada","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Windsor Regional Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Rituximab; Center (category theory); Retrospective cohort study; Disease; Cancer; Gerontology; Lymphoma; Internal medicine","score_opus":0.011134680906223465,"score_gpt":0.27865381948408596,"score_spread":0.26751913857786247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407859877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913504,0.0020836487,0.00008042988,0.0002179828,0.000014292981,0.000042132822,0.004231615,0.000008086933,0.001971285],"genre_scores_gemma":[0.9966008,0.0008097474,0.000052894542,0.00012409521,0.0000232432,0.0000162784,0.002017841,0.0000050085446,0.00034997755],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99911815,0.000055236447,0.000090532885,0.0001797315,0.00026487766,0.0002915286],"domain_scores_gemma":[0.998372,0.00010501894,0.00042083,0.00008774083,0.0005607009,0.00045374542],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040919342,0.00035075628,0.0005353331,0.001224537,0.0013815219,0.0010511926,0.00095422694,0.0004980875,0.0021018651],"category_scores_gemma":[0.0013107798,0.0004062089,0.00043033,0.0033195743,0.00065125985,0.00043712894,0.0006797078,0.0005997064,0.00037891086],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006740988,0.000014286882,0.9976446,0.000020042466,0.000043900603,0.00021985456,0.00013572868,0.000034432353,0.00014643656,0.000021402302,0.0005997961,0.0010522389],"study_design_scores_gemma":[0.0000062834597,0.000027515545,0.99849415,0.000016524411,0.00002993671,0.0003862999,0.00046189313,0.00005623893,0.000027180227,0.0000073092597,0.00048033203,0.0000064351057],"about_ca_topic_score_codex":0.771681,"about_ca_topic_score_gemma":0.8264364,"teacher_disagreement_score":0.771681,"about_ca_system_score_codex":0.008319318,"about_ca_system_score_gemma":0.007813582,"threshold_uncertainty_score":0.45932716},"labels":[],"label_agreement":null},{"id":"W4408305670","doi":"10.1080/10428194.2025.2477725","title":"Time spent in healthcare among older patients with primary central nervous system lymphoma treated with high-dose methotrexate","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"CNS Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Calgary; Alberta Health Services","funders":"","keywords":"Primary central nervous system lymphoma; Methotrexate; Medicine; Central nervous system; Lymphoma; Healthcare system; Primary care; Internal medicine; Health care; Oncology; Family medicine","score_opus":0.004391249264032615,"score_gpt":0.2089634203710185,"score_spread":0.2045721711069859,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408305670","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99478585,0.0014975216,0.000055805504,0.0005638161,0.00003201656,0.0000115781695,0.0005320562,0.000004869859,0.0025164946],"genre_scores_gemma":[0.998713,0.0004658479,0.000037247348,0.00020081532,0.000029275005,0.000006733951,0.00021313432,0.0000015426144,0.00033235262],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997285,0.00007348687,0.000040119332,0.00003114438,0.00006484,0.00006191337],"domain_scores_gemma":[0.99867177,0.00015664108,0.0008104015,0.000024148132,0.00008950113,0.00024754633],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020837346,0.000099232566,0.00021700434,0.00027118073,0.0003016778,0.00037815867,0.000116926254,0.00021509641,0.0031163117],"category_scores_gemma":[0.0020735422,0.00006990449,0.00031991678,0.0005938168,0.000096513286,0.00042189733,0.00028834515,0.00051700725,0.00018945006],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018212436,0.00006668866,0.9910142,0.000034787263,0.000059531903,0.00016924502,0.00015894868,0.00007055182,0.00011599582,0.000028294095,0.00075444696,0.00734533],"study_design_scores_gemma":[0.000010102366,0.00018076015,0.9980089,0.000039359667,0.000047995483,0.0003669586,0.00041359584,0.00013452375,0.00003203723,0.000032404583,0.0007294753,0.000003916024],"about_ca_topic_score_codex":0.009417067,"about_ca_topic_score_gemma":0.020302165,"teacher_disagreement_score":0.009417067,"about_ca_system_score_codex":0.0004811472,"about_ca_system_score_gemma":0.00033965474,"threshold_uncertainty_score":0.018724501},"labels":[],"label_agreement":null},{"id":"W4408914453","doi":"10.1080/10428194.2025.2482890","title":"Analysis of a cancer-care based diagnosis program for lymphoma","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Calgary; Alberta Health Services","funders":"","keywords":"Lymphoma; Cancer; Medicine; Medical physics; Intensive care medicine; Oncology; Internal medicine","score_opus":0.01046438545395141,"score_gpt":0.30284193546222354,"score_spread":0.29237755000827215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408914453","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889338,0.00020300812,0.00066820154,0.00080138963,0.00002273864,0.00090963586,0.0017662894,0.00008419876,0.0066107023],"genre_scores_gemma":[0.9909328,0.00024187456,0.002873225,0.00044345128,0.000031576168,0.0005284949,0.0025657518,0.000023307135,0.0023594832],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99689806,0.0013849628,0.00013227876,0.00018520393,0.0008436363,0.00055588444],"domain_scores_gemma":[0.9908482,0.0030525448,0.0013449155,0.00018988058,0.0022623104,0.0023021533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013144191,0.00020241718,0.00019855399,0.0013820891,0.0008898935,0.0007788118,0.0007661898,0.0003506217,0.0052153487],"category_scores_gemma":[0.011048388,0.00020008424,0.0003935103,0.0021327783,0.00022830284,0.0003194307,0.00076820806,0.00054099946,0.00035633057],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016379491,0.005761354,0.847202,0.0004952496,0.00012232209,0.0006615559,0.0010722936,0.0038873458,0.001589885,0.000930767,0.0070437,0.12959556],"study_design_scores_gemma":[0.00021558863,0.002199841,0.9879495,0.000055051147,0.0000875464,0.00018327576,0.0013785309,0.0038934827,0.000595612,0.000090288646,0.0033368312,0.000014416305],"about_ca_topic_score_codex":0.14929411,"about_ca_topic_score_gemma":0.17045417,"teacher_disagreement_score":0.14929411,"about_ca_system_score_codex":0.008563304,"about_ca_system_score_gemma":0.013745108,"threshold_uncertainty_score":0.29685026},"labels":[],"label_agreement":null},{"id":"W4409274461","doi":"10.1080/10428194.2025.2484367","title":"Hematology-oncology provider perspectives regarding lymphoma treatment and cardioprotective strategies in patients with lymphoma at high risk for heart failure","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"Janssen Research and Development; National Cancer Institute; Incyte; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; CSL Behring; Genentech; Pharmacyclics; Daiichi Sankyo Europe; Sanofi; Amgen; National Heart, Lung, and Blood Institute; Pfizer; ZOLL Medical Corporation","keywords":"Medicine; Hematology; Lymphoma; Internal medicine; Oncology; Clinical Oncology; Heart failure; Intensive care medicine; Cancer","score_opus":0.005310390291872738,"score_gpt":0.23685858464508258,"score_spread":0.23154819435320984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409274461","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9780448,0.0009177103,0.00009459024,0.0168526,0.000060511837,0.000020205123,0.00008957128,0.0000025544334,0.003917383],"genre_scores_gemma":[0.9966667,0.0006579307,0.00011859809,0.002288349,0.000060357328,0.000008874445,0.00003355264,0.0000011270503,0.00016441093],"study_design_codex":"observational","study_design_gemma":"qualitative","domain_scores_codex":[0.9981762,0.0012217651,0.0001002035,0.00006579369,0.00013772398,0.00029838507],"domain_scores_gemma":[0.993779,0.002167898,0.0018624372,0.000043159118,0.0003860521,0.0017613538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020398991,0.00007833093,0.00014997576,0.00032173333,0.0013237245,0.0011173594,0.00019221925,0.00064744084,0.003289549],"category_scores_gemma":[0.009950177,0.00012739848,0.00021609751,0.00043317623,0.00039774965,0.00086780987,0.0006434817,0.0008625938,0.000169812],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005789274,0.00041387946,0.94563437,0.00013646681,0.00007901039,0.0018398371,0.0157082,0.00023356218,0.00049112714,0.0006064171,0.008422934,0.025855223],"study_design_scores_gemma":[0.00018606607,0.0010165691,0.781621,0.00051776733,0.00012293678,0.0031636225,0.19568002,0.0012683286,0.00032720735,0.0008833629,0.015143499,0.00006961764],"about_ca_topic_score_codex":0.006387652,"about_ca_topic_score_gemma":0.017689565,"teacher_disagreement_score":0.006387652,"about_ca_system_score_codex":0.0010945303,"about_ca_system_score_gemma":0.0012530056,"threshold_uncertainty_score":0.012700915},"labels":[],"label_agreement":null},{"id":"W4409684616","doi":"10.1080/10428194.2025.2495112","title":"The paradox of the spleen: is it a nodal or extranodal site of lymphoma?","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"NODAL; Spleen; Lymphoma; Medicine; Pathology; Internal medicine","score_opus":0.012184667552049428,"score_gpt":0.26549384872640247,"score_spread":0.253309181174353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409684616","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.18149376,0.4621231,0.0072462074,0.27434543,0.010426036,0.00004773634,0.00048974575,0.00016077861,0.06366727],"genre_scores_gemma":[0.8424654,0.10392763,0.0016996088,0.023783617,0.024113692,0.000015788202,0.00019809653,0.00006685098,0.0037293243],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9996785,0.000104965795,0.000029641034,0.0000518744,0.00009243776,0.000042486932],"domain_scores_gemma":[0.9978536,0.0011197014,0.00046512534,0.000076908516,0.00027409414,0.00021055668],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009364483,0.0002445285,0.00058530417,0.00067714456,0.00043815875,0.0012998341,0.00055938744,0.001750071,0.005199811],"category_scores_gemma":[0.006598824,0.00014791278,0.00016385422,0.00053048675,0.0019243547,0.002387584,0.00052400463,0.0021625091,0.0016946106],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021390994,0.00019002378,0.16083035,0.0028110542,0.0001881701,0.04284442,0.001295954,0.0005963683,0.0066087954,0.04717423,0.16391546,0.57140607],"study_design_scores_gemma":[0.0005232345,0.0008987555,0.12599489,0.007069474,0.00041573984,0.3409748,0.0053695273,0.003005663,0.0045576193,0.14288732,0.368128,0.00017501207],"about_ca_topic_score_codex":0.00088670675,"about_ca_topic_score_gemma":0.0010260566,"teacher_disagreement_score":0.005199811,"about_ca_system_score_codex":0.00068485667,"about_ca_system_score_gemma":0.000751846,"threshold_uncertainty_score":0.017395139},"labels":[],"label_agreement":null},{"id":"W4411283910","doi":"10.1080/10428194.2025.2514894","title":"Effectiveness of olutasidenib versus ivosidenib in patients with mutated isocitrate dehydrogenase 1 acute myeloid leukemia who are relapsed or refractory to venetoclax: the 2102-HEM-101 trial versus a US electronic health record-based external control arm","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Golder Associates (Canada)","funders":"","keywords":"Venetoclax; Isocitrate dehydrogenase; Refractory (planetary science); Myeloid leukemia; Medicine; Oncology; Leukemia; Internal medicine; Biology; Chronic lymphocytic leukemia; Enzyme","score_opus":0.009896063977063402,"score_gpt":0.2783254034031928,"score_spread":0.2684293394261294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411283910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958139,0.002564209,0.00021504633,0.00011562773,0.00005567373,0.0001234655,0.00023650043,0.000012536599,0.00086305675],"genre_scores_gemma":[0.9978479,0.00067636074,0.00026947746,0.00015300165,0.000058072204,0.000096623444,0.00040748095,0.0000038063893,0.00048737603],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9989724,0.00079431676,0.000043644483,0.00008213921,0.00005577165,0.00005177605],"domain_scores_gemma":[0.9990471,0.00044033842,0.00026424625,0.00008162682,0.00003392531,0.00013267534],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020285107,0.0003640981,0.000858804,0.00021697723,0.00011119144,0.00066502986,0.0003053469,0.00041568375,0.0016417978],"category_scores_gemma":[0.001992006,0.00012353515,0.0010696418,0.00024188758,0.0002976135,0.0003972154,0.00027964704,0.00091453874,0.00020343666],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.84733635,0.0038758505,0.018572891,0.0006998001,0.0032004996,0.00005706851,0.00008994746,0.0020378837,0.004812879,0.00026494625,0.0008643443,0.11818753],"study_design_scores_gemma":[0.42328617,0.43580142,0.10462171,0.00038841547,0.008649557,0.00047109497,0.0002957066,0.009427738,0.008334536,0.0014646197,0.007184149,0.00007495302],"about_ca_topic_score_codex":0.00025311197,"about_ca_topic_score_gemma":0.00077714195,"teacher_disagreement_score":0.0020285107,"about_ca_system_score_codex":0.00042175697,"about_ca_system_score_gemma":0.00032119945,"threshold_uncertainty_score":0.010727942},"labels":[],"label_agreement":null},{"id":"W4411383594","doi":"10.1080/10428194.2025.2518440","title":"Real-world healthcare costs for patients treated with chimeric antigen receptor T-cell therapy in Canada","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; University of Waterloo; Princess Margaret Cancer Centre; Toronto General Hospital","funders":"","keywords":"Chimeric antigen receptor; Reimbursement; Medicine; Activity-based costing; Cohort; Health care; Retrospective cohort study; Internal medicine; Immunotherapy; Cancer; Business","score_opus":0.010594177255934879,"score_gpt":0.26298161148964,"score_spread":0.25238743423370513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411383594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9611269,0.0026900857,0.0005288305,0.0028007075,0.000037923768,0.00010958588,0.027701525,0.000028172397,0.0049763694],"genre_scores_gemma":[0.989516,0.0016130281,0.0004855363,0.00026035038,0.000017156875,0.000029561366,0.007131992,0.000007962201,0.0009384406],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989698,0.00016069738,0.00011993398,0.00009875356,0.00034235942,0.00030846146],"domain_scores_gemma":[0.9980338,0.00021993049,0.000666709,0.000044316545,0.00065293413,0.00038223126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005590189,0.00037125073,0.0003730011,0.0013960294,0.0010023993,0.0016507573,0.0008006018,0.0004612652,0.002118649],"category_scores_gemma":[0.004077075,0.0003497022,0.0010966976,0.004155364,0.00039435545,0.00054944697,0.0006395744,0.00085606007,0.0001491684],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046821343,0.00008036732,0.956558,0.00018926717,0.00058900827,0.00069716503,0.00025413898,0.017711805,0.00020439169,0.0018740875,0.006660912,0.014712618],"study_design_scores_gemma":[0.0001322205,0.00011536362,0.96842426,0.00020782785,0.00027463355,0.0006136222,0.0011542838,0.022041567,0.00022488464,0.00054871285,0.006175258,0.000087368084],"about_ca_topic_score_codex":0.98640627,"about_ca_topic_score_gemma":0.98728263,"teacher_disagreement_score":0.06511001,"about_ca_system_score_codex":0.06511001,"about_ca_system_score_gemma":0.025017116,"threshold_uncertainty_score":0.4724084},"labels":[],"label_agreement":null},{"id":"W4411429251","doi":"10.1080/10428194.2025.2504719","title":"Combinability of epcoritamab CD20-targeting T-cell engager and CD20 antibody-targeted therapies in B-cell non-Hodgkin lymphoma","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"AbbVie Canada","keywords":"Chemoimmunotherapy; CD20; Rituximab; CHOP; Monoclonal antibody; Vincristine; Cancer research; Lymphoma; Medicine; B cell; Antibody-dependent cell-mediated cytotoxicity; Diffuse large B-cell lymphoma; Antibody; Immunology; Internal medicine; Chemotherapy; Cyclophosphamide","score_opus":0.008323771422152333,"score_gpt":0.27149745491985194,"score_spread":0.2631736834976996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411429251","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925156,0.0036874507,0.0017617731,0.00005216331,0.000043020962,0.00012061858,0.00005766446,0.000058647387,0.0017029578],"genre_scores_gemma":[0.996702,0.0010004307,0.0013486076,0.000033994093,0.0000146628045,0.00006227055,0.00008277918,0.000008962552,0.0007462735],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997985,0.000049763807,0.000014748769,0.00003555428,0.00004764808,0.000053712294],"domain_scores_gemma":[0.99994624,0.00001089843,0.000009539153,0.000011217447,0.000006509786,0.000015529373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002310068,0.0003231095,0.000484877,0.00035431221,0.00010341159,0.00039323448,0.00026759633,0.0002348058,0.0006847431],"category_scores_gemma":[0.00017160835,0.00013263583,0.00022963848,0.00021917294,0.0001516226,0.00020913,0.0002973364,0.00037681294,0.00021844546],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015085373,0.001375212,0.0010013261,0.00020906249,0.00013727085,0.0002104279,0.00010718954,0.0028117027,0.92729896,0.0002803671,0.00032347298,0.06473643],"study_design_scores_gemma":[0.0007313026,0.02285114,0.0065871654,0.00002431511,0.0003895225,0.0007762917,0.000066548884,0.008304514,0.9490491,0.00017492176,0.011023628,0.00002163136],"about_ca_topic_score_codex":0.00048813902,"about_ca_topic_score_gemma":0.001270979,"teacher_disagreement_score":0.0006847431,"about_ca_system_score_codex":0.00028822038,"about_ca_system_score_gemma":0.00020170146,"threshold_uncertainty_score":0.002290666},"labels":[],"label_agreement":null},{"id":"W4411521899","doi":"10.1080/10428194.2025.2521650","title":"Risk factors for mortality and re-admission of children with hematological malignancies to the intensive care unit due to sepsis","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"Israel Cancer Association","keywords":"Sepsis; Medicine; Intensive care medicine; Intensive care unit; Pediatric intensive care unit; Emergency medicine; Internal medicine","score_opus":0.021549071423951772,"score_gpt":0.2914854479318599,"score_spread":0.2699363765079081,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411521899","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99830663,0.00096269464,0.00007351593,0.00009762647,0.000010387294,0.0000044250746,0.0002655864,0.0000052167475,0.00027397575],"genre_scores_gemma":[0.99935776,0.00022139367,0.000059124828,0.000018066083,0.000013192457,0.000005210351,0.00027338104,0.0000017120805,0.000050129373],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994742,0.00013707754,0.00009222209,0.0000753076,0.00011033393,0.00011082176],"domain_scores_gemma":[0.9975115,0.0006687806,0.0012229535,0.00010257794,0.0001809444,0.0003132193],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050399953,0.00019593438,0.00024286786,0.0006502384,0.00023334,0.00032949774,0.00022847117,0.00026890603,0.0014019955],"category_scores_gemma":[0.0038503162,0.00013483428,0.00036704887,0.0007172344,0.00016210329,0.00032314984,0.00032502128,0.0007063867,0.00012011105],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016353946,0.000003115849,0.9991627,0.000004453744,0.000008664237,0.00008832095,0.000018424344,0.000013635712,0.000019071005,0.000005115665,0.0000701564,0.00059001177],"study_design_scores_gemma":[0.00000195709,0.000034392986,0.99823415,0.000016862701,0.000020454232,0.0011611626,0.00015258136,0.00009769147,0.0000565582,0.00001212901,0.0002097944,0.0000021987457],"about_ca_topic_score_codex":0.0020655096,"about_ca_topic_score_gemma":0.0026052648,"teacher_disagreement_score":0.0020655096,"about_ca_system_score_codex":0.0002922768,"about_ca_system_score_gemma":0.0003782755,"threshold_uncertainty_score":0.0046901107},"labels":[],"label_agreement":null},{"id":"W4411558199","doi":"10.1080/10428194.2025.2502805","title":"Pembrolizumab in relapsed or refractory Hodgkin lymphoma: a post hoc analysis of KEYNOTE-204 by prior lines of therapy","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Post-hoc analysis; Refractory (planetary science); Medicine; Post hoc; Oncology; Lymphoma; Internal medicine; Cancer; Materials science; Immunotherapy","score_opus":0.009830960614451054,"score_gpt":0.2684047589855079,"score_spread":0.2585737983710569,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411558199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910602,0.0013964728,0.0018299981,0.00020775956,0.0002937002,0.0018346357,0.0016020376,0.00010307556,0.0016720654],"genre_scores_gemma":[0.99037766,0.00026052466,0.0020698453,0.00036691266,0.00017262378,0.003101785,0.0013334112,0.00007354682,0.0022436772],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.98501325,0.011446699,0.00041795737,0.0013239159,0.00059309806,0.0012051398],"domain_scores_gemma":[0.9860789,0.009162379,0.0014199764,0.0020305251,0.0006228454,0.00068523095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015172837,0.0020589111,0.003942629,0.0005509166,0.0005201232,0.0014680625,0.0014649036,0.00147557,0.0055786236],"category_scores_gemma":[0.012428384,0.0006529652,0.008329828,0.0005686173,0.0009413639,0.0016514898,0.0011393076,0.0028536888,0.0007117467],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94807625,0.0032469549,0.012375838,0.00075642666,0.017079893,0.00018039341,0.00016216506,0.0020739795,0.003804773,0.00028669747,0.0015546036,0.010401979],"study_design_scores_gemma":[0.23218094,0.5262754,0.15969764,0.00022694076,0.042576786,0.00037653817,0.0005586611,0.015322608,0.010556229,0.0017187187,0.010282806,0.00022674257],"about_ca_topic_score_codex":0.00068236305,"about_ca_topic_score_gemma":0.0011789325,"teacher_disagreement_score":0.015172837,"about_ca_system_score_codex":0.0011497156,"about_ca_system_score_gemma":0.0016510299,"threshold_uncertainty_score":0.080242574},"labels":[],"label_agreement":null},{"id":"W4412366400","doi":"10.1080/10428194.2025.2521656","title":"A charter for improving care for people living with chronic lymphocytic leukemia: six principles for excellence","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Care Foundation; Alberta Health Services","funders":"AstraZeneca","keywords":"Charter; Chronic lymphocytic leukemia; Excellence; Medicine; Gerontology; Leukemia; Intensive care medicine; Political science; Immunology; Law","score_opus":0.012227065018911371,"score_gpt":0.26680979570576285,"score_spread":0.2545827306868515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412366400","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0022355202,0.009280531,0.028432798,0.8886628,0.03220497,0.0019319877,0.0008187138,0.001534004,0.034898642],"genre_scores_gemma":[0.06486585,0.041620944,0.54575235,0.25280595,0.02475578,0.00725044,0.0065075755,0.0017045425,0.054736536],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.93148375,0.027671503,0.008186166,0.0025427984,0.024994183,0.0051215966],"domain_scores_gemma":[0.8561963,0.01693019,0.009368494,0.0058736084,0.0628812,0.048750263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.06789603,0.002267567,0.0027428807,0.004503456,0.009588604,0.018054279,0.0070173987,0.009061826,0.0069594677],"category_scores_gemma":[0.09422541,0.0010358524,0.0026896272,0.00526389,0.007767317,0.015216957,0.015356304,0.028515367,0.0058636786],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000037442464,0.00021896024,0.0012234128,0.0006232376,0.00004014424,0.00020448926,0.001838267,0.00052184914,0.00022760185,0.029485142,0.87476134,0.090818085],"study_design_scores_gemma":[0.00013758276,0.00037084267,0.0033370047,0.0024556268,0.000059014,0.00045832826,0.0032065874,0.001103253,0.00030784513,0.035741314,0.95262825,0.00019434631],"about_ca_topic_score_codex":0.015745437,"about_ca_topic_score_gemma":0.030263247,"teacher_disagreement_score":0.06789603,"about_ca_system_score_codex":0.015433934,"about_ca_system_score_gemma":0.14014228,"threshold_uncertainty_score":0.3590728},"labels":[],"label_agreement":null},{"id":"W4412395052","doi":"10.1080/10428194.2025.2529451","title":"Expanding the phenotypic spectrum of DDX41-related myeloid neoplasms: a case of mature plasmacytoid dendritic cell proliferation associated with acute myeloid leukemia with germline DDX41 mutation","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Myeloid; Myeloid leukemia; Phenotype; Germline; Mutation; Immunology; Cancer research; Plasmacytoid dendritic cell; Biology; Medicine; Dendritic cell; Gene; Genetics; Immune system","score_opus":0.006061897744530263,"score_gpt":0.24192004138317377,"score_spread":0.23585814363864352,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412395052","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913215,0.0010247708,0.0025278537,0.0004705288,0.00005388466,0.0000663625,0.000104942716,0.000082714556,0.004347385],"genre_scores_gemma":[0.99747485,0.00039871596,0.0014059016,0.000105453226,0.00014585334,0.000012393302,0.00004876338,0.000009658617,0.00039834637],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9996574,0.000033298442,0.00004450681,0.0000964818,0.00005498584,0.00011340289],"domain_scores_gemma":[0.99919695,0.00027275248,0.00016103126,0.000102003,0.00006309564,0.00020410748],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023948903,0.0009423515,0.00048024068,0.0014184248,0.001029086,0.00081659097,0.000512918,0.0014713038,0.001868873],"category_scores_gemma":[0.0012344604,0.0005716956,0.00042333335,0.000789349,0.0008912337,0.00075347524,0.0014449719,0.0010455496,0.00071177783],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004502923,0.000028081538,0.014583809,0.00003999948,0.0000057197763,0.9754015,0.00017991623,0.00007828994,0.006355247,0.00023711806,0.00016171558,0.002883553],"study_design_scores_gemma":[0.000007626676,0.000023867811,0.0037717684,0.0000042351758,0.0000078718795,0.9942781,0.00005722331,0.00019170124,0.0010860855,0.0001456611,0.0004211977,0.000004737417],"about_ca_topic_score_codex":0.0005160157,"about_ca_topic_score_gemma":0.0006485766,"teacher_disagreement_score":0.001868873,"about_ca_system_score_codex":0.00030861277,"about_ca_system_score_gemma":0.00032970074,"threshold_uncertainty_score":0.006251991},"labels":[],"label_agreement":null},{"id":"W4412654447","doi":"10.1080/10428194.2025.2532674","title":"Matching-adjusted indirect comparison of lisocabtagene maraleucel versus axicabtagene ciloleucel for second-line treatment of patients with early relapsed or refractory large B-cell lymphoma","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"European Union Studies Association; Kite Pharma; Genmab; Genentech Foundation; Daiichi Sankyo Europe; Janssen Biotech; AbbVie Canada; Pharmacyclics; Seattle Genetics; Genentech; MorphoSys; Seagen; Incyte; TG Therapeutics; bluebird bio; Novartis Portugal; BeiGene; Merck KGaA; Regeneron Pharmaceuticals; Astellas Pharma; Takeda Pharmaceuticals U.S.A.; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Adverse effect; Oncology; Confidence interval; Odds ratio; Refractory (planetary science); Lymphoma; Cytokine release syndrome; Clinical trial; Chimeric antigen receptor; Immunotherapy; Cancer","score_opus":0.027151610728664,"score_gpt":0.29862573315635244,"score_spread":0.2714741224276884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412654447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95172447,0.02328562,0.0050658765,0.000809963,0.0012451672,0.0038383435,0.0047851824,0.00022085075,0.009024591],"genre_scores_gemma":[0.99067783,0.0017387838,0.0023566096,0.0005940357,0.00016002616,0.0013759044,0.0013316431,0.000019181329,0.0017461071],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9954294,0.0033773321,0.00028144298,0.00036678198,0.000349556,0.00019540625],"domain_scores_gemma":[0.9975267,0.0011958742,0.00070148654,0.00022635228,0.00015664556,0.00019294211],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042130644,0.0012881751,0.002331361,0.0005494784,0.00018902242,0.00095245714,0.0008580519,0.0010453211,0.008635209],"category_scores_gemma":[0.006742716,0.00042127987,0.005569275,0.00042256972,0.00055559113,0.0007987702,0.00089793076,0.002105014,0.00068741373],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94406897,0.0011796533,0.0018111545,0.0022063062,0.019276233,0.000035155026,0.000056894005,0.0014623272,0.0016664575,0.000636785,0.0008888057,0.026711283],"study_design_scores_gemma":[0.7162392,0.18750603,0.023953712,0.0005496057,0.04831421,0.00020052584,0.00014558643,0.0067536924,0.0038271088,0.003548736,0.008837657,0.00012398537],"about_ca_topic_score_codex":0.0011942772,"about_ca_topic_score_gemma":0.00198486,"teacher_disagreement_score":0.008635209,"about_ca_system_score_codex":0.0008685937,"about_ca_system_score_gemma":0.00090508256,"threshold_uncertainty_score":0.02888769},"labels":[],"label_agreement":null},{"id":"W4413052189","doi":"10.1080/10428194.2025.2531154","title":"The evolution of treatment for pediatric advanced stage classic Hodgkin lymphoma – a narrative literature review","year":2025,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Quality of life (healthcare); Clinical trial; Randomized controlled trial; Intensive care medicine; Lymphoma; Hodgkin lymphoma; Pediatrics; Internal medicine; Nursing","score_opus":0.015566333508557956,"score_gpt":0.3100154015530648,"score_spread":0.2944490680445068,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413052189","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009117128,0.99959487,0.000025011155,0.00007663061,0.00003901343,0.0000072717307,0.000019642644,0.0000017401612,0.00014457364],"genre_scores_gemma":[0.00067626615,0.9990632,0.00007156854,0.00009409508,0.000033602893,0.000007958782,0.000021999182,6.246785e-7,0.000030686864],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99934345,0.00015383963,0.00022644036,0.000091706635,0.0001532384,0.000031261956],"domain_scores_gemma":[0.997844,0.0014658292,0.00040454898,0.000031471634,0.00020795224,0.000046230718],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013841842,0.0008270288,0.002130423,0.004532666,0.00034422992,0.0012410093,0.0011395746,0.0009378948,0.0034302624],"category_scores_gemma":[0.0035006015,0.0003804394,0.0015716666,0.0054667257,0.000434406,0.0014060335,0.0006460309,0.0008529397,0.0004739546],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017083007,0.000047399408,0.00040735072,0.3802719,0.0008034383,0.0002772962,0.00016243364,0.00032079965,0.0004361612,0.0012733358,0.013382865,0.60244614],"study_design_scores_gemma":[0.000118612275,0.00035422127,0.004448425,0.4358121,0.009012097,0.0046323645,0.00040768425,0.00022098573,0.00049071776,0.0016023986,0.5428406,0.0000598276],"about_ca_topic_score_codex":0.0022976233,"about_ca_topic_score_gemma":0.004462364,"teacher_disagreement_score":0.004532666,"about_ca_system_score_codex":0.0010238839,"about_ca_system_score_gemma":0.002834827,"threshold_uncertainty_score":0.011475444},"labels":[],"label_agreement":null},{"id":"W4413106872","doi":"10.1080/10428194.2025.2542941","title":"Romidepsin and mogamulizumab sequential treatment for advanced cutaneous T-cell lymphoma","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Cutaneous lymphoproliferative disorders research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"National Cancer Institute","keywords":"Romidepsin; Medicine; Discontinuation; Oncology; Lymphoma; Cutaneous T-cell lymphoma; Internal medicine; Vindesine; Chemotherapy; Mycosis fungoides; Histone deacetylase; Vincristine","score_opus":0.015087531009809824,"score_gpt":0.2961551683350083,"score_spread":0.2810676373251985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413106872","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995861,0.0022502914,0.0005225679,0.00006097249,0.000015444837,0.000072634364,0.00004965564,0.00001539431,0.00115212],"genre_scores_gemma":[0.9985519,0.0005241741,0.00052235986,0.000048223526,0.000026099255,0.000031831914,0.0000769826,0.0000022207926,0.0002162088],"study_design_codex":"design_other","study_design_gemma":"case_report","domain_scores_codex":[0.9998815,0.000040567917,0.000016006814,0.00002473431,0.00001767651,0.000019588688],"domain_scores_gemma":[0.99983966,0.00003830381,0.000044583587,0.000012997697,0.000009088145,0.000055318316],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022503175,0.0001464838,0.0003834833,0.00019383409,0.00015025002,0.00014593017,0.00012337494,0.000111132504,0.00061053294],"category_scores_gemma":[0.00033927656,0.00005309857,0.00019372895,0.0001473303,0.00010949522,0.00014381019,0.00012058293,0.00025923684,0.00014917308],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025015105,0.0047767614,0.14878263,0.00047658294,0.0005137315,0.0053903847,0.00033846076,0.0024629263,0.10679851,0.00028131026,0.0017763865,0.7033872],"study_design_scores_gemma":[0.009383396,0.17004548,0.7045976,0.00016819265,0.0010031306,0.04232872,0.0002796582,0.0062514194,0.044556435,0.00062270736,0.020707326,0.000056008717],"about_ca_topic_score_codex":0.00039436953,"about_ca_topic_score_gemma":0.0013871904,"teacher_disagreement_score":0.00061053294,"about_ca_system_score_codex":0.00018450763,"about_ca_system_score_gemma":0.00018612511,"threshold_uncertainty_score":0.0020424128},"labels":[],"label_agreement":null},{"id":"W4413272991","doi":"10.1080/10428194.2025.2542943","title":"Understanding the clinical approach to “pathologically ambiguous follicular lymphoma” through a Real-World cohort","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"Israel Cancer Research Fund","keywords":"Follicular lymphoma; Cohort; Lymphoma; Follicular phase; Medicine; Oncology; Internal medicine","score_opus":0.06678686074280356,"score_gpt":0.32518067801713424,"score_spread":0.2583938172743307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413272991","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9774579,0.0028874243,0.0049172,0.006910281,0.00013754908,0.000107480366,0.002438489,0.00003604394,0.005107691],"genre_scores_gemma":[0.99600005,0.0008037407,0.0014551686,0.0005054655,0.00008891361,0.000050229144,0.00082320784,0.000015467795,0.00025771768],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974711,0.0013222259,0.00021067257,0.0004718475,0.00024615467,0.00027800427],"domain_scores_gemma":[0.9928824,0.0029543536,0.0018296989,0.00094955316,0.00093810214,0.000445818],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007243372,0.00028095278,0.00023397939,0.0016772457,0.00097073184,0.0021128503,0.0008772631,0.00086774083,0.0036110603],"category_scores_gemma":[0.027710961,0.00032275607,0.00031334627,0.0012604772,0.0007175106,0.0026656091,0.0016234996,0.0013147953,0.0005638965],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011554212,0.00005246315,0.97754675,0.000027791742,0.0000700328,0.00022662623,0.0010135435,0.00014977521,0.00015489668,0.00092734164,0.003935553,0.01577961],"study_design_scores_gemma":[0.000033527096,0.00019944529,0.9576841,0.00035732953,0.00020843223,0.0033152301,0.0083626965,0.0052488963,0.00037055538,0.0075160977,0.016618818,0.00008486364],"about_ca_topic_score_codex":0.010617611,"about_ca_topic_score_gemma":0.0146289645,"teacher_disagreement_score":0.010617611,"about_ca_system_score_codex":0.00090859964,"about_ca_system_score_gemma":0.0011522559,"threshold_uncertainty_score":0.03830701},"labels":[],"label_agreement":null},{"id":"W4413431624","doi":"10.1080/10428194.2025.2536121","title":"Indolent chronic myeloid leukemia – a historical dinosaur?","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Myeloid leukemia; Medicine; Immunology","score_opus":0.010352445609960795,"score_gpt":0.2465565217181639,"score_spread":0.2362040761082031,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413431624","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011234157,0.24867246,0.0014456252,0.6782127,0.03888318,0.000036727255,0.00012024614,0.00006210916,0.021332828],"genre_scores_gemma":[0.09914779,0.19102994,0.0022771752,0.5855166,0.10977956,0.000051618354,0.00012909864,0.00006657753,0.012001638],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994802,0.00017590234,0.000053094795,0.000089381334,0.00009657461,0.00010484214],"domain_scores_gemma":[0.9990388,0.000529878,0.000087044005,0.000050334176,0.00011723568,0.00017672406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013276936,0.0006049668,0.00072684657,0.00079065486,0.0023034709,0.002077995,0.00095568364,0.006140123,0.0023818554],"category_scores_gemma":[0.00381635,0.0002452177,0.00037276684,0.0007132324,0.0035914348,0.005281023,0.0014558197,0.010928351,0.0014462707],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006455555,0.00011469423,0.0049257264,0.001272975,0.000083698855,0.074611135,0.0036183193,0.00020425837,0.0029607988,0.07631069,0.6315188,0.20373333],"study_design_scores_gemma":[0.000052322313,0.00017981311,0.001599111,0.0012766744,0.000045704666,0.11856348,0.002458702,0.00011724366,0.0004974007,0.02377372,0.85136324,0.00007258908],"about_ca_topic_score_codex":0.0020568958,"about_ca_topic_score_gemma":0.003438114,"teacher_disagreement_score":0.006140123,"about_ca_system_score_codex":0.0017345771,"about_ca_system_score_gemma":0.00069616927,"threshold_uncertainty_score":0.012585223},"labels":[],"label_agreement":null},{"id":"W4414152096","doi":"10.1080/10428194.2025.2537597","title":"XXI International Workshop on CLL 2025","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Linguistic Education and Pedagogy","field":"Arts and Humanities","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ibrutinib; Venetoclax; Chronic lymphocytic leukemia; Lymphoma; Phases of clinical research; Leukemia","score_opus":0.028118629096691706,"score_gpt":0.2908320198891648,"score_spread":0.2627133907924731,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414152096","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002792199,0.11585559,0.0052515646,0.10511542,0.21589276,0.00058503164,0.0028735476,0.0015772945,0.5500566],"genre_scores_gemma":[0.010374182,0.08287953,0.0036633292,0.023665514,0.07062467,0.00047578747,0.0042985273,0.000502629,0.80351585],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989774,0.00023134377,0.0000895094,0.00016616381,0.0003390878,0.00019645298],"domain_scores_gemma":[0.997412,0.00022720988,0.00012812494,0.00012404754,0.0008985803,0.0012100198],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018829,0.001155226,0.00067569927,0.0019070205,0.00075121043,0.003737028,0.0017303878,0.0029777086,0.3080954],"category_scores_gemma":[0.0030479971,0.00032846117,0.00081041665,0.0009829093,0.0006049518,0.0022518837,0.0038656252,0.0030540512,0.16757375],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000735896,0.000040579664,0.00029714793,0.00039157784,0.0000072164153,0.00019424592,0.00004467072,0.00006402209,0.00050711544,0.0020369655,0.7822272,0.21411562],"study_design_scores_gemma":[0.0000063286934,0.000023527162,0.00022519713,0.00035124255,0.0000032416447,0.0002674856,0.000033715343,0.000020128417,0.00006892718,0.0005039272,0.99849284,0.0000034899606],"about_ca_topic_score_codex":0.0012618394,"about_ca_topic_score_gemma":0.0026705298,"teacher_disagreement_score":0.3080954,"about_ca_system_score_codex":0.0016057856,"about_ca_system_score_gemma":0.0031002008,"threshold_uncertainty_score":0.986918},"labels":[],"label_agreement":null},{"id":"W4414422124","doi":"10.1080/10428194.2025.2553863","title":"From dimensions through dynamics to outcomes – lymph nodes and skin assessments predict CTCL outcomes","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"","keywords":"Retrospective cohort study; Lymph; Predictive value of tests; Lymph node; Cut-off; Cutoff; Clinical trial","score_opus":0.010649052137224705,"score_gpt":0.2962868721994522,"score_spread":0.2856378200622275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414422124","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936732,0.0011156914,0.0027429194,0.00037246733,0.000021242606,0.000027093012,0.00043749978,0.00003470918,0.0015751636],"genre_scores_gemma":[0.99900836,0.00005459973,0.00048893946,0.000037469024,0.00001740558,0.0000066970747,0.00025704666,0.000004338752,0.00012515225],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988919,0.00061576365,0.00008147019,0.00015163103,0.00016756404,0.000091705246],"domain_scores_gemma":[0.99674124,0.0015777232,0.00094098906,0.00022796619,0.00025426954,0.00025791978],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034846296,0.00033460348,0.0003351178,0.00074033946,0.00013483183,0.0011139341,0.00025935523,0.00023348645,0.0011512208],"category_scores_gemma":[0.007045188,0.00014928948,0.00042455504,0.00053557655,0.00034323815,0.0005984032,0.00046975387,0.00050822453,0.00025182945],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001334074,0.000048993174,0.9681446,0.000027199954,0.00019179298,0.000027974285,0.000031225674,0.003122265,0.0008225998,0.0001242655,0.00045202862,0.025672788],"study_design_scores_gemma":[0.00011661369,0.0013532089,0.9688439,0.000040419243,0.00027451315,0.00025675318,0.000115486815,0.024570609,0.0012929445,0.0014328847,0.0016735544,0.000029112829],"about_ca_topic_score_codex":0.0011880368,"about_ca_topic_score_gemma":0.0022805918,"teacher_disagreement_score":0.0034846296,"about_ca_system_score_codex":0.00035119092,"about_ca_system_score_gemma":0.00029002642,"threshold_uncertainty_score":0.018428743},"labels":[],"label_agreement":null},{"id":"W4414611697","doi":"10.1080/10428194.2025.2560085","title":"The risk of second primary malignancies in patients receiving T-cell directed therapies for multiple myeloma: a systematic review","year":2025,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Incidence (geometry); Confidence interval; Pharmacovigilance; Clinical trial; Clinical endpoint; Cohort; Adverse effect; Cohort study; Malignancy","score_opus":0.012847556902866512,"score_gpt":0.2676493473679365,"score_spread":0.25480179046507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414611697","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00069761655,0.99858093,0.000072217044,0.00010843523,0.000042824006,0.00009202682,0.00024090882,0.00000542591,0.00015971006],"genre_scores_gemma":[0.0087563535,0.99036974,0.00021217272,0.00021215754,0.0000414504,0.0001671345,0.00016158205,0.0000032568769,0.00007605109],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99738747,0.0007819558,0.0010333102,0.00022334313,0.0004730104,0.000100877274],"domain_scores_gemma":[0.9870085,0.009491387,0.0022835077,0.00013973819,0.00092942844,0.00014742272],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036166557,0.0011602339,0.006831049,0.007738727,0.00043188338,0.0019434413,0.0013538735,0.0014059191,0.0045346976],"category_scores_gemma":[0.016075028,0.0007732323,0.007440431,0.008384381,0.0005048677,0.0015407666,0.0011204077,0.0008655075,0.00031249097],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021409315,0.00001094131,0.0005858596,0.9556056,0.009593996,0.00007663537,0.00009184886,0.000081922604,0.000112248206,0.00013139112,0.0012848718,0.03221066],"study_design_scores_gemma":[0.00032444464,0.00026460408,0.005996866,0.8292745,0.1386969,0.0006643695,0.00024726885,0.00012670721,0.00021009542,0.00040282446,0.023743073,0.000048363116],"about_ca_topic_score_codex":0.006452246,"about_ca_topic_score_gemma":0.01577226,"teacher_disagreement_score":0.007738727,"about_ca_system_score_codex":0.0021338065,"about_ca_system_score_gemma":0.0057071815,"threshold_uncertainty_score":0.019126952},"labels":[],"label_agreement":null},{"id":"W4414780017","doi":"10.1080/10428194.2025.2561117","title":"Subcutaneous daratumumab plus carfilzomib and dexamethasone (D-Kd) versus carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma who received previous daratumumab treatment: LYNX study","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital; Institute of Cancer Research; University of Calgary","funders":"","keywords":"Daratumumab; Carfilzomib; Dexamethasone; Multiple myeloma; Clinical endpoint; Interim analysis; Panobinostat; Clinical trial","score_opus":0.013305664650567555,"score_gpt":0.26235908081363185,"score_spread":0.24905341616306428,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414780017","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99421173,0.003769397,0.00017860736,0.00040253665,0.0001711254,0.00039366347,0.00019734468,0.000022352624,0.0006531174],"genre_scores_gemma":[0.99549145,0.0019787506,0.00037631212,0.00048168088,0.0003047618,0.00028328388,0.0003385101,0.0000061693463,0.0007391167],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99930227,0.00043722044,0.000045897166,0.00007997764,0.00006665986,0.000067913046],"domain_scores_gemma":[0.99887353,0.00038902735,0.00023861001,0.00008559899,0.000051202383,0.0003619493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023452353,0.0007079229,0.0020784687,0.00025413287,0.00024355402,0.0008465568,0.00046977962,0.0007977335,0.0024676437],"category_scores_gemma":[0.001650281,0.00035416073,0.0023431224,0.00026993972,0.00062722154,0.0007195823,0.0003046519,0.002247228,0.0004351373],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92777216,0.009756192,0.004151478,0.00053394,0.0023021242,0.00007371997,0.00012525322,0.0006055395,0.004408045,0.00010326087,0.0006875246,0.049480762],"study_design_scores_gemma":[0.64212215,0.33439317,0.017414786,0.00008420611,0.001880062,0.00014701685,0.000062766136,0.001337288,0.0008972012,0.00017646395,0.001460388,0.000024460314],"about_ca_topic_score_codex":0.0006341427,"about_ca_topic_score_gemma":0.001643357,"teacher_disagreement_score":0.0024676437,"about_ca_system_score_codex":0.0006024988,"about_ca_system_score_gemma":0.0007704191,"threshold_uncertainty_score":0.012402952},"labels":[],"label_agreement":null},{"id":"W4414794257","doi":"10.1080/10428194.2025.2561737","title":"Real-world treatment adherence and persistence of FLT3 inhibitors as post-alloHCT maintenance therapy in patients with AML in the United States: a cohort study using administrative claims data","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; Astellas Foundation for Research on Metabolic Disorders; Astellas Pharma; National Center for Advancing Translational Sciences; Astellas Pharma Canada","keywords":"Discontinuation; Midostaurin; Myeloid leukemia; Sorafenib; Hematopoietic cell; Maintenance therapy; Cohort; Transplantation; Persistence (discontinuity)","score_opus":0.0442771537125276,"score_gpt":0.3291058326767186,"score_spread":0.284828678964191,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414794257","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99852884,0.00026472472,0.0000513536,0.00006023331,0.0000065351937,0.000010065113,0.0009448647,0.0000020560135,0.00013128841],"genre_scores_gemma":[0.9987594,0.00010659167,0.000058248996,0.00004635351,0.000011791913,0.000013277692,0.00096309313,0.000001898302,0.00003943828],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975713,0.00081398693,0.0003974644,0.00057272665,0.00039248445,0.00025210416],"domain_scores_gemma":[0.9935819,0.00090660324,0.0038704043,0.00069514004,0.00041265928,0.0005332793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023746677,0.00031249813,0.0005785945,0.0009985084,0.0005393295,0.0012792052,0.0006164367,0.00063494884,0.0008595244],"category_scores_gemma":[0.0059503466,0.00048257364,0.0011867966,0.0022608377,0.00036358106,0.0008641672,0.0009555808,0.0012929542,0.00016959211],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012624546,0.000040715335,0.99893636,0.000009810954,0.00015845604,0.000024401013,0.000065526954,0.000032536842,0.000034709356,0.00001207742,0.00010436343,0.00045496455],"study_design_scores_gemma":[0.000021863823,0.00008824913,0.99867105,0.000017692377,0.00009887431,0.00013715615,0.0002310332,0.00047568555,0.00003079253,0.000021537815,0.00019750671,0.000008561311],"about_ca_topic_score_codex":0.012613577,"about_ca_topic_score_gemma":0.015568688,"teacher_disagreement_score":0.012613577,"about_ca_system_score_codex":0.0006890262,"about_ca_system_score_gemma":0.00059912057,"threshold_uncertainty_score":0.025080264},"labels":[],"label_agreement":null},{"id":"W4415063566","doi":"10.1080/10428194.2025.2562961","title":"Expert consensus opinion on the management of hairy cell leukemia in elderly patients","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Hairy cell leukemia; Cladribine; Expert opinion; Leukemia; MEDLINE","score_opus":0.01441489767900824,"score_gpt":0.2759394004783551,"score_spread":0.26152450279934686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415063566","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012816421,0.3135575,0.0052626957,0.53408253,0.10559865,0.0008141971,0.0028344488,0.0002228883,0.036345482],"genre_scores_gemma":[0.02714633,0.44497782,0.016039114,0.3584661,0.12616403,0.002082659,0.0053950404,0.00017522316,0.0195537],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9868255,0.00524009,0.0030327693,0.00089261093,0.0032805004,0.0007285528],"domain_scores_gemma":[0.94159174,0.018491603,0.0043846164,0.00078101375,0.03132285,0.0034282363],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012945198,0.00086432445,0.0023631037,0.0020898678,0.0011033781,0.0031807113,0.0036515705,0.00942092,0.013695995],"category_scores_gemma":[0.06754336,0.00045526645,0.0031357687,0.0013394348,0.0010636866,0.002763008,0.0021003555,0.0060306313,0.008378745],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000069714544,0.000020052414,0.00035551147,0.00523127,0.000117167285,0.00034007424,0.000117660406,0.00023052086,0.00015653108,0.0012352244,0.87224936,0.11987682],"study_design_scores_gemma":[0.000107688924,0.000051062383,0.0010603874,0.028123055,0.00028790702,0.0013921829,0.00028981167,0.00022034066,0.0002049989,0.0046493188,0.96354973,0.00006341219],"about_ca_topic_score_codex":0.0031826166,"about_ca_topic_score_gemma":0.004086412,"teacher_disagreement_score":0.013695995,"about_ca_system_score_codex":0.003015914,"about_ca_system_score_gemma":0.007465521,"threshold_uncertainty_score":0.0684616},"labels":[],"label_agreement":null},{"id":"W4415791945","doi":"10.1080/10428194.2025.2579735","title":"Reporting and enrollment disparities in hematologic malignancy trials between 2000–2023","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Foundation; Princess Margaret Cancer Centre; Women's College Hospital; University of Toronto","funders":"Leukemia and Lymphoma Society","keywords":"Hematologic malignancy; Clinical trial; Ethnic group; Race (biology); Multiple myeloma; Odds; Odds ratio; Diversity (politics)","score_opus":0.23835864244616492,"score_gpt":0.4826570369256505,"score_spread":0.24429839447948556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415791945","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"reporting","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"reporting","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88903594,0.027146539,0.005671783,0.0340097,0.00047337095,0.0008277227,0.01606867,0.000102257734,0.026663993],"genre_scores_gemma":[0.9805791,0.0030945947,0.0023300345,0.0077051055,0.00034528392,0.0008681414,0.004179725,0.000038059206,0.00086001714],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.89843285,0.06553929,0.018692585,0.004020163,0.010811174,0.0025039774],"domain_scores_gemma":[0.7288903,0.12796582,0.10740076,0.009831478,0.020005409,0.005906292],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.10101511,0.0001250497,0.00047856953,0.0021558006,0.00056514045,0.0020769227,0.000841614,0.00065859075,0.0016606016],"category_scores_gemma":[0.21364057,0.00023718821,0.00056429516,0.0039843908,0.00086679915,0.0017104637,0.002004241,0.0009827052,0.00025355566],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014020072,0.000100412064,0.90524805,0.0008018442,0.00037354854,0.00010268117,0.0020358078,0.0004957637,0.00052309525,0.0040280325,0.012693341,0.07219537],"study_design_scores_gemma":[0.00018950272,0.0003818824,0.95289606,0.0018497843,0.00027260117,0.00041559935,0.0016034768,0.0009087633,0.0011947416,0.0028183362,0.037417404,0.000051750616],"about_ca_topic_score_codex":0.007855926,"about_ca_topic_score_gemma":0.013451567,"teacher_disagreement_score":0.8989849,"about_ca_system_score_codex":0.0024612385,"about_ca_system_score_gemma":0.0053669326,"threshold_uncertainty_score":0.53422534},"labels":[],"label_agreement":null},{"id":"W4415949216","doi":"10.1080/10428194.2025.2577861","title":"Real-world experience and outcomes of decitabine/cedazuridine or azacitidine for the treatment of myelodysplastic syndrome/chronic myelomonocytic leukemia","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McMaster University","funders":"","keywords":"Azacitidine; Myelodysplastic syndromes; Chronic myelomonocytic leukemia; Leukemia; Disease; Clinical trial","score_opus":0.02106423577910986,"score_gpt":0.31566702946963227,"score_spread":0.2946027936905224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415949216","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9786896,0.011893873,0.0008706657,0.0014053233,0.00011875098,0.000103657476,0.0011321765,0.000019706022,0.0057662306],"genre_scores_gemma":[0.99310803,0.003777693,0.00083078025,0.000603781,0.000114062306,0.00004961078,0.001108443,0.00002121773,0.00038637745],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99911803,0.00037674428,0.00014081008,0.000116532545,0.00014552212,0.00010239531],"domain_scores_gemma":[0.9980452,0.0005937058,0.0005289133,0.00011109516,0.00017008303,0.0005508688],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013432693,0.00022925454,0.0003985416,0.00020841579,0.00045427782,0.001013223,0.0003475404,0.00052813796,0.0018551472],"category_scores_gemma":[0.005074863,0.00011835132,0.00059397245,0.0004959175,0.0004372963,0.00054632465,0.00046906347,0.0009060204,0.00043891204],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02831115,0.00878587,0.40739295,0.0018384967,0.0021840539,0.009766668,0.0041323043,0.00805671,0.0072623617,0.0020011244,0.020224152,0.50004417],"study_design_scores_gemma":[0.0071882852,0.0681559,0.7512776,0.0016374377,0.002648468,0.050950915,0.005260361,0.007548673,0.0053353887,0.0020433518,0.09756155,0.0003920449],"about_ca_topic_score_codex":0.0015315016,"about_ca_topic_score_gemma":0.0028412854,"teacher_disagreement_score":0.0018551472,"about_ca_system_score_codex":0.0012301368,"about_ca_system_score_gemma":0.00046355618,"threshold_uncertainty_score":0.008925319},"labels":[],"label_agreement":null},{"id":"W4415949455","doi":"10.1080/10428194.2025.2579721","title":"Clinical outcomes with venetoclax-based therapy in patients with relapsed/refractory B-cell lymphomas","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Lymphoma; Radiation therapy; Disease; MEDLINE; Clinical trial","score_opus":0.00894682280453036,"score_gpt":0.25578112319509644,"score_spread":0.24683430039056609,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415949455","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9775867,0.016536167,0.00018350928,0.0003379562,0.00006638987,0.00005125644,0.0006150878,0.000024210534,0.0045986376],"genre_scores_gemma":[0.9956566,0.0023951093,0.00010319436,0.00020614314,0.00006336387,0.000025348556,0.001030076,0.000004308422,0.00051583705],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9998894,0.000040756277,0.0000088551105,0.000015890704,0.000018739975,0.000026386904],"domain_scores_gemma":[0.9997272,0.00007065071,0.00006530149,0.000015135017,0.000022695838,0.00009910743],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031904204,0.00009779062,0.0003862414,0.0001747225,0.00017921414,0.0003961614,0.00013591991,0.00017775327,0.00092272775],"category_scores_gemma":[0.00071980973,0.000036891168,0.0002693402,0.00029416347,0.00014944273,0.00023336736,0.0001240251,0.00051850855,0.00018425481],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050993703,0.0027022834,0.376602,0.0008108071,0.0010554959,0.0022076606,0.00050876476,0.0040178667,0.012271308,0.00053717283,0.009975785,0.5383171],"study_design_scores_gemma":[0.0048643695,0.03371339,0.93363357,0.0004136082,0.0012417213,0.005621942,0.00032173557,0.002092702,0.0021896649,0.00065554545,0.015203976,0.00004777614],"about_ca_topic_score_codex":0.0008297216,"about_ca_topic_score_gemma":0.0013909036,"teacher_disagreement_score":0.00092272775,"about_ca_system_score_codex":0.00034112524,"about_ca_system_score_gemma":0.00019842508,"threshold_uncertainty_score":0.003086865},"labels":[],"label_agreement":null},{"id":"W4416167189","doi":"10.1080/10428194.2025.2582732","title":"Real-world outcomes in adult histiocytosis: the uncharted territory of orphan diseases","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Histiocytic Disorders and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Cohort; Incidence (geometry); Concomitant; Langerhans cell histiocytosis; Histiocytosis; Disease; Presentation (obstetrics)","score_opus":0.006449946712818376,"score_gpt":0.2540275627804528,"score_spread":0.24757761606763443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416167189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98552567,0.0072070416,0.00058411586,0.0009073352,0.000030887208,0.000014766684,0.0006391801,0.000014563531,0.005076511],"genre_scores_gemma":[0.99779046,0.0016154224,0.000155674,0.00005680392,0.00002323143,0.0000037261148,0.00025122173,0.0000029235061,0.000100491234],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99936014,0.00016663951,0.000057181634,0.00007163216,0.00018883415,0.00015560785],"domain_scores_gemma":[0.99781704,0.0003405813,0.0009918715,0.00016342588,0.00029578665,0.0003911901],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012255481,0.00012791654,0.00022956515,0.00042175056,0.00062073546,0.0012885929,0.0002787048,0.0002219029,0.0010136754],"category_scores_gemma":[0.0033567508,0.00006352661,0.00014803595,0.00096266874,0.0007024375,0.0006430681,0.0006702141,0.00029470975,0.0001280652],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021693038,0.000036304842,0.95765185,0.000110293906,0.00006943834,0.0011220694,0.00079445244,0.00028107731,0.00048102645,0.00048979465,0.0007401623,0.03800662],"study_design_scores_gemma":[0.000016495325,0.00028182904,0.98203087,0.0001763688,0.00008711285,0.0076502473,0.0024406742,0.00039997956,0.0004073095,0.00069471536,0.0057946914,0.000019758578],"about_ca_topic_score_codex":0.023663668,"about_ca_topic_score_gemma":0.05104853,"teacher_disagreement_score":0.023663668,"about_ca_system_score_codex":0.0013967395,"about_ca_system_score_gemma":0.0018010691,"threshold_uncertainty_score":0.047051847},"labels":[],"label_agreement":null},{"id":"W4416176438","doi":"10.1080/10428194.2025.2584685","title":"Allogeneic hematopoietic stem cell transplantation in adult with acute lymphoblastic leukemia: evolving indications and modalities in shifting landscape","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada","funders":"","keywords":"Chimeric antigen receptor; Blinatumomab; Minimal residual disease; Hematopoietic stem cell transplantation; Transplantation; Immunotherapy; Savior sibling; Lymphoblastic Leukemia","score_opus":0.006378976277003266,"score_gpt":0.23520483413680687,"score_spread":0.2288258578598036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416176438","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003195925,0.99140173,0.00068857934,0.0024003363,0.00023626616,0.0000085783395,0.000050061088,0.0000119861415,0.002006432],"genre_scores_gemma":[0.018613344,0.9773337,0.0012554113,0.0017036963,0.0006835715,0.000019266397,0.00010911941,0.000008398544,0.00027350176],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9995024,0.0001803906,0.00011908567,0.00005907989,0.000115683404,0.000023332557],"domain_scores_gemma":[0.9993482,0.00039994207,0.00009589267,0.000018207536,0.00010764192,0.000030017489],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014491314,0.00023835278,0.00049789646,0.00074874045,0.00013745383,0.00071333867,0.00032165513,0.00033045502,0.0008903621],"category_scores_gemma":[0.0017342163,0.00009621153,0.00036180211,0.0008730981,0.00038648138,0.0009582758,0.00040214733,0.0010467577,0.00031355247],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002832091,0.00003596718,0.002038155,0.005461144,0.00009841761,0.00024293656,0.00012485223,0.0005551754,0.0019062483,0.004811665,0.006899949,0.9775423],"study_design_scores_gemma":[0.000115933326,0.00080525735,0.009645212,0.013272348,0.0006537902,0.004892902,0.0005630936,0.00059110974,0.002349432,0.010783779,0.9562756,0.000051554332],"about_ca_topic_score_codex":0.00034517454,"about_ca_topic_score_gemma":0.001189719,"teacher_disagreement_score":0.0014491314,"about_ca_system_score_codex":0.0004125619,"about_ca_system_score_gemma":0.000806791,"threshold_uncertainty_score":0.007663846},"labels":[],"label_agreement":null},{"id":"W4417167552","doi":"10.1080/10428194.2025.2598362","title":"Autologous stem cell transplantation for the treatment of MGRS (monoclonal gammopathy of renal significance): experience from the University of Calgary","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Amyloidosis: Diagnosis, Treatment, Outcomes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Cancer Foundation","funders":"","keywords":"Transplantation; Autologous stem-cell transplantation; Incidence (geometry); Complication; Multiple myeloma; Disease","score_opus":0.008110316246793741,"score_gpt":0.22195686639460535,"score_spread":0.21384655014781162,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417167552","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91838825,0.060319778,0.0017802238,0.0040059313,0.00022941089,0.00023377412,0.0002855636,0.00003957045,0.014717575],"genre_scores_gemma":[0.9286268,0.06174805,0.0022725137,0.002371883,0.00036181766,0.000080696474,0.00061237416,0.000046545778,0.0038794167],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99956805,0.000115558025,0.00003680769,0.000050489143,0.00013010019,0.000098954246],"domain_scores_gemma":[0.99906784,0.0002123037,0.00009336228,0.0000554065,0.00012313483,0.0004479048],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008283147,0.00044071002,0.00038669936,0.00041342684,0.00067604607,0.00092104427,0.000670716,0.00059712643,0.0014270697],"category_scores_gemma":[0.001386161,0.00011966246,0.00035694445,0.0011234515,0.00066417066,0.00029462043,0.0007579156,0.0011183327,0.00045994777],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019241313,0.0042422893,0.15225771,0.00053157425,0.00030125832,0.016717155,0.005547317,0.0021758678,0.006720892,0.0014498641,0.0139543805,0.7941776],"study_design_scores_gemma":[0.0014136258,0.017755007,0.80632406,0.0019110228,0.0006259021,0.05145249,0.006953118,0.0018951488,0.009839134,0.001819105,0.099847116,0.00016427311],"about_ca_topic_score_codex":0.0062286374,"about_ca_topic_score_gemma":0.013015399,"teacher_disagreement_score":0.0062286374,"about_ca_system_score_codex":0.0010455531,"about_ca_system_score_gemma":0.0015252488,"threshold_uncertainty_score":0.012384713},"labels":[],"label_agreement":null},{"id":"W4417304678","doi":"10.1080/10428194.2025.2594059","title":"Treatment patterns and overall survival among patients with myelodysplastic syndromes treated in the US community oncology setting: a real-world retrospective observational study","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"AbbVie Canada","keywords":"Observational study; Retrospective cohort study; Myelodysplastic syndromes; Overall survival; Survival analysis; Proportional hazards model; Hematopoietic stem cell transplantation","score_opus":0.02971087010040666,"score_gpt":0.3065243523480963,"score_spread":0.2768134822476896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417304678","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982582,0.00023577161,0.000088909415,0.00005553981,0.000003474815,0.000016198961,0.001042466,0.0000035428022,0.0002959109],"genre_scores_gemma":[0.99879694,0.0001050917,0.00008173465,0.000054803397,0.0000065886074,0.000013431917,0.00090516894,0.0000025078587,0.000033670145],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988495,0.00031654455,0.00019430774,0.00027203377,0.00018871427,0.0001788743],"domain_scores_gemma":[0.9965252,0.0004908063,0.0020936662,0.00021979184,0.00028678402,0.0003837444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010203905,0.00019527435,0.000372879,0.00099287,0.0004162996,0.0007514606,0.00035468972,0.0003325393,0.00085567764],"category_scores_gemma":[0.003620994,0.00028865653,0.00035194072,0.002058909,0.00033378563,0.0006800493,0.00067342666,0.00063244184,0.00015923043],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000040560066,0.00002437742,0.9990693,0.000008263885,0.00003425844,0.00003490872,0.000054476357,0.000032081305,0.000039262104,0.000010358259,0.000126168,0.0005260917],"study_design_scores_gemma":[0.000010731927,0.00010326292,0.9980508,0.000019633693,0.000035040786,0.00043611167,0.00048251532,0.00028975916,0.000050908486,0.000024704874,0.00048876763,0.000007690593],"about_ca_topic_score_codex":0.009450581,"about_ca_topic_score_gemma":0.0149983885,"teacher_disagreement_score":0.009450581,"about_ca_system_score_codex":0.0005857939,"about_ca_system_score_gemma":0.00070987304,"threshold_uncertainty_score":0.01879114},"labels":[],"label_agreement":null},{"id":"W7117532524","doi":"10.1080/10428194.2025.2598663","title":"Time to diagnosis and treatment in lymphoma and implications for health-related outcomes: a systematic review","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hatch (Canada)","funders":"","keywords":"Checklist; Presentation (obstetrics); Lymphoma; Confidence interval; Interval (graph theory); MEDLINE; Consistency (knowledge bases); Medical diagnosis","score_opus":0.014372511580656168,"score_gpt":0.2987673864370383,"score_spread":0.28439487485638215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117532524","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012270191,0.9974584,0.00013242131,0.0002715034,0.00010749288,0.0001931209,0.00043351497,0.000004589598,0.00017191572],"genre_scores_gemma":[0.026932674,0.9705898,0.000674811,0.00053845823,0.00013029733,0.000638566,0.00038512275,0.000006280726,0.00010401136],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9871902,0.004700415,0.0050253603,0.0008137758,0.0019351934,0.00033504012],"domain_scores_gemma":[0.92607576,0.05810061,0.011169257,0.000684193,0.0034685933,0.000501643],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01209234,0.0011441833,0.0061738673,0.009610192,0.0006661815,0.002868627,0.0014001408,0.0016603747,0.0034702076],"category_scores_gemma":[0.079006836,0.0011031611,0.009708435,0.013076815,0.0007187428,0.002505419,0.0015525905,0.001377747,0.00026310084],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003580131,0.000019282843,0.0028039468,0.9424388,0.017513018,0.0001228438,0.000226279,0.00012597351,0.00008299053,0.00024292635,0.0014844899,0.03458151],"study_design_scores_gemma":[0.0003398243,0.00020559755,0.012056376,0.8614883,0.11042636,0.0003756825,0.00037275816,0.0001180223,0.00012829577,0.00041279578,0.014026808,0.00004917016],"about_ca_topic_score_codex":0.015275166,"about_ca_topic_score_gemma":0.037039608,"teacher_disagreement_score":0.015275166,"about_ca_system_score_codex":0.0045475382,"about_ca_system_score_gemma":0.013640126,"threshold_uncertainty_score":0.063951135},"labels":[],"label_agreement":null}]}